FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Gao, X Chen, HL Choi, HK Curhan, G Schwarzschild, MA Ascherio, A AF Gao, Xiang Chen, Honglei Choi, Hyon K. Curhan, Gary Schwarzschild, Michael A. Ascherio, Alberto TI Diet, urate, and Parkinson's disease risk in men SO AMERICAN JOURNAL OF EPIDEMIOLOGY LA English DT Article DE diet; men; Parkinson disease; uric acid ID FOOD FREQUENCY QUESTIONNAIRE; URIC-ACID CONCENTRATION; PURINE-RICH FOODS; OXIDATIVE STRESS; DAIRY-PRODUCTS; ALCOHOL INTAKE; GOUT; CONSUMPTION; XANTHINE; NEURONS AB The authors examined whether a diet that increases plasma urate level is also related to reduced risk of Parkinson's disease (PD). The study population comprised 47,406 men in the Health Professionals Follow-up Study. The potential effect of diet on plasma urate level was estimated by regressing plasma urate on intakes of selected foods and nutrients in a subsample of 1,387 men. Coefficients of this regression model were then used to calculate a dietary urate index for all cohort participants. Multivariate relative risks of PD were estimated by means of Cox proportional hazards models. After 14 years of follow-up (1986-2000), the authors documented 248 incident cases of PD. A higher dietary urate index was associated with a lower risk of PD (top quintile vs. bottom: relative risk = 0.47, p-trend = 0.0008), after adjustment for age, smoking, caffeine intake, and other potential confounders. This association remained strong and significant after further adjustment for each component of the index individually (p-trend < 0.02 for each). These data support urate as a potentially protective factor in PD and suggest that dietary changes expected to increase plasma urate level may contribute to lower risk of PD. These potential benefits, however, should be weighed against expected adverse effects on risk of gout and other chronic diseases. C1 [Gao, Xiang; Ascherio, Alberto] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA. [Chen, Honglei] Natl Inst Environm Hlth Ssci, Epidemiol Branch, Res Triangle Pk, NC USA. [Choi, Hyon K.; Curhan, Gary; Ascherio, Alberto] Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02115 USA. [Choi, Hyon K.; Curhan, Gary; Ascherio, Alberto] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Choi, Hyon K.] Univ British Columbia, Vancouver Gen Hosp, Dept Med, Vancouver, BC V5Z 1M9, Canada. [Curhan, Gary; Ascherio, Alberto] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [Schwarzschild, Michael A.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. RP Gao, X (reprint author), Harvard Univ, Sch Publ Hlth, Dept Nutr, 655 Huntington Ave, Boston, MA 02115 USA. EM xgao@hsph.harvard.edu OI Chen, Honglei/0000-0003-3446-7779 FU Intramural NIH HHS [Z01 ES101986-02]; NINDS NIH HHS [R01 NS048517, R01 NS048517-01A2, R01 NS048517-03] NR 43 TC 72 Z9 74 U1 2 U2 6 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9262 J9 AM J EPIDEMIOL JI Am. J. Epidemiol. PD APR 1 PY 2008 VL 167 IS 7 BP 831 EP 838 DI 10.1093/aje/kwm385 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 281AW UT WOS:000254469500010 PM 18326873 ER PT J AU Reid, AE AF Reid, Andrea E. TI The impact of race on liver transplant outcomes in the MELD era: Still more questions than answers SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Editorial Material ID CHRONIC HEPATITIS-C; AFRICAN-AMERICAN; GRAFT-SURVIVAL; CARDIAC DEATH; MODEL; MORTALITY; DISEASE; DISPARITIES; VALIDATION; RECIPIENTS AB Liver transplantation is a life-saving therapy for patients with end-stage liver disease (ESLD); however, donor livers are scarce. Several studies have demonstrated racial disparities in access to liver transplant as well as patient and graft survival after liver transplantation. These studies used data gathered before the model for end-stage liver disease (MELD) was used to determine priority for liver transplant. In this issue of the journal, Drs. Ananthakrishnan and Saeian examine survival after transplant in the MELD era by race and ethnicity, and show that the racial disparities in posttransplant outcomes persist despite MELD. This study provides further evidence that race, which is likely a proxy for a variety of biological and sociological factors, must be considered in any prognostic model for liver transplantation. The impact of race on liver transplantation outcomes should be evaluated further in a well-designed, multicentered, prospective study. C1 Massachusetts Gen Hosp, Gastrointestinal Unit GJ 724, Boston, MA 02114 USA. RP Reid, AE (reprint author), Massachusetts Gen Hosp, Gastrointestinal Unit GJ 724, 55 Fruit St, Boston, MA 02114 USA. NR 34 TC 1 Z9 1 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD APR PY 2008 VL 103 IS 4 BP 911 EP 913 DI 10.1111/j.1572-0241.2008.01817.x PG 3 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 283VS UT WOS:000254665200014 PM 18371129 ER PT J AU Pihlajamaki, M DePeau, KM Blacker, D Sperling, RA AF Pihlajamaeki, Maija DePeau, Kristina M. Blacker, Deborah Sperling, Reisa A. TI Impaired medial temporal repetition suppression is related to failure of parietal deactivation in Alzheimer disease SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article DE Alzheimer disease; fMRI; medial temporal lobe; memory; parietal cortex; repetition suppression ID MILD COGNITIVE IMPAIRMENT; HIPPOCAMPAL-FORMATION; FUNCTIONAL MRI; RECOGNITION MEMORY; PERIRHINAL CORTEX; FMRI; BRAIN; ACTIVATION; DEMENTIA; MULTICENTER AB Objectives: Neural networks supporting encoding of new information are affected early in the course of Alzheimer disease (AD). Functional magnetic resonance imaging (fMRI) studies in AD have reported decreased medial temporal lobe (MTL) activation when comparing novel versus repeated stimuli. It is, however, unclear whether this finding is related to a failure of normal suppression of MTL activity to repeated stimuli in AD. Design, Setting, Participants and Measurements: Twenty-nine healthy older subjects comprising a comparison group (OC) and 15 mild AD patients underwent fMRI during an associative memory paradigm in an academic medical center. The task consisted of blocks of Novel and Repeated face-name pairs and visual Fixation. To reveal neural correlates of processing repeatedly presented stimuli, Repeated blocks were contrasted to Fixation. Results: AD patients demonstrated greater activation during Repeated stimuli in the MTL and in prefrontal and superior parietal cortices, compared with OC. In contrast, OC showed greater parietal task-induced deactivation than AD. Increased MTL activity during Repeated was correlated with more impaired parietal deactivation and poorer performance of the postscan recognition memory test of encoding the face-name pairs. Conclusion: Reduction of MTL activity to repeated stimuli, which become highly familiarized to healthy OC, was impaired in AD. This abnormal increased MTL activation was related to disrupted parietal deactivation and to poor recognition memory performance. These preliminary results suggest that the typical episodic memory impairment seen in mild AD may manifest as a failure of normal repetition suppression and loss of "beneficial" deactivation in the MTL-parietal memory networks. C1 [Pihlajamaeki, Maija; DePeau, Kristina M.; Sperling, Reisa A.] Harvard Univ, Dept Neurol, Memory Disorders Unit, Brigham & Womens Hosp,Sch Med, Boston, MA 02115 USA. [Pihlajamaeki, Maija] Univ Kuopio, Dept Neurosci & Neurol, FIN-70211 Kuopio, Finland. [Sperling, Reisa A.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Boston, MA 02114 USA. [Pihlajamaeki, Maija; DePeau, Kristina M.; Blacker, Deborah; Sperling, Reisa A.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. RP Pihlajamaki, M (reprint author), Harvard Univ, Dept Neurol, Memory Disorders Unit, Brigham & Womens Hosp,Sch Med, 221 Longwood Ave, Boston, MA 02115 USA. EM mpihlajamaki@rics.bwh.harvard.edu FU NIA NIH HHS [P01 AG004953, P01-AG04953, P50-AG00513421, R01 AG027435, R01 AG027435-03, R01-AG027435] NR 37 TC 48 Z9 49 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1064-7481 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD APR PY 2008 VL 16 IS 4 BP 283 EP 292 DI 10.1097/JGP.0b013e318162a0a9 PG 10 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 282OM UT WOS:000254577100005 PM 18378553 ER PT J AU Luo, HBR Loison, F AF Luo, Hongbo R. Loison, Fabien TI Constitutive neutrophil apoptosis: Mechanisms and regulation SO AMERICAN JOURNAL OF HEMATOLOGY LA English DT Review ID COLONY-STIMULATING FACTOR; NF-KAPPA-B; PROGRAMMED CELL-DEATH; NECROSIS-FACTOR-ALPHA; INFLAMMATORY RESPONSE SYNDROME; PROTEIN-KINASE-C; HUMAN POLYMORPHONUCLEAR LEUKOCYTES; SYSTEMIC-LUPUS-ERYTHEMATOSUS; TNF-ALPHA; NITRIC-OXIDE AB Neutrophil constitutive death is a critical cellular process for modulating neutrophil number and function, and it plays an essential role in neutrophil homeostasis and the resolution of inflammation. Neutrophils die due to programmed cell death or apoptosis. In this article, we review recent studies on the mechanism of neutrophil apoptosis. The involvement of caspase, calpain, reactive oxygen species, cellular survival/death signaling pathways, mitochondria, and BCL-2 family member proteins are discussed. The fate of neutrophils can be influenced within the inflammatory microenvironment. We summarize the current understanding regarding the modulation of neutrophil apoptotic death by various extracellular stimuli such as proinflammatory cytokines, cell adhesion, phagocytosis, red blood cells, and platelets. The involvement of neutrophil apoptosis in infectious and inflammatory diseases is also addressed. C1 [Luo, Hongbo R.; Loison, Fabien] Harvard Univ, Sch Med, Dept Pathol, Cambridge, MA 02138 USA. [Luo, Hongbo R.; Loison, Fabien] Childrens Hosp, Joint Program Tranfus Med, Stem Cell Program, Dept Lab Med, Boston, MA 02115 USA. [Luo, Hongbo R.; Loison, Fabien] Dana Farber Harvard Canc Ctr, Boston, MA USA. RP Luo, HBR (reprint author), Karp Family Res Bldg,Room 10214,1 Blackfan Circle, Boston, MA 02115 USA. EM Hongbo.Luo@childrens.harvard.edu RI Loison, Fabien/G-3385-2014 OI Loison, Fabien/0000-0002-6678-1730 NR 152 TC 137 Z9 140 U1 3 U2 14 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0361-8609 J9 AM J HEMATOL JI Am. J. Hematol. PD APR PY 2008 VL 83 IS 4 BP 288 EP 295 DI 10.1002/ajh.21078 PG 8 WC Hematology SC Hematology GA 282UH UT WOS:000254592200006 PM 17924549 ER PT J AU Berqwitz, C Jaureguiberry, G Carpenter, TO Forman, S Juppner, H AF Berqwitz, Clemens Jaureguiberry, Graciana Carpenter, Thomas O. Forman, Stuart Juppner, Harald TI Functional analysis of human mutations in NaPi-IIc reveals important residues for surface expression and sodium-phosphate co-transport SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Meeting Abstract CT Spring Clinical Meeting of the National-Kidney-Foundation CY APR 02-06, 2008 CL Dallas, TX SP Natl Kidney Fdn C1 [Berqwitz, Clemens; Jaureguiberry, Graciana; Juppner, Harald] Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA. [Forman, Stuart] Massachusetts Gen Hosp, Dept Anesthesiol, Boston, MA 02114 USA. [Carpenter, Thomas O.] Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06510 USA. [Carpenter, Thomas O.] Yale Univ, Sch Med, Endocrine Unit, New Haven, CT USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD APR PY 2008 VL 51 IS 4 MA 25 BP A34 EP A34 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA 286VP UT WOS:000254874400052 ER PT J AU Boulev, R Nunes, P Brown, D AF Boulev, R. Nunes, P. Brown, D. TI Heterologous downregulation of vasopressin type 2 receptor is induced by transferrin SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Meeting Abstract CT Spring Clinical Meeting of the National-Kidney-Foundation CY APR 02-06, 2008 CL Dallas, TX SP Natl Kidney Fdn C1 [Boulev, R.; Nunes, P.; Brown, D.] Massachusetts Gen Hosp, Div Nephrol, Program Membrane Biol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD APR PY 2008 VL 51 IS 4 MA 33 BP A36 EP A36 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA 286VP UT WOS:000254874400060 ER PT J AU Wahecd, S AF Wahecd, SaInian TI Characterizing treatment of stage 3 chronic kidney disease (CKD) amongst hispanics, African-Americans (AA), and caucasians SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Meeting Abstract CT Spring Clinical Meeting of the National-Kidney-Foundation CY APR 02-06, 2008 CL Dallas, TX SP Natl Kidney Fdn C1 [Wahecd, SaInian] James J Peters VA Med Ctr, Dept Med, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD APR PY 2008 VL 51 IS 4 MA 271 BP A95 EP A95 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA 286VP UT WOS:000254874400298 ER PT J AU Gupta, R Markowitz, Y Berman, L Chapman, P AF Gupta, R. Markowitz, Y. Berman, L. Chapman, P. TI High-resolution imaging of an ancient Egyptian mummified head: New insights into the mummification process SO AMERICAN JOURNAL OF NEURORADIOLOGY LA English DT Article ID CT-SCANNER; VOLUME CT; MUMMIES; BONE AB BACKGROUND AND PURPOSE: Systematic facial mutilations during mummification have never been described before. The purpose of this work was to study a wrapped mummified head using high-resolution CT scanning. MATERIALS AND METHODS: An isolated mummified head from the Egyptian Middle Kingdom was scanned at 200 mu m isotropic resolution. A prototype flat panel CT scanner was used to generate 800 nonoverlapping CT sections at 120 kV and 50 mA. This dataset was analyzed to discern various surgical alterations during mummification. RESULTS: There were large defects in the cribriform plate and the posterior fossa. Systematic mutilations of the facial bones and mandible, involving the anterior and inferior walls of the maxillary sinuses, the floor of both orbits, and the zygomatic arches with contiguous segments of the zygomas, were demonstrated. The coronoid processes of both mandibles had been sharply excised and the articular tubercles of the temporomandibular joints fractured. CONCLUSION: Defects in the ethmoid and the posterior skull base are consistent with previous descriptions of excerebration. Mutilations of the facial skeleton and jaw, which are unrelated to the process of excerebration, have never been described previously. It is noteworthy that the osteotomies selectively include the insertions of the muscles of mastication. These mutilations apparently were designed for mobilization of lower jaw. The "Opening of the Mouth" ceremony, described in the ancient texts, would be difficult to perform in the presence of rigor mortis; it is probable that the observed osteotomies were performed to facilitate this ceremony. Our research suggests that by the Middle Kingdom, Egyptian embalmers had developed highly sophisticated surgical techniques that have not been appreciated previously. C1 [Gupta, R.] Massachusetts Gen Hosp, Dept Neuroradiol, Boston, MA 02114 USA. [Chapman, P.] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. [Markowitz, Y.; Berman, L.] Museum Fine Arts, Dept Art Ancient World, Boston, MA 02115 USA. RP Gupta, R (reprint author), Massachusetts Gen Hosp, Dept Neuroradiol, 55 Fruit St,Room GRB-273A, Boston, MA 02114 USA. EM rgupta1@partners.org NR 16 TC 10 Z9 11 U1 2 U2 9 PU AMER SOC NEURORADIOLOGY PI OAK BROOK PA 2210 MIDWEST RD, OAK BROOK, IL 60521 USA SN 0195-6108 J9 AM J NEURORADIOL JI Am. J. Neuroradiol. PD APR PY 2008 VL 29 IS 4 BP 705 EP 713 DI 10.3174/ajnr.A0909 PG 9 WC Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA 290NO UT WOS:000255129700016 PM 18238847 ER PT J AU Gimbrone, MA Pober, JS AF Gimbrone, Michael A., Jr. Pober, Jordan S. TI Tucker Collins, MD, PhD, 1952-2007 SO AMERICAN JOURNAL OF PATHOLOGY LA English DT Biographical-Item C1 [Gimbrone, Michael A., Jr.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. [Pober, Jordan S.] Yale Univ, Sch Med, New Haven, CT USA. RP Gimbrone, MA (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC INVESTIGATIVE PATHOLOGY, INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3993 USA SN 0002-9440 J9 AM J PATHOL JI Am. J. Pathol. PD APR PY 2008 VL 172 IS 4 BP 855 EP 856 DI 10.2353/ajpath.2008.080100 PG 2 WC Pathology SC Pathology GA 283YO UT WOS:000254672600001 ER PT J AU Tran, N Valentin-Blasini, L Blount, BC McCuistion, CG Fenton, MS Gin, E Salem, A Hershman, JM AF Tran, Neil Valentin-Blasini, Liza Blount, Benjamin C. McCuistion, Caroline Gibbs Fenton, Mike S. Gin, Eric Salem, Andrew Hershman, Jerome M. TI Thyroid-stimulating hormone increases active transport of perchlorate into thyroid cells SO AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM LA English DT Article DE iodide; Na+/I- symporter ID TANDEM MASS-SPECTROMETRY; SODIUM-IODIDE SYMPORTER; TUMOR-NECROSIS-FACTOR; SODIUM/IODIDE SYMPORTER; RADIOACTIVE PERCHLORATE; ION CHROMATOGRAPHY; NA+/I-SYMPORTER; UNITED-STATES; FRTL-5 CELLS; BREAST-MILK AB Perchlorate blocks thyroidal iodide transport in a dose-dependent manner. The human sodium/iodide symporter (NIS) has a 30-fold higher affinity for perchlorate than for iodide. However, active transport of perchlorate into thyroid cells has not previously been demonstrated by direct measurement techniques. To demonstrate intracellular perchlorate accumulation, we incubated NIS-expressing FRTL-5 rat thyroid cells in various concentrations of perchlorate, and we used a sensitive ion chromatography tandem mass spectrometry method to measure perchlorate accumulation in the cells. Perchlorate caused a dose-related inhibition of 125-iodide uptake at 1-10 mu M. The perchlorate content from cell lysate was analyzed, showing a higher amount of perchlorate in cells that were incubated in medium with higher perchlorate concentration. Thyroid-stimulating hormone increased perchlorate uptake in a dose-related manner, thus supporting the hypothesis that perchlorate is actively transported into thyroid cells. Incubation with nonradiolabeled iodide led to a dose-related reduction of intracellular accumulation of perchlorate. To determine potential toxicity of perchlorate, the cells were incubated in 1 nM to 100 mu M perchlorate and cell proliferation was measured. Even the highest concentration of perchlorate (100 mu M) did not inhibit cell proliferation after 72 h of incubation. In conclusion, perchlorate is actively transported into thyroid cells and does not inhibit cell proliferation. C1 [Hershman, Jerome M.] Univ Calif Los Angeles, Sch Med, W Los Angeles Vet Affairs Med Ctr, Endocrine Res Lab, Los Angeles, CA 90073 USA. Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA. RP Hershman, JM (reprint author), Univ Calif Los Angeles, Sch Med, W Los Angeles Vet Affairs Med Ctr, Endocrine Res Lab, Endocrinol 111D,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM jhershmn@ucla.edu NR 37 TC 42 Z9 43 U1 0 U2 11 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0193-1849 J9 AM J PHYSIOL-ENDOC M JI Am. J. Physiol.-Endocrinol. Metab. PD APR PY 2008 VL 294 IS 4 BP E802 EP E806 DI 10.1152/ajpendo.00013.2008 PG 5 WC Endocrinology & Metabolism; Physiology SC Endocrinology & Metabolism; Physiology GA 282NU UT WOS:000254575300018 PM 18303123 ER PT J AU Stearns, AT Balakrishnan, A Rounds, J Rhoads, DB Ashley, SW Tavakkolizadeh, A AF Stearns, Adam T. Balakrishnan, Anita Rounds, Jan Rhoads, David B. Ashley, Stanley W. Tavakkolizadeh, Ali TI Capsaicin-sensitive vagal afferents modulate posttranscriptional regulation of the rat Na+/glucose cotransporter SGLT1 SO AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY LA English DT Article DE glucose transport; vagus; vagotomy ID TRANSPORTER MESSENGER-RNA; D-GLUCOSE; SMALL-INTESTINE; DIURNAL RHYTHM; EXPRESSION; PERIODICITY; INVOLVEMENT; ABSORPTION; SECRETION; VAGOTOMY AB Introduction: the intestinal Na+/glucose cotransporter (SGLT1) displays rapid anticipatory diurnal rhythms in mRNA and protein expression. The vagus nerve has been implicated in the entrainment of some transporters. We aimed to clarify the influence of the vagus nerve on the diurnal entrainment pathway for SGLT1 and examine the role of vagal afferent fibers. Methods: male Sprague-Dawley rats were randomized to three groups, total subdiaphragmatic vagotomy, selective deafferentation of the vagus with capsaicin, or sham laparotomy. Postoperatively, animals were maintained in a 12-h light-dark cycle with food access limited to night. On the ninth postoperative day, animals were euthanized to harvest jejunal mucosa at 6-h intervals starting at 10 AM. Whole cell SGLT1 protein was measured by semiquantitative densitometry of immunoblots. Sglt1 and regulatory subunit RS1 mRNA was assessed by quantitative PCR. Fluorogold tracer technique was used to confirm adequacy of the vagotomy. Results: the diurnal rhythm in intestinal SGLT1, with a 5.3-fold increase in Sglt1 mRNA at 4 PM, was preserved in both vagotomy and capsaicin groups. However, the rhythmicity in SGLT1 protein expression (2.3-fold peak at 10 PM; P = 0.041) was abolished following either total vagotomy or deafferentation. Lack of change in RS1 mRNA suggests this is independent of the RS1 regulatory pathway. Conclusion: SGLT1 transcription is independent of the vagus. However, dissociation of the protein rhythm from the underlying mRNA signal by vagotomy suggests the vagus may be involved in posttranscriptional regulation of SGLT1 in an RS1 independent pathway. Disruption following afferent ablation by capsaicin suggests this limb is specifically necessary. C1 [Stearns, Adam T.; Balakrishnan, Anita; Rounds, Jan; Ashley, Stanley W.; Tavakkolizadeh, Ali] Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA. [Stearns, Adam T.; Balakrishnan, Anita; Rounds, Jan; Ashley, Stanley W.; Tavakkolizadeh, Ali] Harvard Univ, Sch Med, Boston, MA USA. [Stearns, Adam T.] Univ Oxford, Dept Physiol Anat & Genet, Oxford, England. [Rhoads, David B.] MassGen Hosp Children, Pediat Endocrine Unit, Boston, MA USA. RP Tavakkolizadeh, A (reprint author), Brigham & Womens Hosp, Dept Surg, 75 Francis St, Boston, MA 02115 USA. EM atavakkoli@partners.org FU NIDDK NIH HHS [P30-DK040561, 5 R01-DK-047326] NR 39 TC 16 Z9 16 U1 0 U2 2 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0193-1857 J9 AM J PHYSIOL-GASTR L JI Am. J. Physiol.-Gastroint. Liver Physiol. PD APR PY 2008 VL 294 IS 4 BP G1078 EP G1083 DI 10.1152/ajpgi.00591.2007 PG 6 WC Gastroenterology & Hepatology; Physiology SC Gastroenterology & Hepatology; Physiology GA 285PP UT WOS:000254789000029 PM 18308853 ER PT J AU Nagami, GT AF Nagami, Glenn T. TI Role of angiotensin II in the enhancement of ammonia production and secretion by the proximal tubule in metabolic acidosis SO AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY LA English DT Article DE ammonia transport; ammoniagenesis; acid-base physiology; losartan; sodium-hydrogen exchanger ID PERFUSED IN-VITRO; RAT; ALDOSTERONE; TRANSPORT; SEGMENTS; INVITRO; BASE; NEPHRON; KIDNEY AB Acidosis and angiotensin II stimulate ammonia production and transport by the proximal tubule. We examined the modulatory effect of the type 1 angiotensin II receptor blocker losartan on the ability of metabolic acidosis to stimulate ammonia production and secretion by mouse S2 proximal tubule segments. Mice given NH(4)Cl for 7 days developed metabolic acidosis (low serum bicarbonate concentration) and increased urinary excretion of ammonia. S2 tubule segments from acidotic mice displayed higher rates of ammonia production and secretion compared with those from control mice. However, when losartan was coadministered in vivo with NH(4)Cl, both the acidosis-induced increase in urinary ammonia excretion and the adaptive increase in ammonia production and secretion of microperfused S2 segments were largely blocked. In renal cortical tissue, losartan blocked the acid-induced increase in brush-border membrane NHE3 expression but had no effect on the acid-induced upregulation of phosphate-dependent glutaminase or phosphoenolpyruvate carboxykinase 1 in cortical homogenates. Addition of angiotensin II to the microperfusion solution enhanced ammonia secretion and production rates in tubules from NH(4)Cl-treated and control mice in a losartan-inhibitable manner. These results demonstrate that a 7-day acid challenge induces an adaptive increase in ammonia production and secretion by the proximal tubule and suggest that during metabolic acidosis, angiotensin II signaling is necessary for adaptive enhancements of ammonia excretion by the kidney and ammonia production and secretion by S2 proximal tubule segments, as mediated, in part, by angiotensin receptor-dependent enhancement of NHE3 expression. C1 [Nagami, Glenn T.] Vet Affairs Greater Los Angels Healthcare Syst W, Nephrol Sect, Med & Res Serv, Los Angeles, CA USA. [Nagami, Glenn T.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. RP Nagami, GT (reprint author), VA Greater Los Angels Healthcare Syst W Los Angel, Nephrol Sect 111L, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM glenn.nagami@va.gov NR 37 TC 19 Z9 19 U1 0 U2 0 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1931-857X J9 AM J PHYSIOL-RENAL JI Am. J. Physiol.-Renal Physiol. PD APR PY 2008 VL 294 IS 4 BP F874 EP F880 DI 10.1152/ajprenal.00286.2007 PG 7 WC Physiology; Urology & Nephrology SC Physiology; Urology & Nephrology GA 283FX UT WOS:000254623200023 PM 18287403 ER PT J AU Siever, LJ AF Siever, Larry J. TI Neurobiology of aggression and violence SO AMERICAN JOURNAL OF PSYCHIATRY LA English DT Review ID BORDERLINE PERSONALITY-DISORDER; POSITRON-EMISSION-TOMOGRAPHY; INTERMITTENT EXPLOSIVE DISORDER; MONOAMINE-OXIDASE-A; IMPULSIVE-AGGRESSION; CEREBROSPINAL-FLUID; RECEPTOR-BINDING; 5-HYDROXYINDOLEACETIC ACID; EMOTIONAL DYSREGULATION; TRYPTOPHAN DEPLETION AB Acts of violence account for an estimated 1.43 million deaths worldwide annually. While violence can occur in many contexts, individual acts of aggression account for the majority of instances. In some individuals, repetitive acts of aggression are grounded in an underlying neurobiological susceptibility that is just beginning to be understood. The failure of "top-down" control systems in the prefrontal cortex to modulate aggressive acts that are triggered by anger provoking stimuli appears to play an important role. An imbalance between prefrontal regulatory influences and hyper-responsivity of the amygdala and other limbic regions involved in affective evaluation are implicated. Insufficient serotonergic facilitation of "top-down" control, excessive catecholaminergic stimulation, and subcortical imbalances of glutamatergic/gabaminergic systems as well as pathology in neuropeptide systems involved in the regulation of affiliative behavior may contribute to abnormalities in this circuitry. Thus, pharmacological interventions such as mood stabilizers, which dampen limbic irritability, or selective serotonin reuptake inhibitors (SSRIs), which may enhance "top-down" control, as well as psychosocial interventions to develop alternative coping skills and reinforce reflective delays may be therapeutic. C1 [Siever, Larry J.] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. [Siever, Larry J.] James J Peters Vet Affairs Med Ctr, Dept Psychiat, Bronx, NY USA. [Siever, Larry J.] VISN 3 Mental Illness Res Educ & Clin Ctr, Bronx, NY USA. RP Siever, LJ (reprint author), Dept Psychiat OOMH, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM Larry.Siever@va.gov FU NCRR NIH HHS [M01 RR000071, M01-RR-00071]; NIMH NIH HHS [MH-56140, MH-63875, R01 MH056140, R01 MH063875] NR 136 TC 308 Z9 317 U1 11 U2 70 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0002-953X J9 AM J PSYCHIAT JI Am. J. Psychiat. PD APR PY 2008 VL 165 IS 4 BP 429 EP 442 DI 10.1176/appi.ajp.2008.07111774 PG 14 WC Psychiatry SC Psychiatry GA 282OT UT WOS:000254577800007 PM 18346997 ER PT J AU Seal, KH Bertenthal, D Maguen, S Gima, K Chu, A Marmar, CR AF Seal, Karen H. Bertenthal, Daniel Maguen, Shira Gima, Kristian Chu, Ann Marmar, Charles R. TI Getting beyond "Don't Ask; Don't Tell": an evaluation of US veterans administration postdeployment mental health screening of veterans returning from Iraq and Afghanistan SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; POPULATION-BASED SURVEY; PRIMARY-CARE; GULF-WAR; DEPRESSION; MILITARY AB Objectives. We sought to evaluate outcomes of the Veterans Administration (VA) Afghan and Iraq Post-Deployment Screen for mental health symptoms. Methods. Veterans Administration clinicians were encouraged to refer Iraq or Afghanistan veterans who screened positive for posttraumatic stress disorder, depression, or high-risk alcohol use to a VA mental health clinic. Multivariate methods were used to determine predictors of screening, the proportions who screened positive for particular mental health problems, and predictors of VA mental health clinic attendance. Results. Among 750 Iraq and Afghanistan veterans who were referred to a VA medical center and 5 associated community clinics, 338 underwent postdeployment screening; 233 (69%) screened positive for mental health problems. Having been seen in primary care (adjusted odd ratio [AOR] = 13.3; 95% confidence interval [CI] = 8.311, 21.3) and at a VA community clinic (AOR= 3.28; 95% CI=2.03, 5.28) predicted screening. African American veterans were less likely to have been screened than were White veterans (AOR= 0.45; 95% CI = 0.22, 0.91). Of 233 veterans who screened positive, 170 (73%) completed a mental health follow-up visit. Conclusions. A substantial proportion of veterans met screening criteria for co-occurring mental health problems, suggesting that the VA screens may help overcome a "don't ask, don't tell" climate that surrounds stigmatized mental illness. Based on data from 1 VA facility, VA postdeployment screening increases mental health clinic attendance among Iraq and Afghanistan veterans. C1 [Seal, Karen H.; Bertenthal, Daniel; Maguen, Shira; Gima, Kristian; Chu, Ann; Marmar, Charles R.] San Francisco VA Med Ctr, Div Gen Internal Med, San Francisco, CA 94121 USA. [Seal, Karen H.; Maguen, Shira; Marmar, Charles R.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Seal, Karen H.; Maguen, Shira; Marmar, Charles R.] San Francisco Vet Adm Hlth Serv, Res & Dev Res Enhancement Award Program, San Francisco, CA USA. RP Seal, KH (reprint author), San Francisco VA Med Ctr, Div Gen Internal Med, Box 111A-1,4150 Clement St, San Francisco, CA 94121 USA. EM karen.seal@ucsf.edu NR 26 TC 64 Z9 64 U1 1 U2 3 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD APR PY 2008 VL 98 IS 4 BP 714 EP 720 DI 10.2105/AJPH.2007.115519 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 282VO UT WOS:000254595500030 PM 18309130 ER PT J AU Bogart, LM Howerton, D Lange, J Becker, K Setodji, CM Asch, SM AF Bogart, Laura M. Howerton, Devery Lange, James Becker, Kirsten Setodji, Claude Messan Asch, Steven M. TI Scope of rapid HIV testing in private nonprofit urban community health settings in the United States SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID NATIONAL PROBABILITY SAMPLES; LOW-PREVALENCE DISEASES; SERVICES UTILIZATION; EXPERIENCE; ROUTINE; TRIAL; COST AB Objectives. We examined patterns of rapid HIV testing in a multistage national random sample of private, nonprofit, urban community clinics and community-based organizations to determine the extent of rapid HIV test availability outside the public health system. Methods. We randomly sampled 12 primary metropolitan statistical areas in 4 regions; 746 sites were randomly sampled across areas and telephoned. Staff at 575 of the sites (78%) were reached, of which 375 were eligible and subsequently interviewed from 2005 to 2006. Results. Seventeen percent of the sites offered rapid HIV tests (22% of clinics, 10% of community-based organizations). In multivariate models, rapid test availability was more likely among community clinics in the South (vs West), clinics in high HIV/AIDS prevalence areas, clinics with on-site laboratories and multiple locations, and clinics that performed other diagnostic tests. Conclusions. Rapid HIV tests were provided infrequently in private, nonprofit, urban community settings. Policies that encourage greater diffusion of rapid testing are needed, especially in community-based organizations and venues with fewer resources and less access to laboratories. C1 [Bogart, Laura M.; Becker, Kirsten; Setodji, Claude Messan; Asch, Steven M.] RAND Corp, Santa Monica, CA 90407 USA. [Howerton, Devery; Lange, James] Ctr Dis Control & Prevent, Lab Practice Evaluat & Genom Branch, Atlanta, GA USA. [Asch, Steven M.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Bogart, LM (reprint author), RAND Corp, 1776 Main St,POB 2138, Santa Monica, CA 90407 USA. EM lbog-art@rand.org FU NCCDPHP CDC HHS [U48 DP000056, U48/DP000056]; PHS HHS [U65/CCU924523-01] NR 34 TC 15 Z9 15 U1 2 U2 4 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD APR PY 2008 VL 98 IS 4 BP 736 EP 742 DI 10.2105/AJPH.2007.111567 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 282VO UT WOS:000254595500033 PM 18309135 ER PT J AU Stolzmann, KL Gagnon, DR Brown, R Tun, CG Garshick, E AF Stolzmann, Kelly L. Gagnon, David R. Brown, Robert Tun, Carlos G. Garshick, Eric TI Longitudinal change in FEV1 and FVC in chronic spinal cord injury SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Article; Proceedings Paper CT Annual Meeting of the American-Spinal-Injury-Association CY JUN, 2007 CL Tampa, FL SP Amer Spinal Injury Assoc DE respiratory function; longitudinal studies; smoking; body mass index ID FORCED EXPIRATORY VOLUME; PULMONARY-FUNCTION DECLINE; C-REACTIVE PROTEIN; BODY-MASS INDEX; VITAL CAPACITY; RESPIRATORY SYMPTOMS; LUNG-FUNCTION; SERUM LEPTIN; YOUNG-ADULTS; SMOKING AB Rationale: Although respiratory dysfunction is common in chronic spinal cord injury (SCI), determinants of longitudinal change in FEV1 and FVC have not been assessed. Objectives: Determine factors that influence longitudinal lung function decline in SCI. Methods: A total of 174 male participants (mean age of 49 and 17 yr after injury) completed a respiratory questionnaire and underwent spirometry over an average follow-up of 7.5 years (range, 4-14 yr). Measurements and Main Results: In multivariate models, longitudinal decline in FEV1 was significantly related to continued smoking, persistent wheeze, an increase in body mass index, and respiratory muscle strength. Aging was associated with an accelerated decline in FEV1 (for ages < 40, 40-60, > 60 yr: -27, -37, and -71 ml/yr, respectively). Similar effects were observed for FVC. Conclusions: Longitudinal change in FEV1 and FVC was not directly related to level and severity of SCI, but was attributable to potentially modifiable factors in addition to age. These results suggest that weight control, smoking cessation, trials directed at the recognition and treatment of wheeze, and efforts to improve respiratory muscle strength may slow lung function decline after SCI. C1 [Garshick, Eric] VA Boston Healthcare Syst, Pulm & Crit Care Med Sect, Boston, MA 02132 USA. [Stolzmann, Kelly L.; Gagnon, David R.; Tun, Carlos G.; Garshick, Eric] VA Boston Healthcare Syst, Dept Vet Affairs, Res & Dev Serv, Boston, MA USA. [Stolzmann, Kelly L.] Harvard Univ, Sch Med, Programs Res VA Boston, Cambridge, MA 02138 USA. [Gagnon, David R.] Boston Univ, Sch Publ Hlth, Dept Biostat, VA Boston Healthcare Syst,VA Cooperat Studies Pro, Boston, MA 02215 USA. [Brown, Robert] Massachusetts Gen Hosp, Pulm & Crit Care Med Unit, Boston, MA 02114 USA. [Brown, Robert] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Brown, Robert; Tun, Carlos G.; Garshick, Eric] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Tun, Carlos G.] VA Boston Healthcare Syst, Rehabil Med Serv, Boston, MA USA. [Garshick, Eric] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Garshick, Eric] Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02115 USA. RP Garshick, E (reprint author), VA Boston Healthcare Syst, Pulm & Crit Care Med Sect, 1400 VFW Pkwy,W Roxbury, Boston, MA 02132 USA. EM eric.garshick@va.gov OI Gagnon, David/0000-0002-6367-3179 FU NICHD NIH HHS [R01 HD042141-05, R01 HD42141, R01 HD042141] NR 50 TC 23 Z9 24 U1 0 U2 2 PU AMER THORACIC SOC PI NEW YORK PA 1740 BROADWAY, NEW YORK, NY 10019-4374 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD APR 1 PY 2008 VL 177 IS 7 BP 781 EP 786 DI 10.1164/rccm.200709-1332OC PG 6 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 282SI UT WOS:000254587100015 PM 18202346 ER PT J AU Llopis, E Cerezal, L Kassarjian, A Higueras, V Fernandez, E AF Llopis, Eva Cerezal, Luis Kassarjian, Ara Higueras, Victoria Fernandez, Ernesto TI Direct MR arthrography of the hip with leg traction: Feasibility for assessing articular cartilage SO AMERICAN JOURNAL OF ROENTGENOLOGY LA English DT Article DE cartilage; hip; MR arthrography; traction ID ARTHROSCOPY; JOINT AB OBJECTIVE. Hip arthrography is an accurate diagnostic method for evaluation of the peripheral compartment, but its depiction of cartilage lesions is moderate. The purpose of this study was to add leg traction to MR arthrography of the hip to test its effect on visualization of cartilage surfaces. CONCLUSION. Hip MR arthrography with leg traction is a technically feasible and safe procedure that improves visualization of the femoral and acetabular cartilage surfaces. C1 [Llopis, Eva; Higueras, Victoria] Hosp Ribera, Dept Radiol, Valencia 46600, Spain. [Cerezal, Luis] Clin Mompia, Inst Radiol Cantabro, Santander, Spain. [Kassarjian, Ara] Massachusetts Gen Hosp, Dept Radiol, Div Musculoskeletal Radiol, Boston, MA 02114 USA. [Fernandez, Ernesto] Hosp Ribera, Dept Orthoped, Valencia 46600, Spain. RP Llopis, E (reprint author), Hosp Ribera, Dept Radiol, Carretera Corbera Km 1, Valencia 46600, Spain. OI Cerezal, Luis/0000-0002-4934-0255 NR 17 TC 42 Z9 45 U1 0 U2 1 PU AMER ROENTGEN RAY SOC PI RESTON PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA SN 0361-803X J9 AM J ROENTGENOL JI Am. J. Roentgenol. PD APR PY 2008 VL 190 IS 4 BP 1124 EP 1128 DI 10.2214/AJR.07.2559 PG 5 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 278FU UT WOS:000254271100040 PM 18356464 ER PT J AU Park, DY Srivastava, A Kim, GH Mino-Kenudson, M Deshpande, V Zukerberg, LR Song, GA Lauwers, GY AF Park, Do Youn Srivastava, Amitabh Kim, Gwang Ha Mino-Kenudson, Mari Deshpande, Vikram Zukerberg, Lawrence R. Song, Geum Am Lauwers, Gregory Y. TI Adenomatous and foveolar gastric dysplasia: Distinct patterns of mucin expression and background intestinal metaplasia SO AMERICAN JOURNAL OF SURGICAL PATHOLOGY LA English DT Article; Proceedings Paper CT 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 24-30, 2007 CL San Diego, CA SP US & Canadian Acad Pathol DE stomach; dysplasia; mucin; intestinal metaplasia ID DIFFERENTIATED-TYPE ADENOCARCINOMAS; PHENOTYPIC MARKER EXPRESSION; PRECANCEROUS LESIONS; HUMAN STOMACH; FOLLOW-UP; NEOPLASIA; CELLS; CLASSIFICATION; CARCINOMA; CANCER AB Gastric epithelial dysplasia (GED) can be morphologically categorized into adenomatous (or intestinal) and foveolar (or gastric) types. Although limited genetic differences have been demonstrated between these subtypes, the expression of various mucins has not been systematically evaluated in this context. Endoscopic mucosal resections from 69 cases of GEDs were evaluated for the expression of MUC2, MUC5AC, MUC6, and CD10. The results were correlated with morphologic categorization and clinicopathologic parameters. GED was classified as adenomatous, foveolar, or hybrid (showing features of both types), on the basis of histologic evaluation. The neighboring intestinal metaplasia (IM) was also evaluated. An adenomatous morphology was seen in 45%, hybrid type in 33.3%, and a "pure" foveolar type was seen in 21.7% of the cases. Foveolar GED was often depressed/flat on endoscopy and showed a statistically significant association with high-grade morphology (P = 0.046). Immunohistochemistry confirmed the histologic stratification. The foveolar and hybrid types were more often positive for MUC5AC (P = 0.0001 for both) and negative for CD10 (P = 0.019 and 0.016, respectively) as compared with adenomatous GED. High-grade morphology was associated with MUC5AC expression regardless of the morphologic phenotype (P = 0.026). Foveolar (73.3%) and hybrid (86.9%) GEDs were associated more often with IM showing a retained expression of gastric type mucin than adenomatous GED (29%) (P < 0.01 for both). In contrast, adenomatous type (58.1%) of GED was significantly associated with IM showing a complete intestinal phenotype (CD10(+)) compared with the foveolar (13.3%) and hybrid types (17.4%) of GED (P = 0.005 for both comparisons). In conclusion, our study indicates that foveolar and adenomatous types of GED have distinct clinicopathologic features, mucin profiles, and association with different types of IM. C1 [Park, Do Youn; Mino-Kenudson, Mari; Deshpande, Vikram; Zukerberg, Lawrence R.; Lauwers, Gregory Y.] Massachusetts Gen Hosp, Dept Pathol, Gastrointestinal Pathol Serv, Boston, MA 02114 USA. [Srivastava, Amitabh] Dartmouth Hitchcock Med Ctr, Dept Pathol, Lebanon, NH 03766 USA. [Srivastava, Amitabh] Dartmouth Med Sch, Lebanon, NH USA. [Park, Do Youn] Pusan Natl Univ Hosp, Dept Pathol, Pusan, South Korea. [Kim, Gwang Ha; Song, Geum Am] Pusan Natl Univ Hosp, Dept Gastroenterol, Pusan, South Korea. [Kim, Gwang Ha; Song, Geum Am] Pusan Natl Univ, Med Res Inst, Pusan, South Korea. RP Lauwers, GY (reprint author), Massachusetts Gen Hosp, Dept Pathol, Gastrointestinal Pathol Serv, 55 Fruit St, Boston, MA 02114 USA. EM glauwers@partners.org RI Srivastava, Amitabh/A-9386-2009 NR 28 TC 37 Z9 38 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0147-5185 J9 AM J SURG PATHOL JI Am. J. Surg. Pathol. PD APR PY 2008 VL 32 IS 4 BP 524 EP 533 DI 10.1097/PAS.0b013e31815b890e PG 10 WC Pathology; Surgery SC Pathology; Surgery GA 282JD UT WOS:000254562800004 PM 18300795 ER PT J AU Tirabosco, R Mangham, DC Rosenberg, AE Vujovic, S Bousdras, K Pizzolitto, S De Maglio, G den Bakker, MA Di Francesco, L Kalil, RK Athanasou, NA O'Donnell, P McCarthy, EF Flanagan, AM AF Tirabosco, Roberto Mangham, D. Chas Rosenberg, Andrew E. Vujovic, Sonja Bousdras, Konstantinos Pizzolitto, Stefano De Maglio, Giovanna den Bakker, Michael A. Di Francesco, Lisa Kalil, Ricardo K. Athanasou, Nicholas A. O'Donnell, Paul McCarthy, Edward F. Flanagan, Adrienne M. TI Brachyury expression in extra-axial skeletal and soft tissue chordomas: A marker that distinguishes chordoma from mixed tumor/myoepithelioma/parachordoma in soft tissue SO AMERICAN JOURNAL OF SURGICAL PATHOLOGY LA English DT Article DE chordoma; extra-axial chordoma; brachyury; parachordoma; mixed tumor ID EXTRASKELETAL MYXOID CHONDROSARCOMA; MALIGNANT CHONDROID SYRINGOMA; NOTOCHORDAL CELL TUMORS; CLASSIC CHORDOMAS; AXIAL CHORDOMA; PARACHORDOMA; PERIPHERICUM; SECONDARY; DISTINCT; SARCOMA AB Axial chordoma represents approximately 1% of malignant bone tumors. This tumor expresses cytokeratins, specifically cytokeratin 19, and commonly S100. More recently brachyury, a transcription factor important in mesodermal differentiation, including notochord development, has been detected by immunohistochemistry in axial chordomas and hemangioblastomas but not chondrosarcomas or other neoplasms. In this report, we describe 10 cases (6 men, 4 women: age 18 to 68 y; mean 44.6) of extra-axial tumors, 8 in bone and 2 in soft tissue, with morphologic and immunohistochemical features identical to those of axial chordoma. Imaging excluded metastases from axial chordoma. Three tumors occurred in the tibia, the others in the rib, metatarsal, ulna, femur, pubis: 2 intracortical, 6 intramedullary. Both soft tissue brachyury-positive tumors, one involving the thumb the other the wrist, were sited in the juxta-articular region. Seven of the tumors were widely excised and these patients are disease-free but of the 3 tumors that recurred, I was curetted, I was marginally excised, and 1 had a pathologic fracture on presentation. Metastases have not occurred in any of the patients. We also confirm the expression of brachyury in hemangioblastomas, and for the first time demonstrates its expression in spermatogonia and testicular germ cell tumors by immunohistochemistry. Brachyury was not detected in a wide range of tumors including carcinomas, lymphomas.. and sarcomas. In conclusion, we describe the first series of extra-axial skeletal chordomas bringing the total number of such cases reported in the literature to 11, and present the first report of 2 soft tissue chordomas as defined by brachyury expression. C1 [Tirabosco, Roberto; Flanagan, Adrienne M.] UCL, Inst Orthopaed & Musculoskeletal Sci, Royal Natl Orthopaed Hosp, Dept Histopathol, Stanmore HA7 4LP, Middx, England. [O'Donnell, Paul] Royal Natl Orthopaed Hosp, Dept Radiol, Stanmore HA7 4LP, Middx, England. [Mangham, D. Chas] Royal Orthopaed Hosp, Dept Musculoskeletal Pathol, Birmingham, W Midlands, England. [Mangham, D. Chas] Robert Jones & Agnes Hunt Orthopaed Hosp, Oswestry SY10 7AG, Shrops, England. [Bousdras, Konstantinos; Flanagan, Adrienne M.] Univ Coll Hosp, Dept Histopathol, London, England. [Athanasou, Nicholas A.] Nuffield Orthopaed Ctr, Dept Histopathol, Oxford OX3 7LD, England. [Rosenberg, Andrew E.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, James Homer Wright Pathol Labs, Boston, MA USA. [McCarthy, Edward F.] Johns Hopkins Univ Hosp, Dept Pathol, Baltimore, MD 21287 USA. [Pizzolitto, Stefano; De Maglio, Giovanna] Osped S Maria Misericordia, Dept Anat Pathol, Udine, Italy. [den Bakker, Michael A.] Erasmus Univ, Dept Pathol, Med Ctr, NL-3000 DR Rotterdam, Netherlands. [Di Francesco, Lisa] Univ Calgary, Dept Pathol, Foothills Med Ctr, Calgary, AB, Canada. RP Flanagan, AM (reprint author), UCL, Inst Orthopaed & Musculoskeletal Sci, Royal Natl Orthopaed Hosp, Dept Histopathol, Stanmore HA7 4LP, Middx, England. EM a.flanagan@ucl.ac.uk NR 50 TC 93 Z9 94 U1 1 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0147-5185 J9 AM J SURG PATHOL JI Am. J. Surg. Pathol. PD APR PY 2008 VL 32 IS 4 BP 572 EP 580 PG 9 WC Pathology; Surgery SC Pathology; Surgery GA 282JD UT WOS:000254562800010 PM 18301055 ER PT J AU Irving, JA Young, RH AF Irving, Julie A. Young, Robert H. TI Granulosa cell tumors of the ovary with a pseudopapillary pattern: A study of 14 cases of an unusual morphologic variant emphasizing their distinction from transitional cell neoplasms and other papillary ovarian tumors SO AMERICAN JOURNAL OF SURGICAL PATHOLOGY LA English DT Article DE ovary; neoplasm; granulosa cell tumor; papillary pattern ID EPITHELIAL MEMBRANE ANTIGEN; CORD STROMAL TUMORS; DIFFERENTIAL-DIAGNOSIS; CLINICOPATHOLOGICAL ANALYSIS; CARCINOMAS; IMMUNOHISTOCHEMISTRY AB Granulosa cell tumors of the ovary with a pseudopapillary pattern have received only passing mention in the literature. We have reviewed the clinicopathologic features of 10 cases Of juvenile granulosa cell tumor and 4 cases of adult granulosa cell tumor with a pseudopapillary pattern. Twelve cases were received in consultation; the referring pathologist favored a diagnosis of a transitional cell neoplasm in 3 of these cases, and a retiform Sertoli-Leydig cell tumor in 2 cases; in most of the remainder, the diagnosis of granulosa cell tumor was considered but uncertainty expressed because of the unusual papillarylike pattern. All 14 tumors were unilateral, and the majority were predominantly cystic, 3 unilocular, and 6 multilocular. Multiple papillary projections lining the cyst wall were noted grossly in 10 cases; these ranged in size from 0.1 to 1.5 cm and were typically soft, edematous, fleshy, or rubbery. Microscopically, pseudopapillae were formed by intracystic cellular projections with surrounding necrotic debris and/or undulating folds of neoplastic cells in the absence of appreciable necrosis. In all tumors, thorough sampling revealed areas with architectural patterns and cytomorphology typical of granulosa cell tumor. Granulosa cell tumors of adult and juvenile type may have a pseudopapillary pattern that can be confused with other ovarian tumors with a papillary architecture. Identification of areas that are more characteristic of granulosa cell tumor resolves most cases, although immunohistochemistry can be used in more problematic tumors. This phenomenon seems to be related to the cystic change that is a feature of many granulosa cell tumors. C1 [Irving, Julie A.] Royal Jubilee Hosp, Dept Lab Med, Victoria, BC V8R 1J8, Canada. [Irving, Julie A.] Royal Jubilee Hosp, Dept Pathol, Victoria, BC V8R 1J8, Canada. [Irving, Julie A.] Royal Jubilee Hosp, Dept Med Genet, Victoria, BC V8R 1J8, Canada. [Irving, Julie A.] Univ British Columbia, Dept Pathol, Vancouver, BC, Canada. [Young, Robert H.] Massachusetts Gen Hosp, James Homer Wright Pathol Labs, Boston, MA 02114 USA. [Young, Robert H.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. RP Irving, JA (reprint author), Royal Jubilee Hosp, Dept Lab Med, 1952 Bay St, Victoria, BC V8R 1J8, Canada. EM Julie.Irving@viha.ca NR 19 TC 13 Z9 17 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0147-5185 J9 AM J SURG PATHOL JI Am. J. Surg. Pathol. PD APR PY 2008 VL 32 IS 4 BP 581 EP 586 DI 10.1097/PAS.0b013e31815c186f PG 6 WC Pathology; Surgery SC Pathology; Surgery GA 282JD UT WOS:000254562800011 PM 18301054 ER PT J AU Pomfret, EA Sung, RS Allan, J Kinkhabwala, M Melancon, JK Roberts, JP AF Pomfret, E. A. Sung, R. S. Allan, J. Kinkhabwala, M. Melancon, J. K. Roberts, J. P. TI Solving the organ shortage crisis: The 7th Annual American Society of Transplant Surgeons' State-of-the-Art Winter Symposium SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Editorial Material DE access to transplantation; deceased donor kidneys; deceased donor organs; donor/recipient matching; ethics; expanded criteria donors; live donor transplantation; organ donation; organ sales; organ shortage ID DONOR LIVER-TRANSPLANTATION; ANTIBODY-POSITIVE DONORS; LIVING KIDNEY SALES; SAFETY; IMPACT; DONATION; CRITERIA; SYSTEM; COST; RISK AB The 2007 American Society of Transplant Surgeons' (ASTS) State-of-the-Art Winter Symposium entitled, 'Solving the Organ Shortage Crisis' explored ways to increase the supply of donor organs to meet the challenge of increasing waiting lists and deaths while awaiting transplantation. While the increasing use of organs previously considered marginal, such as those from expanded criteria donors (ECD) or donors after cardiac death (DCD) has increased the number of transplants from deceased donors, these transplants are often associated with inferior outcomes and higher costs. The need remains for innovative ways to increase both deceased and living donor transplants. In addition to increasing ECD and DCD utilization, increasing use of deceased donors with certain types of infections such as Hepatitis B and C, and increasing use of living donor liver, lung and intestinal transplants may also augment the organ supply. The extent by which donors may be offered incentives for donation, and the practical, ethical and legal implications of compensating organ donors were also debated. The expanded use of nonstandard organs raises potential ethical considerations about appropriate recipient selection, informed consent and concerns that the current regulatory environment discourages and penalizes these efforts. C1 [Pomfret, E. A.] Lahey Clin Med Ctr, Div Liver Transplantat & Hepatobiliary Surg, Burlington, MA 01803 USA. [Sung, R. S.] Univ Michigan, Ctr Hlth, Div Transplant Surg, Ann Arbor, MI 48109 USA. [Allan, J.] Massachusetts Gen Hosp, Dept Surg, Div Thorac Surg, Boston, MA 02114 USA. [Kinkhabwala, M.] Montefiore Med Ctr, Div Transplantat, Bronx, NY 10467 USA. [Melancon, J. K.] Johns Hopkins Med Inst, Div Transplant Surg, Baltimore, MD 21205 USA. [Roberts, J. P.] Univ Calif San Francisco, Dept Surg, Div Transplantat, San Francisco, CA 94143 USA. RP Pomfret, EA (reprint author), Lahey Clin Med Ctr, Div Liver Transplantat & Hepatobiliary Surg, Burlington, MA 01803 USA. EM Elizabeth.A.Pomfret@Lahey.org NR 37 TC 65 Z9 67 U1 0 U2 5 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD APR PY 2008 VL 8 IS 4 BP 745 EP 752 DI 10.1111/j.1600-6143.2007.02146.x PG 8 WC Surgery; Transplantation SC Surgery; Transplantation GA 270YW UT WOS:000253757100006 PM 18261169 ER PT J AU Solez, K Colvin, RB Racusen, LC Haas, M Sis, B Mengeld, M Halloran, PF Baldwin, W Banfi, G Collins, AB Cosio, F David, DSR Drachenberg, C Einecke, G Fogo, AB Gibson, IW Glotz, D Iskandar, SS Kraus, E Lerut, E Mannon, RB Mihatsch, M Nankivell, BJ Nickeleit, V Papadimitriou, JC Randhawa, P Regele, H Renaudin, K Roberts, I Seron, D Smith, RN Valente, M AF Solez, K. Colvin, R. B. Racusen, L. C. Haas, M. Sis, B. Mengeld, M. Halloran, P. F. Baldwin, W. Banfi, G. Collins, A. B. Cosio, F. David, D. S. R. Drachenberg, C. Einecke, G. Fogo, A. B. Gibson, I. W. Glotz, D. Iskandar, S. S. Kraus, E. Lerut, E. Mannon, R. B. Mihatsch, M. Nankivell, B. J. Nickeleit, V. Papadimitriou, J. C. Randhawa, P. Regele, H. Renaudin, K. Roberts, I. Seron, D. Smith, R. N. Valente, M. TI Banff 07 classification of renal allograft pathology: Updates and future directions SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Editorial Material DE acute allograft rejection; acute cellular rejection; acute rejection; allograft rejection; antibody-mediated rejection; Banff; Banff lesions; Banff schema; classification; chronic allograft nephropathy; chronic allograft rejection; genomic markers; GeneChip ID ANTIBODY-MEDIATED REJECTION; CAPILLARY C4D DEPOSITION; POSITIVE CROSS-MATCH; PROTOCOL BIOPSIES; KIDNEY ALLOGRAFTS; HISTOLOGIC-FINDINGS; PERITUBULAR CAPILLARIES; SUBCLINICAL REJECTION; RISK-FACTOR; TRANSPLANTATION AB The 9th Banff Conference on Allograft Pathology was held in La Coruna, Spain on June 23-29, 2007. A total of 235 pathologists, clinicians and scientists met to address unsolved issues in transplantation and adapt the Banff schema for renal allograft rejection in response to emerging data and technologies. The outcome of the consensus discussions on renal pathology is provided in this article. Major updates from the 2007 Banff Conference were: inclusion of peritubular capillaritis grading, C4d scoring, interpretation of C4d deposition without morphological evidence of active rejection, application of the Banff criteria to zero-time and protocol biopsies and introduction of a new scoring for total interstitial inflammation (ti-score). In addition, emerging research data led to the establishment of collaborative working groups addressing issues like isolated 'v' lesion and incorporation of omics-technologies, paving the way for future combination of graft biopsy and molecular parameters within the Banff process. C1 [Solez, K.; Sis, B.] Univ Alberta, Dept Lab Med & Pathol, Edmonton, AB, Canada. [Colvin, R. B.; Collins, A. B.; Smith, R. N.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Colvin, R. B.; Collins, A. B.; Smith, R. N.] Harvard Univ, Sch Med, Dept Pathol, Cambridge, MA 02138 USA. [Racusen, L. C.; Haas, M.; Baldwin, W.] Johns Hopkins Univ, Dept Pathol, Baltimore, MD USA. [Sis, B.; Mengeld, M.; Halloran, P. F.; Einecke, G.] Univ Alberta, Dept Med, Div Nephrol & Immunol, Alberta Transplant Appl Genom Ctr, Edmonton, AB, Canada. [Banfi, G.] IRCCS, Fdn Osped Maggiore, Div Nephrol, Milan, Italy. [Cosio, F.] Mayo Clin & Mayo Fdn, Div Nephrol & Hypertens, Rochester, MN 55905 USA. [David, D. S. R.] Univ Sao Paulo, Div Pathol, BR-05508 Sao Paulo, Brazil. [David, D. S. R.] Univ Sao Paulo, Renal Transplant Unit, BR-05508 Sao Paulo, Brazil. [Drachenberg, C.] Univ Maryland, Dept Pathol, Baltimore, MD 21201 USA. [Fogo, A. B.] Vanderbilt Univ, Sch Med, Dept Pathol, Nashville, TN 37212 USA. [Gibson, I. W.] Univ Manitoba, Dept Pathol, Winnipeg, MB R3T 2N2, Canada. [Glotz, D.] Hosp St Louis, Dept Nephrol, Paris, France. [Iskandar, S. S.] Wake Forest Univ, Bowman Gray Sch Med, Dept Pathol, Winston Salem, NC 27103 USA. [Kraus, E.] Johns Hopkins Univ, Dept Nephrol, Baltimore, MD USA. [Lerut, E.] Univ Hosp Leuven, Dept Morphol & Mol Pathol, Louvain, Belgium. [Mannon, R. B.] Natl Inst Digest & Kidney Dis, NIH, Transplantat Branch, Bethesda, MD USA. [Mihatsch, M.] Univ Basel, Inst Pathol, Basel, Switzerland. [Nankivell, B. J.] Westmead Hosp, Ctr Transplant Res & Renal Res, Sydney, NSW, Australia. [Nickeleit, V.] Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC USA. [Randhawa, P.] Univ Pittsburgh, Dept Pathol, Div Transplantat Pathol, Pittsburgh, PA USA. [Regele, H.] Univ Vienna, Inst Pathol, A-1010 Vienna, Austria. [Renaudin, K.] CHU Hotel Dieu, Dept Pathol, Nantes, France. [Roberts, I.] John Radcliffe Hosp, Dept Cellular Pathol, Oxford OX3 9DU, England. [Seron, D.] Univ Bellvitge, Dept Nephrol, Barcelona, Spain. [Valente, M.] Univ Padua, Dept Med Diag Sci, Padua, Italy. RP Solez, K (reprint author), Univ Alberta, Dept Lab Med & Pathol, Edmonton, AB, Canada. EM Kim.Solez@ualberta.ca RI Glotz, Denis/F-7881-2011; David, Daisa/G-6272-2012; Halloran, Philip/J-1390-2012; OI Halloran, Philip/0000-0003-1371-1947; Valente, Marialuisa/0000-0002-3662-2878 NR 40 TC 1039 Z9 1108 U1 4 U2 28 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD APR PY 2008 VL 8 IS 4 BP 753 EP 760 DI 10.1111/j.1600-6143.2008.02159.x PG 8 WC Surgery; Transplantation SC Surgery; Transplantation GA 270YW UT WOS:000253757100007 PM 18294345 ER PT J AU Sung, RS Christensen, LL Leichtman, AB Greenstein, SM Distant, DA Wynn, JJ Stegall, MD Delmonico, FL Port, FK AF Sung, R. S. Christensen, L. L. Leichtman, A. B. Greenstein, S. M. Distant, D. A. Wynn, J. J. Stegall, M. D. Delmonico, F. L. Port, F. K. TI Scientific registry of transplant recipients SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Article DE biopsy; delayed graft function; discard rates; expanded criteria donors; glomerulosclerosis; graft failure; machine perfusion ID EXPANDED CRITERIA DONOR; PULSATILE MACHINE PERFUSION; RENAL-TRANSPLANTATION; GRAFT-SURVIVAL; KIDNEYS; PRESERVATION; GLOMERULOSCLEROSIS; PROCUREMENT; BIOPSY AB We examined factors associated with expanded criteria donor (ECD) kidney discard. Scientific Registry of Transplant Recipients (SRTR)/Organ Procurement and Transplantation Network (OPTN) data were examined for donor factors using logistic regression to determine the adjusted odds ratio (AOR) of discard of kidneys recovered between October 1999 and June 2005. Logistic and Cox regression models were used to determine associations with delayed graft function (DGF) and graft failure. Of the 12 536 recovered ECD kidneys, 5139 (41%) were discarded. Both the performance of a biopsy (AOR = 1.21, p = 0.02) and the degree of glomerulosclerosis (GS) on biopsy were significantly associated with increased odds of discard. GS was not consistently associated with DGF or graft failure. The discard rate of pumped ECD kidneys was 29.7% versus 43.6% for unpumped (AOR = 0.52, p < 0.0001). Among pumped kidneys, those with resistances of 0.26-0.38 and > 0.38 mmHg/mL/min were discarded more than those with resistances of 0.18-0.25 mmHg/mL/min (AOR = 2.5 and 7.9, respectively). Among ECD kidneys, pumped kidneys were less likely to have DGF (AOR = 0.59, p < 0.0001) but not graft failure (RR = 0.9, p = 0.27). Biopsy findings and machine perfusion are important correlates of ECD kidney discard; corresponding associations with graft failure require further study. C1 [Sung, R. S.] Univ Michigan, Div Transplantat, Dept Surg, Sci Reg Transplant Recipients, Ann Arbor, MI 48109 USA. [Christensen, L. L.; Port, F. K.] Arbor Res Collaborat Hlth, Sci Reg Transplant Recipients, Ann Arbor, MI USA. [Leichtman, A. B.] Univ Michigan Hlth Syst, Dept Med, Div Nephrol, Sci Reg Transplant Recipients, Ann Arbor, MI USA. [Greenstein, S. M.] Albert Einstein Coll Med, Dept Surg, Bronx, NY 10467 USA. [Distant, D. A.] Sunnybrook Hlth Sci Ctr, Dept Surg, Brooklyn, NY USA. [Wynn, J. J.] Med Coll Georgia, Dept Surg, Augusta, GA 30912 USA. [Stegall, M. D.] Mayo Clin, Dept Surg, Rochester, MN USA. [Delmonico, F. L.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. RP Sung, RS (reprint author), Univ Michigan, Div Transplantat, Dept Surg, Sci Reg Transplant Recipients, Ann Arbor, MI 48109 USA. EM rssung@umich.edu FU PHS HHS [234-2005-37009C] NR 18 TC 115 Z9 120 U1 0 U2 1 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD APR PY 2008 VL 8 IS 4 BP 783 EP 792 DI 10.1111/j.1600-6143.2008.02157.x PG 10 WC Surgery; Transplantation SC Surgery; Transplantation GA 270YW UT WOS:000253757100010 PM 18294347 ER PT J AU Velmahos, GC Spaniolas, K Tabbara, M Duggan, M Li, YQ de Moya, M Alam, HB AF Velmahos, George C. Spaniolas, Konstantinos Tabbara, Malek Duggan, Michael Li, Yongqing de Moya, Marc Alam, Hasan B. TI Abdominal insufflation decreases blood loss without worsening the inflammatory response: Implications for prehospital control of internal bleeding SO AMERICAN SURGEON LA English DT Article ID INJURY AB Abdominal insufflation (AI) by carbon dioxide has been shown to decrease the rate of bleeding in different swine models of abdominal organ injuries. With development of appropriate tools, AI could be used to control bleeding temporarily in the prehospital setting. Concerns have been raised about the inflammatory response to AI, which could damage organs at a later stage despite initial hemostasis. We hypothesized that AI controls bleeding without inducing an unfavorable inflammatory response. An experimental splenic injury was caused in 28 Yorkshire pigs, which were randomized to: 1) standard resuscitation (n = 14) with crystalloids to a mean arterial pressure of 60 mm Hg, or 2) standard resuscitation and AI (n = 14) to an abdominal pressure of 20 cmH(2)O. The experiment lasted for 30 minutes, and intra-abdominal blood loss was measured. Blood serum interleukin 1 beta (IL-1 beta), transforming growth factor beta 1, and lung tissue heat shock protein 70 gene expression were measured at 0, 15, and 30 minutes, as markers of the inflammatory response. All animals survived to the end of the experiment. Total blood loss was significantly less in the AI group compared with the other standard resuscitation animals (733 76 vs 1094 153 mL, P = 0.049). The pH at the end of the experiment was significantly lower in the AI group (7.28 +/- 0.02 vs 7.44 +/- 0.05, P < 0.01) but there was no difference in lactate levels (1.5 +/- 0.4 vs 1.7 +/- 0.3, P = 0.7). Similarly, there was no difference in IL-1 beta, transforming growth factor beta 1, or lung tissue heat shock protein 70 gene expression between the two groups at any time point, although there was a trend towards lower IL-1 beta levels in the AI group. Our conclusion is that AI reduces blood loss from splenic injury without a measurable effect on the early inflammatory response in a clinically relevant animal model. C1 Massachusetts Gen Hosp, Div Trauma Emergency Surg & Surg Crit Care, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. RP Velmahos, GC (reprint author), 165 Cambridge St,Suite 810, Boston, MA 02114 USA. EM gvelmahos@partners.org NR 12 TC 7 Z9 9 U1 0 U2 0 PU SOUTHEASTERN SURGICAL CONGRESS PI ATLANTA PA 141 WEST WIEUCA RD, STE B100, ATLANTA, GA 30342 USA SN 0003-1348 J9 AM SURGEON JI Am. Surg. PD APR PY 2008 VL 74 IS 4 BP 297 EP 301 PG 5 WC Surgery SC Surgery GA 282CA UT WOS:000254544000003 PM 18453291 ER PT J AU Meininger, V Shefner, J Cudkowicz, M AF Meininger, Vincent Shefner, Jeremy Cudkowicz, Merit TI Lithium therapy in ALS SO AMYOTROPHIC LATERAL SCLEROSIS LA English DT Editorial Material C1 [Cudkowicz, Merit] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Charlestown, MA 02129 USA. [Meininger, Vincent] Grp Hosp Pitie Salpetriere, Ctr Maladies Rares SLA APHP, F-75634 Paris, France. [Shefner, Jeremy] SUNY Upstate Med Univ, Syracuse, NY USA. RP Cudkowicz, M (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, 149 13th St, Charlestown, MA 02129 USA. EM MCUDKOWICZ@PARTNERS.ORG OI meininger, vincent/0000-0002-6180-7970 FU NINDS NIH HHS [R01 NS049640] NR 0 TC 10 Z9 10 U1 0 U2 2 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1748-2968 J9 AMYOTROPH LATERAL SC JI Amyotroph. Lateral. Scler. PD APR PY 2008 VL 9 IS 2 BP 122 EP 122 DI 10.1080/17482960802028247 PG 1 WC Clinical Neurology SC Neurosciences & Neurology GA 303RC UT WOS:000256057200009 PM 18428005 ER PT J AU Volpato, GP Searles, R Yu, B Scherrer-Crosbie, M Bloch, KD Ichinose, F Zapol, WM AF Volpato, Gian Paolo Searles, Robert Yu, Binglan Scherrer-Crosbie, Marielle Bloch, Kenneth D. Ichinose, Furnito Zapol, Warren M. TI Inhaled hydrogen sufide - A rapidly reversible inhibitor of cardiac and metabolic function in the mouse SO ANESTHESIOLOGY LA English DT Article ID ANIMATION-LIKE STATE; NITRIC-OXIDE; SULFIDE; TEMPERATURE; MECHANISMS; H2S; RESPONSES; BRAIN; RATS; MICE AB Background: Breathing hydrogen sulfide (H2S) has been reported to induce a suspended animation-like state with hypothermia and a concomitant metabolic reduction in rodents. However, the impact of H,S breathing on cardiovascular function remains incompletely understood. In this study, the authors investigated the cardiovascular and metabolic effects of inhaled H2S in a murine model. Methods: The impact of breathing H2S on cardiovascular function was examined using telemetry and echocardiography in awake mice. The effects of breathing H2S on carbon dioxide production and oxygen consumption were measured at room temperature and in a warmed environment. Results: Breathing H2S at 80 parts per million by volume at 27 degrees C ambient temperature for 6 h markedly reduced heart rate, core body temperature, respiratory rate, and physical activity, whereas blood pressure remained unchanged. Echocardiography demonstrated that H2S exposure decreased both heart rate and cardiac output but preserved stroke volume. Breathing H2S for 6 h at 35 degrees C ambient temperature (to prevent hypothermia) decreased heart rate, physical activity, respiratory rate, and cardiac output without altering stroke volume or body temperature. H2S breathing seems to induce bradycardia by depressing sinus node activity. Breathing H2S for 30 min decreased whole body oxygen consumption and carbon dioxide production at either 27 degrees or 35 degrees C ambient temperature. Both parameters returned to baseline levels within 10 min after the cessation of H2S breathing. Conclusions: Inhalation of H2S at either 27 degrees or 35 degrees C reversibly depresses cardiovascular function without changing blood pressure in mice. Breathing H2S also induces a rapidly reversible reduction of metabolic rate at either body temperature. C1 [Searles, Robert; Bloch, Kenneth D.; Ichinose, Furnito; Zapol, Warren M.] Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Anesthesia Ctr Crit Care Res, Boston, MA 02114 USA. [Scherrer-Crosbie, Marielle] Massachusetts Gen Hosp, Dept Med, Cardiac Ultrasound Lab, Div Cardiol, Boston, MA 02114 USA. RP Zapol, WM (reprint author), Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Anesthesia Ctr Crit Care Res, 55 Fruit St,GRB 444F, Boston, MA 02114 USA. EM wzapol@partners.org FU NHLBI NIH HHS [HL-42397, R01 HL042397, R01 HL042397-18]; NIGMS NIH HHS [GM-79360, R01 GM079360] NR 28 TC 68 Z9 72 U1 0 U2 10 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0003-3022 J9 ANESTHESIOLOGY JI Anesthesiology PD APR PY 2008 VL 108 IS 4 BP 659 EP 668 PG 10 WC Anesthesiology SC Anesthesiology GA 281AE UT WOS:000254467500017 PM 18362598 ER PT J AU Hakeem, A Bhatti, S Williams, EM Biring, T Kosolcharoen, P Chang, SM AF Hakeem, Abdul Bhatti, Sabha Williams, Eric M. Biring, Timinder Kosolcharoen, Peter Chang, Su Min TI Coronary steal due to bilateral internal mammary artery-pulmonary artery fistulas: A rare cause of chest pain after coronary artery bypass grafting SO ANGIOLOGY LA English DT Article DE IMA-PA fistula; CABG; coronary steal ID LUNG PARENCHYMA FISTULA; RECURRENT ANGINA; ARTERIOVENOUS-FISTULA; VASCULATURE AB A 54-year-old man with a history of coronary artery bypass grafting (CABG) presented with chest pain and was found to have non-ST-segment elevation myocardial infarction. Left heart catheterization with coronary angiography demonstrated 100% occlusion of the right internal mammary artery (IMA) to the right coronary artery graft in its midsegment and a patent left IMA to the left anterior descending graft. An unusually large extensive fistulous collateral formation was observed between the right IMA and the left IMA to the pulmonary arterial system, causing left to right shunting. His angina was attributed to substantial coronary steal caused by the shunt. The patient refused any further intervention or surgery and opted for medical treatment. As a complication of CABG, IMA to pulmonary artery (PA) fistulas are rare. Thus far, more than 20 cases have been reported; most have been unilateral. This is the second reported case to date of bilateral IMA-PA fistula formation after CABG. An IMA-PA fistula should be considered in the differential diagnosis of patients presenting with chest pain after CABG and can be diagnosed by selective angiography of IMA grafts. C1 Univ Wisconsin, Hosp & Clin, Dept Cardiovasc Med, Madison, WI 53705 USA. William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. RP Hakeem, A (reprint author), Univ Wisconsin, Hosp & Clin, Dept Cardiovasc Med, 2705 Univ Ave,11, Madison, WI 53705 USA. EM a.hakeem@hosp.wisc.edu NR 22 TC 5 Z9 5 U1 0 U2 0 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0003-3197 J9 ANGIOLOGY JI Angiology PD APR-MAY PY 2008 VL 59 IS 2 BP 244 EP 247 DI 10.1177/0003319707304880 PG 4 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 290QL UT WOS:000255137200018 PM 18403464 ER PT J AU Banerji, A Clark, S Blanda, M LoVecchio, F Snyder, B Camargo, CA AF Banerji, Aleena Clark, Sunday Blanda, Michelle LoVecchio, Frank Snyder, Brian Camargo, Carlos A., Jr. TI Multicenter study of patients with angiotensin-converting enzyme inhibitor-induced angioedema who present to the emergency department SO ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY LA English DT Article ID ACE-INHIBITOR; RECEPTOR BLOCKERS; BRADYKININ; EDEMA; PREVENTION; EXPERIENCE; MANAGEMENT; ENALAPRIL; AMERICANS; ETHNICITY AB Background: Recent data are lacking about the number of patients with angiotensin-converting enzyme inhibitor (ACEI)-induced angioedema who present to the emergency department (ED). Current management of the condition and clinical outcomes also are not known. Objective: To describe the clinical epidemiology of ACEI-induced angioedema in patients who present to the ED. Methods: We performed a medical record review of ACEI-induced angioederna in patients who presented to 5 EDs in the Emergency Medicine Network. A structured data abstraction form was used to collect each patient's demographic factors, medical history, and details about the angioedema that prompted the ED visit. The medical record review also focused on treatment provided in the ED and subsequent need for hospitalization. Results: We identified a total of 220 patients with ACEI-induced angioedema. The frequency of ACEI-induced angioedema among all patients with angioedema who presented to the ED was 30% (95% confidence interval, 26%-34%). The annual rate of visits for ACEI-induced angioedema was 0.7 per 10,000 ED visits. The most frequent presenting signs were shortness of breath, lip and tongue swelling, and laryngeal edema. Most patients (58%) were sent home directly from the ED, whereas 12% were regular inpatient admissions, 11% were admitted to the intensive care unit, and 18% were admitted under observation status (<24 hours). Pharyngeal swelling and respiratory distress were independent predictors of hospital admission and longer length of stay. Conclusion: ACEI-induced angioedema accounted for almost one-third of angioedema treated in the ED, although it remains a rare ED presentation. A subgroup of these patients still needs inpatient hospitalization for management of upper airway angioedema. C1 [Banerji, Aleena] Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02114 USA. [Clark, Sunday] New York Presbyterian Hosp, Dept Emergency Med, New York, NY USA. [Blanda, Michelle] Summa Hlth Syst, Dept Emergency Med, Akron, OH USA. [LoVecchio, Frank] Maricopa Cty Gen Hosp, Dept Emergency Med, Phoenix, AZ USA. [Snyder, Brian] Univ Calif San Diego, Med Ctr, Dept Emergency Med, San Diego, CA 92103 USA. [Camargo, Carlos A., Jr.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA. RP Banerji, A (reprint author), Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, Cox 201,100 Blossom St, Boston, MA 02114 USA. EM abanerji@partners.org NR 34 TC 86 Z9 87 U1 0 U2 1 PU AMER COLL ALLERGY ASTHMA IMMUNOLOGY PI ARLINGTON HTS PA 85 WEST ALGONQUIN RD SUITE 550, ARLINGTON HTS, IL 60005 USA SN 1081-1206 J9 ANN ALLERG ASTHMA IM JI Ann. Allergy Asthma Immunol. PD APR PY 2008 VL 100 IS 4 BP 327 EP 332 PG 6 WC Allergy; Immunology SC Allergy; Immunology GA 284LB UT WOS:000254706800007 PM 18450117 ER PT J AU Munn, LL Dupin, MM AF Munn, Lance L. Dupin, Michael M. TI Blood cell interactions and segregation in flow SO ANNALS OF BIOMEDICAL ENGINEERING LA English DT Article DE blood flow; leukocyte; erythrocyte; segregation; lattice boltzmann; microfluidics; margination; aggregation ID LATTICE BOLTZMANN ANALYSIS; ERYTHROCYTE AGGREGATION; ENDOTHELIAL-CELLS; TUBE FLOW; POSTCAPILLARY EXPANSIONS; LEUKOCYTE MARGINATION; GENE-EXPRESSION; AXIAL MIGRATION; POISEUILLE FLOW; SHEAR-STRESS AB For more than a century, pioneering researchers have been using novel experimental and computational approaches to probe the mysteries of blood flow. Thanks to their efforts, we know that blood cells generally prefer to migrate to the axis of flow, that red and white cells segregate in flow, and that cell deformability and their tendency to reversibly aggregate contribute to the non-Newtonian nature of this unique fluid. All of these properties have beneficial physiological consequences, allowing blood to perform a variety of critical functions. Our current understanding of these unusual flow properties of blood have been made possible by the ingenuity and diligence of a number of researchers, including Harry Goldsmith, who developed novel technologies to visualize and quantify the flow of blood at the level of individual cells. Here we summarize efforts in our lab to continue this tradition and to further our understanding of how blood cells interact with each other and with the blood vessel wall. C1 [Munn, Lance L.; Dupin, Michael M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiat Oncol,EL Steele Lab, Boston, MA 02114 USA. RP Munn, LL (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiat Oncol,EL Steele Lab, 100 Blossom St,COX 7, Boston, MA 02114 USA. EM munn@steele.mgh.harvard.edu RI Munn, Lance/L-3950-2016 OI Munn, Lance/0000-0003-0698-7232 FU NCI NIH HHS [R21 CA126761, R21 CA126761-01, R21 CA126761-02]; NHLBI NIH HHS [R01 HL064240, R01 HL064240-08, R01HL64240] NR 73 TC 48 Z9 48 U1 2 U2 36 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0090-6964 J9 ANN BIOMED ENG JI Ann. Biomed. Eng. PD APR PY 2008 VL 36 IS 4 BP 534 EP 544 DI 10.1007/s10439-007-9429-0 PG 11 WC Engineering, Biomedical SC Engineering GA 276XC UT WOS:000254176000004 PM 18188702 ER PT J AU Davis, MA Landesman, R Tadmor, B Hopmeier, M Shenhar, G Barker, T Pozner, CN Binstadt, ES Nelson, S Look, R Shubina, M Walls, RM AF Davis, Mark A. Landesman, Roxanne Tadmor, Boaz Hopmeier, Michael Shenhar, Gill Barker, Tobias Pozner, Charles N. Binstadt, Emily S. Nelson, Stephen Look, Rodney Shubina, Maria Walls, Ron M. TI Initial test of emergency procedure performance in temporary negative pressure isolation by using simulation technologies SO ANNALS OF EMERGENCY MEDICINE LA English DT Article ID HAND ANTISEPSIS; GUIDELINE; FILTRATION AB Study objective: The potential of infectious disease spread in diseases such as tuberculosis, infectious disease epidemic such as avian flu and the threat of terrorism with agents capable of airborne transmission have focused attention on the need for increased surge capacity for patient isolation. Total negative pressure isolation using portable bioisolation tents may provide a solution. The study assesses the ability of health care workers to perform emergency procedures in this environment. Methods: Physician performance in completing predetermined critical actions in 5 emergency care scenarios inside and outside of a bioisolation tent ("setting") was studied in an advanced medical simulation laboratory. By design, no pretraining of subjects about total negative pressure isolation use occurred. Impact of setting on time to completion of predetermined critical actions was the primary outcome measured. Secondary variables studied included impact of study groups, scenarios, and run order (inside or outside of the tent first). Subjective assessments were obtained through questionnaires. Results: Four teams of 3 physicians completed 5 emergency patient care scenarios during 2 4-hour sessions. Mean time to completion of critical actions was for tent/no tent 298 seconds/284 seconds (P=.69, one way ANOVA), respectively. Mean time to completion for first versus second performance of a scenario in the crossover design was 338 versus 243 (P=.01). The mean score for self-assessed performance did not differ according to setting. Conclusion: The ability of physicians naive to the total negative pressure isolation environment to perform emergency medical critical actions was not significantly degraded by a simulated bioisolation tent patient care environment. C1 [Davis, Mark A.; Landesman, Roxanne; Walls, Ron M.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Emergency Med,Inst Int Emergency Med & Hlth, Boston, MA 02115 USA. [Barker, Tobias; Pozner, Charles N.; Binstadt, Emily S.; Nelson, Stephen; Walls, Ron M.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Emergency Med,STRATUS Ctr Med Similat, Boston, MA USA. [Look, Rodney; Walls, Ron M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Look, Rodney; Walls, Ron M.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. [Shubina, Maria] Brigham & Womens Hosp, Ctr Clin Invest, Boston, MA 02115 USA. RP Davis, MA (reprint author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Emergency Med,Inst Int Emergency Med & Hlth, Boston, MA 02115 USA. NR 18 TC 1 Z9 1 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-0644 J9 ANN EMERG MED JI Ann. Emerg. Med. PD APR PY 2008 VL 51 IS 4 BP 420 EP 425 DI 10.1016/j.annemergmed.2007.04.017 PG 6 WC Emergency Medicine SC Emergency Medicine GA 283PG UT WOS:000254648000013 PM 17719690 ER PT J AU Levine, AC Marsh, R Nelson, S Chapman, J Burke, TF AF Levine, A. C. Marsh, R. Nelson, S. Chapman, J. Burke, T. F. TI Measuring access to emergency obstetric care in rural Zambia SO ANNALS OF EMERGENCY MEDICINE LA English DT Meeting Abstract CT 12th International Conference on Emergency Medicine CY APR 03-04, 2008 CL San Francisco, CA C1 Harvard Univ, Brigham & Womens Hosp, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-0644 J9 ANN EMERG MED JI Ann. Emerg. Med. PD APR PY 2008 VL 51 IS 4 MA 19 BP 477 EP 477 DI 10.1016/j.annemergmed.2008.01.287 PG 1 WC Emergency Medicine SC Emergency Medicine GA 283PG UT WOS:000254648000043 ER PT J AU Herring, AA McNamara, M Ortiz, P AF Herring, A. A. McNamara, M. Ortiz, P. TI Emergency medicine and surveillance of emerging populations: The case of migrant Ngwabe in Costa Rica SO ANNALS OF EMERGENCY MEDICINE LA English DT Meeting Abstract CT 12th International Conference on Emergency Medicine CY APR 03-04, 2008 CL San Francisco, CA C1 Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Caja Costarricense Seguro Social, San Vito, Costa Rica. NR 0 TC 0 Z9 0 U1 0 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-0644 J9 ANN EMERG MED JI Ann. Emerg. Med. PD APR PY 2008 VL 51 IS 4 MA 294 BP 559 EP 560 DI 10.1016/j.annemergmed.2008.01.265 PG 2 WC Emergency Medicine SC Emergency Medicine GA 283PG UT WOS:000254648000316 ER PT J AU Kestenbaum, B Rudser, KD de Boer, IH Peralta, CA Fried, LF Shlipak, MG Palmas, W Stehman-Breen, C Siscovick, DS AF Kestenbaum, Bryan Rudser, Kyle D. de Boer, Ian H. Peralta, Carmen A. Fried, Linda F. Shlipak, Michael G. Palmas, Walter Stehman-Breen, Catherine Siscovick, David S. TI Differences in kidney function and incident hypertension: The multi-ethnic study of atherosclerosis SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID GLOMERULAR-FILTRATION-RATE; SERUM CYSTATIN-C; SALT-SENSITIVE HYPERTENSION; BLOOD-PRESSURE; RENAL-DISEASE; GENERAL-POPULATION; BIRTH-WEIGHT; CREATININE; PROTEINURIA; RISK AB Background: Kidney disease and hypertension commonly coexist, yet the direction of their association is still debated. Objective: To evaluate whether early kidney dysfunction, measured by serum cystatin C levels and urinary albumin excretion, predates hypertension in adults without clinically recognized kidney or cardiovascular disease. Design: Observational cohort study using data from 2000 to 2005. Setting: The MESA (Multi-Ethnic Study of Atherosclerosis), a community-based study of subclinical cardiovascular disease in adults age 45 to 84 years. Participants: 2767 MESA participants without prevalent hypertension, cardiovascular disease, or clinically recognized kidney disease (an estimated glomerular filtration rate <60 mL/min per 1.73 m(2) or microalbuminuria). Measurements: Cystatin C was measured by using a nephelometer, and urinary albumin and creatinine were measured from a spot morning collection. The primary outcome was incident hypertension, defined as systolic blood pressure of at least 140 mm Hg, diastolic blood pressure of at least 90 mm Hg, or use of an anti hypertensive medication. Results: During a median follow-up of 3.1 years, 19.7% of the cohort (545 participants) developed hypertension. After adjustment for established hypertension risk factors, each 15-nmol/L increase in cystatin C was associated with a statistically significant 15% greater incidence of hypertension (P = 0.017). The highest sex-specific quartile of urinary albumin-creatinine ratio was associated with a statistically insignificant 16% greater incidence of hypertension (P = 0.192) compared with the lowest quartile. No statistical evidence suggested a multiplicative interaction. Limitations: Unmeasured characteristics may have confounded observed associations of kidney markers with hypertension. Follow-up was relatively short. Hypertension that may have occurred between study visits or hypertension that was not captured by standard cuff measurements may have been missed. Conclusion: Differences in kidney function, indicated by cystatin C levels, are associated with incident hypertension among individuals without clinical kidney or cardiovascular disease. These population-based findings complement experimental work implicating early kidney damage in the pathogenesis of essential hypertension. C1 [Kestenbaum, Bryan] Univ Washington, Harborview Med Ctr, Div Nephrol, Seattle, WA 98104 USA. San Francisco VA Med Ctr, San Francisco, CA USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. Univ Pittsburgh, Sch Med, Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. Columbia Univ, New York, NY USA. Amgen Inc, Thousand Oaks, CA USA. Univ Pittsburgh, Sch Med, Renal Electrolyte Div, Pittsburgh, PA USA. RP Kestenbaum, B (reprint author), Univ Washington, Harborview Med Ctr, Div Nephrol, Room 10EH11,325 9Th Ave, Seattle, WA 98104 USA. EM brk@u.washington.edu FU NCATS NIH HHS [TL1 TR000422, UL1 TR000423]; NCRR NIH HHS [KL2 RR025015-01, KL2 RR025015]; NHLBI NIH HHS [N01-HC-95164, N01HC95159, N01HC95165, N01-HC-95159, N01-HC-95162, N01HC95169, N01-HC-95165, N01-HC-95161, N01-HC-95163, N01-HC-95169, N01-HC-95160]; NIDDK NIH HHS [K23 DK063274, K23 DK63274-01] NR 39 TC 57 Z9 62 U1 0 U2 3 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD APR 1 PY 2008 VL 148 IS 7 BP 501 EP 508 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 284IV UT WOS:000254701000002 PM 18378946 ER PT J AU Robbins, J Gensler, G Hind, J Logemann, JA Lindblad, AS Brandt, D Baum, H Lilienfeld, D Kosek, S Lundy, D Dikeman, K Kazandjian, M Gramigna, GD McGarvey-Toler, S Gardner, PJM AF Robbins, JoAnne Gensler, Gary Hind, Jacqueline Logemann, Jeri A. Lindblad, Anne S. Brandt, Diane Baum, Herbert Lilienfeld, David Kosek, Steven Lundy, Donna Dikeman, Karen Kazandjian, Marta Gramigna, Gary D. McGarvey-Toler, Susan Gardner, Patricia J. Miller TI Comparison of 2 interventions for liquid aspiration on pneumonia incidence SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID CLINICAL-TRIALS; RISK-FACTORS; PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; MORTALITY; INFECTIONS; PREDICTORS; POSTURE; DESIGN AB Background: Aspiration pneumonia is common among frail elderly persons with dysphagia. Although interventions to prevent aspiration are routinely used in these patients, little is known about the effectiveness of those interventions. Objective: To compare the effectiveness of chin-down posture and 2 consistencies (nectar or honey) of thickened liquids on the 3-month cumulative incidence of pneumonia in patients with dementia or Parkinson disease. Design: Randomized, controlled, parallel-design trial in which patients were enrolled for 3-month periods from 9 June 1998 to 19 September 2005. Setting: 47 hospitals and 79 subacute care facilities. Patients: 515 patients age 50 years or older with dementia or Parkinson disease who aspirated thin liquids (demonstrated video-fluoroscopically). Of these, 504 were followed until death or for 3 months. Intervention: Participants were randomly assigned to drink all liquids in a chin-down posture (n = 259) or to drink nectar-thick (n = 133) or honey-thick (n = 123) liquids in a head-neutral position. Measurements: The primary outcome was pneumonia diagnosed by chest radiography or by the presence of 3 respiratory indicators. Results: 52 participants had pneumonia, yielding an overall estimated 3-month cumulative incidence of 11%. The 3-month cumulative incidence of pneumonia was 0.098 and 0.116 in the chin-down posture and thickened-liquid groups, respectively (hazard ratio, 0.84 [95% Cl, 0.49 to 1.45]; P = 0.53). The 3-month cumulative incidence of pneumonia was 0.084 in the nectar-thick liquid group compared with 0.150 in the honey-thick liquid group (hazard ratio, 0.50 [Cl, 0.23 to 1.09]; P = 0.083). More patients assigned to thickened liquids than those assigned to the chin-down posture intervention had dehydration (6% vs. 2%), urinary tract infection (6% vs. 3%), and fever (4% vs. 2%). Limitations: A no-treatment control group was not included. Follow-up was limited to 3 months. Care providers were not blinded, and differences in cumulative pneumonia incidence between interventions had wide Cls. Conclusion: No definitive conclusions about the superiority of any of the tested interventions can be made. The 3-month cumulative incidence of pneumonia was much lower than expected in this frail elderly population. Future investigation of chin-down posture combined with nectar-thick liquid may be warranted to determine whether this combination better prevents pneumonia than either intervention independently. C1 [Robbins, JoAnne] William S Middleton Mem Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin 11G, Madison, WI 53705 USA. Univ Wisconsin, Madison, WI USA. EMMES Corp & Amer Speech Language Hearing Assoc, Rockville, MD USA. Northwestern Univ, Evanston, IL USA. ORC Macro, Calverton, MD USA. Stanford Univ, Sch Med, Palo Alto, CA 94304 USA. Minneapolis Vet Affairs Med Ctr, Minneapolis, MN USA. Univ Miami, Hosp & Clin, Miami, FL 33152 USA. New York Hosp, Queens Med Ctr, Flushing, NY USA. Vet Affairs Boston Healthcare Syst, W Roxbury, MA USA. Richard L Roudebush Vet Affairs Med Ctr, Indianapolis, IN USA. RP Robbins, J (reprint author), William S Middleton Mem Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin 11G, 2500 Overlook Terrace, Madison, WI 53705 USA. EM jrobbin2@wisc.edu FU NCRR NIH HHS [M01 RR003186-16S10295, M01 RR003186, M01 RR003186-140295, M01 RR003186-150295, M01 RR003186-15S30295, M01 RR003186-160295, M01 RR003186-170295, M01 RR003186-180295, M01 RR003186-190295]; NIDCD NIH HHS [DC03206, U01 DC003206] NR 32 TC 89 Z9 90 U1 0 U2 17 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD APR 1 PY 2008 VL 148 IS 7 BP 509 EP 518 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA 284IV UT WOS:000254701000003 PM 18378947 ER PT J AU Ravaioli, A Monti, F Regan, MM Maffini, F Mastropasqua, MG Spataro, V Castiglione-Gertsch, M Panzini, I Gianni, L Goldhirsch, A Coates, A Price, KN Gusterson, BA Viale, G AF Ravaioli, A. Monti, F. Regan, M. M. Maffini, F. Mastropasqua, M. G. Spataro, V. Castiglione-Gertsch, M. Panzini, I. Gianni, L. Goldhirsch, A. Coates, A. Price, K. N. Gusterson, B. A. Viale, G. CA Int Breast Canc Study Grp TI p27 and Skp2 immunoreactivity and its clinical significance with endocrine and chemo-endocrine treatments in node-negative early breast cancer SO ANNALS OF ONCOLOGY LA English DT Article DE breast cancer; chemotherapy; hormonal therapy; p27; Skp2 ID CELL-CYCLE REGULATORS; ADJUVANT CHEMOTHERAPY; PROGNOSTIC IMPACT; RANDOMIZED-TRIAL; EXPRESSION; P27(KIP1); OVEREXPRESSION; CARCINOMA; THERAPY; AGGRESSIVENESS AB Background: Low p27 and high Skp2 immunoreactivity are associated with a poor prognosis and other poor prognostic features including resistant phenotypes and antiestrogen drug resistance. We investigated these proteins in two International Breast Cancer Study Group trials studying node-negative early breast cancer. Patients and methods: Trial VIII compared chemotherapy followed by goserelin with either modality alone in premenopausal patients. Trial IX compared chemotherapy followed by tamoxifen with tamoxifen alone in postmenopausal patients. Central Pathology Office assessed p27 and Skp2 expression in the primary tumor by immunohistochemistry among 1631 (60%) trial patients. Results: p27 and Skp2 were inversely related; 13% of tumors expressed low p27 and high Skp2. Low p27 and high Skp2 were associated with unfavorable prognostic factors including larger size and higher grade tumors, absence of estrogen receptor and progesterone receptor, human epidermal growth factor receptor 2 overexpression and high Ki-67 (each P < 0.05). Low p27 and high Skp2 were not associated with disease-free survival (P = 0.42 and P = 0.48, respectively). The relative effects of chemo-endocrine versus endocrine therapy were similar regardless of p27 or Skp2. Conclusions: We confirm the association of low p27 and high Skp2 with other poor prognostic features, but found no predictive or prognostic value, and therefore do not recommend routine determination of p27 and Skp2 for node-negative breast cancer. C1 [Ravaioli, A.; Monti, F.; Panzini, I.; Gianni, L.] Osped Infermi Rimni, Dept Oncol, Meldola, FC, Italy. [Ravaioli, A.; Monti, F.; Panzini, I.; Gianni, L.] Ist Sci Romagnolo Studio & Cura Tumori, Meldola, FC, Italy. [Regan, M. M.] Dana Farber Canc Inst, Int Bresat Canc Study Grp, Ctr Stat, Boston, MA 02115 USA. [Regan, M. M.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. [Maffini, F.; Mastropasqua, M. G.] European Inst Oncol, Div Pathol & Lab Med, Milan, Italy. [Spataro, V.] Osped San Giovanni Bellinzona, Dept Oncol, Bellinzona, Switzerland. [Castiglione-Gertsch, M.; Coates, A.] Int Breast Canc Study Grp Coordniating Ctr, Bern, Switzerland. [Goldhirsch, A.] Oncol Inst So Switzerland, Lugano, Switzerland. [Coates, A.] Univ Sydney, Sydney, NSW 2006, Australia. [Price, K. N.] Frontier Sci & Technol Res Fdn Inc, Boston, MA USA. [Viale, G.] Univ Milan, Milan, Italy. [Viale, G.] Univ Glasgow, Div Canc Sci & Mol Pathol, Fac Med, Glasgow, Lanark, Scotland. RP Ravaioli, A (reprint author), Osped Infermi Rimni, Dept Oncol, Meldola, FC, Italy. EM aravaiol@auslrn.net RI gusterson, barry/D-3752-2009; friedlander, michael/G-3490-2013; Maiorano, Eugenio/F-1382-2015; OI friedlander, michael/0000-0002-6488-0604; Hultborn, Ragnar/0000-0002-4289-9339 FU NCI NIH HHS [CA-75362] NR 28 TC 13 Z9 17 U1 1 U2 2 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 J9 ANN ONCOL JI Ann. Oncol. PD APR PY 2008 VL 19 IS 4 BP 660 EP 668 DI 10.1093/annonc/mdm547 PG 9 WC Oncology SC Oncology GA 281BE UT WOS:000254470400009 PM 18272916 ER PT J AU Cappuzzo, F Finocchiaro, G Rossi, E Jaenne, PA Carnaghi, C Calandri, C Bencardino, K Ligorio, C Ciardiello, F Pressiani, T Destro, A Roncalli, M Crino, L Franklin, WA Santoro, A Varella-Garcia, M AF Cappuzzo, F. Finocchiaro, G. Rossi, E. Jaenne, P. A. Carnaghi, C. Calandri, C. Bencardino, K. Ligorio, C. Ciardiello, F. Pressiani, T. Destro, A. Roncalli, M. Crino, L. Franklin, W. A. Santoro, A. Varella-Garcia, M. TI EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients SO ANNALS OF ONCOLOGY LA English DT Article DE cetuximab; colon cancer; EGFR; fluorescence in situ hybridization ID GROWTH-FACTOR RECEPTOR; CELL-LUNG-CANCER; GENE COPY NUMBER; PHASE-III TRIAL; KRAS MUTATION; GEFITINIB SENSITIVITY; CLINICAL-RESPONSE; METASTATIC SITES; SUPPORTIVE CARE; PLUS AB Background: Standardized conditions to distinguish subpopulations of colorectal cancer (CRC) patients more and less sensitive to cetuximab therapy remain undefined. Materials and methods: We retrospectively analyzed epidermal growth factor receptor (EGFR) copy number by fluorescence in situ hybridization (FISH) in paraffin-embedded tumor blocks from 85 chemorefractory CRC patients treated with cetuximab. Results were analyzed according to different score systems previously reported in colorectal and lung cancers. The primary end point of the study was identification of the EGFR FISH score that best associates with response rate (RR). Results: Using receiver operating characteristic (ROC) analysis, the cut-off that best discriminated responders versus nonresponders to cetuximab was a mean of 2.92 EGFR gene copies per cell. This model showed sensitivity of 58.6% (95% confidence interval (CI) = 47.1-70.1) and specificity of 93.3% (95% CI = 80.6-100). EGFR FISH-positive patients (N = 43, 50.6%) had significantly higher RR (P = 0.0001) and significantly longer time to disease progression (P = 0.02) than EGFR FISH negative (N = 42, 49.4%). Other scoring systems resulted less accurate in discriminating patients with the highest likelihood of response to cetuximab therapy. Conclusions: CRC patients with high EGFR gene copy number have an increased likelihood to respond to cetuximab therapy. Prospective clinical trials with a careful standardization of assay conditions and pattern interpretation are urgently needed. C1 [Cappuzzo, F.; Finocchiaro, G.; Pressiani, T.; Destro, A.; Roncalli, M.; Santoro, A.; Varella-Garcia, M.] Ist Clin Humanitas IRCCS, Dept Med Oncol, Rozzano, Italy. [Finocchiaro, G.; Franklin, W. A.] Univ Colorado, Ctr Canc, Dept Med Med Oncol, Aurora, CO USA. [Rossi, E.] CINECA Interuniv Consortium, Bologna, Italy. [Jaenne, P. A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Carnaghi, C.] Bellaria Maggiore Hosp, Dept Med Oncol, Bologna, Italy. [Calandri, C.] San Matteo Hosp, Dept Med Oncol, Pavia, Italy. [Bencardino, K.; Ciardiello, F.] Univ Naples 2, Dept Med Oncol, Naples, Italy. [Destro, A.; Roncalli, M.] Univ Milan, Ist Clin Humanitas IRCCS, Pathol Unit, Rozzano, Italy. [Crino, L.] Osped Silvestrini, Dept Med Oncol, Perugia, Italy. RP Cappuzzo, F (reprint author), Ist Clin Humanitas, Via Manzoni 56, I-20089 Rozzano, Italy. EM federico.cappuzzo@humanitas.it OI Ciardiello, Fortunato/0000-0002-3369-4841; Cappuzzo, Federico/0000-0002-6295-6767; Roncalli, Massimo/0000-0002-7901-8910 NR 36 TC 176 Z9 180 U1 2 U2 6 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 J9 ANN ONCOL JI Ann. Oncol. PD APR PY 2008 VL 19 IS 4 BP 717 EP 723 DI 10.1093/annonc/mdm492 PG 7 WC Oncology SC Oncology GA 281BE UT WOS:000254470400017 PM 17974556 ER PT J AU Colwell, AS Slavin, SA May, JW AF Colwell, Amy S. Slavin, Sumner A. May, James W., Jr. TI Breast augmentation after reduction mammaplasty - Getting the size right SO ANNALS OF PLASTIC SURGERY LA English DT Article DE breast augmentation; breast reduction; body image; reduction mammaplasty; complications ID OUTCOMES AB Although patients are typically satisfied after reduction mammaplasty, a subgroup later deems the volume of remaining breast tissue inadequate and presents for breast enhancement. Our purpose was to identify patient and procedural risk factors that may contribute to an over-reduced breast and the desire for breast augmentation after initial reduction. Seven patients were identified who had breast augmentation an average of 13 years after breast reduction. Four patients were satisfied with breast size immediately after reduction mammaplasty but lost breast volume subsequent to weight loss or childbearing. Three patients with a body mass index of IS to 20 were dissatisfied immediately after reduction. Body image improved in 100% of patients after enhancement. Getting the size right depends upon thorough discussion with the patient regarding desired size, insurance requirements, and potential for decreased size after weight loss or childbearing. Breast augmentation may, improve body image in patients with small breasts after reduction. C1 [Colwell, Amy S.; May, James W., Jr.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Boston, MA 02115 USA. [Slavin, Sumner A.] Harvard Univ, Sch Med, Beth Israel Deaconess Hosp, Div Plast Surg,Dept Surg, Boston, MA 02115 USA. RP May, JW (reprint author), Massachusetts Gen Hosp, Plast & Reconstruct Surg, 15 Parkman St WAC 453, Boston, MA 02114 USA. EM jwmay@partners.org NR 7 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-7043 J9 ANN PLAS SURG JI Ann. Plast. Surg. PD APR PY 2008 VL 60 IS 4 BP 372 EP 374 DI 10.1097/SAP.0b013e31812565fa PG 3 WC Surgery SC Surgery GA 281ML UT WOS:000254501600008 PM 18362562 ER PT J AU Crippa, S Salvia, R Warshaw, AL Dominguez, I Bassi, C Falconi, M Thayer, SP Zamboni, G Lauwers, GY Mino-Kenudson, M Capelli, P Pederzoli, P Fernandez-del Castillo, C AF Crippa, Stefano Salvia, Roberto Warshaw, Andrew L. Dominguez, Ismael Bassi, Claudio Falconi, Massimo Thayer, Sarah P. Zamboni, Giuseppe Lauwers, Gregory Y. Mino-Kenudson, Mari Capelli, Paola Pederzoli, Paolo Fernandez-del Castillo, Carlos TI Mucinous cystic neoplasm of the pancreas is not an aggressive entity - Lessons from 163 resected patients SO ANNALS OF SURGERY LA English DT Article ID EPITHELIAL OVARIAN-CANCER; DISTAL PANCREATECTOMY; CLINICOPATHOLOGICAL FEATURES; UPDATED EXPERIENCE; TUMORS; CYSTADENOCARCINOMA; CYSTADENOMA; STROMA; PRESERVATION; MALIGNANCY AB Objective: Mucinous cystic neoplasms (MCNs) of the pancreas have often been confused with intraductal papillary mucinous neoplasms. We evaluated the clinicopathologic characteristics, prevalence of cancer, and prognosis of a large series of well-characterized MCNs in 2 tertiary centers. Methods: Analysis of 163 patients with resected MCNs, defined by the presence of ovarian stroma and lack of communication with the main pancreatic duct. Results: MCNs were seen mostly in women (95%) and in the distal pancreas (97%); 25% were incidentally discovered. Symptomatic patients typically had mild abdominal pain, but 9% presented with acute pancreatitis. One hundred eighteen patients (72%) had adenoma, 17 (10.5%) borderline tumors, 9 (5.5%) in situ carcinoma, and 19 (12%) invasive carcinoma. Patients with invasive carcinoma were significantly older than those with noninvasive neoplasms (55 vs. 44 years, P = 0.01). Findings associated with malignancy were presence of nodules (P = 0.0001) and diameter >= 60 mm (P = 0.0001). All neoplasms with cancer were either !40 turn in size or had nodules. There was no operative mortality and postoperative morbidity was 49%. Median follow-up was 57 months (range, 4-233); only patients with invasive carcinoma had recurrence. The 5-year disease-specific survival for noninvasive MCNs was 100%, and for those with invasive cancer, 57%. Conclusions: This series, the largest with MCNs defined by ovarian stroma, shows a prevalence of cancer of only 17.5%. Patients with invasive carcinoma are older, suggesting progression from adenoma to carcinoma. Although resection should be considered for all cases, in low-risk MCNs (<= 4 cm/no nodules), nonradical resections are appropriate. C1 [Warshaw, Andrew L.; Dominguez, Ismael; Thayer, Sarah P.; Fernandez-del Castillo, Carlos] Harvard Univ, Sch Med, Dept Surg, Massachusetts Gen Hosp,Wang Ambulatory Care Ctr 4, Boston, MA 02114 USA. [Crippa, Stefano; Salvia, Roberto; Bassi, Claudio; Falconi, Massimo; Pederzoli, Paolo] Univ Verona, Dept Surg, I-37100 Verona, Italy. [Zamboni, Giuseppe; Capelli, Paola] Univ Verona, Dept Pathol, I-37100 Verona, Italy. [Lauwers, Gregory Y.; Mino-Kenudson, Mari] Harvard Univ, Sch Med, Dept Pathol, Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Fernandez-del Castillo, C (reprint author), Harvard Univ, Sch Med, Dept Surg, Massachusetts Gen Hosp,Wang Ambulatory Care Ctr 4, 15 Parkman St, Boston, MA 02114 USA. EM cfernandez@partners.org RI Giuseppe, Zamboni/A-5991-2016; OI Giuseppe, Zamboni/0000-0001-7428-4673; Falconi, Massimo/0000-0001-9654-7243 FU NIDDK NIH HHS [K08 DK071329] NR 55 TC 157 Z9 174 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0003-4932 J9 ANN SURG JI Ann. Surg. PD APR PY 2008 VL 247 IS 4 BP 571 EP 579 DI 10.1097/SLA.0b013e31811f4449 PG 9 WC Surgery SC Surgery GA 282DD UT WOS:000254546900003 PM 18362619 ER PT J AU Greenberg, CC Diaz-Flores, R Lipsitz, SR Regenbogen, SE Mulholland, L Mearn, F Rao, S Toidze, T Gawande, AA AF Greenberg, Caprice C. Diaz-Flores, Rafael Lipsitz, Stuart R. Regenbogen, Scott E. Mulholland, Lynn Mearn, Francine Rao, Shilpa Toidze, Tamara Gawande, Atul A. TI Bar-coding surgical sponges to improve safety - A randomized controlled trial SO ANNALS OF SURGERY LA English DT Article ID PATIENT SAFETY; TECHNOLOGY; INSTRUMENTS; SURGERY AB Objective: A randomized, controlled trial was performed to evaluate a computer-assisted method for counting sponges using a barcode system. Background: Retained sponges are a rare and preventable problem but persist in surgery despite standardized protocols for counting. Technology that improves detection of counting errors could reduce risk to surgical patients. Methods: We performed a randomized controlled trial comparing a bar-coded sponge system with a traditional counting protocol in 300 general surgery operations. Observers monitored sponge and instrument counts and recorded all incidents of miscounted or misplaced sponges. Surgeons and operating room staff completed postoperative and end-of-study surveys evaluating the bar-code system. Results: The bar-code system detected significantly more counting discrepancies than the traditional protocol (32 vs.13 discrepancies, P = 0.007). These discrepancies involved both misplaced sponges (21 vs. 12 sponges, P = 0.17) and miscounted sponges (11 vs. 1 sponge, P = 0.007). The system introduced new technical difficulties (2.04 per 1000 sponges) and increased the time spent counting sponges (5.3 vs. 2.4 minutes, P < 0.0001). In postoperative surveys, there was no difference in surgical teams' confidence that all sponges were accounted for, but they rated the counting process and team performance lower in operations randomized to the bar-code arm. By the end of the study, however, most providers found the system easy to use, felt confident in its ability to track sponges, and reported a positive effect on the counting process. Conclusions: Use of automated counting using bar-coded surgical sponges improved detection of miscounted and misplaced sponges and was well tolerated by surgical staff members. C1 [Greenberg, Caprice C.; Diaz-Flores, Rafael; Lipsitz, Stuart R.; Rao, Shilpa; Toidze, Tamara; Gawande, Atul A.] Brigham & Womens Hosp, Dept Surg, Ctr Surg & Publ Hlth, Boston, MA 02115 USA. [Greenberg, Caprice C.; Diaz-Flores, Rafael; Regenbogen, Scott E.; Rao, Shilpa; Toidze, Tamara; Gawande, Atul A.] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA. [Regenbogen, Scott E.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. [Mulholland, Lynn; Mearn, Francine] Brigham & Womens Hosp, Dept Nursing, Boston, MA 02115 USA. RP Gawande, AA (reprint author), Brigham & Womens Hosp, Dept Surg, Ctr Surg & Publ Hlth, 75 Francis St, Boston, MA 02115 USA. EM agawande@partners.org OI Gawande, Atul/0000-0002-1824-9176 NR 14 TC 50 Z9 50 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0003-4932 J9 ANN SURG JI Ann. Surg. PD APR PY 2008 VL 247 IS 4 BP 612 EP 616 DI 10.1097/SLA.0b013e3181656cd5 PG 5 WC Surgery SC Surgery GA 282DD UT WOS:000254546900007 PM 18362623 ER PT J AU Takayama, T Makuuchi, M Kojiro, M Lauwers, GY Adams, RB Wilson, SR Jang, HJ Charnsangavej, C Taouli, B AF Takayama, Tadatoshi Makuuchi, Masatoshi Kojiro, Masamichi Lauwers, Gregory Y. Adams, Reid B. Wilson, Stephanie R. Jang, Hyun-Jung Charnsangavej, Chusilp Taouli, Bachir TI Early hepatocellular carcinoma: Pathology, imaging, and therapy SO ANNALS OF SURGICAL ONCOLOGY LA English DT Article; Proceedings Paper CT 5th International Meeting on Hepatocellular Carcinoma CY JAN 11-13, 2007 CL Houston, TX DE hepatocellular carcinoma; early HCC; pathology; imaging; therapy ID DYSPLASTIC NODULES; CIRRHOTIC LIVERS; ARTERIAL PHASE; LESIONS; CT; TRANSPLANTATION; EXPRESSION; DIAGNOSIS; TUMORS AB Background: In 1987, Japanese researchers proposed to define the pathological concept of early hepatocellular carcinoma (HCC). However, there are some conceptual differences between the East and the West in the diagnosis and treatment of early HCC. Methods: To provide up-to-date data for making a worldwide consensus, this article has collected six papers focused on the management of early HCC, which were presented in the Fifth International Meeting of "Hepatocellular Carcinoma: Eastern and Western Experiences" in Houston in January 2007. Results: In the pathological perspective, the common criteria to discriminate early HCC from dysplastic nodule included hepatocytic invasion of portal triads and septa (stromal invasion). The current imaging modalities such as contrast-enhanced ultrasound (CEUS), computed tomography (CT), and magnetic resonance imaging (MRI) with the use of intravenous contrast material with multiphasic imaging could enhance their ability to accurately characterize early HCC. From the treatment perspective, a single early HCC had a high chance for cure by resection, ablation, or transplantation, which proved to be the earliest clinical entity (Stage 0 HCC). Conclusions: Early HCC is characterized by its incipient malignant nature and by an extremely favorable clinical outcome, thereby justifying its definition. C1 [Takayama, Tadatoshi] Nihon Univ, Sch Med, Dept Digest Surg, Tokyo, Japan. [Makuuchi, Masatoshi] Univ Tokyo, Grad Sch Med, Dept Surg, Tokyo, Japan. [Kojiro, Masamichi] Kurume Univ, Sch Med, Dept Pathol, Kurume, Fukuoka 830, Japan. [Lauwers, Gregory Y.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pathol, Boston, MA USA. [Adams, Reid B.] Univ Virginia, Dept Surg, Charlottesville, VA USA. [Charnsangavej, Chusilp] Univ Texas MD Anderson Canc Ctr, Dept Radiol, Houston, TX USA. [Wilson, Stephanie R.] Univ Toronto, Dept Med Imaging, Toronto, ON, Canada. [Taouli, Bachir] NYU, Dept Radiol, New York, NY 10016 USA. RP Takayama, T (reprint author), Nihon Univ, Sch Med, Dept Digest Surg, Tokyo, Japan. EM tadtak@med.nihon-u.ac.jp RI 幕内, 雅敏/A-2140-2012 NR 29 TC 33 Z9 40 U1 0 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 1068-9265 J9 ANN SURG ONCOL JI Ann. Surg. Oncol. PD APR PY 2008 VL 15 IS 4 BP 972 EP 978 DI 10.1245/s10434-007-9685-0 PG 7 WC Oncology; Surgery SC Oncology; Surgery GA 272XW UT WOS:000253896000005 PM 18236118 ER PT J AU Sawalha, AH Kaufman, KM Kelly, JA Adler, AJ Aberle, T Kilpatrick, J Wakeland, EK Li, QZ Wandstrat, AE Karp, DR James, JA Merrill, JT Lipsky, P Harley, JB AF Sawalha, A. H. Kaufman, K. M. Kelly, J. A. Adler, A. J. Aberle, T. Kilpatrick, J. Wakeland, E. K. Li, Q-Z Wandstrat, A. E. Karp, D. R. James, J. A. Merrill, J. T. Lipsky, P. Harley, J. B. TI Genetic association of interleukin-21 polymorphisms with systemic lupus erythematosus SO ANNALS OF THE RHEUMATIC DISEASES LA English DT Article ID B-CELLS; IL-21 RECEPTOR; CUTTING EDGE; T-CELLS; DIFFERENTIATION; CHAIN AB Objective: The aetiology of systemic lupus erythematosus (SLE) is incompletely understood. Both genetic and environmental factors are implicated in the pathogenesis of the disease. Herein, we describe genetic association between SLE and polymorphisms in the interleukin (IL)-21 gene. The reported effect of IL-21 on B-cell differentiation into plasma cells and its effect on dendritic cell maturation and T-cell responses make IL-21 an attractive candidate gene for SLE. Methods: Three single nucleotide polymorphisms (SNPs) in the IL-21 gene were genotyped in a total of 2636 individuals (1318 cases and 1318 controls matched for age, sex and race). Population-based case-control association analyses were performed. Results: We found a genetic association with SLE and two SNPs located within the IL-21 gene (rs907715: chi(2) = 11.55, p<0.001; rs2221903: chi(2) = 5.49, p = 0.019). Furthermore, genotypes homozygous for the risk alleles were more frequent than genotypes homozygous for the non-risk alleles in European-American patients as compared to controls (rs907715 (GG versus AA): odds ratio (OR)= 1.66, p = 0.0049; rs2221903 (GG versus AA): OR = 1.60, p = 0.025). Conclusion: Our findings indicate that IL-21 polymorphism is a candidate association with SLE. The functional effects of this association, when revealed, might improve our understanding of the disease and provide new therapeutic targets. C1 [Sawalha, A. H.; Kaufman, K. M.; Harley, J. B.] US Dept Vet Affairs, Med Ctr, Oklahoma City, OK USA. [Sawalha, A. H.; Kaufman, K. M.; Merrill, J. T.; Harley, J. B.] Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK USA. [Sawalha, A. H.; Kaufman, K. M.; Kelly, J. A.; Adler, A. J.; Aberle, T.; Kilpatrick, J.; James, J. A.; Merrill, J. T.; Harley, J. B.] Oklahoma Med Res Fdn, Arthritis & Immunol Program, Oklahoma City, OK 73104 USA. [Wakeland, E. K.; Li, Q-Z; Wandstrat, A. E.] Univ Texas SW Med Ctr Dallas, Ctr Immunol, Dallas, TX 75390 USA. [Karp, D. R.] Univ Texas SW Med Ctr Dallas, Dept Med, Dallas, TX 75390 USA. [Lipsky, P.] NIAMSD, Autoimmun Branch, Bethesda, MD 20892 USA. RP Sawalha, AH (reprint author), 825 NE 13th St,MS 24, Oklahoma City, OK 73104 USA. EM amr-sawalha@omrf.ouhsc.edu FU NCRR NIH HHS [RR020143, P20-RR015577]; NIAID NIH HHS [AI31584, AI24717, AI053747]; NIAMS NIH HHS [AR4894, AR42460, AR12253, P30 AR053483] NR 19 TC 113 Z9 120 U1 0 U2 3 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0003-4967 J9 ANN RHEUM DIS JI Ann. Rheum. Dis. PD APR PY 2008 VL 67 IS 4 BP 458 EP 461 DI 10.1136/ard.2007.075424 PG 4 WC Rheumatology SC Rheumatology GA 276DI UT WOS:000254121100006 PM 17720724 ER PT J AU Akins, CW Miller, DC Turina, MI Kouchoukos, NT Blackstone, EH Grunkemeier, GL Takkenberg, JJM David, TE Butchart, EG Adams, DH Shahian, DM Hagl, S Mayer, JE Lytle, BW AF Akins, Cary W. Miller, D. Craig Turina, Marko I. Kouchoukos, Nicholas T. Blackstone, Eugene H. Grunkemeier, Gary L. Takkenberg, Johanna J. M. David, Tirone E. Butchart, Eric G. Adams, David H. Shahian, David M. Hagl, Siegfried Mayer, John E. Lytle, Bruce W. TI Guidelines for reporting mortality and morbidity after cardiac valve interventions SO ANNALS OF THORACIC SURGERY LA English DT Review ID CONFIDENCE-INTERVALS; VALVULAR OPERATIONS; REGRESSION-ANALYSIS; COX REGRESSION; EVENTS C1 [Akins, Cary W.; Miller, D. Craig; Blackstone, Eugene H.; David, Tirone E.; Lytle, Bruce W.] Amer Assoc Thorac Surg, Beverly, MA USA. [Kouchoukos, Nicholas T.; Grunkemeier, Gary L.; Adams, David H.; Shahian, David M.; Mayer, John E.] Soc Thorac Surg, Chicago, IL USA. [Turina, Marko I.; Takkenberg, Johanna J. M.; Butchart, Eric G.; Hagl, Siegfried] European Assoc Cardiothorac Surg, Windsor, Berks, England. RP Akins, CW (reprint author), Massachusetts Gen Hosp, Cox 648,55 Fruit St, Boston, MA 02114 USA. EM cakins@partners.org RI Takkenberg, Johanna/B-9368-2009; OI Takkenberg, Johanna/0000-0001-9809-5623 NR 32 TC 204 Z9 204 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0003-4975 J9 ANN THORAC SURG JI Ann. Thorac. Surg. PD APR PY 2008 VL 85 IS 4 BP 1490 EP 1495 DI 10.1016/j.athoracsur.2007.12.082 PG 6 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 275PE UT WOS:000254083300070 PM 18355567 ER PT J AU Friedman, RJ Gutkowicz-Krusin, D Farber, MJ Warycha, M Schneider-Kels, L Papastathis, N Mihm, MC Googe, P King, R Prieto, VG Kopf, AW Polsky, D Rabinovitz, H Oliviero, M Cognetta, A Rigel, DS Marghoob, A Rivers, J Johr, R Grant-Kels, JM Tsao, H AF Friedman, Robert J. Gutkowicz-Krusin, Dina Farber, Michele J. Warycha, Melanie Schneider-Kels, Lori Papastathis, Nicole Mihm, Martin C., Jr. Googe, Paul King, Roy Prieto, Victor G. Kopf, Alfred W. Polsky, David Rabinovitz, Harold Oliviero, Margaret Cognetta, Armand Rigel, Darrell S. Marghoob, Ashfaq Rivers, Jason Johr, Robert Grant-Kels, Jane M. Tsao, Hensin TI The diagnostic performance of expert dermoscopists vs a computer-vision system on small-diameter melanomas SO ARCHIVES OF DERMATOLOGY LA English DT Article ID PIGMENTED SKIN-LESIONS; MALIGNANT-MELANOMA; EPILUMINESCENCE MICROSCOPY; CUTANEOUS MELANOMA; MELANOCYTIC NEVI; CRITERIA; SENSITIVITY; ATYPIA; ABCDE AB objective: To evaluate the performance of dermoscopists in diagnosing small pigmented skin lesions (diameter <= 6 mm) compared with an automatic multispectral computer-vision system. Design: Blinded comparison study. Setting: Dermatologic hospital-based clinics and private practice offices. Patients: From a computerized skin imaging database of 990 small (<= 6-mm) pigmented skin lesions, all 49 melanomas from 49 patients were included in this study. Fifty randomly selected nonmelanomas from 46 patients served as a control. Main Outcome Measures: Ten dermoscopists independently examined dermoscopic images of 99 pigmented skin lesions and decided whether they identified the lesions as melanoma and whether they would recommend biopsy to rule out melanoma. Diagnostic and biopsy sensitivity and specificity were computed and then compared with the results of the computer-vision system. Results: Dermoscopists were able to correctly identify small melanomas with an average diagnostic sensitivity of 39% and a specificity of 82% and recommended small melanomas for biopsy with a sensitivity of 71% and specificity of 49%, with only fair interobserver agreement (K=0.31 for diagnosis and 0.34 for biopsy). In comparison, in recommending biopsy to rule out melanoma, the computer-vision system achieved 98% sensitivity and 44% specificity. Conclusions: Differentiation of small melanomas from small benign pigmented lesions challenges even expert physicians. Computer-vision systems can facilitate early detection of small melanomas and may limit the number of biopsies to rule out melanoma performed on benign lesions. C1 [Friedman, Robert J.; Farber, Michele J.; Warycha, Melanie; Schneider-Kels, Lori; Papastathis, Nicole; Kopf, Alfred W.; Polsky, David; Rigel, Darrell S.] NYU, Sch Med, Dept Dermatol, New York, NY 10021 USA. [Marghoob, Ashfaq] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Mihm, Martin C., Jr.; Tsao, Hensin] Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA. [Mihm, Martin C., Jr.] Massachusetts Gen Hosp, Div Dermatopathol, Boston, MA 02114 USA. [Mihm, Martin C., Jr.] Harvard Med Sch, Boston, MA USA. [Googe, Paul; King, Roy] Knoxville Dermatopathol Lab, Knoxville, TN USA. [Prieto, Victor G.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Rabinovitz, Harold; Oliviero, Margaret] Skin & Canc Assoc Plantat, Tallahassee, FL USA. [Cognetta, Armand] Dermatol Assoc Tallahassee, Tallahassee, FL USA. [Johr, Robert] Univ Miami, Sch Med, Dept Dermatol, Miami, FL 33152 USA. [Rivers, Jason] Univ British Columbia, Dept Dermatol, Vancouver, BC V5Z 1M9, Canada. [Rivers, Jason] Gen Hosp, Vancouver, BC, Canada. [Rivers, Jason] British Columbia Canc Agcy, Vancouver, BC, Canada. [Grant-Kels, Jane M.] Univ Connecticut, Ctr Hlth, Farmington, CT USA. RP Friedman, RJ (reprint author), NYU, Sch Med, Dept Dermatol, 124 E 72nd St, New York, NY 10021 USA. NR 32 TC 29 Z9 30 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-987X J9 ARCH DERMATOL JI Arch. Dermatol. PD APR PY 2008 VL 144 IS 4 BP 476 EP 482 DI 10.1001/archderm.144.4.476 PG 7 WC Dermatology SC Dermatology GA 288PW UT WOS:000254999300005 PM 18427041 ER PT J AU Geller, AC Zwirn, J Rutsch, L Gorham, SA Viswanath, V Emmons, KM AF Geller, Alan C. Zwirn, Jodie Rutsch, Linda Gorham, Sue A. Viswanath, Vish Emmons, Karen M. TI Multiple levels of influence in the adoption of sun protection policies in elementary schools in Massachusetts SO ARCHIVES OF DERMATOLOGY LA English DT Article ID SKIN-CANCER; HEALTH AB Objective: To understand the factors that may influence sun protection policy development if the Centers for Disease Control and Prevention guidelines are to be realized. Design: Qualitative research methodology incorporating a socioecological framework using individual or small-group interviews, surveys, and environmental assessments with school superintendents, elementary school principals, elementary school nurses, and parent-teacher organization presidents and co-chairs as well as coding of school documents. Setting: Elementary schools in Massachusetts. Participants: Nine school superintendents, 18 elementary school principals, 18 elementary school nurses, and 16 parent-teacher organization presidents or co-chairs. Main Outcome Measures: Presence of school sun protection policies, sun protection curriculum, and communication portals for sun protection information to parents. Results: None of the schools in the 9 districts had a sun protection policy, and only 1 had any type of sun protection curriculum. However, nearly all principals were receptive to developing sun protection policies and to making structural changes to increase the amount of accessible shade if funding were available. Conclusions: The schools' communication infrastructure could provide a key portal for disseminating sun protection information to parents. Although there are other resources that could be brought to bear, many challenges must be surmounted to develop effective sun protection policies. C1 [Geller, Alan C.] Boston Univ, Sch Med, Dept Dermatol, Boston, MA 02118 USA. [Zwirn, Jodie] Ctr Commun Based Res, Dana Farber Canc Inst, Boston, MA USA. [Viswanath, Vish; Emmons, Karen M.] Harvard Sch Publ Hlth, Dept Soc Human Dev & Hlth, Boston, MA USA. [Rutsch, Linda] US EPA, Washington, DC 20460 USA. [Gorham, Sue A.] SHADE Fdn Amer, Phoenix, AZ USA. RP Geller, AC (reprint author), Boston Univ, Sch Med, Dept Dermatol, 720 Harrison Ave,DOB801A, Boston, MA 02118 USA. EM ageller@bu.edu NR 14 TC 7 Z9 7 U1 1 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-987X J9 ARCH DERMATOL JI Arch. Dermatol. PD APR PY 2008 VL 144 IS 4 BP 491 EP 496 DI 10.1001/archderm.144.4.491 PG 6 WC Dermatology SC Dermatology GA 288PW UT WOS:000254999300007 PM 18427043 ER PT J AU Watson, AJ Kvedar, JC AF Watson, Alice J. Kvedar, Joseph C. TI Staying on top in dermatology - Why we must act now to address the capacity challenge SO ARCHIVES OF DERMATOLOGY LA English DT Editorial Material ID TIMES C1 [Watson, Alice J.; Kvedar, Joseph C.] Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA. [Watson, Alice J.; Kvedar, Joseph C.] Harvard Med Sci, Dept Dermatol, Boston, MA USA. RP Kvedar, JC (reprint author), 25 New Chardon St,Ste 400D, Boston, MA 02114 USA. EM jkvedar@partners.org NR 10 TC 2 Z9 2 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-987X J9 ARCH DERMATOL JI Arch. Dermatol. PD APR PY 2008 VL 144 IS 4 BP 541 EP 544 DI 10.1001/archderm.144.4.541 PG 4 WC Dermatology SC Dermatology GA 288PW UT WOS:000254999300016 PM 18427052 ER PT J AU Bird, TD Lipe, HP Steinbart, E AF Bird, Thomas D. Lipe, Hillary P. Steinbart, Ellenj. TI Geriatric neurogenetics - Oxymoron or reality? SO ARCHIVES OF NEUROLOGY LA English DT Article ID ATAXIA AB Background: Primary genetic diseases are generally associated with pediatric and young adult populations. Little information is available about the occurrence of single-gene mendelian diseases in elderly populations. Objective: To describe the occurrence of single-gene neurogenetic disorders in a group of elderly patients. Design: Retrospective review of neurogenetic cases in an academic medical center. Setting: Academic university and Veterans Affairs medical centers. Patients: Eight elderly patients with single-gene neurogenetic diseases were studied. These patients included an 87-year-old man and an 85-year-old man with Huntington disease, an 84-year-old woman with limb-girdle muscular dystrophy type 2A, a 78-year-old man with spinocerebellar ataxia type 14, an 86-year-old man with spinocerebellar ataxia type 5, an 85-year-old man with a presenilin 1 familial Alzheimer disease mutation, an 87-year-old man with autosomal dominant hereditary neuropathy, and a 78-year-old man with spinocerebellar ataxia type 6. Three patients had no family history of neurologic disease. Main Outcome Measures: Medical histories, physical examination results, and genetic testing results. Conclusions: Single-gene mendelian neurogenetic diseases can be found in the oldest old population (> 85 years). Such cases are currently underrecognized and will become more commonly observed in the future. This phenomenon is a result of (1) the aging of the general population, (2) better recognition of the highly variable ages at onset of genetic diseases, and (3) the availability of specific DNA-based genetic testing. C1 [Bird, Thomas D.; Lipe, Hillary P.] VA Puget Sound Health Care Syst, Geriatr Res Educ Clin Ctr, Seattle, WA 98108 USA. [Bird, Thomas D.; Steinbart, Ellenj.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA. RP Bird, TD (reprint author), VA Puget Sound Health Care Syst, Geriatr Res Educ Clin Ctr, 1660 S Columbian Way,S-182-GRECC, Seattle, WA 98108 USA. EM tomnroz@u.washington.edu FU NIA NIH HHS [P50 AG005136, P50 AG 005136-22, P50 AG005136-25] NR 7 TC 5 Z9 5 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-9942 J9 ARCH NEUROL-CHICAGO JI Arch. Neurol. PD APR PY 2008 VL 65 IS 4 BP 537 EP 539 DI 10.1001/archneur.65.4.537 PG 3 WC Clinical Neurology SC Neurosciences & Neurology GA 286GZ UT WOS:000254835700016 PM 18413479 ER PT J AU Scott, AR Holbrook, EH AF Scott, Andreiv R. Holbrook, Eric H. TI Radiology quiz case 1 - Anaplastic thyroid carcinoma SO ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY LA English DT Editorial Material C1 [Scott, Andreiv R.; Holbrook, Eric H.] Harvard Univ, Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. RP Scott, AR (reprint author), Harvard Univ, Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. NR 10 TC 0 Z9 0 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0886-4470 J9 ARCH OTOLARYNGOL JI Arch. Otolaryngol. Head Neck Surg. PD APR PY 2008 VL 134 IS 4 BP 442 EP + DI 10.1001/archotol.134.4.442 PG 2 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA 285SR UT WOS:000254797000016 PM 18427014 ER PT J AU Mark, EJ Ferry, JA Rosenberg, AE Young, RH AF Mark, Eugene J. Ferry, Judith A. Rosenberg, Andrew E. Young, Robert H. TI Introduction to selected reviews based on the Massachusetts General Hospital, Harvard Medical School postgraduate course - "Current Concepts in Surgical Pathology" SO ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE LA English DT Editorial Material C1 [Mark, Eugene J.; Ferry, Judith A.; Rosenberg, Andrew E.; Young, Robert H.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, James Homer Wright Pathol Labs,Dept Pathol, Boston, MA 02155 USA. RP Mark, EJ (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, James Homer Wright Pathol Labs,Dept Pathol, 55 Fruit St, Boston, MA 02155 USA. EM emark@partners.org NR 0 TC 0 Z9 0 U1 0 U2 0 PU COLLEGE AMER PATHOLOGISTS PI NORTHFIELD PA C/O KIMBERLY GACKI, 325 WAUKEGAN RD, NORTHFIELD, IL 60093-2750 USA SN 0003-9985 J9 ARCH PATHOL LAB MED JI Arch. Pathol. Lab. Med. PD APR PY 2008 VL 132 IS 4 BP 537 EP 538 PG 2 WC Medical Laboratory Technology; Medicine, Research & Experimental; Pathology SC Medical Laboratory Technology; Research & Experimental Medicine; Pathology GA 284TU UT WOS:000254729700002 PM 18384205 ER PT J AU Mark, EJ Ruangchira-Urai, R Kradin, RL AF Mark, Eugene J. Ruangchira-Urai, Ruchira Kradin, Richard L. TI Shirt-sleeve or scanning magnification as an aid to the diagnosis of commonly encountered medical lung diseases SO ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE LA English DT Article; Proceedings Paper CT 28th Annual Postgraduate Cource Current Concepts in Surgical Pathology CY NOV, 2006 CL Boston, MA SP Massachusetts Gen Hosp, Dept Pathol, Harvard Med Sch, Dept Continuing Med Educ ID FEATURES AB Shirt-sleeve magnification ( holding a slide over a white sleeve) and low-power magnification serve as useful adjuncts in the general categorization of noninfectious medical lung disease. This article divides medical lung disease into chronic and acute, where the temporality is determined first by clinical circumstances and then confirmed by histopathology. The low-power patterns of various lung diseases overlap, sometimes greatly. Nevertheless, classic examples of chronic disease can be sorted as linear, lobular filling, nodular dispersed, nodular lymphangitic, or cystic patterns at shirt-sleeve or low-power magnification. Classic examples of acute disease generally produce a solidifying pattern at shirt-sleeve or low-power magnification, which can be followed by a determination as to whether alveolar filling is principally fibrotic or principally fluid or cells at higher magnification. This article gives a simple system for the categorization of medical lung disease by this approach, with an emphasis on the most common diseases to be encountered in a general surgical pathology practice. In our experience, this system also proves useful in arriving at some therapeutic decisions. C1 Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02155 USA. Harvard Univ, Sch Med, Boston, MA USA. RP Mark, EJ (reprint author), Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02155 USA. EM emark@partners.org NR 8 TC 2 Z9 2 U1 0 U2 0 PU COLLEGE AMER PATHOLOGISTS PI NORTHFIELD PA C/O KIMBERLY GACKI, 325 WAUKEGAN RD, NORTHFIELD, IL 60093-2750 USA SN 0003-9985 J9 ARCH PATHOL LAB MED JI Arch. Pathol. Lab. Med. PD APR PY 2008 VL 132 IS 4 BP 539 EP 547 PG 9 WC Medical Laboratory Technology; Medicine, Research & Experimental; Pathology SC Medical Laboratory Technology; Research & Experimental Medicine; Pathology GA 284TU UT WOS:000254729700003 PM 18384206 ER PT J AU Young, RH AF Young, Robert H. TI Testicular tumors - Some new and a few perennial problems SO ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE LA English DT Article; Proceedings Paper CT 28th Annual Postgraduate Cource Current Concepts in Surgical Pathology CY NOV, 2006 CL Boston, MA SP Massachusetts Gen Hosp, Dept Pathol, Harvard Med Sch, Dept Continuing Med Educ ID SERTOLI-CELL TUMOR; JUVENILE GRANULOSA-CELL; CORD-STROMAL TUMORS; YOLK-SAC TUMOR; SPERMATOCYTIC SEMINOMA; CLINICOPATHOLOGICAL ANALYSIS; DIFFERENTIAL-DIAGNOSIS; INFANTILE TESTIS; INCLUDING 3; NEOPLASMS AB The histopathology of testicular tumors is presented, emphasizing new, unusual, or underemphasized aspects. Within the category of seminoma of the usual type, the recent literature has drawn attention to the presence in occasional tumors of solid or hollow tubules or spaces of varying sizes and shape that may result in cribriform or microcystic patterns, causing potential confusion with other neoplasms, most notably Sertoli cell tumor or yolk sac tumor. Although regions of typical neoplasia and awareness of this phenomenon usually will be diagnostic, immunohistochemistry may play a role in excluding Sertoli cell tumor or yolk sac tumor. Although immunohistochemistry can play an undoubted helpful role in this and selected other areas of testicular tumor evaluation, careful evaluation of the gross and routine microscopic features will solve the vast majority of diagnostic problems. An excellent review of immunohistochemistry in this area by R. E. Emerson, MD, and T. M. Ulbright, MD, is cited herein. Spermatocytic seminoma remains a crucial pitfall in diagnosis, and the pathologist must always be alert to the possible diagnosis when looking at a seminomatous neoplasm, particularly in an older patient, although about one third of these tumors occur in the usual seminoma age range. The embryonal carcinoma has a great diversity of patterns, which are briefly noted. The enigmatic and picturesque tumor, polyembryoma, which virtually never occurs in pure form but may be a confusing component of a variety of mixed germ cell tumors, is discussed and illustrated. The phenomenon of burnt-out germ cell neoplasia is also briefly noted and an excellent recent contribution is referred to. Within the sex cord-stromal family of neoplasms, recent contributions and elaborations of unusual morphologic features of Leydig cell tumors and Sertoli cell tumors are presented. Within the Leydig cell family, cyst formation, adipose metaplasia, calcification or ossification, and spindle cell patterns may be particularly confusing, and in the Sertoli cell family, a great array of patterns caused by differing admixtures of tubular, solid, and stromal components occur. The peculiar lesion, intratubular large cell hyalinizing Sertoli cell tumor, of young boys with Peutz-Jeghers syndrome, is briefly discussed. Some of the problems in the family of hematopoietic neoplasms are reviewed, these processes posing diverse problems in differential diagnosis and their correct recognition having crucial therapeutic implications. Although secondary tumors to the testis have not received the same attention in the literature as the similar phenomenon in the female gonad, remarkable examples of testicular spread of diverse neoplasms, usually carcinoma but rarely melanoma, are seen, and the pathologist should be alert to this possibility, particularly when examining an unusual morphology in an older patient. Finally, a few comments are made on the common paratesticular neoplasm, the adenomatoid tumor, highlighting its varied patterns and recent description of some of the issues that may arise when they undergo total or subtotal infarction. C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. RP Young, RH (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pathol, 55 Fruit St, Boston, MA 02114 USA. NR 54 TC 36 Z9 40 U1 0 U2 1 PU COLLEGE AMER PATHOLOGISTS PI NORTHFIELD PA C/O KIMBERLY GACKI, 325 WAUKEGAN RD, NORTHFIELD, IL 60093-2750 USA SN 0003-9985 J9 ARCH PATHOL LAB MED JI Arch. Pathol. Lab. Med. PD APR PY 2008 VL 132 IS 4 BP 548 EP 564 PG 17 WC Medical Laboratory Technology; Medicine, Research & Experimental; Pathology SC Medical Laboratory Technology; Research & Experimental Medicine; Pathology GA 284TU UT WOS:000254729700004 PM 18384207 ER PT J AU Ferry, JA AF Ferry, Judith A. TI Extranodal lymphoma SO ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE LA English DT Article; Proceedings Paper CT 28th Annual Postgraduate Cource Current Concepts in Surgical Pathology CY NOV, 2006 CL Boston, MA SP Massachusetts Gen Hosp, Dept Pathol, Harvard Med Sch, Dept Continuing Med Educ ID B-CELL LYMPHOMA; NON-HODGKINS-LYMPHOMA; EPSTEIN-BARR-VIRUS; PRIMARY EFFUSION LYMPHOMA; PRIMARY FOLLICULAR LYMPHOMA; TISSUE MALT LYMPHOMA; NERVOUS-SYSTEM LYMPHOMA; MARGINAL ZONE LYMPHOMA; AIDS-RELATED LYMPHOMAS; OF-THE-LITERATURE AB Lymphomas arising in extranodal sites are intriguing. The types of lymphomas encountered vary widely from one extranodal site to another. For many types of extranodal lymphomas, there are distinctive clinicopathologic features, sometimes including association with an underlying immunodeficiency syndrome, autoimmune disease, infection, or other immunologic disorder, or a predilection to affect patients of certain ethnic origins. Presented below is a review of lymphomas that are encountered most often in extranodal sites. C1 Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. RP Ferry, JA (reprint author), Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. EM jferry@partners.org NR 140 TC 23 Z9 25 U1 0 U2 2 PU COLLEGE AMER PATHOLOGISTS PI NORTHFIELD PA C/O KIMBERLY GACKI, 325 WAUKEGAN RD, NORTHFIELD, IL 60093-2750 USA SN 0003-9985 J9 ARCH PATHOL LAB MED JI Arch. Pathol. Lab. Med. PD APR PY 2008 VL 132 IS 4 BP 565 EP 578 PG 14 WC Medical Laboratory Technology; Medicine, Research & Experimental; Pathology SC Medical Laboratory Technology; Research & Experimental Medicine; Pathology GA 284TU UT WOS:000254729700005 PM 18384208 ER PT J AU Rosenberg, AE AF Rosenberg, Andrew E. TI Pseudosarcomas of soft tissue SO ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE LA English DT Article; Proceedings Paper CT 28th Annual Postgraduate Cource Current Concepts in Surgical Pathology CY NOV, 2006 CL Boston, MA SP Massachusetts Gen Hosp, Dept Pathol, Harvard Med Sch, Dept Continuing Med Educ ID PAROSTEAL OSTEOCHONDROMATOUS PROLIFERATION; MASSIVE LOCALIZED LYMPHEDEMA; ATYPICAL DECUBITAL FIBROPLASIA; FLORID REACTIVE PERIOSTITIS; NODULAR FASCIITIS; MYOSITIS-OSSIFICANS; NORAS LESION; ISCHEMIC FASCIITIS; MORBIDLY OBESE; HANDS AB One of the most common and important pitfalls in soft tissue pathology are the so-called pseudosarcomas. These lesions are nonneoplastic; however, their rapid growth, hypercellularity, cytologic atypia, and mitotic activity makes them prone to be misinterpreted as sarcoma. The most common of these lesions are fibroblastic/myofibroblastic and matrix- forming proliferations, including nodular fasciitis, proliferative fasciitis and myositis, ischemic fasciitis, massive localized edema, myositis ossificans, and bizarre parosteal osteochondromatous proliferation and related entities. Most of these lesions rarely recur following simple excision; therefore, their accurate recognition helps prevent excessive therapy. C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, James Homer Wright Pathol Labs, Boston, MA 02114 USA. RP Rosenberg, AE (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, James Homer Wright Pathol Labs, 55 Fruit St,Warren Bldg,Room 225, Boston, MA 02114 USA. EM arosenberg@partners.org NR 58 TC 38 Z9 41 U1 0 U2 1 PU COLLEGE AMER PATHOLOGISTS PI NORTHFIELD PA C/O KIMBERLY GACKI, 325 WAUKEGAN RD, NORTHFIELD, IL 60093-2750 USA SN 0003-9985 J9 ARCH PATHOL LAB MED JI Arch. Pathol. Lab. Med. PD APR PY 2008 VL 132 IS 4 BP 579 EP 586 PG 8 WC Medical Laboratory Technology; Medicine, Research & Experimental; Pathology SC Medical Laboratory Technology; Research & Experimental Medicine; Pathology GA 284TU UT WOS:000254729700006 PM 18384209 ER PT J AU Hasserjian, RP AF Hasserjian, Robert P. TI Reactive versus neoplastic bone marrow - Problems and pitfalls SO ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE LA English DT Article; Proceedings Paper CT 28th Annual Postgraduate Cource Current Concepts in Surgical Pathology CY NOV, 2006 CL Boston, MA SP Massachusetts Gen Hosp, Dept Pathol, Harvard Med Sch, Dept Continuing Med Educ ID SYSTEMIC LUPUS-ERYTHEMATOSUS; TYROSINE KINASE JAK2; HAIRY-CELL LEUKEMIA; MYELOPROLIFERATIVE DISORDERS; MYELODYSPLASTIC SYNDROME; POLYCYTHEMIA-VERA; TREPHINE BIOPSY; MUTATION; DECALCIFICATION; MYELOFIBROSIS AB Examination of the bone marrow poses several unique challenges to the pathologist: it is a semisolid organ without helpful gross correlation, it exists in a dynamic state with the peripheral blood and other organs of the lymphohemopoietic system, and the diagnosis of diseases affecting bone marrow often depends heavily on ancillary special studies. The bone marrow examination ideally encompasses review of the bone marrow biopsy histology ( with or without additional nondecalcified clot preparation material), bone marrow aspirate smear cytology, and the peripheral blood smear; optimal procurement and processing of these samples is critical in ensuring that a maximal level of diagnostic information can be extracted. The pathologist must be aware of the clinical context of the bone marrow and the results of ancillary tests, whether these are ordered by the pathologist or the clinician. A combination of excellent diagnostic samples, appropriate ancillary tests, and knowledge of the clinical context provides the best background to distinguish between the common reactive and neoplastic processes that involve the bone marrow and to avoid diagnostic pitfalls in making these distinctions. C1 Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02115 USA. RP Hasserjian, RP (reprint author), Massachusetts Gen Hosp, Dept Pathol, 55 Fruit St, Boston, MA 02115 USA. EM rhasserjian@partners.org NR 45 TC 2 Z9 2 U1 0 U2 0 PU COLLEGE AMER PATHOLOGISTS PI NORTHFIELD PA C/O KIMBERLY GACKI, 325 WAUKEGAN RD, NORTHFIELD, IL 60093-2750 USA SN 0003-9985 J9 ARCH PATHOL LAB MED JI Arch. Pathol. Lab. Med. PD APR PY 2008 VL 132 IS 4 BP 587 EP 594 PG 8 WC Medical Laboratory Technology; Medicine, Research & Experimental; Pathology SC Medical Laboratory Technology; Research & Experimental Medicine; Pathology GA 284TU UT WOS:000254729700007 PM 18384210 ER PT J AU Toledo, G Oliva, E AF Toledo, Gemma Oliva, Esther TI Smooth muscle tumors of the uterus - A practical approach SO ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE LA English DT Article; Proceedings Paper CT 28th Annual Postgraduate Cource Current Concepts in Surgical Pathology CY NOV, 2006 CL Boston, MA SP Massachusetts Gen Hosp, Dept Pathol, Harvard Med Sch, Dept Continuing Med Educ ID PERIVASCULAR EPITHELIOID CELL; SITE TROPHOBLASTIC TUMOR; OF-THE-LITERATURE; SOFT-PART SARCOMA; SEX-CORD TUMORS; MITOTICALLY ACTIVE LEIOMYOMAS; UNUSUAL HISTOLOGIC FEATURES; PLACENTAL-SITE; UTERINE LEIOMYOSARCOMA; MYXOID LEIOMYOSARCOMA AB Smooth muscle tumors (SMTs) are the most frequent mesenchymal tumors of the uterus. The majority of the uterine SMTs are readily classificable as benign or malignant based on their gross and microscopic appearances. However, when unusual features are seen in some leiomyoma variants, the differential diagnosis with a leiomyosarcoma may become challenging. Moreover, diagnostic criteria for the different subtypes of leiomyosarcoma are not uniform. Finally, non-smooth muscle tumors that originate in the uterus may show overlapping histologic and even immunohistochemical features with uterine SMTs, more commonly with the spindle and epithelioid variants, complicating their correct classification. The diagnosis of malignant uterine SMTs has important prognostic and therapeutic implications. This review provides a practical approach to the diagnosis of uterine leiomyosarcoma based on a systematic assessment of histologic parameters as well as a systematic approach to its differential diagnosis based on histologic and immunohistochemical features. C1 [Toledo, Gemma; Oliva, Esther] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. RP Oliva, E (reprint author), Massachusetts Gen Hosp, Dept Pathol, 55 Fruit St,Warren 2, Boston, MA 02114 USA. EM eoliva@partners.org RI Toledo, Gemma/H-9842-2012 NR 97 TC 30 Z9 33 U1 0 U2 0 PU COLLEGE AMER PATHOLOGISTS PI NORTHFIELD PA C/O KIMBERLY GACKI, 325 WAUKEGAN RD, NORTHFIELD, IL 60093-2750 USA SN 0003-9985 J9 ARCH PATHOL LAB MED JI Arch. Pathol. Lab. Med. PD APR PY 2008 VL 132 IS 4 BP 595 EP 605 PG 11 WC Medical Laboratory Technology; Medicine, Research & Experimental; Pathology SC Medical Laboratory Technology; Research & Experimental Medicine; Pathology GA 284TU UT WOS:000254729700008 PM 18384211 ER PT J AU Kradin, RL Mark, EJ AF Kradin, Richard L. Mark, Eugene J. TI The pathology of pulmonary disorders due to Aspergillus spp SO ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE LA English DT Article; Proceedings Paper CT 28th Annual Postgraduate Cource Current Concepts in Surgical Pathology CY NOV, 2006 CL Boston, MA SP Massachusetts Gen Hosp, Dept Pathol, Harvard Med Sch, Dept Continuing Med Educ ID NIGER FUNGUS BALL; INFECTION; DISEASE AB Diagnosing the range of pulmonary disorders caused by Aspergillus spp can be challenging. In instances of hypersensitivity responses to Aspergillus spp (ie, allergic bronchopulmonary aspergillosis, bronchocentric granulomatosis, and hypersensitivity pneumonitis), the surgical pathologist must be cognizant of their relationship to infection, as fungal organisms may be rare or absent from the biopsy specimens. Within the spectrum of opportunistic infection, it is critical to distinguish Aspergillus spp from other fungal mimics, as well as to discern whether infection is limited, progressive, or immanently life threatening. However, the surgical pathologist who establishes expertise in this area will be rewarded by the satisfaction of having contributed primarily to an important area of patient care. This article reviews the spectrum of pulmonary disorders due to infection by Aspergillus spp, with emphasis on the clinical implications of diagnosis. C1 [Kradin, Richard L.; Mark, Eugene J.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Kradin, Richard L.] Massachusetts Gen Hosp, Dept Pulm Crit Care Med, Boston, MA 02114 USA. RP Kradin, RL (reprint author), Massachusetts Gen Hosp, Dept Pathol, Warren 253, Boston, MA 02114 USA. EM rkradin@partners.org NR 16 TC 32 Z9 36 U1 0 U2 0 PU COLLEGE AMER PATHOLOGISTS PI NORTHFIELD PA C/O KIMBERLY GACKI, 325 WAUKEGAN RD, NORTHFIELD, IL 60093-2750 USA SN 0003-9985 J9 ARCH PATHOL LAB MED JI Arch. Pathol. Lab. Med. PD APR PY 2008 VL 132 IS 4 BP 606 EP 614 PG 9 WC Medical Laboratory Technology; Medicine, Research & Experimental; Pathology SC Medical Laboratory Technology; Research & Experimental Medicine; Pathology GA 284TU UT WOS:000254729700009 PM 18384212 ER PT J AU Lerwill, MF AF Lerwill, Melinda F. TI Flat epithelial atypia of the breast SO ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE LA English DT Article; Proceedings Paper CT 28th Annual Postgraduate Cource Current Concepts in Surgical Pathology CY NOV, 2006 CL Boston, MA SP Massachusetts Gen Hosp, Dept Pathol, Harvard Med Sch, Dept Continuing Med Educ ID CARCINOMA-IN-SITU; DUCTAL INTRAEPITHELIAL NEOPLASIA; COLUMNAR CELL LESIONS; PROMINENT APICAL SNOUTS; CYSTIC LOBULES; CANCER PROGRESSION; TUBULAR CARCINOMA; BENIGN-TUMORS; FOLLOW-UP; BIOPSY AB Flat epithelial atypia is a presumably neoplastic alteration of terminal duct-lobular units that is characterized by the replacement of the native luminal epithelium by ductal cells demonstrating low-grade cytologic atypia. The atypical cells maintain a "flat'' pattern of growth without evidence of architectural atypicality. Morphologic, immunohistochemical, and molecular investigations support that flat epithelial atypia represents an early step in the evolution of low-grade ductal carcinomas. It is frequently seen in association with atypical ductal hyperplasia, low-grade ductal carcinoma in situ, invasive tubular carcinoma, and lobular neoplasia. The risk for subsequent breast carcinoma remains to be defined, but flat epithelial atypia likely represents a nonobligate precursor with an extended time course to progression. Certain benign alterations may superficially mimic its appearance; careful attention to cytologic and architectural characteristics can help one distinguish these unrelated entities from flat epithelial atypia. C1 [Lerwill, Melinda F.] Massachusetts Gen Hosp, Dept Pathol, James Homer Wright Pathol Labs, Boston, MA 02114 USA. [Lerwill, Melinda F.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. RP Lerwill, MF (reprint author), Massachusetts Gen Hosp, Dept Pathol, James Homer Wright Pathol Labs, Boston, MA 02114 USA. EM mlerwill@partners.org NR 32 TC 24 Z9 24 U1 0 U2 0 PU COLLEGE AMER PATHOLOGISTS PI NORTHFIELD PA C/O KIMBERLY GACKI, 325 WAUKEGAN RD, NORTHFIELD, IL 60093-2750 USA SN 0003-9985 J9 ARCH PATHOL LAB MED JI Arch. Pathol. Lab. Med. PD APR PY 2008 VL 132 IS 4 BP 615 EP 621 PG 7 WC Medical Laboratory Technology; Medicine, Research & Experimental; Pathology SC Medical Laboratory Technology; Research & Experimental Medicine; Pathology GA 284TU UT WOS:000254729700010 PM 18384213 ER PT J AU Faquin, WC AF Faquin, William C. TI The thyroid gland - Recurring problems in histologic and cytologic evaluation SO ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE LA English DT Article; Proceedings Paper CT 28th Annual Postgraduate Cource Current Concepts in Surgical Pathology CY NOV, 2006 CL Boston, MA SP Massachusetts Gen Hosp, Dept Pathol, Harvard Med Sch, Dept Continuing Med Educ ID FINE-NEEDLE-ASPIRATION; INVASIVE FOLLICULAR CARCINOMA; CRIBRIFORM-MORULAR VARIANT; TALL CELL VARIANT; PAPILLARY CARCINOMA; RISK GROUP; CLINICOPATHOLOGICAL SIGNIFICANCE; DIFFERENTIATED CARCINOMA; MICROFOLLICULAR ADENOMA; PROGNOSTIC FACTORS AB Nodules of the thyroid gland are frequently encountered, occurring in up to 7% of the population, and although most of these nodules are benign, carcinomas of the thyroid gland are the most common malignancy of the endocrine system. Although the different types of thyroid carcinoma are few, a wide variety of recurring problems exists in both their histologic and cytologic evaluation. Here, I will review a selected group of problematic areas, including unusual histologic variants of follicular adenoma, criteria for diagnosing minimally invasive follicular carcinoma, the use of fine-needle aspiration as a screening test for follicular neoplasia, challenging variants of papillary carcinoma, and features of poorly differentiated carcinoma. C1 Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. RP Faquin, WC (reprint author), Massachusetts Gen Hosp, Dept Pathol, WRN 219,55 Fruit St, Boston, MA 02114 USA. EM WFaquin@Partners.org NR 72 TC 22 Z9 24 U1 0 U2 1 PU COLLEGE AMER PATHOLOGISTS PI NORTHFIELD PA C/O KIMBERLY GACKI, 325 WAUKEGAN RD, NORTHFIELD, IL 60093-2750 USA SN 0003-9985 J9 ARCH PATHOL LAB MED JI Arch. Pathol. Lab. Med. PD APR PY 2008 VL 132 IS 4 BP 622 EP 632 PG 11 WC Medical Laboratory Technology; Medicine, Research & Experimental; Pathology SC Medical Laboratory Technology; Research & Experimental Medicine; Pathology GA 284TU UT WOS:000254729700011 PM 18384214 ER PT J AU Park, DY Lauwers, GY AF Park, Do Youn Lauwers, Gregory Y. TI Gastric polyps - Classification and management SO ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE LA English DT Article; Proceedings Paper CT 28th Annual Postgraduate Cource Current Concepts in Surgical Pathology CY NOV, 2006 CL Boston, MA SP Massachusetts Gen Hosp, Dept Pathol, Harvard Med Sch, Dept Continuing Med Educ ID FUNDIC GLAND POLYPS; PEUTZ-JEGHERS-SYNDROME; FAMILIAL ADENOMATOUS POLYPOSIS; INFLAMMATORY FIBROID POLYPS; CRONKHITE-CANADA SYNDROME; HYPERPLASTIC POLYPS; FOLLOW-UP; GASTROINTESTINAL-TRACT; EPITHELIAL DYSPLASIA; HISTOLOGIC PATTERNS AB Gastric polyps can be broadly defined as luminal lesions projecting above the plane of the mucosal surface. They are relatively frequent in routine pathology practice, where the main goal is to rule out the possibility of malignancy. Various subtypes of gastric polyps are recognized and generally divided into nonneoplastic and neoplastic. We will review herein only a limited subset of gastric polyps representing the most common or, sometimes, challenging. C1 Massachusetts Gen Hosp, Dept Pathol, Gastrointestinal Pathol Serv, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. RP Lauwers, GY (reprint author), Massachusetts Gen Hosp, Dept Pathol, Gastrointestinal Pathol Serv, 55 Fruit St, Boston, MA 02114 USA. EM glauwers@partners.org NR 77 TC 31 Z9 32 U1 0 U2 0 PU COLLEGE AMER PATHOLOGISTS PI NORTHFIELD PA C/O KIMBERLY GACKI, 325 WAUKEGAN RD, NORTHFIELD, IL 60093-2750 USA SN 0003-9985 J9 ARCH PATHOL LAB MED JI Arch. Pathol. Lab. Med. PD APR PY 2008 VL 132 IS 4 BP 633 EP 640 PG 8 WC Medical Laboratory Technology; Medicine, Research & Experimental; Pathology SC Medical Laboratory Technology; Research & Experimental Medicine; Pathology GA 284TU UT WOS:000254729700012 PM 18384215 ER PT J AU Roberts, DJ AF Roberts, Drucilla J. TI Placental pathology, a survival guide SO ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE LA English DT Article; Proceedings Paper CT 28th Annual Postgraduate Cource Current Concepts in Surgical Pathology CY NOV, 2006 CL Boston, MA SP Massachusetts Gen Hosp, Dept Pathol, Harvard Med Sch, Dept Continuing Med Educ ID MATERNAL FLOOR INFARCTION; PERIVILLOUS FIBRIN DEPOSITION; FETAL THROMBOTIC VASCULOPATHY; OF-THE-LITERATURE; INTRAUTERINE GROWTH-RETARDATION; MASSIVE CHRONIC INTERVILLOSITIS; HEMORRHAGIC ENDOVASCULITIS; UMBILICAL-CORD; NEUROLOGIC IMPAIRMENT; MESENCHYMAL DYSPLASIA AB Placental pathology continues to be an underutilized, undertaught, and inadequately handled surgical subspecialty. The requests for placental pathology are soaring, due partly to demands from obstetricians and to the litigious environment in which they practice, and to improved obstetrical care leading to pregnancies in medically challenging situations. Evaluation of the placenta requires a good understanding of the questions and issues concerning both the fetus/infant and the mother. Information from placental pathology can be critical in early neonatal care and in reproductive planning for the family, and it can provide risk assessment for neurologic outcome of the infant. A comfortable interaction among the obstetric staff, mothers, and pathologists often obviates need for legal intervention in unexpected pregnancy outcomes. Some critical pathologic features that involve maternal and fetal management are illustrated herein. A template for gross examination and a few critical histopathologic diagnostic features with clincopathologic correlation are included. C1 Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. RP Roberts, DJ (reprint author), Massachusetts Gen Hosp, Dept Pathol, 55 Fruit St, Boston, MA 02114 USA. EM djroberts@partners.org NR 104 TC 15 Z9 15 U1 0 U2 3 PU COLLEGE AMER PATHOLOGISTS PI NORTHFIELD PA C/O KIMBERLY GACKI, 325 WAUKEGAN RD, NORTHFIELD, IL 60093-2750 USA SN 0003-9985 J9 ARCH PATHOL LAB MED JI Arch. Pathol. Lab. Med. PD APR PY 2008 VL 132 IS 4 BP 641 EP 651 PG 11 WC Medical Laboratory Technology; Medicine, Research & Experimental; Pathology SC Medical Laboratory Technology; Research & Experimental Medicine; Pathology GA 284TU UT WOS:000254729700013 PM 18384216 ER PT J AU Crowson, AN Magro, CM Mihm, MC AF Crowson, A. Neil Magro, Cynthia M. Mihm, Martin C., Jr. TI Interface dermatitis SO ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE LA English DT Article; Proceedings Paper CT 28th Annual Postgraduate Cource Current Concepts in Surgical Pathology CY NOV, 2006 CL Boston, MA SP Massachusetts Gen Hosp, Dept Pathol, Harvard Med Sch, Dept Continuing Med Educ ID PITYRIASIS LICHENOIDES CHRONICA; CUTANEOUS LUPUS-ERYTHEMATOSUS; CONNECTIVE-TISSUE DISEASE; PARVOVIRUS B19 INFECTION; MEMBRANE ATTACK COMPLEX; SOLUBLE FAS LIGAND; MOLECULAR CHARACTERIZATION; EPIDERMAL NECROLYSIS; AUTOIMMUNE-DISEASES; DRUG ERUPTIONS AB Interface dermatitis can be classified based upon the cell type that dominates the infiltrate (ie, neutrophilic, lymphocytic, or lymphohistiocytic) or by the intensity of the interface inflammation. Regarding lymphocytic interface dermatitis, there are 2 broad categories: cell-poor interface dermatitis, when only a sparse infiltrate of inflammatory cells is present along the dermoepidermal junction, or cell rich, which typically occurs as a heavy bandlike infiltrate that obscures the basal layers of the epidermis. In the case of lymphocytic interface dermatitis, the latter is often termed a lichenoid interface dermatitis. This review focuses upon the mononuclear cell-predominant forms of interface dermatitis. C1 [Crowson, A. Neil] St Johns Hosp, Reg Med Labs, Tulsa, OK 74104 USA. [Crowson, A. Neil] Univ Oklahoma, Dept Dermatol, Tulsa, OK USA. [Crowson, A. Neil] Univ Oklahoma, Dept Pathol & Surg, Tulsa, OK USA. [Magro, Cynthia M.] Cornell Univ, Weill Med Coll, Dept Pathol & Lab Med, New York, NY USA. [Mihm, Martin C., Jr.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Dermatol, Boston, MA USA. [Mihm, Martin C., Jr.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pathol, Boston, MA USA. RP Crowson, AN (reprint author), St Johns Hosp, Reg Med Labs, 1923 S Utica Ave, Tulsa, OK 74104 USA. EM ncrowson@sjmc.org NR 84 TC 15 Z9 15 U1 0 U2 3 PU COLLEGE AMER PATHOLOGISTS PI NORTHFIELD PA C/O KIMBERLY GACKI, 325 WAUKEGAN RD, NORTHFIELD, IL 60093-2750 USA SN 0003-9985 J9 ARCH PATHOL LAB MED JI Arch. Pathol. Lab. Med. PD APR PY 2008 VL 132 IS 4 BP 652 EP 666 PG 15 WC Medical Laboratory Technology; Medicine, Research & Experimental; Pathology SC Medical Laboratory Technology; Research & Experimental Medicine; Pathology GA 284TU UT WOS:000254729700014 PM 18384217 ER PT J AU Kesselheim, JC Johnson, J Joffe, S AF Kesselheim, Jennifer Cohn Johnson, Judith Joffe, Steven TI Pediatricians' reports of their education in ethics SO ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE LA English DT Article ID MEDICAL HOUSE OFFICERS; PROFESSIONALISM; CONFIDENCE; RESIDENCY; KNOWLEDGE AB Objective: To study pediatricians' assessments of the quality of their ethics education, the impact of various learning methods, and their confidence in confronting ethical dilemmas arising in pediatric practice. Design: Cross-sectional survey. Participants: Two hundred fifty physicians who completed pediatric or medicine/pediatric residency programs in 2004 were randomly selected from the American Medical Association Physician Masterfile. Evaluable responses were received from 150 of 215 eligible pediatricians (70%). Results: of 150 respondents, 44.7% rated their ethics education during residency as fair or poor. More than 80% reported that informal discussions with fellow residents and attending physicians had a moderate or major effect on their ethics education, whereas 53.3% reported that formal teaching conferences had a moderate or major impact. Most respondents (> 60%) reported confidence in addressing 4 of 23 ethical challenges, a moderate proportion (40%-60%) reported confidence in addressing 8 of 23 ethical challenges, and fewer (< 40%) reported confidence in addressing I I of the ethical challenges. Areas associated with low confidence included ethics in end-of-life care and research ethics. Conclusions: Efforts are needed to augment formal and informal ethics teaching during residency. Additional studies at both the individual physician and residency program levels are needed to improve the ethics education that pediatricians-in-training receive. C1 [Kesselheim, Jennifer Cohn; Joffe, Steven] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. [Kesselheim, Jennifer Cohn; Joffe, Steven] Childrens Hosp, Dept Med, Boston, MA 02115 USA. [Johnson, Judith] Childrens Hosp, Off Eth, Boston, MA 02115 USA. RP Joffe, S (reprint author), Dana Farber Canc Inst, Dept Pediat Oncol, 44 Binney St, Boston, MA 02115 USA. EM steven_joffe@dfci.harvard.edu OI Joffe, Steven/0000-0002-0667-7384 FU NCI NIH HHS [T32 CA009172] NR 13 TC 14 Z9 14 U1 1 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 1072-4710 J9 ARCH PEDIAT ADOL MED JI Arch. Pediatr. Adolesc. Med. PD APR PY 2008 VL 162 IS 4 BP 368 EP 373 DI 10.1001/archpedi.162.4.368 PG 6 WC Pediatrics SC Pediatrics GA 285BL UT WOS:000254752200011 PM 18391146 ER PT J AU Iezzoni, LL Ngo, LH Li, D Roetzheim, RG Drews, RE McCarthy, EP AF Iezzoni, Lisa L. Ngo, Long H. Li, Donglin Roetzheim, Richard G. Drews, Reed E. McCarthy, Ellen P. TI Treatment disparities for disabled medicare beneficiaries with stage I non-small cell lung cancer SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE disabled persons; lung cancer; medicare; rehabilitation ID SERIOUS MENTAL-ILLNESS; RACIAL-DIFFERENCES; PROSTATE-CANCER; SUBSTANCE-ABUSE; UNITED-STATES; DISABILITY; DISORDERS; POPULATION; DIAGNOSIS; SERVICES AB Objective: To compare initial treatment and survival of nonelderly adults with and without disabilities newly diagnosed with non-small cell lung cancer. Design: Retrospective analyses; population-based cohorts. Setting: Eleven Surveillance, Epidemiology, and End Results cancer registries. Participants: Persons with disability Medicare entitlement (n=1016) and nondisabled persons (n=8425) ages 21 to 64 years when diagnosed with stage 1, pathologically confirmed first primary non-small cell lung cancer between January 1: 1988, and December 31, 1999. Interventions: Not applicable. Main Outcome Measures: Initial cancer treatments (surgery, radiotherapy), survival (through December 31, 2001). Multivariable logistic regression and Cox proportional hazards regression estimated adjusted associations of disability status with treatments and survival. Results: Persons with disabilities were much more likely to be male, non-Hispanic black, and not currently married. Although 82.2% of nondisabled persons had surgery, 68.5% of disabled persons received operations. Adjusted relative risks (RRs) of receiving surgery were especially low for persons with respiratory disabilities (adjusted RR=.76; 95% confidence interval [CI], .67-.85), nervous system conditions (adjusted RR=.86; 95% CI, .76-.98), and mental health and/or mental retardation disorders (adjusted RR=.92; 95% CI, .86-.99). Persons with disabilities had significantly higher cancer-specific mortality rates (hazard ratio [HR]=1.37; 95% CI, 1.24-1.51) than persons without disabilities. Observed differences in cancer mortality persisted after adjusting for demographic and tumor characteristics (adjusted relative HR=1.23; 95% CI, 1.10-1.39). Further adjustment for surgery use eliminated statistically significant differences in cancer mortality between persons with and without disabilities across disabling conditions. Conclusions: Persons with disabilities were much less likely than nondisabled Medicare beneficiaries to receive surgery; statistically significant cancer-specific mortality differences disappeared after accounting for these treatment differences. Future research must explore reasons for these findings and whether survival of disabled Medicare beneficiaries with early-stage, non-small cell lung cancer could improve if surgical treatment disparities were eliminated. C1 [Iezzoni, Lisa L.] Massachusetts Gen Hosp, Inst Hlth Policy, Boston, MA 02114 USA. [Iezzoni, Lisa L.; Ngo, Long H.; Li, Donglin; McCarthy, Ellen P.] Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, Boston, MA 02215 USA. [Drews, Reed E.] Beth Israel Deaconess Med Ctr, Div Hematol & Oncol, Boston, MA 02215 USA. [Roetzheim, Richard G.] Dept Family Med, Tampa, FL USA. [Roetzheim, Richard G.] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA. RP Iezzoni, LL (reprint author), Massachusetts Gen Hosp, Inst Hlth Policy, 50 Staniford St,Rm 901, Boston, MA 02114 USA. EM liezzoni@partners.org RI Roetzheim, Richard/J-4696-2012 FU NCI NIH HHS [R01 CA100029] NR 45 TC 19 Z9 19 U1 0 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD APR PY 2008 VL 89 IS 4 BP 595 EP 601 DI 10.1016/j.apmr.2007.09.042 PG 7 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 289IG UT WOS:000255047600001 PM 18373987 ER PT J AU Collinger, JL Boninger, ML Koontz, AM Price, R Sisto, SA Tolerico, ML Cooper, RA AF Collinger, Jennifer L. Boninger, Michael L. Koontz, Alicia M. Price, Robert Sisto, Sue Ann Tolerico, Michelle L. Cooper, Rory A. TI Shoulder biomechanics during the push phase of wheelchair propulsion: A multisite study of persons with paraplegia SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE biomechanics; rehabilitation; shoulder; spinal cord injuries; wheelchairs ID SPINAL-CORD-INJURY; AFT SEAT POSITION; COORDINATE SYSTEM; 2 SPEEDS; KINEMATICS; KINETICS; MOTION; USERS; PAIN; PATHOLOGY AB Objectives: To present a descriptive analysis and comparison of shoulder kinetics and kinematics during wheelchair propulsion at multiple speeds (self-selected and steady-state target speeds) for a large group of manual wheelchair users with paraplegia while also investigating the effect of pain and subject demographics on propulsion. Design: Case series. Setting: Three biomechanics laboratories at research institutions. Participants: Volunteer sample of 61 persons with paraplegia who use a manual wheelchair for mobility. Intervention: Subjects propelled their own wheelchairs on a dynamometer at 3 speeds (self-selected, 0.9m/s, 1.8m/s) while kinetic and kinematic data were recorded. Main Outcome Measures: Differences in demographics between sites, correlations between subject characteristics, comparison of demographics and biomechanics between persons with and without pain, linear regression using subject characteristics to predict shoulder biomechanics, comparison of biomechanics between speed conditions. Results: Significant increases in shoulder joint loading with increased propulsion velocity were observed. Resultant force increased from 54.4 +/- 13.5N during the 0.9m/s trial to 75.7 +/- 20.7N at 1.8m/s (P<.001). Body weight was the primary demographic variable that affected shoulder forces, whereas pain did not affect biomechanics. Peak shoulder joint loading occurs when the arm is extended and internally rotated, which may leave the shoulder at risk for injury. Conclusions: Body-weight maintenance, as well as other interventions designed to reduce the force required to propel a wheelchair, should be implemented to reduce the prevalence of shoulder pain and injury among manual wheelchair users. C1 [Collinger, Jennifer L.; Boninger, Michael L.; Koontz, Alicia M.; Tolerico, Michelle L.; Cooper, Rory A.] VA Pittsburgh Hlth Care Syst, Human Engn Res Lab, Pittsburgh, PA 15206 USA. [Collinger, Jennifer L.; Boninger, Michael L.; Koontz, Alicia M.; Tolerico, Michelle L.; Cooper, Rory A.] VA Pittsburgh Hlthcare Syst, Dev Ctr, Pittsburgh, PA USA. [Collinger, Jennifer L.; Boninger, Michael L.; Koontz, Alicia M.; Cooper, Rory A.] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA USA. [Collinger, Jennifer L.; Boninger, Michael L.; Tolerico, Michelle L.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA. [Boninger, Michael L.; Koontz, Alicia M.; Cooper, Rory A.] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA. [Price, Robert] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. [Sisto, Sue Ann] Kessler Med Rehabil Res & Educ Corp, Spinal Cord Injury Rehabil Res, W Orange, NJ USA. [Sisto, Sue Ann] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Phys Med & Rehabil, Newark, NJ 07103 USA. RP Boninger, ML (reprint author), VA Pittsburgh Hlth Care Syst, Human Engn Res Lab, 7180 Highland Dr 151R1-H, Pittsburgh, PA 15206 USA. EM boninger@pitt.edu RI Moro, Juan Carlos/A-4315-2015; OI Moro, Juan Carlos/0000-0002-4886-2967; Boninger, Michael/0000-0001-6966-919X NR 32 TC 41 Z9 42 U1 4 U2 18 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD APR PY 2008 VL 89 IS 4 BP 667 EP 676 DI 10.1016/j.apmr.2007.09.052 PG 10 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 289IG UT WOS:000255047600011 PM 18373997 ER PT J AU Morse, LR Stolzmann, K Nguyen, HP Jain, NB Zayac, C Gagnon, DR Tun, CG Garshick, E AF Morse, Leslie R. Stolzmann, Kelly Nguyen, Hiep P. Jain, Nitin B. Zayac, Cara Gagnon, David R. Tun, Carlos G. Garshick, Eric TI Association between mobility mode and C-reactive protein levels in men with chronic spinal cord injury SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article; Proceedings Paper CT American-Spinal-Injury-Association/45th Annual Meeting of the International-Spinal-Cord-Society CY JUN 27, 2006 CL Boston, MA SP Amer Spinal Injury Assoc, Int Spinal Cord Soc DE cardiovascular diseases; inflammation; rehabilitation; spinal cord injuries ID BODY-MASS INDEX; CARDIOVASCULAR-DISEASE; INFLAMMATORY MARKERS; METABOLIC SYNDROME; MYOCARDIAL-INFARCTION; CIRCULATING LEVELS; PHYSICAL-ACTIVITY; RISK; EXERCISE; HEALTH AB Objective: To assess clinical determinants of systemic inflammation in persons with chronic spinal cord injury (SCI). Design: Cross-sectional survey. Setting: Veterans Affairs medical center. Participants: As part of an epidemiologic study assessing SCI-related health conditions, 63 men with chronic SCI provided a blood sample and information regarding locomotive mode and personal habits. Interventions: Not applicable. Main Outcome Measure: Plasma high-sensitivity C-reactive protein (CRP). Results: The mean +/- standard deviation age was 56 +/- 14y and participants were assessed 21 +/- 13y after injury. Adjusting for heart disease. hypertension, and body mass index (BMI), the mean CRP in 12 motorized wheelchair users (5.11 mg/L) was not Significantly greater than 23 participants who used a manual wheelchair (2.19mg/L) (P=.085) but was significantly greater than the 17 who walked with an assistive device (1.41mg) (P=.005) and the 12 who walked independently (1.63mg/L) (P=.027). CRP was significantly greater in participants with obesity but was not related to age, smoking, or SCI level and severity. CRP was elevated in participants reporting a urinary tract infection (UTI) or pressure ulcer within a year, but adjustment for this did not account for the elevated CRP in motorized wheelchair users. Conclusions: These results suggest that CRP in chronic SCI is independently related to locomotive mode, BMI, and a history of pressure ulcers and UTI. It is suggested that future studies in SCI investigate whether modifying these factors influence systemic inflammation and cardiovascular health. C1 [Morse, Leslie R.] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA 02114 USA. [Stolzmann, Kelly; Nguyen, Hiep P.; Jain, Nitin B.; Zayac, Cara; Gagnon, David R.; Tun, Carlos G.; Garshick, Eric] VA Boston Hlthcare Syst, Dept Vet Affairs, Res & Dev Serv, Boston, MA USA. [Stolzmann, Kelly; Nguyen, Hiep P.; Jain, Nitin B.; Zayac, Cara] Harvard Univ, Sch Med, Program Res VA Boston, Boston, MA 02115 USA. [Gagnon, David R.] Boston Univ, Sch Publ Hlth, Dept Biostat, VA Boston Hlthcare Syst, Boston, MA 02215 USA. [Tun, Carlos G.] Harvard Univ, Sch Med, VA Boston Hlthcare Syst, Rehabil Med Serv, Boston, MA 02115 USA. [Garshick, Eric] Harvard Univ, Sch Med, Pulm & Crit Care Med Sect, Med Serv,VA Boston Hlth Care Syst, Boston, MA 02115 USA. [Jain, Nitin B.; Garshick, Eric] Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02115 USA. RP Morse, LR (reprint author), Harvard Univ, Sch Med, Dept Phys Med & Rehabil, 125 Nashua St, Boston, MA 02114 USA. EM lmorse4@partners.org RI Morse, Leslie/C-9442-2015; OI Morse, Leslie/0000-0002-7426-6341; Gagnon, David/0000-0002-6367-3179 FU NICHD NIH HHS [R01 HD42141, R01 HD042141, R01 HD042141-05] NR 42 TC 13 Z9 13 U1 0 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD APR PY 2008 VL 89 IS 4 BP 726 EP 731 DI 10.1016/j.apmr.2007.09.046 PG 6 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 289IG UT WOS:000255047600018 PM 18374004 ER PT J AU Rask-Madsen, C King, GL AF Rask-Madsen, Christian King, George L. TI More sugar, less blood vessels - Another piece in the puzzle of increased cardiovascular risk in diabetes SO ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY LA English DT Editorial Material ID ENDOTHELIAL GROWTH-FACTOR; INSULIN-RESISTANCE; EXPRESSION; ANGIOGENESIS; ISCHEMIA; RECEPTOR; SYSTEM; CELLS; RAT C1 [Rask-Madsen, Christian; King, George L.] Harvard Univ, Sch Med, Joslin Diabet Ctr, Div Res, Boston, MA 02215 USA. RP King, GL (reprint author), Harvard Univ, Sch Med, Joslin Diabet Ctr, Div Res, 1 Joslin Pl,Room 4504, Boston, MA 02215 USA. EM george.king@joslin.harvard.edu FU NEI NIH HHS [K08 EY018677, K08 EY018677-01, R01 EY016150, R01 EY016150-02]; NIDDK NIH HHS [P30 DK036836, R01 DK053105, R01 DK053105-08, R01 DK53105, P30 DK036836-21] NR 14 TC 6 Z9 6 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1079-5642 J9 ARTERIOSCL THROM VAS JI Arterioscler. Thromb. Vasc. Biol. PD APR PY 2008 VL 28 IS 4 BP 608 EP 610 DI 10.1161/ATVBAHA.108.162057 PG 3 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA 276YK UT WOS:000254179400004 PM 18354093 ER PT J AU Kay, J Matteson, EL Dasgupta, B Nash, P Durez, P Hall, S Hsia, EC Han, J Wagner, C Xu, ZH Visvanathan, S Rahman, MU AF Kay, Jonathan Matteson, Eric L. Dasgupta, Bhaskar Nash, Peter Durez, Patrick Hall, Stephen Hsia, Elizabeth C. Han, John Wagner, Carrie Xu, Zhenhua Visvanathan, Sudha Rahman, Mahboob U. TI Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate SO ARTHRITIS AND RHEUMATISM LA English DT Article ID MONOCLONAL-ANTIBODY; CONTROLLED-TRIAL; ADALIMUMAB; IMMUNOGENICITY; IMPROVEMENT; ETANERCEPT; VALIDATION; INFLIXIMAB; CRITERIA; COUNTS AB Objective. To assess the efficacy, safety, and pharmacology of subcutaneous administration of golimumab in patients with active rheumatoid arthritis (RA) despite treatment with methotrexate (MTX). Methods. Patients were randomly assigned in a double-blinded manner to receive injections of placebo plus MTX or 50 mg or 100 mg golimumab every 2 or 4 weeks plus MTX through week 48. Patients originally assigned to receive injections every 2 weeks had the interval increased to every 4 weeks starting at week 20. The primary end point was the proportion of patients meeting the American College of Rheumatology 20% improvement criteria (achieving an ACR20 response) at week 16. The study was powered to detect a difference in the primary end point when the combined golimumab groups and at least I of the individual dose groups were compared with placebo. Results. The primary end point was attained. Sixty-one percent of patients in the combined golimumab plus MTX dose groups achieved an ACR20 response at week 16 compared with 37% of patients in the placebo plus MTX group (P = 0.010). In addition, 79% of patients in the group receiving 100 mg golimumab every 2 weeks achieved an ACR20 response (P < 0.001 versus placebo). Through week 20 (after which patients receiving placebo were switched to active infliximab therapy), serious adverse events were reported in 9% of patients in the combined golimumab groups and in 6% of patients in the placebo group. Conclusion. Golimumab plus MTX effectively reduces the signs and symptoms of RA and is generally well tolerated in patients with an inadequate response to MTX. C1 [Kay, Jonathan] Massachusetts Gen Hosp, Rheumatol Unit, Boston, MA 02114 USA. [Kay, Jonathan] Harvard Univ, Sch Med, Boston, MA USA. [Matteson, Eric L.] Mayo Clin, Coll Med, Rochester, MN USA. [Dasgupta, Bhaskar] Southend Univ Hosp, W Cliff, Essex, England. [Nash, Peter] Nambour Hosp, Brisbane, Qld, Australia. [Nash, Peter] Univ Queensland, Brisbane, Qld, Australia. [Durez, Patrick] Univ Catholique Louvain, Clin Univ St Luc, B-1200 Brussels, Belgium. [Hall, Stephen] Cabrini Med Ctr, Malvern, Vic, Australia. [Hsia, Elizabeth C.; Han, John; Wagner, Carrie; Xu, Zhenhua; Visvanathan, Sudha; Rahman, Mahboob U.] Centocor Res & Dev Inc, Malvern, PA USA. [Hsia, Elizabeth C.; Rahman, Mahboob U.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. RP Kay, J (reprint author), Massachusetts Gen Hosp, Rheumatol Unit, 32 Fruit St Yawkey 2-174, Boston, MA 02114 USA. EM jkay@partners.org RI Nash, Peter/D-7392-2013; OI Nash, Peter/0000-0002-2571-788X; Kay, Jonathan/0000-0002-8970-4260 NR 17 TC 168 Z9 176 U1 2 U2 5 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0004-3591 J9 ARTHRITIS RHEUM JI Arthritis Rheum. PD APR PY 2008 VL 58 IS 4 BP 964 EP 975 DI 10.1002/art.23383 PG 12 WC Rheumatology SC Rheumatology GA 293OS UT WOS:000255345200007 PM 18383539 ER PT J AU Zee, RYL Germer, S Thomas, A Raji, A Rhees, B Ridker, PM Lindpaintner, K Williams, GH Nathan, DM Martin, M AF Zee, Robert Y. L. Germer, Soren Thomas, Abraham Raji, Annaswammy Rhees, Brian Ridker, Paul M. Lindpaintner, Klaus Williams, Gordon H. Nathan, David M. Martin, Mitchell TI C-reactive protein gene variation and type 2 diabetes mellitus: A case-control study SO ATHEROSCLEROSIS LA English DT Article DE CRP gene variation; type 2 diabetes ID INNATE IMMUNE-SYSTEM; GENOME-WIDE SEARCH; HAPLOTYPE RECONSTRUCTION; SUSCEPTIBILITY LOCUS; INSULIN-RESISTANCE; PIMA-INDIANS; CRP LEVELS; ASSOCIATION; POLYMORPHISMS; POPULATION AB Objective: C-reactive protein (CRP) gene variation, in particular an rs2794521 variant was recently associated with type 2 diabetes mellitus (T2DM) in Pima Indians. Research design and methods: The present investigation was conducted to replicate this previous association, and to further examine the potential association of a set of common CRP gene variants with the prevalence of T2DM in a case-control investigation. A total of 629 T2DM cases (476 Whites, and 153 Blacks), and 579 controls (481 Whites, and 98 Blacks) were examined. Seven CRP variants were evaluated: rs3093059, rs2794521, rs3091244, rs1417938, rs1800947, rs1130864, and rs1205. Results: Using a marker-by- marker logistic regression analysis, adjusting for age, smoking, gender, and body mass index, we found an association of rs3093059 (recessive: OR, 7.01; 95% CI, 1.16-42.22; p = 0.03) with T2DM in the white study population, and an association, albeit not statistically significant, of rs2794521 with T2DM in the Black study population. Moreover, further analysis using a haplotype-based analysis showed no evidence for an association of the haplotypes tested with T2DM. Conclusion: Further studies are needed to examine the possible involvement of C-reactive protein gene variation in the pathogenesis of type 2 diabetes mellitus. (c) 2007 Elsevier Ireland Ltd. All rights reserved. C1 [Zee, Robert Y. L.] Brigham & Womens Hosp, Ctr Cardiovasc Dis Prevent, Lab Genet & Mol Epidemiol, Boston, MA 02215 USA. [Thomas, Abraham; Raji, Annaswammy; Williams, Gordon H.] Brigham & Womens Hosp, Div Endocrinol Diabet & Hypertens, Boston, MA 02215 USA. [Nathan, David M.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Diabet, Boston, MA USA. [Lindpaintner, Klaus] Roche Ctr Med Genom, Basel, Switzerland. [Rhees, Brian] Roche Mol Syst Inc, Alameda, CA USA. [Germer, Soren; Martin, Mitchell] Roche Pharma, Nutley, NJ USA. [Thomas, Abraham] Henry Ford Hlth Syst, Div Endocrinol Diabet Bone & Mineral Disorders, Detroit, MI USA. RP Zee, RYL (reprint author), Brigham & Womens Hosp, Ctr Cardiovasc Dis Prevent, Lab Genet & Mol Epidemiol, 900 Commonwealth Ave E, Boston, MA 02215 USA. EM rzee@rics.bwh.harvard.edu FU NCRR NIH HHS [5K23RR017394] NR 22 TC 25 Z9 26 U1 0 U2 2 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0021-9150 J9 ATHEROSCLEROSIS JI Atherosclerosis PD APR PY 2008 VL 197 IS 2 BP 931 EP 936 DI 10.1016/j.atherosclerosis.2007.08.013 PG 6 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 295DJ UT WOS:000255454900058 PM 17900590 ER PT J AU Iosifescu, DV Jensen, JE Charles, D Medeiros, CL Nierenberg, AA Fava, M Renshaw, PF AF Iosifescu, Dan V. Jensen, J. Eric Charles, Dana Medeiros, Carissa L. Nierenberg, Andrew A. Fava, Maurizio Renshaw, Perry F. TI The antidepressant effect of the SSRI Escitalopram is associated with increases in GABA and in bioenergetic metabolism SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 63rd Annual Convention of the Society-of-Biological-Psychiatry CY 2008 CL Washington, DC SP Soc Biol Psychiat C1 [Iosifescu, Dan V.; Charles, Dana; Nierenberg, Andrew A.; Fava, Maurizio] Massachusetts Gen Hosp, Depress Clin & Res Program, Boston, MA 02114 USA. [Jensen, J. Eric; Medeiros, Carissa L.; Renshaw, Perry F.] McLean Hosp, Brain Imaging Ctr, Belmont, MA 02178 USA. NR 0 TC 2 Z9 2 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 1 PY 2008 VL 63 IS 7 SU S MA 118E BP 41S EP 41S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 276SV UT WOS:000254163700129 ER PT J AU Shin, LM Lasko, N Karpf, R Milad, MR Fischman, AJ Rauch, SL Pitman, RK AF Shin, Lisa M. Lasko, Natasha Karpf, Rachel Milad, Mohammed R. Fischman, Alan J. Rauch, Scott L. Pitman, Roger K. TI Regional cerebral glucose metabolic rates in dorsal anterior Cingulate cortex: A pre-existing risk factor for PTSD SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 63rd Annual Convention of the Society-of-Biological-Psychiatry CY 2008 CL Washington, DC SP Soc Biol Psychiat C1 [Shin, Lisa M.] Tufts Univ, Dept Psychol, Medford, MA 02155 USA. [Lasko, Natasha; Karpf, Rachel; Milad, Mohammed R.; Pitman, Roger K.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat, Boston, MA USA. [Fischman, Alan J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol, Boston, MA USA. [Rauch, Scott L.] Harvard Univ, Sch Med, McLean Hosp, Dept Psychiat, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 1 PY 2008 VL 63 IS 7 SU S MA 119B BP 42S EP 42S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 276SV UT WOS:000254163700132 ER PT J AU Koenigsberg, HW Fan, J Ochsner, K Pizzarello, S Guise, K Tecuta, L New, A Goodman, M Siever, LJ AF Koenigsberg, Harold W. Fan, Jin Ochsner, Kevin Pizzarello, Scott Guise, Kevin Tecuta, Lucia New, Antonia Goodman, Marianne Siever, Larry J. TI Dysregulated networks in the cognitive control of emotion in borderline personality disorder SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 63rd Annual Convention of the Society-of-Biological-Psychiatry CY 2008 CL Washington, DC SP Soc Biol Psychiat C1 [Koenigsberg, Harold W.; Fan, Jin; Pizzarello, Scott; Guise, Kevin; Tecuta, Lucia; New, Antonia; Goodman, Marianne; Siever, Larry J.] Mt Sinai Sch Med, New York, NY USA. [Koenigsberg, Harold W.; Goodman, Marianne] James J Peters VA Med Ctr, Bronx, NY USA. [Ochsner, Kevin] Columbia Univ, Dept Psychol, New York, NY 10027 USA. [Siever, Larry J.] Mirecc, James J Peters VA Med Ctr, New York, NY USA. RI Guise, Kevin/C-1145-2009 NR 0 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 1 PY 2008 VL 63 IS 7 SU S MA 145 BP 51S EP 52S PG 2 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 276SV UT WOS:000254163700162 ER PT J AU Radant, A Dobie, D Meichle, S Goodnow, S Pritzl, D Tsuang, D AF Radant, Allen Dobie, Dorcas Meichle, Sean Goodnow, Sara Pritzl, Denise Tsuang, Debby TI Novel analog of the antisaccade task with manual response: Application to schizophrenia patients SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 63rd Annual Convention of the Society-of-Biological-Psychiatry CY 2008 CL Washington, DC SP Soc Biol Psychiat C1 [Radant, Allen; Dobie, Dorcas; Meichle, Sean; Goodnow, Sara; Pritzl, Denise; Tsuang, Debby] Univ Washington, Seattle, WA 98195 USA. [Radant, Allen; Dobie, Dorcas; Meichle, Sean; Goodnow, Sara; Pritzl, Denise; Tsuang, Debby] VA Puget Sound Hlth Care Syst, Seattle Div, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 1 PY 2008 VL 63 IS 7 SU S MA 229 BP 77S EP 77S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 276SV UT WOS:000254163700246 ER PT J AU Greenwood, TA Light, GA Cadenhead, KS Freedman, R Green, MF Gur, RE Kelsoe, JR Murray, SS Nuechterlein, KH Olincy, A Radant, AD Schork, NJ Seidman, LJ Siever, LJ Silverman, JM Swerdlow, NR Tsuang, DW Turetsky, BI Weinberger, DR Braff, DL AF Greenwood, Tiffany A. Light, Gregory A. Cadenhead, Kristin S. Freedman, Robert Green, Michael F. Gur, Raquel E. Kelsoe, John R. Murray, Sarah S. Nuechterlein, Keith H. Olincy, Ann Radant, Allen D. Schork, Nicholas J. Seidman, Larry J. Siever, Larry J. Silverman, Jeremy M. Swerdlow, Neal R. Tsuang, Debby W. Turetsky, Bruce I. Weinberger, Daniel R. Braff, David L. TI Initial analyses of 94 candidate genes and twelve endophenotypes for schizophrenia from the consortium on the genetics of schizophrenia SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 63rd Annual Convention of the Society-of-Biological-Psychiatry CY 2008 CL Washington, DC SP Soc Biol Psychiat C1 [Greenwood, Tiffany A.; Light, Gregory A.; Cadenhead, Kristin S.; Kelsoe, John R.; Swerdlow, Neal R.; Braff, David L.] Univ Calif San Diego, La Jolla, CA 92093 USA. [Greenwood, Tiffany A.; Kelsoe, John R.] Univ Colorado, Hlth Sci Ctr, Hlth Care Syst, San Diego, CA USA. [Freedman, Robert; Olincy, Ann] Univ Colorado, Hlth Sci Ctr, Denver, CO 80202 USA. [Green, Michael F.; Nuechterlein, Keith H.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Gur, Raquel E.; Turetsky, Bruce I.] Univ Penn, Philadelphia, PA 19104 USA. [Murray, Sarah S.] Scripps, La Jolla, CA USA. [Radant, Allen D.; Tsuang, Debby W.] Univ Washington, Seattle, WA 98195 USA. [Radant, Allen D.; Tsuang, Debby W.] Puget Sound Vet Adm, Hlth Care Syst, Seattle, WA USA. [Schork, Nicholas J.] Scripps Res Inst, La Jolla, CA USA. [Seidman, Larry J.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Massachusetts Mental Hlth Ctr Publ Psychiat Div, Boston, MA USA. [Siever, Larry J.; Silverman, Jeremy M.] Mt Sinai Sch Med, New York, NY USA. [Siever, Larry J.] James J Peters VA Med Ctr, New York, NY USA. [Weinberger, Daniel R.] NIMH, Clin Brain Disorders Branch, Genes Cognit & Psychosis Program, NIH, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 1 PY 2008 VL 63 IS 7 SU S MA 247 BP 82S EP 83S PG 2 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 276SV UT WOS:000254163700264 ER PT J AU Yao, JK Dougherty, GG Reddy, RD Keshavan, MS Montrose, DM Matson, WR Rozen, S McEvoy, J Kaddurah-Daouk, R AF Yao, Jeffrey K. Dougherty, George G. Reddy, Ravinder D. Keshavan, Matcheri S. Montrose, Debra M. Matson, Wayne R. Rozen, Steve McEvoy, Joseph Kaddurah-Daouk, Rima TI Discriminative tryptophan pathway in first-episode neuroleptic-naive patients with schizophrenia SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 63rd Annual Convention of the Society-of-Biological-Psychiatry CY 2008 CL Washington, DC SP Soc Biol Psychiat C1 [Yao, Jeffrey K.; Dougherty, George G.] VA Pittsburgh Healthcare Syst, Med Res Serv, Pittsburgh, PA USA. [Yao, Jeffrey K.; Dougherty, George G.; Reddy, Ravinder D.; Keshavan, Matcheri S.; Montrose, Debra M.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA. [Yao, Jeffrey K.] Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, Pittsburgh, PA 15261 USA. [Keshavan, Matcheri S.] Wayne State Univ, Dept Psychiat, Detroit, MI USA. [Matson, Wayne R.] Bedford VA Med Ctr, Med Res Serv, Bedford, MA USA. [Rozen, Steve] Whitehead Inst Biomed Res, Cambridge, MA 02142 USA. [McEvoy, Joseph; Kaddurah-Daouk, Rima] Duke Univ, Ctr Med, Dept Psychiat, Durham, NC USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 1 PY 2008 VL 63 IS 7 SU S MA 272 BP 91S EP 91S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 276SV UT WOS:000254163700289 ER PT J AU Kuperberg, GR Kreher, DA Goff, DC Swain, A Holt, DJ AF Kuperberg, Gina R. Kreher, Donna A. Goff, Don C. Swain, Abigail Holt, Daphne J. TI Selective neural deficits in comprehending emotional information within social vignettes in schizophrenia SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 63rd Annual Convention of the Society-of-Biological-Psychiatry CY 2008 CL Washington, DC SP Soc Biol Psychiat C1 [Kuperberg, Gina R.; Goff, Don C.; Holt, Daphne J.] Massachusetts Gen Hosp, Charlestown, MA USA. [Kreher, Donna A.; Swain, Abigail] Tufts Univ, Boston, MA 02111 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 1 PY 2008 VL 63 IS 7 SU S MA 368 BP 121S EP 122S PG 2 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 276SV UT WOS:000254163700385 ER PT J AU Koenigsberg, HW Fan, J Ochsner, K Pizzarello, S Guise, K Dorantes, C New, A Goodman, M Siever, LJ AF Koenigsberg, Harold W. Fan, Jin Ochsner, Kevin Pizzarello, Scott Guise, Kevin Dorantes, Christine New, Antonia Goodman, Marianne Siever, Larry J. TI Neural networks activated during cognitive reappraisal by emotional detachment SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 63rd Annual Convention of the Society-of-Biological-Psychiatry CY 2008 CL Washington, DC SP Soc Biol Psychiat C1 [Koenigsberg, Harold W.; Fan, Jin; Pizzarello, Scott; Guise, Kevin; Dorantes, Christine; New, Antonia; Goodman, Marianne; Siever, Larry J.] Mt Sinai Sch Med, New York, NY USA. [Ochsner, Kevin] Columbia Univ, Dept Psychol, New York, NY 10027 USA. [Koenigsberg, Harold W.; Goodman, Marianne; Siever, Larry J.] James J Peters VA Med Ctr, Bronx, NY USA. RI Guise, Kevin/C-1145-2009 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 1 PY 2008 VL 63 IS 7 SU S MA 413 BP 135S EP 135S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 276SV UT WOS:000254163700430 ER PT J AU Katzman, M Brawman-Mintzer, O Reyes, E Olausson, B Liu, S Brecher, M AF Katzman, Martin Brawman-Mintzer, Olga Reyes, Efren Olausson, Bengt Liu, Sherry Brecher, Martin TI Extended release quetiapine fumarate (quetiapine XR) monotherapy in long-term treatment of generalized anxiety disorder (GAD): Efficacy and tolerability results from a randomized, placebo-controlled trial SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 63rd Annual Convention of the Society-of-Biological-Psychiatry CY 2008 CL Washington, DC SP Soc Biol Psychiat C1 [Katzman, Martin] START Clin, Toronto, ON, Canada. [Katzman, Martin] Univ Toronto, Dept Psychiat, Toronto, ON, Canada. [Katzman, Martin] No Ontario Sch Med, Thunder Bay, ON, Canada. [Katzman, Martin] Lakehead Univ, Dept Psychol, Thunder Bay, ON P7B 5E1, Canada. [Brawman-Mintzer, Olga] Med Univ S Carolina, Dept Psychiat & Behav Sci, N Charleston, SC USA. [Brawman-Mintzer, Olga] Ralph H Johnson VA Med Ctr, N Charleston, SC USA. [Reyes, Efren] Natl Ctr Mental Hlth, Mandaluyong City, Philippines. [Olausson, Bengt] AstraZeneca, Res & Dev, Sodertalje, Sweden. [Liu, Sherry; Brecher, Martin] AstraZeneca, Wilmington, DE USA. NR 0 TC 3 Z9 3 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 1 PY 2008 VL 63 IS 7 SU S MA 435 BP 141S EP 141S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 276SV UT WOS:000254163700451 ER PT J AU Adler, CM DelBello, M Perlis, R Chang, KK AF Adler, Caleb M. DelBello, Melissa Perlis, Roy Chang, Kiki TI Bipolar disorder in adolescents and adults, continuum or dichotomy? SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 63rd Annual Convention of the Society-of-Biological-Psychiatry CY 2008 CL Washington, DC SP Soc Biol Psychiat C1 [Adler, Caleb M.; DelBello, Melissa] Univ Cincinnati, Coll Med, Cincinnati, OH USA. [Perlis, Roy] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Chang, Kiki] Stanford Univ, Stanford, CA 94305 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 1 PY 2008 VL 63 IS 7 SU S MA 451 BP 145S EP 145S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 276SV UT WOS:000254163700467 ER PT J AU Koenigsberg, HW Fan, J Ochsner, K Pizzarello, S Dorantes, C Goodman, M New, A Siever, LJ AF Koenigsberg, Harold W. Fan, Jin Ochsner, Kevin Pizzarello, Scott Dorantes, Christine Goodman, Marianne New, Antonia Siever, Larry J. TI Neural networks activated during cognitive reappraisal by emotional detachment SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 63rd Annual Convention of the Society-of-Biological-Psychiatry CY 2008 CL Washington, DC SP Soc Biol Psychiat C1 [Koenigsberg, Harold W.; Fan, Jin; Pizzarello, Scott; Dorantes, Christine; Goodman, Marianne; New, Antonia; Siever, Larry J.] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. [Koenigsberg, Harold W.; Goodman, Marianne; Siever, Larry J.] James J Peters VA Med Ctr, Bronx, NY USA. [Ochsner, Kevin] Columbia Univ, Dept Psychol, New York, NY 10027 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 1 PY 2008 VL 63 IS 7 SU S MA 473 BP 151S EP 151S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 276SV UT WOS:000254163700483 ER PT J AU Buck, K AF Buck, Kari TI Genetic control of sedative-hypnotic drug physiological dependence and associated withdrawal in mice SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 63rd Annual Convention of the Society-of-Biological-Psychiatry CY 2008 CL Washington, DC SP Soc Biol Psychiat C1 [Buck, Kari] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Buck, Kari] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 1 PY 2008 VL 63 IS 7 SU S MA 492 BP 157S EP 157S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 276SV UT WOS:000254163700502 ER PT J AU Siever, LJ Ducci, F Hodgkinson, CA New, AS Koenigsberg, HW Goodman, M Goldman, D AF Siever, Larry J. Ducci, Francesca Hodgkinson, Colin A. New, Antonia S. Koenigsberg, Harold W. Goodman, Marianne Goldman, David TI Genotypes and endophenotypes in borderline personality disorder SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 63rd Annual Convention of the Society-of-Biological-Psychiatry CY 2008 CL Washington, DC SP Soc Biol Psychiat C1 [Siever, Larry J.; New, Antonia S.; Koenigsberg, Harold W.; Goodman, Marianne] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. [Siever, Larry J.; New, Antonia S.; Koenigsberg, Harold W.; Goodman, Marianne] Bronx Vet Affairs Med Ctr, Dept Psychiat, Bronx, NY USA. [Ducci, Francesca; Hodgkinson, Colin A.; Goldman, David] NIAAA, Neurogenet Lab, NIH, Rockville, MD 20852 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 1 PY 2008 VL 63 IS 7 SU S MA 505 BP 161S EP 161S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 276SV UT WOS:000254163700515 ER PT J AU Berlin, HA Koran, LM Jenike, MA Shapira, NA Chaplin, W Pallanti, S Hollander, E AF Berlin, Heather A. Koran, Lorrin M. Jenike, Michael A. Shapira, Nathan A. Chaplin, William Pallanti, Stefano Hollander, Eric TI Double-blind, placebo-controlled trial of topiramate augmentation in the treatment of obsessive-compulsive disorder SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 63rd Annual Convention of the Society-of-Biological-Psychiatry CY 2008 CL Washington, DC SP Soc Biol Psychiat C1 [Koran, Lorrin M.] Stanford Univ, Med Ctr, Sch Med, Stanford, CA 94305 USA. [Berlin, Heather A.; Chaplin, William; Pallanti, Stefano; Hollander, Eric] Mt Sinai Sch Med, New York, NY USA. [Jenike, Michael A.] Harvard Univ, Sch Med, Boston, MA USA. [Jenike, Michael A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Shapira, Nathan A.] Univ Florida, Ctr Med, Gainesville, FL USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 1 PY 2008 VL 63 IS 7 SU S MA 532 BP 170S EP 170S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 276SV UT WOS:000254163700542 ER PT J AU Liebman, RE aan het Rot, M New, AS Charney, DS AF Liebman, Rachel E. aan het Rot, Marije New, Antonia S. Charney, Dennis S. TI Interpersonal functioning in women after sexual assault: Is it determined by trauma burden? SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 63rd Annual Convention of the Society-of-Biological-Psychiatry CY MAY 01-03, 2008 CL Washington, DC SP Soc Biol Psychiat C1 [Liebman, Rachel E.; aan het Rot, Marije; New, Antonia S.; Charney, Dennis S.] Mt Sinai Sch Med, New York, NY USA. [New, Antonia S.] Bronx Vet Affairs Med Ctr, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 1 PY 2008 VL 63 IS 7 SU S MA 552 BP 176S EP 176S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 276SV UT WOS:000254163700562 ER PT J AU Milad, MR Gold, AL Shin, LM Handwerger, K Lasko, N Orr, SP Pitman, RK Rauch, SL AF Milad, Mohammed R. Gold, Andrea L. Shin, Lisa M. Handwerger, Katie Lasko, Natasha Orr, Scott P. Pitman, Roger K. Rauch, Scott L. TI Neuroimaging correlates of impaired extinction memory in PTSD SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 63rd Annual Convention of the Society-of-Biological-Psychiatry CY 2008 CL Washington, DC SP Soc Biol Psychiat C1 [Milad, Mohammed R.; Gold, Andrea L.; Shin, Lisa M.; Lasko, Natasha; Orr, Scott P.; Pitman, Roger K.; Rauch, Scott L.] Massachusetts Gen Hosp, Charlestown, MA USA. [Milad, Mohammed R.; Gold, Andrea L.; Shin, Lisa M.; Lasko, Natasha; Orr, Scott P.; Pitman, Roger K.; Rauch, Scott L.] Harvard Univ, Sch Med, Charlestown, MA USA. [Shin, Lisa M.; Handwerger, Katie] Tufts Univ, Medford, MA 02155 USA. [Lasko, Natasha; Orr, Scott P.] Manchester Vet Affairs Med Ctr, Res Serv, Manchester, NH USA. [Rauch, Scott L.] McLean Hosp, Belmont, MA 02178 USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 1 PY 2008 VL 63 IS 7 SU S MA 556 BP 178S EP 178S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 276SV UT WOS:000254163700566 ER PT J AU Dias, RS Sachs, GS Lafer, B Del Debbio, A Nierenberg, AA Joffe, H AF Dias, Rodrigo S. Sachs, Gary S. Lafer, Beny Del Debbio, Alessandro Nierenberg, Andrew A. Joffe, Hadine TI Clinical correlates of premenstrual mood changes in women with bipolar disorder SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 63rd Annual Convention of the Society-of-Biological-Psychiatry CY 2008 CL Washington, DC SP Soc Biol Psychiat C1 [Dias, Rodrigo S.] Massachusetts Gen Hosp, Bipolar Clin & Res Program, Sao Paulo, Brazil. [Dias, Rodrigo S.] Massachusetts Gen Hosp, Dept Psychiat, Sao Paulo, Brazil. [Dias, Rodrigo S.] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil. [Sachs, Gary S.; Nierenberg, Andrew A.] Massachusetts Gen Hosp, Bipolar Clin & Res Program, Boston, MA 02114 USA. [Lafer, Beny] Univ Sao Paulo, Sch Med, Dept Psychiat, Sao Paulo, Brazil. [Del Debbio, Alessandro] Univ Pisa, Bipolar Clin, Pisa, Italy. [Del Debbio, Alessandro] Univ Pisa, Res Program & Neurobiol, Pisa, Italy. [Del Debbio, Alessandro] Univ Pisa, Clin Affect Disorders Program, Pisa, Italy. [Joffe, Hadine] Univ Pisa, Massachusetts Gen Hosp & Neurobiol, Pisa, Italy. Massachusetts Gen Hosp, Perinata Psychiat Res Unit, Boston, MA 02114 USA. RI Lafer, Beny/C-1055-2012; Lafer, Beny/F-9390-2015; Dias, Rodrigo/N-8985-2013 OI Lafer, Beny/0000-0002-6132-9999; Lafer, Beny/0000-0002-6132-9999; Dias, Rodrigo/0000-0002-1315-7205 NR 0 TC 0 Z9 0 U1 2 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 1 PY 2008 VL 63 IS 7 SU S MA 570 BP 182S EP 182S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 276SV UT WOS:000254163700580 ER PT J AU Ostacher, MJ Lebeau, RT Nierenberg, AA Lund, H Sachs, GS Simon, NM AF Ostacher, Michael J. Lebeau, Richard T. Nierenberg, Andrew A. Lund, Hannah Sachs, Gary S. Simon, Naomi M. TI Cigarette smoking is associated with suicidality in bipolar disorder SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 63rd Annual Convention of the Society-of-Biological-Psychiatry CY 2008 CL Washington, DC SP Soc Biol Psychiat C1 [Ostacher, Michael J.; Nierenberg, Andrew A.; Sachs, Gary S.; Simon, Naomi M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02115 USA. [Lebeau, Richard T.; Lund, Hannah] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 1 PY 2008 VL 63 IS 7 SU S MA 591 BP 188S EP 188S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 276SV UT WOS:000254163700601 ER PT J AU Thermenos, HW Whitfield-Gabrieli, S Giuliano, A Makris, N Brown, AB Lee, E Koch, JK Faraone, SV Tsuang, MT Seidman, LJ AF Thermenos, Heidi W. Whitfield-Gabrieli, Susan Giuliano, Anthony Makris, Nikos Brown, Ariel B. Lee, Erica Koch, Jennifer K. Faraone, Stephen V. Tsuang, Ming T. Seidman, Larry J. TI Neural correlates of working memory in adolescents and young adults at genetic risk for bipolar disorder SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 63rd Annual Convention of the Society-of-Biological-Psychiatry CY 2008 CL Washington, DC SP Soc Biol Psychiat C1 [Thermenos, Heidi W.; Giuliano, Anthony; Lee, Erica; Koch, Jennifer K.; Seidman, Larry J.] Harvard Univ, Sch Med, Dept Psychiat, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA. [Thermenos, Heidi W.; Makris, Nikos; Seidman, Larry J.] Harvard Univ, Sch Med, MIT, Charlestown, MA USA. [Thermenos, Heidi W.; Makris, Nikos; Seidman, Larry J.] Massachusetts Gen Hosp, Martinos Ctr Biomed imaging, Charlestown, MA USA. [Whitfield-Gabrieli, Susan] MIT, Dept Brain & Cognit Sci, Boston, MA USA. [Brown, Ariel B.; Seidman, Larry J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat, Boston, MA 02115 USA. [Faraone, Stephen V.] SUNY Upstate Med Univ, Dept Psychiat, Syracuse, NY USA. [Faraone, Stephen V.] SUNY Upstate Med Univ, Med Genet Res Program, Syracuse, NY USA. [Tsuang, Ming T.] Univ Calif San Diego, Ctr Behav Genom, Dept Psychiat, La Jolla, CA 92093 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 1 PY 2008 VL 63 IS 7 SU S MA 598 BP 190S EP 190S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 276SV UT WOS:000254163700608 ER PT J AU Wang, LY Petrie, EC Rohde, K Hart, KL Hoff, DJ Shofer, JB Raskind, MA Peskind, ER AF Wang, Lucy Y. Petrie, Eric C. Rohde, Kirsten Hart, Kim L. Hoff, David J. Shofer, Jane B. Raskind, Murray A. Peskind, Elaine R. TI Prazosin for treatment of disruptive agitation in Alzheimer's disease SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 63rd Annual Convention of the Society-of-Biological-Psychiatry CY 2008 CL Washington, DC SP Soc Biol Psychiat C1 [Wang, Lucy Y.; Petrie, Eric C.; Shofer, Jane B.; Raskind, Murray A.; Peskind, Elaine R.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Wang, Lucy Y.; Petrie, Eric C.; Rohde, Kirsten; Hart, Kim L.; Hoff, David J.; Raskind, Murray A.; Peskind, Elaine R.] VA Puget Sound Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 1 PY 2008 VL 63 IS 7 SU S MA 629 BP 200S EP 200S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 276SV UT WOS:000254163700639 ER PT J AU Baker, RA Fava, M Mankoski, R Tran, QV Pikalov, A Owen, R Berman, RM AF Baker, Ross A. Fava, Maurizio Mankoski, Raymond Tran, Quynh-Van Pikalov, Andrei Owen, Randall Berman, Robert M. TI Adjunctive aripiprazole provides beneficial effects in sexual functioning for patients with an inadequate response to standard antidepressant monotherapy SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 63rd Annual Convention of the Society-of-Biological-Psychiatry CY 2008 CL Washington, DC SP Soc Biol Psychiat C1 [Baker, Ross A.; Mankoski, Raymond] Bristol Myers Squibb Co, Plainsboro, NJ USA. [Fava, Maurizio] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Tran, Quynh-Van; Pikalov, Andrei] Otsuka Amer Pharmaceut Inc, Rockville, MD USA. [Owen, Randall; Berman, Robert M.] Bristol Myers Squibb Co, Wallingford, CT 06492 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 1 PY 2008 VL 63 IS 7 SU S MA 630 BP 201S EP 201S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 276SV UT WOS:000254163700640 ER PT J AU Houston, J Fijal, B Perlis, R Sutton, V Trivedi, M AF Houston, John Fijal, Bonnie Perlis, Roy Sutton, Virginia Trivedi, Madhukar TI A candidate gene association analysis of the common adverse events in a randomized clinical trial for major depression SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 63rd Annual Convention of the Society-of-Biological-Psychiatry CY 2008 CL Washington, DC SP Soc Biol Psychiat C1 [Houston, John; Fijal, Bonnie] Eli Lilly & Co, Indianapolis, IN 46285 USA. [Perlis, Roy] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Perlis, Roy; Sutton, Virginia] i3, Stat Anal, Cary, NC USA. [Trivedi, Madhukar] Univ Texas SW Med Ctr Dallas, Sch Med, Dallas, TX 75390 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 1 PY 2008 VL 63 IS 7 SU S MA 643 BP 204S EP 205S PG 2 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 276SV UT WOS:000254163700653 ER PT J AU Leuchter, AF Cook, IA Marangell, LB Gilmer, WS Burgoyne, KS Howland, RH Trivedi, MH Zisook, S Jain, R Losifescu, D Fava, M Greenwald, S AF Leuchter, Andrew F. Cook, Ian A. Marangell, Lauren B. Gilmer, William S. Burgoyne, Karl S. Howland, Robert H. Trivedi, Madhukar H. Zisook, Sidney Jain, Rakesh Losifescu, Daniel Fava, Maurizio Greenwald, Scott TI Biomarkers for rapid identification of treatment effectiveness in major depression (BRITE-MD): Predictors of response and remission SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 63rd Annual Convention of the Society-of-Biological-Psychiatry CY 2008 CL Washington, DC SP Soc Biol Psychiat C1 [Leuchter, Andrew F.; Cook, Ian A.] Univ Calif Los Angeles, Inst Neuropsychiat, Los Angeles, CA 90024 USA. [Marangell, Lauren B.] Eli Lilly & Co, Indianapolis, IN 46285 USA. [Gilmer, William S.] Northwestern Univ, Chicago, IL 60611 USA. [Burgoyne, Karl S.] Univ Calif Los Angeles, Harbor Med Ctr, Los Angeles, CA 90024 USA. [Howland, Robert H.] Univ Pittsburgh, Pittsburgh, PA USA. [Trivedi, Madhukar H.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. [Zisook, Sidney] Univ Calif San Diego, San Diego, CA 92103 USA. [Jain, Rakesh] RD Clin Res, Houston, TX USA. [Fava, Maurizio] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Greenwald, Scott] Aspect Med Syst, Norwood, MA USA. RI Howland, Robert/K-6937-2015 OI Howland, Robert/0000-0002-6533-6010 NR 0 TC 0 Z9 0 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 1 PY 2008 VL 63 IS 7 SU S MA 651 BP 207S EP 207S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 276SV UT WOS:000254163700661 ER PT J AU Perlis, R Fijal, B Houston, J Sutton, V Adams, D Trivedi, M AF Perlis, Roy Fijal, Bonnie Houston, John Sutton, Virginia Adams, David Trivedi, Madhukar TI COMT variants associated with duloxetine response: A candidate gene association analysis of a randomized clinical treatment trial for major depression SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 63rd Annual Convention of the Society-of-Biological-Psychiatry CY 2008 CL Washington, DC SP Soc Biol Psychiat C1 [Perlis, Roy] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA. [Fijal, Bonnie; Houston, John; Adams, David] Eli Lilly & Co, Indianapolis, IN 46285 USA. [Sutton, Virginia] i3, Stat Anal, Cary, NC USA. [Trivedi, Madhukar] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 1 PY 2008 VL 63 IS 7 SU S MA 663 BP 211S EP 211S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 276SV UT WOS:000254163700673 ER PT J AU Pizzagalli, DA Dillon, DG Evins, AE Holmes, AJ Birk, J Goetz, E Pachas, G Loebl, T AF Pizzagalli, Diego A. Dillon, Daniel G. Evins, A. Eden Holmes, Avram J. Birk, Jeffrey Goetz, Elena Pachas, Gladys Loebl, Tsafrir TI Effects of a single dose of bupropion on the neural substrates of reward processing in major depression: A double-blind, placebo-controlled fMRI study SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 63rd Annual Convention of the Society-of-Biological-Psychiatry CY MAY 01-03, 2008 CL Washington, DC SP Soc Biol Psychiat C1 [Pizzagalli, Diego A.; Dillon, Daniel G.; Holmes, Avram J.; Birk, Jeffrey; Goetz, Elena] Harvard Univ, Cambridge, MA 02138 USA. [Evins, A. Eden; Pachas, Gladys; Loebl, Tsafrir] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 1 PY 2008 VL 63 IS 7 SU S MA 665 BP 211S EP 211S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 276SV UT WOS:000254163700675 ER PT J AU Spencer, KM McCarley, RW AF Spencer, Kevin M. McCarley, Robert W. TI Source analysis of the 40 Hz auditory steady-state response deficit in schizophrenia SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 63rd Annual Convention of the Society-of-Biological-Psychiatry CY 2008 CL Washington, DC SP Soc Biol Psychiat C1 [Spencer, Kevin M.; McCarley, Robert W.] Harvard Univ, Sch Med, VA Boston Healthcare Syst, Brockton, MA 02401 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 1 PY 2008 VL 63 IS 7 SU S MA 695 BP 220S EP 220S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 276SV UT WOS:000254163700705 ER PT J AU Seidman, LJ AF Seidman, Larry J. TI Functional and structural indices of adolescent brain development in the risk for schizophrenia SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 63rd Annual Convention of the Society-of-Biological-Psychiatry CY 2008 CL Washington, DC SP Soc Biol Psychiat C1 [Seidman, Larry J.] Beth Israel Deaconess Med Ctr, Dept Psychiat, Boston, MA 02215 USA. [Seidman, Larry J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 1 PY 2008 VL 63 IS 7 SU S MA 756 BP 241S EP 241S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 276SV UT WOS:000254163700766 ER PT J AU Biederman, J Makris, N Valera, EM Monuteaux, M Hodge, S Kaiser, J Brown, AB Aleardi, M Caviness, V Faraone, S Seidman, L AF Biederman, Joseph Makris, Nikos Valera, Eve M. Monuteaux, Michael Hodge, Steven Kaiser, Jonathan Brown, Ariel B. Aleardi, Megan Caviness, Verne Faraone, Stephen Seidman, Larry TI Cortical thinning in comorbid ADHD and bipolar disorder SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 63rd Annual Convention of the Society-of-Biological-Psychiatry CY MAY 01-03, 2008 CL Washington, DC SP Soc Biol Psychiat C1 [Biederman, Joseph; Valera, Eve M.; Monuteaux, Michael; Brown, Ariel B.; Aleardi, Megan; Seidman, Larry] Massachusetts Gen Hosp, Clin & Res Program Pediat Psychopharmacol & Adult, Boston, MA 02114 USA. [Makris, Nikos] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Makris, Nikos] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [Valera, Eve M.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA. [Hodge, Steven; Kaiser, Jonathan] Martinos Ctr Biomed Imaging, Ctr Morphometr Anal, Charlestown, MA USA. [Brown, Ariel B.] Boston Univ, Sch Med, Program Behav Neurosci, Boston, MA 02215 USA. [Caviness, Verne] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Faraone, Stephen] SUNY Upstate Med Univ, Dept Psychiat & Behav Sci, Syracuse, NY USA. [Seidman, Larry] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Massachusetts Mental Hlth Ctr,Publ Psychiat Div, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 1 PY 2008 VL 63 IS 7 SU S MA 763 BP 243S EP 243S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 276SV UT WOS:000254163700773 ER PT J AU Brown, AB Biederman, J Valera, EM Bush, G Spencer, T Makris, N Faraone, S Doyle, A Mick, E Monuteaux, M Seidman, L AF Brown, Ariel B. Biederman, Joseph Valera, Eve M. Bush, George Spencer, Thomas Makris, Nikos Faraone, Stephen Doyle, Alysa Mick, Eric Monuteaux, Michael Seidman, Larry TI Effect of dopamine transporter gene (DAT1) on dorsal anterior Cingulate activation in ADHD SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 63rd Annual Convention of the Society-of-Biological-Psychiatry CY MAY 01-03, 2008 CL Washington, DC SP Soc Biol Psychiat C1 [Brown, Ariel B.] Boston Univ, Sch Med, Program Behav Neurosci, Boston, MA 02118 USA. [Brown, Ariel B.; Biederman, Joseph; Spencer, Thomas; Mick, Eric; Monuteaux, Michael; Seidman, Larry] Massachusetts Gen Hosp, Clin & Res Program Pediat Psychopharm & Adult ADH, Boston, MA 02114 USA. [Valera, Eve M.; Bush, George] Massachusetts Gen Hosp, Dept Psychiat, Charlestown, MA USA. [Makris, Nikos] Massachusetts Gen Hosp, Dept Neurol & Radiol, Charlestown, MA USA. [Faraone, Stephen] SUNY Upstate Med Univ, Dept Psychiat, Syracuse, NY USA. SUNY Upstate Med Univ, Dept Psychiat, Syracuse, NY USA. [Faraone, Stephen] SUNY Upstate Med Univ, Dept Neurosci & Physiol, Syracuse, NY USA. [Seidman, Larry] Harvard Univ, Beth Israel Deaconess Med Ctr, Massachusetts Mental Hlth Ctr, Publ Psychiat Div, Boston, MA 02215 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 1 PY 2008 VL 63 IS 7 SU S MA 764 BP 244S EP 244S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 276SV UT WOS:000254163700774 ER PT J AU Goodman, M Patil, U Triebwasser, J Diamond, E New, A Siever, L AF Goodman, Marianne Patil, Uday Triebwasser, Joseph Diamond, Elizabeth New, Antonia Siever, Larry TI Gender differences in the developmental trajectories of borderline personality SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 63rd Annual Convention of the Society-of-Biological-Psychiatry CY 2008 CL Washington, DC SP Soc Biol Psychiat C1 [Goodman, Marianne; Triebwasser, Joseph; New, Antonia; Siever, Larry] James J Peter Va Med Ctr, Bronx, NY USA. [Goodman, Marianne; Patil, Uday; Triebwasser, Joseph; Diamond, Elizabeth; New, Antonia; Siever, Larry] Mt Sinai Sch Med, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 1 PY 2008 VL 63 IS 7 SU S MA 770 BP 245S EP 246S PG 2 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 276SV UT WOS:000254163700780 ER PT J AU Monuteaux, MC AF Monuteaux, Michael C. TI Does DRD4 genotype predict brain volumes in adults with ADHD? SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 63rd Annual Convention of the Society-of-Biological-Psychiatry CY 2008 CL Washington, DC SP Soc Biol Psychiat C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 1 PY 2008 VL 63 IS 7 SU S MA 73 BP 246S EP 246S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 276SV UT WOS:000254163700783 ER PT J AU Sallee, F McGough, JJ Wigall, T Farrand, K Lyne, A Biederman, J AF Sallee, Floyd McGough, James J. Wigall, Timothy Farrand, Kimberly Lyne, Andrew Biederman, Joseph TI Long-term safety and efficacy of guanfacine extended release in children and adolescents with Attention-Deficit/Hyperactivity disorder SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 63rd Annual Convention of the Society-of-Biological-Psychiatry CY 2008 CL Washington, DC SP Soc Biol Psychiat C1 [Sallee, Floyd] Univ Cincinnati, Dept Psychiat, Cincinnati, OH USA. [McGough, James J.] Univ Calif Los Angeles, Los Angeles, CA USA. [Wigall, Timothy] Univ Calif Irvine, Child Dev Ctr, Irvine, CA USA. [Farrand, Kimberly] Shire Dev Inc, Wayne, PA USA. [Lyne, Andrew] Shire Pharmavceut Dev LTD, Basingstoke, Hants, England. [Biederman, Joseph] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Clin & Res Program Pediat Psychopharm, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 1 PY 2008 VL 63 IS 7 SU S MA 776 BP 247S EP 247S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 276SV UT WOS:000254163700786 ER PT J AU Kanellopoulou, I Bowie, C Anderson, H Halpern, B Harvey, PD AF Kanellopoulou, Isabella Bowie, Christopher Anderson, Hannah Halpern, Brooke Harvey, Phil D. TI Effect of metabolic syndrome on cognition in older schizophrenic patients SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 63rd Annual Convention of the Society-of-Biological-Psychiatry CY 2008 CL Washington, DC SP Soc Biol Psychiat C1 Mt Sinai Sch Med, James J Peters VAMC, Bronx, NY USA. [Harvey, Phil D.] Emory Univ, Sch Med, Atlanta, GA 30322 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 1 PY 2008 VL 63 IS 7 SU S MA 804 BP 256S EP 256S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 276SV UT WOS:000254163700814 ER PT J AU Levitt, J Alvarado, JL Kubicki, M Nestor, PG McCarley, RW Shenton, ME AF Levitt, James Alvarado, Jorge L. Kubicki, Marek Nestor, Paul G. McCarley, Robert W. Shenton, Martha E. TI Decreased fractional anisotropy in the anterior limb of the internal capsule in schizophrenia: A diffusion tensor Imaging study SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 63rd Annual Convention of the Society-of-Biological-Psychiatry CY 2008 CL Washington, DC SP Soc Biol Psychiat C1 [Levitt, James; Nestor, Paul G.; McCarley, Robert W.; Shenton, Martha E.] Harvard Univ, VA Boston Health Care Syst, Brockton, MA 02401 USA. [Levitt, James; Alvarado, Jorge L.; Kubicki, Marek; Shenton, Martha E.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Psychiat Neuroimaging Lab, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 1 PY 2008 VL 63 IS 7 SU S MA 810 BP 258S EP 258S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 276SV UT WOS:000254163700820 ER PT J AU Milanovic, SM Thermenos, HW Goldstein, JM Gabrieli, SW Makris, N Brown, A LaViolette, P Koch, JK Tsuang, MT Buka, SL Seidman, LJ AF Milanovic, Snezana M. Thermenos, Heidi W. Goldstein, Jill M. Gabrieli, Susan W. Makris, Nikos Brown, Ariel LaViolette, Peter Koch, Jennifer K. Tsuang, Ming T. Buka, Stephen L. Seidman, Larry J. TI Direct comparison of fMRI of working memory in schizophrenia and psychotic bipolar disorder SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 63rd Annual Convention of the Society-of-Biological-Psychiatry CY 2008 CL Washington, DC SP Soc Biol Psychiat C1 [Milanovic, Snezana M.; Goldstein, Jill M.; Koch, Jennifer K.; Tsuang, Ming T.; Seidman, Larry J.] Harvard Univ, Sch Med, Massachusetts Mental Hlth Ctr, Dept Psychiat,Div Publ Psychiat, Boston, MA 02115 USA. [Milanovic, Snezana M.; Goldstein, Jill M.; Brown, Ariel; LaViolette, Peter; Tsuang, Ming T.; Seidman, Larry J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat, Boston, MA 02114 USA. [Milanovic, Snezana M.; Thermenos, Heidi W.; Seidman, Larry J.] Massachusetts Gen Hosp, Martinos Ctr Biomed Imaging, Dept Psychiat, Charlestown, MA 02129 USA. [Thermenos, Heidi W.] Harvard Univ, Sch Med, Massachusetts Mental Hlth Ctr,Div Publ Psychiat, Beth Israel Deaconess Med Ctr,Dept Psychiat, Boston, MA 02115 USA. [Goldstein, Jill M.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Div Womens Hlth,Connors Ctr Womens Hlth, Boston, MA 02115 USA. [Goldstein, Jill M.] Dept Psychiat, Boston, MA 02115 USA. [Gabrieli, Susan W.] MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA. [Makris, Nikos] Massachusetts Gen Hosp, Ctr Morphometr Anal, Charlestown, MA 02129 USA. [Brown, Ariel] Boston Univ, Dept Psychol, Ph D Program Behav Neurosci, Boston, MA 02215 USA. [Tsuang, Ming T.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA. [Tsuang, Ming T.; Buka, Stephen L.] Brown Univ, Dept Community Hlth, Providence, RI 02912 USA. RI Buka, Stephen/H-7335-2014 OI Buka, Stephen/0000-0002-8578-9308 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 1 PY 2008 VL 63 IS 7 SU S MA 818 BP 260S EP 261S PG 2 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 276SV UT WOS:000254163700828 ER PT J AU Whitfield-Gabrieli, S Thermenos, HW Milanovic, S Tsuang, MT Faraone, SV McCarley, RW Shenton, ME Green, AI LaViolette, P Wojcik, J Gabrieli, JDE Seidman, LJ AF Whitfield-Gabrieli, Susan Thermenos, Heidi W. Milanovic, Snezana Tsuang, Ming T. Faraone, Stephen V. McCarley, Robert W. Shenton, Martha E. Green, Alan I. LaViolette, Peter Wojcik, Joanne Gabrieli, John D. E. Seidman, Larry J. TI Hyperactivity and hyperconnectivity of the default network in schizophrenia and in first degree relatives of persons with schizophrenia SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 63rd Annual Convention of the Society-of-Biological-Psychiatry CY 2008 CL Washington, DC SP Soc Biol Psychiat C1 [Whitfield-Gabrieli, Susan; Gabrieli, John D. E.] MIT, Dept Brain & Cognit Sci, Boston, MA USA. [Thermenos, Heidi W.; Milanovic, Snezana; McCarley, Robert W.; Wojcik, Joanne; Seidman, Larry J.] Harvard Univ, Sch Med, Dept Psychiat, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA. [Thermenos, Heidi W.; Seidman, Larry J.] Harvard Univ, Sch Med, MIT, Charlestown, MA USA. [Thermenos, Heidi W.; Seidman, Larry J.] Massachusetts Gen Hosp, Martinos Ctr Biomed Imaging, Charlestown, MA USA. [Milanovic, Snezana; LaViolette, Peter; Seidman, Larry J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat, Boston, MA USA. [Tsuang, Ming T.] Univ Calif San Diego, Dept Psychiat, Inst Behav Genom, La Jolla, CA 92093 USA. [Faraone, Stephen V.] SUNY Upstate Med Univ, Dept Psychiat, SUNY Genet Res Program, Syracuse, NY USA. [McCarley, Robert W.; Shenton, Martha E.] Harvard Univ, Sch Med, Dept Psychiat, Brockton W Roxbury VA Med Ctr, Brockton, MA 02401 USA. [Shenton, Martha E.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Psychiat, Boston, MA 02115 USA. [Green, Alan I.] Dartmouth Med Sch, Dept Psychiat, Hanover, NH USA. [Green, Alan I.] Dartmouth Med Sch, Dept Pharmacol & Toxicol, Hanover, NH USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 1 PY 2008 VL 63 IS 7 SU S MA 856 BP 272S EP 272S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 276SV UT WOS:000254163700866 ER PT J AU Taylor, G Salisbury, D McCarley, R AF Taylor, Grantley Salisbury, Dean McCarley, Robert TI Gamma band abnormalities in schizophrenia and bipolar disorder during an auditory oddball task SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 63rd Annual Convention of the Society-of-Biological-Psychiatry CY 2008 CL Washington, DC SP Soc Biol Psychiat C1 [Taylor, Grantley] McLean Hosp, Harvard Med Sch, Belmont, MA 02178 USA. [Salisbury, Dean] McLean Hosp, Harvard Med Sch, Cognit Neurosci Lab, Belmont, MA 02178 USA. [McCarley, Robert] VA Boston Healthcare Syst, Brockton, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 1 PY 2008 VL 63 IS 7 SU S MA 879 BP 279S EP 279S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 276SV UT WOS:000254163700889 ER PT J AU Dougherty, DD Thase, ME Howland, RH Evans, KC Harsch, H Kondziolka, D Eskandar, E Pascual-Leone, A AF Dougherty, Darin D. Thase, Michael E. Howland, Robert H. Evans, Karleyton C. Harsch, Harold Kondziolka, Douglas Eskandar, Ernad Pascual-Leone, Alvaro TI Feasibility study of an implantable cortical stimulation system for patients with major depressive disorder SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 63rd Annual Convention of the Society-of-Biological-Psychiatry CY 2008 CL Washington, DC SP Soc Biol Psychiat C1 [Dougherty, Darin D.; Evans, Karleyton C.] Massachusetts Gen Hosp, Charlestown, MA USA. [Thase, Michael E.] Univ Penn, Philadelphia, PA 19104 USA. [Howland, Robert H.] Univ Pittsburgh, Pittsburgh, PA USA. [Harsch, Harold] Med Coll Wisconsin, Milwaukee, WI 53226 USA. [Kondziolka, Douglas] Univ Pittsburgh, Pittsburgh, PA USA. [Eskandar, Ernad] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Pascual-Leone, Alvaro] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. RI Howland, Robert/K-6937-2015 OI Howland, Robert/0000-0002-6533-6010 NR 0 TC 5 Z9 5 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 1 PY 2008 VL 63 IS 7 SU S MA 930 BP 294S EP 295S PG 2 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 276SV UT WOS:000254163700939 ER PT J AU Valera, EM Biederman, J Zeffiro, T Rogel, A Patel, M Spencer, R Makris, N Spencer, T Faraone, SV Rosen, B Seidman, L AF Valera, Eve M. Biederman, Joseph Zeffiro, Thomas Rogel, Ainat Patel, Megha Spencer, Rebecca Makris, Nikos Spencer, Thomas Faraone, Stephen V. Rosen, Bruce Seidman, Larry TI Functional abnormalities during motor control in adults with ADHD SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 63rd Annual Convention of the Society-of-Biological-Psychiatry CY 2008 CL Washington, DC SP Soc Biol Psychiat C1 [Valera, Eve M.; Biederman, Joseph; Spencer, Thomas] Harvard Univ, Sch Med, Clin & Res Programs Pediat Psychopharmacol & Adul, Massachusetts Gen Hosp, Charlestown, MA USA. [Zeffiro, Thomas; Rogel, Ainat] Massachusetts Gen Hosp, Charlestown, MA USA. [Patel, Megha] Brandeis Univ, Waltham, MA 02254 USA. [Spencer, Rebecca] Univ Calif Berkeley, Berkeley, CA 94720 USA. [Faraone, Stephen V.] SUNY Upstate Med Univ, Syracuse, NY USA. [Rosen, Bruce] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA. [Seidman, Larry] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Res Programs Pediat Psychopharmacol & Adult ADHD, Boston, MA 02215 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 1 PY 2008 VL 63 IS 7 SU S MA 948 BP 300S EP 300S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 276SV UT WOS:000254163700957 ER PT J AU Papakostas, GI Fava, M Thase, ME AF Papakostas, George I. Fava, Maurizio Thase, Michael E. TI Treatment of SSRI-resistant depression: A meta-analysis comparing within-versus across-class switches SO BIOLOGICAL PSYCHIATRY LA English DT Article DE antidepressant; class; depression; remission; resistant; switch ID DOUBLE-BLIND; REFRACTORY DEPRESSION; CLINICAL-TRIALS; VENLAFAXINE-XR; DISORDER; ANTIDEPRESSANT; FLUOXETINE; IMIPRAMINE; SERTRALINE; REMISSION AB Background: Two broad treatment options exist for switching antidepressants for depressed patients who fail to respond to a selective serotonin reuptake inhibitor (SSRI): either a second course of SSRI therapy or a different class of antidepressants. The goal of the present work was to conduct a meta-analysis of studies comparing these two switch strategies. Methods: Several sources were searched for randomized clinical trials comparing these two switch strategies. Results: Data from four clinical trials (n = 1496) were combined using a random-effects model. Patients randomized to switch to a non-SSRI antidepressant (bupropion, mirtazapine, venlafaxine) were more likely to experience remission than patients switched to a second SSRI (risk ratio = 1.29, p = .007). Pooled remission rates were 28% (for non-SSRIs) and 23.5% (for SSRls). There was also a nonsignificant trend (p = .1) in the rate of discontinuation due to intolerance favoring the within-class switch strategy (risk ratio = 1.23). There was no difference in response rates between the two treatment groups. Conclusions: These results suggest a modest yet statistically significant advantage in remission rates when switching patients with SSRI-resistant depression to a non-SSRI rather than an SSRI antidepressant. With the number needed to treat (NNT) statistic as one indicator of clinical significance, nearly 22 SSRI nonresponders would need to be switched to a non-SSRI rather than a second SSRI antidepressant to obtain one additional remitter. This difference falls well below the mark of NNT = 10 suggested by the United Kingdom's National Institute of Clinical Excellence but nonetheless might be of public health relevance given the large number of SSRI-resistant patients switched to an SSRI versus a non-SSRI antidepressant. C1 [Papakostas, George I.; Fava, Maurizio] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat, Boston, MA 02114 USA. [Thase, Michael E.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Thase, Michael E.] Univ Pittsburgh, Dept Psychiat, Med Ctr, Pittsburgh, PA USA. RP Papakostas, GI (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat, 15 Parkman St,WACC 812, Boston, MA 02114 USA. EM gpapakostas@partners.org RI Papakostas, George/I-6905-2013 OI Papakostas, George/0000-0002-2465-5103 FU NIMH NIH HHS [K23 MH069629] NR 29 TC 99 Z9 105 U1 3 U2 18 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 1 PY 2008 VL 63 IS 7 BP 699 EP 704 DI 10.1016/j.biopsych.2007.08.010 PG 6 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 275YB UT WOS:000254107100010 PM 17919460 ER PT J AU Armand, P Kim, HT Ho, VT Cutler, CS Koreth, J Antin, JH LaCasce, AS Jacobsen, ED Fisher, DC Brown, JR Canellos, GP Freedman, AS Soiffer, RJ Alyea, EP AF Armand, Philippe Kim, Haesook T. Ho, Vincent T. Cutler, Corey S. Koreth, John Antin, Joseph H. LaCasce, Ann S. Jacobsen, Eric D. Fisher, David C. Brown, Jennifer R. Canellos, George P. Freedman, Arnold S. Soiffer, Rohert J. Alyea, Edwin P. TI Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: Importance of histology for outcome SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Article DE allogeneic stem cell transplantation; reduced-intensity conditioning; Hodgkin lymphoma; non-Hodgkin lymphoma; mantle cell lymphoma ID STEM-CELL TRANSPLANTATION; BONE-MARROW TRANSPLANT; AUTOLOGOUS TRANSPLANTATION; FOLLICULAR LYMPHOMA; EUROPEAN GROUP; DISEASE; BLOOD; MORTALITY; SURVIVAL; REGISTRY AB Allogeneic stem cell transplantation (SCT) with reduced-intensity conditioning (RIC) has the potential to lead to long-term remissions for patients with lymphoma. However, the role of RIC SCT in the treatment of lymphoma is still unclear. Specifically, the relative benefit of RIC SCT across lymphoma histologies and the prognostic factors in this population are incompletely defined. We retrospectively analyzed the outcomes of 87 patients with advanced lymphoma who underwent RIC SCT at the Dana-Farber Cancer Institute over a 6-year period with a homogeneous conditioning regimen consisting of fludarabine and low-dose busulfan. Thirty-six patients had Hodgkin disease (HD) and 51 had non-Hodgkin lymphoma (NBL). Sixty-eight percent had undergone prior autologous transplantation. The 1-year cumulative incidence of nonrelapse mortality was 13% and the 3-year cumulative incidence of progression was 49%. The incidence of grade 3-4 acute GVHD was 11%. The 2-year cumulative incidence of chronic GVHD was 68%, and its development was associated with a decreased risk of progression and an improved progression-free survival (PFS). Three-year overall survival (OS) was 56% for patients with HD, 81% for indolent NHL, 42% for aggressive NHL, and 40% for mantle cell lymphoma. The corresponding figures for 3-year PFS were 22%, 59%, 22%, and 30%, respectively. Multivariate analysis identified elevated pretransplantation lactate dehydrogenase (LDH) as an adverse factor for PFS, while indolent NHL histology was favorable. For OS, advanced age and elevated pretransplantation LDH were adverse factors, whereas indolent NHL histology was favorable. Low early donor chimerism was not predictive of poor outcome in univariate or multivariate analyses. Moreover, progression was not associated with loss of chimerism. These results emphasize the importance of lymphoma histology for patients undergoing RIC SCT, as well as the lack of relevance of donor chimerism for outcome in this patient population. (c) 2008 American Society for Blood and Marrow Transplantation. C1 [Armand, Philippe; Ho, Vincent T.; Cutler, Corey S.; Koreth, John; Antin, Joseph H.; LaCasce, Ann S.; Jacobsen, Eric D.; Fisher, David C.; Canellos, George P.; Freedman, Arnold S.; Soiffer, Rohert J.; Alyea, Edwin P.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Kim, Haesook T.] Dana Farber Canc Inst, Dept Biostat, Boston, MA 02115 USA. RP Armand, P (reprint author), Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St, Boston, MA 02115 USA. EM parmand@partners.org FU NCI NIH HHS [T32 CA009172]; NHLBI NIH HHS [P01 HL070149-05, HL070149, P01 HL070149] NR 26 TC 76 Z9 78 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD APR PY 2008 VL 14 IS 4 BP 418 EP 425 DI 10.1016/j.bbmt.2008.01.008 PG 8 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA 280IC UT WOS:000254418500006 PM 18342784 ER PT J AU Chau, Y Luo, Y Cheung, ACY Nagai, Y Zhang, SG Kobler, JB Zeitels, SM Langer, R AF Chau, Ying Luo, Ying Cheung, Alex C. Y. Nagai, Yusuke Zhang, Shuguang Kobler, James B. Zeitels, Steven M. Langer, Robert TI Incorporation of a matrix metalloproteinase-sensitive substrate into self-assembling peptides - A model for biofunctional scaffolds SO BIOMATERIALS LA English DT Article DE self-assembly; peptide; biomimetic material; matrix metalloproteinase; nanofiber; hydrogel ID COMPLEMENTARY OLIGOPEPTIDE; BIOMATERIALS; HYDROGELS; SURFACE; CELLS; MEMBRANE; CLEAVAGE AB Controlling and guiding cell behavior requires scaffolding materials capable of programming the three-dimensional (3-D) extracellular environment. In this study, we devised a new self-assembling peptide template for synthesizing nanofibrous hydrogels containing cell-responsive ligands. In particular, the insertion of a matrix metalloproteinase-2 (MMP-2) labile hexapeptide into the self-assembling building blocks of arginine-alanine-aspartate-alanine (RADA) was investigated. A series of peptides, varied by the position of the MMP-2 hexapeptide substrate and the length of RADA blocks, were prepared by parallel synthesis. Their self-assembling capabilities were characterized and compared by circular dichroism spectroscopy and dynamical mechanical analysis. Among all the different insertion patterns, the sequence comprising a centrically positioned MMP-2 substrate was flanked with three RADA units on each side self-assembled into a hydrogel matrix, with mechanical properties and nanofiber morphology comparable to the native material built with (RADA)4 alone. Exposure of the new gel to MMP-2 resulted in peptide cleavage, as confirmed by mass spectroscopy, and a decrease in surface hardness, as detected by nanoindentor, indicating that the enzyme mediated degradation was localized to the gel surface. The new design can be used for introducing biological functions into self-assembling peptides to create scaffolding materials with potential applications in areas such as tissue engineering and regenerative medicine. (c) 2007 Elsevier Ltd. All rights reserved. C1 [Langer, Robert] MIT, Dept Chem Engn, Cambridge, MA 02139 USA. [Chau, Ying; Cheung, Alex C. Y.] Hong Kong Univ Sci & Technol, Dept Chem Engn, Clear Water Bay, Hong Kong, Peoples R China. [Zhang, Shuguang] MIT, Ctr Biomed Engn, Cambridge, MA 02139 USA. [Zhang, Shuguang] MIT, Ctr Bits & Atoms, Cambridge, MA 02139 USA. [Kobler, James B.; Zeitels, Steven M.] Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA. [Kobler, James B.; Zeitels, Steven M.] Massachusetts Gen Hosp, Ctr Laryngeal Surg & Voice Rehabil, Boston, MA 02114 USA. [Luo, Ying] Peking Univ, Dept Biomed Engn, Beijing 100871, Peoples R China. RP Langer, R (reprint author), MIT, Dept Chem Engn, 77 Massachusetts Ave,E25-342, Cambridge, MA 02139 USA. EM rlanger@mit.edu RI Luo, Ying/A-9920-2012; OI Luo, Ying/0000-0001-9834-9419; Chau, Ying/0000-0003-1759-934X NR 30 TC 93 Z9 94 U1 8 U2 62 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0142-9612 J9 BIOMATERIALS JI Biomaterials PD APR PY 2008 VL 29 IS 11 BP 1713 EP 1719 DI 10.1016/j.biomaterials.2007.11.046 PG 7 WC Engineering, Biomedical; Materials Science, Biomaterials SC Engineering; Materials Science GA 268ZS UT WOS:000253619900018 PM 18192002 ER PT J AU Wakao, M Saito, A Ohishi, K Kishimoto, Y Nishimura, T Sobel, M Suda, Y AF Wakao, Masahiro Saito, Akihiro Ohishi, Koh Kishimoto, Yuko Nishimura, Tomoaki Sobel, Michael Suda, Yasuo TI Sugar Chips immobilized with synthetic sulfated disaccharides of heparin/heparan sulfate partial structure SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS LA English DT Article DE Sugar; carbohydrate; chip; heparin; heparan sulfate; carbohydrate-protein interaction; surface plasmon resonance; SPR; SPR-imaging ID HEPARAN-SULFATE; CARBOHYDRATE MICROARRAYS; BIOLOGICAL-ACTIVITIES; BUILDING-BLOCKS; DNA CHIPS; BINDING; PROTEIN; SURFACE; ARRAY; OLIGOSACCHARIDES AB Carbohydrate chip technology has a great potential for the high-throughput evaluation of carbohydrate-protein interactions. Herein, we report syntheses of novel sulfated oligosaccharides possessing heparin and heparan sulfate partial disaccharide structures, their immobilization on gold-coated chips to prepare array-type Sugar Chips, and evaluation of binding potencies of proteins by surface plasmon resonance (SPR) imaging technology. Sulfated oligosaccharides were efficiently synthesized from glucosamine and uronic acid moieties. Synthesized sulfated oligosaccharides were then easily immobilized on gold-coated chips using previously reported methods. The effectiveness of this analytical method was confirmed in binding experiments between the chips and heparin binding proteins, fibronectin and recombinant human von Willebrand factor A1 domain ( rh-vWf-A1), where specific partial structures of heparin or heparan sulfate responsible for binding were identified. (C) 2008 Elsevier Ltd. All rights reserved. C1 [Wakao, Masahiro; Saito, Akihiro; Ohishi, Koh; Nishimura, Tomoaki; Suda, Yasuo] Kagoshima Univ, Grad Sch Sci & Engn, Dept Nanostruct & Adv Mat, Kagoshima 8900065, Japan. [Kishimoto, Yuko; Nishimura, Tomoaki; Suda, Yasuo] SUDx Biotec Corp, Kobe, Hyogo 6500047, Japan. [Sobel, Michael] Univ Washington, Dept Surg, Seattle, WA 98108 USA. [Sobel, Michael] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. RP Suda, Y (reprint author), Kagoshima Univ, Grad Sch Sci & Engn, Dept Nanostruct & Adv Mat, 1-21-40 Korimoto, Kagoshima 8900065, Japan. EM ysuda@eng.kagoshima-u.ac.jp FU NHLBI NIH HHS [HL079182, R01 HL079182, R01 HL079182-03] NR 50 TC 27 Z9 27 U1 1 U2 10 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0960-894X J9 BIOORG MED CHEM LETT JI Bioorg. Med. Chem. Lett. PD APR 1 PY 2008 VL 18 IS 7 BP 2499 EP 2504 DI 10.1016/j.bmcl.2008.01.069 PG 6 WC Chemistry, Medicinal; Chemistry, Organic SC Pharmacology & Pharmacy; Chemistry GA 292DI UT WOS:000255246300052 PM 18343110 ER PT J AU Hagopian, K Ramsey, JJ Weindruch, R AF Hagopian, Kevork Ramsey, Jon J. Weindruch, Richard TI Enzymes of glycerol and glyceraldehyde metabolism in mouse liver: effects of caloric restriction and age on activities SO BIOSCIENCE REPORTS LA English DT Article DE aging; caloric restriction; energy source; glyceralclehyde metabolism; glycerol metabolism; liver ID KETO REDUCTASE SUPERFAMILY; ALDEHYDE DEHYDROGENASE-ACTIVITY; ALCOHOL-DEHYDROGENASE; RAT-LIVER; FRUCTOSE METABOLISM; THYROID-HORMONES; FOOD RESTRICTION; LIFE-SPAN; MUSCLE; OXIDATION AB The influence of caloric restriction on hepatic glyceraldehyde- and glycerol-metabolizing enzyme activities of young and old mice were studied. Glycerol kinase and cytoplasmic glycerol-3-phosphate dehydrogenase activities were increased in both young and old CR (calorie-restricted) mice when compared with controls, whereas triokinase increased only in old CR mice. Aldehyde dehydrogenase and aldehyde reductase activities in both young and old CR mice were unchanged by caloric restriction. Mitochondrial glycerol-3-phosphate dehydrogenase showed a trend towards an increased activity in old CR mice, whereas a trend towards a decreased activity in alcohol dehydrogenase was observed in both young and old CR mice. Serum glycerol levels decreased in young and old CR mice. Therefore increases in glycerol kinase and glycerol-3-phosphate dehydrogenase were associated with a decrease in fasting blood glycerol levels in CR animals. A prominent role for triokinase in glyceraldehyde metabolism with CR was also observed. The results indicate that long-term caloric restriction induces sustained increases in the capacity for gluconeogenesis from glycerol. C1 [Hagopian, Kevork; Ramsey, Jon J.] Univ Calif Davis, Sch Vet Med, Dept Mol Biosci, Davis, CA 95616 USA. [Weindruch, Richard] Univ Wisconsin, Sch Med, Dept Med, Madison, WI 53706 USA. [Weindruch, Richard] William S Middleton Mem Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Madison, WI 53705 USA. RP Hagopian, K (reprint author), Univ Calif Davis, Sch Vet Med, Dept Mol Biosci, Davis, CA 95616 USA. EM khagopian@ucdavis.edu FU NIA NIH HHS [R01 AG028125-01A1, P01 AG011915-06A1, R01 AG28125, P01 AG011915, R01 AG028125, P01 AG11915] NR 73 TC 11 Z9 13 U1 0 U2 0 PU PORTLAND PRESS LTD PI LONDON PA THIRD FLOOR, EAGLE HOUSE, 16 PROCTER STREET, LONDON WC1V 6 NX, ENGLAND SN 0144-8463 J9 BIOSCIENCE REP JI Biosci. Rep. PD APR PY 2008 VL 28 IS 2 BP 107 EP 115 DI 10.1042/BSR20080015 PG 9 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 317KS UT WOS:000257019700006 PM 18429748 ER PT J AU Desantis, SM Houseman, EA Coull, BA Stemmer-Rachamimov, A Betensky, RA AF Desantis, Stacia M. Houseman, E. Andres Coull, Brent A. Stemmer-Rachamimov, Anat Betensky, Rebecca A. TI A penalized latent class model for ordinal data SO BIOSTATISTICS LA English DT Article ID DIAGNOSTIC-CRITERIA; SCHWANNOMATOSIS; VARIABLES; SELECTION AB Latent class models provide a useful framework for clustering observations based on several features. Application of latent class methodology to correlated, high-dimensional ordinal data poses many challenges. Unconstrained analyses may not result in an estimable model. Thus, information contained in ordinal variables may not be fully exploited by researchers. We develop a penalized latent class model to facilitate analysis of high-dimensional ordinal data. By stabilizing maximum likelihood estimation, we are able to fit an ordinal latent class model that would otherwise not be identifiable without application of strict constraints. We illustrate our methodology in a study of schwannoma, a peripheral nerve sheath tumor, that included 3 clinical subtypes and 23 ordinal histological measures. C1 [Desantis, Stacia M.; Houseman, E. Andres; Coull, Brent A.] Harvard Univ, Dept Biostat, Boston, MA 02115 USA. [Stemmer-Rachamimov, Anat] Massachusetts Gen Hosp, Dept Pathol, Charlestown, MA 02129 USA. [Betensky, Rebecca A.] Harvard Univ, Dept Biostat, Boston, MA 02115 USA. RP Desantis, SM (reprint author), Harvard Univ, Dept Biostat, 655 Huntington Ave, Boston, MA 02115 USA. EM sdesanti@hsph.harvard.edu OI Houseman, Eugene Andres/0000-0003-0703-1830 FU NCI NIH HHS [CA075971, R01 CA075971]; NINDS NIH HHS [P01NS24279-18] NR 23 TC 11 Z9 11 U1 0 U2 6 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1465-4644 J9 BIOSTATISTICS JI Biostatistics PD APR PY 2008 VL 9 IS 2 BP 249 EP 262 DI 10.1093/biostatistics/kxm026 PG 14 WC Mathematical & Computational Biology; Statistics & Probability SC Mathematical & Computational Biology; Mathematics GA 278NK UT WOS:000254293400004 PM 17626225 ER PT J AU Sonpavde, G Ross, R Powles, T Sweeney, CJ Hahn, N Hutson, TE Galsky, MD Lerner, SP Sternberg, CN AF Sonpavde, Guru Ross, Robert Powles, Thomas Sweeney, Christopher J. Hahn, Noah Hutson, Thomas E. Galsky, Matthew D. Lerner, Seth P. Sternberg, Cora N. TI Novel agents for muscle-invasive and advanced urothelial cancer SO BJU INTERNATIONAL LA English DT Review DE urothelial carcinoma; chemotherapy; biological agents ID TRANSITIONAL-CELL CARCINOMA; PHASE-II TRIAL; CISPLATIN-BASED CHEMOTHERAPY; FARNESYL TRANSFERASE INHIBITOR; GEMCITABINE PLUS CISPLATIN; COOPERATIVE-ONCOLOGY-GROUP; ADVANCED BLADDER-CANCER; LONG-TERM-SURVIVAL; NEOADJUVANT CHEMOTHERAPY; WEEKLY PACLITAXEL AB Conventional front-line platinum-based combination chemotherapy yields high response rates but suboptimal long-term outcomes for advanced urothelial cancer. Salvage therapy is an unmet need, with disappointing outcomes. The profusion of novel biological agents offers the promise of improved outcomes. Neoadjuvant therapy before cystectomy for muscle-invasive bladder cancer provides an important paradigm and an interesting approach in developing novel agents. Patients who are not candidates for cisplatin require special attention. A multidisciplinary approach and collaboration among laboratory scientists, oncologists, urologists and radiation oncologists is necessary to make therapeutic advances. Recent and ongoing trials of novel chemotherapeutic and biologic agents are reviewed. C1 [Sonpavde, Guru; Hutson, Thomas E.; Galsky, Matthew D.] US Oncol Res, Philadelphia, PA USA. [Sonpavde, Guru; Lerner, Seth P.] Baylor Coll Med, Houston, TX 77030 USA. [Ross, Robert] Dana Farber Canc Inst, Boston, MA 02115 USA. [Sweeney, Christopher J.; Hahn, Noah] Indiana Univ, Med Ctr, Indianapolis, IN USA. [Powles, Thomas] Barts London Hosp, London, England. [Sternberg, Cora N.] San Camillo Forlanini Hosp, Rome, Italy. RP Sonpavde, G (reprint author), Baylor Coll Med, Genitourinary Oncol Program, US Oncol Res, 501 Med Ctr Blvd, Webster, TX 77598 USA. EM guru.sonpavde@usoncology.com RI Mendez, Pedro /J-8955-2016 OI Mendez, Pedro /0000-0001-6713-7907 NR 49 TC 6 Z9 7 U1 0 U2 1 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1464-4096 J9 BJU INT JI BJU Int. PD APR PY 2008 VL 101 IS 8 BP 937 EP 943 DI 10.1111/j.1464-410X.2007.07326.x PG 7 WC Urology & Nephrology SC Urology & Nephrology GA 277CD UT WOS:000254189400004 PM 18005203 ER PT J AU Chauhan, AK Walsh, MT Zhu, GJ Ginsburg, D Wagner, DD Motto, DG AF Chauhan, Anil K. Walsh, Meghan T. Zhu, Guojing Ginsburg, David Wagner, Denisa D. Motto, David G. TI The combined roles of ADAMTS13 and VWF in murine models of TTP, endotoxemia, and thrombosis SO BLOOD LA English DT Article ID VON-WILLEBRAND-FACTOR; VONWILLEBRAND-FACTOR MULTIMERS; HEMOLYTIC-UREMIC SYNDROME; FACTOR-CLEAVING PROTEASE; THROMBOCYTOPENIC PURPURA; FACTOR-VIII; SEVERE SEPSIS; MOUSE MODEL; DEFICIENCY; BIOSYNTHESIS AB Ultralarge von Willebrand factor (UL-VWF) multimers are thought to play a central role in pathogenesis of the disease thrombotic thrombocytopenic purpura (TTP); however, experimental evidence in support of this hypothesis has been difficult to establish. Therefore, to examine directly the requirement for VWF in TTP pathogenesis, we generated ADAMTS13-deficient mice on a TTP-susceptible genetic background that were also either haploinsufficient (Vwf(+/-)) or completely deficient (Vwf(-/-)) in VWF. Absence of VWF resulted in complete protection from shigatoxin (Stx)-induced thrombocytopenia, demonstrating an absolute requirement for VWF in this model (Stx has been shown previously to trigger TTP in ADAMTS13-deficient mice). We next investigated the requirements for ADAMTS13 and VWF in a murine model of endotoxemia. Unlike Stx-induced TTP findings, LPS-Induced thrombocytopenia and mortality were not affected by either VWF or ADAMTS13 deficiency, suggesting divergent mechanisms of thrombocy-topenia between these 2 disorders. Finally, we show that VWF deficiency abrogates the ADAMTS13-deficient prothrombotic state, suggesting VWF as the only relevant ADAMTS13 substrate under these conditions. Together, these findings shed new light on the potential roles played by ADAMTS13 and VWF in TTP, endotoxemia, and normal hemostasis. C1 [Chauhan, Anil K.; Walsh, Meghan T.; Wagner, Denisa D.] Harvard Med Sch, CBR Inst Biomed Res, Boston, MA USA. [Chauhan, Anil K.; Wagner, Denisa D.] Harvard Med Sch, Dept Pathol, Boston, MA USA. [Zhu, Guojing; Ginsburg, David] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA. [Ginsburg, David] Univ Michigan, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA. [Motto, David G.] Univ Iowa, Coll Med, Dept Internal Med, Iowa City, IA 52242 USA. [Motto, David G.] Univ Iowa, Coll Med, Dept Pediat, Iowa City, IA 52242 USA. RP Motto, DG (reprint author), Univ Iowa, 3269C Carver Biomed Res Bldg, Iowa City, IA 52242 USA. EM david-motto@uiowa.edu FU NHLBI NIH HHS [K08 HL076539, P01 HL066105, R37-HL41002, P01-HL057346, P01 HL057346, P01-HL066105, R37 HL041002, K08-HL076539, R37-HL39693, R37 HL039693] NR 30 TC 39 Z9 41 U1 1 U2 3 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD APR 1 PY 2008 VL 111 IS 7 BP 3452 EP 3457 DI 10.1182/blood-2007-08-108571 PG 6 WC Hematology SC Hematology GA 282LM UT WOS:000254569300031 PM 18083848 ER PT J AU Weisberg, E Banerji, L Wright, RD Barrett, R Ray, A Moreno, D Catley, L Jiang, J Hall-Meyers, E Sauveur-Michel, M Stone, R Galinsky, I Fox, E Kung, AL Griffin, JD AF Weisberg, Ellen Banerji, Lolita Wright, Renee D. Barrett, Rosemary Ray, Arghya Moreno, Daisy Catley, Laurence Jiang, Jingrui Hall-Meyers, Elizabeth Sauveur-Michel, Maira Stone, Richard Galinsky, Ilene Fox, Edward Kung, Andrew L. Griffin, James D. TI Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells SO BLOOD LA English DT Article ID ACUTE MYELOID-LEUKEMIA; INTERNAL TANDEM DUPLICATION; CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; TYROSINE KINASE INHIBITOR; ACTIVATING MUTATION; FLT3 GENE; PHOSPHOINOSITIDE 3-KINASE; CYCLE PROGRESSION; S6 KINASE AB Mediators of PI3K/AKT signaling have been implicated in chronic myeloid leukemia (CML) and acute myeloid leukemia (AML). Studies have shown that inhibitors of PI3K/AKT signaling, such as wortmannin and LY294002, are able to inhibit CML and AML cell proliferation and synergize with targeted tyrosine kinase inhibitors. We investigated the ability of BAG956, a dual PI3K/PDK-1 inhibitor, to be used in combination with inhibitors of BCR-ABL and mutant FLT3, as well as with the mTOR inhibitor, rapamycin, and the rapamycin derivative, RAD001. BAG956 was shown to block AKT phosphorylation induced by BCR-ABL-, and induce apoptosis of BCR-ABL-expressing cell lines and patient bone marrow cells at concentrations that also inhibit PI3K signaling. Enhancement of the inhibitory effects of the tyrosine kinase inhibitors, imatinib and nilotinib, by BAG956 was demonstrated against BCR-ABL expressing cells both in vitro and in vivo. We have also shown that BAG956 is effective against mutant FLT3-expressing cell lines and AML patient bone marrow cells. Enhancement of the inhibitory effects of the tyrosine kinase inhibitor, PKC412, by BAG956 was demonstrated against mutant FLT3-expressing cells. Finally, BAG956 and rapamycin/RAD001 were shown to combine in a nonantagonistic fashion against BCR-ABL- and mutant FLT3-expressing cells both in vitro and in vivo. C1 [Weisberg, Ellen; Barrett, Rosemary; Ray, Arghya; Jiang, Jingrui; Stone, Richard; Galinsky, Ilene; Griffin, James D.] Dana Farber Canc Inst, Dept Med Oncol Hematol Neoplasia, Boston, MA 02115 USA. [Banerji, Lolita] PAREXEL Int, Waltham, MA USA. [Wright, Renee D.; Kung, Andrew L.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. [Wright, Renee D.; Kung, Andrew L.] Childrens Hosp, Boston, MA 02115 USA. [Moreno, Daisy; Hall-Meyers, Elizabeth] Dana Farber Canc Inst, Anim Resources Facil, Boston, MA 02115 USA. [Catley, Laurence] Mater Hlth Serv, Brisbane, Australia. [Sauveur-Michel, Maira] Novartis Pharmaceut, Basel, Switzerland. [Stone, Richard] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA. [Fox, Edward] Dana Farber Canc Inst, Mol Diagnost Lab, Boston, MA 02115 USA. RP Griffin, JD (reprint author), Dana Farber Canc Inst, Dept Adult Oncol, 44 Binney St, Boston, MA 02115 USA. EM James_Griffin@dfci.harvard.edu RI Catley, Laurence/E-5313-2013; OI Kung, Andrew/0000-0002-9091-488X FU NCI NIH HHS [CA66996, R37 CA036167, P01 CA066996, R01 CA036167, CA36167]; NIDDK NIH HHS [DK50654, P01 DK050654] NR 66 TC 58 Z9 60 U1 0 U2 4 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD APR 1 PY 2008 VL 111 IS 7 BP 3723 EP 3734 DI 10.1182/blood-2007-09-114454 PG 12 WC Hematology SC Hematology GA 282LM UT WOS:000254569300061 PM 18184863 ER PT J AU Wernig, G Gonneville, JRR Crowley, BJ Rodrigues, MS Reddy, MM Hudon, HE Walz, C Reiter, A Podar, K Royer, Y Constantinescu, SN Tomasson, MH Griffin, JD Gilliland, DG Sattler, M AF Wernig, Gerlincle Gonneville, Jeff Rey R. Crowley, Brian J. Rodrigues, Margret S. Reddy, Mamatha M. Hudon, Heidi E. Walz, Christoph Reiter, Andreas Podar, Klaus Royer, Yohan Constantinescu, Stefan N. Tomasson, Michael H. Griffin, James D. Gilliland, D. Gary Sattler, Martin TI The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes SO BLOOD LA English DT Article ID CHRONIC MYELOID-LEUKEMIA; TYROSINE KINASE JAK2; POLYCYTHEMIA-VERA; ERYTHROPOIETIN RECEPTOR; GENOMIC INSTABILITY; HEMATOPOIETIC-CELLS; ACTIVATING MUTATION; GENE-EXPRESSION; TRANSGENIC MICE; V617F MUTATION AB The V617F activating point mutation in Jak2 is associated with a proportion of myeloproliferative disorders. In normal hematopoietic cells, Jak2 signals only when associated with a growth factor receptor, such as the erythropoietin receptor (EpoR). We sought to identify the molecular requirements for activation of Jak2V617F by introducing a point mutation in the FERM domain (Y114A), required for receptor binding. Whereas BaF3.EpoR cells are readily transformed by Jak2V617F to Epo independence, we found that the addition of the FERM domain mutation blocked transformation and the induction of reactive oxygen species. Further, while cells expressing Jak2V617F had constitutive activation of STAT5, cells expressing Jak2V617F/ Y114A did not, suggesting that signaling is defective at a very proximal level. In addition, expression of the Myc and Pim proto-oncogenes by Jak2V617F was found to be FERM domain dependent. An inducible constitutively active STAT5 mutant expressed in BaF3 cells was sufficient to induce Myc and Pim. Finally, the FERM domain in Jak2V617F was also required for abnormal hematopoiesis in transduced primary murine fetal liver cells. Overall, our results suggest that constitutive activation of Jak2 requires an intact FERM domain for a transforming phenotype, and is necessary for activation of the major target of Jak2, STAT5. C1 [Gonneville, Jeff Rey R.; Crowley, Brian J.; Rodrigues, Margret S.; Reddy, Mamatha M.; Hudon, Heidi E.; Walz, Christoph; Podar, Klaus; Griffin, James D.; Sattler, Martin] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Wernig, Gerlincle; Rodrigues, Margret S.; Reddy, Mamatha M.; Podar, Klaus; Griffin, James D.; Gilliland, D. Gary; Sattler, Martin] Harvard Univ, Sch Med, Boston, MA USA. [Wernig, Gerlincle; Rodrigues, Margret S.; Reddy, Mamatha M.; Podar, Klaus; Griffin, James D.; Gilliland, D. Gary; Sattler, Martin] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. [Reiter, Andreas] Heidelberg Univ, Med Univ Klin 3, Fak Klin Med Mannheim, D-6800 Mannheim, Germany. [Royer, Yohan; Constantinescu, Stefan N.] Ludwig Inst Canc Res, Brussels, Belgium. [Tomasson, Michael H.] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA. RP Sattler, M (reprint author), Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St, Boston, MA 02115 USA. EM martin_sattler@dfci.harvard.edu RI Constantinescu, Stefan /E-5277-2012; OI Constantinescu, Stefan/0000-0002-8599-2699 FU NIDDK NIH HHS [DK66996] NR 44 TC 80 Z9 83 U1 1 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD APR 1 PY 2008 VL 111 IS 7 BP 3751 EP 3759 DI 10.1182/blood-2007-07-102186 PG 9 WC Hematology SC Hematology GA 282LM UT WOS:000254569300064 PM 18216297 ER PT J AU Jeanneret-Sozzi, W Taghian, A Epelbaum, R Poortmans, P Zwahlen, D Amsler, B Villette, S Belkacemi, Y Nguyen, T Scalliet, P Maingon, P Gutierrez, C Gastelblum, P Krengli, M Raad, RA Ozsahin, M Mirimanoff, RO AF Jeanneret-Sozzi, Wendy Taghian, Alphonse Epelbaum, Ron Poortmans, Philip Zwahlen, Daniel Amsler, Beat Villette, Sylviane Belkacemi, Yazid Nguyen, Tan Scalliet, Pierre Maingon, Philippe Gutierrez, Cristina Gastelblum, Pauline Krengli, Marco Raad, Rita Abi Ozsahin, Mahmut Mirimanoff, Rene-Olivier TI Primary breast lymphoma: Patient profile, outcome and prognostic factors. A multicentre Rare Cancer Network study SO BMC CANCER LA English DT Article ID NON-HODGKIN-LYMPHOMA; B-CELL LYMPHOMA; MALIGNANT-LYMPHOMA; RITUXIMAB; INVOLVEMENT; CHOP AB Background: To asses the clinical profile, treatment outcome and prognostic factors in primary breast lymphoma (PBL). Methods: Between 1970 and 2000, 84 consecutive patients with PBL were treated in 20 institutions of the Rare Cancer Network. Forty-six patients had Ann Arbor stage IE, 33 stage IIE, 1 stage IIIE, 2 stage IVE and 2 an unknown stage. Twenty-one underwent a mastectomy, 39 conservative surgery and 23 biopsy; 51 received radiotherapy (RT) with (n = 37) or without (n = 14) chemotherapy. Median RT dose was 40 Gy (range 12-55 Gy). Results: Ten (12%) patients progressed locally and 43 (55%) had a systemic relapse. Central nervous system (CNS) was the site of relapse in 12 (14%) cases. The 5-yr overall survival, lymphoma-specific survival, disease-free survival and local control rates were 53%, 59%, 41% and 87% respectively. In the univariate analyses, favorable prognostic factors were early stage, conservative surgery, RT administration and combined modality treatment. Multivariate analysis showed that early stage and the use of RT were favorable prognostic factors. Conclusion: The outcome of PBL is fair. Local control is excellent with RT or combined modality treatment but systemic relapses, including that in the CNS, occurs frequently. C1 [Jeanneret-Sozzi, Wendy; Ozsahin, Mahmut; Mirimanoff, Rene-Olivier] CHU Vaudois, CH-1011 Lausanne, Switzerland. [Jeanneret-Sozzi, Wendy; Ozsahin, Mahmut; Mirimanoff, Rene-Olivier] Univ Lausanne, CH-1011 Lausanne, Switzerland. [Taghian, Alphonse; Raad, Rita Abi] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Epelbaum, Ron] Rambam Med Ctr, IL-31096 Haifa, Israel. [Poortmans, Philip] Dr Bernard Verbeeten Inst, NL-5000 LE Tilburg, Netherlands. [Zwahlen, Daniel] Univ Zurich Hosp, CH-8091 Zurich, Switzerland. [Amsler, Beat] Univ Kliniken, CH-4031 Basel, Switzerland. [Villette, Sylviane; Belkacemi, Yazid] Ctr Oscar Lambret, F-59000 Lille, France. [Belkacemi, Yazid] Hop Tenon, F-75020 Paris, France. [Nguyen, Tan] Ctr Jean Godinot, F-51100 Reims, France. Clin Univ St Luc, St Luc, Belgium. Ctr Georges Francois Leclerc, F-21034 Dijon, France. [Gutierrez, Cristina] Hosp Barcelona, Inst Catala Oncol, E-08907 Barcelona, Spain. [Gastelblum, Pauline] Inst Jules Bordet, B-1000 Brussels, Belgium. [Krengli, Marco] Univ Piemonte Orientale, Osped Maggiore Carita, I-28100 Novara, Italy. RP Mirimanoff, RO (reprint author), CHU Vaudois, Rue Bugnon, CH-1011 Lausanne, Switzerland. EM wendy.jeanneret@chuv.ch; ataghian@partners.org; epelbaum@rambam.health.gov.il; poortmans.ph@bvi.nl; daniel.zwahlen@usz.ch; beat.amsler@aerztehaus-allschwil.ch; y-belkacemi@o-lambret.fr; y-belkacemi@o-lambret.fr; tandat.nguyen@reims.fnclcc.fr; scalliet@rbnt.ucl.ac.be; pmaingon@dijon.fnclcc.fr; svilla@iconcologia.net; paul.vanhoutte@bordet.be; krengli@tera.it; ataghian@partners.org; esat-mahmut.ozsahin@chuv.ch; reneolivier.mirimanoff@chuv.ch RI Poortmans, P.M.P./L-4581-2015 NR 36 TC 47 Z9 59 U1 0 U2 3 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2407 J9 BMC CANCER JI BMC Cancer PD APR 1 PY 2008 VL 8 AR 86 DI 10.1186/1471-2407-8-86 PG 7 WC Oncology SC Oncology GA 301ZX UT WOS:000255936600001 PM 18380889 ER PT J AU van Dellen, A Cordery, PM Spires, TL Blakemore, C Hannan, AJ AF van Dellen, Anton Cordery, Patricia M. Spires, Tara L. Blakemore, Colin Hannan, Anthony J. TI Wheel running from a juvenile age delays onset of specific motor deficits but does not alter protein aggregate density in a mouse model of Huntington's disease SO BMC NEUROSCIENCE LA English DT Article ID NEURONAL INTRANUCLEAR INCLUSIONS; DEPENDENT CORTICAL PLASTICITY; LONG-TERM POTENTIATION; TRANSGENIC MICE; ENVIRONMENTAL ENRICHMENT; SYNAPTIC PLASTICITY; NEUROTROPHIC FACTOR; AMYLOID DEPOSITION; CELL-PROLIFERATION; ALZHEIMERS-DISEASE AB Background: Huntington's disease (HD) is a neurodegenerative disorder predominantly affecting the cerebral cortex and striatum. Transgenic mice (R6/I line), expressing a CAG repeat encoding an expanded polyglutamine tract in the N-terminus of the huntingtin protein, closely model HD. We have previously shown that environmental enrichment of these HD mice delays the onset of motor deficits. Furthermore, wheel running initiated in adulthood ameliorates the rear-paw clasping motor sign, but not an accelerating rotarod deficit. Results: We have now examined the effects of enhanced physical activity via wheel running, commenced at a juvenile age (4 weeks), with respect to the onset of various behavioral deficits and their neuropathological correlates in R6/I HD mice. HD mice housed post-weaning with running wheels only, to enhance voluntary physical exercise, have delayed onset of a motor co-ordination deficit on the static horizontal rod, as well as rear-paw clasping, although the accelerating rotarod deficit remains unaffected. Both wheel running and environmental enrichment rescued HD-induced abnormal habituation of locomotor activity and exploratory behavior in the open field. We have found that neither environment enrichment nor wheel running ameliorates the shrinkage of the striatum and anterior cingulate cortex (ACC) in HD mice, nor the overall decrease in brain weight, measured at 9 months of age. At this age, the density of ubiquitinated protein aggregates in the striatum and ACC is also not significantly ameliorated by environmental enrichment or wheel running. Conclusion: These results indicate that enhanced voluntary physical activity, commenced at an early presymptomatic stage, contributes to the positive effects of environmental enrichment. However, sensory and cognitive stimulation, as well as motor stimulation not associated with running, may constitute major components of the therapeutic benefits associated with enrichment. Comparison of different environmental manipulations, performed in specific time windows, can identify critical periods for the induction of neuroprotective 'brain reserve' in animal models of HD and related neurodegenerative diseases. C1 [van Dellen, Anton; Cordery, Patricia M.; Spires, Tara L.; Blakemore, Colin; Hannan, Anthony J.] Univ Oxford, Dept Phys Anat & Genet, Oxford OX1 3PT, England. [Spires, Tara L.] Massachusetts Gen Hosp, MassGen Inst Neurodegenerat Dis, Charlestown, MA USA. [Spires, Tara L.] Harvard Univ, Sch Med, Charlestown, MA USA. [Hannan, Anthony J.] Univ Melbourne, Howard Florey Inst, Melbourne, Vic 3010, Australia. [Hannan, Anthony J.] Univ Melbourne, Dept Anat & Cell Biol, Melbourne, Vic 3010, Australia. RP Hannan, AJ (reprint author), Univ Oxford, Dept Phys Anat & Genet, S Parks Rd, Oxford OX1 3PT, England. EM avd325@cam.ac.uk; patricia.cordery@physiol.ox.ac.uk; tspires@partners.org; Colin.Blakemore@ndm.ox.ac.uk; anthony.hannan@florey.edu.au OI Spires-Jones, Tara/0000-0003-2530-0598 FU Medical Research Council NR 59 TC 52 Z9 52 U1 0 U2 5 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2202 J9 BMC NEUROSCI JI BMC Neurosci. PD APR 1 PY 2008 VL 9 AR 34 DI 10.1186/1471-2202-9-34 PG 12 WC Neurosciences SC Neurosciences & Neurology GA 296SG UT WOS:000255565500001 PM 18380890 ER PT J AU Polli, FE Barton, JJS Thakkar, KN Greve, DN Goff, DC Rauch, SL Manoach, DS AF Polli, Frida E. Barton, Jason J. S. Thakkar, Katharine N. Greve, Douglas N. Goff, Donald C. Rauch, Scott L. Manoach, Dara S. TI Reduced error-related activation in two anterior cingulate circuits is related to impaired performance in schizophrenia SO BRAIN LA English DT Article DE schizophrenia; anterior cingulate cortex; response monitoring; functional MRI; error processing ID EVENT-RELATED FMRI; WORKING-MEMORY PERFORMANCE; SURFACE-BASED ANALYSIS; ANTISACCADE PERFORMANCE; CORTICAL SURFACE; HUMAN BRAIN; ELECTROPHYSIOLOGICAL ANALYSIS; 1ST-EPISODE SCHIZOPHRENIA; CORTEX DYSFUNCTION; PREFRONTAL CORTEX AB To perform well on any challenging task, it is necessary to evaluate your performance so that you can learn from errors. Recent theoretical and experimental work suggests that the neural sequellae of error commission in a dorsal anterior cingulate circuit index a type of contingency- or reinforcement-based learning, while activation in a rostral anterior cingulate circuit reflects appraisal of the affective or motivational significance of errors. Patients with schizophrenia show rigid, perseverative behaviour that is not optimally responsive to outcome. Findings of reduced anterior cingulate cortex (ACC) activity during error commission in schizophrenia suggest that difficulties in evaluating and modifying behaviour in response to errors may contribute to behavioural rigidity. Using event-related functional MRI and an antisaccade paradigm with concurrent monitoring of eye position, the present study examined error-related activation and its relation to task performance in the anatomic components of two ACC circuits that are theorized to make distinct contributions to error processing. Eighteen chronic-medicated schizophrenia patients and 15 healthy controls participated. Compared to controls, patients showed increased antisaccade error rates and decreased error-related activation in the reinforcement learning networkdorsal ACC, striatum and brainstem (possibly substantia nigra)and also in the affective appraisal networkrostral ACC, insula and amygdala. These reductions remained when the effects of antipsychotic medication dose and error rate were statistically controlled. Activation in these networks was inversely related to error rate in both patient and control groups, but the slope of this relation was shallower in patients (i.e. across participants with schizophrenia, decrements in error rate were associated with smaller decrements in activation). This indicates that the blunted neural response to errors in schizophrenia was not simply a reflection of more frequent errors. Our findings demonstrate a blunted response to error commission that is associated with worse performance in two ACC circuits in schizophrenia. In the dACC circuit, the blunted response may reflect deficient modification of prepotent stimulus-response mappings in response to errors, and in the rACC network it may reflect diminished concern regarding behavioural outcomes. However, despite these deficits and in the absence of external feedback regarding errors, patients corrected their errors as frequently as controls suggesting intact error recognition and ability to institute corrective action. Impairments in evaluating and learning from errors in schizophrenia may contribute to behaviour that is rigid and perseverative rather than optimally guided by outcomes, and may compromise performance across a wide range of tasks. C1 [Polli, Frida E.; Thakkar, Katharine N.; Goff, Donald C.; Rauch, Scott L.; Manoach, Dara S.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02215 USA. [Greve, Douglas N.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02215 USA. [Polli, Frida E.] Suffolk Univ, Dept Psychol, Boston, MA 02114 USA. [Barton, Jason J. S.] Univ British Columbia, Dept Neurol, Vancouver, BC, Canada. [Barton, Jason J. S.] Univ British Columbia, Dept Ophthalmol, Vancouver, BC, Canada. [Barton, Jason J. S.] Univ British Columbia, Dept Visual Sci, Vancouver, BC, Canada. [Greve, Douglas N.; Manoach, Dara S.] Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA. RP Manoach, DS (reprint author), 149 13th St,Room 2608, Charlestown, MA 02129 USA. EM dara@nmr.mgh.harvard.edu RI Barton, Jason/A-6362-2012; OI Thakkar, Katharine/0000-0002-0026-2030 FU NCRR NIH HHS [P41RR14075]; NIMH NIH HHS [MH72120, R01 MH67720] NR 100 TC 73 Z9 78 U1 11 U2 15 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0006-8950 J9 BRAIN JI Brain PD APR PY 2008 VL 131 BP 971 EP 986 DI 10.1093/brain/awm307 PN 4 PG 16 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 284CH UT WOS:000254682300010 PM 18158315 ER PT J AU Rosas, HD Salat, DH Lee, SY Zaleta, AK Pappu, V Fischl, B Greve, D Hevelone, N Hersch, SM AF Rosas, H. Diana Salat, David H. Lee, Stephanie Y. Zaleta, Alexandra K. Pappu, Vasanth Fischl, Bruce Greve, Doug Hevelone, Nathanael Hersch, Steven M. TI Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity SO BRAIN LA English DT Article DE Huntington's disease; cortex; phenotypic variability; biomarker ID POSITRON EMISSION TOMOGRAPHY; FUNCTIONAL-ANATOMY; VERBAL FLUENCY; PARKINSONS-DISEASE; PREMOTOR CORTEX; BRAIN ATROPHY; WHITE-MATTER; FMRI; PATHOLOGY; TASK AB The clinical phenotype of Huntingtons disease (HD) is far more complex and variable than depictions of it as a progressive movement disorder dominated by neostriatal pathology represent. The availability of novel neuro-imaging methods has enabled us to evaluate cerebral cortical changes in HD, which we have found to occur early and to be topographically selective. What is less clear, however, is how these changes influence the clinical expression of the disease. In this study, we used a high-resolution surface based analysis of in vivo MRI data to measure cortical thickness in 33 individuals with HD, spanning the spectrum of disease and 22 age- and sex-matched controls. We found close relationships between specific functional and cognitive measures and topologically specific cortical regions. We also found that distinct motor phenotypes were associated with discrete patterns of cortical thinning. The selective topographical associations of cortical thinning with clinical features of HD suggest that we are not simply correlating global worsening with global cortical degeneration. Our results indicate that cortical involvement contributes to important symptoms, including those that have been ascribed primarily to the striatum, and that topologically selective changes in the cortex might explain much of the clinical heterogeneity found in HD. Additionally, a significant association between regional cortical thinning and total functional capacity, currently the leading primary outcome measure used in neuroprotection trials for HD, establishes cortical MRI morphometry as a potential biomarker of disease progression. C1 [Rosas, H. Diana; Lee, Stephanie Y.; Zaleta, Alexandra K.; Pappu, Vasanth; Hersch, Steven M.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Rosas, H. Diana; Salat, David H.; Lee, Stephanie Y.; Zaleta, Alexandra K.; Pappu, Vasanth] Massachusetts Gen Hosp, Ctr Neuroimaging Aging & Neurodegenerat Dis, Boston, MA 02114 USA. [Rosas, H. Diana; Salat, David H.; Lee, Stephanie Y.; Zaleta, Alexandra K.; Pappu, Vasanth; Fischl, Bruce; Greve, Doug] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Boston, MA 02114 USA. [Fischl, Bruce; Greve, Doug] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [Hevelone, Nathanael] Dana Farber Canc Inst, Boston, MA 02115 USA. RP Rosas, HD (reprint author), Ctr Neuroimaging Aging & Neurodegenerat Dis, 149 13th St,Room 2275, Charlestown, MA 02129 USA. EM rosas@helix.mgh.harvard.edu OI Hevelone, Nathanael/0000-0003-4740-2085 FU NCCIH NIH HHS [AT000613, R01 AT000613, R01 AT000613-05, U01 AT000613, U01 AT000613-06A1, U01 AT000613-07]; NCRR NIH HHS [P01RR4075, RR4075]; NIA NIH HHS [AG024898]; NINDS NIH HHS [P01NS058793, NS042861, NS045242, P01 NS045242, P01 NS045242-05, P01 NS045242-050005, P01 NS058793, P01 NS058793-01A1, P01 NS058793-01A10004, P01 NS058793-01A19001, P01 NS058793-01A19002]; PHS HHS [R16594] NR 68 TC 196 Z9 196 U1 2 U2 12 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0006-8950 J9 BRAIN JI Brain PD APR PY 2008 VL 131 BP 1057 EP 1068 DI 10.1093/brain/awn025 PN 4 PG 12 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 284CH UT WOS:000254682300017 PM 18337273 ER PT J AU Chen, JW Breckwoldt, MO Aikawa, E Chiang, G Weissleder, R AF Chen, John W. Breckwoldt, Michael O. Aikawa, Elena Chiang, Gloria Weissleder, Ralph TI Myeloperoxidase-targeted imaging of active inflammatory lesions in murine experimental autoimmune encephalomyelitis SO BRAIN LA English DT Article DE myeloperoxidase; neuroinflammation; demyelination; targeted imaging; MRI ID EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; BRAIN-BARRIER DAMAGE; MULTIPLE-SCLEROSIS; CORTICAL DEMYELINATION; MACROPHAGE ACTIVATION; MEDICAL PROGRESS; RELAPSING EAE; IRON-OXIDE; MRI; GADOLINIUM AB Inflammatory demyelinating plaques are the pathologic hallmark of active multiple sclerosis and often precede clinical manifestations. Non-invasive early detection of active plaques would thus be crucial in establishing pre-symptomatic diagnosis and could lead to early preventive treatment strategies. Using murine experimental autoimmune encephalomyelitis as a model of multiple sclerosis, we demonstrate that a prototype paramagnetic myeloperoxidase (MPO) sensor can detect and confirm more, smaller, and earlier active inflammatory lesions in living mice by in vivo MRI. We show that MPO expression corresponded with areas of inflammatory cell infiltration and demyelination, and higher MPO activity as detected by MPO imaging, biochemical assays, and histopathological analyses correlated with increased clinical disease severity. Our findings present a potential new translational approach for specific non-invasive inflammatory plaque imaging. This approach could be used in longitudinal studies to identify active demyelinating plaques as well as to more accurately track disease course following treatment in clinical trials. C1 [Chen, John W.; Weissleder, Ralph] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Syst Biol, Charlestown, MA 02129 USA. [Chen, John W.; Breckwoldt, Michael O.; Aikawa, Elena; Chiang, Gloria; Weissleder, Ralph] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Mol Imaging Res, Charlestown, MA 02129 USA. RP Chen, JW (reprint author), 5404 Bldg 149,13th St, Charlestown, MA 02129 USA. EM chenjo@helix.mgh.harvard.edu FU NCI NIH HHS [R24 CA092782, R24 CA092782-05, R24-CA92782]; NHLBI NIH HHS [R01 HL078641, R01 HL078641-03, R01-HL078641] NR 46 TC 55 Z9 56 U1 1 U2 6 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0006-8950 J9 BRAIN JI Brain PD APR PY 2008 VL 131 BP 1123 EP 1133 DI 10.1093/brain/awn004 PN 4 PG 11 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 284CH UT WOS:000254682300023 PM 18234693 ER PT J AU Billiards, SS Haynes, RL Folkerth, RD Borenstein, NS Trachtenberg, FL Rowitch, DH Ligon, KL Volpe, JJ Kinney, HC AF Billiards, Saraid S. Haynes, Robin L. Folkerth, Rebecca D. Borenstein, Natalia S. Trachtenberg, Felicia L. Rowitch, David H. Ligon, Keith L. Volpe, Joseph J. Kinney, Hannah C. TI Myelin abnormalities without oligodendrocyte loss in periventricular leukomalacia SO BRAIN PATHOLOGY LA English DT Article DE periventricular leukomalacia; oligodendrocytes; Olig2; myelin ID CENTRAL-NERVOUS-SYSTEM; WHITE-MATTER INJURY; SUBVENTRICULAR ZONE; MATURE OLIGODENDROCYTES; SELECTIVE VULNERABILITY; INTRAUTERINE INFECTION; TRANSCRIPTION FACTORS; PRETERM INFANTS; NMDA RECEPTORS; RAT-BRAIN AB The cellular basis of myelin deficits detected by neuroimaging in long-term survivors of periventricular leukomalacia (PVL) is poorly understood. We tested the hypothesis that oligodendrocyte lineage (OL) cell density is reduced in PVL, thereby contributing to subsequent myelin deficits. Using computer-based methods, we determined OL cell density in sections from 18 PVL and 18 age-adjusted control cases, immunostained with the OL-lineage marker Olig2. Myelination was assessed with myelin basic protein (MBP) immunostaining. We found no significant difference between PVL and control cases in Olig2 cell density in the periventricular or intragyral white matter. We did find, however, a significant increase in Olig2 cell density at the necrotic foci, compared with distant areas. Although no significant difference was found in the degree of MBP immunostaining, we observed qualitative abnormalities of MBP immunostaining in both the diffuse and necrotic components of PVL. Abnormal MBP immunostaining in PVL despite preserved Olig2 cell density may be secondary to arrested OL maturation, damage to OL processes, and/or impaired axonal-OL signaling. OL migration toward the "core" of injury may occur to replenish OL cell number. This study provides new insight into the cellular basis of the myelin deficits observed in survivors of PVL. C1 [Billiards, Saraid S.; Haynes, Robin L.; Folkerth, Rebecca D.; Borenstein, Natalia S.; Ligon, Keith L.; Kinney, Hannah C.] Childrens Hosp, Dept Pathol, Boston, MA 02115 USA. [Haynes, Robin L.; Volpe, Joseph J.] Childrens Hosp, Dept Neurol, Boston, MA 02115 USA. [Rowitch, David H.] Childrens Hosp, Div Neonatol, Boston, MA 02115 USA. [Rowitch, David H.] Childrens Hosp, Div Hematol, Boston, MA 02115 USA. [Folkerth, Rebecca D.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. [Trachtenberg, Felicia L.] New England Res Inst, Watertown, MA 02172 USA. [Rowitch, David H.; Ligon, Keith L.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. RP Kinney, HC (reprint author), Childrens Hosp, Dept Pathol, Enders Bldg,Room 1112,300 Longwood Ave, Boston, MA 02115 USA. EM hannah.kinney@childrens.harvard.edu RI Haynes, Robin/M-4401-2016 OI Haynes, Robin/0000-0003-4909-9585 FU NICHD NIH HHS [P30 HD018655, P30-HD18655]; NINDS NIH HHS [P01 NS038475-09, P01 NS038475, P01-NS38475] NR 52 TC 113 Z9 119 U1 0 U2 1 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1015-6305 J9 BRAIN PATHOL JI Brain Pathol. PD APR PY 2008 VL 18 IS 2 BP 153 EP 163 DI 10.1111/j.1750-3639.2007.00107.x PG 11 WC Clinical Neurology; Neurosciences; Pathology SC Neurosciences & Neurology; Pathology GA 278GJ UT WOS:000254272700002 PM 18177464 ER PT J AU Leverenz, JB Hamilton, R Tsuang, DW Schantz, A Vavrek, D Larson, EB Kukull, WA Lopez, O Galasko, D Masliah, E Kaye, J Woltjer, R Clark, C Trojanowski, JQ Montine, TJ AF Leverenz, James B. Hamilton, Ronald Tsuang, Debby W. Schantz, Aimee Vavrek, Darcy Larson, Eric B. Kukull, Walter A. Lopez, Oscar Galasko, Douglas Masliah, Eliezer Kaye, Jeffrey Woltjer, Randall Clark, Christopher Trojanowski, John Q. Montine, Thomas J. TI Empiric refinement of the pathologic assessment of Lewy-related pathology in the dementia patient SO BRAIN PATHOLOGY LA English DT Article DE Lewy bodies; dementia; alpha-synuclein ID SPORADIC PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; ALPHA-SYNUCLEIN; INTERNATIONAL WORKSHOP; BODY PATHOLOGY; BODIES; DIAGNOSIS; CONSORTIUM; BRAINS; DLB AB Lewy-related pathology (LRP) is a common pathologic finding at autopsy in dementia patients. Recently criteria for categorizing types of LRP in dementia patients were published, though these criteria have yet to be systematically applied to large dementia samples. We examined a large (n = 208) referral-based autopsy sample for LRP, and applied the published criteria for LRP categorization to these cases. We found almost half (49%) of LRP positive cases from this sample were not classifiable. However, modifying the published criteria by reducing the number of regions requiring examination, allowing more variability in LRP severity scores within specific brain regions, and adding an amygdala predominant category permitted classification of 97% of LRP positive cases from the referral-based sample. Application of the modified criteria to an unrelated community-based autopsy sample (n = 226) allowed classification of 96% of LRP positive cases. Modest modifications in the published criteria permit a significantly greater number of dementia cases with LRP to be classified. In addition, this modification allows for more limited sampling of brain regions for classification of LRP. We propose that these modified criteria for the categorization of LRP be utilized in patients with a history of dementia. C1 [Leverenz, James B.; Tsuang, Debby W.; Vavrek, Darcy] Univ Washington, Dept Vet Affairs NW Network Mental Illness, Seattle, WA 98195 USA. [Leverenz, James B.] Univ Washington, Dept Parkinsons Dis Res, Educ & Clin Ctr, Seattle, WA 98195 USA. [Kukull, Walter A.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Larson, Eric B.] Univ Washington, Dept Med, Seattle, WA 98195 USA. [Leverenz, James B.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA. [Schantz, Aimee; Montine, Thomas J.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA. [Leverenz, James B.; Tsuang, Debby W.; Vavrek, Darcy] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Larson, Eric B.] Grp Hlth Cooperat Puget Sound, Seattle, WA 98121 USA. [Lopez, Oscar] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA. [Hamilton, Ronald] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15260 USA. [Galasko, Douglas] Univ Calif San Diego, Dept Neurol, San Diego, CA USA. [Masliah, Eliezer] Univ Calif San Diego, Dept Pathol, San Diego, CA USA. [Kaye, Jeffrey; Montine, Thomas J.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Woltjer, Randall] Oregon Hlth & Sci Univ, Dept Pathol, Portland, OR 97201 USA. [Clark, Christopher] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA. [Trojanowski, John Q.] Univ Penn, Dept Pathol, Philadelphia, PA 19104 USA. RP Leverenz, JB (reprint author), VA Puget Sound Hlth Care Syst, MIRECC 116MIRECC, 1660 S Columbian Way, Seattle, WA 98108 USA. EM leverenz@u.washington.edu RI Tsuang, Debby/L-7234-2016; OI Tsuang, Debby/0000-0002-4716-1894; Kukull, Walter/0000-0001-8761-9014; Kaye, Jeffrey/0000-0002-9971-3478 FU NIA NIH HHS [AG05133, AG05136, AG06781, AG10124, AG10845, P30 AG010124, P30 AG010124-09, P50 AG005133, P50 AG005133-229002, P50 AG005136, P50 AG005136-229003, P50 AG005136-25, U01 AG006781, U01 AG006781-13, U01 AG016976]; NINDS NIH HHS [R01 NS048595, NS053488, NS48595, P50 NS053488, P50 NS053488-01A2, R01 NS048595-01, R01 NS048595-05] NR 22 TC 57 Z9 57 U1 1 U2 2 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1015-6305 J9 BRAIN PATHOL JI Brain Pathol. PD APR PY 2008 VL 18 IS 2 BP 220 EP 224 DI 10.1111/j.1750-3639.2007.00117.xd PG 5 WC Clinical Neurology; Neurosciences; Pathology SC Neurosciences & Neurology; Pathology GA 278GJ UT WOS:000254272700008 PM 18241240 ER PT J AU Zuccato, C Marullo, M Conforti, P MacDonald, ME Tartari, M Cattaneo, E AF Zuccato, Chiara Marullo, Manuela Conforti, Paola MacDonald, Marcy E. Tartari, Marzia Cattaneo, Elena TI Systematic assessment of BDNF and its receptor levels in human cortices affected by Huntington's disease SO BRAIN PATHOLOGY LA English DT Article DE BDNF; TrkB; T-Sch; p75(NTR); Huntington's disease; human brain ID STRIATAL PROJECTION NEURONS; NEUROTROPHIC-FACTOR; MOUSE MODEL; HUMAN BRAIN; IN-VITRO; PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; GABAERGIC NEURONS; TYROSINE KINASE; GENE-EXPRESSION AB One cardinal feature of Huntington's disease (HD) is the degeneration of striatal neurons, whose survival greatly depends on the binding of cortical brain-derived neurotrophic factor (BDNF) with high-affinity (TrkB) and low-affinity neurotrophin receptors [p75 pan-neurotrophin receptor (p75(NTR))]. With a few exceptions, results obtained in HD mouse models demonstrate a reduction in cortical BDNF mRNA and protein, although autopsy data from a limited number of human HD cortices are conflicting. These studies indicate the presence of defects in cortical BDNF gene transcription and transport to striatum. We provide new evidence indicating a significant reduction in BDNF mRNA and protein in the cortex of 20 HD subjects in comparison with 17 controls, which supports the hypothesis of impaired BDNF production in human HD cortex. Analyses of the BDNF isoforms show that transcription from BDNF promoter II and IV is down-regulated in human HD cortex from an early symptomatic stage. We also found that TrkB mRNA levels are reduced in caudate tissue but not in the cortex, whereas the mRNA levels of T-Shc (a truncated TrkB isoform) and p75(NTR) are increased in the caudate. This indicates that, in addition to the reduction in BDNF mRNA, there is also unbalanced neurotrophic receptor signaling in HD. C1 [Zuccato, Chiara; Marullo, Manuela; Conforti, Paola; Tartari, Marzia; Cattaneo, Elena] Univ Milan, Dept Pharmacol Sci, I-20133 Milan, Italy. [Zuccato, Chiara; Marullo, Manuela; Conforti, Paola; Tartari, Marzia; Cattaneo, Elena] Univ Milan, Ctr Stem Cell Res, I-20133 Milan, Italy. [MacDonald, Marcy E.] Massachusetts Gen Hosp, Richard B Simches Res Ctr, Ctr Human Genet Res, Boston, MA 02114 USA. RP Cattaneo, E (reprint author), Univ Milan, Dept Pharmacol Sci, Via Balzaretti 9, I-20133 Milan, Italy. EM elena.cattaneo@unimi.it OI ZUCCATO, CHIARA/0000-0003-1771-3392; CATTANEO, ELENA/0000-0002-0755-4917 FU Telethon [GGP06250] NR 61 TC 96 Z9 101 U1 1 U2 9 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1015-6305 J9 BRAIN PATHOL JI Brain Pathol. PD APR PY 2008 VL 18 IS 2 BP 225 EP 238 DI 10.1111/j.1750-3639.2007.00111.x PG 14 WC Clinical Neurology; Neurosciences; Pathology SC Neurosciences & Neurology; Pathology GA 278GJ UT WOS:000254272700009 PM 18093249 ER PT J AU George, MS Ward, HE Ninan, PT Pollack, M Nahas, Z Anderson, B Kose, S Howland, RH Goodman, WK Ballenger, JC AF George, Mark S. Ward, Herbert E., Jr. Ninan, Philip T. Pollack, Mark Nahas, Ziad Anderson, Berry Kose, Samet Howland, Robert H. Goodman, Wayne K. Ballenger, James C. TI A pilot study of vagus nerve stimulation (VNS) for treatment-resistant anxiety disorders SO BRAIN STIMULATION LA English DT Article DE vagus nerve stimulation (VNS); anxiety disorder; obsessive compulsive disorder; panic disorder; posuttraumatic stress disorder; clinical trial; efficacy; side effects ID OBSESSIVE-COMPULSIVE DISORDER; PERIPHERAL C-FIBERS; PARTIAL SEIZURES; MOOD DISORDERS; LOCUS-CERULEUS; DEPRESSION; SUPPRESSION; EXPRESSION; EFFICACY; THERAPY AB Background Vagus nerve stimulation (VNS) is an effective anticonvulsant device and has shown antidepressant effects in chronic treatment resistant depression. Because the vagus nerve sends information to brain regions important in anxiety regulation (locus coeruleus, orbitofrontal cortex, insula, hippocampus and amygdala), this pathway might be involved in perceiving or manifesting various somatic and cognitive symptoms that characterize anxiety disorders. On the basis of this reasoning and reports of anxiolytic effects of VNS in patients treated for epilepsy and depression, we organized an open-label pilot acute trial of adjunctive VNS on top of stable medications, followed by long-term follow-up, to assess the safety and potential efficacy of VNS for patients with treatment resistant anxiety disorders. Methods Eleven adult outpatients with treatment resistant obsessive-compulsive disorder (OCD), panic disorder (PD), or posttraumatic stress disorder (PTSD) were recruited. Patients had failed several medication trials as well as cognitive behavioral therapy (CBT). All patients were rated with the Hamilton Anxiety Scale (HAM-A) and the clinical global impressions improvement scale (CGI-1). Patients with OCD were also rated with the Yale-Brown Obsessive Compulsive Scale (Y-BOCS). Patients were maintained on their current psychotropic medications at fixed doses during the acute 12-week phase. Changes in medications and VNS stimulus parameters were allowed during the long-term follow-up. Response was defined as a 50% or greater improvement on the HAM-A for all Patients and a 25% or greater improvement on the Y-BOCS for patients with OCD. Results Eleven patients were recruited. Seven patients had a primary diagnosis of OCD, two had PTSD, and one had PD. One OCD patient changed their mind and was never implanted. One patient with OCD withdrew consent before the end of the acute phase, so long-term results were available for nine patients. Three patients were acute responders. based oil the HAM-A. and there was some improvement in anxiety ratings over time (with statistically significant improvements at 14 of 8 quarters during long-term follow-up). Of the seven patients with OCD who received stimulation, three were acute responders, based on the Y-BOCS, and there was some improvement in Y-BOCS scores over time (with statistically significant improvements at 7 of IS quarters during long-term follow-up). VNS was relatively well tolerated. Four years after implantation, four patients (diagnoses two OCD. one PD, one PTSD) were still receiving VNS with continued and Sustained improvement in anxiety scores compared with their baseline scores. Conclusions These patients with treatment-resistant anxiety disorders generally tolerated VNS treatment, and there was evidence of acute and long-term improvement in some patients. These open data suggest that further double-blind studies assessing, the VNS role in treating anxiety disorders, particularly OCD, may be warranted. (C) 2008 Elsevier Inc. All rights reserved. C1 [George, Mark S.] Med Univ S Carolina, IOP, Dept Psychiat, Charleston, SC 29425 USA. [Ward, Herbert E., Jr.; Goodman, Wayne K.] Univ Florida, Sch Med, Dept Psychiat, Gainesville, FL USA. [Ninan, Philip T.] Emory Univ, Sch Med, Dept Psychiat & Behav Sci, Atlanta, GA USA. [Pollack, Mark] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Howland, Robert H.] Western Psychiat Inst & Clin, Pittsburgh, PA USA. RP George, MS (reprint author), Med Univ S Carolina, IOP, Dept Psychiat, 502N,67 President St, Charleston, SC 29425 USA. EM georgem@musc.edu RI Howland, Robert/K-6937-2015; OI Howland, Robert/0000-0002-6533-6010; Ninan, Philip/0000-0001-6633-1142 FU Cyberonics, Inc FX This study was supported in part by grants from Cyberonics, Inc. Data wei-e collected by Quintiles Tran national Corp. Statistical analyses were performed by Amara K. Jayewarderie, MS, and John Allen, Jr., PhD. of Cyberonics, Inc., manufacturer of the VNS Therapy System and reviewed by the authors. Susan E. Siefert, ELS, CBC, also of Cyberonics. assisted with the development of the manuscript. NR 41 TC 31 Z9 34 U1 4 U2 36 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1935-861X J9 BRAIN STIMUL JI Brain Stimul. PD APR PY 2008 VL 1 IS 2 BP 112 EP 121 DI 10.1016/j.brs.2008.02.001 PG 10 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 398EY UT WOS:000262716600010 PM 20633378 ER PT J AU Tchinda, J O'Neil, J Gutierrez, A Moreau, L Maser, RS Wong, KK Li, W McKenna, K Liu, XS Feng, B Neuberg, D Silverman, L DeAngelo, DJ Kutok, J Look, AT Lee, C Rothstein, R DePinho, R Chin, L AF Tchinda, J. O'Neil, J. Gutierrez, A. Moreau, L. Maser, R. S. Wong, K. K. Li, W. McKenna, K. Liu, X. S. Feng, B. Neuberg, D. Silverman, L. DeAngelo, D. J. Kutok, J. Look, A. T. Lee, C. Rothstein, R. DePinho, R. Chin, L. TI Alu elements mediate MYB gene tandem duplication in human T-ALL SO BRITISH JOURNAL OF HAEMATOLOGY LA English DT Meeting Abstract CT 48th Annual Scientific Meeting of the British-Society-for-Haematology CY APR 07-09, 2008 CL Glasgow, SCOTLAND SP British Soc Haematol C1 [Tchinda, J.; Kutok, J.; Lee, C.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. [O'Neil, J.; Gutierrez, A.; Moreau, L.; McKenna, K.; Silverman, L.; Look, A. T.; Chin, L.] Dana Farber Canc Inst, Dept Paediat Oncol, Boston, MA 02115 USA. [O'Neil, J.; Gutierrez, A.; Look, A. T.; Chin, L.] Childrens Hosp, Div Haematol, Boston, MA 02115 USA. [Maser, R. S.; Wong, K. K.; DeAngelo, D. J.; DePinho, R.; Chin, L.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Liu, X. S.; Neuberg, D.] Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Dept Biostat & Computat Biol,Dept Biostat, Boston, MA 02115 USA. [DePinho, R.; Chin, L.] Dana Farber Canc Inst, Ctr Appl Canc Sci, Belfer Fdn Inst Innovat Canc Sci, Boston, MA 02115 USA. [Chin, L.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA. [Rothstein, R.] Columbia Univ, Med Ctr, Dept Genet Dev, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0007-1048 J9 BRIT J HAEMATOL JI Br. J. Haematol. PD APR PY 2008 VL 141 SU 1 MA 70 BP 26 EP 26 PG 1 WC Hematology SC Hematology GA 289CL UT WOS:000255032500071 ER PT J AU Payne, E Rhodes, I Sbrogna, J Kanki, J Cotter, F Look, AT AF Payne, E. Rhodes, I. Sbrogna, J. Kanki, J. Cotter, F. Look, A. T. TI Zebrafish screens reveal a role for dead-box 18 in haematopoiesis SO BRITISH JOURNAL OF HAEMATOLOGY LA English DT Meeting Abstract CT 48th Annual Scientific Meeting of the British-Society-for-Haematology CY APR 07-09, 2008 CL Glasgow, SCOTLAND SP British Soc Haematol C1 [Payne, E.; Rhodes, I.; Sbrogna, J.; Kanki, J.; Look, A. T.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Payne, E.; Cotter, F.] Queen Mary Univ London, London, England. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0007-1048 J9 BRIT J HAEMATOL JI Br. J. Haematol. PD APR PY 2008 VL 141 SU 1 MA 171 BP 63 EP 63 PG 1 WC Hematology SC Hematology GA 289CL UT WOS:000255032500172 ER PT J AU Werning, G Kharas, MG Okabe, R Moore, SA Leeman, DS Cullen, DE Gozo, M McDowell, EP Levine, RL Doukas, J Mak, CC Noronha, G Martin, M Ko, YD Lee, BH Soll, RM Tefferi, A Hood, JD Gilliland, DG AF Werning, Gerlinde Kharas, Michael G. Okabe, Rachel Moore, Sandra A. Leeman, Dena S. Cullen, Dana E. Gozo, Maricel McDowell, Elizabeth P. Levine, Ross L. Doukas, John Mak, Chi Ching Noronha, Glenn Martin, Michael Ko, Yon D. Lee, Benjamin H. Soll, Richard M. Tefferi, Ayalew Hood, John D. Gilliland, D. Gary TI Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera SO CANCER CELL LA English DT Article ID CHRONIC MYELOID-LEUKEMIA; TYROSINE KINASE JAK2; MYELOPROLIFERATIVE DISORDERS; ESSENTIAL THROMBOCYTHEMIA; ACTIVATING MUTATION; MYELOFIBROSIS; RECEPTOR; EXPRESSION; METAPLASIA; IMATINIB AB We report that TG101348, a selective small-molecule inhibitor of JAK2 with an in vitro IC50 of similar to 3 nM, shows therapeutic efficacy in a murine model of myeloproliferative disease induced by the JAK2V617F mutation. In treated animals, there was a statistically significant reduction in hematocrit and leukocyte count, a dose-dependent reduction/elimination of extramedullary hematopoiesis, and, at least in some instances, evidence for attenuation of myelofibrosis. There were no apparent toxicities and no effect on T cell number. In vivo responses were correlated with surrogate endpoints, including reduction/elimination of JAK2V617F disease burden assessed by quantitative genomic PCR, suppression of endogenous erythroid colony formation, and in vivo inhibition of JAK-STAT signal transduction as assessed by flow cytometric measurement of phosphorylated Stat5. C1 [Werning, Gerlinde; Kharas, Michael G.; Okabe, Rachel; Moore, Sandra A.; Leeman, Dena S.; Cullen, Dana E.; Gozo, Maricel; McDowell, Elizabeth P.; Levine, Ross L.; Lee, Benjamin H.; Gilliland, D. Gary] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Hematol, Boston, MA 02115 USA. [Gilliland, D. Gary] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA. [Levine, Ross L.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Gilliland, D. Gary] Howard Hughes Med Inst, Boston, MA 02115 USA. [Doukas, John; Mak, Chi Ching; Noronha, Glenn; Martin, Michael; Soll, Richard M.; Hood, John D.] TargeGen Inc, San Diego, CA 92121 USA. [Ko, Yon D.] Johanniter KH, Div Hematol, D-0228 Bonn, Germany. [Tefferi, Ayalew] Mayo Clin, Dept Med, Rochester, MN 55905 USA. RP Gilliland, DG (reprint author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Hematol, Boston, MA 02115 USA. EM ggilliland@rics.bwh.harvard.edu FU Howard Hughes Medical Institute; NCI NIH HHS [CA66996, CA105423, P01 CA066996] NR 23 TC 199 Z9 207 U1 1 U2 7 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 1535-6108 J9 CANCER CELL JI Cancer Cell PD APR PY 2008 VL 13 IS 4 BP 311 EP 320 DI 10.1016/j.ccr.2008.02.009 PG 10 WC Oncology; Cell Biology SC Oncology; Cell Biology GA 286AM UT WOS:000254817400006 PM 18394554 ER PT J AU Wiedemeyer, R Brennan, C Heffernan, TP Xiao, YH Mahoney, J Protopopov, A Zheng, H Bignell, G Furnari, F Cavenee, WK Hahn, WC Ichimura, K Collins, VP Chu, GC Stratton, MR Ligon, KL Futreal, PA Chin, L AF Wiedemeyer, Ruprecht Brennan, Cameron Heffernan, Timothy P. Xiao, Yonghong Mahoney, John Protopopov, Alexei Zheng, Hongwu Bignell, Graham Furnari, Frank Cavenee, Webster K. Hahn, William C. Ichimura, Koichi Collins, V. Peter Chu, Gerald C. Stratton, Michael R. Ligon, Keith L. Futreal, P. Andrew Chin, Lynda TI Feedback circuit among INK4 tumor suppressors constrains human glioblastoma development SO CANCER CELL LA English DT Article ID COMPARATIVE GENOMIC HYBRIDIZATION; HUMAN LUNG-CANCER; ARRAY CGH DATA; GENE; REVEALS; EXPRESSION; DELETIONS; PROFILES; INACTIVATION; P18(INK4C) AB We have developed a nonheuristic genome topography scan (GTS) algorithm to characterize the patterns of genomic alterations in human glioblastoma (GBM), identifying frequent p18(INK4C) and p16(INK4A) codeletion. Functional reconstitution of p18(INK4C) in GBM cells null for both p16(INK4A) and p18(INK4C) resulted in impaired cell-cycle progression and tumorigenic potential. Conversely, RNAi-mediated depletion of p18(INK4C) in p16(INK4A)-deficient primary astrocytes or established GBM cells enhanced tumorigenicity in vitro and in vivo. Furthermore, acute suppression of p16(INK4A) in primary astrocytes induced a concomitant increase in p18(INK4C). Together, these findings uncover a feedback regulatory circuit in the astrocytic lineage and demonstrate a bona fide tumor suppressor role for p18(INK4C) in human GBM wherein it functions cooperatively with other INK4 family members to constrain inappropriate proliferation. C1 [Brennan, Cameron] Mem Sloan Kettering Canc Ctr, Dept Neurosurg, New York, NY 10065 USA. [Wiedemeyer, Ruprecht; Heffernan, Timothy P.; Zheng, Hongwu; Hahn, William C.; Chu, Gerald C.; Ligon, Keith L.; Chin, Lynda] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Wiedemeyer, Ruprecht; Heffernan, Timothy P.; Zheng, Hongwu; Hahn, William C.; Chu, Gerald C.; Ligon, Keith L.; Chin, Lynda] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Xiao, Yonghong; Mahoney, John; Protopopov, Alexei; Chu, Gerald C.; Chin, Lynda] Dana Farber Canc Inst, Ctr Appl Canc Sci, Belfer Inst Innovat Canc Sci, Boston, MA 02115 USA. [Hahn, William C.] Dana Farber Canc Inst, Ctr Canc Genome Discovery, Boston, MA 02115 USA. [Ligon, Keith L.] Dana Farber Canc Inst, Ctr Mol Oncol Pathol, Boston, MA 02115 USA. [Brennan, Cameron] Weill Cornell Med Coll, Dept Neurosurg, New York, NY 10065 USA. [Bignell, Graham; Stratton, Michael R.; Futreal, P. Andrew] Wellcome Trust Sanger Inst, Canc Genome Project, Cambridge CB10 1SA, England. [Furnari, Frank] Univ Calif San Diego, Ludwig Inst Canc Res, La Jolla, CA 92093 USA. [Hahn, William C.] Broad Inst Harvard, Cambridge, MA 02142 USA. [Hahn, William C.] MIT, Cambridge, MA 02142 USA. [Ichimura, Koichi; Collins, V. Peter] Univ Cambridge, Dept Pathol, Cambridge CB2 1QP, England. [Stratton, Michael R.] Inst Canc Res, Sutton SM2 5NG, Surrey, England. [Ligon, Keith L.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. [Chin, Lynda] Brigham & Womens Hosp, Dept Dermatol, Boston, MA 02115 USA. [Hahn, William C.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. [Brennan, Cameron; Hahn, William C.; Ligon, Keith L.; Chin, Lynda] Harvard Univ, Sch Med, Boston, MA 02115 USA. RP Brennan, C (reprint author), Mem Sloan Kettering Canc Ctr, Dept Neurosurg, New York, NY 10065 USA. EM cbrennan@mskcc.org; lynda-chin@dfci.harvard.edu OI Zheng, Hongwu/0000-0002-5823-4913; Brennan, Cameron/0000-0003-4064-8891 FU NCI NIH HHS [P01CA95616, P01 CA095616, P01 CA095616-060004, P01 CA095616-070004, R01 CA099041, R01 CA099041-05, R01CA99041]; NIAMS NIH HHS [T32 AR007098]; Wellcome Trust NR 41 TC 78 Z9 81 U1 0 U2 1 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 1535-6108 J9 CANCER CELL JI Cancer Cell PD APR PY 2008 VL 13 IS 4 BP 355 EP 364 DI 10.1016/j.ccr.2008.02.010 PG 10 WC Oncology; Cell Biology SC Oncology; Cell Biology GA 286AM UT WOS:000254817400010 PM 18394558 ER PT J AU Gordon, GJ Mani, M Maulik, G Mukhopadhyay, L Yeap, BY Kindler, HL Salgia, R Sugarbaker, DJ Bueno, R AF Gordon, Gavin J. Mani, Madhubalan Maulik, Gautam Mukhopadhyay, Lipi Yeap, Beow Y. Kindler, Hedy L. Salgia, Ravi Sugarbaker, David J. Bueno, Raphael TI Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma SO CANCER CHEMOTHERAPY AND PHARMACOLOGY LA English DT Article DE mesothelioma; bortezomib; cisplatin; pemetrexed; inhibitor of apoptosis protein ID APOPTOSIS PROTEINS; LUNG-CANCER; PHASE-II; CELLS; EXPRESSION; THERAPY; CHEMOTHERAPY; COMBINATION; CISPLATIN; SURVIVIN AB Malignant pleural mesothelioma (MPM) is a highly lethal neoplasm that is resistant to chemotherapy. Bortezomib is an FDA-approved proteasome inhibitor that is currently under clinical investigation in multiple neoplasms but has not been studied extensively in MPM. In this report, we determine the biological and molecular response of cultured MPM cells to bortezomib alone and in combination with cisplatin or pemetrexed. We used four MPM cell lines (MS589, H28, H2052, JMN), a normal mesothelial cell line (HM3), and a lung cancer cell line (H23) in survival studies utilizing bortezomib, cisplatin, and pemetrexed alone and in combination by administering concurrently or by varying the order of administration. We determined the effect of bortezomib on the cell cycle, apoptosis, and on the expression of cell cycle proteins p21/WAF1 and p27/KIP1 and on apoptosis-related proteins IAP-1, IAP-2, survivin, and XIAP. Bortezomib was highly cytotoxic to MPM cells and induced both G(2)/M and G(1)/S cell cycle arrest. Apoptosis increased in a concentration-and time-dependent manner in 3 of 4 MPM cell lines. Bortezomib stabilized or increased protein levels of p21/WAF1 and IAP-1 and to a lesser degree p27/KIP1, IAP-2, XIAP, and survivin. In combination studies with cisplatin, bortezomib was generally synergistic at high concentrations and antagonistic at low concentrations. Bortezomib increased the cytotoxicity of cisplatin and pemetrexed in a concentration-dependent manner when administered prior to either. Bortezomib may improve outcome in MPM patients alone or in combination with standard chemotherapy but the order of administration is likely to be important. This study justifies further evaluation of bortezomib in MPM. C1 [Gordon, Gavin J.; Bueno, Raphael] Harvard Univ, Brigham & Womens Hosp, Sch Med, Thorac Surg Oncol Lab, Boston, MA 02115 USA. [Gordon, Gavin J.; Mani, Madhubalan; Maulik, Gautam; Mukhopadhyay, Lipi; Bueno, Raphael] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Thorac Surg, Boston, MA 02115 USA. [Yeap, Beow Y.] Massachusetts Gen Hosp, Dept Med, Hematol Oncol Unit, Boston, MA 02114 USA. [Kindler, Hedy L.; Salgia, Ravi] Univ Chicago, Med Ctr, Dept Med,Pritzker Sch Med, Canc Res Ctr,Sect Hematol Oncol, Chicago, IL 60637 USA. [Sugarbaker, David J.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Thorac Surg, Boston, MA 02115 USA. RP Gordon, GJ (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Thorac Surg Oncol Lab, 75 Francis St, Boston, MA 02115 USA. EM ggordon@partners.org FU NCI NIH HHS [CA100315, CA120528] NR 43 TC 44 Z9 45 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0344-5704 J9 CANCER CHEMOTH PHARM JI Cancer Chemother. Pharmacol. PD APR PY 2008 VL 61 IS 4 BP 549 EP 558 DI 10.1007/s00280-007-0500-1 PG 10 WC Oncology; Pharmacology & Pharmacy SC Oncology; Pharmacology & Pharmacy GA 249JA UT WOS:000252222900002 PM 17522864 ER PT J AU Kelly, KA Setlur, SR Ross, R Anbazhagan, R Waterman, P Rubin, MA Weissleder, R AF Kelly, Kimberly A. Setlur, Sunita R. Ross, Robert Anbazhagan, Rajesh Waterman, Peter Rubin, Mark A. Weissleder, Ralph TI Detection of early prostate cancer using a hepsin-targeted imaging agent SO CANCER RESEARCH LA English DT Article ID GENE-EXPRESSION ANALYSIS; RADICAL PROSTATECTOMY; ANTIGEN; CARCINOMA; MARKERS; PHAGE; CELLS; MEN AB Early detection and diagnosis of prostate cancer is key to designing effective treatment strategies. Microarrays have resulted in the discovery of hepsin (HPN) as a biomarker for detection of prostate cancer. In this study, we explore the development of HPN imaging probes for detection of prostate cancer. We used phage display to isolate HPN binding peptides with 190 + 2.2 nmol/L affinity in monomeric form and high specificity. The identified peptides were able to detect human prostate cancer on tissue microarrays and in cell-based assays. HPN-targeted imaging agents were synthesized by conjugating multiple peptides to fluorescent nanoparticles to further improve avidity through multivalency and to improve pharmacokinetics. When injected into mouse xenograft models, RPN-targeted nanoparticles bound specifically to RPN-expressing LNCaP xenografts compared with non-HPN-expressing PC3 xenografts. HpN imaging may provide a new method for detection of prostate cancer. C1 [Kelly, Kimberly A.; Ross, Robert; Anbazhagan, Rajesh; Waterman, Peter; Weissleder, Ralph] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Mol Imaging Res, Charlestown, MA 02129 USA. [Waterman, Peter; Weissleder, Ralph] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Syst Biol, Charlestown, MA 02129 USA. [Waterman, Peter; Weissleder, Ralph] Harvard Univ, Sch Med, Dept Syst Biol, Charlestown, MA 02129 USA. [Setlur, Sunita R.; Rubin, Mark A.; Weissleder, Ralph] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. [Ross, Robert; Rubin, Mark A.; Weissleder, Ralph] Dana Farber Harvard Canc Ctr, Boston, MA USA. [Weissleder, Ralph] MIT, Ctr Canc Res, Cambridge, MA 02139 USA. [Weissleder, Ralph] MIT, Broad Inst, Cambridge, MA 02139 USA. RP Kelly, KA (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Mol Imaging Res, 149 13th St,Room 5420, Charlestown, MA 02129 USA. EM kkelly9@partners.org OI Rubin, Mark/0000-0002-8321-9950 FU NCI NIH HHS [P50 CA086355, P50 CA086355-03, P50 CA090381, U54-CA119349, R24-CA92782, R24 CA092782-05, R24 CA092782, P50-CA86355, U54 CA119349, U54 CA119349-040003, P50-CA090381]; NIA NIH HHS [R01 AG021404, R01AG21404] NR 29 TC 63 Z9 67 U1 2 U2 13 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 J9 CANCER RES JI Cancer Res. PD APR 1 PY 2008 VL 68 IS 7 BP 2286 EP 2291 DI 10.1158/0008-5472.CAN-07-1349 PG 6 WC Oncology SC Oncology GA 284WU UT WOS:000254738500030 PM 18381435 ER PT J AU Fuchs, BC Fujii, T Dorfman, JD Goodwin, JM Zhu, AX Lanuti, M Tanabe, KK AF Fuchs, Bryan C. Fujii, Tsutomu Dorfman, Jon D. Goodwin, Jonathan M. Zhu, Andrew X. Lanuti, Michael Tanabe, Kenneth K. TI Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells SO CANCER RESEARCH LA English DT Article ID ADVANCED HEPATOCELLULAR-CARCINOMA; E-CADHERIN EXPRESSION; LUNG-CANCER; GEFITINIB IRESSA; PROTEIN-KINASE; LINES; ERLOTINIB; GENE; THERAPY; RESISTANCE AB Hepatocellular carcinoma (HCC) is associated with a poor prognosis due to late diagnoses and a lack of effective treatment options. Epidermal growth factor receptor (EGFR)-targeted therapies have been effective in other cancers. However, erlotinib and cetuximab have shown only modest efficacy in clinical trials of HCC. We examined epithelial-to-mesenchymal transition (EMT) as a determinant of sensitivity of HCC to EGFR inhibitors. A panel of 12 human hepatoma cell lines were classified as epithelial or mesenchymal based on their expression of E-cadherin and vimentin. The resulting classification correlated with a previous microarray analysis of human hepatoma cell lines whereby the mesenchymal cell lines were shown to have increased expression of genes involved in metastasis and invasion. Sensitivity to erlotinib, gefitinib, and cetuximab was assessed and the epithelial cell lines were found to be significantly more susceptible to all three agents. Analysis of the EGFR pathway showed that EMT status was independent of EGFR expression or downstream extracellular signal-regulated kinase activation and only the epithelial cell lines expressed ErbB3. Interestingly, mesenchymal cells resistant to EGFR inhibitors had increased AKT and signal transducer and activator of transcription-3 activation through elevated expression of integrin-linked kinase (ILK). Mesenchymal cell lines were therefore experimentally transformed with kinase-inactive ILK (KI-ILK) with a resulting decrease in ILK activity and activation of AKT. KI-ILK transformants showed increased sensitivity to EGFR inhibitors both in vitro and in an in vivo xenograft model. These data suggest that EMT predicts HCC sensitivity to EGFR-targeted therapies and that ILK is a novel target to overcome HCC resistance to EGFR inhibition. C1 [Fuchs, Bryan C.; Fujii, Tsutomu; Dorfman, Jon D.; Tanabe, Kenneth K.] Massachusetts Gen Hosp, Div Surg Oncol, Boston, MA 02114 USA. [Goodwin, Jonathan M.; Lanuti, Michael] Massachusetts Gen Hosp, Div Thorac Surg, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. [Zhu, Andrew X.] Massachusetts Gen Hosp, Div Hematol Oncol, Boston, MA 02114 USA. RP Tanabe, KK (reprint author), Massachusetts Gen Hosp, Div Surg Oncol, Yawkey 7-924,55 Fruit St, Boston, MA 02114 USA. EM KTanabe@Partners.org RI Fujii, Tsutomu/M-4838-2014 FU NCI NIH HHS [2R01CA076183, 5T32CA009535] NR 50 TC 175 Z9 185 U1 2 U2 11 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 J9 CANCER RES JI Cancer Res. PD APR 1 PY 2008 VL 68 IS 7 BP 2391 EP 2399 DI 10.1158/0008-5472.CAN-07-2460 PG 9 WC Oncology SC Oncology GA 284WU UT WOS:000254738500042 PM 18381447 ER PT J AU Viswanathan, AN Feskanich, D Schernhammer, ES Hankinson, SE AF Viswanathan, Akila N. Feskanich, Diane Schernhammer, Eva S. Hankinson, Susan E. TI Aspirin, NSAID, and acetaminophen use and the risk of endometrial cancer SO CANCER RESEARCH LA English DT Article ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; LOW-DOSE ASPIRIN; COLORECTAL-CANCER; BREAST-CANCER; CYCLOOXYGENASE-2 EXPRESSION; PRIMARY PREVENTION; PANCREATIC-CANCER; RANDOMIZED-TRIAL; WOMENS HEALTH; NURSES HEALTH AB To date, no prospective studies have explored the relationship between the use of aspirin, other nonsteroidal anti-inflammatory medications (NSAID), and acetaminophen and endometrial adenocarcinoma. Of the 82,971 women enrolled in a prospective cohort study, 747 developed medical record-confirmed invasive endometrial cancer over a 24-year period. Use of aspirin was ascertained from 1980 to 2004, and for other NSAIDs and acetaminophen, from 1990 to 2004. Cox regression models calculated multivariate relative risks (MV RR), controlling for body mass index (BMI), postmenopausal hormone (PMH) use, and other endometrial cancer risk factors. Currency, duration, and quantity of aspirin were not associated with endometrial cancer risk overall [current use: MV RR, 1.03; 95% confidence interval (CI) 0.83-1.27; >10 years of use: NIV RR, 1.01; 95% Cl, 0.78-1.30; and cumulative average >7 tablets per week: (MV RR, 1.10; 95% CI, 0.84-1.44)]. However, stratified analyses showed that a lower risk of endometrial cancer among obese (BMI, >= 30 kg/m(2)) women was seen with current aspirin use (MV RR, 0.66; 95% CI, 0.46-0.95). The greatest risk reduction for current aspirin users was seen in postmenopausal obese women who had never used PMH (MV RR, 0.43; 95% CI, 0.26-0.73). The use of other NSAIDs or acetaminophen was not associated with endometrial cancer. Our data suggest that use of aspirin or other NSAIDs does not play an important role in endometrial cancer risk overall. However, risk was significantly lower for current aspirin users who were obese or who were postmenopausal and had never used PMHs; these subgroup findings require further confirmation. C1 [Viswanathan, Akila N.] Brigham & Womens Hosp, Dept Radiat Oncol, Dana Farber Canc Inst, Boston, MA 02115 USA. [Viswanathan, Akila N.; Feskanich, Diane; Schernhammer, Eva S.; Hankinson, Susan E.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [Feskanich, Diane; Schernhammer, Eva S.; Hankinson, Susan E.] Brigham & Womens Hosp, Channing Lab, Dept Med, Boston, MA 02115 USA. [Schernhammer, Eva S.; Hankinson, Susan E.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. RP Viswanathan, AN (reprint author), 75 Francis St L2, Boston, MA 02115 USA. EM aviswanathan@lroc.harvard.edu FU NCI NIH HHS [K07 CA117979, K07 CA117979-01, K07 CA117979-03, P01 CA087969, K07 CA117979-02, 5K07 CA117979-01, CA87969, K07 CA117979-04] NR 51 TC 39 Z9 40 U1 0 U2 2 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 J9 CANCER RES JI Cancer Res. PD APR 1 PY 2008 VL 68 IS 7 BP 2507 EP 2513 DI 10.1158/0008-5472.CAN-07-6257 PG 7 WC Oncology SC Oncology GA 284WU UT WOS:000254738500055 PM 18381460 ER PT J AU Perera, SA Maser, RS Xia, H McNamara, K Protopopov, A Chen, L Hezel, AF Kim, CF Bronson, RT Castrillon, DH Chin, L Bardeesy, N DePinho, RA Wong, KK AF Perera, Samanthi A. Maser, Richard S. Xia, Huili McNamara, Kate Protopopov, Alexei Chen, Liang Hezel, Aram F. Kim, Carla F. Bronson, Roderick T. Castrillon, Diego H. Chin, Lynda Bardeesy, Nabeel DePinho, Ronald A. Wong, Kwok-Kin TI Telomere dysfunction promotes genome instability and metastatic potential in a K-ras p53 mouse model of lung cancer SO CARCINOGENESIS LA English DT Article ID TUMOR-SUPPRESSOR; IN-VIVO; CELLS; CHROMOSOMES; SENESCENCE; MICE; PROLIFERATION; TUMORIGENESIS; ACTIVATION AB Current mouse models of lung cancer recapitulate signature genetic lesions and some phenotypic features of human lung cancer. However, because mice have long telomeres, models to date do not recapitulate the aspects of lung carcinogenesis-telomere attrition and the genomic instability that ensues-believed to serve as key mechanisms driving lung tumor initiation and progression. To explore the contributions of telomere dysfunction to lung cancer progression, we combined a telomerase catalytic subunit (mTerc) mutation with the well-characterized K-rasG12D mouse lung cancer model. K-ras(G12D) mTerc(-/-) mice with telomere dysfunction but intact p53 exhibited increased lung epithelial apoptosis, delayed tumor formation and increased life span relative to K-ras(G12D) mTerc(+/-) mice with intact telomere function. This demonstrates that by itself, telomere dysfunction acts in a tumor-suppressive mechanism. Introduction of a heterozygous p53 mutation exerted a marked histopathological, biological and genomic impact. K-ras(G12D) mTerc(-/-) p53(+/-) mice developed aggressive tumors with more chromosomal instabilities and high metastatic potential, leading to decreased overall survival. Thus, we have generated a murine model that more faithfully recapitulates key aspects of the human disease. Furthermore, these findings clearly demonstrate (in an in vivo model system) the dual nature of telomere shortening as both a tumor-suppressive and tumor-promoting mechanism in lung cancer, dependent on p53 status. C1 [Perera, Samanthi A.; Maser, Richard S.; Xia, Huili; McNamara, Kate; Chen, Liang; Hezel, Aram F.; Chin, Lynda; DePinho, Ronald A.; Wong, Kwok-Kin] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Protopopov, Alexei; DePinho, Ronald A.] Dana Farber Canc Inst, Belfer Inst Innovat Canc Sci, Ctr Appl Canc Sci, Boston, MA 02115 USA. [Kim, Carla F.] Harvard Univ, Sch Med, Dept Genet,Harvard Stem Cell Inst, Childrens Hosp Stem Cell Program, Boston, MA 02115 USA. [Bronson, Roderick T.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. [Castrillon, Diego H.] Univ Texas SW Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA. [Castrillon, Diego H.] Univ Texas SW Med Ctr Dallas, Simmons Comprehens Canc Ctr, Dallas, TX 75390 USA. [Bardeesy, Nabeel] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA. [DePinho, Ronald A.] Harvard Univ, Sch Med, Dept Genet & Med, Boston, MA 02115 USA. [Wong, Kwok-Kin] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. RP Wong, KK (reprint author), Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. EM kwong1@partners.org RI Maser, Richard/B-2970-2012; OI wong, kwok kin/0000-0001-6323-235X FU NCI NIH HHS [CA122794]; NCRR NIH HHS [K26 RR024196-02, K26 RR024196]; NIA NIH HHS [AG027757] NR 38 TC 28 Z9 29 U1 0 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0143-3334 J9 CARCINOGENESIS JI Carcinogenesis PD APR PY 2008 VL 29 IS 4 BP 747 EP 753 DI 10.1093/carcin/bgn050 PG 7 WC Oncology SC Oncology GA 284CV UT WOS:000254683800010 PM 18283039 ER PT J AU Wang, Y Armstrong, SA AF Wang, Yingzi Armstrong, Scott A. TI Cancer: Inappropriate expression of stem cell programs? SO CELL STEM CELL LA English DT Editorial Material ID MODULE MAP; LEUKEMIA; MLL-AF9 AB Cancer stem cells (CSCs) are a subpopulation of cancer cells that possess characteristics, including self-renewal, associated with normal stem cells. In this issue of Cell Stem Cell, Wong et al. (2008) define a core embryonic stem cell (ESC)-like gene expression program that may be important for CSC function in multiple epithelial cancers. C1 [Wang, Yingzi; Armstrong, Scott A.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. [Wang, Yingzi; Armstrong, Scott A.] Harvard Univ, Sch Med, Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA. RP Armstrong, SA (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. EM scott.armstrong@childrens.harvard.edu NR 10 TC 16 Z9 17 U1 0 U2 2 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 1934-5909 J9 CELL STEM CELL JI Cell Stem Cell PD APR PY 2008 VL 2 IS 4 BP 297 EP 299 DI 10.1016/j.stem.2008.03.014 PG 3 WC Cell & Tissue Engineering; Cell Biology SC Cell Biology GA 293HT UT WOS:000255327000003 PM 18397746 ER PT J AU Martin-Puig, S Wang, Z Chien, KR AF Martin-Puig, Silvia Wang, Zhong Chien, Kenneth R. TI Lives of a heart cell: Tracing the origins of cardiac progenitors SO CELL STEM CELL LA English DT Review ID MESENCHYMAL STEM-CELLS; BONE-MARROW; SMOOTH-MUSCLE; CARDIOVASCULAR PROGENITORS; IN-VITRO; MOLECULAR-MECHANISMS; NEUREGULIN RECEPTOR; CHAMBER FORMATION; MAMMALIAN HEART; NEURAL CREST AB Heart cells are the unitary elements that define cardiac function and disease. The recent identification of distinct families of cardiovascular progenitor cells begins to build a foundation for our understanding of the developmental logic of human cardiovascular disease, and also points to new approaches to arrest and/or reverse its progression, a major goal of regenerative medicine. In this review, we highlight recent clarifications, revisions, and advances in our understanding of the many lives of a heart cell, with a primary focus on the emerging links between cardiogenesis and heart stem cell biology. C1 [Martin-Puig, Silvia; Wang, Zhong; Chien, Kenneth R.] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA. [Martin-Puig, Silvia; Wang, Zhong; Chien, Kenneth R.] Harvard Univ, Sch Med, Boston, MA 02114 USA. [Chien, Kenneth R.] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA. [Chien, Kenneth R.] Harvard Stem Cell Inst, Cambridge, MA 02138 USA. RP Chien, KR (reprint author), Massachusetts Gen Hosp, Cardiovasc Res Ctr, 185 Cambridge St, Boston, MA 02114 USA. EM kchien@partners.org OI Martin-Puig, Silvia/0000-0003-3048-6729 NR 94 TC 116 Z9 117 U1 0 U2 13 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 1934-5909 J9 CELL STEM CELL JI Cell Stem Cell PD APR PY 2008 VL 2 IS 4 BP 320 EP 331 DI 10.1016/j.stem.2008.03.010 PG 12 WC Cell & Tissue Engineering; Cell Biology SC Cell Biology GA 293HT UT WOS:000255327000009 PM 18397752 ER PT J AU Min, IM Pietramaggiori, G Kim, FS Passegue, E Stevenson, KE Wagers, AJ AF Min, Irene M. Pietramaggiori, Giorgio Kim, Francis S. Passegue, Emmanuelle Stevenson, Kristen E. Wagers, Amy J. TI The transcription factor EGR1 controls both the proliferation and localization of hematopoietic stem cells SO CELL STEM CELL LA English DT Article ID GROWTH-RESPONSE GENE-1; SELF-RENEWAL; PROGENITOR CELLS; MICE LACKING; NGFI-A; IN-VITRO; DIFFERENTIATION; MOBILIZATION; BMI-1; EXPRESSION AB EGR1 is a member of the immediate early response transcription factor family and functions in cell growth, development, and stress responses in many tissues. Here we report an additional role for EGR1 in regulating homeostasis of hernatopoietic stem cells (HSCs). HSCs normally express Egr1 at high levels, but dramatically downregulate its expression when induced to divide and migrate. Consistent with this finding, mice lacking Egr1 exhibit significant increases in steady-state levels of dividing HSCs in the bone marrow (BM), and a striking spontaneous mobilization of HSCs into the peripheral blood. These data identify EGR1 as a transcriptional regulator of stem cell migration that normally functions to promote HSC quiescence and retention in the niche. The ability of this single factor to regulate both proliferation and mobilization of HSCs suggests that EGR1 commands a genetic program that coordinates stem cell division and migration to maintain appropriate HSC number and function. C1 [Min, Irene M.; Pietramaggiori, Giorgio; Kim, Francis S.; Wagers, Amy J.] Joslin Diabet Ctr, Sect Dev & Stem Cell Biol, Boston, MA 02115 USA. [Pietramaggiori, Giorgio] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Plast Surg, Boston, MA 02115 USA. [Stevenson, Kristen E.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Min, Irene M.; Pietramaggiori, Giorgio; Kim, Francis S.; Wagers, Amy J.] Harvard Univ, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA. [Min, Irene M.; Pietramaggiori, Giorgio; Kim, Francis S.; Wagers, Amy J.] Harvard Stem Cell Inst, Cambridge, MA 02138 USA. [Passegue, Emmanuelle] Univ Calif San Francisco, Inst Regenerat Med, San Francisco, CA 94143 USA. RP Wagers, AJ (reprint author), Joslin Diabet Ctr, Sect Dev & Stem Cell Biol, Boston, MA 02115 USA. EM amy.wagers@joslin.harvard.edu FU NIDDK NIH HHS [T32 DK07260-30] NR 52 TC 130 Z9 132 U1 0 U2 5 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 1934-5909 J9 CELL STEM CELL JI Cell Stem Cell PD APR PY 2008 VL 2 IS 4 BP 380 EP 391 DI 10.1016/j.stem.2008.01.015 PG 12 WC Cell & Tissue Engineering; Cell Biology SC Cell Biology GA 293HT UT WOS:000255327000014 PM 18397757 ER PT J AU Tabassam, FH Graham, DY Yamaoka, Y AF Tabassam, Fazal H. Graham, David Y. Yamaoka, Yoshio TI OipA plays a role in Helicobacter pylori-induced focal adhesion kinase activation and cytoskeletal re-organization SO CELLULAR MICROBIOLOGY LA English DT Article ID GASTRIC EPITHELIAL-CELLS; MUCOSAL INTERLEUKIN-8 PRODUCTION; GROWTH-FACTOR; PATHOGENICITY ISLAND; SIGNAL-TRANSDUCTION; TYROSINE KINASE; IV SECRETION; IN-VIVO; SRC; INTEGRIN AB The initial signalling events leading to Helicobacter pylori infection associated changes in motility, cytoskeletal reorganization and elongation of gastric epithelial cells remain poorly understood. Because focal adhesion kinase (FAK) is known to play important roles in regulating actin cytoskeletal organization and cell motility we examined the effect of H. pylori in gastric epithelial cells co-cultured with H. pylori or its isogenic cag pathogenicity island (PAI) or oipA mutants. H. pylori induced FAK phosphorylation at distinct tyrosine residues in a dose- and time-dependent manner. Autophosphorylation of FAK Y397 was followed by phosphorylation of Src Y418 and resulted in phosphorylation of the five remaining FAK tyrosine sites. Phosphorylated FAK and Src activated Erk and induced actin stress fibre formation. FAK knock-down by FAK-siRNA inhibited H. pylori-mediated Erk phosphorylation and abolished stress fibre formation. Infection with oipA mutants reduced phosphorylation of Y397, Y576, Y577, Y861 and Y925, inhibited stress fibre formation and altered cell morphology. cag PAI mutants reduced phosphorylation of only FAK Y407 and had less effect on stress fibre formation than oipA mutants. We propose that activation of FAK and Src are responsible for H. pylori-induced induction of signalling pathways resulting in the changes in cell phenotype important for pathogenesis. C1 [Yamaoka, Yoshio] Michael DeBakey Vet Affairs Med Ctr, Dept Med Gastroenterol, Houston, TX 77030 USA. Baylor Coll Med, Houston, TX 77030 USA. RP Yamaoka, Y (reprint author), Michael DeBakey Vet Affairs Med Ctr, Dept Med Gastroenterol, Houston, TX 77030 USA. EM yyamaoka@bcm.tmc.edu FU NIDDK NIH HHS [R01 DK062813-04, P30 DK056338, DK62813, R01 DK062813, DK56338, R01 DK062813-05] NR 49 TC 30 Z9 30 U1 0 U2 1 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1462-5814 J9 CELL MICROBIOL JI Cell Microbiol. PD APR PY 2008 VL 10 IS 4 BP 1008 EP 1020 DI 10.1111/j.1462-5822.2007.01104.x PG 13 WC Cell Biology; Microbiology SC Cell Biology; Microbiology GA 274BY UT WOS:000253978000016 PM 18067607 ER PT J AU Mick, E Faraone, SV AF Mick, Eric Faraone, Stephen V. TI Genetics of attention deficit hyperactivity disorder SO CHILD AND ADOLESCENT PSYCHIATRIC CLINICS OF NORTH AMERICA LA English DT Review ID DOPAMINE TRANSPORTER GENE; FAMILY-BASED ASSOCIATION; ALPHA-2A ADRENERGIC-RECEPTOR; MONOAMINE-OXIDASE-A; TRYPTOPHAN-HYDROXYLASE GENE; HAN CHINESE SUBJECTS; SEASONAL AFFECTIVE-DISORDER; RISK COMMUNITY SAMPLE; PERFORMANCE-TEST TOVA; DNA POOLING ANALYSIS AB Results of behavioral genetic and molecular genetic studies have converged. to suggest that both genetic and nongenctic factors contribute to the development of attention deficit hyperactivity disorder (ADHD). Family, twin, and adoption studies provide compelling evidence that genes play a strong role in mediating susceptibility to AMID. In contrast to a handful of genome-wide scans conducted thus far, many candidate gene studies of ADHD have produced substantial evidence implicating several genes in the etiology of the disorder. Yet, even these associations are small and consistent with the idea that the genetic vulnerability to ADHD is mediated by many genes of small effects. These small effects emphasize the need for future candidate gene studies to implement strategies that will provide enough statistical power to detect such small effects. C1 [Mick, Eric; Faraone, Stephen V.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Mick, Eric] Harvard Univ, Sch Med, Boston, MA 02114 USA. [Faraone, Stephen V.] SUNY Upstate Med Univ, Dept Psychiat, Syracuse, NY 13210 USA. [Faraone, Stephen V.] SUNY Upstate Med Univ, Dept Neurosci & Physiol, Syracuse, NY 13210 USA. RP Faraone, SV (reprint author), Massachusetts Gen Hosp, Dept Psychiat, Warren 705,55 Fruit St, Boston, MA 02114 USA. EM faraones@upstate.edu OI Mick, Eric/0000-0001-8505-8145; Faraone, Stephen/0000-0002-9217-3982 NR 157 TC 83 Z9 85 U1 4 U2 10 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1056-4993 J9 CHILD ADOL PSYCH CL JI Child Adolesc. Psychiatr. N. Am. PD APR PY 2008 VL 17 IS 2 BP 261 EP + DI 10.1016/j.chc.2007.11.011 PG 26 WC Psychiatry SC Psychiatry GA 280UH UT WOS:000254451300003 PM 18295146 ER PT J AU Bush, G AF Bush, George TI Neuroimaging of attention deficit hyperactivity disorder: Can new imaging findings be integrated in clinical practice? SO CHILD AND ADOLESCENT PSYCHIATRIC CLINICS OF NORTH AMERICA LA English DT Article ID ANTERIOR CINGULATE CORTEX; H-1-MAGNETIC RESONANCE SPECTROSCOPY; MULTISOURCE INTERFERENCE TASK; CEREBRAL BLOOD-FLOW; DEFICIT/HYPERACTIVITY DISORDER; DOPAMINE TRANSPORTER; QUANTITATIVE ELECTROENCEPHALOGRAPHY; MAGNETIC-RESONANCE; THERAPEUTIC ACTIONS; PERFUSION FMRI AB Recent advances in neuroimaging research have helped elucidate the neurobiology of attention deficit hyperactivity disorder (ADHD) and the mechanisms by which medications used to treat ADHD exert their effects. The complex nature and array of imaging techniques, however, present challenges for the busy clinician in assessing possible clinical uses of brain imaging. Even though currently there are no accepted uses for imaging in diagnosing ADHD (other than ruling out identifiable medical or neurologic conditions that may mimic ADHD), this review introduces the main imaging techniques used to study ADHD, identifies relevant complexities facing psychiatric researchers in implementing neuroimaging techniques for clinical purposes, and provides benchmarks to help determine when imaging modalities have advanced to a point that they are deemed clinically useful. C1 [Bush, George] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA. [Bush, George] Massachusetts Gen Hosp, Dept Psychiat, Psychiat Neurosci Div, Boston, MA 02114 USA. [Bush, George] Harvard Univ, MGH E,Sch Med, MIT, Athinoula A Marinos Ctr Funct & Struct Biomed Ima, Charlestown, MA 02129 USA. [Bush, George] Massachusetts Gen Hosp, Cling & Res Program Pediat Psychopharmacol, Boston, MA 02114 USA. RP Bush, G (reprint author), Massachusetts Gen Hosp E, Psychiat Neurosci Program, CNY 2614,Bldg 149,13th St, Charlestown, MA 02129 USA. EM geo@nmr.mgh.harvard.edu FU NCRR NIH HHS [P41RR14075] NR 79 TC 22 Z9 22 U1 1 U2 6 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1056-4993 J9 CHILD ADOL PSYCH CL JI Child Adolesc. Psychiatr. N. Am. PD APR PY 2008 VL 17 IS 2 BP 385 EP + DI 10.1016/j.chc.2007.11.002 PG 21 WC Psychiatry SC Psychiatry GA 280UH UT WOS:000254451300009 PM 18295152 ER PT J AU Biederman, J Spencer, TJ AF Biederman, Joseph Spencer, Thomas J. TI Psychopharmacological interventions SO CHILD AND ADOLESCENT PSYCHIATRIC CLINICS OF NORTH AMERICA LA English DT Review ID ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; DEFICIT HYPERACTIVITY DISORDER; PRELIMINARY CLINICAL-EXPERIENCE; FILM-COATED TABLETS; SLI381 ADDERALL XR; ONCE-A-DAY; DOUBLE-BLIND; TOURETTES-SYNDROME; CONTROLLED-TRIAL; EXTENDED-RELEASE AB Currently stimulants and atomoxetine are the most established treatments for attention deficit hyperactivity disorder (ADHD); more than 170 controlled studies with more than 9000 subjects have documented their efficacy in 50% to 70% of subjects. Although the stimulant medications tend to show a dose-related improvement in ADHD symptoms, atomoxetine is generally dosed based on weight. The literature clearly documents that stimulants improve not only abnormal behaviors of ADHD but also selfe-steem, cognition, and social and family functioning. However, efficacy varies with age and psychiatric comorbidities. Although most of the existing studies are brief, an increasing number of long-term studies have documented persistent response up to 1 and 2 years. Recent studies are extending the knowledge of treatment to younger and older subjects, women, and ethnic minorities. Cognitive and cognitive/behaviorally based psychotherapies combined with medication may play a role in treating behavioral and organizational issues and comorbid psychopathology. C1 [Biederman, Joseph; Spencer, Thomas J.] Massachusetts Gen Hosp, Pediat Psychopharmacol Res Unit, Boston, MA 02114 USA. [Biederman, Joseph; Spencer, Thomas J.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA. RP Biederman, J (reprint author), Massachusetts Gen Hosp, Pediat Psychopharmacol Res Unit, 32 Fruit ST,Yaw 6A, Boston, MA 02114 USA. EM biederman@helix.mgh.harvard.edu NR 122 TC 31 Z9 34 U1 11 U2 17 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1056-4993 J9 CHILD ADOL PSYCH CL JI Child Adolesc. Psychiatr. N. Am. PD APR PY 2008 VL 17 IS 2 BP 439 EP + DI 10.1016/j.chc.2007.12.001 PG 21 WC Psychiatry SC Psychiatry GA 280UH UT WOS:000254451300012 PM 18295155 ER PT J AU Dietrich, T Jimenez, M Kaye, EAK Vokonas, PS Garcia, RI AF Dietrich, Thomas Jimenez, Monik Kaye, Elizabeth A. Krall Vokonas, Pantel S. Garcia, Raul I. TI Age-dependent associations between chronic periodontitis/edentulism and risk of coronary heart disease SO CIRCULATION LA English DT Article DE coronary disease; epidemiology; infection; inflammation; risk factors ID C-REACTIVE PROTEIN; PERIODONTAL-DISEASE; CARDIOVASCULAR-DISEASE; PLASMA-FIBRINOGEN; ISCHEMIC-STROKE; ORAL HEALTH; TOOTH LOSS; DEFINITIONS; POPULATION; MARKERS AB Background - Several epidemiological studies have suggested periodontitis as a risk factor for coronary heart disease (CHD), but results have been inconsistent. Methods and Results - We evaluated the association between clinical and radiographic measures of periodontitis, edentulism, and incident CHD (angina, myocardial infarction, or fatal CHD) among 1203 men in the VA Normative Aging and Dental Longitudinal Studies who were followed up with triennial comprehensive medical and dental examinations up to 35 years (median 24 years). Cox proportional hazards models with time-varying effects of exposure and potential confounders were fit. We found a significant dose-dependent association between periodontitis and CHD incidence among men <60 years of age (hazard ratio 2.12, 95% confidence interval 1.26 to 3.60 comparing highest versus lowest category of radiographic bone loss, P for trend = 0.02), independent of age, body mass index, smoking, alcohol intake, diabetes mellitus, fasting glucose, total cholesterol, high-density lipoprotein cholesterol, triglycerides, hypertension, systolic and diastolic blood pressure, education, marital status, income, and occupation. No association was found among men >60 years of age. Similar results were found when the sum of probing pocket depths was used as a measure of periodontitis. Among men >= 60 years of age, edentulous men tended to have a higher risk of CHD than dentate men in the lowest bone loss (hazard ratio 1.61, 95% confidence interval 0.95 to 2.73) and lowest pocket depth (hazard ratio 1.72, 95% confidence interval 1.03 to 2.85) categories, independent of confounders. Conclusions - Chronic periodontitis is associated with incidence of CHD among younger men, independent of established cardiovascular risk factors. C1 [Dietrich, Thomas] Univ Birmingham, Sch Dent, Dept Oral Surg, Birmingham B4 6NN, W Midlands, England. [Dietrich, Thomas; Jimenez, Monik; Kaye, Elizabeth A. Krall; Garcia, Raul I.] Boston Univ, Goldman Sch Dent Med, Dept Hlth Policy, Boston, MA 02215 USA. [Dietrich, Thomas; Jimenez, Monik; Kaye, Elizabeth A. Krall; Garcia, Raul I.] Boston Univ, Goldman Sch Dent Med, Hlth Serv Res, Boston, MA 02215 USA. [Dietrich, Thomas] Boston Univ, Goldman Sch Dent Med, Dept Periodontol & Oral Biol, Boston, MA 02215 USA. [Jimenez, Monik] Harvard Sch Publ Hlth, Dept Epidemiol, Boston, MA USA. [Jimenez, Monik] Harvard Sch Dent Med, Dept Oral Hlth Policy & Epidemiol, Boston, MA USA. [Vokonas, Pantel S.] VA Boston Healthcare Syst, VA Normat Aging Study, Boston, MA USA. [Garcia, Raul I.] VA Boston Healthcare Syst, VA Dent Longitudinal Study, Boston, MA USA. [Vokonas, Pantel S.] Boston Univ, Sch Med, Dept Med, Boston, MA 02215 USA. RP Dietrich, T (reprint author), Univ Birmingham, Sch Dent, Dept Oral Surg, St Chads Queensway, Birmingham B4 6NN, W Midlands, England. EM t.dietrich@bham.ac.uk OI Kaye, Elizabeth/0000-0001-7529-2501; Garcia, Raul/0000-0003-2153-4629; Dietrich, Thomas/0000-0002-2557-7645 FU NIDCR NIH HHS [R03 DE016357, K24 DE-00419, R03 DE016357-01A1, R03 DE-016357, K24 DE000419] NR 38 TC 122 Z9 132 U1 0 U2 13 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD APR 1 PY 2008 VL 117 IS 13 BP 1668 EP 1674 DI 10.1161/CIRCULATIONAHA.107.711507 PG 7 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 282OG UT WOS:000254576500007 PM 18362228 ER PT J AU Patel, AM d'Avila, A Neuzil, P Kim, SJ Mela, T Singh, JP Ruskin, JN Reddy, VY AF Patel, Anshul M. d'Avila, Andre Neuzil, Petr Kim, Steven J. Mela, Theofanie Singh, Jagmeet P. Ruskin, Jeremy N. Reddy, Vivek Y. TI Atrial Tachycardia After Ablation of Persistent Atrial Fibrillation Identification of the Critical Isthmus With a Combination of Multielectrode Activation Mapping and Targeted Entrainment Mapping SO CIRCULATION-ARRHYTHMIA AND ELECTROPHYSIOLOGY LA English DT Article CT 28th Annual Scientific Session of the Heart-Rhythm-Society CY MAY 10, 2007 CL Denver, CO SP Heart Rhythm Soc DE arrhythmia; ablation; fibrillation; mapping; tachycardia ID PULMONARY VEIN ABLATION; RADIOFREQUENCY CATHETER ABLATION; FLUTTER; ARRHYTHMIAS; MECHANISMS AB Background-Atrial tachycardia (AT) that develops after ablation of atrial fibrillation often poses a more difficult clinical situation than the index arrhythmia. This study details the use of all impedance-based electroanatomic mapping system (Ensite NavX) in concert with a specialized multielectrode mapping catheter for rapid, high-density atrial mapping. In this study, this activation mapping was combined with entrainment mapping to eliminate ATs developing late after atrial fibrillation ablation. Methods and Results-All study patients developed AT after ablation for atrial fibrillation. The approach to AT ablation consisted of 4 steps: use of a 20-pole penta-array catheter to map the chamber rapidly during the rhythm of interest, analysis of the patterns of atrial activation to identify wave fronts of electric propagation, targeted entrainment at putative channels, and catheter ablation at these "isthmuses." All ablations were performed with irrigated radiofrequency ablation catheters. Forty-one ATs were identified in 17 patients (2.4 +/- 1.6 ATs per patient). Using the multielectrode catheter in conjunction with the Ensite NavX system. we created activation maps of 33 of 41 ATs (81%) (mea cycle length, 284 +/- 71 seconds) with a mean of 365 +/- 108 points per map and an average mapping time of 8 +/- 3 minutes. Of the 33 mapped ATs, 7 terminated either spontaneously or during entrainment maneuvers. Radiofrequency energy was used to attempt ablation of 26 ATs; 25 of 26 of the ATs (96%) were terminated Successfully by ablation or catheter pressure. Conclusions-This study demonstrates a strategy for rapidly defining and eliminating the scar-related ATs typically encountered after ablation of atrial fibrillation. (Circ Arrhythmia Electrophysiol. 2008;1:14-22.) C1 [Reddy, Vivek Y.] Massachusetts Gen Hosp, Cardiac Arrhythmia Serv, Boston, MA 02114 USA. [Neuzil, Petr] Homolka Hosp, Prague, Czech Republic. [Kim, Steven J.] St Jude Med, Minneapolis, MN USA. RP Reddy, VY (reprint author), Massachusetts Gen Hosp, Cardiac Arrhythmia Serv, 55 Fruit St,GRB 109, Boston, MA 02114 USA. EM vreddy@partners.org RI d'Avila, Andre Luiz/F-8009-2010; d'Avila, Andre/A-7693-2009 OI d'Avila, Andre Luiz/0000-0001-8769-1411; NR 28 TC 47 Z9 47 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1941-3149 J9 CIRC-ARRHYTHMIA ELEC JI Circ.-Arrhythmia Electrophysiol. PD APR PY 2008 VL 1 IS 1 BP 14 EP 22 DI 10.1161/CIRCEP.107.748160 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 445GN UT WOS:000266038500004 PM 19808389 ER PT J AU Napolitano, DR Pollock, N Kashino, SS Rodrigues, V Campos-Neto, A AF Napolitano, Danielle R. Pollock, Nira Kashino, Suely S. Rodrigues, Virmondes, Jr. Campos-Neto, Antonio TI Identification of Mycobacterium tuberculosis ornithine carboamyltransferase in urine as a possible molecular marker of active pulmonary tuberculosis SO CLINICAL AND VACCINE IMMUNOLOGY LA English DT Article ID STREPTOCOCCUS-PNEUMONIAE ANTIGEN; IMMUNOCHROMATOGRAPHIC TEST; PROTEIN; LIPOARABINOMANNAN; MORTALITY; DIAGNOSIS; CLONING; SAMPLES; COUNTRIES; FEATURES AB Although the antigen detection assay has the potential to discriminate active tuberculosis from latent infection, development of such a test for the accurate diagnosis of this serious disease has only recently become a matter of interest. Here we present evidence that a Mycobacterium tuberculosis protein (ornithine carboamyltransferase, coded for by MT_1694; Rv1656 [argF]) is an interesting candidate molecule for this test development. The protein was initially discovered by mass spectroscopy in urine of patients with pulmonary tuberculosis and shown by Western blot analysis to be present in M. tuberculosis crude cell extract as well as in the culture supernatant ("secreted" protein). In addition, a recombinant ornithine carboamyltransferase (rMT1694) produced in Escherichia coli was recognized by immunoglobulin G (IgG) antibodies from patients with active tuberculosis but not by IgG from uninfected healthy subjects. Moreover, rMT1694 was strongly recognized by peripheral blood mononuclear cells from both healthy tuberculin purified protein derivative (PPD)-positive individuals and patients with pulmonary tuberculosis. More importantly, a capture enzyme-linked immunosorbent assay formatted with rabbit IgG antibodies specific to rMT1694 was able to identify the presence of this antigen in urine samples from 6 of 16 patients with pulmonary tuberculosis and in none of 16 urine samples collected from healthy PPD+ controls. These results indicate that an improved antigen detection assay based on M. tuberculosis ornithine carboamyltransferase may represent an important new strategy for the development of a specific and accurate diagnostic test for tuberculosis. C1 [Napolitano, Danielle R.; Kashino, Suely S.; Campos-Neto, Antonio] Forsyth Inst, Boston, MA 02115 USA. [Pollock, Nira] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Rodrigues, Virmondes, Jr.] Univ Fed Triangulo Mineiro, Uberaba, MG, Brazil. [Campos-Neto, Antonio] Univ Massachusetts, Sch Med, Worcester, MA 01655 USA. RP Campos-Neto, A (reprint author), Forsyth Inst, 140 Fenway, Boston, MA 02115 USA. EM acampos@forsyth.org RI Kashino, Suely/F-4171-2012 FU National Institutes of Health [R41AI068291, R01AI076425]; Research Facilities Improvement [C06RR11244]; National Center for Research Resources; National Institutes of Health FX This work was supported by National Institutes of Health grants R41AI068291 and R01AI076425 to A. Campos-Neto. This investigation was conducted in a Forsyth Institute facility renovated with support from Research Facilities Improvement grant C06RR11244 from the National Center for Research Resources, National Institutes of Health.; We thank John Beslile and Karen Dobos, Colorado State University (NIAID/NIH Tuberculosis Research Materials contract no. 1-A125174), for kindly supplying M. tuberculosis-related reagents.; None of the authors has any financial conflict of interest. NR 25 TC 16 Z9 17 U1 0 U2 6 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 1556-6811 J9 CLIN VACCINE IMMUNOL JI Clin. Vaccine Immunol. PD APR PY 2008 VL 15 IS 4 BP 638 EP 643 DI 10.1128/CVI.00010-08 PG 6 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 340TB UT WOS:000258666800009 PM 18305107 ER PT J AU Van Cott, EM AF Van Cott, Elizabeth M. TI Evaluation of a prolonged prothrombin time - Commentary SO CLINICAL CHEMISTRY LA English DT Editorial Material C1 Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. RP Van Cott, EM (reprint author), Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. NR 2 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CLINICAL CHEMISTRY PI WASHINGTON PA 2101 L STREET NW, SUITE 202, WASHINGTON, DC 20037-1526 USA SN 0009-9147 J9 CLIN CHEM JI Clin. Chem. PD APR PY 2008 VL 54 IS 4 BP 769 EP 769 DI 10.1373/clinchem.2008.103168 PG 1 WC Medical Laboratory Technology SC Medical Laboratory Technology GA 282NP UT WOS:000254574800024 ER PT J AU McCarley, RW Nakamura, M Shenton, ME Salisbury, DF AF McCarley, Robert W. Nakamura, Motoaki Shenton, Martha E. Salisbury, Dean F. TI Combining ERP and structural MRI information in first episode schizophrenia and bipolar disorder SO CLINICAL EEG AND NEUROSCIENCE LA English DT Article DE bipolar disorder; event-related potential; magnetic resonance imaging; multimodal imaging; schizophrenia ID TEMPORAL GYRUS VOLUME; 1ST-EPISODE SCHIZOPHRENIA; P300 AMPLITUDE; ABNORMALITIES; REDUCTION; LOBE AB The electrical activity in the electroencephalogram (EEG) and the event-related potentials extracted from the EEG provide the greatest temporal resolution for examining brain function. When coupled with the high spatial resolution of structural magnetic resonance imaging (sMRI), the combined techniques provide a powerful tool for neuroscience in the examination of brain abnormalities in major psychiatric illnesses. Over the last 20 years, our work has examined brain structure and function in schizophrenia. Both EEG and MRI measures have indicated profound abnormalities in schizophrenia within the temporal lobe, particularly marked over the left hemisphere. Our studies of patients first hospitalized due to psychosis revealed the early course of the disease to be characterized by progressive impairment and cortical gray matter reduction, most intense near the time of first hospitalization. Knowledge of those locations and brain signals affected early should help understand the basic physiological defect underlying this progression, with potential implications for new therapeutic interventions. C1 [McCarley, Robert W.] Harvard Univ, Dept Psychiat, Neurosci Lab Chair, Cambridge, MA 02138 USA. [McCarley, Robert W.] VA Boston Healthcare, Brockton, MA USA. [McCarley, Robert W.; Nakamura, Motoaki; Shenton, Martha E.; Salisbury, Dean F.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA USA. [McCarley, Robert W.; Nakamura, Motoaki] Boston Vet Affairs Healthcare Syst, Brockton Lab, Boston, MA USA. [Nakamura, Motoaki; Shenton, Martha E.] Brigham & Womens Hosp, Psychiat Neuroimaging Lab, Boston, MA 02115 USA. [Salisbury, Dean F.] McLean Hosp, Cognit Neurosci Lab, Belmont, MA 02178 USA. RP McCarley, RW (reprint author), VA Boston Hosp, Brockton Campus Psychiat 116A,640 Belmont St, Brockton, MA 02301 USA. EM robert_mccadey@hms.harvard.edu RI McCarley, Robert/N-5562-2014 OI McCarley, Robert/0000-0001-5705-7495 FU NIMH NIH HHS [R01 MH058704, K02 MH001110, K02 MH001110-10, K05 MH01110, P50 MH080272, R01 MH040799, R01 MH052807, R01 MH40799, R01 MH50747, R01 MH58704] NR 10 TC 16 Z9 16 U1 0 U2 3 PU EEG & CLINICAL NEUROSCIENCE SOC (E C N S) PI WHEATON PA 805 W LIBERTY DR, PO BOX 725, WHEATON, IL 60187 USA SN 1550-0594 J9 CLIN EEG NEUROSCI JI Clin. EEG Neurosci. PD APR PY 2008 VL 39 IS 2 BP 57 EP 60 PG 4 WC Clinical Neurology; Neurosciences; Neuroimaging; Psychiatry; Psychology SC Neurosciences & Neurology; Psychiatry; Psychology GA 289WB UT WOS:000255083500002 PM 18450168 ER PT J AU Spencer, KM AF Spencer, Kevin M. TI Visual gamma oscillations in schizophrenia: Implications for understanding neural circuitry abnormalities SO CLINICAL EEG AND NEUROSCIENCE LA English DT Article DE feature-binding; gamma oscillation; schizophrenia; visual perception ID PREFRONTAL CORTEX; BAND ACTIVITY; IN-VITRO; SYNCHRONIZATION; MEMORY; HUMANS; MODEL; DYSFUNCTION; PERCEPTION; MODULATION AB Gamma oscillations may play an important role in the representation of information in the brain by synchronizing the firing of neurons in local and distributed neural circuits. The Bleulerian conceptualization of schizophrenia as "disintegration of thought and personality" suggests that neural mechanisms responsible for the integration of neural activity, such as gamma oscillations, might be particularly disrupted in this disorder. Here we review studies of gamma oscillations in healthy and schizophrenic individuals performing visual perception tasks. The findings suggest that schizophrenia is associated with a variety of abnormalities of visual gamma oscillations, which appear to be linked to core symptoms and cognitive deficits of schizophrenia. The relationships between these abnormalities and neural circuitry abnormalities in schizophrenia are discussed. C1 [Spencer, Kevin M.] VA Boston Healthcare Syst, Dept Psychiat, Brockton, MA USA. [Spencer, Kevin M.] Harvard Univ, Sch Med, Boston, MA USA. RP Spencer, KM (reprint author), VA Boston Healthcare Syst, Dept Psychiat, Psychiat 116A,940 Belmont St, Brockton, MA USA. EM kevin_spencer@hms.harvard.edu FU NIMH NIH HHS [R03 MH076760] NR 41 TC 24 Z9 24 U1 0 U2 3 PU EEG & CLINICAL NEUROSCIENCE SOC (E C N S) PI WHEATON PA 805 W LIBERTY DR, PO BOX 725, WHEATON, IL 60187 USA SN 1550-0594 J9 CLIN EEG NEUROSCI JI Clin. EEG Neurosci. PD APR PY 2008 VL 39 IS 2 BP 65 EP 68 PG 4 WC Clinical Neurology; Neurosciences; Neuroimaging; Psychiatry; Psychology SC Neurosciences & Neurology; Psychiatry; Psychology GA 289WB UT WOS:000255083500004 PM 18450170 ER PT J AU Mathalon, DH Ford, JM AF Mathalon, Daniel H. Ford, Judith M. TI Corollary discharge dysfunction in schizophrenia: Evidence for an elemental deficit SO CLINICAL EEG AND NEUROSCIENCE LA English DT Article DE apathy; corollary discharge; efference copy; electroencephalography; hallucination; schizophrenia ID AUDITORY-CORTEX; CORTICAL RESPONSIVENESS; POTENTIAL STUDY/; HALLUCINATIONS; SPEECH; CONSCIOUSNESS; DISORDERS; DYNAMICS; THINKING; TALKING AB Evidence is accumulating that schizophrenia is characterized by dysfunction of efference copy/corollary discharge mechanisms that normally allow us to unconsciously recognize and disregard sensations resulting from our own actions. This dysfunction may give rise to subtle but pervasive sensory/perceptual aberrations in schizophrenic patients, altering their experience of their own overt and covert actions, as well as their interactions with the environment. It may also contribute to symptoms such as hallucinations and delusions, and may disrupt the motivation to engage with people and in activities. We developed neurophysiological paradigms to study motor-sensory feed-forward processes, or efference copy/corollary discharge mechanisms, in the speech-auditory system, and showed these processes to be deficient in chronic schizophrenia. Specifically, we observed neural responses during talking that made evident the suppressive consequences of a successful corollary discharge mechanism. We also observed synchronous neural activity preceding talking that we believe reflects the efference copy in action. Recently, we extended this neurophysiological research to the somatosensory system, again finding evidence of deficient motor-sensory feed-forward processes in schizophrenia. If dysfunction of this elemental mechanism is reliable, valid, and not the result of antipsychotic medications, it might represent a major new class of electrophysiological measures sensitive to a fundamental and ubiquitous pathophysiological process in schizophrenia. C1 [Mathalon, Daniel H.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94121 USA. San Francisco VA Med Ctr, Psychiat Serv, San Francisco, CA USA. RP Mathalon, DH (reprint author), Univ Calif San Francisco, Dept Psychiat, 4150 Clement St, San Francisco, CA 94121 USA. EM daniel.mathalon@ucsf.edu OI Mathalon, Daniel/0000-0001-6090-4974 FU NIMH NIH HHS [K02 MH067967, MH067967, MH40052, MH58262, R01 MH040052] NR 31 TC 23 Z9 24 U1 0 U2 6 PU EEG & CLINICAL NEUROSCIENCE SOC (E C N S) PI WHEATON PA 805 W LIBERTY DR, PO BOX 725, WHEATON, IL 60187 USA SN 1550-0594 J9 CLIN EEG NEUROSCI JI Clin. EEG Neurosci. PD APR PY 2008 VL 39 IS 2 BP 82 EP 86 PG 5 WC Clinical Neurology; Neurosciences; Neuroimaging; Psychiatry; Psychology SC Neurosciences & Neurology; Psychiatry; Psychology GA 289WB UT WOS:000255083500008 PM 18450174 ER PT J AU Kuperberg, GR AF Kuperberg, Gina R. TI Building meaning in schizophrenia SO CLINICAL EEG AND NEUROSCIENCE LA English DT Article DE dorsolateral prefrontal cortex/DLPFC; event-related potentials/ERP; functional magnetic resonance imaging/fMRI; language; N400; prefrontal cortex; real-world events; semantic; schizophrenia; syntax; temporal cortex ID LANGUAGE COMPREHENSION; THEMATIC RELATIONSHIPS; SENTENCES; DISTINCTIONS; POTENTIALS; DISCOURSE AB The schizophrenia syndrome is clinically characterized by abnormal constructions of meaning during comprehension (delusions), perception (hallucinations), action (disorganized and non-goal-directed behavior) and language production (thought disorder). This article provides an overview of recent studies from our laboratory that have used even-trelated potentials and functional magnetic resonance imaging to elucidate abnormalities in temporal and spatial patterns of neural activity as meaning is built from language and real-world visual events in schizophrenia. Our findings support the hypothesis that automatic activity across semantic memory spreads further within a shorter period of time in thought-disordered patients, relative to non-thought-disordered patients and healthy controls. Neuroanatomically, increased activity to semantic associates is reflected by inappropriate recruitment of temporal cortices. In building meaning within sentences, the fine balance between semantic memory-based mechanisms and semantic-syntactic integration (dictating "who does what to whom") is disrupted, such that comprehension is driven primarily by semantic memory-based processes. Neuroanatomically, this imbalance is reflected by preserved (and sometimes increased) activity within temporal and inferior prefrontal cortices, but abnormal modulation of dorsolateral prefrontal and parietal cortices. In building meaning across sentences (discourse), patients fail to immediately construct coherence links, but may show inappropriate recruitment of temporal and inferior prefrontal cortices to incoherent discourse, again reflecting inappropriate semantic memory-based processing (abnormal inferencing). Finally, these abnormalities may generalize to real-world visual event comprehension, where patients show reduced neural activity in determining relationships around goal-directed actions, and comprehension is again dominated by semantic memory-based mechanisms. C1 [Kuperberg, Gina R.] Tufts Univ, Dept Psychol, Medford, MA 02155 USA. [Kuperberg, Gina R.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA. RP Kuperberg, GR (reprint author), Massachusetts Gen Hosp E, Dept Psychiat, 13th St, Charlestown, MA 02129 USA. EM kupeter@nmr.mgh.harvard.edu FU NIMH NIH HHS [R01 MH071635, R01 MH071635-03] NR 40 TC 11 Z9 12 U1 0 U2 2 PU EEG & CLINICAL NEUROSCIENCE SOC (E C N S) PI WHEATON PA 805 W LIBERTY DR, PO BOX 725, WHEATON, IL 60187 USA SN 1550-0594 J9 CLIN EEG NEUROSCI JI Clin. EEG Neurosci. PD APR PY 2008 VL 39 IS 2 BP 99 EP 102 PG 4 WC Clinical Neurology; Neurosciences; Neuroimaging; Psychiatry; Psychology SC Neurosciences & Neurology; Psychiatry; Psychology GA 289WB UT WOS:000255083500012 PM 18450178 ER PT J AU Welt, CK AF Welt, Corrine K. TI Primary ovarian insufficiency: a more accurate term for premature ovarian failure SO CLINICAL ENDOCRINOLOGY LA English DT Review ID FRAGILE-X-SYNDROME; FOLLICLE-STIMULATING-HORMONE; CHILDHOOD-CANCER SURVIVOR; GERMLINE STEM-CELLS; AUTOIMMUNE OOPHORITIS; BONE-MARROW; ADRENAL INSUFFICIENCY; NATURAL MENOPAUSE; ADDISONS-DISEASE; GONADAL-FUNCTION AB Premature ovarian failure (POF) is a disorder with a complicated clinical presentation and course that is poorly defined by its name. A more scientifically accurate term for the disorder is primary ovarian insufficiency (POI), a term that can be appropriately modified to describe the state of ovarian function. In recent years, the known aetiologies of POI have expanded, although the cause of POI in a majority of clinical cases remains undefined. The most common aetiologies should be ruled out clinically including chromosomal abnormalities, fragile X premutations and autoimmune causes. Management should be directed at symptom resolution and bone protection, but most importantly should include psychosocial support for women facing this devastating diagnosis. C1 Harvard Univ, Massachusetts Gen Hosp, Reprod Endocrine Unit, Boston, MA 02114 USA. RP Welt, CK (reprint author), Harvard Univ, Massachusetts Gen Hosp, Reprod Endocrine Unit, BHX 511,55 Fruit St, Boston, MA 02114 USA. EM cwelt@partners.org OI Welt, Corrine/0000-0002-8219-5504 NR 101 TC 159 Z9 173 U1 2 U2 21 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0300-0664 J9 CLIN ENDOCRINOL JI Clin. Endocrinol. PD APR PY 2008 VL 68 IS 4 BP 499 EP 509 DI 10.1111/j.1365-2265.2007.03073.x PG 11 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 274BW UT WOS:000253977800001 PM 17970776 ER PT J AU Amorosi, S D'Armiento, M Calcagno, G Russo, I Adriani, M Christiano, AM Weiner, L Brissette, JL Pignata, C AF Amorosi, S. D'Armiento, M. Calcagno, G. Russo, I. Adriani, M. Christiano, A. M. Weiner, L. Brissette, J. L. Pignata, C. TI FOXN1 homozygous mutation associated with anencephaly and severe neural tube defect in human athymic Nude/SCID fetus SO CLINICAL GENETICS LA English DT Article DE anencephaly; FOXN1; neural tube defects; SCID; thymic aplasia ID TRANSCRIPTION FACTORS; GENE-EXPRESSION; CHOROID-PLEXUS; FORK HEAD; MOUSE; IMMUNODEFICIENCY; DIFFERENTIATION; PHENOTYPE; GENOTYPE; ALOPECIA AB The forkhead, Fox, gene family comprises a diverse group of 'winged-helix' transcription factors that play important roles in development, metabolism, cancer and aging. Recently, several forkhead genes have been demonstrated to play critical roles in lymphocyte development and effector functions. Alterations of the FOXN1 gene in both mice and humans result in a severe combined immunodeficiency caused by an intrinsic defect of the thymus associated with congenital alopecia (Nude/severe combined immunodeficiency phenotype). FOXN1 is a member of the class of proteins involved in the development and differentiation of the central nervous system. We identified a human fetus homozygous for a mutation in FOXN1 gene who lacked the thymus and also had abnormal skin, anencephaly and spina bifida. Moreover, we found that FOXN1 gene is expressed in mouse developing choroid plexus. These observations suggest that FOXN1 may be involved in neurulation in humans. C1 [Amorosi, S.; Russo, I.; Pignata, C.] Univ Naples Federico 2, Dept Pediat, Immunol Unit, I-80131 Naples, Italy. [D'Armiento, M.] Univ Naples Federico 2, Dept Biomorphol Sci, I-80131 Naples, Italy. [Calcagno, G.] Univ Naples Federico 2, Dept Biochem & CEINGE Scarl, I-80131 Naples, Italy. [Adriani, M.] NHGRI, NIH, Genet & Mol Biol Branch, Bethesda, MD 20892 USA. [Christiano, A. M.] Columbia Univ, Dept Dermatol, New York, NY 10027 USA. [Christiano, A. M.] Columbia Univ, Dept Genet & Dev, New York, NY USA. [Weiner, L.; Brissette, J. L.] Massachusetts Gen Hosp, Harvard Med Sch, Cutaneous Biol Res Ctr, Dept Dermatol, Charlestown, MA USA. RP Pignata, C (reprint author), Univ Naples Federico 2, Dept Pediat, Immunol Unit, Via S Pansini 5, I-80131 Naples, Italy. EM pignata@unina.it RI Adriani, Marsilio/F-2553-2013; Pignata, Claudio/O-2466-2013; OI Pignata, Claudio/0000-0003-1568-9843; Calcagno, Giuseppe/0000-0003-4680-1535 FU NIAMS NIH HHS [R01 AR045284, R01 AR045284-10, R01 AR055218, R01 AR055218-01A1] NR 28 TC 27 Z9 28 U1 0 U2 7 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0009-9163 J9 CLIN GENET JI Clin. Genet. PD APR PY 2008 VL 73 IS 4 BP 380 EP 384 DI 10.1111/j.1399-0004.2008.00977.x PG 5 WC Genetics & Heredity SC Genetics & Heredity GA 274BX UT WOS:000253977900014 PM 18339010 ER PT J AU Montoya, CJ Catano, JC Ramirez, Z Rugeles, MT Wilson, SB Landay, AL AF Montoya, Carlos J. Catano, Juan C. Ramirez, Zoraida Rugeles, Maria T. Wilson, S. Brian Landay, Alan L. TI Invariant NKT cells from HIV-1 or Mycobacterium tuberculosis-infected patients express an activated phenotype SO CLINICAL IMMUNOLOGY LA English DT Article DE invariant NKT cells; activation markers; HIV-1; HAART; tuberculosis ID KILLER T-CELLS; IMMUNODEFICIENCY-VIRUS-INFECTION; EXPANSION; IMMUNITY; DISEASE; CD1D AB The frequency, subsets and activation status of peripheral blood invariant NKT (iNKT) cells were evaluated in pulmonary tuberculosis (TB) patients and in chronically HIV-1-infected subjects. The absolute numbers of iNKT cells were significantly decreased in TB patients and in HIV-1+ individuals who were antiretrovirat therapy naive or had detectable viremia despite receiving HAART. iNKT cell subset analysis demonstrated a decreased percentage of CD4(+) iNKT cells in HIV-1 + subjects, and a decreased percentage of double negative iNKT cells in TB patients. Peripheral blood iNKT cells from HIV-1 + and TB patients had significantly increased expression of CD69, CD38, HLA-DR, CID16, CD56, and CD62L. The expression of CD25 was significantly increased only on iNKT cells from TB patients. These findings indicate that peripheral blood iNKT cells in these two chronic infections show an up-regulated expression of activation markers, suggesting their role in the immune response to infection. (C) 2007 Elsevier Inc. All rights reserved. C1 [Montoya, Carlos J.; Ramirez, Zoraida; Rugeles, Maria T.] Univ Antioquia, Grp Immunovirol, Medellin, Colombia. [Montoya, Carlos J.; Landay, Alan L.] Rush Univ, Ctr Med, Dept Immunol & Microbiol, Chicago, IL 60612 USA. [Catano, Juan C.] Univ Antioquia, Sch Med, Dept Internal Med, Div Infect Dis, Medellin, Colombia. [Wilson, S. Brian] Massachusetts Gen Hosp, Diabet Unit, Boston, MA 02114 USA. RP Montoya, CJ (reprint author), Univ Antioquia, Grp Immunovirol, Calle 62,52-29 Torre 2,Lab 532, Medellin, Colombia. EM cjmonto@une.net.co FU NIAID NIH HHS [2R01 AI 45051, 5P01 AI055793] NR 29 TC 37 Z9 39 U1 0 U2 2 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1521-6616 J9 CLIN IMMUNOL JI Clin. Immunol. PD APR PY 2008 VL 127 IS 1 BP 1 EP 6 DI 10.1016/j.clim.2007.12.006 PG 6 WC Immunology SC Immunology GA 281MM UT WOS:000254501700001 PM 18304877 ER PT J AU Seiderer, J Dambacher, J Leistner, D Tillack, C Glas, J Niess, JH Pfennig, S Jurgens, M Muller-Myhsok, B Goke, B Ochsenkuhn, T Lohse, P Reinecker, HC Brand, S AF Seiderer, Julia Dambacher, Julia Leistner, Dorothea Tillack, Cornelia Glas, Juergen Niess, Jan-Hendrik Pfennig, Simone Juergens, Matthias Mueller-Myhsok, Bertram Goeke, Burkhard Ochsenkuehn, Thomas Lohse, Peter Reinecker, Hans-Christian Brand, Stephan TI Genotype-phenotype analysis of the CXCL 16 p.Ala181Val polymorphism in inflammatory bowel disease SO CLINICAL IMMUNOLOGY LA English DT Article DE Crohn's disease; ulcerative colitis; inflammatory bowel; disease; chemokine; CXCL1 6; CXCR6; polymorphism; genetics; intestinal inflammation; CARD15 ID TRANSMEMBRANE CXC-CHEMOKINE; INTESTINAL EPITHELIAL-CELLS; GENOME-WIDE ASSOCIATION; COLORECTAL-CANCER CELLS; CROHNS-DISEASE; FRAMESHIFT MUTATION; EXPRESSION CLONING; TERMINAL ILEUM; SUSCEPTIBILITY; CARD15 AB To identify if genetic determinants of CXCL16 modulate the susceptibility and phenotype of inflammatory bowel diseases (IBD), we analyzed genomic DNA from 574 individuats (365 IBD patients, 209 healthy controls) for the CXCL16 p.Ala181Va1 polymorphism. In this study, we demonstrate that in Crohn's disease (CD), the CXCL16 p.ALa181Val polymorphism is not a disease susceptibility gene but associated with younger age at disease onset (p=0.016) and higher frequency of ilea( involvement (p=0.024; OR 2.17; 95% CI 1.12-4.21) in ValVal carriers compared to a higher frequency of colonic involvement in AlaAla carriers (p = 0.009; OR 2.60; CI 1.29-5.25). Carriers of at least one Val allele and one CARD15/NOD2 variant had a higher incidence of a stricturing and penetrating phenotype (p = 0.030, OR 4.04, CI 1.27-12.84) and of stenoses (p = 0.014; OR 3.97; Cl 1.38-11.40) than patients carrying NOD2 variants only, suggesting that this polymorphism contributes to a severe disease phenotype in CD. (C) 2007 Elsevier Inc. All rights reserved. C1 [Seiderer, Julia; Dambacher, Julia; Leistner, Dorothea; Tillack, Cornelia; Glas, Juergen; Pfennig, Simone; Juergens, Matthias; Goeke, Burkhard; Ochsenkuehn, Thomas; Brand, Stephan] Univ Munich, Dept Med Grosshadern 2, D-80539 Munich, Germany. [Glas, Juergen] Univ Munich, Clin Prevent Dent & Periodontol, D-80539 Munich, Germany. [Niess, Jan-Hendrik] Univ Ulm, Dept Internal Med 1, D-89069 Ulm, Germany. Harvard Univ, Sch Med, Boston, MA USA. Massachusetts Gen Hosp, Dept Med, Gastroenterol Unit, Boston, MA 02114 USA. Massachusetts Gen Hosp, Dept Med, Ctr Study Inflammatory Bowel Dis, Boston, MA 02114 USA. [Mueller-Myhsok, Bertram] Max Planck Inst Psychiat, D-80804 Munich, Germany. [Lohse, Peter] Univ Munich, Dept Clin Chem Grosshadern, D-80539 Munich, Germany. RP Brand, S (reprint author), Univ Munich, Univ Hosp Munich Grosshadern, Dept Med 2, Marchioninistr 15, D-81377 Munich, Germany. EM stephan.brand@med.uni-muenchen.de RI Muller-Myhsok, Bertram/A-3289-2013; Niess, Jan /E-8361-2017 OI Niess, Jan /0000-0001-6902-5650 FU NIDDK NIH HHS [P01 DK003506, R01 DK068181] NR 38 TC 12 Z9 12 U1 0 U2 1 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1521-6616 EI 1521-7035 J9 CLIN IMMUNOL JI Clin. Immunol. PD APR PY 2008 VL 127 IS 1 BP 49 EP 55 DI 10.1016/j.ctim.2007.11.016 PG 7 WC Immunology SC Immunology GA 281MM UT WOS:000254501700007 PM 18248772 ER PT J AU Fujitani, S Rowlinson, MC George, WL AF Fujitani, Shigeki Rowlinson, Marie-Claire George, W. Lance TI Penicillin G-resistant viridans group streptococcal endocarditis and interpretation of the American Heart Association's guidelines for the treatment of infective endocarditis SO CLINICAL INFECTIOUS DISEASES LA English DT Editorial Material ID COMBINATION AB We report a case of endocarditis due to a penicillin-"resistant" Streptococcus parasanguinis, discuss interpretations of the American Heart Association's guidelines for the treatment of viridans group streptococcal infection, and comment on therapy for infective endocarditis due to penicillin-resistant viridans group streptococci. C1 [George, W. Lance] VA Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA 90073 USA. [Fujitani, Shigeki] Univ Calif Los Angeles, Affiliated Infect Dis Fellowship Training Program, Los Angeles, CA USA. [Rowlinson, Marie-Claire] VA Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA 90073 USA. [George, W. Lance] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. RP George, WL (reprint author), VA Greater Los Angeles Healthcare Syst, Dept Med, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM William.george@med.va.gov NR 8 TC 6 Z9 7 U1 0 U2 1 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD APR 1 PY 2008 VL 46 IS 7 BP 1064 EP 1066 DI 10.1086/529199 PG 3 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 271VW UT WOS:000253817800016 PM 18444825 ER PT J AU Rodriguez-Barradas, MC Goulet, J Brown, S Goetz, MB Rimland, D Simberkoff, MS Crothers, K Justice, AC AF Rodriguez-Barradas, Maria C. Goulet, Joseph Brown, Sheldon Goetz, Matthew Bidwell Rimland, David Simberkoff, Michael S. Crothers, Kristina Justice, Amy C. TI Impact of pneumococcal vaccination on the incidence of pneumonia by HIV infection status among patients enrolled in the veterans aging cohort 5-Site Study SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY; POLYSACCHARIDE VACCINE; RISK-FACTORS; BACTERIAL PNEUMONIA; CIGARETTE-SMOKING; DISEASE; ADULTS; INDIVIDUALS; ERA AB Background. Human immunodeficiency virus (HIV)-infected persons have a high incidence of pneumonia and pneumococcal disease. Benefits of vaccination with the 23-valent pneumococcal polysaccharide vaccine (PPV) among these patients continue to be debated. Methods. The impact of PPV vaccination on the incidence of pneumonia events (i.e., the composite of pneumococcal pneumonia and pneumonia due to nonspecified organisms) was examined among participants in the Veterans Aging Cohort 5-Site Study, an ongoing prospective study of HIV-infected patients matched to an HIV-uninfected control group. Dates of PPV vaccination and pneumonia were determined by retrospective review of electronic medical records. Time to events was measured for up to 2 years from PPV vaccination or from enrollment for vaccinated and unvaccinated patients, respectively. Kaplan-Meier and Cox proportional hazards regression methods were used to examine the incidence of pneumonia by HIV infection and PPV vaccination status. Results. Among 692 HIV-uninfected and 934 HIV-infected study participants, 59% were vaccinated with PPV. The 2-year incidence of pneumonia was 6% (97 participants developed pneumonia). HIV-infected patients had a higher rate of pneumonia (hazard ratio, 5.81; 95% confidence interval, 3.15-10.71); overall, vaccinated patients showed a trend toward lower risk of pneumonia (hazard ratio, 0.75; 95% confidence interval, 0.50-1.13). Among HIV-infected patients, after controlling for HIV-specific and other variables, vaccination significantly reduced the risk of pneumonia (hazard ratio, 0.65; 95% confidence interval, 0.42-1.00); current smoking, low hemoglobin level, and low CD4 cell count significantly increased such risk. The effect of PPV vaccination among HIV-uninfected patients was not significant. Conclusions. Among HIV-infected patients, PPV vaccination offered protection against pneumonia. Smoking cessation needs to be pursued as an additional strategy for preventing pneumonia. C1 [Rodriguez-Barradas, Maria C.] Michael E DeBakey VAMC, Med Serv, Houston, TX 77030 USA. [Rodriguez-Barradas, Maria C.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Goulet, Joseph; Crothers, Kristina; Justice, Amy C.] VA Connecticut Healthcare Syst, Vet Aging Cohort Study Ctr, New Haven, CT USA. [Goulet, Joseph; Crothers, Kristina; Justice, Amy C.] Yale Univ, Sch Med, Dept Med, New Haven, CT 06510 USA. [Brown, Sheldon] Bronx VA Med Ctr, New York, NY USA. [Brown, Sheldon] Mt Sinai Sch Med, New York, NY USA. [Simberkoff, Michael S.] VA New York Harbor Healthcare Syst, New York, NY USA. [Simberkoff, Michael S.] NYU, Sch Med, New York, NY USA. [Goetz, Matthew Bidwell] VA Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA USA. [Goetz, Matthew Bidwell] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Rimland, David] VA Med Ctr, Atlanta, GA USA. [Rimland, David] Emory Univ, Sch Med, Atlanta, GA USA. RP Rodriguez-Barradas, MC (reprint author), Michael E DeBakey VAMC, Med Serv, 2002 Holcombe Blvd MS 111G, Houston, TX 77030 USA. EM maria.rodriguez-barradas2@med.va.gov OI Goetz, Matthew/0000-0003-4542-992X; Goulet, Joseph/0000-0002-0842-804X; Crothers, Kristina/0000-0001-9702-0371 FU NIA NIH HHS [K23 AG00826]; NIAAA NIH HHS [U01 AA 13566, U01 AA013566, U10 AA 13566, U10 AA013566, U10 AA013566-07] NR 33 TC 51 Z9 51 U1 1 U2 2 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD APR 1 PY 2008 VL 46 IS 7 BP 1093 EP 1100 DI 10.1086/529201 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 271VW UT WOS:000253817800021 PM 18444830 ER PT J AU Woolery, M Bisanz, A Lyons, HF Gaido, L Yenulevich, M Fulton, S McMillan, SC AF Woolery, Myra Bisanz, Annette Lyons, Hannah F. Gaido, Lindsay Yenulevich, Mary Fulton, Stephanie McMillan, Susan C. TI Putting evidence into Practice (R): Evidence-based interventions for the prevention and management of constipation in patients with cancer SO CLINICAL JOURNAL OF ONCOLOGY NURSING LA English DT Review ID CHRONIC NONCANCER PAIN; RELEASE ORAL MORPHINE; TRANSDERMAL FENTANYL; OPIOID ANTAGONISTS; BOWEL DYSFUNCTION; DIETARY FIBER; DOUBLE-BLIND; LACTULOSE; EFFICACY; CHILDREN AB Constipation is a major source of distress for patients with cancer, significantly affecting quality of life. It can be secondary to disease sequelae, side effects of treatment, or preexisting conditions. It often is unrecognized, underassessed, and ineffectively managed. Nurses play a key role in the prevention and management of constipation and need evidence-based interventions. This article summarizes the existing research evidence for constipation interventions and identifies gaps, Many of the strategies have been evaluated in nononcology populations; researchers should evaluate their effectiveness in oncology populations. C1 [Woolery, Myra] Natl Inst Hlth, Bethesda, MD 20892 USA. [Woolery, Myra] Univ Maryland, Sch Nursing, Baltimore, MD 21201 USA. [Bisanz, Annette] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Lyons, Hannah F.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Gaido, Lindsay; Fulton, Stephanie] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Yenulevich, Mary] Dana Farber Canc Inst, Boston, MA 02115 USA. [McMillan, Susan C.] Univ S Florida, Coll Nursing, Tampa, FL USA. RP Woolery, M (reprint author), Natl Inst Hlth, Bethesda, MD 20892 USA. EM mwoolery@cc.nih.gov NR 82 TC 22 Z9 24 U1 0 U2 4 PU ONCOLOGY NURSING SOC PI PITTSBURGH PA 125 ENTERPRISE DR, PITTSBURGH, PA 15275 USA SN 1092-1095 J9 CLIN J ONCOL NURS JI Clin. J. Oncol. Nurs. PD APR PY 2008 VL 12 IS 2 BP 317 EP 337 DI 10.1188/08.CJON.317-337 PG 21 WC Oncology; Nursing SC Oncology; Nursing GA 299DN UT WOS:000255736100018 PM 18390467 ER PT J AU Malluche, HH Monier-Faugere, MC Wang, G Frazao, JM Charytan, C Coburn, JW Coyne, DW Kaplan, MR Baker, N McCary, LC Turner, SA Goodman, WG AF Malluche, H. H. Monier-Faugere, M. -C. Wang, G. Frazao, J. M. Charytan, C. Coburn, J. W. Coyne, D. W. Kaplan, M. R. Baker, N. McCary, L. C. Turner, S. A. Goodman, W. G. TI An assessment of cinacalcet HCl effects on bone histology in dialysis patients with secondary hyperparathyroidism SO CLINICAL NEPHROLOGY LA English DT Article DE cinacalcet; randomized; clinical trial; renal; osteodystrophy secondary; hyperparathyroidism ID HEMODIALYSIS-PATIENTS; CALCIMIMETIC AGENT; RENAL-FAILURE; DOUBLE-BLIND; MARKERS; TURNOVER; THERAPY AB Aims: Cinacalcet lowers plasma parathyroid hormone (PTH) levels in patients with secondary hyperparathyroidism (sHPT), but the bone histologic response has not been described. This prospective, double-blind, placebo-controlled trial assessed the effects of cinacalcet on bone histology and serum markers of bone metabolism in dialysis patients with sHPT. Methods: Patients with intact PTH (iPTH) >= 300 pg/ml were randomly assigned 2:1 to receive cinacalcet or placebo with concurrent vitamin D and/or phosphate bindertherapy. Cinacalcet (30-180 mg/day) was used to achieve iPTH levels! 200 pg/ml. Bone biopsies were performed before and after one year of treatment. Results: Baseline and end-of-study data were available from 32 patients (19 cinacalcet, 13 placebo). Baseline bone tunnover was elevated in 27, reduced in 3 and normal in 2 patients. Serum bone-specific alkaline phosphatase (BSAP) and N-telopeptide (NTx) were elevated. Cinacalcet treatment decreased PTH and diminished activation frequency, bone formation rate/bone surface, and fibrosis surface/bone surface. Adynamic bone was observed in three patients receiving cinacalcet; in two of these, PTH levels were persistently low (< 100 pg/ml). The histomorphometric parameter changes in bone corresponded to PTH, BSAP and NTx reductions. Bone mineralization parameters remained normal. Conclusions: Treatment with cinacalcet lowered PTH and reduced bone turnover and tissue fibrosis among most dialysis patients with biochemical evience of sHPT. C1 [Malluche, H. H.; Monier-Faugere, M. -C.; Wang, G.] Univ Kentucky, Div Nephrol Bone & Mineral Metab, Lexington, KY 40536 USA. [Frazao, J. M.] Univ Porto, Sch Med, Nephrol Res & Dev Unit, Oporto, Portugal. [Charytan, C.] New York Hosp, Queens Med Ctr, Flushing, NY USA. [Coburn, J. W.] VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. [Coyne, D. W.] Washington Univ, Sch Med, St Louis, MO USA. [Kaplan, M. R.] Nephrol Assoc, Nashville, TN USA. [Baker, N.; McCary, L. C.; Turner, S. A.] Amgen Inc, Thousand Oaks, CA USA. [Goodman, W. G.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA. RP Malluche, HH (reprint author), Univ Kentucky, Div Nephrol Bone & Mineral Metab, Room MN 564,800 Rose St, Lexington, KY 40536 USA. EM hhmall@uky.edu RI Frazao, Joao/J-9811-2013 OI Frazao, Joao/0000-0002-8081-5474 NR 19 TC 61 Z9 64 U1 0 U2 4 PU DUSTRI-VERLAG DR KARL FEISTLE PI DEISENHOFEN-MUENCHEN PA BAHNHOFSTRASSE 9 POSTFACH 49, D-82032 DEISENHOFEN-MUENCHEN, GERMANY SN 0301-0430 J9 CLIN NEPHROL JI Clin. Nephrol. PD APR PY 2008 VL 69 IS 4 BP 269 EP 278 PG 10 WC Urology & Nephrology SC Urology & Nephrology GA 287NM UT WOS:000254923800006 PM 18397701 ER PT J AU Shields, AE Lerman, C AF Shields, A. E. Lerman, C. TI Anticipating clinical integration of pharmacogenetic treatment strategies for addiction: Are primary care physicians ready? SO CLINICAL PHARMACOLOGY & THERAPEUTICS LA English DT Article ID CANCER SUSCEPTIBILITY; DISPARITIES; GENETICS; SMOKING; GENOMICS; RACE AB Emerging pharmacogenomics research on addiction to nicotine,(1) alcohol,(2) cocaine, and opiates(3) may soon lead to improved clinical outcomes by tailoring the type, dose and duration of treatment to individual patients' genotypes. To realize the potential of pharmacogenomics in reducing the burden of addiction, several challenges related to clinical integration of novel treatment strategies will need to be addressed concomitantly with ongoing empirical research.(4) These challenges include the preparedness of primary care physicians (PCPs) to incorporate pharmacogenetics into clinical practice, patients' willingness to undergo genetic testing, the resources and infrastructure needed to deliver such services, adequate financing and reimbursement of pharmacogenetic testing, and privacy and antidiscrimination protections sufficient to reassure physicians and patients that genetic testing will not lead to stigmatization and discrimination.(4). C1 [Shields, A. E.] Harvard Univ, MGH Ctr Genom Vulnerable Populat & Hlth Dispariti, Boston, MA 02115 USA. [Lerman, C.] Univ Penn, Dept Psychiat, Transdisciplinary Tobacco Use Res Ctr, Philadelphia, PA 19104 USA. [Lerman, C.] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA. [Shields, A. E.] Massachusetts Gen Hosp Partners Health Care, Inst Hlth Policy, Boston, MA USA. [Shields, A. E.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. RP Shields, AE (reprint author), Harvard Univ, MGH Ctr Genom Vulnerable Populat & Hlth Dispariti, Boston, MA 02115 USA. EM ashields@partners.org FU NCI NIH HHS [P50 CA84718]; NHGRI NIH HHS [R01 HG003475-01A1] NR 27 TC 28 Z9 28 U1 0 U2 4 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0009-9236 J9 CLIN PHARMACOL THER JI Clin. Pharmacol. Ther. PD APR PY 2008 VL 83 IS 4 BP 635 EP 639 DI 10.1038/clpt.2008.4 PG 5 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 279BM UT WOS:000254330000028 PM 18323859 ER PT J AU Buhlmann, U Teachman, BA Gerbershagen, A Kikul, J Rief, W AF Buhlmann, Ulrike Teachman, Bethany A. Gerbershagen, Anke Kikul, Julia Rief, Winfried TI Implicit and explicit self-esteem and attractiveness beliefs among individuals with body dysmorphic disorder SO COGNITIVE THERAPY AND RESEARCH LA English DT Article DE body dysmorphic disorder; body image; self-esteem; importance of attractiveness; implicit associations ID ASSOCIATION TEST; SOCIAL COGNITION; ANXIETY; RELIABILITY; INFORMATION; VALIDITY; SCALE; BIAS AB Body Dysmorphic Disorder (BDD) is characterized by a preoccupation about imagined or slight defects in one's appearance. In the present study, we evaluated explicit and implicit biases among individuals diagnosed with BDD (n = 15), individuals with subclinical BDD symptoms (n = 20), and healthy control participants (n = 20). Specifically, we used the Implicit Association Test [(IAT; Greenwald, McGhee, & Schwartz, (1998) Journal of personality and social psychology, 74, 1464] to measure automatic associations related to self-esteem (evaluations of the self vs. others as good vs. bad) and the importance of attractiveness (evaluations of attractiveness vs. kindness as important vs. meaninglessness). Results indicated that, as predicted, BDD participants had significantly lower implicit self-esteem, relative to healthy control participants, and the subclinical BDD participants were intermediate between these groups. Further, lower implicit self-esteem was positively related to each of the other implicit and explicit BDD-relevant indicators, including explicit beliefs about attractiveness. However, no group differences were observed on the implicit importance of attractiveness task. These findings mostly support cognitive-behavioral models of BDD that suggest vulnerable persons exaggerate the significance of appearance for self-evaluation. C1 [Buhlmann, Ulrike] Massachusetts Gen Hosp, Body Dysmorph Disorder Clin, Boston, MA 02114 USA. [Buhlmann, Ulrike] Harvard Univ, Sch Med, Boston, MA 02114 USA. [Teachman, Bethany A.] Univ Virginia, Charlottesville, VA USA. [Gerbershagen, Anke; Kikul, Julia; Rief, Winfried] Univ Marburg, Marburg, Germany. RP Buhlmann, U (reprint author), Massachusetts Gen Hosp, Body Dysmorph Disorder Clin, Simches Res Bldg,185 Cambridge St,Suite 2280, Boston, MA 02114 USA. EM buhlmann@psych.mgh.harvard.edu NR 39 TC 18 Z9 18 U1 1 U2 7 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0147-5916 J9 COGNITIVE THER RES JI Cogn. Ther. Res. PD APR PY 2008 VL 32 IS 2 BP 213 EP 225 DI 10.1007/s10608-006-9095-9 PG 13 WC Psychology, Clinical SC Psychology GA 270BT UT WOS:000253695600005 ER PT J AU Sun, CH Munn, LL AF Sun, Chenghai Munn, Lance L. TI Lattice-Boltzmann simulation of blood flow in digitized vessel networks SO COMPUTERS & MATHEMATICS WITH APPLICATIONS LA English DT Article; Proceedings Paper CT 2nd International Conference on Mesoscopic Methods in Engineering and Science (ICMMES) CY JUL 25-29, 2005 CL Hong Kong Polytechn Univ, Hong Kong, PEOPLES R CHINA HO Hong Kong Polytechn Univ DE lattice Boltzmann; RBC aggregation; blood rheology; leukocyte adhesion; microcirculation ID ERYTHROCYTE AGGREGATION; SHEAR-FLOW; POSTCAPILLARY EXPANSIONS; PARTICULATE SUSPENSIONS; LEUKOCYTE MARGINATION; EQUATION; CELLS; DEFORMATION; VISCOSITY; MECHANICS AB Efficient flow of red blood cells (RBCs) and white blood cells (WBCs) through the microcirculation is necessary for oxygen and nutrient delivery as well as immune cell function. Because blood is a dense particulate suspension, consisting of 40% RBCs by volume, it is difficult to analyze the physical mechanisms by which individual blood cells contribute to the bulk flow properties of blood. Both experimental and computational approaches are hindered by these non-Newtonian properties, and predicting macroscopic blood flow characteristics such as viscosity has historically been an empirical process. In order to examine the effect of the individual cells on macroscopic blood rheology, we developed a lattice-Boltzmann model that considers the blood as a suspension of particles in plasma, accounting explicitly for cell-cell and cell-wall interactions. Previous studies have concluded that the abundance of leukocyte rolling in postcapillary venules is due to the interactions between red blood cells and leukocytes as they enter postcapillary expansions. Similar fluid dynamics may be involved in the initiation of rolling at branch points, a phenomenon linked to atherosclerosis. The lattice-Boltzmann approach is used to analyze the interactions of red and white blood cells as they flow through vascular networks digitized from normal and tumor tissue. A major advantage of the lattice-Boltzmann method is the ability to simulate particulate flow dynamically and in any geometry. Using this approach, we can accurately determine RBC-WBC forces, particle trajectories, the pressure changes in each segment that accompany cellular traffic in the network, and the forces felt by the vessel wall at any location. In this technique, intravital imaging using vascular contrast agents produces the network outline that is fed to the lattice-Boltzmann model. This powerful and flexible model can be used to predict blood flow properties in any vessel geometry and with any blood composition. (c) 2007 Elsevier Ltd. All rights reserved. C1 Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02114 USA. RP Sun, CH (reprint author), Exa Corp, 3 Burlington Woods Dr, Burlington, MA 01803 USA. EM chenghai@exa.com; lance@steele.mgh.harvard.edu RI Munn, Lance/L-3950-2016 OI Munn, Lance/0000-0003-0698-7232 FU NCI NIH HHS [P01 CA080124, P01 CA080124-06A20006, P01 CA080124-06A29001]; NHLBI NIH HHS [R01 HL064240-01, R01 HL064240, R01 HL064240-02, R01 HL064240-03, R01 HL064240-04, R01 HL064240-05, R01 HL064240-06, R01 HL064240-07, R01 HL064240-08] NR 31 TC 29 Z9 29 U1 1 U2 19 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0898-1221 J9 COMPUT MATH APPL JI Comput. Math. Appl. PD APR PY 2008 VL 55 IS 7 BP 1594 EP 1600 DI 10.1016/j.camwa.2007.08.019 PG 7 WC Mathematics, Applied SC Mathematics GA 296KJ UT WOS:000255541600024 PM 19343080 ER PT J AU Fan, VS Giardino, ND Blough, DK Kaplan, RM Ramsey, SD AF Fan, Vincent S. Giardino, Nicholas D. Blough, David K. Kaplan, Robert M. Ramsey, Scott D. CA NETT Res Grp TI Costs of Pulmonary Rehabilitation and Predictors of Adherence in the National Emphysema Treatment Trial SO COPD-JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE LA English DT Article DE Rehabilitation; Chronic Obstructive Pulmonary Disease; Depression ID VOLUME-REDUCTION SURGERY; AIR-FLOW OBSTRUCTION; RESPIRATORY REHABILITATION; DISEASE; MORBIDITY; MORTALITY; INDEX; COPD AB This study reports the costs associated with rehabilitation among participants in the National Emphysema Treatment Trial (NETT), and evaluates factors associated with adherence to rehabilitation. Pulmonary rehabilitation is recommended for moderate-to-severe COPD and required by the Centers for Medicare and Medicaid Services (CMS) prior to lung volume reduction surgery (LVRS). Between January 1998 and July 2002,1,218 subjects with emphysema and severe airflow limitation (FEV(1) < 45% predicted) were randomized. Primary outcome measures were designated as mortality and maximal exercise capacity 2 years after randomization. Pre-randomization, estimated mean total cost per patient of rehabilitation was $2,218 (SD $314; 2006 dollars) for the medical group and $2,187 (SD $304) for the surgical group. Post-randomization, mean cost per patient in the medical and surgical groups was $766 and $962 respectively. Among patients who attended >= 1 post-randomization rehabilitation session, LVRS patients, patients with an FEV(1) >= 20% predicted, and higher education were significantly more likely to complete rehabilitation. Patients with depressive and anxiety symptoms, and those who live > 36 miles compared to < 6 miles away were less likely to be adherent. Patients who underwent LVRS completed more exercise sessions than those in the medical group and were more likely to be adherent with post-randomization rehabilitation. A better understanding of patient factors such as socioeconomic status, depression, anxiety and transportation issues may improve adherence to pulmonary rehabilitation. C1 [Blough, David K.; Ramsey, Scott D.] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98109 USA. [Fan, Vincent S.] Hlth Serv Res & Dev Ctr Excellence, VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Fan, Vincent S.; Ramsey, Scott D.] Univ Washington, Dept Med, Seattle, WA USA. [Giardino, Nicholas D.] Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA. [Kaplan, Robert M.] Univ Calif Los Angeles, Dept Hlth Serv, Los Angeles, CA USA. RP Ramsey, SD (reprint author), Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, 1100 Fairview Ave N,Box 19024,M3-B232, Seattle, WA 98109 USA. EM Vincent.Fan@med.va.gov; ngiardin@umich.edu; dkblough@u.washington.edu; rmkaplan@ucla.edu; sramsey@fhcrc.org FU National Heart, Lung, and Blood Institute [N01HR76101, N01HR76102, N01HR76103, N01HR76104, N01HR76105, N01HR76106, N01HR76107, N01HR76108, N01HR76109, N01HR761 10, N01HR76111, N01HR76112, N01HR76113, N01HR76114, N01HR76115, N01HR76116, N01HR76118, N01HR76119]; Centers for Medicare and Medicaid Services; Agency for Healthcare Research and Quality FX The research reported here was supported by the Department of Veteran Affairs, Health Services Research and Development Service Grants RCD 02-170-2 and by the NETT Coordinating Center. The National Emphysema Treatment Trial (NETT) is supported by contracts with the National Heart, Lung, and Blood Institute (N01HR76101, N01HR76102, N01HR76103, N01HR76104, N01HR76105, N01HR76106, N01HR76107, N01HR76108, N01HR76109, N01HR761 10, N01HR7611 1, N01HR76112, N01HR76113, N01HR76114, N01HR76115, N01HR76116, N01HR76118, and N01HR76119), the Centers for Medicare and Medicaid Services (CMS; formerly the Health Care Financing Administration); and the Agency for Healthcare Research and Quality (AHRO). NR 25 TC 37 Z9 38 U1 0 U2 4 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1541-2555 J9 COPD JI COPD-J. Chronic Obstr. Pulm. Dis. PD APR PY 2008 VL 5 IS 2 BP 105 EP 116 DI 10.1080/15412550801941190 PG 12 WC Respiratory System SC Respiratory System GA 428GP UT WOS:000264836300005 PM 18415809 ER PT J AU Musher, DM Aslam, S AF Musher, Daniel M. Aslam, Saima TI Treatment of Clostridium difficile colitis in the critical care setting SO CRITICAL CARE CLINICS LA English DT Article ID ANTIBIOTIC-ASSOCIATED COLITIS; IN-VITRO ACTIVITY; CLINDAMYCIN-ASSOCIATED COLITIS; 15 ANTIMICROBIAL AGENTS; PSEUDOMEMBRANOUS COLITIS; ORAL VANCOMYCIN; DISEASE SEVERITY; DOUBLE-BLIND; STAPHYLOCOCCAL ENTEROCOLITIS; INTRAVENOUS IMMUNOGLOBULIN AB Clostridium difficile colitis is a debilitating infection with a remarkably high associated mortality. Infection is contagious and spreads especially rapidly in an intensive care setting because patients who are there have all the associated risk factors, including major underlying illnesses, prior antibiotic therapy, and use of agents that suppress gastric acidity. Prevention of disease is the responsibility of every health care provider in the critical care setting. This article emphasizes treatment of Clostridium difficile colitis, considers diagnostic techniques, and describes means for preventing the spread of this infection in the intensive care setting. C1 [Musher, Daniel M.; Aslam, Saima] Michael E DeBakey Vet Affairs Med Ctr, Infect Dis Sect, Houston, TX 77030 USA. [Musher, Daniel M.; Aslam, Saima] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Musher, Daniel M.] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA. RP Musher, DM (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Infect Dis Sect, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM daniel.musher@med.va.gov NR 84 TC 11 Z9 12 U1 0 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0749-0704 J9 CRIT CARE CLIN JI Crit. Care Clin. PD APR PY 2008 VL 24 IS 2 BP 279 EP + DI 10.1016/j.ccc.2007.12.006 PG 14 WC Critical Care Medicine SC General & Internal Medicine GA 291XK UT WOS:000255230400005 PM 18361946 ER PT J AU Arroliga, AC Thompson, BT Ancukiewicz, M Gonzales, JP Guntupalli, KK Park, PK Wiedemann, HP Anzueto, A AF Arroliga, Alejandro C. Thompson, B. Taylor Ancukiewicz, Marek Gonzales, Jeffrey P. Guntupalli, Kalpalatha K. Park, Pauline K. Wiedemann, Herbert P. Anzueto, Antonio CA Acute Respiratory Distress Syndro TI Use of sedatives, opioids, and neuromuscular blocking agents in patients with acute lung injury and acute respiratory distress syndrome SO CRITICAL CARE MEDICINE LA English DT Article DE sedatives; opioids; neuromuscular blockers; benzodiazepines; propofol; acute respiratory distress syndrome ID CRITICALLY-ILL PATIENTS; INTENSIVE-CARE-UNIT; MECHANICAL VENTILATION; TIDAL VOLUMES; LIFE; ANALGESICS; MODEL AB Objective: The use of sedatives, opioids, and neuromuscular blocking agents (NMBAs) may delay weaning and prolong intensive care unit length of stay. We hypothesized that in patients on higher positive end-expiratory pressure (PEEP), sedatives, opioids, and NMBAs are used in a higher proportion of patients and in higher doses and that the use of these medications is associated with prolongation of weaning and mortality. Design. Retrospective analysis. Setting: The ALVEOLI trial. Patients: Five hundred forty-nine patients with acute lung injury/acute respiratory distress syndrome (ALI/ARDS) who were enrolled in the ALVEOLI trial. Interventions: We analyzed prospectively collected data regarding the impact of sedatives, opioids, and NMBAs in ALI/ARDS patients on duration of mechanical ventilation, time to weaning landmarks, and mortality. Measurements and Main Results. Sedatives and opioids were used in >80% of the patients in similar proportion in the two groups. The use of sedatives and opioids, but not the use of NMBAs, was associated with longer time on mechanical ventilation and an increased time to achieve a 2-hr spontaneous breathing trial (p <.0001). Sedatives were also associated with increased time to achieve unassisted breathing. NMBAs were used for a short period of time, in a higher proportion of patients in the lower PEEP group, and for a longer time (0.23 days). Conclusions: Sedatives and opioids use was similar in the higher and lower PEEP groups. The use of sedatives and opioids, but not NMBAs, was associated with a longer time to achieve important weaning landmarks. C1 [Arroliga, Alejandro C.] Scott & White & Texas A&M Hlth Sci Ctr, Coll Med, Temple, TX USA. [Thompson, B. Taylor; Ancukiewicz, Marek] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Thompson, B. Taylor; Ancukiewicz, Marek] Harvard Univ, Sch Med, Boston, MA USA. [Gonzales, Jeffrey P.] Univ Maryland, Sch Med, Baltimore, MD 21201 USA. [Guntupalli, Kalpalatha K.] Baylor Coll Med, Houston, TX 77030 USA. [Park, Pauline K.] Univ Michigan Hlth Syst, Ann Arbor, MI USA. [Wiedemann, Herbert P.] Cleveland Clin, Cleveland, OH 44106 USA. [Anzueto, Antonio] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Anzueto, Antonio] S Texas Vet Hlth Care Syst San Antonio, San Antonio, TX USA. RP Arroliga, AC (reprint author), Scott & White & Texas A&M Hlth Sci Ctr, Coll Med, Temple, TX USA. EM aarroliga@swmaii.sw.org OI Wiedemann, Herbert/0000-0002-4587-4401 FU NHLBI NIH HHS [1-HR 46058, 1-HR 46054, 1-HR 46055, 1-HR 46056, 1-HR 46057, 1-HR 46059, 1-HR 46060, 1-HR 46061, 1-HR 46062, 1-HR 46063, 1-HR 46064] NR 23 TC 44 Z9 45 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0090-3493 J9 CRIT CARE MED JI Crit. Care Med. PD APR PY 2008 VL 36 IS 4 BP 1083 EP 1088 DI 10.1097/CCM.0B013E3181653895 PG 6 WC Critical Care Medicine SC General & Internal Medicine GA 284BJ UT WOS:000254679900007 PM 18401254 ER PT J AU Williams, Z Chan, R Kelly, E AF Williams, Zev Chan, Rodney Kelly, Edward TI A simple device to increase rates of compliance in maintaining 30-degree head-of-bed elevation in ventilated patients SO CRITICAL CARE MEDICINE LA English DT Article DE ventilator-associated pneumonia; head-of-bed elevation; nosocomial infections; infection prevention ID BODY POSITION; PNEUMONIA; OUTCOMES AB Objective: To determine whether a highly visible device that clearly indicates whether the head-of-bed is adequately elevated would increase rates of compliance with head-of-bed elevation guidelines. Design. A prospective, single-center, mult-unit two-phase study. Setting. Surgical, thoracic, trauma, and medical intensive care units. Patients: Cohort of intubated patients. Interventions. A 4-wk trial was performed. At the onset of the trial, nurses were reminded to maintain head-of-bed elevation >30 degrees. Over the subsequent 2 wks, head-of-bed elevations of intubated patient beds were measured. An Angle Indicator, designed to clearly display whether the head-of-bed was adequately elevated, was then placed on side rails of beds of ventilated patients, and head-of-bed elevation measurements were taken for an additional 2 wks. A survey was then handed out to nursing staff to assess satisfaction with the device. Measurements and Main Results. A total of 268 bed measurements were made. The average head-of-bed elevation was 21.8 degrees on beds without the device (n = 166) and 30.9 degrees on beds with the device (n = 102; p <.005). When compliance is defined as a bed angle of :28 degrees, 23% of beds without the device were compliant while 71.5% of the beds with the device were compliant. The relative risk and odds ratio of having the device on a compliant bed were 2.2 and 9.25, respectively (p <.005). Seventy-two percent of nurses surveyed (n = 32) found it to be an improvement over existing methods, 88% found it helpful, and 84% would like it routinely used. Conclusions: The Angle Indicator improved rates of adherence to bed-elevation guidelines, and hospital staff found it helpful. C1 [Williams, Zev; Chan, Rodney; Kelly, Edward] Brigham & Womens Hosp, Boston, MA 02115 USA. [Williams, Zev] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Williams, Z (reprint author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. EM zwilliams2@partners.org OI Chan, Rodney/0000-0002-5061-847X NR 12 TC 12 Z9 15 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0090-3493 J9 CRIT CARE MED JI Crit. Care Med. PD APR PY 2008 VL 36 IS 4 BP 1155 EP 1157 DI 10.1097/CCM.0b013e318168fa59 PG 3 WC Critical Care Medicine SC General & Internal Medicine GA 284BJ UT WOS:000254679900017 PM 18379241 ER PT J AU Palevsky, PM AF Palevsky, Paul M. TI Indications and timing of renal replacement therapy in acute kidney injury SO CRITICAL CARE MEDICINE LA English DT Article DE renal replacement therapy; acute kidney injury; volume overload; hyperkalemia; metabolic acidosis ID CRITICALLY-ILL PATIENTS; CONTINUOUS VENOVENOUS HEMOFILTRATION; RANDOMIZED-TRIAL; CARDIAC-SURGERY; COHORT ANALYSIS; FAILURE; DIALYSIS; INTERMITTENT; HEMODIALYSIS; MORTALITY AB The optimal timing for initiation of renal replacement therapy in patients with acute kidney injury remains uncertain. Conventionally accepted indications include volume overload, hyperkalemia, metabolic acidosis, overt uremia, and even progressive azotemia in the absence of specific symptoms; however, precise definitions for these indications are lacking, Data from recent observational. trials have suggested that early initiation of renal replacement therapy may be associated with decreased mortality; however, the results of these studies are inconclusive. Existing data on timing of initiation of renal replacement therapy in acute kidney injury that guide current clinical practice are summarized and issues that need to be addressed in future clinical trials are discussed. C1 [Palevsky, Paul M.] Vet Affairs Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA 15260 USA. [Palevsky, Paul M.] Univ Pittsburgh, Dept Med, Renal Electrolyte Div, Pittsburgh, PA USA. RP Palevsky, PM (reprint author), Vet Affairs Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA 15260 USA. EM palevsky@piff.edu OI Palevsky, Paul/0000-0002-7334-5400 NR 32 TC 26 Z9 28 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0090-3493 J9 CRIT CARE MED JI Crit. Care Med. PD APR PY 2008 VL 36 IS 4 SU S BP S224 EP S228 DI 10.1097/CCM.0b013e318168e3fb PG 5 WC Critical Care Medicine SC General & Internal Medicine GA 284BO UT WOS:000254680400014 PM 18382198 ER PT J AU Musen, G AF Musen, Gail TI Cognition and Brain Imaging in Type 1 Diabetes SO CURRENT DIABETES REPORTS LA English DT Article ID RECURRENT SEVERE HYPOGLYCEMIA; VOXEL-BASED MORPHOMETRY; MR SPECTROSCOPY; DISEASE ONSET; NEUROPSYCHOLOGICAL PROFILES; CEREBRAL EDEMA; IDDM PATIENTS; CHILDREN; MELLITUS; COMPLICATIONS AB Type 1 diabetes has mild effects on cognition that are influenced by age of onset, hyperglycermia, and hypoglycemic episodes. Some of these changes occur quite early in the disease course. Studies using relatively new brain imaging techniques have also shown brain changes in adults and children that appear to be influenced by metabolic abnormalities present in diabetes. Early detections of brain changes may be early indicators of subsequent cognitive abnormalities. C1 Joslin Diabet Ctr, Boston, MA 02215 USA. RP Musen, G (reprint author), Joslin Diabet Ctr, 1 Joslin Pl, Boston, MA 02215 USA. EM gail.musen@joslin.harvard.edu FU National Institutes of Health [DK60754, DK62218, DK073843, P30 DK36836]; Herbert Graetz Fund FX National Institutes of Health grants DK60754, DK62218, DK073843, P30 DK36836 (Joslin Diabetes and Endocrinology Research Center - DERC), and the Herbert Graetz Fund. NR 54 TC 10 Z9 10 U1 4 U2 6 PU CURRENT MEDICINE GROUP PI PHILADELPHIA PA 400 MARKET STREET, STE 700, PHILADELPHIA, PA 19106 USA SN 1534-4827 EI 1539-0829 J9 CURR DIABETES REP JI Curr. Diabetes Rep. PD APR PY 2008 VL 8 IS 2 BP 132 EP 137 DI 10.1007/s11892-008-0024-z PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 375FU UT WOS:000261100300008 PM 18445356 ER PT J AU Duh, MS Weiner, JR Lefebvre, P Neary, M Skarin, AT AF Duh, Mei Sheng Weiner, Jennifer Reynolds Lefebvre, Patrick Neary, Maureen Skarin, Arthur T. TI Costs associated with intravenous chemotherapy administration in patients with small cell lung cancer: a retrospective claims database analysis SO CURRENT MEDICAL RESEARCH AND OPINION LA English DT Article; Proceedings Paper CT 12th World Conference on Lung Cancer CY SEP 02-06, 2007 CL Seoul, SOUTH KOREA DE cost; IV chemotherapy; small cell lung cancer ID MEDICARE CLAIMS; CARE; STAGE AB Objectives: With new oral chemotherapy drugs emerging, it is useful to understand the costs associated with traditional intravenous (IV) therapy. This study aims to assess costs associated with IV chemotherapy in patients with small cell lung cancer (SCLC) from the perspective Of large employer-payers. Study design: Descriptive retrospective claims database analysis. Methods: Using medical claims data from 5.5 million beneficiaries between 01/01/1998 and 01/31/2006, we identified patients with lung cancer (ICD-9 codes 162.3-162.9, 176.4, or 197.0) who received IV chemotherapy. A case-finding SCLC algorithm was then applied which selected patients who were treated with chemotherapies commonly used in SCLC (cisplatin/ etoposide, cisplatin/irinotecan, carboplatin/etoposide, topotecan, or cyclophosphamide/doxorubicin/vincristine) and then excluded those who had treatments or procedures indicative of non-small cell lung cancer (NSCLC) (positron emission tomography [PET] scan imaging, lung surgery, common NSCLC chemotherapies). Average total costs paid per day of IV chemotherapy administration were computed, along with separate costs for IV chemotherapy drugs, IV chemotherapy administration procedures, and other drugs and services received on IV visit days. Costs were also estimated per course of treatment based on the assumption of four chemotherapy cycles per course with three visits per cycle. Results: Among 8010 patients with a lung cancer diagnosis, 802 were identified as SCLC. In the SCLC subset, the average total daily cost was $787 ($9449/ course), with $395 ($4742/course; 50.2%) attributable to IV chemotherapy drugs, $93 ($1112/course; 11.8%) to IV chemotherapy administration, and $300 ($3595/course; 38.0%) to other drugs and services. Conclusions: The proposed algorithm identified about 10% of patients with lung cancer receiving IV chemotherapy as likely SCLC cases. Future studies should validate this algorithm with medical records data. IV chemotherapy administration and other visit-related drugs and services represented about half of the total cost per IV visit day, with the remainder attributable to direct costs for IV chemotherapy drugs. C1 [Duh, Mei Sheng; Weiner, Jennifer Reynolds; Lefebvre, Patrick] Anal Grp Inc, Boston, MA 02199 USA. [Neary, Maureen] GlaxoSmithKline Inc, Collegeville, PA USA. [Skarin, Arthur T.] Dana Farber Canc Inst, Boston, MA 02115 USA. RP Duh, MS (reprint author), Anal Grp Inc, 111 Huntington Ave,10th Floor, Boston, MA 02199 USA. EM mduh@analysisgroup.com NR 20 TC 6 Z9 7 U1 2 U2 2 PU LIBRAPHARM/INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4 LQ, ENGLAND SN 0300-7995 J9 CURR MED RES OPIN JI Curr. Med. Res. Opin. PD APR PY 2008 VL 24 IS 4 BP 967 EP 974 DI 10.1185/030079908X280464 PG 8 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 293NJ UT WOS:000255341700004 PM 18282373 ER PT J AU Goldfine, AB AF Goldfine, Allison B. TI The rough road for rosiglitazone SO CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY LA English DT Review DE cardiovascular disease; ischemic heart disease; rosiglitazone; type 2 diabetes AB Purpose of review Rosiglitazone is effective in lowering blood sugars in patients with type 2 diabetes and may be expected to reduce microvascular complications associated with hyperglycemia. Whereas preliminary studies using surrogate outcomes for cardiovascular disease have suggested the potential for cardioprotective effects, the drug is associated with fluid retention and increased risk of congestive heart failure. Long-term cardiovascular safety remains incompletely understood. In this review the potential for increased ischemic cardiovascular risk associated with rosiglitazone use is discussed. Recent findings Meta-analysis of patients participating in controlled clinical trials suggests increased risk of cardiovascular events for patients using rosiglitazone. Considering only clinical trials in patients with type 2 diabetes with patient-level data, a double-masked, randomized design, and using approved doses of rosiglitazone, independent meta-analysis shows that cardiovascular event rates are low, and suggests that increased ischemic cardiovascular risk may be particularly manifest in subgroups of patients with type 2 diabetes who are using nitrates or insulin. Summary There continues to be uncertainty about the risk of ischemic heart disease in patients with type 2 diabetes associated with the use of rosiglitazone. Caution should be used in patients with underlying heart disease using nitrates, and when added to ongoing insulin-based therapy. C1 [Goldfine, Allison B.] Joslin Diabet Ctr, Boston, MA 02215 USA. [Goldfine, Allison B.] Harvard Univ, Sch Med, Boston, MA USA. RP Goldfine, AB (reprint author), Joslin Diabet Ctr, 1 Joslin Pl, Boston, MA 02215 USA. EM allison.goldfine@joslin.harvard.edu FU GlaxoSmithKline FX Dr Goldfine participated in the Joint Meeting of the Endocrine and Metabolic Drugs Advisory Committee and Drug Safety Risk Management Advisory Committee, 30 July 2007. All opinions expressed in this article do not necessarily reflect those of the other members of either the advisory panel or the US Food and Drug Administration. Dr Goldfine may receive funds from GlaxoSmithKline or other pharmaceutical companies in mutual and managed fund accounts. NR 18 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1752-296X J9 CURR OPIN ENDOCRINOL JI Curr. Opin. Endocrinol. Diabetes Obes. PD APR PY 2008 VL 15 IS 2 BP 113 EP 117 DI 10.1097/MED.0b013e3282f8b483 PG 5 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA V14SS UT WOS:000207754700001 PM 18316944 ER PT J AU Mendenhall, EM Bernstein, BE AF Mendenhall, Eric M. Bernstein, Bradley E. TI Chromatin state maps: new technologies, new insights SO CURRENT OPINION IN GENETICS & DEVELOPMENT LA English DT Review ID EMBRYONIC STEM-CELLS; WHOLE-GENOME ANALYSIS; DEVELOPMENTAL REGULATORS; HISTONE-H3 LYSINE-4; NONCODING RNAS; PHD FINGER; METHYLATION; POLYCOMB; DNA; TRANSCRIPTION AB Recent years have seen unprecedented characterization of mammalian chromatin thanks to advances in chromatin assays, antibody development, and genomics. Genome-wide maps of chromatin state can now be readily acquired using microarrays or next-generation sequencing technologies. These datasets reveal local and long-range chromatin patterns that offer insight into the locations and functions of underlying regulatory elements and genes. These patterns are dynamic across developmental stages and lineages. Global studies of chromatin in embryonic stem cells have led to intriguing hypotheses regarding Polycomb/trithorax and RNA polymerase roles in 'poising' transcription. Chromatin state maps thus provide a rich resource for understanding chromatin at a 'systems level', and a starting point for mechanistic studies aimed at defining epigenetic controls that underlie development. C1 [Mendenhall, Eric M.; Bernstein, Bradley E.] Massachusetts Gen Hosp, Mol Pathol Unit, Charlestown, MA 02129 USA. [Mendenhall, Eric M.; Bernstein, Bradley E.] Massachusetts Gen Hosp, Ctr Canc Res, Charlestown, MA 02129 USA. [Mendenhall, Eric M.; Bernstein, Bradley E.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. [Mendenhall, Eric M.; Bernstein, Bradley E.] Broad Inst Harvard, Cambridge, MA USA. [Mendenhall, Eric M.; Bernstein, Bradley E.] MIT, Cambridge, MA 02139 USA. RP Bernstein, BE (reprint author), Massachusetts Gen Hosp, Mol Pathol Unit, Charlestown, MA 02129 USA. EM bbernstein@partners.org OI Mendenhall, Eric/0000-0002-7395-6295 FU NHGRI NIH HHS [U54 HG004570, U54 HG004570-01] NR 49 TC 51 Z9 52 U1 0 U2 11 PU CURRENT BIOLOGY LTD PI LONDON PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND SN 0959-437X J9 CURR OPIN GENET DEV JI Curr. Opin. Genet. Dev. PD APR PY 2008 VL 18 IS 2 BP 109 EP 115 DI 10.1016/j.gde.2008.01.010 PG 7 WC Cell Biology; Genetics & Heredity SC Cell Biology; Genetics & Heredity GA 321BT UT WOS:000257279900002 PM 18339538 ER PT J AU Rajewsky, K von Boehmer, H AF Rajewsky, Klaus von Boehmer, Harald TI Editorial overview: Lymphocyte development SO CURRENT OPINION IN IMMUNOLOGY LA English DT Editorial Material C1 [Rajewsky, Klaus] Harvard Univ, Sch Med, CBR Inst Biomed Res, Boston, MA 02115 USA. [von Boehmer, Harald] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. RP Rajewsky, K (reprint author), Harvard Univ, Sch Med, CBR Inst Biomed Res, 200 Longwood Ave, Boston, MA 02115 USA. EM rajewsky@cbr.med.harvard.edu FU NCI NIH HHS [P01 CA092625, P01 CA092625-068736, R01 CA098285, R01 CA098285-05]; NIAID NIH HHS [P01 AI052343, P01 AI052343-050002, R01 AI057947, R01 AI057947-05, R01 AI064345, R01 AI064345-04, R37 AI054636, R37 AI054636-06] NR 0 TC 6 Z9 6 U1 0 U2 3 PU CURRENT BIOLOGY LTD PI LONDON PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND SN 0952-7915 J9 CURR OPIN IMMUNOL JI Curr. Opin. Immunol. PD APR PY 2008 VL 20 IS 2 BP 127 EP 130 DI 10.1016/j.coi.2008.04.005 PG 4 WC Immunology SC Immunology GA 323FB UT WOS:000257428600001 PM 18513936 ER PT J AU Allman, D Pillai, S AF Allman, David Pillai, Shiv TI Peripheral B cell subsets SO CURRENT OPINION IN IMMUNOLOGY LA English DT Review ID TOLL-LIKE RECEPTORS; MARGINAL-ZONE; BONE-MARROW; INDEPENDENT RESPONSES; POSITIVE SELECTION; SURVIVAL SIGNALS; DENDRITIC CELLS; T-CELLS; LYMPHOCYTES; SPLEEN AB Our understanding of the origins and the biological functions of different peripheral B cell subsets continues to evolve. Some understanding has been obtained regarding the synergy between BCR-derived signals and other receptors and signaling pathways that drive the development of follicular, marginal zone, and B-1 B cells, but this remains a complex and poorly understood issue. More recent information regarding the origins of B-1 and B-2 B cells, the ability of follicular B cells to mature both in the bone marrow and the spleen, the existence of a definable precursor for MZ B cells, and the ability of follicular B cells to occupy two distinct niches are all highlighted in this review. C1 [Allman, David] Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA. [Pillai, Shiv] Massachusetts Gen Hosp, Ctr Canc Res, Boston, MA 02129 USA. [Pillai, Shiv] Harvard Univ, Sch Med, Boston, MA 02129 USA. RP Allman, D (reprint author), Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA. EM dallman@mail.med.upenn.edu; pillai@helix.mgh.harvard.edu FU NIAID NIH HHS [R21 AI057486, R01 AI064930, R01 AI064930-03, R21 AI057486-01] NR 54 TC 196 Z9 201 U1 0 U2 15 PU CURRENT BIOLOGY LTD PI LONDON PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND SN 0952-7915 J9 CURR OPIN IMMUNOL JI Curr. Opin. Immunol. PD APR PY 2008 VL 20 IS 2 BP 149 EP 157 DI 10.1016/j.coi.2008.03.014 PG 9 WC Immunology SC Immunology GA 323FB UT WOS:000257428600004 PM 18434123 ER PT J AU Kathiresan, S Musunuru, K Orho-Melander, M AF Kathiresan, Sekar Musunuru, Kiran Orho-Melander, Marju TI Defining the spectrum of alleles that contribute to blood lipid concentrations in humans SO CURRENT OPINION IN LIPIDOLOGY LA English DT Review DE complex trait genetics; genome-wide association; HDL cholesterol; LDL cholesterol; single nucleotide polymorphism; triglycerides ID GENOME-WIDE ASSOCIATION; DENSITY-LIPOPROTEIN CHOLESTEROL; CASSETTE TRANSPORTER 1; TANGIER-DISEASE; NONFASTING TRIGLYCERIDES; CARDIOVASCULAR RISK; GENERAL-POPULATION; LDL CHOLESTEROL; HDL CHOLESTEROL; HEART-DISEASE AB Purpose of review Recently, genome-wide genetic screening of common DNA sequence variants has proven a successful approach to identify novel genetic contributors to complex traits. This review summarizes recent genome-wide association studies for lipid phenotypes, and evaluates the next steps needed to obtain a full picture of genotype-phenotype correlation and apply these findings to inform clinical practice. Recent findings So far, genome-wide association studies have defined at least 19 genomic regions that contain common DNA single nucleotide polymorphisms associated with LDL cholesterol, HDL cholesterol and/or triglycerides. Of these, eight represent novel loci in humans, whereas 11 genes have been previously implicated in lipoprotein metabolism. Many of the same loci with common variants have already been shown to lead to monogenic lipid disorders in humans and/or mice, suggesting that a spectrum of common and rare alleles at each validated locus contributes to blood lipid concentrations. Summary At least 19 loci harbor common variations that contribute to blood lipid concentrations in humans. Larger scale genome-wide association studies should identify additional loci, and sequencing of these loci should pinpoint all relevant alleles. With a full catalog of DNA polymorphisms in hand, a panel of lipid-related variants can be studied to provide clinical risk stratification and targeting of therapeutic interventions. C1 [Kathiresan, Sekar] Massachusetts Gen Hosp, Div Cardiol, Cardiovasc Dis Prevent Ctr, Boston, MA 02114 USA. [Musunuru, Kiran] Johns Hopkins Ciccarone Prevent Cardiol Ctr, Baltimore, MD USA. [Orho-Melander, Marju] Dept Clin Sci Diabetes & Endocrinol, S-20502 Malmo, Sweden. [Orho-Melander, Marju] Lund Univ Malmo, Univ Hosp Malmo, Dept Clin Sci Diabetes & Endocrinol, Lund, Sweden. RP Kathiresan, S (reprint author), Massachusetts Gen Hosp, Div Cardiol, Cardiovasc Dis Prevent Ctr, 25 New Chardon St,Suite 301, Boston, MA 02114 USA. EM skathiresan@partners.org; marju.orho-melander@med.lu.se NR 55 TC 34 Z9 34 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0957-9672 J9 CURR OPIN LIPIDOL JI Curr. Opin. Lipidology PD APR PY 2008 VL 19 IS 2 BP 122 EP 127 PG 6 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Peripheral Vascular Disease SC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Cardiovascular System & Cardiology GA 281AS UT WOS:000254469100004 PM 18388691 ER PT J AU Surman, OS Saidi, R Burke, TF AF Surman, Owen S. Saidi, Reza Burke, Thomas F. TI Regulating the sale of human organs: a discussion in context with the global market SO CURRENT OPINION IN ORGAN TRANSPLANTATION LA English DT Review DE ethics; human trafficking; organs; policy; transplantation ID UNRELATED KIDNEY DONORS; RENAL-TRANSPLANTATION; LIVER-TRANSPLANTATION; DONATION; CHINA; INCENTIVES; SYSTEM AB Purpose of review Insufficient availability of human organs for transplantation has given rise to a flourishing global market. This review addresses current thinking and practical considerations regarding legalization of organ sales. Recent findings Increasing competition for human organs has led to egregious human rights violations. Governmental proscription of organ sales has failed to slow this process. Organ sales in China and the regulated market in Iran have received much attention. Some believe that a regulated market is an ethical vehicle for shortening waiting lists and decreasing illegal organ sales. Others consider it a blow to human dignity and to altruistic donation. There is alternative support toward reimbursing living donors for their financial losses. The World Health Organization advocates increased reliance on cadaver donor transplantation. Some countries have enacted presumed consent laws that have increased cadaver organ donation. In the USA an Organ Breakthrough Collaborative has generated comparable success. Summary Serious discussion continues with regard to regulated sale of human organs. There is increased interest in reimbursement for living organ donation. Research is needed to elucidate workings of the global organ market, and to assess attitudes about stakeholders with regard to proposed changes in transplantation policy. C1 Massachusetts Gen Hosp, Dept Psychiat, Transplant Serv, Wang Ambulatory Care Ctr, Boston, MA 02114 USA. Massachusetts Gen Hosp, Ctr Global Hlth, Boston, MA 02114 USA. RP Surman, OS (reprint author), Massachusetts Gen Hosp, Dept Psychiat, Transplant Serv, Wang Ambulatory Care Ctr, Suite 815,15 Parkman St, Boston, MA 02114 USA. EM osurman@partners.org NR 48 TC 3 Z9 3 U1 0 U2 12 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1087-2418 J9 CURR OPIN ORGAN TRAN JI Curr. Opin. Organ Transpl. PD APR PY 2008 VL 13 IS 2 BP 196 EP 201 PG 6 WC Transplantation SC Transplantation GA 281MZ UT WOS:000254503000013 PM 18685303 ER PT J AU Newton, AW Vandeven, AM AF Newton, Alice W. Vandeven, Andrea M. TI Update on child maltreatment SO CURRENT OPINION IN PEDIATRICS LA English DT Review DE child abuse; child maltreatment; child sexual abuse; neglect; shaken baby syndrome; traumatic brain injury ID SHAKEN BABY SYNDROME; HEAD TRAUMA; FRACTURE-DISLOCATION; GENITAL INJURIES; ADOLESCENT GIRLS; BRAIN-INJURY; ABUSE; HEALTH; IDENTIFICATION; HEMORRHAGES AB Purpose of review The authors discuss the significance of studies published over the previous year regarding assessment and treatment and prevention of child maltreatment, including physical and sexual abuse, inflicted traumatic brain injury, and child neglect. Recent findings The evidence base for many forms of child abuse is growing. As clinicians begin to understand the factors which may increase child vulnerability to abuse, more sophisticated and focused prevention efforts are being implemented. In response to a very public reprimand by the General Medical Council of two child abuse pediatricians, which was felt by many to be unwarranted, the UK government re-emphasized its commitment to the protection of children. In the US, this well-publicized set of events has renewed the medical community's commitment to the recognition of child abuse pediatrics as a formal subspecialty. Several authors detail the short-term and long-term outcome of varying forms of abuse for children as they grow into adults, reinforcing the importance of community efforts to prevent abuse and support families during times of heightened stress such as the current war in Iraq. Summary The short-term and long-term impact of child maltreatment is significant not only for individuals, but for families and communities where abuse is taking place. General pediatricians have an important role to play with families and in the community as advocates for the protection of children. C1 [Newton, Alice W.] Harvard Univ, Sch Med,Massachusetts Gen Hosp, Dept Pediat,Child Protect Consultat Program, Child Protect Program,Childrens Hosp, Boston, MA 02115 USA. [Vandeven, Andrea M.] Univ Missouri, Dept Pediat, CARE Program, Childrens Mercy Hosp, Kansas City, MO 64110 USA. RP Newton, AW (reprint author), Childrens Hosp, Child Protect Program, 300 Longwood Ave, Boston, MA 02115 USA. EM alice.newton@childrens.harvard.edu NR 50 TC 7 Z9 8 U1 5 U2 10 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1040-8703 J9 CURR OPIN PEDIATR JI CURR. OPIN. PEDIATR. PD APR PY 2008 VL 20 IS 2 BP 205 EP 212 DI 10.1097/MOP.0b013e3282f6a4d8 PG 8 WC Pediatrics SC Pediatrics GA 285RC UT WOS:000254792900017 PM 18332719 ER PT J AU Modi, S Rosen, T AF Modi, Sapna Rosen, Ted TI Micropapular cutaneous sarcoidosis: Case series successfully managed with hydroxychloroquine sulfate SO CUTIS LA English DT Article ID CHILDREN AB Micropapular lesions constitute a rare morphologic variety of cutaneous sarcoidosis. We report 3 patients with this unusual entity and highlight the universal suppressive response to oral hydroxy-chloroquine sulfate. Although ocular involvement has been found to be common in conjunction with micropapular cutaneous sarcoidosis, none of our patients had demonstrable eye disease. C1 Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. RP Modi, S (reprint author), Baylor Coll Med, Dept Dermatol, Houston, TX 77030 USA. NR 12 TC 3 Z9 3 U1 0 U2 0 PU QUADRANT HEALTHCOM INC PI PARSIPPANY PA 7 CENTURY DRIVE, STE 302, PARSIPPANY, NJ 07054-4603 USA SN 0011-4162 J9 CUTIS JI Cutis PD APR PY 2008 VL 81 IS 4 BP 351 EP 354 PG 4 WC Dermatology SC Dermatology GA 291YF UT WOS:000255232700011 PM 18491485 ER PT J AU Goldsmith, B Morrison, RS Vanderwerker, LC Prigerson, HG AF Goldsmith, B. Morrison, R. S. Vanderwerker, L. C. Prigerson, H. G. TI Elevated rates of Prolonged Grief Disorder in African Americans SO DEATH STUDIES LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; BEREAVEMENT-RELATED DEPRESSION; CONFIRMATORY FACTOR-ANALYSIS; HEALTH-SERVICE USE; COMPLICATED GRIEF; MENTAL-HEALTH; PSYCHIATRIC-DISORDERS; TRAUMATIC GRIEF; DSM-V; DISTINCT AB The prevalence of Prolonged Grief Disorder (PGD) in non-Whites is currently unknown. This study was performed to explore the prevalence of PGD in African Americans (AAs). Multivariable analysis of two studies of recently bereaved individuals found AAs to have significantly higher rates of PGD than Whites (21% [14 of 66] vs. 12% [55 of 471], respectively; p=0.03). Experiencing a loved one's death as sudden or unexpected was also significantly associated with PGD over and above the effects of race/ethnicity. AAs may be at increased risk for the development of PGD. The development of effective interventions to treat PGD highlights the need to identify high-risk individuals and refer them to therapy and suggests the potential need for such therapies to adopt culturally sensitive approaches to care. C1 [Goldsmith, B.; Morrison, R. S.] Mt Sinai Sch Med, Brookdale Dept Geriatr & Adult Dev, Herztberg Palliat Care Inst, New York, NY USA. [Vanderwerker, L. C.; Prigerson, H. G.] Brigham & Womens Hosp, Dana Farber Canc Inst, Ctr Psychooncol & Palliat Care Res, Boston, MA 02115 USA. [Vanderwerker, L. C.; Prigerson, H. G.] Brigham & Womens Hosp, Dept Psychiat, Boston, MA 02115 USA. [Prigerson, H. G.] Harvard Univ, Sch Med, Ctr Palliat Care, Boston, MA USA. RP Morrison, RS (reprint author), Mt Sinai Sch Med, Dept Geriatr, Box 1070, New York, NY 10029 USA. EM sean.morrison@mssm.edu FU NCI NIH HHS [CA106370, R01 CA106370]; NIA NIH HHS [K24-AG022345]; NIMH NIH HHS [MH56529, MH63892] NR 33 TC 36 Z9 39 U1 3 U2 3 PU BRUNNER/MAZEL INC PI BRISTOL PA 1900 FROST RD, STE 101, BRISTOL, PA 19007-1598 USA SN 0748-1187 J9 DEATH STUD JI Death Stud. PD APR PY 2008 VL 32 IS 4 BP 352 EP 365 DI 10.1080/07481180801929012 PG 14 WC Psychology, Multidisciplinary; Social Issues; Social Sciences, Biomedical SC Psychology; Social Issues; Biomedical Social Sciences GA 289OD UT WOS:000255062900003 PM 18850684 ER PT J AU Del Rossi, G Lisman, P Signorile, J AF Del Rossi, Gianluca Lisman, Peter Signorile, Joseph TI Fabricating a better mouthguard. Part II: The effect of color on adaptation and fit SO DENTAL TRAUMATOLOGY LA English DT Article ID PLAYERS AB The thermoforming process involves the heating of plastic sheets to a critical temperature followed by the shaping of the heated material into a three-dimensional structure. Given that custom-fabricated mouthguards are produced using the thermoforming process, the adaptation of plastic sheets to a stone model of the dentition is likely to be affected by the ability of the mouthguard material to be heated. The purpose of this study was to establish if material color affected the adaptation and fit of custom-made mouthguards. Twelve stone models were used in this investigation. Five mouthguards were produced using each model. These mouthguards were made using clear-, white-, black-, blue- and green-colored ethyl vinyl acetate. The force required to remove the various colored mouthguards from the corresponding stone models was determined using a strain gauge housed within a specially designed apparatus. Each of the mouthguards were tested three times at two different angles of pull -45 degrees and 90 degrees. Statistical tests performed using the average amount of force required for mouthguard removal revealed an angle by color interaction. Post hoc analyses revealed that the mean force required to remove the clear-colored mouthguards from their respective stone models was significantly less than the force required to pull away blue-, black- and green-colored mouthguards. This difference between clear- and dark-colored mouthguards was observed at both angles tested with the exception of the black mouthguard which differed from the clear-colored mouthguard only when removed at an angle of 90 degrees. The results of the present study indicate that by using dark-colored mouthguard material, one can achieve superior adaptation and thus produce a more firmly fitting mouthguard. C1 [Del Rossi, Gianluca] Univ S Florida, Coll Med, Dept Orthopaed & Sports Med, Athelet Training Educ Program, Tampa, FL 33612 USA. [Lisman, Peter; Signorile, Joseph] Univ Miami, Dept Exercise & Sport Sci, Coral Gables, FL 33124 USA. [Signorile, Joseph] US Dept Vet Affairs, Ctr Geriatr Res Educ & Clin, Miami, FL USA. RP Del Rossi, G (reprint author), Univ S Florida, Coll Med, Dept Orthopaed & Sports Med, Athelet Training Educ Program, 3500 E,Fletcher Ave,Suite 511, Tampa, FL 33612 USA. EM gdelross@health.usf.edu RI Del Rossi, Gianluca/I-4963-2012 NR 8 TC 13 Z9 13 U1 0 U2 1 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1600-4469 J9 DENT TRAUMATOL JI Dent. Traumatol. PD APR PY 2008 VL 24 IS 2 BP 197 EP 200 DI 10.1111/j.1600-9657.2007.00570.x PG 4 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 277CU UT WOS:000254191100010 PM 18352924 ER PT J AU Loscertales, M Mikels, AJ Hu, JKH Donahoe, PK Roberts, DJ AF Loscertales, Maria Mikels, Amanda J. Hu, Jimmy Kuang-Hsein Donahoe, Patricia K. Roberts, Drucilla J. TI Chick pulmonary Wnt5a directs airway and vascular tubulogenesis SO DEVELOPMENT LA English DT Article DE lung development; Wnt5a; Shh; fibronectin; Ror2; VEGF; Flk1 ID MOUSE EMBRYONIC LUNG; REPLICATION-COMPETENT RETROVIRUSES; REGULATES BRANCHING-MORPHOGENESIS; CONGENITAL DIAPHRAGMATIC-HERNIA; CELLS IN-VITRO; SONIC-HEDGEHOG; ENDOTHELIAL-CELLS; SIGNALING PATHWAY; MOLECULAR-MECHANISMS; EXPRESSION AB Wnt5a is an important factor patterning many aspects of early development, including the lung. We find pulmonary non-canonical Wnt5a uses Ror2 to control patterning of both distal air and vascular tubulogenesis (alveolarization). Lungs with mis/overexpressed Wnt5a develop with severe pulmonary hypoplasia associated with altered expression patterns of Shh, L-CAM, fibronectin, VEGF and Flk1. This hypoplastic phenotype is rescued by either replacement of the Shh protein or inhibition of fibronectin function. We find that the effect of Wnt5a on vascular patterning is likely to be through fibronectin-mediated VEGF signaling. These results demonstrate the pivotal role of Wnt5a in directing the essential coordinated development of pulmonary airway and vasculature, by affecting fibronectin levels directly, and by affecting the fibronectin pattern of expression through its regulation of Shh. Data herein suggest that Wnt5a functions in mid-pulmonary patterning (during alveolarization), and is distinct from the Wnt canonical pathway which is more important in earlier lung development. C1 [Loscertales, Maria; Donahoe, Patricia K.; Roberts, Drucilla J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Surg,Pediat Surg Res Labs, Boston, MA 02114 USA. [Mikels, Amanda J.] Stanford Univ, Sch Med, Dept Dev Biol, Stanford, CA 94305 USA. [Hu, Jimmy Kuang-Hsein] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA. [Roberts, Drucilla J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pathol, Boston, MA 02114 USA. RP Roberts, DJ (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Surg,Pediat Surg Res Labs, 185 Cambridge St, Boston, MA 02114 USA. EM djroberts@partners.org RI Congregado, Miguel/B-9062-2009 OI Congregado, Miguel/0000-0002-2404-0176 FU NICHD NIH HHS [HD055150, HD39942, T32HD007396-16] NR 81 TC 32 Z9 33 U1 0 U2 0 PU COMPANY OF BIOLOGISTS LTD PI CAMBRIDGE PA BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE CB4 4DL, CAMBS, ENGLAND SN 0950-1991 J9 DEVELOPMENT JI Development PD APR 1 PY 2008 VL 135 IS 7 BP 1365 EP 1376 DI 10.1242/dev.010504 PG 12 WC Developmental Biology SC Developmental Biology GA 287LB UT WOS:000254917500016 PM 18305003 ER PT J AU Insinna, C Pathak, N Perkins, B Drummond, I Besharse, JC AF Insinna, Christine Pathak, Narendra Perkins, Brian Drummond, Iain Besharse, Joseph C. TI The homodimeric kinesin, Kif17, is essential for vertebrate photoreceptor sensory outer segment development SO DEVELOPMENTAL BIOLOGY LA English DT Article DE Kifl7; photoreceptors; cilia; ciliogenesis; IFT; zebrafish ID MOTOR PROTEIN KIF17; INTRAFLAGELLAR TRANSPORT; PRIMARY CILIUM; C-ELEGANS; CAENORHABDITIS-ELEGANS; SUBUNIT; NEURONS; LOCALIZATION; MEMBRANE; KNOCKOUT AB Sensory cilia and intraflagellar transport (IFT), a pathway essential for ciliogenesis, play important roles in embryonic development and cell differentiation. In vertebrate photoreceptors IFT is required for the early development of ciliated sensory outer segments (OS), an elaborate organelle that sequesters the many proteins comprising the phototransduction machinery. As in other cilia and flagella, heterotrimeric members of the kinesin 2 family have been implicated as the anterograde IFT motor in OS. However, in Caenorhabditis elegans, OSM-3, a homodimeric kinesin 2 motor, plays an essential role in some, but not all sensory cilia. Kif17, a vertebrate OSM-3 homologue, is known for its role in dendritic trafficking in neurons, but a function in ciliogenesis has not been determined. We show that in zebrafish Kif17 is widely expressed in the nervous system and retina. In photoreceptors Kif17 co-localizes with IFT proteins within the OS, and co-immunoprecipitates with IFT proteins. Knockdown of Kif17 has little if any effect in early embryogenesis, including the formation of motile sensory cilia in the pronephros. However, OS formation and targeting of the visual pigment protein is severely disrupted. Our analysis shows that Kif17 is essential for photoreceptor OS development, and suggests that Kif17 plays a cell type specific role in vertebrate ciliogenesis. (C) 2008 Elsevier Inc. All rights reserved. C1 [Insinna, Christine; Besharse, Joseph C.] Med Coll Wisconsin, Dept Cell Biol Neurobiol & Anat, Milwaukee, WI 53226 USA. [Pathak, Narendra; Drummond, Iain] Massachusetts Gen Hosp, Div Nephrol, Charlestown, MA 02129 USA. [Pathak, Narendra; Drummond, Iain] Harvard Univ, Sch Med, Dept Med, Charlestown, MA 02129 USA. [Perkins, Brian] Coll Sci, Dept Biol, College Stn, TX 77843 USA. RP Besharse, JC (reprint author), Med Coll Wisconsin, Dept Cell Biol Neurobiol & Anat, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA. EM jbeshars@mcw.edu FU NCRR NIH HHS [S10 RR015679-01]; NEI NIH HHS [P30 EY001931, EY017037, EY03222, R01 EY003222, R01 EY003222-27, R01 EY017037, R01 EY017037-02, T32 EY014537, T32 EY014537-05, T32-EY014537]; NIDDK NIH HHS [DK53093, R01 DK053093, T32 DK007540, T32-DK007540] NR 31 TC 82 Z9 83 U1 0 U2 3 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0012-1606 J9 DEV BIOL JI Dev. Biol. PD APR 1 PY 2008 VL 316 IS 1 BP 160 EP 170 DI 10.1016/j.ydbio.2008.01.025 PG 11 WC Developmental Biology SC Developmental Biology GA 286KQ UT WOS:000254845200014 PM 18304522 ER PT J AU Moriyama, M Durham, AD Moriyama, H Hasegawa, K Nishikawa, SI Radtke, F Osawa, M AF Moriyama, Mariko Durham, Andre-Dante Moriyama, Hiroyuki Hasegawa, Kiyotaka Nishikawa, Shin-Ichi Radtke, Freddy Osawa, Masatake TI Multiple roles of notch signaling in the regulation of epidermal development SO DEVELOPMENTAL CELL LA English DT Article ID STEM-CELLS; DIFFERENTIATION; TRANSCRIPTION; COMMITMENT; EXPRESSION; SWITCH; LEADS; LOOP; P63 AB Recent studies have shown that Notch signaling plays an important role in epidermal development, but the underlying molecular mechanisms remain unclear. Here, by integrating loss- and gain -of-function studies of Notch receptors and Hes1, we describe molecular information about the role of Notch signaling in epidermal development. We show that Notch signaling determines spinous cell fate and induces terminal differentiation by a mechanism independent of Hes1, but Hes1 is required for maintenance of the immature state of spinous cells. Notch signaling induces Ascl2 expression to promote terminal differentiation, while simultaneously repressing Ascl2 through Hes1 to inhibit premature terminal differentiation. Despite the critical role of Hes1 in epidermal development, Hes1 null epidermis transplanted to adult mice showed no obvious defects, suggesting that this role of Hes1 may be restricted to developmental stages. Overall, we conclude that Notch signaling orchestrates the balance between differentiation and immature programs in suprabasal cells during epidermal development. C1 [Moriyama, Mariko; Moriyama, Hiroyuki; Hasegawa, Kiyotaka; Osawa, Masatake] Massachusetts Gen Hosp East, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA. Massachusetts Gen Hosp East, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA. [Moriyama, Mariko; Moriyama, Hiroyuki; Hasegawa, Kiyotaka; Osawa, Masatake] Harvard Med Sch, Charlestown, MA 02129 USA. [Nishikawa, Shin-Ichi; Osawa, Masatake] Ecole Polytech Fed Lausanne, ISREC, Swiss Inst Expt Canc Res, CH-1066 Epalinges, Switzerland. RP Osawa, M (reprint author), Massachusetts Gen Hosp East, Cutaneous Biol Res Ctr, Bldg 149,13th St, Charlestown, MA 02129 USA. EM masatake.osawa@cbrc2.mgh.harvard.edu NR 13 TC 69 Z9 72 U1 0 U2 8 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 1534-5807 J9 DEV CELL JI Dev. Cell PD APR PY 2008 VL 14 IS 4 BP 594 EP 604 DI 10.1016/j.devcel.2008.01.017 PG 11 WC Cell Biology; Developmental Biology SC Cell Biology; Developmental Biology GA 289HR UT WOS:000255046100018 PM 18410734 ER PT J AU Martinez-Monedero, R Yi, EY Oshima, K Glowatzki, E Edge, ASB AF Martinez-Monedero, Rodrigo Yi, Eunyoung Oshima, Kazuo Glowatzki, Elisabeth Edge, Albert S. B. TI Differentiation of inner ear stem cells to functional sensory neurons SO DEVELOPMENTAL NEUROBIOLOGY LA English DT Article DE neural progenitor; sodium current; regeneration; deafness; auditory; spiral ganglion ID SPIRAL GANGLION NEURONS; RETINOIC ACID SYNTHESIS; NEURAL CREST STEM; RAT SPINAL-CORD; STEM/PROGENITOR CELLS; FATE SPECIFICATION; VESTIBULAR NEURONS; PROGENITOR CELLS; MUTANT MICE; HAIR-CELLS AB inner ear stem cells can be isolated by neurosphere formation from the vestibular organs and the cochlea. The cells are pluripotent, with the potential to become hair cells and neurons, the cochlear cell types whose loss causes deafness. Here we describe the control of cell fate decisions that determine the phenotype adopted by these progenitors, and we determine whether differentiation to sensory neurons is preferred over other types of neurons. Differentiation of progenitor cells recapitulated developmental pathways of embryonic sensory neurons. Based on marker expression, retinoic acid increased the yield of neurons and the percentage of sensory neurons obtained and caused a sharp increase in Pax2, a key transcription factor of cranial placodes. Markers of embryonic auditory and other sensory neurons, GATA3, Brn3a, and islet1, could be detected after 3 days of differentiation of the cells, and markers of the sensory phenotype, peripherin, calretinin, TrkC, and TrkB were expressed after 10 days. The differentiated cells had tetrodotoxin-sensitive sodium currents and fired action potentials, and recordings revealed functional AMPA type-glutamate receptors, further indicating that these cells had developed neuronal features. Neurons differentiated from these stem cells grew processes to hair cells in vitro. Development of functional activity in cells with the markers of sensory neurons suggested that the inner ear stem cells might have the capacity to replace cells lost due to neural degeneration. (C) 2008 Wiley Periodicals, Inc. C1 [Martinez-Monedero, Rodrigo; Oshima, Kazuo; Edge, Albert S. B.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA. [Martinez-Monedero, Rodrigo; Oshima, Kazuo; Edge, Albert S. B.] Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, Boston, MA 02114 USA. [Yi, Eunyoung; Glowatzki, Elisabeth] Johns Hopkins Sch Med, Dept Otolaryngol Head & Neck Surg, Baltimore, MD USA. [Edge, Albert S. B.] Harvard & MIT, Program Speech & Hearing Biosci & Technol, Div Hlth Sci & Technol, Cambridge, MA 02139 USA. RP Edge, ASB (reprint author), Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA. EM albert_edge@meei.harvard.edu FU NIDCD NIH HHS [R01 DC006476, R01 DC007174, P30 DC05209] NR 57 TC 52 Z9 54 U1 0 U2 4 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1932-8451 J9 DEV NEUROBIOL JI Dev. Neurobiol. PD APR PY 2008 VL 68 IS 5 BP 669 EP 684 DI 10.1002/dneu.20616 PG 16 WC Developmental Biology; Neurosciences SC Developmental Biology; Neurosciences & Neurology GA 287AE UT WOS:000254887800009 PM 18278797 ER PT J AU Mather, KJ Funahashi, T Matsuzawa, Y Edelstein, S Bray, GA Kahn, SE Crandall, J Marcovina, S Goldstein, B Goldberg, R AF Mather, Kieren J. Funahashi, Tohru Matsuzawa, Yuji Edelstein, Sharon Bray, George A. Kahn, Steven E. Crandall, Jill Marcovina, Santica Goldstein, Barry Goldberg, Ronald CA Diabet Prevention Program TI Adiponectin, change in adiponectin, and progression to diabetes in the Diabetes Prevention Program SO DIABETES LA English DT Article ID LIFE-STYLE INTERVENTION; INSULIN-RESISTANCE; METABOLIC SYNDROME; JAPANESE POPULATION; PLASMA ADIPONECTIN; METFORMIN; RISK; SENSITIVITY; GLUCOSE; RECEPTORS AB OBJECTIVE - To determine whether baseline adiponectin levels or intervention-associated change in adiponectin levels were independently associated with progression to diabetes in the Diabetes Prevention Program (DPP). RESEARCH DESIGN AND METHODS - Cox proportional hazards analysis was used to evaluate the contribution of adiponectin and treatment-related change in adiponectin to risk of progression to diabetes. RESULTS-Baseline adiponectin was a strong independent predictor of incident diabetes in all treatment groups (hazard ratio per similar to 3 mu g/ml higher level; 0.61 in the lifestyle, 0.76 in the metformin, and the 0.79 in placebo groups; all P < 0.001, P = 0.13 comparing groups). Baseline differences in adiponectin between sexes and race/ethnicity groups were not reflected in differences in diabetes risk. DPP interventions increased adiponectin levels ([means +/- SE] 0.83 +/- 0.05 mu g/ml in the lifestyle group, 0.23 +/- 0.05 mu g/ml in the metformin group, and 0.10 +/- 0.05 mu g/ml in the placebo group; P < 0.001 for increases versus baseline, P < 0.01 comparing groups). These increases were associated with reductions in diabetes incidence independent of baseline adiponectin levels in the lifestyle and placebo groups but not in the metformin subjects (hazard ratio 0.72 in the lifestyle group (P < 0.001), 0.92 in the metformin group (P = 0.18), and 0.89 in the placebo group; P = 0.02 per similar to 1 mu g/ml increase, P = 0.02 comparing groups). In the lifestyle group, adjusting for change in weight reduced, but did not remove, the effect of increased adiponectin. CONCLUSIONS-Adiponectin is a powerful marker of diabetes risk in subjects at high risk for diabetes, even after adjustment for weight. An increase in adiponectin in the lifestyle and placebo groups was associated with a reduction in diabetes risk. However, these changes in adiponectin were comparatively small and less strongly related to diabetes outcome than baseline adiponectin levels. C1 [Edelstein, Sharon] George Washington Univ, Ctr Biostat, Diabet Prevent Program Coordinating Ctr, Rockville, MD 20852 USA. [Mather, Kieren J.] Indiana Univ, Sch Med, Div Endocrinol & Metab, Indianapolis, IN USA. [Funahashi, Tohru; Matsuzawa, Yuji] Osaka Univ, Dept Internal Med & Mol Sci, Osaka, Japan. [Bray, George A.] Louisiana State Univ, Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA. [Kahn, Steven E.] Univ Washington, Seattle, WA 98195 USA. [Kahn, Steven E.] VA Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA. [Crandall, Jill] Albert Einstein Coll Med, Diabet Res Ctr, Bronx, NY 10467 USA. [Goldstein, Barry] Univ Washington, NW Lipid Metab & Diabet Res Labs, Seattle, WA 98195 USA. [Goldstein, Barry] Thomas Jefferson Univ, Jefferson Med Coll, Div Endocrinol Diabet & Metab Dis, Philadelphia, PA USA. [Goldberg, Ronald] Univ Miami, Sch Med, Diabet Res Inst, Miami, FL USA. RP Mather, KJ (reprint author), George Washington Univ, Ctr Biostat, Diabet Prevent Program Coordinating Ctr, 6110 Execut Blvd,Suite 750, Rockville, MD 20852 USA. EM dppmail@biostat.bsc.gwu.edu OI Kahn, Steven/0000-0001-7307-9002 FU NIDDK NIH HHS [U01 DK048489, U01 DK048489-06] NR 36 TC 92 Z9 99 U1 0 U2 5 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0012-1797 J9 DIABETES JI Diabetes PD APR PY 2008 VL 57 IS 4 BP 980 EP 986 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 282UC UT WOS:000254591700022 PM 18192541 ER PT J AU Lachin, JM Genuth, S Nathan, DM Zinman, B Rutledge, BN AF Lachin, John M. Genuth, Saul Nathan, David M. Zinman, Bernard Rutledge, Brandy N. CA DCCT EDIC Res Grp TI Effect of glycemic exposure on the risk of microvascular complications in the diabetes trial - Revisited SO DIABETES LA English DT Article ID VARIABILITY; PROGRESSION AB OBJECTIVE - The Diabetes Control and Complications Trial (Diabetes 44:968-983, 1995) presented statistical models suggesting that subjects with similar A1C levels had a higher risk of retinopathy progression in the conventional treatment group than in the intensive treatment group. That analysis has been cited to support the hypothesis that specific patterns of glucose variation, in particular postprandial hyperglycemia, contribute uniquely to an increased risk of microvascular complications above and beyond that explained by the A1C level. RESEARCH DESIGN AND METHODS - We performed statistical evaluations of these models and additional analyses to assess whether the original analyses were flawed. RESULTS - Statistically, we show that the original results are an artifact of the assumptions of the statistical model used. Additional analyses show that virtually all (96%) of the beneficial effect of intensive versus conventional therapy on progression of retinopathy is explained by the reductions in the mean A1C levels, similarly for other outcomes. Furthermore, subjects within the intensive and conventional treatment groups with similar A1C levels over time have similar risks of retinopathy progression, especially after adjusting for factors in which they differ. CONCLUSIONS - A1C explains virtually all of the difference in risk of complications between the intensive and conventional groups, and a given A1C level has similar effects within the two treatment groups. While other components of hyperglycemia, such as glucose variation, may contribute to the risk of complications, such factors can only explain a small part of the differences in risk between intensive and conventional therapy over time. C1 [Lachin, John M.; Rutledge, Brandy N.] George Washington Univ, Ctr Biostat, Rockville, MD 20852 USA. [Genuth, Saul] Case Western Reserve Univ, Cleveland, OH 44106 USA. [Nathan, David M.] Harvard Univ, Sch Med, Boston, MA USA. [Nathan, David M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Zinman, Bernard] Univ Toronto, Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada. RP Lachin, JM (reprint author), George Washington Univ, Ctr Biostat, 6110 Execut Blvd, Rockville, MD 20852 USA. EM jml@biostat.bsc.gwu.edu RI Zinman, Bernard/E-7266-2013; OI Lachin, John/0000-0001-9838-2841 NR 12 TC 180 Z9 187 U1 2 U2 4 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0012-1797 J9 DIABETES JI Diabetes PD APR PY 2008 VL 57 IS 4 BP 995 EP 1001 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 282UC UT WOS:000254591700024 PM 18223010 ER PT J AU Lehtinen, AB Newton-Cheh, C Ziegler, JT Langefeld, CD Freedman, BI Daniel, KR Herrington, DM Bowden, DW AF Lehtinen, Allison B. Newton-Cheh, Christopher Ziegler, Julie T. Langefeld, Carl D. Freedman, Barry I. Daniel, Kurt R. Herrington, David M. Bowden, Donald W. TI Association of NOS1AP genetic variants with QT interval duration in families from the Diabetes Heart Study SO DIABETES LA English DT Article ID PRIMARY CARDIAC-ARREST; SUDDEN-DEATH; MYOCARDIAL-INFARCTION; QUANTITATIVE-TRAIT; LINKAGE ANALYSIS; RISK-FACTOR; PROLONGATION; REPOLARIZATION; POPULATION; DISPERSION AB OBJECTIVES-Prolongation of the electrocardiographic QT interval is a risk factor for sudden cardiac death (SCD). Diabetic individuals are at increased risk for prolonged QT interval and SCD. We sought to replicate the finding that genetic variants in the nitric oxide synthase 1 adaptor protein (NOS1AP) gene are associated with QT interval duration in a type 2 diabetes-enriched sample of European ancestry. RESEARCH DESIGN AND METHODS-Two single nucleotide polymorphisms (SNPs) in NOS1AP were genotyped in 624 European Americans and 127 African Americans from 400 pedigrees enriched for type 2 diabetes. An additive genetic model was tested for each SNP in ancestry-specific analyses in the total sample and the diabetic subset (European Americans, n = 514; African Americans, n = 115), excluding from the analyses individuals taking QT-altering medications. RESULTS-In European Americans, rs10494366 minor homozygotes had a 9.3-ms-longer QT interval compared with major homozygotes (P = 5.7 x 10(-5)); rs10918594 minor homozygotes had a 12.5-ms-longer QT interval compared with major homozygotes (P = 1.5 x 10(-6)). Restricting analyses to the diabetic European Americans strengthened the effect despite the reduction in sample size (11.3-ms difference, P = 5.1 x 10(-5); 13.9-ms difference, P = 1.6 x 10(-6), respectively). No association between the NOS1AP SNPs and QT interval duration was observed in the limited number of African Americans. CONCLUSIONS-Two NOS1AP SNPs are strongly associated with QT interval duration in a predominately diabetic European-American sample. Stronger effects of NOS1AP variants in diabetic individuals suggest that this patient subset may be particularly susceptible to genetic variants that influence myocardial depolarization and repolarization as manifest in the QT interval. C1 [Lehtinen, Allison B.; Bowden, Donald W.] Wake Forest Univ, Bowman Gray Sch Med, Dept Biochem, Winston Salem, NC 27157 USA. [Lehtinen, Allison B.; Bowden, Donald W.] Wake Forest Univ, Bowman Gray Sch Med, Ctr Human Gen, Winston Salem, NC 27157 USA. [Newton-Cheh, Christopher] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA. [Newton-Cheh, Christopher] Broad Inst Harvard, Program Med & Populat Genet, Cambridge, MA USA. [Newton-Cheh, Christopher] MIT, Cambridge, MA 02139 USA. [Ziegler, Julie T.; Langefeld, Carl D.] Wake Forest Univ, Bowman Gray Sch Med, Dept Publ Hlth Sci, Winston Salem, NC 27157 USA. [Freedman, Barry I.; Daniel, Kurt R.; Herrington, David M.; Bowden, Donald W.] Wake Forest Univ, Bowman Gray Sch Med, Dept Internal Med, Winston Salem, NC 27157 USA. RP Bowden, DW (reprint author), Wake Forest Univ, Bowman Gray Sch Med, Dept Biochem, 300 S Hawthorne Rd, Winston Salem, NC 27157 USA. EM dbowden@wfubmc.edu FU NCRR NIH HHS [M01 RR07122]; NHLBI NIH HHS [F32-HL-085989, K23-HL-080025, R01-HL-67348, T32-HL-076132-02] NR 38 TC 36 Z9 38 U1 1 U2 4 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0012-1797 J9 DIABETES JI Diabetes PD APR PY 2008 VL 57 IS 4 BP 1108 EP 1114 DI 10.2337/db07-1365 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 282UC UT WOS:000254591700038 PM 18235038 ER PT J AU McAteer, JB Prudente, S Bacci, S Lyon, HN Hirschhorn, JN Trischitta, V Jose, CF AF McAteer, Jarred B. Prudente, Sabrina Bacci, Simonetta Lyon, Helen N. Hirschhorn, Joel N. Trischitta, Vincenzo Florez, Jose C. CA ENPP Consortium TI The EBPP1 K121Q polymorphism is associated with type 2 diabetes in European populations: Evidence from an updated meta-analysis in 42,042 subjects SO DIABETES LA English DT Article ID MEMBRANE GLYCOPROTEIN PC-1; INSULIN-RECEPTOR INHIBITOR; GENETIC SUSCEPTIBILITY; GLUCOSE-INTOLERANCE; COMMON VARIANTS; ENPP1 PC-1; RESISTANCE; OBESITY; RISK; DISEASE AB OBJECTIVE-Functional studies suggest that the nonsynonymous K121Q polymorphism in the ectoenzyme nucleotide pyrophosphate phosphodiesterase 1 (ENPP1) may confer susceptibility to insulin resistance; genetic evidence on its effect on type 2 diabetes, however, has been conflicting. We therefore conducted a new meta-analysis that includes novel unpublished data from the ENPP1 Consortium and recent negative findings from large association studies to address the contribution of K121Q to type 2 diabetes. RESEARCH DESIGN AND METHODS-After a systematic review of the literature, we evaluated the effect of ENPP1 K121Q on diabetes risk under three genetic models using a random-effects approach. Our primary analysis consisted of 30 studies comprising 15,801 case and 26,241 control subjects. Due to considerable heterogeneity and large differences in allele frequencies across populations, we limited our meta-analysis to those of self-reported European descent and, when available, included BMI as a covariate. RESULTS-We found a modest increase in risk of type 2 diabetes for QQ homozygotes in white populations (combined odds ratio [OR] 1.38 [95% CI 1.10-1.74], P = 0.005). There was no evidence of publication bias, but we noted significant residual heterogeneity among studies (P = 0.02). On meta-regression, 16% of the effect was accounted for by the mean BMI of control subjects. This association was stronger in studies in which control subjects were leaner but disappeared after adjustment for mean control BMI (combined OR 0.93 [95% CI 0.75-1.15], P = 0.50). CONCLUSIONS-The ENPP1 Q121 variant increases risk of type 2 diabetes under a recessive model of inheritance in whites, an effect that appears to be modulated by BMI. C1 [McAteer, Jarred B.; Florez, Jose C.] Massachusetts Gen Hosp, Diabet Unit, Boston, MA 02114 USA. [McAteer, Jarred B.; Florez, Jose C.] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA. [McAteer, Jarred B.; Lyon, Helen N.; Hirschhorn, Joel N.; Florez, Jose C.] Broad Inst Harvard, Program Med & Populat Genet, Cambridge, MA USA. [McAteer, Jarred B.; Lyon, Helen N.; Hirschhorn, Joel N.; Florez, Jose C.] MIT, Cambridge, MA 02139 USA. [Prudente, Sabrina; Trischitta, Vincenzo] CSS Sci Inst, Res Unit Diabet & Endocrine Dis, San Giovanni Rotondo, Italy. [Prudente, Sabrina; Trischitta, Vincenzo] CSS Mendel Inst, Rome, Italy. [Bacci, Simonetta; Trischitta, Vincenzo] CSS Sci Inst, Unit Endocrinol, San Giovanni Rotondo, Italy. [Lyon, Helen N.; Hirschhorn, Joel N.] Childrens Hosp Boston, Div Genet & Endocrinol, Boston, MA USA. [Lyon, Helen N.; Hirschhorn, Joel N.] Harvard Univ, Sch Med, Dept Genet, Boston, MA USA. RP Jose, CF (reprint author), Massachusetts Gen Hosp, Diabet Unit, Simches Res Bldg,CPZN 5 250, Boston, MA 02114 USA. EM jcflorez@partners.org RI Prudente, Sabrina/H-2886-2016; Trischitta, Vincenzo/K-1487-2016; OI Prudente, Sabrina/0000-0001-9220-8981; Trischitta, Vincenzo/0000-0003-1174-127X; Menzaghi, Claudia/0000-0002-7438-8955 FU NIDDK NIH HHS [1 K23 DK65978-04] NR 40 TC 66 Z9 69 U1 1 U2 8 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0012-1797 J9 DIABETES JI Diabetes PD APR PY 2008 VL 57 IS 4 BP 1125 EP 1130 DI 10.2337/db07-1336 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 282UC UT WOS:000254591700041 PM 18071025 ER PT J AU Malecki, MT Cyganek, K Mirkiewicz-Sieradzka, B Wolkow, PP Wanic, K Skupien, J Solnica, B Sieradzki, J AF Malecki, Maciej T. Cyganek, Katarzyna Mirkiewicz-Sieradzka, Barbara Wolkow, Pawel P. Wanic, Krzysztof Skupien, Jan Solnica, Bogdan Sieradzki, Jacek TI Alanine variant of the Pro12A1a polymorphism of the PPAR gamma gene might be associated with decreased risk of diabetic retinopathy in type 2 diabetes SO DIABETES RESEARCH AND CLINICAL PRACTICE LA English DT Article ID PROLIFERATOR-ACTIVATED RECEPTOR-GAMMA-2; TYROSINE-PHOSPHATASE 1B; INSULIN-RESISTANCE; PPAR-GAMMA-2 GENE; CALPAIN-10 GENE; MICROVASCULAR COMPLICATIONS; POLISH POPULATION; PIMA-INDIANS; FATTY-ACIDS; PROTEIN AB Objective: Molecular background of diabetic retinopathy (DR) remains unknown. An interesting group of candidate genes encode proteins involved in insulin resistance. Aim: To search for association between the PPAR gamma, calpain 10, PTPN1 genes and DR in type 2 diabetes mellitus (T2DM). Methods: We examined 238 T2DM subjects without DR (NDR) and 121 with DR (mean diabetes duration: 9.1 +/- 6.8 and 15.1 +/- 7.7, respectively). The subjects were genotyped for four markers: Pro12Ala of PPAR gamma, SNP43 of calpain 10, rs3787345 and rs754118 of PTPN1. The distributions of the genotypes were compared using the X-2-test and Fisher exact test. Results: The alleles and genotypes were not associated with DR in non-stratified analysis. To investigate the impact of T2DM duration, we performed analysis that excluded short duration NDR subjects and long-duration DR subjects. It allowed obtaining groups with similar T2DM duration but different DR status (DR: 88 individuals, 11.4 +/- 5.3 years; NDR: 136 individuals, 13.2 years +/- 6.2, respectively). This analysis suggested that the alanine variant of Pro12A1a might be associated with decreased risk of DR (p = 0.026 for alleles, p = 0.038 and p = 0.014 for genotypes in additive and dominant models, respectively). In multivariable logistic regression that included non-genetic parameters, Pro12Ala was not an independent risk factor (p = 0.28). Further analysis showed, however, that Pro12Ala remained significant when urea level was excluded from the model. Conclusion: The alanine variant of the Pro12A1a polymorphism of PPAR gamma might be associated with decreased risk of DR in T2DM. This effect may be indirect, at least in part, due to diabetic kidney disease. (c) 2007 Elsevier Ireland Ltd. All rights reserved. C1 [Malecki, Maciej T.; Cyganek, Katarzyna; Mirkiewicz-Sieradzka, Barbara; Skupien, Jan; Sieradzki, Jacek] Jagiellonian Univ, Coll Med, Dept Metab Dis, PL-31501 Krakow, Poland. [Wolkow, Pawel P.] Jagiellonian Univ, Coll Med, Dept Pharmacol, PL-31501 Krakow, Poland. [Wanic, Krzysztof] Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02115 USA. [Wanic, Krzysztof] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. [Solnica, Bogdan] Jagiellonian Univ, Coll Med, Dept Clin Biochem, PL-31501 Krakow, Poland. RP Malecki, MT (reprint author), Jagiellonian Univ, Coll Med, Dept Metab Dis, 15 Kopernika St, PL-31501 Krakow, Poland. EM malecki_malecki@yahoo.com NR 48 TC 16 Z9 17 U1 1 U2 1 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0168-8227 J9 DIABETES RES CLIN PR JI Diabetes Res. Clin. Pract. PD APR PY 2008 VL 80 IS 1 BP 139 EP 145 DI 10.1016/j.diabres.2007'.11.001 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 294SM UT WOS:000255425900022 PM 18077048 ER PT J AU Hermos, JA Cohen, SA Hall, R Gagnon, DR Brophy, MT Fiore, LD AF Hermos, John A. Cohen, Seth A. Hall, Robert Gagnon, Dauid R. Brophy, Mary T. Fiore, Louis D. TI Association of elevated alanine aminotransferase with BMI and diabetes in older veteran outpatients SO DIABETES RESEARCH AND CLINICAL PRACTICE LA English DT Article DE alanine aminotransferase (ALAT); diabetes body mass index (BMI); US veterans; elderly ID NONALCOHOLIC FATTY LIVER; GAMMA-GLUTAMYL-TRANSFERASE; METABOLIC SYNDROME; UNITED-STATES; FOLLOW-UP; SERUM; STEATOHEPATITIS; POPULATION; HEPATOTOXICITY; RISK AB Aims: We determined age-stratified associations of elevated alanine aminotransferase (ALAT), as a likely indicator of non-alcoholic steatonecrosis (NASH), with body mass index (BMI) and diabetes among older male, veteran outpatients. Methods: Administrative files at three, urban Veteran Administration Healthcare Systems were surveyed. 47.916 male outpatients, mean age 69.2 years, without ICD-9CM documented liver diseases or alcohol- or drug-abuse, had the highest of one or more ALAT results analyzed. Logistic regression determined age-stratified predictors of elevated ALAT among groups < 50 ("younger-aged"), 50-70 ("middle-aged") and > 70 ("older-aged"). BMI, diabetes and "statin" use were predictors. Results: 1272 (2.7%) patients had their highest ALAT greater than the upper limit of normal (mean = 98.4 U/L). 4.9% of all diabetics and 15.2,6.1 and 3.4% of the "younger-aged", middleaged" and "older-aged" diabetics, respectively, had elevated ALATs. BMI values from 25 to < 30 and 30 to 45, compared with those from > 20 to < 25, predicted elevated ALAT in the two younger groups. In contrast, among "older-aged" patients, diabetes independently predicted elevated ALAT, whereas BMI did not. Conclusions: The cross-sectional findings support previous epidemiologic data associating ALAT elevations with obesity and diabetes, and provide new evidence that in elderly male patients, ALAT elevations, absent other known liver diseases, may selectively associate with diabetes. (c) Published by Elsevier Ireland Ltd. C1 [Hermos, John A.; Cohen, Seth A.; Hall, Robert; Gagnon, Dauid R.; Brophy, Mary T.; Fiore, Louis D.] Vet Affairs Boston Healthcare Syst 151MAV, VA Cooperat Studies Program, Massachusetts Vet Epidemiol Res & Informat Ctr, Boston, MA 02130 USA. [Hermos, John A.; Brophy, Mary T.; Fiore, Louis D.] Boston Univ, Sch Med, Boston, MA 02215 USA. [Hermos, John A.; Gagnon, Dauid R.; Brophy, Mary T.; Fiore, Louis D.] Boston Univ, Sch Publ Hlth, Boston, MA 02215 USA. RP Hermos, JA (reprint author), Vet Affairs Boston Healthcare Syst 151MAV, VA Cooperat Studies Program, Massachusetts Vet Epidemiol Res & Informat Ctr, 150 S Huntington Ave, Boston, MA 02130 USA. EM john.hermos@va.gov OI Gagnon, David/0000-0002-6367-3179 NR 25 TC 6 Z9 7 U1 0 U2 1 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0168-8227 J9 DIABETES RES CLIN PR JI Diabetes Res. Clin. Pract. PD APR PY 2008 VL 80 IS 1 BP 153 EP 158 DI 10.1016/j.diabres.2007.11.008 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 294SM UT WOS:000255425900024 PM 18178283 ER PT J AU Lu, L Reiter, MJ Xu, Y Chicco, A Greyson, CR Schwartz, GG AF Lu, L. Reiter, M. J. Xu, Y. Chicco, A. Greyson, C. R. Schwartz, G. G. TI Thiazolidinedione drugs block cardiac K-ATP channels and may increase propensity for ischaemic ventricular fibrillation in pigs SO DIABETOLOGIA LA English DT Article DE action potential; ischaemia; K-ATP channels; thiazolidinedione; ventricular fibrillation ID SENSITIVE POTASSIUM CHANNEL; ACTION-POTENTIAL DURATION; LOW-FLOW ISCHEMIA; MYOCARDIAL-ISCHEMIA; HMR 1883; INSULIN-SENSITIZERS; GAMMA-ACTIVATOR; SMOOTH-MUSCLE; CANINE HEART; REPERFUSION AB Aims/hypothesis Opening of ATP-sensitive potassium (K-ATP) channels during myocardial ischaemia shortens action potential duration and is believed to be an adaptive, energy-sparing response. Thiazolidinedione drugs block K-ATP channels in non-cardiac cells in vitro. This study determined whether thiazolidinedione drugs block cardiac K-ATP channels in vivo. Methods Experiments in 68 anaesthetised pigs determined: (1) effects of inert vehicle, troglitazone (10 mg/kg i.v.) or rosiglitazone (0.1 or 1.0 mg/kg i.v.) on epicardial monophasic action potential (MAP) during 90 min low-flow ischaemia; (2) effects of troglitazone, rosiglitazone or pioglitazone (1 mg/kg i.v.) on response of MAP to intracoronary infusion of a K-ATP channel opener, levcromakalim; and (3) effects of inert vehicle, rosiglitazone (1 mg/kg i.v.) or the sarcolemmal K-ATP blocker HMR-1098 on time to onset of ventricular fibrillation following complete coronary occlusion. Results With vehicle, epicardial MAP shortened by 44 +/- 9 ms during ischaemia. This effect was attenuated to 12 +/- 8 ms with troglitazone and 6 +/- 6 ms with rosiglitazone (p < 0.01 for both vs vehicle), suggesting K-ATP blockade. Intracoronary levcromakalim shortened MAP by 38 +/- 10 ms, an effect attenuated to 12 +/- 8, 13 +/- 4 and 9 +/- 5 ms during co-treatment with troglitazone, rosiglitazone or pioglitazone (p < 0.05 for each), confirming K-ATP blockade. During coronary occlusion, median time to ventricular fibrillation was 29 min in pigs treated with vehicle and 6 min in pigs treated with rosiglitazone or HMR-1098 (p < 0.05 for both vs vehicle), indicating that K-ATP blockade promotes ischaemic ventricular fibrillation in this model. Conclusions/interpretation Thiazolidinedione drugs block cardiac K-ATP channels at clinically relevant doses and promote onset of ventricular fibrillation during severe ischaemia. C1 [Schwartz, G. G.] Denver VA Med Ctr, Cardiol Sect 111B, Denver, CO 80220 USA. [Lu, L.; Reiter, M. J.; Xu, Y.; Chicco, A.; Greyson, C. R.; Schwartz, G. G.] VA Med Ctr, Denver, CO USA. [Lu, L.; Reiter, M. J.; Xu, Y.; Chicco, A.; Greyson, C. R.; Schwartz, G. G.] Univ Colorado, Hlth Sci Ctr, Denver, CO USA. RP Schwartz, GG (reprint author), Denver VA Med Ctr, Cardiol Sect 111B, 1055 Clermont St, Denver, CO 80220 USA. EM Gregory.Schwartz@va.gov FU NHLBI NIH HHS [R56 HL049944, HL49944, R01 HL049944, R01 HL049944-10] NR 50 TC 29 Z9 29 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0012-186X J9 DIABETOLOGIA JI Diabetologia PD APR PY 2008 VL 51 IS 4 BP 675 EP 685 DI 10.1007/s00125-008-0924-0 PG 11 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 277SO UT WOS:000254235200020 PM 18251006 ER PT J AU Belsley, NA Tambouret, RH Misdraji, J Muzikansky, A Russell, DK Wilbur, DC AF Belsley, Nicole A. Tambouret, Rosemary H. Misdraji, Joseph Muzikansky, Alona Russell, Donna K. Wilbur, David C. TI Cytologic features of endocervical glandular lesions: Comparison of SurePath, ThinPrep, and conventional smear specimen preparations SO DIAGNOSTIC CYTOPATHOLOGY LA English DT Article; Proceedings Paper CT 52nd Annual Scientific Meeting of the American-Society-of-Cytopathology CY NOV 12-17, 2004 CL Chicago, IL SP Amer Soc Cytopathol DE cervical cytology; adenocarcinoma; adenocarcinoma in situ; ThinPrep; SurePath ID CELL BLOCK PREPARATION; ADENOCARCINOMA INSITU; INTRAEPITHELIAL LESIONS; CERVIX UTERI; PAP TESTS; CRITERIA; DIAGNOSIS; CYTOMORPHOLOGY; NEOPLASIA; VALIDITY AB The cytologic features of endocervical neoplasia have been well-described for conventional and ThinPrep, but not for SurePath, methods. This study is designed to ascertain if cytological features are similar in SurePath specimens. Conventional, ThinPrep and SurePath specimens with either endocervical adenocarcinoma in situ or invasive endocervical adenocarcinoma were evaluated,for architectural and cytological features previously described for endocervical neoplasia. A generalized linear model was used to assess the differences of ordinal multinomial data. Of 18 evaluated, the only features showing statistical differences were architectural: large groups of cells and single cells were more frequent in SurePath preparations and conventional smears. Feathering was more frequently noted in conventional smears. Individual cytological features were identical across all groups. Mitoses and apoptotic debris were seen with equal frequency in all preparations. The architectural and cytologic features of endocervical glandular neoplasia in liquid-based specimens show only subtle architectural differences when compared with conventional smears. Keeping these differences in mind, virtually the same criteria can be used to identify endocervical glandular lesions in all three specimen types. C1 [Belsley, Nicole A.; Tambouret, Rosemary H.; Misdraji, Joseph; Wilbur, David C.] Massachusetts Gen Hosp, Dept Pathol, James Homer Wright Pathol Labs, Boston, MA 02114 USA. [Belsley, Nicole A.; Tambouret, Rosemary H.; Misdraji, Joseph; Wilbur, David C.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. [Muzikansky, Alona] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA. [Russell, Donna K.] Univ Rochester, Med Ctr, Dept Pathol, Rochester, NY 14642 USA. RP Wilbur, DC (reprint author), Massachusetts Gen Hosp, Dept Pathol, James Homer Wright Pathol Labs, Warren Bldg 2, Boston, MA 02114 USA. EM dwilbur@partners.org NR 20 TC 20 Z9 20 U1 0 U2 1 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 8755-1039 J9 DIAGN CYTOPATHOL JI Diagn. Cytopathol. PD APR PY 2008 VL 36 IS 4 BP 232 EP 237 DI 10.1002/dc.20782 PG 6 WC Medical Laboratory Technology; Pathology SC Medical Laboratory Technology; Pathology GA 282UB UT WOS:000254591600007 PM 18335553 ER PT J AU Bennett, JW Murray, CK Holmes, RL Patterson, JE Jorgensen, JH AF Bennett, Jason W. Murray, Clinton K. Holmes, Robert L. Patterson, Jan E. Jorgensen, James H. TI Diminished vancomycin and daptomycin susceptibility during prolonged bacteremia with methicillin-resistant Staphylococcus aureus SO DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE LA English DT Article DE vancomycin tolerance; daptomycin resistance; MRSA bacteremia; minimum inhibitory concentration; bactericidal effect ID BACTERICIDAL ACTIVITY; GLYCOPEPTIDE TOLERANCE; ANTIBIOTIC TOLERANCE; IN-VIVO; STRAINS; ENDOCARDITIS; EFFICACY AB An elderly patient with methicillin-resistant Staphylococcus aureus (MRSA) bacteremia was treated sequentially with vancomycin plus rifampin then daptomycin plus gentamicin. The MRSA strain developed diminished susceptibility to vancomycin (MIC increase and tolerance), daptomycin, and gentamicin, and resistance to rifampin during therapy. (C) 2008 Elsevier Inc. All rights reserved. C1 [Bennett, Jason W.; Murray, Clinton K.] Brooke Army Med Ctr, Infect Dis MCHE MDI, Dept Med, Ft Sam Houston, TX 78234 USA. [Holmes, Robert L.] Wilford Hall USAF Med Ctr, Dept Infect Dis, San Antonio, TX 78201 USA. [Patterson, Jan E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med Infect Dis & Pathol, San Antonio, TX 78229 USA. [Patterson, Jan E.] S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Jorgensen, James H.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. RP Bennett, JW (reprint author), Brooke Army Med Ctr, Infect Dis MCHE MDI, Dept Med, 3851 Roger Brooke Dr, Ft Sam Houston, TX 78234 USA. EM jason.bennett@amedd.army.mil RI Valle, Ruben/A-7512-2013 NR 22 TC 17 Z9 17 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0732-8893 J9 DIAGN MICR INFEC DIS JI Diagn. Microbiol. Infect. Dis. PD APR PY 2008 VL 60 IS 4 BP 437 EP 440 DI 10.1016/j.diagmicrobio.2007.11.002 PG 4 WC Infectious Diseases; Microbiology SC Infectious Diseases; Microbiology GA 282KA UT WOS:000254565300019 PM 18096352 ER PT J AU Pimentel, M Chatterjee, S Chang, C Low, K Song, Y Liu, CX Morales, W Ali, L Lezcano, S Conklin, J Finegold, S AF Pimentel, Mark Chatterjee, Soumya Chang, Christopher Low, Kimberly Song, Yuli Liu, Chengxu Morales, Walter Ali, Lemeesa Lezcano, Sheila Conklin, Jeffery Finegold, Sydney TI A new rat model links two contemporary theories in irritable bowel syndrome SO DIGESTIVE DISEASES AND SCIENCES LA English DT Article DE bacterial overgrowth; Campylobacter jejuni; post-infectious IBS ID INTESTINAL BACTERIAL OVERGROWTH; DOUBLE-BLIND; SYMPTOMS; GASTROENTERITIS; PREVALENCE; RIFAXIMIN; COMPLEX; TRIAL AB Rationale Two proposed hypotheses for irritable bowel syndrome (IBS) are acute gastroenteritis and bacterial overgrowth. We studied whether acute infection with Campylobacter could precipitate bacterial overgrowth in a rat model in order to link the two hypotheses. Methods Sprague-Dawley outbred rats were randomly administered a vehicle or Campylobacter jejuni strain 81-176 by oral gavage. Three months after clearance of the infectious agent, rats had a stool consistency evaluation. After euthanasia, lumenal bacteria counts were measured via quantitative real-time PCR from self-contained segments of the duodenum, jejunum, ileum, cecum and left colon. Adjacent sections of bowel were fixed in formalin for evaluation of intraepithelial lymphocyte counts. Results Three months after clearance of Campylobacter infection, 57% of Campylobacter infected rats had some alteration in stool consistency compared to 7.4% in mock-infected controls (P < 0.001). Among the rats that received Campylobacter, 27% had evidence of bacterial overgrowth by PCR. These rats also had the highest prevalence of altered stool form and had lower body weight. Consistent with post-infectious IBS in humans, bacterial overgrowth rats demonstrated a significant increase in rectal and left colon intraepithelial lymphocytes. Conclusions Acute infection with C. jejuni 81-176 precipitates alterations in stool consistency, bacterial overgrowth and rectal lymphocytosis consistent with findings in IBS patients. C1 [Pimentel, Mark; Chatterjee, Soumya; Low, Kimberly; Morales, Walter; Ali, Lemeesa; Lezcano, Sheila; Conklin, Jeffery] Cedars Sinai Med Ctr, GI Motilty Program, Burns & Allen Res Inst, Los Angeles, CA 90048 USA. [Chang, Christopher; Finegold, Sydney] Univ Calif Los Angeles, David Geffen Sch Med, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA USA. [Song, Yuli; Liu, Chengxu; Finegold, Sydney] W Los Angeles Vet Affairs Med Ctr, Div Gastroenterol & Infect Dis, Los Angeles, CA 90073 USA. RP Pimentel, M (reprint author), Cedars Sinai Med Ctr, GI Motilty Program, Burns & Allen Res Inst, 8730 Alden Dr,Suite 225E, Los Angeles, CA 90048 USA. EM pimentelm@cshs.org RI Chatterjee, Soumya/E-2009-2013 NR 23 TC 32 Z9 36 U1 1 U2 2 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0163-2116 J9 DIGEST DIS SCI JI Dig. Dis. Sci. PD APR PY 2008 VL 53 IS 4 BP 982 EP 989 DI 10.1007/s10620-007-9977-z PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 274AS UT WOS:000253974800017 PM 17934822 ER PT J AU Nosek, MA Robinson-Whelen, S Hughes, RB Petersen, NJ Taylor, HB Byrne, MM Morgan, R AF Nosek, Margaret A. Robinson-Whelen, Susan Hughes, Rosemary B. Petersen, Nancy J. Taylor, Heather B. Byrne, Margaret M. Morgan, Robert TI Overweight and obesity in women with physical disabilities: Associations with demographic and disability characteristics and secondary conditions SO DISABILITY AND HEALTH JOURNAL LA English DT Article DE Disabled persons; Minority groups; Overweight; Obesity; Rehabilitation; Women ID SPINAL-CORD-INJURY; BODY-MASS INDEX; AFRICAN-AMERICAN WOMEN; HEALTH-PROMOTION; MULTIPLE-SCLEROSIS; NEUROMUSCULAR DISEASE; US ADULTS; INTERVENTION; PREVALENCE; BARRIERS AB Background: This cross-sectional study was designed to examine weight in association with demographic and disability characteristics and secondary conditions in a sample of community living women with physical disabilities. Methods: 443 predominantly ethnic minority women with physical disabilities were recruited through public and private health clinics and community organizations. They completed questionnaires including measures of body mass index and a health conditions checklist. Results: Data showed that nearly three-quarters of the sample were overweight (26.6%) or obese (47.6%) with 14% extremely obese. Obesity was highest among middle aged women (aged 45-54, 52.7%; aged 55-64, 52.5%; compared to aged 18-44, 37.8%; or aged >= 65, 39.1%). Black (84.0%) and Hispanic women (83.8%) were more likely to be overweight or obese compared to non-Hispanic white women (56.7%). Women with joint and connective tissue diseases and women with more extensive functional limitations were more likely to have excess weight. Disability factors were more strongly associated with excess weight than demographic factors other than age. Weight classification was significantly related to whether or not the women had ever had diabetes or blood pressure problems. Diabetes was reported 4 times as often as among women in general (36.3% versus 8.9%), and hypertension nearly twice as often (56.2% versus 30.9%). Conclusions: These findings indicate extremely high rates of overweight and obesity in women with physical disabilities, a growing population greatly in need of effective weight management interventions. Overweight and obesity in combination with disability in women was associated with disproportionately high rates of diabetes and hypertension. (C) 2008 Elsevier Inc. All rights reserved. C1 [Nosek, Margaret A.; Robinson-Whelen, Susan] Baylor Coll Med, Ctr Res Women Disabil, Dept Phys Med & Rehabil, Houston, TX 77030 USA. [Hughes, Rosemary B.] Univ Montana, Rural Inst Disabil, Missoula, MT 59812 USA. [Petersen, Nancy J.; Morgan, Robert] Dept Vet Affairs Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Hlth Serv Res & Dev Serv, Houston, TX 77021 USA. [Petersen, Nancy J.; Morgan, Robert] Baylor Coll Med, Sect Hlth Serv Res, Dept Med, Houston, TX 77021 USA. [Taylor, Heather B.] Univ Texas Hlth Sci Ctr, Div Dev Pediat, Houston, TX 77030 USA. [Byrne, Margaret M.] Univ Miami, Miller Sch Med, Dept Epidemiol & Publ Hlth, Miami, FL 33136 USA. EM mnosek@bcm.edu FU Centers for Disease Control and Prevention [RO4/CCR618805] FX This work was supported by the Centers for Disease Control and Prevention (grant RO4/CCR618805). NR 73 TC 15 Z9 15 U1 3 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1936-6574 J9 DISABIL HEALTH J JI Disabil. Health J. PD APR PY 2008 VL 1 IS 2 BP 89 EP 98 DI 10.1016/j.dhjo.2008.01.003 PG 10 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health; Rehabilitation SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Rehabilitation GA V18JS UT WOS:000208001700004 PM 21122716 ER PT J AU Chirikos, TN Roetzheim, RG McCarthy, EP Iezzoni, LI AF Chirikos, Thomas N. Roetzheim, Richard G. McCarthy, Ellen P. Iezzoni, Lisa I. TI Cost disparities in lung cancer treatment by disability status, sex, and race SO DISABILITY AND HEALTH JOURNAL LA English DT Article DE Disability; Health disparities; Medicare; Cancer costs; Lung cancer treatment; Cancer care delivery; SEER-Medicare database AB Background: The recent literature contains numerous reports of disparities in the diagnosis, treatment, and outcomes of lung cancer across a growing list of population subgroups, including disability status. A common assumption is that disparities stem mainly from variations in the level and type of treatment resources available to specific subgroups. Few studies, however, have directly measured resource differentials. Since policy makers identify reducing health disparities as a critical priority, this study examined whether cumulative Medicare costs (resource consumption) for lung cancer treatment differ across eight patient subgroups defined by disability status, sex, and race. Hypothesis: Treatment disparities across the eight subgroups will be reflected in variations in the cumulative cost profiles of those subgroups, controlling for other plausible cost drivers. Failure to detect statistically significant differentials in these cost profiles implies that treatment disparities stem from factors other than access to, and utilization of, health care services. Methods: Linked SEER-Medicare data were used to construct cost profiles by service type and treatment phase for roughly 80,000 incident lung cancer cases in patients aged 45 to 85 years at diagnosis. Multiple regression models then tested for cost differentials across the eight subgroups, controlling for various patient and disease characteristics. Results: Significant cost differentials were detected, some unanticipated. Women tended to have higher treatment costs than men; they also had more favorable survivals. Nonwhites also tended to have higher treatment costs than whites, although they had significantly shorter survivals. On average, men with disabilities consumed the fewest treatment resources and had the shortest survivals. Mixed results were obtained for women with disabilities. Conclusions: Among others, the findings suggest that reducing disparities will take more than just improving access to health care. Special attention must be paid to lung cancer patients with disabilities by both policy makers and clinicians. (C) 2008 Elsevier Inc. All rights reserved. C1 [Chirikos, Thomas N.; Roetzheim, Richard G.] Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA. [Roetzheim, Richard G.] Univ S Florida, Dept Family Med, Tampa, FL 33612 USA. [McCarthy, Ellen P.] Harvard Univ, Sch Med, Div Gen Med & Primary Care, Beth Israel Deaconess Med Ctr, Brookline, MA 02446 USA. [Iezzoni, Lisa I.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Inst Hlth Policy, Boston, MA 02114 USA. RP Chirikos, TN (reprint author), 9128 Regents Pk Dr, Tampa, FL 33647 USA. EM tchiriko@health.usf.edu RI Roetzheim, Richard/J-4696-2012 FU National Cancer Institute [RO1 CA100029] FX This research was supported by grant RO1 CA100029 from the National Cancer Institute. The study sponsors were not involved in the study design, in the analysis or interpretation of the data, or in writing and submitting the manuscript for publication. The study used the linked SEER-Medicare database. Approvals from the respective institutional review boards were obtained to analyze these data. The interpretation and reporting of the data here are the sole responsibility of the authors. The authors acknowledge the efforts of several groups responsible for the creation and dissemination of the Linked Database, including the Applied Research Branch, Division of Cancer Control and Population Sciences, National Cancer Institute; the Office of Information Services, and the Office of Strategic Planning, Centers for Medicare and Medicaid Services; Information Management Services, Inc.; and the Surveillance, Epidemiology, and End Results Program Tumor Registries. NR 24 TC 8 Z9 8 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1936-6574 J9 DISABIL HEALTH J JI Disabil. Health J. PD APR PY 2008 VL 1 IS 2 BP 108 EP 115 DI 10.1016/j.dhjo.2008.01.004 PG 8 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health; Rehabilitation SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Rehabilitation GA V18JS UT WOS:000208001700006 PM 19881893 ER PT J AU Becker, WC Fiellin, DA Merrill, JO Schulman, B Finkelstein, R Olsen, Y Busch, SH AF Becker, William C. Fiellin, David A. Merrill, Joseph O. Schulman, Beryl Finkelstein, Ruth Olsen, Yngvild Busch, Susan H. TI Opioid use disorder in the United States: Insurance status and treatment access SO DRUG AND ALCOHOL DEPENDENCE LA English DT Article; Proceedings Paper CT 69th Annual Meeting of the College-of-Problems-on-Drug-Dependence CY JUN 19, 2007 CL Quebec City, CANADA SP Coll Problems Drug Dependence DE opioid use disorder; insurance; access to care ID METHADONE AB Background: In the United States, insurance status and rates of treatment for individuals with opioid use disorder are unknown. Methods: Cross-sectional survey: 2002-2004 National Survey on Drug Use and Health (NSDUH). Bivariate and multivariate associations between demographics, treatment and insurance status and presence or absence of opioid use disorder were investigated. Results: On unadjusted analysis, young respondents, respondents of Hispanic ethnicity (OR 1.5; 95% CI 1.1-2.2), unemployed respondents (OR 2.6; 95% CI 1.8-3.8) and respondents with Medicaid (OR 4.5; 95% CI 2.5-8.3) or lack of insurance (OR 3.2; 95% CI 1.8-5.9) were more likely to have opioid use disorder. On unadjusted analysis among those with any substance use disorder, 12-16 year olds were more likely to have opioid use disorder (OR 3.4; 95% CI 2.0-5.8) than a non-opioid substance use disorder, as were women (OR for men 0.6; 95% CI 0.5-0.7) and unemployed respondents (OR 1.5; 95% CI 1.02-2.1). Only 15.2% of those with past-year opioid use disorder received treatment in the past year. Respondents treated for opioid use had higher rates of Medicaid (p < 0.01), Medicare (p < 0.01) and other public assistance (P = 0.01) compared with those treated for other substances. Treatments for opioid use were more likely to be hospital (p = 0.04) and inpatient rehabilitation (p = 0.02) settings compared to treatment for other substance use. Among those with opioid use disorder, not being employed was independently associated with receiving treatment (AOR 3.5; 95% CI 1.4-8.5). Conclusions: In the U.S., high rates of unemployment, Medicaid and uninsurance among those with opioid use disorder and low rates of treatment suggest that efforts to expand treatment must include policy strategies to help reach a population with significant barriers to treatment access. (c) 2007 Elsevier Ireland Ltd. All rights reserved. C1 [Becker, William C.] Philadelphia Vet Affairs Med Ctr, Dept Internal Med, Philadelphia, PA 19104 USA. [Fiellin, David A.] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA. [Busch, Susan H.] Yale Univ, Sch Med, Sch Epidemiol & Publ Hlth, New Haven, CT 06510 USA. [Merrill, Joseph O.; Schulman, Beryl] Univ Washington, Dept Med, Seattle, WA USA. [Finkelstein, Ruth] New York Acad Med, New York, NY USA. [Olsen, Yngvild] Johns Hopkins Univ, Baltimore, MD USA. RP Becker, WC (reprint author), Philadelphia Vet Affairs Med Ctr, Dept Internal Med, 3900 Woodland Ave, Philadelphia, PA 19104 USA. EM william.becker4@va.gov OI Becker, William/0000-0002-0788-1467; Fiellin, David/0000-0002-4006-010X FU NIDA NIH HHS [T32DA007238] NR 9 TC 25 Z9 25 U1 2 U2 4 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0376-8716 J9 DRUG ALCOHOL DEPEN JI Drug Alcohol Depend. PD APR 1 PY 2008 VL 94 IS 1-3 BP 207 EP 213 DI 10.1016/j.drugalcdep.2007.11.018 PG 7 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA 273KS UT WOS:000253929700025 PM 18222051 ER PT J AU Miao, XS Miao, S Song, P Savage, RE Zhong, C Yang, RY Kizer, D Wu, H Volckova, E Ashwell, MA Supko, JG He, XY Chan, TCK AF Miao, Xiu-Sheng Miao, Sheng Song, Pengfei Savage, Ronald E. Zhong, Caiyun Yang, Rui-Yang Kizer, Darin Wu, Hui Volckova, Erika Ashwell, Mark A. Supko, Jeffrey G. He, Xiaoying Chan, Thomas C. K. TI Identification of the in vitro metabolites of 3,4-dihydro-2,2-dimethyl-2H-naphthol[1,2-b]pyran-5,6-dione(ARQ 501; beta-lapachone) in whole blood SO DRUG METABOLISM AND DISPOSITION LA English DT Article ID HYDROGEN-PEROXIDE; BETA-LAPACHONE; CELLS AB 3,4-Dihydro-2,2-dimethyl-2H-naphthol[1,2-b]pyran-5,6-dione(ARQ 501; beta-lapachone) showed promising anticancer activity in phase I clinical trials as monotherapy and in combination with cytotoxic drugs. ARQ 501 is currently in multiple phase II clinical trials. In vitro incubation in fresh whole blood at 37 C revealed that ARQ 501 is stable in plasma but disappears rapidly in whole blood. Our data showed that extensive metabolism in red blood cells (RBCs) was mainly responsible for the rapid disappearance of ARQ 501 in whole blood. By comparison, covalent binding of ARQ 501 and/ or its metabolites to whole blood components was a minor contributor to the disappearance of this compound. Sequestration of intact ARQ 501 in RBCs was not observed. Cross-species metabolite profiles from incubating [C-14] ARQ 501 in freshly drawn blood were characterized using a liquid chromatography- mass spectrometry-accurate radioactivity counter. The results show that ARQ 501 was metabolized more rapidly in mouse and rat blood than in dog, monkey, and human blood, with qualitatively similar metabolite profiles. Six metabolites were identified in human blood using ultra-high performance liquid chromatography/time-of-flight mass spectrometry, and the postulated structure of five metabolites was confirmed using synthetic standards. We conclude that the primary metabolic pathway of ARQ 501 in human blood involved oxidation of the two adjacent carbonyl groups to produce dicarboxylic and monocarboxylic metabolites, elimination of a carbonyl group to form a ring-contracted metabolite, and lactonization to produce two metabolites with a pyrone ring to form a ring-contracted metabolite. Metabolism by RBCs may play a role in clearance of ARQ 501 from the blood compartment in cancer patients. C1 [Miao, Xiu-Sheng; Song, Pengfei; Savage, Ronald E.; Zhong, Caiyun; Chan, Thomas C. K.] ArQule Inc, Dept Preclin Dev & Clin Pharmacol, Woburn, MA 01801 USA. [Miao, Xiu-Sheng; Song, Pengfei; Savage, Ronald E.; Zhong, Caiyun; Chan, Thomas C. K.] ArQule Inc, Dept Chem, Woburn, MA 01801 USA. [Supko, Jeffrey G.; He, Xiaoying] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. RP Chan, TCK (reprint author), ArQule Inc, Dept Preclin Dev & Clin Pharmacol, 19 Presidential Way, Woburn, MA 01801 USA. EM tchan@arqule.com NR 25 TC 20 Z9 20 U1 0 U2 1 PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA SN 0090-9556 J9 DRUG METAB DISPOS JI Drug Metab. Dispos. PD APR PY 2008 VL 36 IS 4 BP 641 EP 648 DI 10.1124/dmd.107.018572 PG 8 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 277FF UT WOS:000254197400003 PM 18180274 ER PT J AU Cardoso, F Winer, E AF Cardoso, Fatima Winer, Eric CA ESO-EBCC MBC Task Force TI Metastatic breast cancer session SO EJC SUPPLEMENTS LA English DT Meeting Abstract CT 6th European Breast Cancer Conference CY APR 15-19, 2008 CL Berlin, GERMANY C1 [Cardoso, Fatima] Inst Jules Bordet, B-1000 Brussels, Belgium. [Winer, Eric] Dana Farber Canc Inst, Boston, MA 02115 USA. OI Cardoso, Fatima/0000-0002-6692-2249 NR 1 TC 0 Z9 0 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 1359-6349 J9 EJC SUPPL JI EJC Suppl. PD APR PY 2008 VL 6 IS 7 BP 26 EP 26 DI 10.1016/S1359-6349(08)70304-5 PG 1 WC Oncology SC Oncology GA 313TD UT WOS:000256762000013 ER PT J AU Burstein, HJ AF Burstein, Harold J. TI Angiogenesis inhibitors in breast cancer SO EJC SUPPLEMENTS LA English DT Meeting Abstract CT 6th European Breast Cancer Conference CY APR 15-19, 2008 CL Berlin, GERMANY C1 [Burstein, Harold J.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 1359-6349 J9 EJC SUPPL JI EJC Suppl. PD APR PY 2008 VL 6 IS 7 BP 41 EP 41 PG 1 WC Oncology SC Oncology GA 313TD UT WOS:000256762000020 ER PT J AU Winer, E AF Winer, E. TI The doctor's view SO EJC SUPPLEMENTS LA English DT Meeting Abstract CT 6th European Breast Cancer Conference CY APR 15-19, 2008 CL Berlin, GERMANY C1 [Winer, E.] Harvard Univ, Sch Med, Dana Farber Canc Ctr, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 1359-6349 J9 EJC SUPPL JI EJC Suppl. PD APR PY 2008 VL 6 IS 7 BP 52 EP 52 DI 10.1016/S1359-6349(08)70323-9 PG 1 WC Oncology SC Oncology GA 313TD UT WOS:000256762000030 ER PT J AU De Azambuja, E McCaskill-Stevens, W Quinaux, E Buyse, M Crown, J Francis, P Gelber, R Piccart-Gebhart, M AF De Azambuja, E. McCaskill-Stevens, W. Quinaux, E. Buyse, M. Crown, J. Francis, P. Gelber, R. Piccart-Gebhart, M. TI The effect of body mass index (BMI) on disease-free and overall survival in node-positive breast cancer treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial SO EJC SUPPLEMENTS LA English DT Meeting Abstract CT 6th European Breast Cancer Conference CY APR 15-19, 2008 CL Berlin, GERMANY C1 [De Azambuja, E.] Inst Jules Bordet, Med Oncol Clin, B-1000 Brussels, Belgium. [McCaskill-Stevens, W.] NIH, Canc Prevent Div, Bethesda, MD 20892 USA. [Quinaux, E.; Buyse, M.] Int Inst Drug Dev, Louvain, Belgium. [Crown, J.] Breast Comm, Irish Clin Oncol Res Grp, Dublin, Ireland. [Francis, P.] ANZ BCTG & IBCSG, Peter MacCallum Canc Ctr, Melbourne, Australia. [Gelber, R.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Piccart-Gebhart, M.] Inst Jules Bordet, Dept Med, B-1000 Brussels, Belgium. NR 0 TC 0 Z9 0 U1 0 U2 4 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 1359-6349 J9 EJC SUPPL JI EJC Suppl. PD APR PY 2008 VL 6 IS 7 BP 58 EP 59 DI 10.1016/S1359-6349(08)70345-8 PG 2 WC Oncology SC Oncology GA 313TD UT WOS:000256762000052 ER PT J AU Penny, SA Kelly, CM Brennan, DJ Culhane, AC Higgins, DG Dervan, PA Jirstrom, K Ponten, F Uhlen, M Gallagher, WM AF Penny, S. A. Kelly, C. M. Brennan, D. J. Culhane, A. C. Higgins, D. G. Dervan, P. A. Jirstrom, K. Ponten, F. Uhlen, M. Gallagher, W. M. TI Systematic validation of novel breast cancer progression-associated biomarkers via high-throughput antibody generation and application of tissue microarray technology SO EJC SUPPLEMENTS LA English DT Meeting Abstract CT 6th European Breast Cancer Conference CY APR 15-19, 2008 CL Berlin, GERMANY C1 [Penny, S. A.; Kelly, C. M.; Brennan, D. J.; Gallagher, W. M.] Conway Inst, Sch Biomol & Biomed Sci, Dublin, Ireland. [Culhane, A. C.] Dana Farber Canc Inst, Computat Biol & Funct Genom Lab, Boston, MA 02115 USA. [Higgins, D. G.; Dervan, P. A.] Conway Inst, Sch Med & Med Sci, Dublin, Ireland. [Jirstrom, K.] Lund Univ, Dept Pathol, Lund, Sweden. [Ponten, F.] Uppsala Univ, Dept Genet & Pathol, Uppsala, Sweden. [Uhlen, M.] Karolinska Inst, Dept Med Biochem & Biophys, Stockholm, Sweden. RI Higgins, des/J-6314-2012 NR 0 TC 0 Z9 0 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 1359-6349 J9 EJC SUPPL JI EJC Suppl. PD APR PY 2008 VL 6 IS 7 BP 59 EP 59 DI 10.1016/S1359-6349(08)70347-1 PG 1 WC Oncology SC Oncology GA 313TD UT WOS:000256762000054 ER PT J AU Polyak, K Shipitsin, M Qimron, N Campbell, L Yao, J AF Polyak, K. Shipitsin, M. Qimron, N. Campbell, L. Yao, J. TI Targeting breast cancer stem cells SO EJC SUPPLEMENTS LA English DT Meeting Abstract CT 6th European Breast Cancer Conference CY APR 15-19, 2008 CL Berlin, GERMANY C1 [Polyak, K.; Shipitsin, M.; Qimron, N.; Campbell, L.; Yao, J.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 1359-6349 J9 EJC SUPPL JI EJC Suppl. PD APR PY 2008 VL 6 IS 7 BP 105 EP 106 PG 2 WC Oncology SC Oncology GA 313TD UT WOS:000256762000216 ER PT J AU Singer, C Kuter, I Hegg, R Badwe, R Harbeck, N Bines, J Lowe, E AF Singer, C. Kuter, I. Hegg, R. Badwe, R. Harbeck, N. Bines, J. Lowe, E. CA NEWEST Investigators TI NEWEST: a Phase II, randomised, neoadjuvant trial comparing fulvestrant 500 mg vs 250 mg in postmenopausal women with locally advanced, oestrogen receptor-positive (ER+) breast cancer SO EJC SUPPLEMENTS LA English DT Meeting Abstract CT 6th European Breast Cancer Conference CY APR 15-19, 2008 CL Berlin, GERMANY C1 [Singer, C.] Med Univ Vienna, Div Special Gynecol, Vienna, Austria. [Kuter, I.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Hegg, R.] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil. [Hegg, R.] Perola Bygton Hosp, Sch Med, Sao Paulo, Brazil. [Badwe, R.] Tata Mem Hosp, Mumbai 400012, Maharashtra, India. [Harbeck, N.] Tech Univ Munich, Frauenklin, Munich, Germany. [Bines, J.] Inst Nacl Canc, Breast Canc Unit, Rio De Janeiro, Brazil. [Lowe, E.] AstraZeneca, Clin Res, Wilmington, DE 19850 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 1359-6349 J9 EJC SUPPL JI EJC Suppl. PD APR PY 2008 VL 6 IS 7 BP 115 EP 115 DI 10.1016/S1359-6349(08)70543-3 PG 1 WC Oncology SC Oncology GA 313TD UT WOS:000256762000247 ER PT J AU Moy, B Maltzman, JD Rappold, E Finkelstein, D Williams, LS Goss, PE AF Moy, B. Maltzman, J. D. Rappold, E. Finkelstein, D. Williams, L. S. Goss, P. E. TI TEACH phase III study of lapatinib after completion of adjuvant chemotherapy in trastuzumab-naive women with HER2-overexpressing breast cancer SO EJC SUPPLEMENTS LA English DT Meeting Abstract CT 6th European Breast Cancer Conference CY APR 15-19, 2008 CL Berlin, GERMANY C1 [Moy, B.; Goss, P. E.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Maltzman, J. D.; Rappold, E.; Williams, L. S.] GlaxoSmithKline Inc, Med Dev Ctr, Collegeville, PA USA. [Finkelstein, D.] Massachusetts Gen Hosp, Dept Biostat, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 1359-6349 J9 EJC SUPPL JI EJC Suppl. PD APR PY 2008 VL 6 IS 7 BP 120 EP 121 PG 2 WC Oncology SC Oncology GA 313TD UT WOS:000256762000264 ER PT J AU Sloan, DM Marx, BP Epstein, EA Dobbs, JL AF Sloan, Denise M. Marx, Brian P. Epstein, Eva A. Dobbs, Jennifer L. TI Expressive writing buffers against maladaptive rumination SO EMOTION LA English DT Article DE rumination; brooding; reflective pondering; depression; expressive writing ID ANXIETY STRESS SCALES; WRITTEN EMOTIONAL EXPRESSION; PSYCHOMETRIC PROPERTIES; RANDOMIZED-TRIAL; DEPRESSED MOOD; DISCLOSURE; EXPERIENCES; INHIBITION; MODERATORS; SYMPTOMS AB This study examined whether ruminative style moderated the effects of expressive writing. Sixty-nine participants were assessed for ruminative style and depression symptoms at the beginning of their 1st college semester. Participants were then randomized to either an expressive writing or a control writing condition. Changes in depression symptoms were assessed 2, 4, and 6 months later. Results showed that a brooding ruminative style moderated the effects of expressive writing such that among those assigned to the expressive writing condition, individuals with greater brooding scores reported significantly fewer depression symptoms at all of the follow-up assessments relative to individuals with lower brooding scores. In contrast, reflective pondering ruminative style did not moderate the effects of expressive writing on depression symptoms. These findings suggest that expressive writing could be used as a means of reducing depression symptoms among those with a maladaptive ruminative tendency to brood. C1 [Sloan, Denise M.; Marx, Brian P.] VA Boston Hlthcare Syst, Behav Sci Div, Natl Ctr PTSD, Boston, MA 02130 USA. [Sloan, Denise M.; Marx, Brian P.] Boston Univ, Dept Psychiat, Boston, MA 02215 USA. [Epstein, Eva A.; Dobbs, Jennifer L.] Temple Univ, Dept Psychol, Philadelphia, PA 19122 USA. RP Sloan, DM (reprint author), VA Boston Hlthcare Syst, Behav Sci Div, Natl Ctr PTSD, Boston, MA 02130 USA. EM denise.sloan@va.gov OI Sloan, Denise/0000-0002-0962-478X FU NIMH NIH HHS [R03MH068223] NR 30 TC 27 Z9 27 U1 4 U2 17 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 1528-3542 J9 EMOTION JI Emotion PD APR PY 2008 VL 8 IS 2 BP 302 EP 306 DI 10.1037/1528-3542.8.2.302 PG 5 WC Psychology, Experimental SC Psychology GA 292KX UT WOS:000255266000016 PM 18410204 ER PT J AU Wilkinson, CW AF Wilkinson, Charles W. TI Circadian clocks: Showtime for the adrenal cortex SO ENDOCRINOLOGY LA English DT Editorial Material ID GENE-EXPRESSION; LOCOMOTOR-ACTIVITY; GLAND; MELATONIN; RHYTHM; ENDOCRINE; DRINKING; TISSUES; LESIONS; RATS C1 [Wilkinson, Charles W.] VA Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA 98108 USA. [Wilkinson, Charles W.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. RP Wilkinson, CW (reprint author), VA Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, S-182 GRECC,1660 S Columbian Way, Seattle, WA 98108 USA. EM wilkinso@u.washington.edu NR 23 TC 3 Z9 4 U1 0 U2 1 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0013-7227 J9 ENDOCRINOLOGY JI Endocrinology PD APR PY 2008 VL 149 IS 4 BP 1451 EP 1453 DI 10.1210/en.2008-0166 PG 3 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 278DO UT WOS:000254264100003 PM 18359750 ER PT J AU Yang, DH Guo, J Divieti, P Shioda, T Bringhurst, FR AF Yang, Dehong Guo, Jun Divieti, Paola Shioda, Toshi Bringhurst, F. Richard TI CBP/p300-interacting protein CITED1 modulates parathyroid hormone regulation of osteoblastic differentiation SO ENDOCRINOLOGY LA English DT Article ID TRANSCRIPTION FACTORS; PTH/PTHRP RECEPTOR; SIGNALING PATHWAYS; BONE; CELLS; MICE; MSG1; TRANSACTIVATOR; GENE; PTH AB PTH regulates osteoblastic differentiation and activity and exerts different overall skeletal effects in vivo, depending on the schedule and dose of administration. In clonal Wt9 murine osteoblastic cells, mRNA and protein levels of CITED1 transcriptional coactivator were strongly up-regulated by human (h) PTH(1-34). Stimulation of CITED1 mRNA by PTH was transient, peaking at 4 h, concentration dependent, and blocked by actinomycin D but not cycloheximide. The stimulation was mimicked by forskolin, phorbol ester, and the cAMP-selective PTH analog [G(1), R-19] hPTH (1-28) and inhibited completely by the protein kinase A inhibitor, H89 and partially by phorbol ester-induced protein kinase C depletion. Increased CITED1 expression was not maintained during persistent (24 h) PTH exposure. Cultured primary calvarial osteoblasts from neonatal homozygous or hemizygous CITED1-knockout (KO) mice achieved 2-fold greater mineralized nodule formation in comparison with wild type (WT) osteoblasts. This effect was blocked by restoration of CITED1 expression via adenoviral gene transfer. Intermittent administration of hPTH(1-34) (10 nM, for 4 h every 48 h) for 3-6 wk increased mineralization up to 2-fold over basal levels in both WT and CITED1 KO mouse calvarial cell cultures. Whereas the cAMP-selective [G(1), R-19] hPTH(1-28) analog [at 100 nM, equivalent to 10 nM hPTH(1-34)] did not stimulate mineralization in WT cultures, it was twice as effective as hPTH(1-34) in CITED1 KO cultures. Thus, CITED1 negatively regulates osteoblastic differentiation in vitro and inhibits the cAMP-dependent stimulation of differentiation by intermittent PTH. We conclude also that PTH receptor signaling pathways independent of cAMP restrain osteoblastic differentiation, an effect normally obscured in the presence of CITED1 but revealed in its absence. C1 [Yang, Dehong; Guo, Jun; Divieti, Paola; Bringhurst, F. Richard] Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA. [Yang, Dehong; Guo, Jun; Divieti, Paola; Bringhurst, F. Richard] Harvard Univ, Sch Med, Boston, MA 02114 USA. [Shioda, Toshi] Massachusetts Gen Hosp, Ctr Canc, Mol Profiling Lab, Charlestown, MA 02129 USA. RP Bringhurst, FR (reprint author), Massachusetts Gen Hosp, Endocrine Unit, Thier 11, Boston, MA 02114 USA. EM rbringhurst@partners.org FU NCI NIH HHS [CA 082230, R01 CA082230]; NIDDK NIH HHS [DK 11794, P01 DK011794] NR 21 TC 11 Z9 15 U1 0 U2 1 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0013-7227 J9 ENDOCRINOLOGY JI Endocrinology PD APR PY 2008 VL 149 IS 4 BP 1728 EP 1735 DI 10.1210/en.2007-0826 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 278DO UT WOS:000254264100033 PM 18187554 ER PT J AU Abreu, DV Tamura, TK Sipp, JA Keamy, DG Eavey, RD AF Abreu, Daniel V. Tamura, Thomas K. Sipp, J. Andrew Keamy, Donald G., Jr. Eavey, Roland D. TI Podcasting: Contemporary patient education SO ENT-EAR NOSE & THROAT JOURNAL LA English DT Article; Proceedings Paper CT 22nd Annual Meeting of the American-Society-of-Pediatric-Otolaryngology CY APR 27-29, 2007 CL San Diego, CA SP Amer Soc Pediat Otolaryngol ID TECHNOLOGIES AB Portable video technology is a widely available new tool with potential to be used by pediatricotolaryngology practices for patient and family education. Podcasts are media broadcasts that employ this new technology. They can be accessed via the Internet and viewed either on a personal computer or on a handheld device, such as an iPod or an MP3 player. We wished to examine the feasibility of establishing a podcast-hosting Web site. We digitally recorded pediatric otologic procedures in the operating room and saved the digital files to DVDs. We then edited the DVDs at home with video-editing software on a personal computer. Next, spoken narrative was recorded with audio-recording software and combined with the edited video clips. The final products were converted into the M4V file format, and the final versions were uploaded onto our hospital's Web site. We then downloaded the podcasts onto a high-quality portable media player so that we could evaluate their quality. All of the podcasts are now on the hospital Web site, where they can be downloaded by patients and families at no cost. The site includes instructions on how to download the appropriate free software for viewing the podcasts on aportable media player or on a computer. Using this technology for patient education expands the audience and permits portability of information. We conclude that a home computer can be used to inexpensively create informative surgery demonstrations that can be accessed via a Web site and transferred to portable viewing devices with excellent quality. C1 [Abreu, Daniel V.; Tamura, Thomas K.; Sipp, J. Andrew; Keamy, Donald G., Jr.; Eavey, Roland D.] Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Pediat Oncol Serv,Dept Otolaryngol, Boston, MA 02114 USA. RP Eavey, RD (reprint author), Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Pediat Oncol Serv,Dept Otolaryngol, 243 Charles St,2nd Fl, Boston, MA 02114 USA. EM Roland_Eavey@MEEI.harvard.edu NR 10 TC 4 Z9 4 U1 0 U2 0 PU VENDOME GROUP LLC PI NEW YORK PA 149 FIFTH AVE, 10TH FLOOR, NEW YORK, NY 10010 USA SN 0145-5613 J9 ENT-EAR NOSE THROAT JI ENT-Ear Nose Throat J. PD APR PY 2008 VL 87 IS 4 BP 208 EP + PG 3 WC Otorhinolaryngology SC Otorhinolaryngology GA 286ZW UT WOS:000254886800010 PM 18478793 ER PT J AU Ellinor, PT Milan, DJ AF Ellinor, Patrick T. Milan, David J. TI Polymorphisms and atrial fibrillation: sorting the wheat from the chaff SO EUROPEAN HEART JOURNAL LA English DT Editorial Material ID OF-FUNCTION MUTATION; QT INTERVAL; FUNCTIONAL-CHARACTERIZATION; FAMILIAL AGGREGATION; KCNH2 HERG C1 Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA. Massachusetts Gen Hosp, Cardiac Arrhythmia Serv, Boston, MA 02114 USA. RP Ellinor, PT (reprint author), Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA. EM pellinor@partners.org NR 15 TC 1 Z9 1 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0195-668X J9 EUR HEART J JI Eur. Heart J. PD APR PY 2008 VL 29 IS 7 BP 843 EP 845 DI 10.1093/eurheartj/ehn066 PG 3 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 284DE UT WOS:000254684900007 PM 18310053 ER PT J AU O'Donoghue, M Morrow, DA Cannon, CP Guo, W Murphy, SA Gibson, CM Sabatine, MS AF O'Donoghue, Michelle Morrow, David A. Cannon, Christopher P. Guo, Wei Murphy, Sabina A. Gibson, C. Michael Sabatine, Marc S. TI Association between baseline neutrophil count, clopidogrel therapy, and clinical and angiographic outcomes in patients with ST-elevation myocardial infarction receiving fibrinolytic therapy SO EUROPEAN HEART JOURNAL LA English DT Article DE acute coronary syndrome; ST-elevation myocardial infarction; fibrinolysis; white blood cell; clopidogrel ID BLOOD-CELL COUNT; ACUTE CORONARY SYNDROMES; P-SELECTIN EXPRESSION; SEGMENT ELEVATION; ARTERY-DISEASE; CD40 LIGAND; UNSTABLE ANGINA; MORTALITY; REPERFUSION; ASPIRIN AB Aims To investigate the association between neutrophil count, outcomes, and benefit of clopidogrel therapy in ST-elevation myocardial infarction (STEMI). Methods and results Baseline neutrophil count was measured in 2865 patients in CLARITY-TIMI 28, a randomized trial of clopidogrel vs. placebo in STEMI patients undergoing fibrinolysis. Angiography was performed at 2 - 8 days following enrolment. Analyses were adjusted for demographics, time from symptom onset, Killip class, peak CK-MB, and therapies received. A baseline neutrophil count in the highest quartile was independently associated with the risk of cardiovascular (CV) death [adj (adjusted) OR (odds ratio) 5.8, P < 0.001] and congestive heart failure (adj OR 3.0, P=0.009) at 30 days. Patients with higher neutrophil counts were less likely to achieve complete ST-segment resolution (adj OR 0.76, P=0.03) or TIMI myocardial perfusion grade 2/3 (adj OR 0.71, P=0.017). Clopidogrel had a lesser effect on reducing the odds of a closed infarct-related artery, or death or MI before angiography, in patients with a neutrophil count above the median (adjusted OR 0.83, 0.61-1.13) vs. in those below the median (adjusted OR 0.46, 0.33-0.64) (P-interaction= 0.008). Conclusion In patients with STEMI, higher baseline neutrophil count is associated with worse angiographic findings and increased CV mortality, as well as a diminished benefit of clopidogrel. C1 [O'Donoghue, Michelle; Morrow, David A.; Cannon, Christopher P.; Murphy, Sabina A.; Sabatine, Marc S.] Brigham & Womens Hosp, Div Cardiovasc, TIMI Study Grp, Boston, MA 02115 USA. [Guo, Wei] Harvard Clin Res Inst, Boston, MA USA. [Gibson, C. Michael] Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA. RP O'Donoghue, M (reprint author), Brigham & Womens Hosp, Div Cardiovasc, TIMI Study Grp, 350 Longwood Ave,1st Floor, Boston, MA 02115 USA. EM modonoghue@partners.org FU NHLBI NIH HHS [U01 HL083-1341] NR 36 TC 27 Z9 28 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0195-668X J9 EUR HEART J JI Eur. Heart J. PD APR PY 2008 VL 29 IS 8 BP 984 EP 991 DI 10.1093/eurheartj/ehn112 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 290VM UT WOS:000255150800008 PM 18346960 ER PT J AU Pascual-Figal, DA Domingo, M Casas, T Gich, I Ordonez-Llanos, J Martinez, P Cinca, J Valdes, M Januzzi, JL Bayes-Genis, A AF Pascual-Figal, Domingo A. Domingo, Maite Casas, Teresa Gich, Ignasi Ordonez-Llanos, Jordi Martinez, Pedro Cinca, Juan Valdes, Mariano Januzzi, James L. Bayes-Genis, Antoni TI Usefulness of clinical and NT-proBNP monitoring for prognostic guidance in destabilized heart failure outpatients SO EUROPEAN HEART JOURNAL LA English DT Article DE B-type natriuretic peptide; clinical score; heart failure; outpatient; prognosis ID BRAIN NATRIURETIC PEPTIDE; MORTALITY; DIAGNOSIS; OUTCOMES; THERAPY; RISK AB Aims To study the relative prognostic value of N-terminal pro-B-type natriuretic peptide (NT-proBNP) monitoring in addition to clinical disease severity scores (CDSSs) in outpatients with destabilized heart failure (HF). Methods and results Seventy-one outpatients with recently destabilized HF were recruited. At baseline, and at all following visits, a CDSS based on Framingham criteria was obtained, and NT-proBNP levels were measured in a blind fashion. CDSS did not correlate with NT-proBNP levels at any time (P > 0.1), although their relative changes correlated during follow-up (P < 0.001). Forty patients (56%) had clinical events (cardiovascular death and/or HF hospitalization) within 1 year of follow-up. Changes in CDSS from baseline were not predictive of subsequent events (P > 0.1 for all visits), whereas changes in NT-proBNP levels were predictive at several time points: week 2 (P=0.005), week 3 (P=0.037), week 4 (P=0.015), and 6 months (P=0.026). A change in NT-proBNP levels at follow-up week 2 (%) added independent prognostic information (P < 0.001, HR 0.982, 95% CI 0.972-0.992) to baseline CDSS (P=0.002, HR 2.05, 95% CI 1.290-3.266), age (P=0.007, HR 1.034, 95% CI 1.009-1.059), and left ventricular ejection fraction (P=0.013, HR 0.942, 95% CI 0.898-0.987). Conclusion Serial monitoring for per cent change in NT-proBNP concentrations offers superior prognostic information to clinical assessment among outpatients with recent destabilized HF. C1 [Pascual-Figal, Domingo A.; Valdes, Mariano] Univ Hosp Virgen Arrixaca, Dept Cardiol, Murcia 30120, Spain. [Domingo, Maite; Cinca, Juan; Bayes-Genis, Antoni] Univ Autonoma Barcelona, Dept Med, Univ Hosp Santa Creu & St Pau, E-08193 Barcelona, Spain. [Casas, Teresa; Martinez, Pedro] Univ Hosp Virgen Arrixaca, Dept Bioquim, Murcia 30120, Spain. [Gich, Ignasi] Univ Hosp Santa Creu & St Pau, Dept Stat, Barcelona, Spain. [Ordonez-Llanos, Jordi] Univ Autonoma Barcelona, Dept Bioquim, Univ Hosp Santa Creu & St Pau, E-08193 Barcelona, Spain. [Januzzi, James L.] Massachusetts Gen Hosp, Dept Cardiol, Boston, MA 02114 USA. RP Pascual-Figal, DA (reprint author), Univ Hosp Virgen Arrixaca, Dept Cardiol, Ctra Madrid Cartagena S-N, Murcia 30120, Spain. EM dapascual@servicam.com RI Ordonez-Llanos, Jorge/A-9335-2010; Ordonez-Llanos, Jordi/B-4961-2011; Pascual Figal, Domingo /B-3794-2008; Bayes-Genis, Antoni/C-4002-2015 OI Ordonez-Llanos, Jordi/0000-0003-4896-5832; Pascual Figal, Domingo /0000-0002-4993-9540; Bayes-Genis, Antoni/0000-0002-3044-197X NR 23 TC 45 Z9 46 U1 0 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0195-668X J9 EUR HEART J JI Eur. Heart J. PD APR PY 2008 VL 29 IS 8 BP 1011 EP 1018 DI 10.1093/eurheartj/ehn023 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 290VM UT WOS:000255150800011 PM 18263871 ER PT J AU Akins, CW Miller, DC Turina, MI Kouchoukos, NT Blackstone, EH Grunkemeier, GL Takkenberg, JJM David, TE Butchart, EG Adams, DH Shahian, DM Hagl, S Mayer, JE Lytle, BW AF Akins, Cary W. Miller, D. Craig Turina, Marko I. Kouchoukos, Nicholas T. Blackstone, Eugene H. Grunkemeier, Gary L. Takkenberg, Johanna J. M. David, Tirone E. Butchart, Eric G. Adams, David H. Shahian, David M. Hagl, Siegfried Mayer, John E. Lytle, Bruce W. TI Guidelines for reporting mortality and morbidity after cardiac valve interventions SO EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY LA English DT Editorial Material ID CONFIDENCE-INTERVALS; VALVULAR OPERATIONS; REGRESSION-ANALYSIS; COX REGRESSION; EVENTS; APPLES C1 [Akins, Cary W.; Miller, D. Craig; Blackstone, Eugene H.; David, Tirone E.; Lytle, Bruce W.] Amer Assoc Thorac Surg, Beverly, MA USA. [Kouchoukos, Nicholas T.; Grunkemeier, Gary L.; Adams, David H.; Shahian, David M.; Mayer, John E.] Soc Thorac Surg, Chicago, IL USA. [Turina, Marko I.; Takkenberg, Johanna J. M.; Butchart, Eric G.; Hagl, Siegfried] European Assoc Cardio Thorac Surg, Windsor, Berks, England. RP Akins, CW (reprint author), Massachusetts Gen Hosp, Cox 648,55 Fruit St, Boston, MA 02114 USA. EM cakins@partners.org RI Takkenberg, Johanna/B-9368-2009; OI Takkenberg, Johanna/0000-0001-9809-5623 NR 33 TC 91 Z9 93 U1 0 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1010-7940 J9 EUR J CARDIO-THORAC JI Eur. J. Cardio-Thorac. Surg. PD APR PY 2008 VL 33 IS 4 BP 523 EP 528 DI 10.1016/j.ejcts.2007.12.055 PG 6 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 292KU UT WOS:000255265700001 PM 18313319 ER PT J AU Li, Z Aronson, WJ Arteaga, JR Hong, K Thames, G Henning, SM Liu, W Elashoff, R Ashley, JM Heber, D AF Li, Z. Aronson, W. J. Arteaga, J. R. Hong, K. Thames, G. Henning, S. M. Liu, W. Elashoff, R. Ashley, J. M. Heber, D. TI Feasibility of a low-fat/high-fiber diet intervention with soy supplementation in prostate cancer patients after prostatectomy SO EUROPEAN JOURNAL OF CLINICAL NUTRITION LA English DT Article DE prostate cancer; low fat diet; soy supplement; high fiber ID FACTOR-BINDING-PROTEINS; GROWTH-FACTOR AXIS; LOW-FAT DIET; PHYSICAL-ACTIVITY; UNITED-STATES; HIGH-FRUIT; FACTOR-I; INSULIN; MEN; ANTIGEN AB Objectives: To evaluate the feasibility and long- term compliance with a low- fat diet supplemented with soy protein in men at increased risk for recurrence after radical prostatectomy. Design: Randomized, control study. Setting: Academic center in USA. Subject: Forty men who had undergone radical prostatectomy and were at increased risk for recurrence. Intervention: Low- fat ( 15% fat), high- fiber ( 18 g/ 1000 kcal) diet supplemented with 40 g soy protein isolate ( n 26) was compared to USDA recommended diet ( n 14). Results: Over 4 years, subjects in the intervention group but not in the control group made and sustained significant changes in their diet as measured by the dietary assessment instruments and urinary isoflavone excretion. In the intervention group, dietary fat intake was reduced from 33.46 +/- 1.27% energy/ day to 21.04 +/- 1.74% ( P<0.05), fiber intake increased from 14.6 +/- 1.06 to 21.05 +/- 2.29 g/ day. The insulin growth factor- 1 ( IGF- 1) level was decreased from 260.4 +/- 8.6 ng/ ml at baseline to 220.5 +/- 7.9 ng/ ml at 6 months ( P<0.05) in the intervention group with no significant change in the control group. An ex vivo assay demonstrated inhibition of LNCaP cell growth ( - 20.0 +/- 7.7%, P<0.05) by sera from patients in the intervention group after 6 months of dietary change compared to baseline. Conclusion: These data suggest that long- term low- fat dietary interventions as part of prospective randomized trials in prostate cancer survivors are feasible, and lead to reductions in circulating hormones or other growth factors stimulating prostate cancer growth ex vivo. C1 [Li, Z.; Arteaga, J. R.; Hong, K.; Thames, G.; Henning, S. M.; Heber, D.] Univ Calif Los Angeles, David Geffen Sch Med, Ctr Human Nutr, Los Angeles, CA 90095 USA. [Li, Z.; Aronson, W. J.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Aronson, W. J.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Los Angeles, CA 90095 USA. [Liu, W.; Elashoff, R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Biomath, Los Angeles, CA 90095 USA. [Ashley, J. M.] Univ Nevada, Reno, NV 89557 USA. RP Li, Z (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Ctr Human Nutr, 900 Vet Ave,Room 12-217, Los Angeles, CA 90095 USA. EM zli@mednet.ucla.edu FU NCI NIH HHS [P50 CA92131, P30 CA 42710, CA100938]; NIDDK NIH HHS [T32 DK 57688] NR 32 TC 10 Z9 10 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0954-3007 J9 EUR J CLIN NUTR JI Eur. J. Clin. Nutr. PD APR PY 2008 VL 62 IS 4 BP 526 EP 536 DI 10.1038/sj.ejcn.1602743 PG 11 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 282IH UT WOS:000254560600010 PM 17392697 ER PT J AU Shapiro, MD Pena, AJ Nichols, JH Worrell, S Bamberg, F Dannemann, N Abbara, S Cury, RC Brady, TJ Hoffmann, U AF Shapiro, Michael D. Pena, Antonio J. Nichols, John H. Worrell, Stewart Bamberg, Fabian Dannemann, Nina Abbara, Suhny Cury, Ricardo C. Brady, Thomas J. Hoffmann, Udo TI Efficacy of pre-scan beta-blockade and impact of heart rate on image quality in patients undergoing coronary multidetector computed tomography angiography SO EUROPEAN JOURNAL OF RADIOLOGY LA English DT Article DE multidetector computed tomography; computed tomography angiography; beta-blocker; image quality; heart rate ID INTRAVASCULAR ULTRASOUND; RECONSTRUCTION TECHNIQUE; ATHEROSCLEROTIC PLAQUE; ARTERY STENOSES; ROW CT; ACCURACY; COLLIMATION; ROTATION AB Objective: While beta-blockers are routinely administered to patients prior to coronary computed tomography angiography (CTA), their effectiveness is unknown. We therefore assessed the efficacy of beta-blockade with regards to heart rate (HR) control and image quality in an unselected patient cohort. Methods: We studied 150 consecutive patients (104 men/46 female; mean age, 56 13 years) referred for coronary CTA. Intravenous metoprolol (5-20 mg) was administered to patients with a HR > 65 beats per minute (bpm). The goal HR was defined as an average HR < 65 bpm without a single measurement above 68 bpm. Results: Overall, 45% (68/150) of patients met the HR criteria for beta-blocker administration of which 76% (52/68) received metoprolol (mean dose 12 +/- 10 mg). Of the 52 patients who received beta-blocker versus the 98 who did not, 18 (35%) versus 62 (64%) patients achieved the goal HR, respectively. All patients who achieved the target HR had an evaluable CTA while five patients who did not achieve the target HR had at least one non-evaluable coronary artery due to motion artifact. There was also a significant reduction in any motion artifact among those who achieved the goal HR as compared to those who did not (p = 0.001). Logistic regression revealed an increase in the odds of stair step artifact of 11.6% (95% CI: 2.4% decrease, 27.5% increase) per 1 bpm increase in the standard deviation of scan HR. Conclusion: Overall, efficacy of beta-blocker administration to reach target HR is limited. Improvements in CT scanner temporal resolution are mandatory to achieve consistently high image quality independent of HR and beta-blocker administration. (c) 2007 Elsevier Ireland Ltd. All rights reserved. C1 [Shapiro, Michael D.; Pena, Antonio J.; Nichols, John H.; Bamberg, Fabian; Dannemann, Nina; Abbara, Suhny; Cury, Ricardo C.; Brady, Thomas J.; Hoffmann, Udo] Massachusetts Gen Hosp, Cardiac MR PET CT Program, Boston, MA 02114 USA. [Shapiro, Michael D.; Pena, Antonio J.; Nichols, John H.; Bamberg, Fabian; Dannemann, Nina; Abbara, Suhny; Cury, Ricardo C.; Brady, Thomas J.; Hoffmann, Udo] Harvard Univ, Sch Med, Cardiac MR PET CT Program, Boston, MA USA. [Shapiro, Michael D.; Worrell, Stewart; Bamberg, Fabian; Abbara, Suhny; Cury, Ricardo C.; Brady, Thomas J.; Hoffmann, Udo] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [Shapiro, Michael D.; Worrell, Stewart; Bamberg, Fabian; Abbara, Suhny; Cury, Ricardo C.; Brady, Thomas J.; Hoffmann, Udo] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA. RP Hoffmann, U (reprint author), Massachusetts Gen Hosp, Cardiac MR PET CT Program, 165 Cambridge St,Suite 400, Boston, MA 02114 USA. EM uhoffmann@partners.org FU NHLBI NIH HHS [1T32 HL076136-02] NR 23 TC 45 Z9 49 U1 0 U2 3 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0720-048X J9 EUR J RADIOL JI Eur. J. Radiol. PD APR PY 2008 VL 66 IS 1 BP 37 EP 41 DI 10.1016/j.ejrad.2007.05.006 PG 5 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 296YG UT WOS:000255581200007 PM 17587526 ER PT J AU Fava, M Pollack, M Montgomery, S Wessel, T Amato, D Krystal, A Hayduk, R McCall, WV AF Fava, M. Pollack, M. Montgomery, S. Wessel, T. Amato, D. Krystal, A. Hayduk, R. McCall, W. V. TI Evaluation of the HAM-D17 following eszopiclone treatment in patients with insomnia co-morbid with major depressive disorder or generalized anxiety disorder SO EUROPEAN PSYCHIATRY LA English DT Meeting Abstract C1 [Fava, M.; Pollack, M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Montgomery, S.] Imperial Coll Med, London, England. [Wessel, T.; Amato, D.] Sepracor Inc, Marlborough, MA USA. [Krystal, A.] Duke Univ, Ctr Med, Durham, NC USA. [Hayduk, R.] Quintiles Inc, San Diego, CA USA. [McCall, W. V.] Wake Forest Univ Hlth Sci, Winston Salem, NC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER PI PARIS PA 23 RUE LINOIS, 75724 PARIS, FRANCE SN 0924-9338 J9 EUR PSYCHIAT JI Eur. Psychiat. PD APR PY 2008 VL 23 SU 2 BP S360 EP S360 DI 10.1016/j.eurpsy.2008.01.1247 PG 1 WC Psychiatry SC Psychiatry GA 288LL UT WOS:000254987801522 ER PT J AU Kennedy, A Wood, AE Tapp, A AF Kennedy, A. Wood, A. E. Tapp, A. TI Adjunctive galantamine's effect on functioning in schizophrenia: No clear benefit SO EUROPEAN PSYCHIATRY LA English DT Meeting Abstract C1 [Kennedy, A.; Wood, A. E.; Tapp, A.] VA Puget Sound Hlth Care Syst, MIRECC, Seattle, WA USA. [Kennedy, A.; Wood, A. E.; Tapp, A.] VA Puget Sound Hlth Care Syst, MIRECC, Tacoma, WA USA. [Kennedy, A.] Seattle Inst Biomed & Clin Res, Seattle, WA USA. [Wood, A. E.; Tapp, A.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER PI PARIS PA 23 RUE LINOIS, 75724 PARIS, FRANCE SN 0924-9338 J9 EUR PSYCHIAT JI Eur. Psychiat. PD APR PY 2008 VL 23 SU 2 BP S240 EP S240 DI 10.1016/j.eurpsy.2008.01.454 PG 1 WC Psychiatry SC Psychiatry GA 288LL UT WOS:000254987801107 ER PT J AU Kornstein, SG Fava, M Tourian, K Lamm, L Jiang, Q Patroneva, A Ahmed, S AF Kornstein, S. G. Fava, M. Tourian, K. Lamm, L. Jiang, Q. Patroneva, A. Ahmed, S. TI Age and gender analysis of baseline depressive symptoms in patients with major depressive disorder treated with Desvenlafaxine Succinate or placebo SO EUROPEAN PSYCHIATRY LA English DT Meeting Abstract C1 [Kornstein, S. G.] Virginia Commonwealth Univ, Richmond, VA USA. [Fava, M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Tourian, K.; Lamm, L.; Jiang, Q.; Patroneva, A.; Ahmed, S.] Wyeth Res, Collegeville, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER PI PARIS PA 23 RUE LINOIS, 75724 PARIS, FRANCE SN 0924-9338 J9 EUR PSYCHIAT JI Eur. Psychiat. PD APR PY 2008 VL 23 SU 2 BP S256 EP S256 DI 10.1016/j.eurpsy.2008.01.506 PG 1 WC Psychiatry SC Psychiatry GA 288LL UT WOS:000254987801159 ER PT J AU Papakostas, GL Cooper, JA Richard, NE AF Papakostas, G. L. Cooper, J. A. Richard, N. E. TI Resolution of sleepiness and fatigue: A comparison of bupropion and ssris in Patients achieving remission in MDD SO EUROPEAN PSYCHIATRY LA English DT Meeting Abstract C1 [Papakostas, G. L.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Cooper, J. A.] GlaxoSmithKline Inc, Greenford, Middx, England. [Richard, N. E.] GlaxoSmithKline Inc, Res Triangle Pk, NC USA. NR 0 TC 3 Z9 3 U1 0 U2 1 PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER PI PARIS PA 23 RUE LINOIS, 75724 PARIS, FRANCE SN 0924-9338 J9 EUR PSYCHIAT JI Eur. Psychiat. PD APR PY 2008 VL 23 SU 2 BP S205 EP S205 DI 10.1016/j.eurpsy.2008.01.336 PG 1 WC Psychiatry SC Psychiatry GA 288LL UT WOS:000254987800707 ER PT J AU Pompili, M Innamorati, M Del Casale, A Ferrara, C Celentano, A Angelone, M Buffo, S Manfredi, G Giupponi, G Di Veroli, G Berry, I Girardi, P Tatarelli, R De Pisa, E Comazzetto, C Falcone, I AF Pompili, M. Innamorati, M. Del Casale, A. Ferrara, C. Celentano, A. Angelone, M. Buffo, S. Manfredi, G. Giupponi, G. Di Veroli, G. Berry, I. Girardi, P. Tatarelli, R. De Pisa, E. Comazzetto, C. Falcone, I. TI Response to antidepressant treatment by suicidal major affective disorder patients SO EUROPEAN PSYCHIATRY LA English DT Meeting Abstract C1 [Pompili, M.; Del Casale, A.; Ferrara, C.; Celentano, A.; Angelone, M.; Buffo, S.; Manfredi, G.; Di Veroli, G.; Berry, I.; Girardi, P.; Tatarelli, R.; De Pisa, E.; Comazzetto, C.; Falcone, I.] Univ Roma La Sapienza, Sant Andrea Hosp, Dept Psychiat, Rome, Italy. [Pompili, M.] Harvard Univ, Sch Med, Dept Psychiat, Belmont, MA 02178 USA. [Innamorati, M.] Massachusetts Gen Hosp, McLean Div, Int Consortium Bipolar Disorder Res, Belmont, MA USA. [Giupponi, G.] Dept Psychiat, Bolzano, Italy. RI Manfredi, Giovanni/C-2176-2011; Innamorati, Marco/H-8877-2013 OI Innamorati, Marco/0000-0003-1389-2290 NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER PI PARIS PA 23 RUE LINOIS, 75724 PARIS, FRANCE SN 0924-9338 J9 EUR PSYCHIAT JI Eur. Psychiat. PD APR PY 2008 VL 23 SU 2 BP S233 EP S234 DI 10.1016/j.eurpsy.2008.01.432 PG 2 WC Psychiatry SC Psychiatry GA 288LL UT WOS:000254987801085 ER PT J AU Shenton, ME Kawashima, T Nakamura, M Bouix, S Salisbury, DF Westin, CF McCarley, RW Kubicki, M AF Shenton, M. E. Kawashima, T. Nakamura, M. Bouix, S. Salisbury, D. F. Westin, C. F. McCarley, R. W. Kubicki, M. TI Uncinate fasciculus and cingulum bundle findings in first episode schizophrenia and first episode bipolar disorder: A diffusion tensor imaging study SO EUROPEAN PSYCHIATRY LA English DT Meeting Abstract C1 [Shenton, M. E.; Kawashima, T.; Bouix, S.; Westin, C. F.; Kubicki, M.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA USA. [Kawashima, T.] VA Boston Healthcare Syst, Dept Psychiat, Boston, MA USA. [Nakamura, M.] Yokahama City Univ Med, Dept Psychiat, Yokohama, Japan. [Salisbury, D. F.] Harvard Univ, McLean Hosp, Sch Med, Dept Psychiat, Belmont, MA 02178 USA. [McCarley, R. W.] VA Boston Healthcare Syst, Dept Psychiat, Brockton, MA USA. NR 0 TC 1 Z9 1 U1 1 U2 2 PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER PI PARIS PA 23 RUE LINOIS, 75724 PARIS, FRANCE SN 0924-9338 J9 EUR PSYCHIAT JI Eur. Psychiat. PD APR PY 2008 VL 23 SU 2 BP S43 EP S43 DI 10.1016/j.eurpsy.2008.01.155 PG 1 WC Psychiatry SC Psychiatry GA 288LL UT WOS:000254987800153 ER PT J AU Strom, BL Faich, G Eng, SM Reynolds, RF D'Agostino, RB Ruskin, J Kane, JM AF Strom, B. L. Faich, G. Eng, S. M. Reynolds, R. F. D'Agostino, R. B. Ruskin, J. Kane, J. M. TI Comparative mortality associated with ziprasidone vs. olanzapine in real-world use: The ziprasidone observational study of cardiac outcomes (zodiac) SO EUROPEAN PSYCHIATRY LA English DT Meeting Abstract C1 [Strom, B. L.] Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Strom, B. L.] Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Faich, G.] United BioSource Corp, Dept Epidemiol, Blue Bell, PA USA. [Eng, S. M.; Reynolds, R. F.] Pfizer Inc, New York, NY USA. [D'Agostino, R. B.] Boston Univ, Boston, MA 02215 USA. [Ruskin, J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Kane, J. M.] Zucker Hillside Hosp, Dept Psychiat, Glen Oaks, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER PI PARIS PA 23 RUE LINOIS, 75724 PARIS, FRANCE SN 0924-9338 J9 EUR PSYCHIAT JI Eur. Psychiat. PD APR PY 2008 VL 23 SU 2 BP S158 EP S158 DI 10.1016/j.eurpsy.2008.01.928 PG 1 WC Psychiatry SC Psychiatry GA 288LL UT WOS:000254987800547 ER PT J AU Tapp, A Kilzieh, N AF Tapp, A. Kilzieh, N. TI Time to discontinuation of olanzapine and risperidone as a measure of effectiveness in a clinical setting SO EUROPEAN PSYCHIATRY LA English DT Meeting Abstract C1 [Tapp, A.; Kilzieh, N.] Va Puget Sound Hlth Care Syst, Amer Lake Div, Tacoma, WA USA. [Tapp, A.; Kilzieh, N.] Mental Illness Res Educ & Clin Ctr MIRREC, Tacoma, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER PI PARIS PA 23 RUE LINOIS, 75724 PARIS, FRANCE SN 0924-9338 J9 EUR PSYCHIAT JI Eur. Psychiat. PD APR PY 2008 VL 23 SU 2 BP S149 EP S150 DI 10.1016/j.eurpsy.2008.01.901 PG 2 WC Psychiatry SC Psychiatry GA 288LL UT WOS:000254987800520 ER PT J AU Cantwell, CP Hahn, PF Gervais, DA Mueller, PR AF Cantwell, Colin P. Hahn, Peter F. Gervais, Debra A. Mueller, Peter R. TI Prostate biopsy after ano-rectal resection: value of CT-guided trans-gluteal biopsy SO EUROPEAN RADIOLOGY LA English DT Article DE prostate; prostate cancer; percutaneous biopsy; techniques ID ABDOMINOPERINEAL RESECTION; ULTRASOUND; CANCER; TRANSGLUTEAL AB We describe our single-institutional experience with computed tomography (CT)-guided percutaneous transgluteal biopsy of the prostate in patients in whom transrectal ultrasound-guided biopsy is precluded by prior ano-rectal resection. Between March 1995 and April 2007, 22 patients had 34 prostate biopsies (mean age 68; mean PSA 29 ng/ml; mean follow-up 6.1 years). The charts of patients who had transgluteal biopsy were reviewed for demographic, complications and pathology. Ninety-five percent (21/22) of primary biopsies were diagnostic. Of the 21 diagnostic biopsies, 11 were positive for prostate cancer and ten were definitive benign samples. Seventy-three percent (8/11) of the patients had progressive PSA elevation that mandated 11 further prostate biopsies. Six patients had a second biopsy, one patient had a third and one patient had a fourth biopsy. Among patients who had serial biopsies, 38% (3/8) had prostate cancer. No complications or death occurred. A malignant biopsy was not significantly associated with core number (P=0.58) or a high PSA level (P=0.15). CT-guided transgluteal biopsy of the prostate is safe and effective. C1 [Cantwell, Colin P.; Hahn, Peter F.; Gervais, Debra A.; Mueller, Peter R.] Massachusetts Gen Hosp, Div Abdominal Imaging & Intervent Radiol, Boston, MA 02114 USA. [Cantwell, Colin P.; Hahn, Peter F.; Gervais, Debra A.; Mueller, Peter R.] Harvard Univ, Sch Med, Boston, MA 02114 USA. RP Mueller, PR (reprint author), Massachusetts Gen Hosp, Div Abdominal Imaging & Intervent Radiol, White Bldg,Room 270,55 Fruit St, Boston, MA 02114 USA. EM pmueller@partners.org NR 10 TC 6 Z9 7 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0938-7994 J9 EUR RADIOL JI Eur. Radiol. PD APR PY 2008 VL 18 IS 4 BP 738 EP 742 DI 10.1007/s00330-007-0828-2 PG 5 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 277SV UT WOS:000254235900014 PM 18196247 ER PT J AU Freedland, SJ Hotaling, JM Fitzsimons, NJ Presti, JC Kane, CJ Terris, MK Aronson, WJ Amling, CL AF Freedland, Stephen J. Hotaling, James M. Fitzsimons, Nicholas J. Presti, Joseph C., Jr. Kane, Christopher J. Terris, Martha K. Aronson, William J. Amling, Christopher L. TI PSA in the new millennium: A powerful predictor of prostate cancer prognosis and radical prostatectomy outcomes - Results from the SEARCH database SO EUROPEAN UROLOGY LA English DT Article DE biochemical recurrence; prostate cancer; PSA; radical prostatectomy ID ANTIGEN ERA; BIOCHEMICAL RECURRENCE; PREOPERATIVE PSA; FREE SURVIVAL; SERUM; MEN; PROGRESSION; CARCINOMA; THERAPY; FAILURE AB Objectives: As a result of prostate-specific antigen (PSA) screening, most men today with prostate cancer present with localized disease and serum PSA values < 10 ng/ml. Within this context, it is debated whether PSA remains an important prognostic variable in more recently treated patients. We examined the prognostic significance of preoperative PSA to predict pathologic stage and biochemical progression among men undergoing radical prostatectomy in the new millennium (2000-2006). Methods: We performed a review of 925 men with prostate cancer treated by radical prostatectomy since 2000 within the Shared Equal Access Regional Cancer Hospital (SEARCH) database. We examined the association between preoperative PSA and risk of adverse pathologic features and biochemical progression using logistic regression and Cox proportional hazards analysis. Results: After adjusting for multiple clinical preoperative characteristics, higher preoperative PSA values were associated with increased odds of extracapsular extension (p < 0.001), positive surgical margins (p < 0.001), and seminal vesicle invasion (p < 0.001) and increased risk of biochemical progression (p = 0.009). When the analyses were limited to the 690 men with a preoperative PSA < 10 ng/ml and after adjusting for multiple clinical characteristics, higher preoperative PSA values remained associated with increased risk of biochemical progression (hazard ratio [HR] 1.16, 95% confidence interval [CI] 1.06-1.28, p = 0.002). Even among the 448 men with a PSA < 10 ng/ml and clinical stage T1c disease, preoperative PSA was associated with increased risk of biochemical progression (HR 1.14, 95% CI 1.00-1.31, p = 0.047). Conclusions: PSA remains an important prognostic marker among men diagnosed with prostate cancer in the new millennium treated with radical prostatectomy and remains an important predictor of outcome even among men with preoperative PSA level < 10 ng/ml. (C) 2007 European Association of Urology. Published by Elsevier B.V. All rights reserved. C1 [Freedland, Stephen J.; Hotaling, James M.; Fitzsimons, Nicholas J.] Duke Univ, Sch Med, Div Urol Surg, Durham, NC 27710 USA. [Freedland, Stephen J.; Hotaling, James M.; Fitzsimons, Nicholas J.] Duke Univ, Sch Med, Duke Prostate Ctr, Durham, NC 27710 USA. [Freedland, Stephen J.] Vet Affairs Med Ctr, Urol Sect, Durham, NC USA. [Freedland, Stephen J.] Duke Univ, Sch Med, Dept Pathol, Durham, NC 27706 USA. [Presti, Joseph C., Jr.] Stanford Univ, Sch Med, Dept Urol, Palo Alto, CA 94304 USA. [Presti, Joseph C., Jr.] Vet Affairs Med Ctr, Urol Sect, Palo Alto, CA 94304 USA. [Kane, Christopher J.] Vet Affairs Med Ctr, Urol Sect, San Francisco, CA 94121 USA. [Kane, Christopher J.] Univ Calif San Francisco, Sch Med, Dept Urol, San Francisco, CA 94143 USA. [Terris, Martha K.] Vet Affairs Med Ctr, Urol Sect, Augusta, GA USA. [Terris, Martha K.] Med Coll Georgia, Urol Sect, Augusta, GA 30912 USA. [Aronson, William J.] Vet Affairs Greater Los Angeles Healthcare Syst, Urol Sect, Los Angeles, CA USA. [Aronson, William J.] Univ Calif Los Angeles, Dept Urol, Los Angeles, CA USA. [Amling, Christopher L.] Univ Alabama, Dept Surg, Div Urol, Birmingham, AL 35294 USA. RP Freedland, SJ (reprint author), Duke Univ, Sch Med, Div Urol Surg, Box 2626 DUMC, Durham, NC 27710 USA. EM steve.freedland@duke.edu OI Terris, Martha/0000-0002-3843-7270 FU NCI NIH HHS [P50 CA92131-01A1, R01CA100938] NR 34 TC 17 Z9 18 U1 0 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0302-2838 J9 EUR UROL JI Eur. Urol. PD APR PY 2008 VL 53 IS 4 BP 758 EP 766 DI 10.1016/j.eururo.2007.08.047 PG 9 WC Urology & Nephrology SC Urology & Nephrology GA 283XT UT WOS:000254670500015 PM 17868976 ER PT J AU de la Rosette, J Collins, E Bachmann, A Choi, B Muir, G Reich, O Sancha, FG Tabatabaei, S Woo, H AF de la Rosette, Jean Collins, Edward Bachmann, Alexander Choi, Benjamin Muir, Gordon Reich, Oliver Gomez Sancha, Fernando Tabatabaei, Shahin Woo, Henry TI Historical aspects of laser therapy for benign prostatic hyperplasia SO EUROPEAN UROLOGY SUPPLEMENTS LA English DT Article DE benign prostatic hyperplasia; GreenLight HPS laser; potassium-titanyl phosphate; holmium laser enucleation of the prostate; interstitial laser coagulation; visual laser ablation of the prostate; neodymium : yttrium-aluminium-garnet las ID TRANSURETHRAL RESECTION; FOLLOW-UP; RANDOMIZED-TRIAL; PHOTOSELECTIVE VAPORIZATION; INDUCED PROSTATECTOMY; ENUCLEATION; COAGULATION; OBSTRUCTION; RADIATION; ABLATION AB The gold standard treatment of benign prostatic hyperplasia (BPH) has been the transurethral resection of the prostate (TURP). However, this procedure is associated with a number of complications, and other surgical therapies, including laser prostatectomy, have been developed to overcome these issues. Laser prostatectomy involves tissue coagulation or vaporization. Coagulation of the tissue results in debulking of the gland through sloughing of necrotic tissue, while vaporization results in an instantaneous debulking of prostatic tissue. The laser procedures developed over the past decade include visual laser ablation of the prostate using the neodymium:yttrium-aluminium-garnet laser. Clinical outcome with this procedure shows good results up to 3 yr. The same laser can be applied through direct insertion of the laser fibres into the prostate in a procedure termed interstitial laser coagulation. Holmium laser enucleation of the prostate is one of the most investigated of the laser procedures and is associated with a good outcome over a long follow-up period. one drawback is the high degree of training required to master the technicalities of the procedure. The latest addition to laser therapy for BPH is photoselective vaporization of the prostate. This procedure results in rapid vaporization of prostate tissue with good outcome up to 5 yr reported. The procedure can be applied to large glands, patients in retention, and those on anticoagulants. Clinical evidence now exists on the effectiveness of both the holmium and potassium-titanyl phosphate lasers, and these therapies now represent a valid clinical alternative to TURP. (c) 2008 European Association of Urology. Published by Elsevier B.V. All rights reserved. C1 [de la Rosette, Jean; Choi, Benjamin] Univ Amsterdam, Acad Med Ctr, Dept Urol, NL-1012 WX Amsterdam, Netherlands. [Collins, Edward] Calif Urolog Serv, San Francisco, CA USA. [Bachmann, Alexander] Univ Hosp, Dept Urol, Basel, Switzerland. [Choi, Benjamin] Cornell Univ, Weill Med Coll, Dept Urol, Ithaca, NY USA. [Muir, Gordon] Kings Coll Hosp London, Dept Urol, London, England. [Reich, Oliver] Univ Munich, Dept Urol, Munich, Germany. [Gomez Sancha, Fernando] Inst Adv Urolog Surg, Madrid, Spain. [Tabatabaei, Shahin] Massachusetts Gen Hosp, Dept Urol, Boston, MA 02114 USA. [Woo, Henry] Univ Sydney, Westmead Hosp, Dept Urol, Sydney, NSW 2006, Australia. RP de la Rosette, J (reprint author), AMC Univ Hosp, Dept Urol, G4 105,Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands. EM J.J.delarosette@amc.uva.nl NR 29 TC 6 Z9 6 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1569-9056 J9 EUR UROL SUPPL JI Eur. Urol. Suppl. PD APR PY 2008 VL 7 IS 4 BP 363 EP 369 DI 10.1016/j.eursup.2008.01.014 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA 283XW UT WOS:000254670800002 ER PT J AU Muir, G Sancha, FG Bachmann, A Choi, B Collins, E de la Rosette, J Reich, O Tabatabaei, S Woo, H AF Muir, Gordon Gomez Sancha, Fernando Bachmann, Alexander Choi, Benjamin Collins, Edward de la Rosette, Jean Reich, Oliver Tabatabaei, Shahin Woo, Henry TI Techniques and training with GreenLight HPS120-W laser therapy of the prostate: Position paper SO EUROPEAN UROLOGY SUPPLEMENTS LA English DT Article DE GreenLight HPS laser; photoselective vaporization of the prostate; benign prostatic hyperplasia; technique; training ID PHOTOSELECTIVE VAPORIZATION AB We report the technical recommendations of the International GreenLight User Group on photoselective vaporization of the prostate in men with benign prostatic hyperplasia using the GreenLight HPS system (American Medical Systems, Minnetonka, Minnesota, USA). This high-power system employs a 120-W laser, which is a modification of the previous 80-W potassium-titanyl-phosphate (KTP) laser. The objective of this report is to optimize the efficacy and safety of the procedure by drawing on the experience of this multicentre international group. In this regard, recommendations for training are made, which relate to existing users of the 80-W KTP laser as well as to new laser users. (c) 2007 European Association of Urology. Published by Elsevier B.V. All rights reserved. C1 [Gomez Sancha, Fernando] Inst Adv Urolog Surg, Madrid 28046, Spain. [Muir, Gordon] Kings Coll Hosp London, Dept Urol, London, England. [Bachmann, Alexander] Univ Hosp, Dept Urol, Basel, Switzerland. [Choi, Benjamin] Cornell Univ, Weill Med Coll, Dept Urol, Ithaca, NY USA. [Collins, Edward] Calif Urolog Serv, San Francisco, CA USA. [de la Rosette, Jean] Univ Amsterdam, Acad Med Ctr, Dept Urol, NL-1012 WX Amsterdam, Netherlands. [Reich, Oliver] Univ Munich, Dept Urol, Munich, Germany. [Tabatabaei, Shahin] Massachusetts Gen Hosp, Dept Urol, Boston, MA 02114 USA. [Woo, Henry] Univ Sydney, Westmead Hosp, Dept Urol, Sydney, NSW 2006, Australia. RP Sancha, FG (reprint author), Inst Adv Urolog Surg, Paseo De Castellana 23, Madrid 28046, Spain. EM fernando@icua.es NR 2 TC 43 Z9 47 U1 0 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1569-9056 J9 EUR UROL SUPPL JI Eur. Urol. Suppl. PD APR PY 2008 VL 7 IS 4 BP 370 EP 377 DI 10.1016/j.eursup.2008.01.012 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA 283XW UT WOS:000254670800003 ER PT J AU Woo, H Reich, O Bachmann, A Choi, B Collins, E de la Rosette, J Sancha, FG Muir, G Tabatabaei, S AF Woo, Henry Reich, Oliver Bachmann, Alexander Choi, Benjamin Collins, Edward de la Rosette, Jean Gomez Sancha, Fernando Muir, Gordon Tabatabaei, Shahin TI Outcome of GreenLight HPS 120-w laser therapy in specific patient populations: Those in retention, on anticoagulants, and with large prostates (>= 80 ml) SO EUROPEAN UROLOGY SUPPLEMENTS LA English DT Article DE GreenLight HPS 120-w laser; benign prostatic hyperplasia; anticoagulants; urinary retention; prostate size ID TITANYL-PHOSPHATE LASER; PHOTOSELECTIVE VAPORIZATION; TRANSURETHRAL RESECTION; KTP LASER; MEN; HYPERPLASIA; TRIAL; PVP AB A total of 305 consecutive patients who were treated with the GreenLight HPS laser (American Medical Systems, Minnetonka, Minnesota, USA) at eight international centres since July 2006 were included: This subgroup analysis involved 63 patients in urinary retention, 70 patients on anticoagulants, and 52 patients with prostate volume >= 80 ml. Observation period was a maximum of 11 mo, and mean follow-up was 4.2 mo (SD: 4.5). For all patients, the changes in maximum flow rate (Qmax), postvoid residual urine, International Prostate Symptom Score, and prostate volume from baseline to follow-up were significant (p < 0.001). For those patients in retention prior to therapy, the only significant difference between groups with regard to change from baseline was for Qmax (p < 0.001). The use of anticoagulants had no significant effect on changes from baseline values. For those patients with glands >= 80 ml, the only significant difference in change from baseline was for prostate volume reduction (p < 0.001). The rate of complications reported was low in all groups. This study shows that the GreenLight HPS 120-W laser can be used effectively and safely in patients in retention, on anticoagulant therapy, and with large prostates. (c) 2008 European Association of Urology. Published by Elsevier B.V. All rights reserved. C1 [Woo, Henry] Univ Sydney, Westmead Hosp, Dept Urol, Sydney, NSW 2006, Australia. [Reich, Oliver] Univ Munich, Dept Urol, Munich, Germany. [Bachmann, Alexander] Univ Hosp, Dept Urol, Basel, Switzerland. [Choi, Benjamin] Cornell Univ, Weill Med Coll, Dept Urol, Ithaca, NY USA. [Collins, Edward] Calif Urolog Serv, San Francisco, CA USA. [de la Rosette, Jean] Univ Amsterdam, Acad Med Ctr, Dept Urol, NL-1012 WX Amsterdam, Netherlands. [Gomez Sancha, Fernando] Inst Adv Urolog Surg, Madrid, Spain. [Muir, Gordon] Kings Coll Hosp London, Dept Urol, London, England. [Tabatabaei, Shahin] Massachusetts Gen Hosp, Dept Urol, Boston, MA 02114 USA. RP Woo, H (reprint author), Univ Sydney, Westmead Hosp, Dept Urol, Sydney, NSW 2006, Australia. EM hwoo@urologist.net.au NR 18 TC 66 Z9 70 U1 0 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1569-9056 J9 EUR UROL SUPPL JI Eur. Urol. Suppl. PD APR PY 2008 VL 7 IS 4 BP 378 EP 383 DI 10.1016/j.eursup.2008.01.016 PG 6 WC Urology & Nephrology SC Urology & Nephrology GA 283XW UT WOS:000254670800004 ER PT J AU Choi, B Tabatabaei, S Bachmann, A Collins, E de la Rosette, J Sancha, FG Muir, G Reich, O Woo, H AF Choi, Benjamin Tabatabaei, Shahin Bachmann, Alexander Collins, Edward de la Rosette, Jean Gomez Sancha, Fernando Muir, Gordon Reich, Oliver Woo, Henry TI GreenLight HPS 120-w laser for benign prostatic hyperplasia: Comparative complications and technical recommendations SO EUROPEAN UROLOGY SUPPLEMENTS LA English DT Article DE benign prostatic hyperplasia; GreenLight HPS laser; photoselective vaporization of the prostate; complications ID TRANSURETHRAL NEEDLE ABLATION; LOWER-ENERGY THERMOTHERAPY; 2-YEAR FOLLOW-UP; HOLMIUM LASER; OPEN PROSTATECTOMY; MICROWAVE THERMOTHERAPY; CLINICAL-TRIAL; PHOTOSELECTIVE VAPORIZATION; RANDOMIZED-TRIAL; LEARNING-CURVE AB The most common surgical procedure for symptomatic benign prostatic hyperplasia is transurethral resection of the prostate. However, this procedure has complications, including bleeding, erectile dysfunction, and retrograde ejaculation. Alternative therapies have been developed with the aim of reducing the level of complications while maintaining efficacy. These include microwave therapy, transurethral needle ablation, and a range of laser procedures. Recently, photoselective vaporization of the prostate (PVP) was introduced using the GreenLight 60-W laser (American Medical Systems, Minnetonka, Minnesota, USA) and later the 80-W laser, which is the predominant device used in PVP trials. The latest evolution is the GreenLight HPS 120-W laser (532 nm), which produces not only rapid vaporization of prostate tissue but also an acceptable rate of complications. Here we present a review of complications associated with surgical therapies for benign prostatic hyperplasia including data on the initial use of the GreenLight HPS 120-W system. Recommendations are provided on how the low complication rates achieved with PVP can be reduced even further through modification of the operating procedure. (c) 2008 European Association of Urology. Published by Elsevier B.V. All rights reserved. C1 [Tabatabaei, Shahin] Massachusetts Gen Hosp, Dept Urol, Boston, MA 02114 USA. [Choi, Benjamin] Cornell Univ, Weill Med Coll, Dept Urol, Ithaca, NY USA. [Bachmann, Alexander] Univ Hosp, Dept Urol, Basel, Switzerland. [Collins, Edward] Calif Urolog Serv, San Francisco, CA USA. [de la Rosette, Jean] Univ Amsterdam, Acad Med Ctr, Dept Urol, NL-1012 WX Amsterdam, Netherlands. [Gomez Sancha, Fernando] Inst Adv Urolog Surg, Madrid, Spain. [Muir, Gordon] Kings Coll Hosp London, Dept Urol, London, England. [Reich, Oliver] Univ Munich, Dept Urol, Munich, Germany. [Woo, Henry] Univ Sydney, Westmead Hosp, Dept Urol, Sydney, NSW 2006, Australia. RP Tabatabaei, S (reprint author), Massachusetts Gen Hosp, Dept Urol, 55 Fruit St, Boston, MA 02114 USA. EM stabatabaei@partners.org NR 51 TC 25 Z9 27 U1 0 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1569-9056 J9 EUR UROL SUPPL JI Eur. Urol. Suppl. PD APR PY 2008 VL 7 IS 4 BP 384 EP 392 DI 10.1016/j.eursup.2008.01.013 PG 9 WC Urology & Nephrology SC Urology & Nephrology GA 283XW UT WOS:000254670800005 ER PT J AU Patard, JJ Choueiri, TK Lechevallier, E Mottet, N AF Patard, Jean-Jacques Choueiri, Toni K. Lechevallier, Eric Mottet, Nicolas TI Recent developments in research on kidney cancer: Highlights from urological and oncological congresses in 2007 SO EUROPEAN UROLOGY SUPPLEMENTS LA English DT Article; Proceedings Paper CT Oncoforum Urology Meeting CY SEP 15, 2007 CL Brussels, BELGIUM DE angiogenesis inhibitors; bevacizumab; partial nephrectomy; radical nephrectomy; renal cell cancer; sorafenib; sunitinib; temsirolimus ID RENAL-CELL CARCINOMA; NEPHRON-SPARING SURGERY; OPEN PARTIAL NEPHRECTOMIES; RADICAL NEPHRECTOMY; TUMORS; SURVIVAL; MASSES; EXPERIENCE; SUNITINIB; THERAPY AB Objectives: This paper communicates the major new findings on renal cell carcinoma (RCC) that were presented at the 2007 annual meetings of the European Association of Urology (EAU), American Urological Association (AUA) and American Society of Clinical Oncology (ASCO) and discussed during a closed meeting in September 2007. Methods: The most relevant new findings were selected by urological experts in the field of RCC. Results: Although laparoscopic partial nephrectomy (LPN) is a promising technique, it may be associated with additional postoperative morbidity and prolonged warm ischemia time (WIT) compared with open PN. WIT is the strongest modifiable risk factor to avoid decreased renal function after PN. LPN is not recommended in patients with a unique/solitary kidney. However, PN should be preferred to radical nephrectomy whenever PN is technically feasible, because data suggest that overall survival is decreased in patients with small renal turnours who underwent a radical nephrectomy. Conclusions: Additional data have been accumulated regarding targeted therapies. The efficacy of sunitinib and sorafenib as first- and second-line therapy, respectively, has been confirmed. Prognostic factors have been identified for both therapies., Although, sorafenib was not superior to interferon-alpha as first-line treatment, dose escalation with sorafenib could be an interesting approach. Bevacizumab improves progression-free survival when combined with interferon-alpha as first-line therapy. New drugs as well as drug combinations are now being investigated. (C) 2008 European Association of Urology. Published by Elsevier B.V. All rights reserved. C1 [Patard, Jean-Jacques] CHU Pontchaillou, Serv Urol, F-35033 Rennes, France. [Choueiri, Toni K.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Brigham & Womens Hosp, Boston, MA 02115 USA. [Lechevallier, Eric] Hop Salvator, Marseille, France. [Mottet, Nicolas] Clin Mutualiste, St Etienne, France. RP Patard, JJ (reprint author), CHU Pontchaillou, Serv Urol, Rue Henri le Guillou, F-35033 Rennes, France. EM jean-jacques.patard@univ-rennes1.fr NR 49 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1569-9056 J9 EUR UROL SUPPL JI Eur. Urol. Suppl. PD APR PY 2008 VL 7 IS 6 BP 494 EP 507 DI 10.1016/j.eursup.2008.01.001 PG 14 WC Urology & Nephrology SC Urology & Nephrology GA 285KX UT WOS:000254776800005 ER PT J AU Grabherr, L Nicoucar, K Mast, FW Merfeld, DM AF Grabherr, Luzia Nicoucar, Keyvan Mast, Fred W. Merfeld, Daniel M. TI Vestibular thresholds for yaw rotation about an earth-vertical axis as a function of frequency SO EXPERIMENTAL BRAIN RESEARCH LA English DT Article DE vestibular; psychophysics; semicircular canals; sensory threshold; human ID QUALITATIVELY DIFFERENT MECHANISMS; PERCEPTUAL RESPONSES; TRANSLATION; TILT; VOR AB Perceptual direction detection thresholds for yaw rotation about an earth-vertical axis were measured at seven frequencies (0.05, 0.1, 0.2, 0.5, 1, 2, and 5 Hz) in seven subjects in the dark. Motion stimuli consisted of single cycles of sinusoidal acceleration and were generated by a motion platform. An adaptive two-alternative categorical forced-choice procedure was used. The subjects had to indicate by button presses whether they perceived yaw rotation to the left or to the right. Thresholds were measured using a 3-down, 1-up staircase paradigm. Mean yaw rotation velocity thresholds were 2.8 deg s(-1) for 0.05 Hz, 2.5 deg s(-1) for 0.1 Hz, 1.7 deg s(-1) for 0.2 Hz, 0.7 deg s(-1) for 0.5 Hz, 0.6 deg s(-1) for 1 Hz, 0.4 deg s(-1) for 2 Hz, and 0.6 deg s(-1) for 5 Hz. The results show that motion thresholds increase at 0.2 Hz and below and plateau at 0.5 Hz and above. Increasing velocity thresholds at lower frequencies qualitatively mimic the high-pass characteristics of the semicircular canals, since the increase at 0.2 Hz and below would be consistent with decreased gain/sensitivity observed in the VOR at lower frequencies. In fact, the measured dynamics are consistent with a high pass filter having a threshold plateau of 0.71 deg s(-1) and a cut-off frequency of 0.23 Hz, which corresponds to a time constant of approximately 0.70 s. These findings provide no evidence for an influence of velocity storage on perceptual yaw rotation thresholds. C1 [Grabherr, Luzia; Mast, Fred W.] Univ Lausanne, Dept Psychol, CH-1015 Lausanne, Switzerland. [Nicoucar, Keyvan; Merfeld, Daniel M.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Otol & Laryngol, Boston, MA 02114 USA. RP Grabherr, L (reprint author), Univ Lausanne, Dept Psychol, Batiment Anthropole, CH-1015 Lausanne, Switzerland. EM Luzia.Grabherr@unil.ch RI Mast, Fred/B-5058-2013 FU NIDCD NIH HHS [DC04158] NR 15 TC 84 Z9 85 U1 0 U2 15 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0014-4819 J9 EXP BRAIN RES JI Exp. Brain Res. PD APR PY 2008 VL 186 IS 4 BP 677 EP 681 DI 10.1007/s00221-008-1350-8 PG 5 WC Neurosciences SC Neurosciences & Neurology GA 284YE UT WOS:000254743500017 PM 18350283 ER PT J AU Galloway, JL Wingert, RA Thisse, C Thisse, B Zon, LI AF Galloway, Jenna L. Wingert, Rebecca A. Thisse, Christine Thisse, Bernard Zon, Leonard I. TI Combinatorial regulation of novel erythroid gene expression in zebrafish SO EXPERIMENTAL HEMATOLOGY LA English DT Article ID TRANSCRIPTION FACTOR; MICE LACKING; CELL-DIFFERENTIATION; VASCULAR DEVELOPMENT; BLOOD FORMATION; WILD-TYPE; YOLK-SAC; EMBRYOS; HEMATOPOIESIS; PROGENITORS AB Objective. The specification and differentiation of hematopoietic stem cells into red blood cells requires precise coordination by multiple transcription factors. Most genes important for erythroid maturation are regulated by the Gata family of DNA-binding proteins. Previously, we identified three novel genes kelch-repeat containing protein (krcp), kiaa0650, and testhymin/glucocorticoid inducible transcript 1 (glcci1) to be expressed in erythroid cells in a Gata-ndependent manner, and we sought to further understand how these transcripts are regulated during zebrafish hematopoiesis. Materials and Methods. We employed a loss-of-function approach, using combinations of antisense morpholinos to hematopoietic transcription factors and assayed for changes in gene expression in zebrafish embryos. Results. Upon examination of embryos deficient for Gata1, Gata2, Biklf, and/or Set, we found distinct gene combinations were required for expression of the novel genes. While krcp expression was dependent upon Gata1 and Biklf, kiaa0650 expression was greatly reduced and glcci1 was maintained in Gata1/Gata2/Biklf-deficient embryos. As with the gata1 gene, kiaa0650 and krcp required Scl for blood expression. Although reduced, glcci1 was expressed in posterior blood precursors in the absence of SO and Gata2. Conclusions. This work identifies glcci1 as having Scl-independent expression in the posterior hematopoietic mesoderm, suggesting that its posterior expression is activated by factors upstream or parallel to Scl and Gata2. Additionally, these studies establish that blood gene expression programs are regulated by transcription factors acting in combination during erythroid maturation. (C) 2008 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. C1 [Galloway, Jenna L.; Zon, Leonard I.] Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA. [Galloway, Jenna L.; Zon, Leonard I.] Childrens Hosp, Stem Cell Program, Boston, MA 02115 USA. [Galloway, Jenna L.; Zon, Leonard I.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Galloway, Jenna L.; Zon, Leonard I.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Hematol, Boston, MA USA. [Wingert, Rebecca A.] Massachusetts Gen Hosp, Harvard Stem Cell Inst, Ctr Regenerat Med, Boston, MA 02114 USA. [Thisse, Christine; Thisse, Bernard] ULP, INSERM, CNRS, IGBMC, Illkirch Graffenstaden, France. RP Zon, LI (reprint author), Childrens Hosp, Div Hematol Oncol, Karp 7,1 Blackfan Circle, Boston, MA 02115 USA. EM zon@enders.tch.harvard.edu FU NCRR NIH HHS [R01 RR15402, R01 RR015402]; NHLBI NIH HHS [R01 HL048801-13, R01 HL48801-13, R01 HL048801]; NIDDK NIH HHS [R37 DK055381, R37 DK055381-06] NR 47 TC 13 Z9 13 U1 3 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0301-472X J9 EXP HEMATOL JI Exp. Hematol. PD APR PY 2008 VL 36 IS 4 BP 424 EP 432 DI 10.1016/j.exphem.2007.11.015 PG 9 WC Hematology; Medicine, Research & Experimental SC Hematology; Research & Experimental Medicine GA 282FQ UT WOS:000254553400006 PM 18243489 ER PT J AU Shaulov, A Yue, S Wang, R Joyce, RM Balk, SP Kim, HT Avigan, DE Uhl, L Sackstein, R Exley, MA AF Shaulov, Angela Yue, Simon Wang, RuoJie Joyce, Robin M. Balk, Steven P. Kim, Haesook T. Avigan, David E. Uhl, Lynne Sackstein, Robert Exley, Mark A. TI Peripheral blood progenitor cell product contains Th1-biased noninvariant CD1d-reactive natural killer T cells: Implications for posttransplant survival SO EXPERIMENTAL HEMATOLOGY LA English DT Article ID VERSUS-HOST-DISEASE; HUMAN BONE-MARROW; NKT CELLS; CUTTING EDGE; IN-VITRO; INFECTION; VIRUS; TRANSPLANTATION; IMMUNOTHERAPY; RECOGNITION AB Objective. Bone marrow (BM) Th1 populations can contribute to graft-vs-leukemia responses. Granulocyte/granulocyte macrophage colony-stimulating factor (CSF)-mobilized peripheral blood progenitor cells (PBPC) have become widely accepted alternatives to BM transplantation. T cells coexpressing natural killer cell proteins (NKT) include a CD1d-reactive subset that influences immunity by rapidly producing large amounts of Th1 and/or Th2 cytokines dependent upon microenvironment and disease. There are two types of CD1d-reactive NKT. iNKT express a semi-invariant T-cell receptor-alpha. Other noninvariant CD1d-reactive NKT from BM and liver produce large amounts of interleukin-4 or interferon-gamma, respectively, and within the intestine can be biased in either direction. Recent data suggests that NKT might contribute to clinical benefits of PBPC. Materials and Methods. To address these issues, we phenotypically and functionally studied PBPC NKT. Results. Similarly to BM, NKT-like cells were common in allogeneic and autologous PBPC, there were relatively few classical iNKT, but high CD1d-reactivity concentrated in NKT fractions. Significantly, PBPC CD1d-reactive cells were relatively Th1-biased and their presence was associated with better prognosis. Granulocyte CSF treatment of BM to yield PBPC in vivo as well as in vitro Th2-polarizes conventional T cells and iNKT. However, granulocyte CSF treatment of BM in vitro produced Th1-biased NKT, providing a mechanism for opposite polarization of NKT from BM vs PBPC. Conclusions. These results suggest distinct Th1 CD1d-reactive NKT cells could stimulate anti-tumor responses from those previously described, which can suppress graft-vs-host disease. (C) 2008 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. C1 [Shaulov, Angela; Yue, Simon; Wang, RuoJie; Joyce, Robin M.; Balk, Steven P.; Avigan, David E.; Exley, Mark A.] Beth Israel Deaconess Med Ctr, Dept Hematol, Boston, MA 02215 USA. [Shaulov, Angela; Yue, Simon; Wang, RuoJie; Joyce, Robin M.; Balk, Steven P.; Avigan, David E.; Exley, Mark A.] Beth Israel Deaconess Med Ctr, Dept Oncol, Boston, MA 02215 USA. [Kim, Haesook T.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Uhl, Lynne] Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA. [Sackstein, Robert] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Dermatol, Boston, MA USA. [Sackstein, Robert] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med, Boston, MA USA. RP Exley, MA (reprint author), Beth Israel Deaconess Med Ctr, Dept Hematol, NRB 1030L,330 Brookline Ave, Boston, MA 02215 USA. EM mexley@bidmc.harvard.edu FU NCI NIH HHS [CA89567, CA84156, R21 CA089567, R21 CA089567-02, R21 CA089567-01, R01 CA084156]; NIAID NIH HHS [AI42955]; NIDDK NIH HHS [R01 DK066917-01, R01 DK066917-02, DK66917, R01 DK066917-04, R01 DK066917, R01 DK066917-03] NR 32 TC 13 Z9 14 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0301-472X J9 EXP HEMATOL JI Exp. Hematol. PD APR PY 2008 VL 36 IS 4 BP 464 EP 472 DI 10.1016/j.exphem.2007.12.010 PG 9 WC Hematology; Medicine, Research & Experimental SC Hematology; Research & Experimental Medicine GA 282FQ UT WOS:000254553400010 PM 18261838 ER PT J AU Paintlia, MK Paintlia, AS Contreras, MA Singh, I Singh, AK AF Paintlia, Manjeet K. Paintlia, Ajaib S. Contreras, Miguel A. Singh, Inderjit Singh, Avtar K. TI Lipopolysaccharide-induced peroxisomal dysfunction exacerbates cerebral white matter injury: Attenuation by N-acetyl cysteine SO EXPERIMENTAL NEUROLOGY LA English DT Article DE lipopolysaccharide; periventricular leukomalacia; cerebral white matter injury; cerebral palsy; peroxisome proliferators-activated receptor-alpha; N-acetyl cysteine ID EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; LATE OLIGODENDROCYTE PROGENITORS; RECEPTOR-ALPHA ACTIVATION; PERINATAL BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; NECROSIS-FACTOR-ALPHA; DEVELOPING RAT-BRAIN; KAPPA-B; OXIDATIVE STRESS; PERIVENTRICULAR LEUKOMALACIA AB Cerebral white matter injury during prenatal maternal infection characterized as periventricular leukomalacia is the main substrate for cerebral palsy (CP) in premature infants. Previously, we reported that maternal LPS exposure causes oligodendrocyte (OL)-injury/hypomyelination in the developing brain which can be attenuated by an antioxidant agent, N-acetyl cysteine (NAC). Herein, we elucidated the role of peroxisomes in LPS-induced neuroinflammation and cerebral white matter injury. Peroxisomes are important for detoxification of reactive oxidative species (ROS) and metabolism of myelin-lipids in OLs. Maternal LPS exposure induced selective depletion of developing OLs in the fetal brain which was associated with ROS generation, glutathione depletion and peroxisomal dysfunction. Likewise, hypomyelination in the postnatal brain was associated with decrease in peroxisomes and OLs after maternal LPS exposure. Conversely, NAC abolished these LPS-induced effects in the developing brain. CP brains imitated these observed changes in peroxisomal/myelin proteins in the postnatal brain after maternal LPS exposure. In vitro studies revealed that pro-inflammatory cytokines cause OL-injury via peroxisomal dysfunction and ROS generation. NAC or WY14643 (peroxisome proliferators activated receptor (PPAR)-alpha agonist) reverses these effects of pro-inflammatory cytokines in the wild-type OLs, but not in PPAR-alpha((-/-)) OLs. Similarly treated B 12 oligodenroglial cells co-transfected with PPAR-alpha siRNAs/pTK-PPREx3-Luc, and LPS exposed PPAR-alpha((-/-)) pregnant mice treated with NAC or WY14643 further suggested that PPAR-a activity mediates NAC-induced protective effects. Collectively, these data provide unprecedented evidence that LPS-induced peroxisomal dysfunction exacerbates cerebral white matter injury and its attenuation by NAC via a PPAR-a dependent mechanism expands therapeutic avenues for CP and related demyclinating diseases. Published by Elsevier Inc. C1 [Paintlia, Manjeet K.; Paintlia, Ajaib S.; Contreras, Miguel A.; Singh, Inderjit] Med Univ S Carolina, Dept Pediat, Darby Childrens Res Inst 513, Charleston, SC 29425 USA. [Singh, Avtar K.] Ralph H Johnson VA Med Ctr, Dept Pathol & Lab Med, Charleston, SC USA. RP Singh, AK (reprint author), Med Univ S Carolina, Dept Pediat, Darby Childrens Res Inst 513, 173 Ashley Ave, Charleston, SC 29425 USA. EM singhi@musc.edu OI Paintlia, Ajaib/0000-0003-4525-5333 FU NCRR NIH HHS [C06 RR015455, C06 RR018823]; NINDS NIH HHS [R37 NS022576, NS-22576, NS-34741, NS-37766, NS-40810, R01 NS022576, R01 NS034741, R01 NS034741-08, R01 NS037766, R01 NS037766-08, R01 NS040810, R37 NS022576-22] NR 76 TC 51 Z9 52 U1 0 U2 3 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0014-4886 J9 EXP NEUROL JI Exp. Neurol. PD APR PY 2008 VL 210 IS 2 BP 560 EP 576 DI 10.1016/j.expneurol.2007.12.011 PG 17 WC Neurosciences SC Neurosciences & Neurology GA 287CL UT WOS:000254894200029 PM 18291369 ER PT J AU Reardon, DA Wen, PY Desjardins, A Batchelor, TT Vredenburgh, JJ AF Reardon, David A. Wen, Patrick Y. Desjardins, Annick Batchelor, Tracy T. Vredenburgh, James J. TI Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy SO EXPERT OPINION ON BIOLOGICAL THERAPY LA English DT Review DE angiogenesis; bevacizumab; glioblastoma multiforme; malignant glioma; vascular endothelial growth factor ID ENDOTHELIAL GROWTH-FACTOR; RECURRENT MALIGNANT GLIOMA; TYROSINE KINASE INHIBITOR; PHASE-II TRIAL; METASTATIC COLORECTAL-CANCER; BEVACIZUMAB PLUS IRINOTECAN; RENAL-CELL CARCINOMA; HUMAN BRAIN-TUMORS; FACTOR RECEPTOR; ANTIANGIOGENIC THERAPY AB Background: Adults with malignant glioma, especially the most common subtype, glioblastoma multiforme, have an unacceptably poor outcome with current therapies. Malignant gliomas are amongst the most angiogenic of cancers, and VEGF is the dominant angiogenic mediator in these tumors. Objective: To summarize the clinical experience of VEGF-directed treatment for malignant glioma. Methods: We reviewed the completed, ongoing and planned clinical trials evaluating anti-VEGF strategies for malignant glioma patients. Results/conclusions: Recent studies incorporating anti-VEGF agents plus cytotoxic therapy among recurrent malignant glioma patients have achieved unprecedented improvements in radiographic response, time to progression and survival. Furthermore, acceptable toxicity was observed. Hence, a major current focus in neuro-oncology is to further develop antiangiogenic strategies for this desperate patient population. C1 [Reardon, David A.] Duke Univ, Med Ctr, NeuroOncol Program, Dept Surg,Div Neurosurg, Durham, NC 27710 USA. [Wen, Patrick Y.] Dana Farber Brigham & Womens Canc Inst, Ctr Neurooncol, Boston, MA 02115 USA. [Desjardins, Annick; Vredenburgh, James J.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA. [Batchelor, Tracy T.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. RP Reardon, DA (reprint author), Duke Univ, Med Ctr, NeuroOncol Program, Dept Surg,Div Neurosurg, 047 Baker House,Box 3624, Durham, NC 27710 USA. EM reard003@mc.duke.edu FU NCI NIH HHS [1-P50-CA108786-01, CA11898, P50 CA108786, P50 CA108786-019003, P50 CA108786-029003, P50 CA108786-039003, P50 CA108786-049003, P50 CA108786-059003, P50 CA108786-05S19003, R37 CA011898]; NCRR NIH HHS [MO1 RR 30]; NINDS NIH HHS [NS20023, P50 NS020023, P50 NS020023-210020, P50 NS020023-220020, P50 NS020023-230020, P50 NS020023-240020, P50 NS020023-250020, P50 NS020023-268626] NR 141 TC 50 Z9 55 U1 1 U2 3 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1471-2598 EI 1744-7682 J9 EXPERT OPIN BIOL TH JI Expert Opin. Biol. Ther. PD APR PY 2008 VL 8 IS 4 BP 541 EP 553 DI 10.1517/14712598.8.4.541 PG 13 WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental SC Biotechnology & Applied Microbiology; Research & Experimental Medicine GA 289PA UT WOS:000255065200015 PM 18352856 ER PT J AU Cornia, PB Davidson, HL Lipsky, BA AF Cornia, Paul B. Davidson, Heather L. Lipsky, Benjamin A. TI The evaluation and treatment of complicated skin and skin structure infections SO EXPERT OPINION ON PHARMACOTHERAPY LA English DT Review DE bacterial myonecrosis; complicated skin and skin structure infection; necrotizing fasciitis ID SOFT-TISSUE INFECTIONS; RESISTANT STAPHYLOCOCCUS-AUREUS; DIABETIC FOOT INFECTIONS; GRAM-POSITIVE BACTERIA; ENTEROCOCCUS-FAECIUM INFECTIONS; DOUBLE-BLIND; NECROTIZING FASCIITIS; HOSPITALIZED-PATIENTS; TRIMETHOPRIM-SULFAMETHOXAZOLE; QUINUPRISTIN-DALFOPRISTIN AB Background: Skin and skin structure infections are frequently encountered in clinical practice. Fortunately, these infections usually produce only mild to moderate symptoms and signs. Some, however, are severe and may even be life-threatening. Objective: To review the approach to the evaluation and treatment of patients with complicated skin and skin structure infections and to discuss when to consider using either established antibiotics or recently licensed agents for treating these infections. Methods: In addition to a non-systematic literature review of complicated skin and skin structure infections and necrotizing fasciitis, we identified recent articles examining the microbiology and describing recently licensed antibiotics for treating these infections. Results/conclusions: Clinicians must learn to recognize the early symptoms and signs of severe skin and skin structure infections to ensure they select appropriate empiric antibiotic therapy and, when needed, obtain prompt surgical consultation. While the recent approvals of new agents for treating these infections are welcome, particularly in light of the continued emergence of anti biotic-resistant bacteria, traditional antibiotic regimens remain appropriate for most cases. C1 [Cornia, Paul B.; Davidson, Heather L.; Lipsky, Benjamin A.] Univ Washington, Sch Med, Primary & Specialty Med Serv, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Cornia, Paul B.; Davidson, Heather L.; Lipsky, Benjamin A.] Univ Washington, Sch Med, Primary & Specialty Med Serv, Dept Med, Seattle, WA 98108 USA. [Cornia, Paul B.] Univ Washington, VA Puget Sound Hlth Care Syst S111, Seattle, WA 98108 USA. RP Cornia, PB (reprint author), Univ Washington, Sch Med, Primary & Specialty Med Serv, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. EM paul.cornia@med.va.gov OI Lipsky, Benjamin A./0000-0001-9886-5114 NR 99 TC 4 Z9 5 U1 0 U2 0 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1465-6566 J9 EXPERT OPIN PHARMACO JI Expert Opin. Pharmacother. PD APR PY 2008 VL 9 IS 5 BP 717 EP 730 DI 10.1517/14656S66.9.5.717 PG 14 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 285MI UT WOS:000254780500005 PM 18345950 ER PT J AU Zhu, AX AF Zhu, Andrew X. TI Successful targeted therapies for hepatocellular carcinoma: are we really getting there? SO EXPERT REVIEW OF ANTICANCER THERAPY LA English DT Editorial Material ID ENDOTHELIAL GROWTH-FACTOR; RECEPTOR TYROSINE KINASES; FACTOR-ALPHA; PHASE-II; PROGNOSTIC-SIGNIFICANCE; RAF/MEK/ERK PATHWAY; ANTITUMOR-ACTIVITY; TUMOR VASCULATURE; BREAST-CANCER; EXPRESSION C1 Massachusetts Gen Hosp, Ctr Canc, Tucker Gosnell Ctr Gastrointestinal Canc, Boston, MA 02114 USA. RP Zhu, AX (reprint author), Massachusetts Gen Hosp, Ctr Canc, Tucker Gosnell Ctr Gastrointestinal Canc, Lawrence House,POB 232,55 Fruit St, Boston, MA 02114 USA. EM azhu@partners.org NR 52 TC 2 Z9 2 U1 0 U2 1 PU EXPERT REVIEWS PI LONDON PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB, ENGLAND SN 1473-7140 EI 1744-8328 J9 EXPERT REV ANTICANC JI Expert Rev. Anticancer Ther PD APR PY 2008 VL 8 IS 4 BP 499 EP 505 DI 10.1586/14737140.8.4.499 PG 7 WC Oncology SC Oncology GA 343EY UT WOS:000258836900001 PM 18402516 ER PT J AU Bertram, KM Bula, DV Pulido, JS Shippy, SA Gautam, S Lu, MJ Hatfield, RM Kim, JH Quirk, MT Arroyo, JG AF Bertram, K. M. Bula, D. V. Pulido, J. S. Shippy, S. A. Gautam, S. Lu, M-J Hatfield, R. M. Kim, J-H Quirk, M. T. Arroyo, J. G. TI Amino-acid levels in subretinal and vitreous fluid of patients with retinal detachment SO EYE LA English DT Article DE amino acids; glutamate; retinal detachment; subretinal fluid ID GLIAL-CELL REACTIVITY; CAT RETINA; GLUTAMATE TRANSPORTERS; OXYGEN SUPPLEMENTATION; ELECTRON MICROSCOPY; REATTACHED RETINA; NEURAL RETINA; OWL MONKEY; RAT RETINA; ISCHEMIA AB Purpose To compare the concentration of amino acids in subretinal and vitreous fluid of patients with primary rhegmatogenous retinal detachment to that of control vitreous. Methods This prospective, observational study measured amino-acid levels in subretinal fluid of patients undergoing scleral buckle placement (n = 20) and vitreous fluid in patients undergoing pars plana vitrectomy (n = 5) for primary retinal detachment. Vitreous fluid from patients undergoing vitrectomy for macular hole (n = 7) or epiretinal membrane (n = 3) served as a control. Subretinal fluid and control vitreous were analysed using high-pressure liquid chromatography. Retinal detachment vitreous was analysed using capillary electrophoresis-laser-induced fluorescence. Results Mean levels of glutamate (27.0+/-1.7 mu M), aspartate (4.1+/-4.0 mu M), and glycine (44.1+/-31.0 mu M) in subretinal fluid and glutamate (13.4+/-11.9 mu M) in the vitreous were significantly elevated in retinal detachment compared to control vitreous. A significant, positive association was observed between levels of aspartate and glutamate in subretinal fluid (Spearman's correlation coefficient: 0.74, P<0.01). Mean arginine levels did not differ significantly between subretinal fluid and control vitreous. Levels of alanine, tyrosine, valine, isoleucine, leucine, and phenylalanine were significantly lower in subretinal fluid compared to control vitreous (all P<0.01). Conclusions Glutamate levels in subretinal fluid and vitreous of patients with primary retinal detachment is significantly elevated in comparison to control vitreous. This finding lends further support to the hypothesis that elevated glutamate levels may result from ischaemia of the outer retina secondary to retinal detachment. C1 [Bertram, K. M.; Bula, D. V.; Quirk, M. T.; Arroyo, J. G.] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA. [Bertram, K. M.; Bula, D. V.; Gautam, S.; Kim, J-H; Quirk, M. T.; Arroyo, J. G.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA USA. [Bula, D. V.; Arroyo, J. G.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Boston, MA USA. [Pulido, J. S.] Mayo Clin, Dept Ophthalmol, Rochester, MN USA. [Shippy, S. A.; Lu, M-J] Univ Illinois, Dept Chem, Chicago, IL 60680 USA. [Gautam, S.] Harvard Univ, Sch Med, Gen Clin Res Ctr & Biometr, Boston, MA USA. RP Arroyo, JG (reprint author), Beth Israel Deaconess Med Ctr, Div Ophthalmol, Retina Serv, Shapiro 5th Floor,330 Brookline Ave, Boston, MA 02215 USA. EM jarroyo@bidmc.harvard.edu FU NEI NIH HHS [EY014908] NR 51 TC 17 Z9 18 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0950-222X J9 EYE JI Eye PD APR PY 2008 VL 22 IS 4 BP 582 EP 589 DI 10.1038/sj.eye.6702993 PG 8 WC Ophthalmology SC Ophthalmology GA 289LV UT WOS:000255056900020 PM 17948040 ER PT J AU Noda, K Miyahara, S Nakazawa, T Almulki, L Nakao, S Hisatomi, T She, H Thomas, KL Garland, RC Miller, JW Gragoudas, ES Kawai, Y Mashima, Y Hafezi-Moghadam, A AF Noda, Kousuke Miyahara, Shinsuke Nakazawa, Torn Almulki, Lama Nakao, Shintaro Hisatomi, Toshio She, Haicheng Thomas, Kennard L. Garland, Rebecca C. Miller, Joan W. Gragoudas, Evangelos S. Kawai, Yosuke Mashima, Yukihiko Hafezi-Moghadam, Ali TI Inhibition of vascular adhesion protein-1 suppresses endotoxin-induced uveifs SO FASEB JOURNAL LA English DT Article DE semicarbazide-sensitize amine oxidase; ocular inflammation; leukocyte recruitment ID SENSITIVE AMINE OXIDASE; NECROSIS-FACTOR-ALPHA; IN-VIVO EVALUATION; INDUCED UVEITIS; P-SELECTIN; RETINAL MICROCIRCULATION; ENDOTHELIAL INTERACTIONS; OCULAR INFLAMMATION; MONOAMINE-OXIDASE; LEUKOCYTE BINDING AB Inflammatory leukocyte accumulation is a common feature of major ocular diseases, such as uveitis, diabetic retinopathy, and age-related macular degeneration. Vascular adhesion protein-1 (VAP-1), a cell surface and soluble molecule that possesses semicarbazide-sensitive amine oxidase (SSAO) activity, is involved in leukocyte recruitment. However, the expression of VAP-1 in the eye and its contribution to ocular inflammation are unknown. Here, we investigated the role of VAP-1 in an established model of ocular inflammation, the endotoxin-induced uveitis (EIU), using a novel and specific inhibitor. Our inhibitor has a half-maximal inhibitory concentration (IC(50)) of 0.007 mu M against human and 0.008 mu M against rat SSAO, while its IC(50) against the functionally related monoamine oxidase (MAO) -A and MAO-B is > 10 mu M. In the retina, VAP-1 was exclusively expressed in the vasculature, and its expression level was elevated during EIU. VAP-1 inhibition in EIU animals significantly suppressed leukocyte recruitment to the anterior chamber, vitreous, and retina, as well as retinal endothelial P-selectin expression. Our data suggest an important role for VAP-1 in the recruitment of leukocytes to the immune-privileged ocular tissues during acute inflammation. VAP-1 inhibition may become a novel strategy in the treatment of ocular inflammatory diseases. C1 [Noda, Kousuke; Miyahara, Shinsuke; Nakazawa, Torn; Almulki, Lama; Nakao, Shintaro; Hisatomi, Toshio; She, Haicheng; Thomas, Kennard L.; Garland, Rebecca C.; Miller, Joan W.; Gragoudas, Evangelos S.; Hafezi-Moghadam, Ali] Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Boston, MA 02114 USA. [Kawai, Yosuke; Mashima, Yukihiko] Harvard Univ, Sch Med, Boston, MA 02115 USA. RP Hafezi-Moghadam, A (reprint author), Angiogenesis Lab, 325 Cambridge St,3rd Floor, Boston, MA 02114 USA. EM ahm@meei.harvard.edu FU NEI NIH HHS [EY14104]; NIAID NIH HHS [AI-050775] NR 43 TC 31 Z9 31 U1 1 U2 2 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 IS 4 BP 1094 EP 1103 DI 10.1096/fj.07-9377com PG 10 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 282PZ UT WOS:000254581000015 PM 18032635 ER PT J AU Sato-Jin, K Nishimura, EK Akasaka, E Huber, W Nakano, H Miller, A Du, JY Wu, M Hanada, K Sawamura, D Fisher, DE Imokawa, G AF Sato-Jin, Kayo Nishimura, Emi K. Akasaka, Eijiro Huber, Wade Nakano, Hajime Miller, Arlo Du, Jinyan Wu, Min Hanada, Katsumi Sawamura, Daisuke Fisher, David E. Imokawa, Genji TI Epistatic connections between microphthalmia-associated transcription factor and endothelin signaling in Waardenburg syndrome and other pigmentary disorders SO FASEB JOURNAL LA English DT Article DE cAMP response element-binding protein; CREB; cyclin-dependent kinase 2; melanocyte; endothelin B receptor ID B RECEPTOR GENE; HUMAN MELANOCYTES; GROWTH-FACTOR; SYNDROME TYPE-2; CELL-CYCLE; HUMAN KERATINOCYTES; HUMAN HOMOLOG; MITF; EXPRESSION; DIFFERENTIATION AB Waardenburg syndrome (WS) is an inherited sensorineural deafness condition in humans caused by melanocyte deficiencies in the inner ear and forelock. Mutation of microphthalmia-associated transcription factor (MITF) is known to produce WS type IIA whereas mutations of either endothelin (EDN) or its receptor endothelin receptor B (EDNRB) produce WS type IV. However, a link between MITF haploinsufficiency and EDN signaling has not yet been established. Here we demonstrate mechanistic connections between EDN and MITF and their functional importance in melanocytes. Addition of EDN to cultured human melanocytes stimulated the phosphorylation of MITF in an EDNRB-dependent manner, which was completely abolished by mitogen-activated protein kinase kinase inhibition. The expression of melanocyte-specific MITF mRNA transcripts was markedly augmented after incubation with EDN1 and was followed by increased expression of MITF protein. Up-regulated expression of MITF was found to be mediated via both the mitogen-activated protein kinase-p90 ribosomal S6 kinase-cAMP response element-binding protein (CREB) and CAMP-protein kinase A-CREB pathways. In addition, EDNRB expression itself was seen to be dependent on MITE. The functional importance of these connections is illustrated by the ability of EDN to stimulate expression of melanocytic pigmentation and proliferation markers in an MITF-dependent fashion. Collectively these data provide mechanistic and epistatic links between MITF and EDN/EDNRB, critical melanocytic survival factors and WS genes. C1 [Imokawa, Genji] Tokyo Univ Technol, Sch Bion, Katayanagi Inst, Hachioji, Tokyo 1920982, Japan. [Sato-Jin, Kayo; Akasaka, Eijiro; Nakano, Hajime; Hanada, Katsumi; Sawamura, Daisuke; Imokawa, Genji] Hirosaki Univ, Grad Sch Med, Dept Dermatol, Hirosaki, Aomori, Japan. [Nishimura, Emi K.] Kanazawa Univ, Canc Res Inst, Dept Stem Cell Med, Kanazawa, Ishikawa 920, Japan. [Nishimura, Emi K.; Huber, Wade; Miller, Arlo; Du, Jinyan; Wu, Min; Fisher, David E.] Harvard Univ, Childrens Hosp, Sch Med, Dept Pediat Hematol Oncol, Boston, MA 02115 USA. [Nishimura, Emi K.; Huber, Wade; Miller, Arlo; Du, Jinyan; Wu, Min; Fisher, David E.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Melanoma Program, Boston, MA 02115 USA. RP Imokawa, G (reprint author), Tokyo Univ Technol, Sch Bion, Katayanagi Inst, W204,1404-1 Katakura, Hachioji, Tokyo 1920982, Japan. EM imokawag@dream.ocn.ne.jp NR 56 TC 46 Z9 48 U1 0 U2 5 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 IS 4 BP 1155 EP 1168 DI 10.1096/fj.07-9080com PG 14 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 282PZ UT WOS:000254581000021 PM 18039926 ER PT J AU Liu, CH You, ZR Ren, JQ Kim, YR Eikermann-Haerter, K Liu, PK AF Liu, Christina H. You, Zerong Ren, JiaQian Kim, Young R. Eikermann-Haerter, Katharina Liu, Philip K. TI Noninvasive delivery of gene targeting probes to live brains for transcription MRI SO FASEB JOURNAL LA English DT Article DE angiogenesis; antisense technology; blood-brain barrier; bulbar conjunctiva; gene expression; molecular imaging ID FOREBRAIN ISCHEMIA-REPERFUSION; CORTICAL SPREADING DEPRESSION; FIBRILLARY ACIDIC PROTEIN; CEREBRAL-ISCHEMIA; CARDIAC-ARREST; NEURONAL SENSITIVITY; MOUSE-BRAIN; EXPRESSION; DAMAGE; INJURY AB We aimed to test the feasibility of detecting gliosis in living brains when the blood-brain barrier (BBB) is disrupted. We designed a novel magnetic resonance (MR) probe that contains superparamagnetic iron oxide nanoparticles (SPION, a T2 susceptibility contrast agent) linked to a short DNA sequence complementary to the cerebral mRNA of glial fibrillary acidic protein (GFAP) found in glia and astrocytes. As a control, we also used a sequence complementary to the mRNA of P-actin. Our objectives are to demonstrate that this new probe, SPION-gfap, could be delivered to the brain when administered by eyedrop solution to the conjunctival sac. We induced BBB leakage by puncture wound, global cerebral ischemia, and cortical spreading depression in C57BL6 mice; I day after probe delivery we acquired T2* MR images and R2* (R2* = 1/T2*) maps using a transcription MRI technique in live mice. We found that the SPION-gfap probe reported foci with elevated signal in subtraction R2* maps and that these foci matched areas identified as having extensive glial network (gliosis) in postmortem immunohistochemistry. Similarly, animals administered the control probe exhibited foci of R2* elevation that matched P-actin-expressing endothelia in the vascular wall. We conclude that our modular MR probe, delivered in an eyedrop solution, effectively reports gliosis associated with acute neurological disorders in living animals. As BBB leakage is often observed in acute neurological disorders, this study also served to validate noninvasive delivery of MR probes to the brains of live animals after acute neurological disorders. C1 [Liu, Christina H.; Ren, JiaQian; Kim, Young R.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA. [Liu, Christina H.; Liu, Philip K.] Massachusetts Gen Hosp, Div Neuroradiol, Gene Transcript Targeting & Repair Lab, Charlestown, MA USA. [Liu, Christina H.; Ren, JiaQian; Kim, Young R.; Eikermann-Haerter, Katharina; Liu, Philip K.] Massachusetts Gen Hosp, Dept Radiol, Charlestown, MA USA. [You, Zerong] Massachusetts Gen Hosp, Dept Pediat, Charlestown, MA USA. [You, Zerong] Harvard Univ, Sch Med, Charlestown, MA USA. RP Liu, PK (reprint author), 149 13th St,Rm 2410, Charlestown, MA 02129 USA. EM philip1@nmr.mgh.harvard.edu OI Liu, Christina/0000-0002-5723-177X FU NCI NIH HHS [5T32CA009502, T32 CA009502]; NCRR NIH HHS [P41 RR014075, P41RR14075]; NIDA NIH HHS [DA024235, R01 DA026108, R01 DA026108-01, R21 DA024235, R21 DA024235-01]; NINDS NIH HHS [NS045845, NS057556, R01 NS045845, R01 NS045845-04, R21 NS057556, R21 NS057556-01A1S1, R21 NS057556-02] NR 37 TC 21 Z9 21 U1 1 U2 5 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 IS 4 BP 1193 EP 1203 DI 10.1096/fj.07-9557com PG 11 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 282PZ UT WOS:000254581000024 PM 18029447 ER PT J AU Agyemang, A Alimzhanov, MB Imanishi-Kari, T Carroll, MC AF Agyemang, Amma Alimzhanov, Marat B. Imanishi-Kari, Thereza Carroll, Michael C. TI Role of Complement C4 in the Regulation of Self-Reactive B Cells SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Agyemang, Amma] Harvard Univ, Sch Med, Div Med Sci, Immune Dis Inst, Boston, MA USA. [Alimzhanov, Marat B.] AstraZeneca R&D Boston, Waltham, MA USA. [Imanishi-Kari, Thereza] Tufts Univ, Sch Med, Dept Pathol, Boston, MA 02111 USA. [Imanishi-Kari, Thereza] Tufts Univ, Sch Med, Program Immunol, Boston, MA 02111 USA. [Imanishi-Kari, Thereza] Tufts Univ, Sackler Sch Grad Biomed Sci, Boston, MA 02111 USA. [Carroll, Michael C.] Harvard Univ, Sch Med, Dept Pathol, Immune Dis Inst, Boston, MA 02115 USA. [Carroll, Michael C.] Harvard Univ, Sch Med, Dept Pediat, Immune Dis Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GY UT WOS:000208467700846 ER PT J AU Ansel, KM Pastor, WA Rath, N Lapan, AD Thai, TH Rao, A Heissmeyer, VH AF Ansel, Karl Mark Pastor, William A. Rath, Nicola Lapan, Ariya Dararutana Thai, To-Ha Rao, Anjana Heissmeyer, Vigo H. TI Enhanced RNAi-1 (Eni-1) regulates miRNA homeostasis, rRNA processing, and lymphocyte effector functions SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Ansel, Karl Mark] Univ Calif San Francisco, Dept Microbiol & Immunol, Sandler Asthma Basic Res Ctr, San Francisco, CA 94143 USA. [Pastor, William A.; Lapan, Ariya Dararutana; Thai, To-Ha; Rao, Anjana] Harvard Univ, Sch Med, Immune Dis Inst, Boston, MA USA. [Rao, Anjana] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. [Rath, Nicola; Heissmeyer, Vigo H.] GSF Natl Res Ctr Environm & Hlth, Inst Mol Immunol, Munich, Germany. NR 0 TC 0 Z9 0 U1 0 U2 1 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467808447 ER PT J AU Barber, DL Antonelli, LR Feng, CG Sharpe, AH Freeman, GJ Sher, A AF Barber, Daniel L. Antonelli, Lis R. Feng, Carl G. Sharpe, Arlene H. Freeman, Gordon J. Sher, Alan TI PD-L1 interaction limits excessive Th1 effector function during Mycobacterium tuberculosis infection SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Barber, Daniel L.; Antonelli, Lis R.; Feng, Carl G.] NIAID, Parasit Dis Lab, NIH, Bethesda, MD 20892 USA. [Sharpe, Arlene H.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. [Sharpe, Arlene H.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Freeman, Gordon J.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. [Freeman, Gordon J.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MD USA. RI Antonelli, Lis/G-2907-2012 NR 0 TC 0 Z9 0 U1 0 U2 2 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467806008 ER PT J AU Barteneva, N Steen, R Feist, F Buhlman, J Lim, B Barrington, R AF Barteneva, Natasha Steen, Robert Feist, Frank Buhlman, Janet Lim, Bing Barrington, Robert TI Novel method for deconstructing humoral responses SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Barteneva, Natasha] Immune Dis Inst, Boston, MA USA. [Steen, Robert] Harvard Univ, Sch Med, Boston, MA USA. [Feist, Frank; Barrington, Robert] Advalytix, Concord, MA USA. [Buhlman, Janet; Lim, Bing] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GY UT WOS:000208467700722 ER PT J AU Beasley, D Celestin, F Moore, K Mendelsohn, M AF Beasley, Debbie Celestin, Flore Moore, Kathryn Mendelsohn, Michael TI Pathogenic roles of Toll-like receptor 2 and intracellular bacteria in intimal hyperplasia in apolipoprotein E-deficient mice SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Beasley, Debbie; Celestin, Flore; Mendelsohn, Michael] Tufts Univ New England Med Ctr, Boston, MA USA. [Moore, Kathryn] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467809250 ER PT J AU Brandauer, J Koh, HJ Jung, MM Toyoda, T An, D Yu, HY Fujii, N Hirshman, MF Witters, LA Goodyear, LJ AF Brandauer, Josef Koh, Ho-Jin Jung, Michelle M. Toyoda, Taro An, Ding Yu, Haiyan Fujii, Nobuharu Hirshman, Michael F. Witters, Lee A. Goodyear, Laurie J. TI Effect of altered AMP-activated protein kinase activity and exercise training on muscle PBEF-1/visfatin levels. SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Brandauer, Josef; Koh, Ho-Jin; Jung, Michelle M.; Toyoda, Taro; An, Ding; Yu, Haiyan; Fujii, Nobuharu; Hirshman, Michael F.; Goodyear, Laurie J.] Joslin Diabet Ctr, Boston, MA 02215 USA. [Witters, Lee A.] Hitchcock Med Sch, Hanover, NH USA. RI Fujii, Nobuharu/J-2724-2014 OI Fujii, Nobuharu/0000-0002-0974-3033 NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467804352 ER PT J AU Bunni, MA Kramarenko, II Walker, L Raymond, JR Garnovskaya, MN AF Bunni, Marlene A. Kramarenko, Inga I. Walker, Linda Raymond, John R. Garnovskaya, Maria N. TI Role of Integrins in Angiotensin II-induced Proliferation of Vascular Smooth Muscle Cells SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Bunni, Marlene A.; Raymond, John R.; Garnovskaya, Maria N.] Ralph H Johnson VAMC, Med Serv, Charleston, SC USA. [Bunni, Marlene A.; Raymond, John R.; Garnovskaya, Maria N.] Ralph H Johnson VAMC, Res Serv, Charleston, SC USA. [Bunni, Marlene A.; Kramarenko, Inga I.; Walker, Linda; Raymond, John R.; Garnovskaya, Maria N.] Med Univ S Carolina, Charleston, SC 29425 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467806379 ER PT J AU Chattergoon, NN Louey, S Grandy, DK Scanlan, TS Hohimer, R Giraud, GD Thornburg, KL AF Chattergoon, Natasha N. Louey, Samantha Grandy, David K. Scanlan, Thomas S. Hohimer, Roger Giraud, George D. Thornburg, Kent L. TI 3-Iodothyronamine is a novel suppressor of fetal sheep cardiomyocyte proliferation in vitro SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Chattergoon, Natasha N.; Louey, Samantha; Giraud, George D.; Thornburg, Kent L.] Oregon Hlth & Sci Univ, Heart Res Ctr, Portland, OR USA. [Grandy, David K.; Scanlan, Thomas S.] Oregon Hlth & Sci Univ, Dept Physiol & Pharmacol, Portland, OR USA. [Hohimer, Roger] Oregon Hlth & Sci Univ, OB GYN Perinatal Div, Portland, OR USA. [Giraud, George D.] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467804144 ER PT J AU Coaxum, SD Raymond, JR AF Coaxum, Sonya Denise Raymond, John R. TI Mutations in the i3N loop calmodulin (CaM)-binding domain of 5-HT1A receptor attenuate ERK phosphorylation in CHO-K1 cells SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Coaxum, Sonya Denise; Raymond, John R.] Med Univ S Carolina, Charleston, SC 29425 USA. [Coaxum, Sonya Denise; Raymond, John R.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467806101 ER PT J AU Collier, ARY Reynoso, E Tjota, M Turley, SJ AF Collier, Ai-ris Yonekura Reynoso, Erika Tjota, Melissa Turley, Shannon J. TI Antigen presentation by lymph node stroma: Potential for tolerogenic immunotherapy SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Collier, Ai-ris Yonekura; Reynoso, Erika; Tjota, Melissa; Turley, Shannon J.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Collier, Ai-ris Yonekura] Harvard Univ, Sch Med, Harvard Mit Div Hlth Sci & Technol, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GY UT WOS:000208467700763 ER PT J AU Contreras, MA Phaneuf, MD Wu, SQ Bide, MJ LoGerfo, FW AF Contreras, Mauricio Antonio Phaneuf, Mathew Douglas Wu, Shengqian Bide, Martin J. LoGerfo, Frank W. TI BIOSPUN VASCULAR GRAFTS: IN VIVO EVALUATION OF A NOVEL SMALL-DIAMETER BIOACTIVE NANOFIBROUS VASCULAR GRAFT FOR ARTERIAL RECONSTRUCTION SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Contreras, Mauricio Antonio; Wu, Shengqian; LoGerfo, Frank W.] BIDMC, Boston, MA USA. [Phaneuf, Mathew Douglas] Biosurfaces, Ashland, MA USA. [Bide, Martin J.] URI, Kingston, RI USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GY UT WOS:000208467700360 ER PT J AU Corriden, R Insel, PA Chen, Y Junger, WG AF Corriden, Ross Insel, Paul A. Chen, Yu Junger, Wolfgang G. TI E-NTPDase1 and alkaline phosphatase control chemotaxis of human neutrophils by generating adenosine from released ATP SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Corriden, Ross; Insel, Paul A.] Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA. [Corriden, Ross] Univ Calif San Diego, Dept Surg, La Jolla, CA 92093 USA. [Insel, Paul A.] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA. [Chen, Yu; Junger, Wolfgang G.] Beth Israel Deaconess Med Ctr Harvard, Dept Surg, Boston, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467804764 ER PT J AU Dange, M Hartong, DT McGee, TL Berson, EL Dryja, TP Colman, RF AF Dange, Mayura Hartong, Dyonne T. McGee, Terri L. Berson, Eliot L. Dryja, Thaddeus P. Colman, Roberta F. TI Mutations of the beta-subunit of human NAD-specific isocitrate dehydrogenase in patients with Retinitis Pigmentosa SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Dange, Mayura; Colman, Roberta F.] Univ DE, Newark, DE USA. [Hartong, Dyonne T.; McGee, Terri L.; Berson, Eliot L.; Dryja, Thaddeus P.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Berman Gund Lab, Boston, MA USA. [Hartong, Dyonne T.; McGee, Terri L.; Berson, Eliot L.; Dryja, Thaddeus P.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Ocular Mol Genet Inst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467800277 ER PT J AU Duda, DG Jones, R Dawson, M Capen, D Tyrrell, A Fukumura, D Jain, RK AF Duda, Dan G. Jones, Rosemary Dawson, Michelle Capen, Diane Tyrrell, Alex Fukumura, Dai Jain, Rakesh K. TI Phenotypic and functional characterization of proangiogenic monocytes SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Duda, Dan G.; Dawson, Michelle; Tyrrell, Alex; Fukumura, Dai; Jain, Rakesh K.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Jones, Rosemary; Capen, Diane] Massachusetts Gen Hosp, Charlestown, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467802410 ER PT J AU Freyschmidt, EJ Mathias, C Caplan, B Laouar, A Swamy, MN Campbell, J Wurbel, MA Chatila, T Oettgen, H AF Freyschmidt, Eva-Jasmin Mathias, Clinton Caplan, Benjamin Laouar, Amale Swamy, Manjunath N. Campbell, James Wurbel, Marc-Andre Chatila, Talal Oettgen, Hans TI Eczema-prone CCR4(-/-) FoxP3(-) bone marrow chimeras display defective immune responses following skin infection with vaccinia SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Freyschmidt, Eva-Jasmin; Mathias, Clinton; Caplan, Benjamin; Oettgen, Hans] Childrens Hosp, Boston, MA 02115 USA. [Laouar, Amale; Swamy, Manjunath N.] CBR, Boston, MA USA. [Campbell, James; Wurbel, Marc-Andre] BWH, Boston, MA USA. [Chatila, Talal] Univ Calif Los Angeles, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GY UT WOS:000208467700127 ER PT J AU Frosch, MP Prada, CM Garci-Alloza, M Betensky, RA Bacskai, BJ Greenberg, SM AF Frosch, Matthew P. Prada, Claudia M. Garci-Alloza, Monica Betensky, Rebecca A. Bacskai, Brian J. Greenberg, Steven M. TI Effect of Gelsolin on Cerebral Amyloid Angiopathy (CAA) in Transgenic Mice SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Frosch, Matthew P.] Mass Gen Hosp, CS Kubik Lab Neuropathol, Boston, MA USA. [Frosch, Matthew P.; Prada, Claudia M.; Garci-Alloza, Monica; Bacskai, Brian J.; Greenberg, Steven M.] Mass Gen Hosp, MassGen Inst Neurodegenerat Dis, Charlestown, MA USA. [Betensky, Rebecca A.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467803473 ER PT J AU Fukumura, D Au, P Tam, J Koike, N Jain, RK AF Fukumura, Dai Au, Patrick Tam, Joshua Koike, Naoto Jain, Rakesh K. TI Creation of long-lasting blood vessels in vivo SO FASEB JOURNAL LA English DT Meeting Abstract C1 Massachusetts Gen Hosp, Dept Radiat Oncol, Edwin L Steele Lab, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 4 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467800439 ER PT J AU Garnovskaya, MN Bunni, M Kramarenko, I Raymond, JR Morinelli, TA AF Garnovskaya, Maria N. Bunni, Marlene Kramarenko, Inga Raymond, John R. Morinelli, Thomas A. TI Bradykinin B-2 Receptor Induces Multiple Cellular Responses Leading to Proliferation of Renal Carcinoma Cells SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Garnovskaya, Maria N.; Bunni, Marlene; Raymond, John R.; Morinelli, Thomas A.] Ralph H Johnson VAMC, Med Serv, Charleston, SC USA. [Garnovskaya, Maria N.; Bunni, Marlene; Raymond, John R.; Morinelli, Thomas A.] Ralph H Johnson VAMC, Res Serv, Charleston, SC USA. [Garnovskaya, Maria N.; Bunni, Marlene; Kramarenko, Inga; Raymond, John R.; Morinelli, Thomas A.] Med Univ S Carolina, Nephrol Div, Charleston, SC 29425 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GY UT WOS:000208467700282 ER PT J AU Goldman, RK Azar, AS Mulvaney, JM Brooks, VL AF Goldman, Robert K. Azar, Afaf S. Mulvaney, Julia M. Brooks, Virginia L. TI Baroreflex sensitivity varies during the estrus cycle of the rat SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Goldman, Robert K.; Azar, Afaf S.; Mulvaney, Julia M.; Brooks, Virginia L.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Goldman, Robert K.] Portland VA Med Ctr, Surgery, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467808766 ER PT J AU Goldman, RK Azar, AS Mulaney, JM Brooks, VL AF Goldman, Robert K. Azar, Afaf S. Mulaney, Julia M. Brooks, Virginia L. TI Changes in gain of baroreflex control of heart rate during delivery and the early post partum period of the rat SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Goldman, Robert K.; Azar, Afaf S.; Mulaney, Julia M.; Brooks, Virginia L.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Goldman, Robert K.] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467804650 ER PT J AU Hsu, HC Yang, PA Wu, Q Job, G Guentert, T Wang, J Mountz, JD AF Hsu, Hui-Chen Yang, PingAr Wu, Qi Job, Godwin Guentert, Tanja Wang, John Mountz, John D. TI Inhibition of Activation-Induced Cytidine Deaminase (AID) Preserved Spontaneous Germinal Centers but Suppressed Autoimmune Disease in BXD2 Mice SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Hsu, Hui-Chen; Yang, PingAr; Wu, Qi; Job, Godwin; Guentert, Tanja; Wang, John; Mountz, John D.] Univ Alabama Birmingham, Birmingham, AL USA. [Mountz, John D.] Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467802571 ER PT J AU Kolliputi, NV Meloney, LG Kathryn, SM Waxman, AB AF Kolliputi, Narasaiah V. Meloney, Laura G. Kathryn, Steiner M. Waxman, Aaron B. TI IL-6 Inhibits Hyperoxia Induced Bax Translocation Through Pi3kinase/AKT Mediated Bax Phosphorylation SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Kolliputi, Narasaiah V.; Meloney, Laura G.; Kathryn, Steiner M.; Waxman, Aaron B.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Pulm Crit Care Unit,Dept Med, Boston, MA USA. RI Kolliputi, Narasaiah/I-6050-2012 OI Kolliputi, Narasaiah/0000-0002-2654-1900 NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467802298 ER PT J AU Kramarenko, I Bunni, M Raymond, JR Garnovskaya, MN AF Kramarenko, Inga Bunni, Marlene Raymond, John R. Garnovskaya, Maria N. TI Identification of a Functional Bradykinin B-2 Receptor Expressed in HEK293 Cells SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Kramarenko, Inga; Bunni, Marlene; Raymond, John R.; Garnovskaya, Maria N.] Med Univ S Carolina, Div Nephrol, Charleston, SC 29425 USA. [Bunni, Marlene; Raymond, John R.; Garnovskaya, Maria N.] Ralph H Johnson VAMC, Med Serv, Charleston, SC USA. [Bunni, Marlene; Raymond, John R.; Garnovskaya, Maria N.] Ralph H Johnson VAMC, Res Serv, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GY UT WOS:000208467700479 ER PT J AU Kramarenko, II Bunni, M Raymond, JR Garnovskaya, MN AF Kramarenko, Inga I. Bunni, Marlene Raymond, John R. Garnovskaya, Maria N. TI Bradykinin B-2 Receptor Interacts with Integrin alpha 5 beta 1 to Transactivate Epidermal Growth Factor Receptor in Kidney Cells SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Kramarenko, Inga I.; Bunni, Marlene; Raymond, John R.; Garnovskaya, Maria N.] Med Univ S Carolina, Charleston, SC 29425 USA. [Raymond, John R.; Garnovskaya, Maria N.] Ralph H Johnson VAMC, Med Serv, Charleston, SC USA. [Raymond, John R.; Garnovskaya, Maria N.] Ralph H Johnson VAMC, Res Serv, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467804688 ER PT J AU La Fountaine, M Radulovic, M Wecht, J Cardozo, C Spungen, A De Meersman, R Bauman, W AF La Fountaine, Michael Radulovic, Miroslav Wecht, Jill Cardozo, Chrstopher Spungen, Ann De Meersman, Ronald Bauman, William TI Vascular reactivity to L-NAME administration in chronic tetraplegia SO FASEB JOURNAL LA English DT Meeting Abstract C1 [La Fountaine, Michael; Radulovic, Miroslav; Wecht, Jill; Cardozo, Chrstopher; Spungen, Ann; Bauman, William] James J Peters VAMC, VA Ctr Excellence Med Consequences Spinal Cord In, Bronx, NY USA. [La Fountaine, Michael; De Meersman, Ronald] Columbia Univ Teachers Coll, New York, NY 10027 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467801272 ER PT J AU Lam, F Burns, A Rumbaut, R AF Lam, Fong Burns, Alan Rumbaut, Rolando TI Activated platelets enhance early neutrophil transmigration across IL-1 beta stimulated endothelium SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Lam, Fong; Burns, Alan] Baylor Coll Med, Houston, TX 77030 USA. [Rumbaut, Rolando] VA Med Ctr, MCL, Houston, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GY UT WOS:000208467700556 ER PT J AU Lawlor, MW Roumm, E DeChene, ET Geggel, A Moghadasadeh, B Beggs, AH AF Lawlor, Michael William Roumm, Emily DeChene, Elizabeth Taylor Geggel, Amelia Moghadasadeh, Behzad Beggs, Alan H. TI Morphologic Assessment of Muscle Biopsy Abnormalities in Patients with Congenital Fiber Type Disproportion and Tropomyosin 3 Mutation SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Lawlor, Michael William] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Lawlor, Michael William; Roumm, Emily; Moghadasadeh, Behzad; Beggs, Alan H.] Harvard Univ, Sch Med, Boston, MA USA. [DeChene, Elizabeth Taylor; Geggel, Amelia; Moghadasadeh, Behzad; Beggs, Alan H.] Childrens Hosp Boston, Program Genom, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467807765 ER PT J AU Lee, JT AF Lee, Jeannie T. TI X-chromosome inactivation: Sex, heterochromatin, pairing, and noncoding RNA SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Lee, Jeannie T.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467803311 ER PT J AU Litovchick, A Szostak, JW AF Litovchick, Alexander Szostak, Jack W. TI Selection of cyclic peptide aptamers to HCV IRES RNA using mRNA display SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Szostak, Jack W.] Massachusetts Gen Hosp, Ctr Computat & Integrat Biol, Howard Hughes Med Inst, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GY UT WOS:000208467700499 ER PT J AU Lu, LR Kim, HJ Werneck, M Cantor, H AF Lu, Linrong Kim, Hye-Jung Werneck, Miriam Cantor, Harvey TI Manipulation of Qa-1-restricted CD8 Suppressor Cell Activity in Experimental Autoimmune Encephalomyelitis SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Lu, Linrong; Kim, Hye-Jung; Werneck, Miriam; Cantor, Harvey] Dana Farber Canc Inst, Boston, MA 02115 USA. [Lu, Linrong; Kim, Hye-Jung; Werneck, Miriam; Cantor, Harvey] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GY UT WOS:000208467700490 ER PT J AU Mailloux, AW Young, MRI AF Mailloux, Adam William Young, M. Rita I. TI Lewis Lung Carcinoma (LLC) alters the phenotype of murine lung mast cells resulting in a phenotype consistent with myeloid-derived suppressor cells (MDSCs) SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Mailloux, Adam William; Young, M. Rita I.] Med Univ S Carolina, Charleston, SC 29425 USA. [Young, M. Rita I.] Ralph H Johnson VAMC, Dept Otolaryngol, Charleston, SC USA. [Young, M. Rita I.] Ralph H Johnson VAMC, Dept Med, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467804792 ER PT J AU Mailloux, AW Young, MRI AF Mailloux, Adam William Young, M. Rita I. TI Myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs) produce CCL22 which selectively recruits regulatory T-cells (Tregs) to the tumor microenvironment SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Young, M. Rita I.] Med Univ S Carolina, Dept Otolaryngol, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Young, M. Rita I.] Ralph H Johnson VAMC, Res Serv, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 2 U2 3 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467804693 ER PT J AU Manocha, M Rietdijk, S Laouar, A Bhan, A Terhost, C Swamy, MN AF Manocha, Monika Rietdijk, Svend Laouar, Amale Bhan, Atul Terhost, Cox Swamy, Manjunath N. TI CD70 antibody therapy for the prevention and treatment of experimental Inflammatory Bowel Disease (IBD). SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Manocha, Monika; Laouar, Amale; Swamy, Manjunath N.] Harvard Univ, Sch Med, Immune Dis Inst, Boston, MA USA. [Rietdijk, Svend; Terhost, Cox] Harvard Inst Med, Beth Israel Deaconess Med Ctr, Boston, MA USA. [Bhan, Atul] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467800434 ER PT J AU Mayhew, D Roth, C Cross, J Bamman, M AF Mayhew, David Roth, Christopher Cross, James Bamman, Marcas TI p70S6K signaling induces load-mediated myofiber hypertrophy in humans in an mTOR- and RPS6-indedpendent manner SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Mayhew, David] Univ Alabama Birmingham, Med Scientist Training Program, Birmingham, AL USA. [Roth, Christopher] Univ Alabama Birmingham, Sch Med, Birmingham, AL USA. [Bamman, Marcas] Birmingham VA Med Ctr, Geriatr Res Educ & Clin Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467809154 ER PT J AU Mercado, A Babilonia, E Mount, D AF Mercado, Adriana Babilonia, Elisa Mount, David TI The Functional Roles of Cysteine Residues in the KCC4 K-Cl Cotransporter SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Mercado, Adriana; Mount, David] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Renal, Boston, MA 02115 USA. [Babilonia, Elisa] Harvard Univ, Sch Med, Briugham & Womens Hosp, Div Renal, Boston, MA USA. [Mount, David] VA Boston Healthcare Syst, Div Renal, W Roxbury, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467808736 ER PT J AU Merkulova, M Marshansky, V AF Merkulova, Maria Marshansky, Vladimir TI Function of V-ATPase as a putative endosomal pH-senor: mapping the interaction sites between V-ATPase a2-isoform and ARNO SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Merkulova, Maria; Marshansky, Vladimir] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Program Membrane Biol,Ctr Syst Biol,Simches Res C, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467808789 ER PT J AU Mershon, KL Vasuthasawat, A Morrison, SL Beenhouwer, DO AF Mershon, Kileen Louise Vasuthasawat, Alex Morrison, Sherie L. Beenhouwer, David O. TI Both the lectin and alternative pathways of complement activation play roles in Cryptococcus gattii infection SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Mershon, Kileen Louise; Vasuthasawat, Alex; Morrison, Sherie L.; Beenhouwer, David O.] Univ Calif Los Angeles, Los Angeles, CA USA. [Beenhouwer, David O.] Vet Affairs Greater Los Angeles Healthcare Syst, Div Infect Dis, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467803341 ER PT J AU Morissette, MR Xiao, CY Rosenzweig, A AF Morissette, Michael R. Xiao, Chun Yang Rosenzweig, Anthony TI Cardiac-specific expression of myostatin or an inhibitor of myostatin regulate heart size at baseline and in response to hypertrophic stimuli SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Morissette, Michael R.; Xiao, Chun Yang; Rosenzweig, Anthony] Harvard Univ, Sch Med, BIDMC, Boston, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GY UT WOS:000208467700152 ER PT J AU Mountz, JD Yang, PA Wu, Q Guentert, T Wang, J Hsu, HC AF Mountz, John D. Yang, PingAr Wu, Qi Guentert, Tanja Wang, John Hsu, Hui-Chen TI IL-17 Upregulates Regulator of G-protein Signaling (Rgs)13 and Rgs16 for the Formation of Autoreactive Germinal Centers in BXD2 Mice SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Mountz, John D.; Yang, PingAr; Wu, Qi; Guentert, Tanja; Wang, John; Hsu, Hui-Chen] Univ Alabama Birmingham, Birmingham, AL USA. [Mountz, John D.] Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467802581 ER PT J AU Mulligan, J Young, MRI AF Mulligan, Jennifer Young, M. Rita I. TI Role of Endothelial Cells in a Novel Mechanism of Tumor-Induced Immune Suppression SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Mulligan, Jennifer; Young, M. Rita I.] Ralph H Johnson VA Med Ctr, Res Serv, Charleston, SC USA. [Mulligan, Jennifer; Young, M. Rita I.] Med Univ S Carolina, Charleston, SC 29425 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467804167 ER PT J AU Myers, RC Carter, RH AF Myers, Riley C. Carter, Robert H. TI B cells fail to mature or form LZ despite GC formation in CD19-deficient mice SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Myers, Riley C.; Carter, Robert H.] Univ Alabama Birmingham, Birmingham, AL USA. [Carter, Robert H.] Birmingham VAMC, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467804775 ER PT J AU Nath, N Khan, M Singh, AK Singh, I Giri, S AF Nath, Narender Khan, Mushfiquddin Singh, Avtar K. Singh, Inderjit Giri, Shailendra TI Metformin, a diabetic drug attenuated autoimmune inflammatory disease of CNS in animal models of multiple sclerosis SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Nath, Narender; Khan, Mushfiquddin; Singh, Inderjit; Giri, Shailendra] Med Univ S Carolina, Charleston, SC 29425 USA. [Singh, Avtar K.] Ralph Johnson Vet Affairs Med Ctr, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467807722 ER PT J AU Neve, KA Liu, Y AF Neve, Kim A. Liu, Yong TI Interactions of the Dopamine D2 Receptor with the Calcium-Binding Protein S100B SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Neve, Kim A.] Portland VA Med Ctr, Portland, OR USA. [Neve, Kim A.; Liu, Yong] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467804617 ER PT J AU O'Tierney, PF Chattergoon, N Louey, S Giraud, G Thornburg, K AF O'Tierney, Perrie Faye Chattergoon, Natasha Louey, Samantha Giraud, George Thornburg, Kent TI Atrial natriuretic peptide inhibits angiotensin II-induced cell proliferation in fetal sheep cardiomyocytes in vitro SO FASEB JOURNAL LA English DT Meeting Abstract C1 [O'Tierney, Perrie Faye; Chattergoon, Natasha; Louey, Samantha; Giraud, George; Thornburg, Kent] Oregon Hlth & Sci Univ, Heart Res Ctr, Portland, OR 97201 USA. [Giraud, George] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467802639 ER PT J AU Olausson, KH Learner, E Ligon, KL AF Olausson, Karl Holmberg Learner, Emily Ligon, Keith Lloyd TI CD133 RNA expression marks a rare and widely distributed cell population in the adult mouse brain SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Ligon, Keith Lloyd] Harvard Univ, Sch Med, Boston, MA USA. [Ligon, Keith Lloyd] Brigham & Womens Hosp, Dana Farber Canc Inst, Ctr Mol Oncol Pathol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467808363 ER PT J AU Osorio, YE Travi, BL Melby, PC AF Osorio, Yaneth E. Travi, Bruno L. Melby, Peter C. TI An ex vivo splenic explant model system for the identification of small molecule therapeutics for visceral leishmaniasis SO FASEB JOURNAL LA English DT Meeting Abstract C1 Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467805262 ER PT J AU Osorio, YE Zhao, WG Espitia, C Travi, BL Hawel, L Byus, CV Saldarriaga, OA Melby, PC AF Osorio, Yaneth E. Zhao, Weiguo Espitia, Claudia Travi, Bruno L. Hawel, Leo Byus, Craig V. Saldarriaga, Omar A. Melby, Peter C. TI Dominant arginase expression in a model of progressive visceral leishmaniasis SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Osorio, Yaneth E.; Zhao, Weiguo; Espitia, Claudia; Travi, Bruno L.; Saldarriaga, Omar A.; Melby, Peter C.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Osorio, Yaneth E.; Zhao, Weiguo; Espitia, Claudia; Travi, Bruno L.; Saldarriaga, Omar A.; Melby, Peter C.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Hawel, Leo; Byus, Craig V.] Univ Calif Riverside, Riverside, CA 92521 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467802511 ER PT J AU Padera, TP AF Padera, Timothy P. TI Imaging the steps of lymphatic metastasis SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Padera, Timothy P.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467801427 ER PT J AU Peebles, ER Roberts, MF Giraud, GD Holden, WE AF Peebles, Evan Richard Roberts, M. F. Giraud, G. D. Holden, W. E. TI Inhalation of Dry, Normobaric Hypoxic Air Impairs Thermal Conditioning of Nasal Air in Humans: Potential Role of Nitric Oxide SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Peebles, Evan Richard; Roberts, M. F.] Linfield Coll, Mcminnville, OR USA. [Giraud, G. D.; Holden, W. E.] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467801516 ER PT J AU Percival, J Anderson, K Huang, P Froehner, S AF Percival, Justin Anderson, Kendra Huang, Paul Froehner, Stanley TI A Novel nNOS Signaling Pathway Regulates Skeletal Muscle Size, Strength and Fatigue Resistance SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Percival, Justin; Anderson, Kendra; Froehner, Stanley] Univ Washington, Seattle, WA 98195 USA. [Huang, Paul] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467807545 ER PT J AU Peterson, R AF Peterson, Randall TI Connecting development and disease pathways through zebrafish chemical biology SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Peterson, Randall] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Charlestown, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467802032 ER PT J AU Puigserver, P AF Puigserver, Pere TI Nutrient Sensing Through Metabolic Transcription-Dependent Acetylation SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Puigserver, Pere] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467801087 ER PT J AU Roberts, JD Sugiura, T Nakanishi, H AF Roberts, Jesse David, Jr. Sugiura, Takahiro Nakanishi, Hidehiko TI A novel constitutively active isoform of cGMP-dependent protein kinase I (PKGI) is localized in the nucleus of vascular smooth muscle cells (VSMC) SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Roberts, Jesse David, Jr.] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Charlestown, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467803055 ER PT J AU Robertson, SA Koleva, RI Marto, JA Argetsinger, LS Carter-Su, C Feener, EP Myers, MG AF Robertson, Scott Andrew Koleva, Rositsa Ivanova Marto, Jarrod A. Argetsinger, Lawrence Stanton Carter-Su, Christin Feener, Edward P. Myers, Martin G. TI Identification and Characterization of Novel Phosphorylation Sites on Jak2 SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Robertson, Scott Andrew] Univ Michigan, Ann Arbor, MI 48109 USA. [Koleva, Rositsa Ivanova; Marto, Jarrod A.] Dana Farber Canc Inst, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA. [Argetsinger, Lawrence Stanton; Carter-Su, Christin; Myers, Martin G.] Univ Michigan, Sch Med, Dept Mol & Integrat Physiol, Ann Arbor, MI USA. [Myers, Martin G.] Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI USA. [Feener, Edward P.] Joslin Diabet Ctr, Div Res, Boston, MA 02215 USA. [Feener, Edward P.] Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GY UT WOS:000208467700379 ER PT J AU Ross, ES Johnson, SL Shroyer, AL Prochazka, A Dickinson, LM Krebs, N Pharo, SA AF Ross, Erin Sundseth Johnson, Susan L. Shroyer, A. Laurie Prochazka, Allan Dickinson, L. Miriam Krebs, Nancy Pharo, Susan A. TI Early growth velocity predicts longitudinal growth failure SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Ross, Erin Sundseth; Johnson, Susan L.; Krebs, Nancy] Univ Colorado, Sect Nutr, Denver, CO 80202 USA. [Shroyer, A. Laurie] VA Hosp Northport, Northport, NY USA. [Prochazka, Allan] Denver VA Hosp, Denver, CO USA. [Pharo, Susan A.] Kaiser Permanente, Aurora, CO USA. RI Shroyer, Annie Laurie/B-8836-2016 OI Shroyer, Annie Laurie/0000-0001-6461-0623 NR 0 TC 0 Z9 0 U1 0 U2 1 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467805217 ER PT J AU Sakamoto, K Bouskila, M Ibrahim, A Peggie, M Hirshman, MF Goodyear, LJ Jensen, J AF Sakamoto, Kei Bouskila, Michale Ibrahim, Adel Peggie, Mark Hirshman, Michael F. Goodyear, Laurie J. Jensen, Jorgen TI Investigating the mechanism of regulation of muscle glycogen synthase SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Sakamoto, Kei; Bouskila, Michale; Ibrahim, Adel; Peggie, Mark] Univ Dundee, MRC Prot Phosphorylat Unit, Dundee, Scotland. [Hirshman, Michael F.; Goodyear, Laurie J.] Joslin Diabet Ctr, Boston, MA 02215 USA. [Jensen, Jorgen] Natl Inst Occupat Hlth, Dept Physiol, Oslo, Norway. RI Ibrahim, Adel/E-5273-2012 NR 0 TC 0 Z9 0 U1 0 U2 1 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467800659 ER PT J AU Sarkar, S Kalia, V Haining, WN Konieczny, BT Subramaniam, S Ahmed, R AF Sarkar, Surojit Kalia, Vandana Haining, W. Nicholas Konieczny, Bogumila T. Subramaniam, Shruti Ahmed, Rafi TI Functional and Genomic Profiling of Effector CD8 T Cell Subsets with Distinct Fates SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Sarkar, Surojit; Kalia, Vandana; Konieczny, Bogumila T.; Subramaniam, Shruti; Ahmed, Rafi] Emory Univ, Sch Med, Atlanta, GA USA. [Haining, W. Nicholas] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467808492 ER PT J AU Scalapino, KJ Daikh, DI AF Scalapino, Kenneth John Daikh, David I. TI In vitro and in vivo activation of CD4+CD25-Foxp3+Tregs in NZB/W mice SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Scalapino, Kenneth John; Daikh, David I.] San Francisco VA Med Ctr, Div Rheumatol, San Francisco, CA USA. [Daikh, David I.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467805279 ER PT J AU Shi, Y Liang, HY Liu, YH Ward, WF Van Remmen, H AF Shi, Yun Liang, Huiyun Liu, Yuhong Ward, Walter F. Van Remmen, Holly TI PGC-1 alpha plays a protective role against oxidative stress in skeletal muscle SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Shi, Yun; Liang, Huiyun; Liu, Yuhong; Ward, Walter F.; Van Remmen, Holly] Univ Texas Hlth Sci Ctr, San Antonio, TX USA. [Ward, Walter F.] Barshop Inst Longev & Aging Studies, San Antonio, TX USA. [Van Remmen, Holly] S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467807817 ER PT J AU Smith, MA Goodyear, LJ Reid, MB AF Smith, Melissa A. Goodyear, Laurie J. Reid, Michael B. TI Reactive oxygen species and nitric oxide, but not AMPK, mediate stretch-induced glucose uptake by muscle. SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Smith, Melissa A.; Reid, Michael B.] Univ Kentucky, Dept Physiol, Lexington, KY USA. [Goodyear, Laurie J.] Joslin Diabet Ctr, Div Res, Boston, MA 02215 USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467807257 ER PT J AU Smithey, MJ Higgins, D Freitag, NE Bouwer, HGA AF Smithey, Megan J. Higgins, Darren Freitag, Nancy E. Bouwer, H. G. Archie TI Influence of virulence attenuation on the efficacy of Listeria monocytogenes as a vaccine vector for stimulating anti-tumor immunity SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Smithey, Megan J.; Bouwer, H. G. Archie] Portland VA Med Ctr, Portland, OR USA. [Higgins, Darren] Harvard Univ, Sch Med, Boston, MA USA. [Freitag, Nancy E.] Univ Illinois, Chicago, IL USA. [Bouwer, H. G. Archie] EACRI, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467804523 ER PT J AU Snuderl, M Chi, SN DeSantis, S Stemmer-Rachamimov, A Betensky, RA DeGirolami, U Kieran, MW AF Snuderl, Matija Chi, Susan N. DeSantis, Stacia Stemmer-Rachamimov, Anat Betensky, Rebecca A. DeGirolami, Umberto Kieran, Mark W. TI Prognostic value of tumor microinvasion and metalloproteinases expression in intracranial pediatric ependymomas SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Snuderl, Matija; Stemmer-Rachamimov, Anat] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Chi, Susan N.; Kieran, Mark W.] Dana Farber Canc Inst, Boston, MA 02115 USA. [DeSantis, Stacia; Betensky, Rebecca A.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. [DeGirolami, Umberto] ChildrensHospital, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467804585 ER PT J AU Vezys, V Masopust, D Sharpe, A Freeman, G Newell, K Ahmed, R AF Vezys, Vaiva Masopust, David Sharpe, Arlene Freeman, Gordon Newell, Kenneth Ahmed, Rafi TI PD-1 negatively regulates CD8 T cell-mediated mucosal autoimmunity SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Vezys, Vaiva; Masopust, David] Univ Minnesota, Dept Microbiol, Minneapolis, MN 55455 USA. [Sharpe, Arlene] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. [Freeman, Gordon] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Newell, Kenneth] Emory Univ, Sch Med, Dept Surg, Atlanta, GA 30322 USA. [Ahmed, Rafi] Emory Univ, Sch Med, Emory Vaccine Ctr, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467806892 ER PT J AU Vidal, M AF Vidal, Marc TI Interactome Networks SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Vidal, Marc] Dana Farber Canc Inst, CCSB, Boston, MA 02115 USA. [Vidal, Marc] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA. [Vidal, Marc] Harvard Univ, Sch Med, Dept Genet, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467800601 ER PT J AU Vilardaga, JP Nikolaev, VO Lorenz, K Ferrandon, S AF Vilardaga, Jean-Pierre Nikolaev, Viacheslav O. Lorenz, Kristina Ferrandon, Sebastien TI Conformational cross-talk between alpha(2A)-adrenergic and mu-opioid receptors controls cell signaling SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Vilardaga, Jean-Pierre; Ferrandon, Sebastien] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Vilardaga, Jean-Pierre; Ferrandon, Sebastien] Harvard Univ, Sch Med, Boston, MA USA. [Nikolaev, Viacheslav O.; Lorenz, Kristina] Inst Pharmacol & Toxicol, Wurzburg, Germany. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467807805 ER PT J AU Wainwright, DA Xin, JP Mesnard, NA Sanders, VM Jones, KJ AF Wainwright, Derek Alan Xin, Junping Mesnard, Nicole A. Sanders, Virginia M. Jones, Kathryn J. TI T cells and chemokine expression in the CNS: relevance to motoneuron injury and ALS SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Wainwright, Derek Alan; Xin, Junping; Mesnard, Nicole A.; Jones, Kathryn J.] Loyola Univ Chicago, Maywood, IL USA. [Wainwright, Derek Alan; Xin, Junping; Mesnard, Nicole A.; Jones, Kathryn J.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Res Serv, Hines, IL 60141 USA. [Sanders, Virginia M.] Ohio State Univ, Columbus, OH 43210 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467801330 ER PT J AU Walsh, JE Young, MRI AF Walsh, Jarrett E. Young, M. Rita I. TI Phosphatase regulation of cellular motility in the tumor microenvironment SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Walsh, Jarrett E.; Young, M. Rita I.] Med Univ S Carolina, Charleston, SC 29425 USA. [Young, M. Rita I.] Ralph H Johnson VAMC, Res Serv, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467802437 ER PT J AU Wang, JLY Roehr, MH AF Wang, Julia Y. Roehr, Michael H. TI Towards a new generation of potent and multifunctional anthrax vaccines SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Wang, Julia Y.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Roehr, Michael H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467807599 ER PT J AU Yip, S Cahill, DP Louis, DN AF Yip, Stephen Cahill, Daniel P. Louis, David N. TI Mismatch repair defects underlying temozolomide chemoresistance in recurrent glioblastomas SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Yip, Stephen; Cahill, Daniel P.; Louis, David N.] Massachusetts Gen Hosp, Charlestown, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467802512 ER PT J AU Yoshida, M Booth, SL Meigs, JB Saltzman, E Jacques, PF AF Yoshida, Makiko Booth, Sarah L. Meigs, James B. Saltzman, Edward Jacques, Paul F. TI Phylloquinone intake is associated with glucose metabolism in middle- and older-aged men and women SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Yoshida, Makiko; Booth, Sarah L.; Saltzman, Edward; Jacques, Paul F.] Tufts Univ, USDA, Human Nutr Res Ctr Aging, Boston, MA 02111 USA. [Meigs, James B.] Massachusetts Gen Hosp, Div Gen Med, Boston, MA 02114 USA. [Meigs, James B.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Meigs, James B.] Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467803722 ER PT J AU Zang, S Hsu, HC Yang, P Wu, Q Job, G Guentert, T Nandakumar, KS Holmdahl, R Mountz, JD AF Zang, Song Hsu, Hui-Chen Yang, PingAr Wu, Qi Job, Godwin Guentert, Tanja Nandakumar, Kutty Selva Holmdahl, Rikard Mountz, John D. TI Development of Collagen II (CII)-induced Arthritis Was Associated with High AID and IL-17 Expression in BXD2 Mice SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Zang, Song; Hsu, Hui-Chen; Yang, PingAr; Wu, Qi; Job, Godwin; Guentert, Tanja; Mountz, John D.] Univ Alabama Birmingham, Birmingham, AL USA. [Nandakumar, Kutty Selva; Holmdahl, Rikard] Lund Univ, Lund, Sweden. [Mountz, John D.] Birmingham VA Med Ctr, Birmingham, AL USA. RI Nandakumar, Kutty Selva/D-5438-2011 OI Nandakumar, Kutty Selva/0000-0001-7790-8197 NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467803086 ER PT J AU Doolittle, MH Peterfy, M AF Doolittle, Mark H. Peterfy, Miklos TI Lipase maturation factor 1 (Lmf1), a new gene in hypertriglyceridemia SO FUTURE LIPIDOLOGY LA English DT Editorial Material ID LIPOPROTEIN-LIPASE; ENDOPLASMIC-RETICULUM; MUTATIONS; CLD; DEFICIENCY C1 [Peterfy, Miklos] Cedars Sinai Med Ctr, Inst Med Genet, Los Angeles, CA 90048 USA. [Doolittle, Mark H.; Peterfy, Miklos] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Doolittle, Mark H.; Peterfy, Miklos] VA Greater Angeles Healthcare Syst, Los Angeles, CA 90073 USA. RP Peterfy, M (reprint author), Cedars Sinai Med Ctr, Inst Med Genet, Los Angeles, CA 90048 USA. EM mpeterfy@ucla.edu NR 14 TC 1 Z9 1 U1 0 U2 2 PU FUTURE MEDICINE LTD PI LONDON PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND SN 1746-0875 J9 FUTURE LIPIDOL JI Future Lipidol. PD APR PY 2008 VL 3 IS 2 BP 119 EP 122 DI 10.2217/17460875.3.2.119 PG 4 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 343EQ UT WOS:000258836100001 ER PT J AU Loomba, R Hwang, SJ O'Donnell, CJ Ellison, RC Vasan, RS D'Agostino, RB Liang, TJ Fox, CS AF Loomba, Rohit Hwang, Shih-Jen O'Donnell, Christopher J. Ellison, R. Curtis Vasan, Ramachandran S. D'Agostino, Ralph B., Sr. Liang, T. Jake Fox, Caroline S. TI Parental obesity and offspring serum alanine and aspartate aminotransferase levels: The Framingham heart study SO GASTROENTEROLOGY LA English DT Article ID FATTY LIVER-DISEASE; MIDDLE-AGED MEN; BODY-MASS INDEX; NONALCOHOLIC STEATOHEPATITIS; UNITED-STATES; INSULIN-RESISTANCE; CRYPTOGENIC CIRRHOSIS; METABOLIC SYNDROME; 7 COUNTRIES; PREVALENCE AB Background & Aims: Obesity is an important correlate of serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels. We sought to examine the relations between parental obesity and the serum ALT and AST levels among offspring in a community-based sample. Methods: Participants (n = 1732) of the Framingham Offspring Study (50% women; mean age, 42 years) who had serum ALT and AST measurements and both parents in the original Framingham cohort were studied. Study participants were grouped into early-onset parental obesity (n = 193) (at least one parent obese), later-onset parental obesity (n = 460), and no parental obesity (n = 1079) subgroups. The association between elevated ALT or AST levels and parental obesity was tested using generalized estimating equations to account for familial correlations. Results: In multivariable analysis including adjustment for offspring obesity, significantly higher ALT levels were observed among individuals with paternal early-onset obesity as compared with those without paternal obesity (P =.02). Offspring with early-onset paternal obesity were more likely to have elevated ALT levels compared with those without paternal obesity (odds ratio, 1.75; 95% confidence interval, 1.06-2.89; P =.03). There was no association with elevated ALT levels among offspring with maternal early-onset obesity (odds ratio, 1.10; 95% confidence interval, 0.76-1.59; P =.61). There was no association between parental obesity and serum AST levels. Conclusions: Earlyonset paternal obesity, but not maternal obesity, increases the odds of elevated serum ALT levels in offspring, suggesting a predisposition to developing elevated serum ALT levels that may be mediated through familial early-onset obesity. C1 [Loomba, Rohit; Liang, T. Jake] NIDDK, Liver Dis Branch, NIH, Bethesda, MD USA. [Hwang, Shih-Jen; O'Donnell, Christopher J.; Ellison, R. Curtis; Vasan, Ramachandran S.; D'Agostino, Ralph B., Sr.; Fox, Caroline S.] NHLBI, NIH, Framingham, MA USA. [O'Donnell, Christopher J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med,Cardiol Div, Boston, MA USA. [Ellison, R. Curtis] Boston Univ, Sch Med, Sect Prevent Med, Boston, MA 02118 USA. [Vasan, Ramachandran S.] Boston Univ, Sch Med, Cardiol Sect, Boston, MA 02118 USA. [Vasan, Ramachandran S.] Boston Univ, Sch Med, Dept Med, Prevent Med & Epidemiol Sect, Boston, MA 02118 USA. [D'Agostino, Ralph B., Sr.] Boston Univ, Dept Math, Boston, MA 02215 USA. [Fox, Caroline S.] Harvard Univ, Brigham & Womens Hosp, Dept Endocrinol Diabet & Hypertens, Boston, MA 02115 USA. RP Fox, CS (reprint author), 73 Mt Wayte Ave,Suite 2, Framingham, MA 01702 USA. EM foxca@nhlbl.nih.gov FU Intramural NIH HHS [Z99 HL999999]; NHLBI NIH HHS [K-24-HL-04334, K24 HL004334, N01-HC-25195, N01HC25195] NR 41 TC 26 Z9 27 U1 0 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD APR PY 2008 VL 134 IS 4 BP 953 EP 959 DI 10.1053/j.gastro.2008.0:L.037 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 286NY UT WOS:000254853800015 PM 18395076 ER PT J AU Magnusson, FC Liblau, RS Von Boehmer, H Pittet, MJ Lee, JW Turley, SJ Khazaie, K AF Magnusson, Fay C. Liblau, Roland S. Von Boehmer, Harald Pittet, Mikael J. Lee, Je-Wook Turley, Shannon J. Khazaie, Khashayarsha TI Direct presentation of antigen by lymph node stromal cells protects against CD8 T-cell-mediated intestinal autoimmunity SO GASTROENTEROLOGY LA English DT Article ID INFLAMMATORY-BOWEL-DISEASE; ENTERIC GLIAL-CELLS; CROHNS-DISEASE; TRANSGENIC MICE; SCID MICE; RESPONSES; INDUCE; SELF; EPITHELIUM; TOLERANCE AB Background & Aims: Disruption of the enteric glial cell (EGC) network is an early pathologic feature in Crohn's disease. To determine the contribution of antigen-specific CD8 and CD4 T cells to the breakdown of the EGC network, we studied specific autoimmune targeting of an ectopic antigen expressed by EGCs. Methods: Transgenic mice (GFAP-HA), which express the influenza hemagglutinin (HA) in EGCs, were either crossed with mice transgenic for a T-cell receptor (TCR) specific for a major histocompatibility complex (MHC) class I epitope of HA (CL4-TCR) or were adoptively transferred with conventional CL4 T cells. These were compared with GFAP-HA mice transferred with conventional T cells specific for an MHC class II epitope of HA (6.5). Results: Both CD8 and CD4 T-cell subtypes were activated in vivo in an antigen-specific manner; however, they differed substantially in their ability to expand in the mesenteric lymph nodes, trigger proinflammatory cytokines, and induce autoimmune damage in the intestine. Direct presentation of antigen, provided by lymph node stromal. cells, caused the activation and deletion of CD8 T cells. This mechanism of T-cell tolerance did not affect CD4 T cells, which produced antigen-specific lethal autoimmunity. Conclusions: Our observations support a recently identified mechanism of peripheral T-cell tolerance that specifically protects against autoimmunity mediated by conventional CD8 T cells. Furthermore, we show that conventional CD4 T cells are not affected by this mechanism of tolerance, and their targeting of EGCs produces lethal intestinal autoimmunity. C1 [Magnusson, Fay C.; Von Boehmer, Harald; Lee, Je-Wook; Turley, Shannon J.; Khazaie, Khashayarsha] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Magnusson, Fay C.; Liblau, Roland S.] Univ Toulouse 3, Ctr Physiopathol Toulose Purpan, INSERM, U563, F-31062 Toulouse, France. [Pittet, Mikael J.; Khazaie, Khashayarsha] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Mol Imaging Res, Charlestown, MA USA. RP Khazaie, K (reprint author), Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Div Gastroenterol, 303 E Super St,3-250 Lurie, Chicago, IL 60611 USA. EM khazaie@northwestern.edu FU NCI NIH HHS [R01 CA104547-03]; NIAID NIH HHS [R37 AI053102, R37AI053102] NR 34 TC 49 Z9 52 U1 0 U2 5 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD APR PY 2008 VL 134 IS 4 BP 1028 EP 1037 DI 10.1053/j.gastro.2008.01.070 PG 10 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 286NY UT WOS:000254853800023 PM 18395084 ER PT J AU Gross, RG Reiter, B Korsten, MA AF Gross, Rebekah G. Reiter, Bruce Korsten, Mark A. TI Pyogenic liver abscess complicating colonoscopic polypectomy SO GASTROINTESTINAL ENDOSCOPY LA English DT Editorial Material ID ULCERATIVE-COLITIS C1 [Gross, Rebekah G.] Mt Sinai Sch Med, Div Gastroenterol, New York, NY 10029 USA. [Reiter, Bruce] James J Peters Vet Affairs Med Ctr, Dept Radiol, Bronx, NY USA. [Korsten, Mark A.] James J Peters Vet Affairs Med Ctr, Div Gastroenterol, Bronx, NY USA. RP Gross, RG (reprint author), Mt Sinai Sch Med, Div Gastroenterol, 1 Gustave L Levy Pl,POB 1069, New York, NY 10029 USA. NR 11 TC 3 Z9 3 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0016-5107 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD APR PY 2008 VL 67 IS 4 BP 767 EP 768 DI 10.1016/j.gie.2007.08.028 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 282VW UT WOS:000254596300042 PM 18155212 ER PT J AU Kelly, JA Kelley, JM Kaufman, KM Kilpatrick, J Bruner, GR Merrill, JT James, JA Frank, SG Reams, E Brown, EE Gibson, AW Marion, MC Langefeld, CD Li, QZ Karp, DR Wakeland, EK Petri, M Ramsey-Goldman, R Reveille, JD Vila, LM Alarcon, GS Kimberly, RP Harley, JB Edberg, JC AF Kelly, J. A. Kelley, J. M. Kaufman, K. M. Kilpatrick, J. Bruner, G. R. Merrill, J. T. James, J. A. Frank, S. G. Reams, E. Brown, E. E. Gibson, A. W. Marion, M. C. Langefeld, C. D. Li, Q-Z Karp, D. R. Wakeland, E. K. Petri, M. Ramsey-Goldman, R. Reveille, J. D. Vila, L. M. Alarcon, G. S. Kimberly, R. P. Harley, J. B. Edberg, J. C. TI Interferon regulatory factor-5 is genetically associated with systemic lupus erythematosus in African Americans SO GENES AND IMMUNITY LA English DT Article DE SLE; African Americans; IRF5; genetic association ID REVISED CRITERIA; RISK HAPLOTYPE; IRF5; POLYMORPHISM; SLE; POPULATION; GENE; COHORT; CLASSIFICATION; REPLICATION AB Increased expression of interferon (IFN)-inducible genes is implicated in the pathogenesis of systemic lupus erythematosus (SLE). One transcription factor responsible for regulating IFN, interferon regulatory factor-5 (IRF5), has been associated with SLE in genetic studies of Asian, Caucasian and Hispanic populations. We genotyped up to seven polymorphic loci in or near IRF5 in a total of 4870 African-American and Caucasian subjects ( 1829 SLE sporadic cases and 3041 controls) from two independent studies. Population-based case-control comparisons were performed using the Pearson's x(2)-test statistics and haplotypes were inferred using Haplo View. We observed significant novel associations with the IRF5 variants rs2004640 and rs3807306 in African Americans and replicated previously reported associations in Caucasians. While we identified risk haplotypes, the majority of haplotypic effects were accounted for by one SNP ( rs3807306) in conditional analyses. We conclude that genetic variants of IRF5 associate with SLE in multiple populations, providing evidence that IRF5 is likely to be a crucial component in SLE pathogenesis among multiple ethnic groups. C1 [Kelly, J. A.; Kaufman, K. M.; Kilpatrick, J.; Bruner, G. R.; Merrill, J. T.; James, J. A.; Frank, S. G.; Harley, J. B.] Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA. [Kelley, J. M.; Reams, E.; Brown, E. E.; Gibson, A. W.; Alarcon, G. S.; Kimberly, R. P.; Edberg, J. C.] Univ Alabama, Birmingham, AL USA. [Kaufman, K. M.; Harley, J. B.] US Dept Vet Affairs, Med Ctr, Oklahoma City, OK USA. [Kaufman, K. M.; James, J. A.; Harley, J. B.] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA. [Langefeld, C. D.] Wake Forest Univ, Sch Med, Winston Salem, NC 27109 USA. [Li, Q-Z; Karp, D. R.; Wakeland, E. K.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. [Petri, M.] Johns Hopkins Univ, Baltimore, MD USA. [Ramsey-Goldman, R.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. [Reveille, J. D.] Univ Texas Houston, Hlth Sci Ctr, Houston, TX USA. [Vila, L. M.] Univ Puerto Rico, San Juan, PR 00936 USA. RP Harley, JB (reprint author), Oklahoma Med Res Fdn, 825 NE 13th St, Oklahoma City, OK 73104 USA. EM john-harley@mail.omrf.ouhsc.edu; jedberg@uab.edu RI Frank, Summer/E-6861-2016; OI Frank, Summer/0000-0003-0779-4926; Kimberly, Robert/0000-0002-5330-3086 FU NCRR NIH HHS [MO1-RR00048, MO1-RR00032, RR15577, RR20143, M01-RR00052]; NIAID NIH HHS [AI24717, AI31584, AI53747, AI62629]; NIAMS NIH HHS [AR12253, AR33062, AR42460, AR42476, AR43727, K24-AR02138, P01-AR49084, P30 AR053483, P60-AR48098, R01 AR033062, T32-AR07450]; NIDCR NIH HHS [DE15223] NR 32 TC 65 Z9 71 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1466-4879 J9 GENES IMMUN JI Genes Immun. PD APR PY 2008 VL 9 IS 3 BP 187 EP 194 DI 10.1038/gene.2008.4 PG 8 WC Genetics & Heredity; Immunology SC Genetics & Heredity; Immunology GA 292LP UT WOS:000255267800001 PM 18288123 ER PT J AU Schlisio, S Kenchappa, RS Vredeveld, LCW George, RE Stewart, R Greulich, H Shahriari, K Nguyen, NV Pigny, P Dahia, PL Pomeroy, SL Maris, JM Look, AT Meyerson, M Peeper, DS Carter, BD Kaelin, WG AF Schlisio, Susanne Kenchappa, Rajappa S. Vredeveld, Liesbeth C. W. George, Rani E. Stewart, Rodney Greulich, Heidi Shahriari, Kristina Nguyen, Nguyen V. Pigny, Pascal Dahia, Patricia L. Pomeroy, Scott L. Maris, John M. Look, A. Thomas Meyerson, Matthew Peeper, Daniel S. Carter, Bruce D. Kaelin, William G., Jr. TI The kinesin KIF1B beta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor SO GENES & DEVELOPMENT LA English DT Article DE apoptosis; kinesin; neuroblastoma; pheochromocytoma; prolyl hydroxylase ID NEUROBLASTOMA CELL-LINES; FAMILIAL PHEOCHROMOCYTOMA; SYMPATHETIC NEURONS; GENE-MUTATIONS; CHROMOSOME 1P; DEATH; IDENTIFICATION; EXPRESSION; REGION; DEFINITION AB VHL, NF-1, c-Ret, and Succinate Dehydrogenase Subunits B and D act on a developmental apoptotic pathway that is activated when nerve growth factor (NGF) becomes limiting for neuronal progenitor cells and requires the EglN3 prolyl hydroxylase as a downstream effector. Germline mutations of these genes cause familial pheochromocytoma and other neural crest-derived tumors. Using an unbiased shRNA screen we found that the kinesin KIF1B beta acts downstream from EglN3 and is both necessary and sufficient for neuronal apoptosis when NGF becomes limiting. KIF1B beta maps to chromosome 1p36.2, which is frequently deleted in neural crest-derived tumors including neuroblastomas. We identified inherited loss-of-function KIF1B beta missense mutations in neuroblastomas and pheochromocytomas and an acquired loss-of-function mutation in a medulloblastoma, arguing that KIF1B beta is a pathogenic target of these deletions. C1 [Schlisio, Susanne; Shahriari, Kristina; Meyerson, Matthew; Kaelin, William G., Jr.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Kenchappa, Rajappa S.; Carter, Bruce D.] Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA. [Kenchappa, Rajappa S.; Carter, Bruce D.] Vanderbilt Univ, Sch Med, Ctr Mol Neurosci, Nashville, TN 37232 USA. [Vredeveld, Liesbeth C. W.; Peeper, Daniel S.] Netherlands Canc Inst, Div Mol Genet, NL-1066 BE Amsterdam, Netherlands. [George, Rani E.; Stewart, Rodney; Look, A. Thomas] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. [Greulich, Heidi; Meyerson, Matthew] Harvard Univ, Sch Med, Dana Farber Canc Inst, Ctr Canc Genome Discovery, Boston, MA 02115 USA. [Greulich, Heidi] Broad Inst Harvard, Cambridge, MA 02141 USA. [Greulich, Heidi] MIT, Cambridge, MA 02141 USA. [Nguyen, Nguyen V.; Dahia, Patricia L.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio Canc Inst, Dept Mol & Cellular & Struct Biol, San Antonio, TX 78229 USA. [Pigny, Pascal] CHRU Lille, Ctr Biol & Pathol, Lab Biochim & Harmonol, F-59037 Lille, France. [Pomeroy, Scott L.] Harvard Univ, Childrens Hosp, Sch Med, Boston, MA 02115 USA. [Maris, John M.] Univ Penn, Childrens Hosp Philadelphia, Abramson Family Can Res Inst, Philadelphia, PA 19104 USA. [Kaelin, William G., Jr.] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA. RP Kaelin, WG (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St, Boston, MA 02115 USA. EM william_kaelin@dfci.harvard.edu; william_kaelin@dfci.harvard.edu RI Meyerson, Matthew/E-7123-2012; OI Schlisio, Susanne/0000-0002-2605-3771 NR 49 TC 186 Z9 191 U1 0 U2 9 PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT PI WOODBURY PA 500 SUNNYSIDE BLVD, WOODBURY, NY 11797-2924 USA SN 0890-9369 J9 GENE DEV JI Genes Dev. PD APR 1 PY 2008 VL 22 IS 7 BP 884 EP 893 DI 10.1101/gad.1648608 PG 10 WC Cell Biology; Developmental Biology; Genetics & Heredity SC Cell Biology; Developmental Biology; Genetics & Heredity GA 282IW UT WOS:000254562100008 PM 18334619 ER PT J AU Bird, TD AF Bird, Thomas D. TI Genetic aspects of Alzheimer disease SO GENETICS IN MEDICINE LA English DT Review DE Alzheimer; dementia; amyloid; neurogenetics ID PLACEBO-CONTROLLED TRIAL; RANDOMIZED CONTROLLED-TRIAL; APOLIPOPROTEIN-E GENOTYPE; DOWN-SYNDROME; PREIMPLANTATION DIAGNOSIS; NEUROPATHOLOGIC CHANGES; COGNITIVE IMPAIRMENT; SUSCEPTIBILITY LOCUS; PROSPECTIVE COHORT; BETA IMMUNIZATION AB Alzheimer disease is the most common cause of dementia and represents a major public health problem. The neuropathologic findings of amyloid-beta plaques and tau containing neurofibrillary tangles represent important molecular clues to the underlying pathogenesis. Genetic factors are well recognized, but complicated. Three rare forms of autosomal-dominant early-onset familial Alzheimer disease have been identified and are associated with mutations in amyloid precursor protein, presenilin 1, and presenilin 2 genes. The more common late-onset form of Alzheimer disease is assumed to be polygenic/multifactorial. However, thus far the only clearly identified genetic risk factor for Alzheimer disease is Apo lipoprotein E. The epsilon 4 allele of Apo lipoprotein E influences age at onset of Alzheimer disease, but is neither necessary nor Sufficient for the disease. The search continues for the discovery of additional genetic influences. C1 Univ Washington, Ctr Geriatr Res Educ & Clin, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. RP Bird, TD (reprint author), Univ Washington, Ctr Geriatr Res Educ & Clin, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. EM tomnroz@u.washington.com FU NIA NIH HHS [P50 AG 005136-22, P50 AG005136, P50 AG005136-140003, P50 AG005136-229007, P50 AG005136-25] NR 113 TC 79 Z9 86 U1 3 U2 9 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1098-3600 J9 GENET MED JI Genet. Med. PD APR PY 2008 VL 10 IS 4 BP 231 EP 239 DI 10.1097/GIM.0b013e31816b64dc PG 9 WC Genetics & Heredity SC Genetics & Heredity GA 291XP UT WOS:000255231000001 PM 18414205 ER PT J AU Campbell, CD Kirby, A Nemesh, J Daly, MJ Hirschhorn, JN AF Campbell, Catarina D. Kirby, Andrew Nemesh, James Daly, Mark J. Hirschhorn, Joel N. TI A survey of allelic imbalance in F1 mice SO GENOME RESEARCH LA English DT Article ID HUMAN GENE-EXPRESSION; GENOME-WIDE ASSOCIATION; REGULATORY VARIATION; RISK; HAPLOTYPE; COMMON; MOUSE; IRF5; POLYMORPHISM; DISEASE AB There are widespread, genetically determined differences in gene expression. However, methods that compare transcript levels between individuals are subject to trans-acting effects and environmental differences. By looking at allele-specific expression in the F1 progeny of inbred mice, we can directly test for allelic imbalance (AI), which must be due to cis-acting variants in the parental strains. We tested over one hundred genes for AI between C57BI/6J and A/J alleles in F1 mice, including a validation set of 23 genes enriched for cis-acting variants and a second set of 92 genes whose orthologs were previously examined for AI in humans. We assayed an average of two transcribed SNPs per gene in liver, spleen, and brain from three male and three female F1 mice. In the set of 92 genes, we observed 33 genes (36%) with significant AI including genes with AI that was specific to certain tissues or transcripts. We also observed extensive tissue-specific AI, with 11 out of 92 genes (12%) having differences in AI between tissues. Interestingly, several genes with alternate transcripts have transcript-specific AI. Finally, we observed that the presence of AI in human genes was correlated to the presence of AI in the mouse orthologs (one-tailed P = 0.003), suggesting that certain genes may be more tolerant of cis-acting variation across species. C1 [Campbell, Catarina D.; Nemesh, James; Hirschhorn, Joel N.] Childrens Hosp, Program Genom, Boston, MA 02115 USA. [Campbell, Catarina D.; Nemesh, James; Hirschhorn, Joel N.] Childrens Hosp, Div Endocrinol, Boston, MA 02115 USA. [Campbell, Catarina D.; Hirschhorn, Joel N.] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA. [Kirby, Andrew; Nemesh, James; Daly, Mark J.; Hirschhorn, Joel N.] Broad Inst MIT & Harvard, Program Med & Populat Genet, Cambridge, MA 02142 USA. [Kirby, Andrew; Daly, Mark J.] Harvard Univ, Sch Med, Ctr Human Genet Res, Boston, MA USA. [Kirby, Andrew; Daly, Mark J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Mol Biol, Boston, MA USA. [Kirby, Andrew; Daly, Mark J.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. RP Hirschhorn, JN (reprint author), Childrens Hosp, Program Genom, 300 Longwood Ave, Boston, MA 02115 USA. EM joelh@broad.mit.edu NR 32 TC 18 Z9 18 U1 0 U2 2 PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT PI COLD SPRING HARBOR PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA SN 1088-9051 J9 GENOME RES JI Genome Res. PD APR PY 2008 VL 18 IS 4 BP 555 EP 563 DI 10.1101/gr.068692.107 PG 9 WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Genetics & Heredity SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Genetics & Heredity GA 282IZ UT WOS:000254562400005 PM 18256236 ER PT J AU Flaiz, C Utermark, T Parkinson, DB Poetsch, A Hanemann, CO AF Flaiz, C. Utermark, T. Parkinson, D. B. Poetsch, A. Hanemann, C. O. TI Impaired intercellular adhesion and immature adherens junctions in merlin-deficient human primary schwannoma cells SO GLIA LA English DT Article DE schwannoma; neurofibromatosis type 2; merlin; GTPase activation; ruffling; immature adherens junctions; cadherin-catenin system ID NF2 TUMOR-SUPPRESSOR; NEUROFIBROMATOSIS TYPE-2; ARP2/3 COMPLEX; GENE-PRODUCT; IN-VITRO; EXPRESSION; PROLIFERATION; ACTIVATION; MEMBRANE; GROWTH AB Schwannomas that occur spontaneously or in patients with neurofibromatosis Type 2, lack both alleles for the tumor suppressor and plasma membrane-cytoskeleton linker merlin. We have shown that human primary schwannoma cells display activation of the RhoGTPases Rac1 and Cdc42 which results in highly dynamic and ongoing protrusive activity like ruffling. Ruffling is an initial and temporally limited step in the formation of intercellular contacts like adherens junctions that are based on the cadherin-catenin system. We tested if there is a connection between Rac1-induced ongoing ruffling and the maintenance, stabilization and functionality of adherens junctions and if this is of relevance in human, merlin-deficient schwannoma cells. We show intense ongoing ruffling is not limited to membranes of single human primary schwannoma cells, but occurs also in membranes of contacting cells, even when confluent. Live cell imaging shows that newly formed contacts are released after a short time, suggesting disturbed formation or stabilization of adherens junctions. Morphology, high phospho-tyrosine levels and cortactin staining indicate that adherens junctions are immature in human primary schwannoma cells, whereas they display characteristics of mature adherens junctions in human primary Schwann cells. When merlin is reintroduced, human primary schwannoma cells show only initial ruffling in contacting cells and adherens junctions appear more mature. We therefore propose that ongoing Rac-induced ruffling causes immature adherens junctions and leads to impaired, nonfunctional intercellular adhesion in aggregation assays in merlin-deficient schwannoma cells that could be an explanation for increased proliferation rates due to loss of contact inhibition or tumor development in general. (C) 2008 Wiley-Liss, Inc. C1 [Flaiz, C.; Parkinson, D. B.; Hanemann, C. O.] Peninsula Coll Med & Dent, Inst Biomed & Clin Sci, Dept Clin Neurobiol, Plymouth PL6 8BU, Devon, England. [Utermark, T.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Poetsch, A.] Ruhr Univ Bochum, Dept Plant Biochem, Bochum, Germany. RP Hanemann, CO (reprint author), Peninsula Coll Med & Dent, Inst Biomed & Clin Sci, Dept Clin Neurobiol, John Bull Bldg,Tamar Sci Pk,Res Way, Plymouth PL6 8BU, Devon, England. EM oliver.hanemann@pms.ac.uk RI Poetsch, Ansgar/A-1862-2013; OI Poetsch, Ansgar/0000-0002-7540-3475; Hanemann, Clemens Oliver/0000-0002-1951-1025 NR 35 TC 24 Z9 24 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0894-1491 J9 GLIA JI Glia PD APR PY 2008 VL 56 IS 5 BP 506 EP 515 DI 10.1002/glia.20629 PG 10 WC Neurosciences SC Neurosciences & Neurology GA 275KM UT WOS:000254070300003 PM 18240308 ER PT J AU Moore, R McMeeken, S Brown, A DiSilvestro, P Miller, C Allard, J Gajewski, W Kurman, R Bast, R Skates, S AF Moore, R. McMeeken, S. Brown, A. DiSilvestro, P. Miller, C. Allard, J. Gajewski, W. Kurman, R. Bast, R., Jr. Skates, S. TI A novel multiple marker bioassay utilizing HE4 and CA125II for the prediction of ovarian cancer in patients with a pelvic mass SO GYNECOLOGIC ONCOLOGY LA English DT Meeting Abstract C1 [Moore, R.; DiSilvestro, P.] Brown Univ, Women & Infants Hosp, Providence, RI USA. [McMeeken, S.] Univ Oklahoma, Oklahoma City, OK USA. [Brown, A.] Hartford Hosp, Hartford, CT 06115 USA. [Miller, C.; Allard, J.] Fujirebio Diagnost Inc, Malvern, PA USA. [Gajewski, W.] New Hanover Reg Med Ctr, Wilmington, NC USA. [Kurman, R.] Johns Hopkins Med Sch, Baltimore, MD USA. [Bast, R., Jr.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Skates, S.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. RI Bast, Robert/E-6585-2011 OI Bast, Robert/0000-0003-4621-8462 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0090-8258 J9 GYNECOL ONCOL JI Gynecol. Oncol. PD APR PY 2008 VL 109 IS 1 MA 3 BP 159 EP 159 PG 1 WC Oncology; Obstetrics & Gynecology SC Oncology; Obstetrics & Gynecology GA 288VO UT WOS:000255014100036 ER PT J AU Pizer, SD Frakt, AB Feldmanc, R AF Pizer, Steven D. Frakt, Austin B. Feldmanc, Roger TI Predicting risk selection following major changes in medicare SO HEALTH ECONOMICS LA English DT Article DE medicare; adverse selection; econometrics; financing and insurance ID COMPETITION; PROGRAM AB The Medicare Modernization Act of 2003 created several new types of private insurance plans within Medicare, starting in 2006. Some of these plan types previously did not exist in the commercial market and there was great uncertainty about their prospects. In this paper, we show that statistical models and historical data from the Medicare Current Beneficiary Survey can be used to predict the experience of new plan types with reasonable accuracy. This lays the foundation for the analysis of program modifications currently under consideration. We predict market share, risk selection, and stability for the most prominent new plan type, the stand-alone Medicare prescription drug plan (PDP). First, we estimate a model of consumer choice across Medicare insurance plans available in the data. Next, we modify the data to include PDPs and use the model to predict the probability of enrollment for each beneficiary in each plan type. Finally, we calculate mean-adjusted actual spending by plan type. We predict that adverse selection into PDPs will be substantial, but that enrollment and premiums will be stable. Our predictions correspond well to actual experience in 2006. Copyright (c) 2007 John Wiley & Sons, Ltd. C1 [Pizer, Steven D.; Frakt, Austin B.] US Dept Vet Affairs, Hlth Care Financing & Econ, Boston, MA 02130 USA. [Pizer, Steven D.] Boston Univ, Sch Publ Hlth, Boston, MA USA. [Feldmanc, Roger] Univ Minnesota, Sch Publ Hlth, Minneapolis, MN USA. RP Pizer, SD (reprint author), US Dept Vet Affairs, Hlth Care Financing & Econ, 150 S Huntington Ave,Mail Stop 152H, Boston, MA 02130 USA. EM pizer@bu.edu NR 25 TC 9 Z9 9 U1 0 U2 1 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND SN 1057-9230 J9 HEALTH ECON JI Health Econ. PD APR PY 2008 VL 17 IS 4 BP 453 EP 468 DI 10.1002/hec.1252 PG 16 WC Economics; Health Care Sciences & Services; Health Policy & Services SC Business & Economics; Health Care Sciences & Services GA 293GW UT WOS:000255324600002 PM 17557273 ER PT J AU Frakt, AB Pizer, SD AF Frakt, Austin B. Pizer, Steven D. TI Attribute substitution in early enrollment decisions into medicare prescription drug plans SO HEALTH ECONOMICS LA English DT Article DE Medicare part D; prescription drugs; competition; enrollment; behavioral economics ID PLUS CHOICE; COMPETITION; SELECTION; PROGRAM; HMO AB Stand-alone outpatient prescription drug plans (PDPs), introduced in January 2006, have become the most popular source for coverage of outpatient prescription drugs under Medicare relative to other available Medicare plan types (e.g. Medicare Advantage drug plans). Using county-level enrollment figures from the Centers for Medicare & Medicaid Services linked to other public sources, we study attribute substitution in beneficiary decision-making with respect to PDP enrollment. To do so, we relate county-level PDP market share to county-level political support for the administration implementing the new benefit (the Bush Administration), controlling for socio-demographic and market characteristics. We find statistically significant evidence that greater support for the Bush administration is associated with increased PDP market share. Copyright (c) 2007 John Wiley & Sons, Ltd. C1 [Frakt, Austin B.; Pizer, Steven D.] VA Boston Healthcare Syst, Boston, MA USA. [Pizer, Steven D.] Boston Univ, Sch Publ Hlth, Boston, MA USA. RP Frakt, AB (reprint author), VA Boston Healthcare Syst 152H, Boston, MA 02130 USA. EM frakt@bu.edu NR 20 TC 0 Z9 0 U1 0 U2 2 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND SN 1057-9230 J9 HEALTH ECON JI Health Econ. PD APR PY 2008 VL 17 IS 4 BP 513 EP 521 DI 10.1002/hec.1303 PG 9 WC Economics; Health Care Sciences & Services; Health Policy & Services SC Business & Economics; Health Care Sciences & Services GA 293GW UT WOS:000255324600006 PM 17935198 ER PT J AU Ng, AK Travis, LB AF Ng, Andrea K. Travis, Lois B. TI Second primary cancers: An overview SO HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA LA English DT Review ID NON-HODGKINS-LYMPHOMA; SURGICAL ADJUVANT BREAST; LONG-TERM SURVIVORS; MALIGNANCIES FOLLOWING TREATMENT; MULTIPLE PRIMARY TUMORS; ACUTE MYELOID-LEUKEMIA; SOFT-TISSUE SARCOMA; RADIATION-THERAPY; CONTRALATERAL BREAST; TESTICULAR-CANCER AB Substantial improvements in die past few decades in cancer detection and supportive care along with advances in therapy have led to growing numbers of cancer survivors. In view of the prolongation of survival in increasing numbers of patients, identification and quantification of the late effects of cancer and its therapy have become critical. One of die most serious events experienced by cancer survivors is the diagnosis of a new cancer. The number of patients who have second or higher-order cancers is increasing, and solid tumors are a leading cause of mortality among several populations of long-term survivors, including patients who have Hodgkin lymphoma. The focus of this article is treatment-associated malignancies in survivors of selected adult cancers. C1 [Ng, Andrea K.] Brigham & Womens Hosp, Dana Faber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA. [Travis, Lois B.] NCI, NIH, Div Canc Epidemiol & Genet, Dept Hlth & Human Serv, Bethesda, MD 20892 USA. RP Ng, AK (reprint author), Brigham & Womens Hosp, Dana Faber Canc Inst, Dept Radiat Oncol, 75 Francis St, Boston, MA 02115 USA. EM ang@lroc.harvord.edu NR 119 TC 32 Z9 33 U1 2 U2 4 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0889-8588 J9 HEMATOL ONCOL CLIN N JI Hematol. Oncol. Clin. North Am. PD APR PY 2008 VL 22 IS 2 BP 271 EP + DI 10.1016/j.hoc.2008.01.007 PG 20 WC Oncology; Hematology SC Oncology; Hematology GA 293GS UT WOS:000255324200008 PM 18395150 ER PT J AU Carreon, M Fried, LF Palevsky, PM Kimmel, PL Arnold, RM Weisbord, SD AF Carreon, Myra Fried, Linda F. Palevsky, Paul M. Kimmel, Paul L. Arnold, Robert M. Weisbord, Steven D. TI Clinical correlates and treatment of bone/joint pain and difficulty with sexual arousal in patients on maintenance hemodialysis SO HEMODIALYSIS INTERNATIONAL LA English DT Article DE pain; sexual dysfunction; hemodialysis; treatment ID QUALITY-OF-LIFE; CHRONIC-RENAL-FAILURE; SYMPTOM ASSESSMENT SYSTEM; ERECTILE DYSFUNCTION; DIALYSIS PATIENTS; PALLIATIVE CARE; MINI-COG; PREVALENCE; SEVERITY; DISEASE AB Bone/joint pain and difficulty with sexual arousal are prevalent, frequently severe, and potentially treatable in patients on maintenance hemodialysis. However, the mediators and adequacy of treatment for these symptoms have been less well studied. We sought to assess the clinical correlates and treatment of these symptoms in patients receiving chronic hemodialysis. Using the Dialysis Symptom Index, we assessed the presence and severity of bone/joint pain and difficulty with sexual arousal in 75 patients on chronic hemodialysis. Associations of demographic and clinical variables with these 2 symptoms were assessed. We also recorded the use of analgesics for bone/joint pain and, among men, phosphodiesterase-5 inhibitors for difficulty with sexual arousal. Twenty-eight patients (37%) reported bone/joint pain, of whom 20 (71%) described it as moderate to severe. Nineteen of 50 male patients (38%) reported difficulty with sexual arousal, which was described as moderate to severe by 15 (79%). Patients' demographic and clinical characteristics were not correlated with bone/joint pain. Among men, there were no correlations between patients' demographic and clinical characteristics and difficulty with sexual arousal. Only 48% of patients with bone/joint pain were receiving analgesics, while 2 1 % of men who described difficulty with sexual arousal were receiving phosphodiesterase-5 inhibitors. Demographic, clinical, and dialysis-related variables are poorly correlated with bone/joint pain and difficulty with sexual arousal. However, these symptoms are prevalent and under-treated, which should spur efforts to assess the impact of improving provider assessment and treatment of these symptoms on patient outcomes, including health-related quality of life. C1 [Weisbord, Steven D.] VA Pittsburgh Healthcare Syst, Renal Sect, Med Specialty Serv Line, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15240 USA. [Carreon, Myra; Arnold, Robert M.] Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med, Pittsburgh, PA USA. [Fried, Linda F.; Palevsky, Paul M.; Weisbord, Steven D.] Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, Pittsburgh, PA USA. [Kimmel, Paul L.] George Washington Univ, Sch Med, Div Renal Dis & Hypertens, Washington, DC USA. RP Weisbord, SD (reprint author), VA Pittsburgh Healthcare Syst, Renal Sect, Med Specialty Serv Line, Ctr Hlth Equ Res & Promot, Mailstop 111F-U,7E Room 120, Pittsburgh, PA 15240 USA. EM weisbordsd@upmc.edu OI Palevsky, Paul/0000-0002-7334-5400 FU NCATS NIH HHS [UL1 TR000005] NR 29 TC 10 Z9 10 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1492-7535 J9 HEMODIAL INT JI Hemodial. Int. PD APR PY 2008 VL 12 IS 2 BP 268 EP 274 DI 10.1111/j.1542-4758.2008.00264.x PG 7 WC Urology & Nephrology SC Urology & Nephrology GA 307WG UT WOS:000256348900013 PM 18394062 ER PT J AU Kamal, SM Nasser, IA AF Kamal, Sanaa M. Nasser, Imad A. TI Hepatitis C genotype 4: What we know and what we don't yet know SO HEPATOLOGY LA English DT Review ID ALPHA-2B PLUS RIBAVIRIN; COMPLETE NUCLEOTIDE-SEQUENCE; EARLY VIROLOGICAL RESPONSE; CD4(+) T-CELL; VIRUS GENOTYPE-4; PEGINTERFERON ALPHA-2B; HEPATOCELLULAR-CARCINOMA; LIVER-TRANSPLANTATION; MOLECULAR EPIDEMIOLOGY; INITIAL TREATMENT AB Hepatitis C virus genotype 4 (HCV-4) is the most common variant of the hepatitis C virus (HCV) in the Middle East and Africa, particularly Egypt. This region has the highest prevelance of HCV worldwide, with more than 90% of infections due to genotype 4. HCV-4 has recently spread in several Western countries, particularly in Europe, due to variations in population structure, immigration, and routes of transmission. The features of HCV-4 infection and the appropriate therapeutic regimen have not been well characterized. This review discusses the virology, epidemiology, natural history, histology, clinical data, and treatment options for patients with HCV-4 infections. Early reports on the treatment of patients with chronic HCV-4 with conventional interferon (IFN)-alpha monotherapy indicated poor rates of sustained viral response (SVR), which improved slightly when combined with ribavirin. Pegylated IFN and ribavirin combination therapy has dramatically improved the response rates, with recent clinical trials showing rates that exceed 60%. These data can now be used as a platform for further research to define optimal treatment duration and predictors of SVR in patients with HCV-4 infection. Conclusion: HCV-4 infection is spreading beyond its strongholds in Africa and the Middle East. Recent clinical trials show that HCV-4 is not difficult to treat, as the response to treatment may be at an intermediate level compared with genotype 1 and genotypes 2 or 3. Tailored treatment options that are comparable to the treatment approaches for genotype 1, 2, and 3 patients to optimize treatment for each patient are now being developed. C1 [Kamal, Sanaa M.; Nasser, Imad A.] Ain Shams fac Med, Dept Gastroenterol & Liver Dis, Cairo, Egypt. [Kamal, Sanaa M.; Nasser, Imad A.] BIDMC, Boston, MA USA. RP Kamal, SM (reprint author), Ain Shams fac Med, Dept Gastroenterol & Liver Dis, 22 Al Ahram St, Cairo, Egypt. EM Sanaa.Kamal@link.net OI Kamal, Sanaa/0000-0002-2052-7956 NR 99 TC 162 Z9 165 U1 2 U2 5 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD APR PY 2008 VL 47 IS 4 BP 1371 EP 1383 DI 10.1002/hep.22127 PG 13 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 283LG UT WOS:000254637100029 PM 18240152 ER PT J AU Tyrka, AR Wier, LM Price, LH Rikhye, K Ross, NS Anderson, GM Wilkinson, CW Carpenter, LL AF Tyrka, Audrey R. Wier, Lauren M. Price, Lawrence H. Rikhye, Kobita Ross, Nicole S. Anderson, George M. Wilkinson, Charles W. Carpenter, Linda L. TI Cortisol and ACTH responses to the Dex/CRH test: Influence of temperament SO HORMONES AND BEHAVIOR LA English DT Article DE cortisol; Dex/CRH test; HPA axis; temperament; personality; inhibition ID POPULATION-BASED TWIN; CORTICOTROPIN-RELEASING-FACTOR; PITUITARY-ADRENAL AXIS; DEXAMETHASONE-CRH TEST; MAJOR DEPRESSION; BEHAVIORAL-INHIBITION; ADRENOCORTICOTROPIC HORMONE; PSYCHOBIOLOGICAL MODEL; INDIVIDUAL-DIFFERENCES; PREMORBID PERSONALITY AB Temperament and personality traits such as neuroticism and behavioral inhibition are prospective predictors of the onset of depression and anxiety disorders. Exposure to stress is also linked to the development of these disorders, and neuroticism and inhibition may confer or reflect sensitivity to stressors. Several lines of research have documented hyperactivity of the hypothalamic-pituitary-adrenal (HPA) axis in some patients with major depression, as well as in children and non-human primates with inhibited temperaments. The present investigation tested the hypothesis that stressreactive temperaments would be predictive of plasma adrenocorticotropin (ACTH) and cortisol concentrations in the dexamethasone/corticotropinreleasing hormone (Dex/CRH) test. Sixty adults completed diagnostic interviews and questionnaires assessing the temperament domains of novelty seeking and harm avoidance and symptoms of anxiety and depression. All subjects were free of any current or past Axis I psychiatric disorder. The Dex/CRH test was performed on a separate visit. A repeated-measures general linear model (GLM) showed a main effect of harm avoidance in predicting cortisol concentrations in the test (F(1, 58)=4.86, p <.05). The GLM for novelty seeking and corfisol response also showed a main effect (F(2, 58)= 5.28,p <.05). Higher cortisol concentrations were associated with higher levels of harm avoidance and lower levels of novelty seeking. A significant interaction of time with harm avoidance and novelty seeking (F(4, 53)= 3.37, p <.05) revealed that participants with both high levels of harm avoidance and low levels of novelty seeking had the highest cortisol responses to the Dex/CRH test. Plasma ACTH concentrations did not differ as a function of temperament. The results indicate that temperament traits linked to sensitivity to negative stimuli are associated with greater cortisol reactivity during the Dex/CRH test. Increased adrenocortical reactivity, which previously has been linked to major depression and anxiety disorders, may contribute to the association between temperament/personality traits and these disorders. (c) 2007 Elsevier Inc. All rights reserved. C1 [Tyrka, Audrey R.; Wier, Lauren M.; Price, Lawrence H.; Rikhye, Kobita; Ross, Nicole S.; Carpenter, Linda L.] Butler Hosp, Mood Disorders Res Program, Providence, RI 02906 USA. Butler Hosp, Lab Clin Neurosci, Providence, RI 02906 USA. [Tyrka, Audrey R.; Price, Lawrence H.; Rikhye, Kobita; Carpenter, Linda L.] Brown Med Sch, Dept Psychiat & Human Behav, Providence, RI USA. [Anderson, George M.] Yale Univ, Sch Med, Ctr Child Study, New Haven, CT 06510 USA. [Wilkinson, Charles W.] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. [Wilkinson, Charles W.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. RP Tyrka, AR (reprint author), Butler Hosp, Mood Disorders Res Program, 345 Blackstone Blvd, Providence, RI 02906 USA. EM Audrey_Tyrka@Brown.edu RI Tyrka, Audrey/L-2504-2014 FU NIMH NIH HHS [K23 MH067947, 1K23 MH067947, K23 MH067947-01A1, R01 MH068767] NR 75 TC 39 Z9 39 U1 2 U2 6 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0018-506X J9 HORM BEHAV JI Horm. Behav. PD APR PY 2008 VL 53 IS 4 BP 518 EP 525 DI 10.1016/j.yhbeh.2007.12.004 PG 8 WC Behavioral Sciences; Endocrinology & Metabolism SC Behavioral Sciences; Endocrinology & Metabolism GA 290CN UT WOS:000255100700003 PM 18294637 ER PT J AU McCulloch, CC Kay, DM Factor, SA Samii, A Nutt, JG Higgins, DS Griffith, A Roberts, JW Leis, BC Montimurro, JS Zabetian, CP Payami, H AF McCulloch, Colin C. Kay, Denise M. Factor, Stewart A. Samii, Ali Nutt, John G. Higgins, Donald S. Griffith, Alida Roberts, John W. Leis, Berta C. Montimurro, Jennifer S. Zabetian, Cyrus P. Payami, Haydeh TI Exploring gene-environment interactions in Parkinson's disease SO HUMAN GENETICS LA English DT Article ID SUSCEPTIBILITY GENE; COMPLEX DISEASES; TAU-GENE; ASSOCIATION; HAPLOTYPE; ANTAGONISTS; NEURONS AB The objective of this study was to explore combined effects of four candidate susceptibility genes and two exposures on Parkinson's disease (PD) risk; namely, alpha-synuclein (SNCA) promoter polymorphism REP1, microtubule-associated protein tau (MAPT) H1/H2 haplotypes, apolipoprotein E (APOE) epsilon 2/epsilon 3/epsilon 4 polymorphism, ubiquitin carboxy-terminal esterase L1 (UCHL1) S18Y variant, cigarette smoking and caffeinated coffee consumption. 932 PD patients and 664 control subjects from the NeuroGenetics Research Consortium, with complete data on all six factors, were studied. Uniform protocols were used for diagnosis, recruitment, data collection and genotyping. A logistic regression model which included gene-exposure interactions was applied. Likelihood ratio tests (LRTs) were used for significance testing and Bayesian inference was used to estimate odds ratios (ORs). MAPT (P = 0.007), SNCA REP1 (P = 0.012), smoking (P = 0.001), and coffee (P = 0.011) were associated with PD risk. Two novel interactions were detected: APOE with coffee (P = 0.005), and REP1 with smoking (P = 0.021). While the individual main effects were modest, each yielding OR < 1.6, the effects were cumulative, with some combinations reaching OR = 12.6 (95% CI: 5.9-26.8). This study provides evidence for the long-held notion that PD risk is modulated by cumulative and interactive effects of genes and exposures. Furthermore, the study demonstrates that while interaction studies are useful for exploring risk relationships that might otherwise go undetected, results should be interpreted with caution because of the inherent loss of power due to multiple testing. The novel findings of this study that warrant replication are the evidence for interaction of coffee with APOE, and of smoking with REP1 on PD risk. C1 [Kay, Denise M.; Montimurro, Jennifer S.; Payami, Haydeh] New York State Dept Hlth, Wadsworth Ctr, Genom Inst, Albany, NY 12201 USA. [McCulloch, Colin C.] Gen Elect Global Res Ctr, Appl Stat Lab, Niskayuna, NY USA. [Samii, Ali; Zabetian, Cyrus P.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA USA. [Samii, Ali; Zabetian, Cyrus P.] VA Puget Sound Hlth Care Syst, Parkinsons Dis Res Educ & Clin Ctr, Seattle, WA USA. [Zabetian, Cyrus P.] VA Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA USA. [Factor, Stewart A.] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA. [Higgins, Donald S.] Albany Med Ctr, Parkinsons Dis & Movement Disorder Clin, Albany, NY USA. [Nutt, John G.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Griffith, Alida; Leis, Berta C.] Evergreen Hosp Med Ctr, Booth Gardner Parkinsons Care Ctr, Kirkland, WA USA. [Roberts, John W.] Virginia Mason Med Ctr, Seattle, WA 98101 USA. RP Payami, H (reprint author), New York State Dept Hlth, Wadsworth Ctr, Genom Inst, POB 22002, Albany, NY 12201 USA. EM hpayami@wadsworth.org OI Zabetian, Cyrus/0000-0002-7739-4306; Kay, Denise/0000-0002-9928-2698 FU NINDS NIH HHS [K08-NS044138, NS R01-36960] NR 34 TC 56 Z9 59 U1 0 U2 6 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0340-6717 J9 HUM GENET JI Hum. Genet. PD APR PY 2008 VL 123 IS 3 BP 257 EP 265 DI 10.1007/s00439-008-0466-z PG 9 WC Genetics & Heredity SC Genetics & Heredity GA 277AL UT WOS:000254184700004 PM 18210157 ER PT J AU Williams, TM Winden, T Setterholm, M Vierra-Green, CA Spellman, S Flesch, S Awdeh, Z Baxter-Lowe, LA Begovich, AB Fernandez-Vina, M Hegland, J Hurley, CK Johnson, D Noreen, H Salazar, M Schmeckpeper, B Yunis, EJ AF Williams, T. M. Winden, T. Setterholm, M. Vierra-Green, C. A. Spellman, S. Flesch, S. Awdeh, Z. Baxter-Lowe, L. A. Begovich, A. B. Fernandez-Vina, M. Hegland, J. Hurley, C. K. Johnson, D. Noreen, H. Salazar, M. Schmeckpeper, B. Yunis, E. J. TI Strategies and technical challenges in allele level Class II typing in 2578 bone marrow transplantation donor-recipient pairs SO HUMAN IMMUNOLOGY LA English DT Article DE bone marrow transplantation; histocompatibility antigens class II; HLA antigens ID MAJOR HISTOCOMPATIBILITY COMPLEX; HLA CLASS-I; LINKAGE DISEQUILIBRIUM; RELATIVE FREQUENCIES; GENETIC-VARIABILITY; DRB3 ASSOCIATIONS; US POPULATIONS; DP REGION; PCR-SSP; DISPARITY AB Human leukocyte antigen typing of 2578 donor-recipient pairs whose transplantation was facilitated by the National Marrow Donor Program allowed for an in-depth analysis of the accuracy of high-volume allele level testing data. The methods employed provided allele level typing at DRB1/3/5, DQA1, DQB1, DPA1, and DPB1 using sequence-specific oligonucleotide probe hybridization (SSOPH), polymerase chain reaction (PCR) restriction fragment Length polymorphism analysis, sequence specific PCR, and direct sequence-based typing (SBT). Each typing was independently tested by two laboratories in Phase 1, and in subsequent phases targeted samples were typed in duplicate by SBT to monitor typing quality. Comparison with prior transplant center typing was also evaluated. SSOPH detected discrepancies ranged from 0.6% at DPB1 to 5.1% at DQB1 in Phase 1. The majority of discrepancies, 62%, resulted from human error such as sample handling, result interpretation, or clerical errors. Alleles that are frequently discrepant have been identified in this predominantly white population. (C) 2008 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved. C1 [Williams, T. M.] Univ New Mexico, Albuquerque, NM 87131 USA. [Winden, T.] HealthE Care Syst, St Paul, MN USA. [Setterholm, M.; Vierra-Green, C. A.; Spellman, S.; Flesch, S.] Natl Marrow Donor Program, Minneapolis, MN USA. [Awdeh, Z.] Ctr Blood Res, Boston, MA 02115 USA. [Baxter-Lowe, L. A.; Johnson, D.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Begovich, A. B.] Celera, Alameda, CA USA. [Fernandez-Vina, M.] Univ Texas Houston, MD Anderson Canc Ctr, Houston, TX 77030 USA. [Hegland, J.] Univ Minnesota, Minneapolis, MN USA. [Hurley, C. K.] Georgetown Univ, Washington, DC USA. [Noreen, H.] Fairview Univ Med Ctr, Minneapolis, MN USA. [Salazar, M.] Ctr Aquaculture Res, Bogota, Colombia. [Schmeckpeper, B.] Summercrest Consulting, Columbia, MD USA. [Yunis, E. J.] Dana Farber Canc Inst, Boston, MA 02115 USA. RP Williams, TM (reprint author), Univ New Mexico, Albuquerque, NM 87131 USA. EM twilliams@salud.unm.edu NR 35 TC 1 Z9 2 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0198-8859 J9 HUM IMMUNOL JI Hum. Immunol. PD APR-MAY PY 2008 VL 69 IS 4-5 BP 227 EP 234 DI 10.1016/j.humimm.2008.03.004 PG 8 WC Immunology SC Immunology GA 309MS UT WOS:000256465200001 PM 18486756 ER PT J AU Keyhani, S Scobie, JV Hebert, PL McLaughlin, MA AF Keyhani, Salomeh Scobie, Janice V. Hebert, Paul L. McLaughlin, Mary Ann TI Gender disparities in blood pressure control and cardiovascular care in a national sample of ambulatory care visits SO HYPERTENSION LA English DT Article DE women's health; quality of health care; hypertension; chronic disease; ambulatory care ID NUTRITION EXAMINATION SURVEY; CORONARY-ARTERY-DISEASE; HEART-DISEASE; UNITED-STATES; ASPIRIN USE; MYOCARDIAL-INFARCTION; SECONDARY PREVENTION; WOMENS AWARENESS; SEX DISPARITIES; TRENDS AB The purpose of this study was to provide an analysis of gender-based disparities in hypertension and cardiovascular disease care in ambulatory practices across the United States. Using data from the 2005 National Ambulatory Medical Care Survey and the National Hospital Ambulatory Medical Care Survey, we conducted a cross-sectional analysis of patient visits with their primary care providers and examined the association between gender and blood pressure control, use of any antihypertensive medication or initiation of new therapy for patients with uncontrolled hypertension, and receipt of recommended therapy for select cardiovascular conditions. Multivariable models were estimated to examine the association between gender and each outcome controlling for other variables. A total of 12 064 patient visits were identified (7786 women and 4278 men). Among patients with hypertension, women were less likely than men to meet blood pressure control targets (54.0% versus 58.7%; P < 0.02). In multivariate analyses, women aged 65 to 80 years were less likely than men to have controlled hypertension (odds ratio: 0.62; 95% CI: 0.45 to 0.85). There was no association between gender and use of any antihypertensive medication or initiating a new therapy among patients with uncontrolled hypertension. In multivariate analyses, women were less likely than men to receive aspirin (odds ratio: 0.43; 95% CI: 0.27 to 0.67) and beta-blockers (odds ratio: 0.60; 95% CI: 0.36 to 0.99) for secondary prevention of cardiovascular disease. Our study highlights the persistent gender disparities in blood pressure control and cardiovascular disease management and also reveals the inadequate delivery of cardiovascular care to all patients. C1 [Keyhani, Salomeh] Ctr Geriatr Res Educ & Clin, James J Peters Vet Adm Med Ctr, Bronx, NY USA. [Keyhani, Salomeh; Hebert, Paul L.; McLaughlin, Mary Ann] Mt Sinai Sch Med, Dept Hlth Policy, New York, NY USA. [Scobie, Janice V.; McLaughlin, Mary Ann] Mt Sinai Sch Med, Dept Med, New York, NY USA. [McLaughlin, Mary Ann] Mt Sinai Sch Med, Dept Geriatr & Adult Dev, New York, NY USA. [Keyhani, Salomeh] Mt Sinai Sch Med, Dept Gen Internal Med, New York, NY USA. RP Keyhani, S (reprint author), Mt Sinai Sch Med, Dept Hlth Policy, Box 1077,1 Gustave L Levy Pl, New York, NY 10029 USA. EM salomeh.keyhani@mountsinai.org NR 33 TC 61 Z9 63 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0194-911X J9 HYPERTENSION JI Hypertension PD APR PY 2008 VL 51 IS 4 BP 1149 EP 1155 DI 10.1161/HYPERTENSIONAHA.107.107342 PG 7 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 276SA UT WOS:000254161300060 PM 18259013 ER PT J AU Mitchell, DA Fecci, PE Sampson, JH AF Mitchell, Duane A. Fecci, Peter E. Sampson, John H. TI Immunotherapy of malignant brain tumors SO IMMUNOLOGICAL REVIEWS LA English DT Review DE glioma; immunotherapy; brain tumor; cancer vaccines ID REGULATORY T-CELLS; GROWTH-FACTOR-RECEPTOR; CENTRAL-NERVOUS-SYSTEM; PRIMARY INTRACRANIAL TUMORS; MONOCLONAL-ANTIBODY 81C6; RECURRENT GLIOBLASTOMA-MULTIFORME; PHASE-I TRIAL; ANTIGEN-PRESENTING CELLS; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS AB Despite aggressive multi-modality therapy including surgery, radiation, and chemotherapy, the prognosis for patients with malignant primary brain tumors remains very poor. Moreover, the non-specific nature of conventional therapy for brain tumors often results in incapacitating damage to surrounding normal brain and systemic tissues. Thus, there is an urgent need for the development of therapeutic strategies that precisely target tumor cells while minimizing collateral damage to neighboring eloquent cerebral cortex. The rationale for using the immune system to target brain tumors is based on the premise that the inherent specificity of immunologic reactivity could meet the clear need for more specific and precise therapy. The success of this modality is dependent on our ability to understand the mechanisms of immune regulation within the central nervous system (CNS), as well as counter the broad defects in host cell-mediated immunity that malignant gliomas are known to elicit. Recent advances in our understanding of tumor-induced and host-mediated immunosuppressive mechanisms, the development of effective strategies to combat these suppressive effects, and a better understanding of how to deliver immunologic effector molecules more efficiently to CNS tumors have all facilitated significant progress toward the realization of true clinical benefit from immunotherapeutic treatment of malignant gliomas. C1 [Mitchell, Duane A.; Sampson, John H.] Preston Robert Tisch Brain Ctr, Dept Surg, Div Neurosurg, Duke, NC USA. [Fecci, Peter E.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Surg,Neurosurg Div, Boston, MA USA. [Sampson, John H.] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA. RP Mitchell, DA (reprint author), Duke Univ, Med Ctr, Dept Surg, Div Neurosurg, DUMC Box 305, Durham, NC 27710 USA. EM d.mitchell@duke.edu RI duan, hf/F-9166-2011 FU NINDS NIH HHS [P50 NS020023] NR 398 TC 44 Z9 47 U1 1 U2 6 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0105-2896 J9 IMMUNOL REV JI Immunol. Rev. PD APR PY 2008 VL 222 BP 70 EP 100 DI 10.1111/j.1600-065X.2008.00603.x PG 31 WC Immunology SC Immunology GA 278HD UT WOS:000254274900005 PM 18363995 ER PT J AU Jinushi, M Hodi, FS Dranoff, G AF Jinushi, Masahisa Hodi, F. Stephen Dranoff, Glenn TI Enhancing the clinical activity of granulocyte-macrophage colony-stimulating factor-secreting tumor cell vaccines SO IMMUNOLOGICAL REVIEWS LA English DT Review DE cancer vaccine; GM-CSF; MFG-E8; CTLA-4; MICA; NKG2D ID LYMPHOCYTE-ASSOCIATED ANTIGEN-4; REGULATORY T-CELLS; AUTOLOGOUS MELANOMA-CELLS; PHASE-I TRIAL; PULMONARY ALVEOLAR PROTEINOSIS; AUGMENTS ANTITUMOR IMMUNITY; MYELOID SUPPRESSOR-CELLS; TRANSGENIC MOUSE MODEL; MARROW-DERIVED CELLS; NATURAL-KILLER-CELL AB A comparative analysis of vaccination with irradiated, murine tumor cells engineered to express a large number of immunostimulatory molecules established the superior ability of granulocyte-macrophage colony-stimulating factor (GM-CSF) to evoke potent, specific, and long-lasting anti-tumor immunity. Early stage clinical testing of this vaccination strategy in patients with diverse solid and hematologic malignancies revealed the consistent induction of a coordinated humoral and cellular reaction that effectuated substantial tumor destruction. Nonetheless, most subjects eventually succumbed to progressive disease, implying that additional immune defects remained to be addressed. More detailed investigations of the mechanisms underlying protective immunity in murine systems together with the characterization of the anti-tumor reactions of patients who achieved durable clinical benefits in response to immunotherapy uncovered several pathways that restrain the efficacy of GM-CSF-secreting tumor cell vaccines. These include milk fat globule epidermal growth factor protein-8 expansion of forkhead box protein 3(+) regulatory T cells, cytotoxic T-lymphocyte antigen-4-mediated negative costimulation, and soluble major histocompatibility complex class I chain-related protein A suppression of NKG2D-dependent innate and adaptive anti-tumor cytotoxicity. Together, these results define key regulatory circuits that attenuate immune-mediated tumor destruction and suggest novel combinatorial therapies that might enhance the clinical activity of GM-CSF-secreting tumor cell vaccines. C1 [Jinushi, Masahisa; Hodi, F. Stephen; Dranoff, Glenn] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Jinushi, Masahisa; Hodi, F. Stephen; Dranoff, Glenn] Dana Farber Canc Inst, Canc Vaccine Ctr, Boston, MA 02115 USA. [Jinushi, Masahisa; Hodi, F. Stephen; Dranoff, Glenn] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. [Jinushi, Masahisa; Hodi, F. Stephen; Dranoff, Glenn] Harvard Univ, Sch Med, Boston, MA USA. [Jinushi, Masahisa] Univ Tokyo, Inst Med Sci, Dept Bioengn, Adv Clin Res Ctr, Tokyo, Japan. RP Dranoff, G (reprint author), Dana Farber Canc Inst, Dept Med Oncol, Dana 520C, Boston, MA 02115 USA. EM glenn_dranoff@dfci.harvard.edu RI Jinushi, Masahisa/A-4311-2012 NR 154 TC 54 Z9 55 U1 0 U2 7 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0105-2896 J9 IMMUNOL REV JI Immunol. Rev. PD APR PY 2008 VL 222 BP 287 EP 298 DI 10.1111/j.1600-065X.2008.00618.x PG 12 WC Immunology SC Immunology GA 278HD UT WOS:000254274900019 PM 18364009 ER PT J AU Miller, G Randolph, S Patterson, JE AF Miller, George Randolph, Stephen Patterson, Jan E. TI Responding to simulated pandemic influenza in San Antonio, Texas SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID COMMUNITY TRANSMISSION PARAMETERS; STRATEGIES; HOUSEHOLD AB OBJECTIVE. To describe the results of a simulation study of the spread of pandemic influenza, the effects of public health measures on the simulated pandemic, and the resultant adequacy of the surge capacity of the hospital infrastructure and to investigate the adequacy of key elements of the national pandemic influenza plan to reduce the overall attack rate so that surge capacity would not be overwhelmed. DESIGN. We used 2 discrete-event simulation models: the first model simulates the contact and disease transmission process, as affected by public health interventions, to produce a stream of arriving patients, and the second model simulates the diagnosis and treatment process and determines patient outcomes. SETTING. Hypothetical scenarios were based on the response plans, infrastructure, and demographic data of the population of San Antonio, Texas. RESULTS. Use of a mix of strategies, including social distancing, antiviral medications, and targeted vaccination, may limit the overall attack rate so that demand for care would not exceed the capacity of the infrastructure. Additional simulations to assess social distancing as a sole mitigation strategy suggest that a reduction of infectious community contacts to half of normal levels would have to occur within approximately 7 days. CONCLUSIONS. Under ideal conditions, the mix of strategies may limit demand, which can then be met by community surge capacity. Given inadequate supplies of vaccines and antiviral medications, aggressive social distancing alone might allow for the control of a local epidemic without reliance on outside support. C1 [Miller, George] Altarum Inst, Ann Arbor, MI 48113 USA. [Patterson, Jan E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Patterson, Jan E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. [Patterson, Jan E.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Randolph, Stephen] Altarum Inst, San Antonio, TX USA. RP Miller, G (reprint author), Altarum Inst, POB 134001, Ann Arbor, MI 48113 USA. EM george.miller@altarum.org NR 26 TC 4 Z9 4 U1 0 U2 1 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD APR PY 2008 VL 29 IS 4 BP 320 EP 326 DI 10.1086/529212 PG 7 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 271VP UT WOS:000253817100007 PM 18462144 ER PT J AU Nguyen, DD AF Nguyen, Deanna D. TI Are E-coli the culprit? SO INFLAMMATORY BOWEL DISEASES LA English DT Editorial Material ID INFLAMMATORY BOWEL-DISEASE; CROHNS-DISEASE; ILEAL MUCOSA C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Nguyen, DD (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 10 TC 1 Z9 1 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1078-0998 J9 INFLAMM BOWEL DIS JI Inflamm. Bowel Dis. PD APR PY 2008 VL 14 IS 4 BP 575 EP 576 DI 10.1002/ibd.20350 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 285NN UT WOS:000254783600017 PM 18088052 ER PT J AU Dellinger, RP Levy, MM Carlet, JM Bion, J Parker, MM Jaeschke, R Reinhart, K Angus, DC Brun-Buisson, C Beale, R Calandra, T Dhainaut, JF Gerlach, H Harvey, M Marini, JJ Marshall, J Ranieri, M Ramsay, G Sevransky, J Thompson, BT Townsend, S Vender, JS Zimmerman, JL Vincent, JL AF Dellinger, R. Phillip Levy, Mitchell M. Carlet, Jean M. Bion, Julian Parker, Margaret M. Jaeschke, Roman Reinhart, Konrad Angus, Derek C. Brun-Buisson, Christian Beale, Richard Calandra, Thierry Dhainaut, Jean-Francois Gerlach, Herwig Harvey, Maurene Marini, John J. Marshall, John Ranieri, Marco Ramsay, Graham Sevransky, Jonathan Thompson, B. Taylor Townsend, Sean Vender, Jeffrey S. Zimmerman, Janice L. Vincent, Jean-Louis TI Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008 (vol 34, pg 17, 2008) SO INTENSIVE CARE MEDICINE LA English DT Correction C1 Cooper Univ Hosp, Camden, NJ 08103 USA. [Levy, Mitchell M.; Townsend, Sean] Rhode Isl Hosp, Providence, RI USA. [Carlet, Jean M.] St Joseph Hosp, Paris, France. [Bion, Julian] Univ Birmingham, Birmingham, W Midlands, England. [Parker, Margaret M.] SUNY Stony Brook, Stony Brook, NY 11794 USA. [Jaeschke, Roman] McMaster Univ, Hamilton, ON, Canada. [Reinhart, Konrad] Univ Jena, Jena, Germany. [Angus, Derek C.] Univ Pittsburgh, Pittsburgh, PA USA. [Brun-Buisson, Christian] Hop Henri Mondor, F-94010 Creteil, France. [Beale, Richard] Guys & St Thomas Hosp Trust, London, England. [Calandra, Thierry] CHU Vaudois, Lausanne, Switzerland. [Dhainaut, Jean-Francois] French Agcy Evaluat Res Higher Educ, Paris, France. [Gerlach, Herwig] Vivantes Klinikum Neukoelln, Berlin, Germany. [Harvey, Maurene] Crit Care Inc, Glenbrook, NV USA. [Marini, John J.] Univ Minnesota, St Paul, MN 55108 USA. [Marshall, John] St Michaels Hosp, Toronto, ON M5B 1W8, Canada. [Ranieri, Marco] Univ Turin, Turin, Italy. [Ramsay, Graham] W Hertfordshire Hlth Trust, Hempstead, NY USA. [Sevransky, Jonathan] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Thompson, B. Taylor] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Vender, Jeffrey S.] Evanston Northwestern Hlthcare, Evanston, IL USA. [Zimmerman, Janice L.] Methodist Hosp, Houston, TX 77030 USA. [Vincent, Jean-Louis] Erasme Univ Hosp, B-1070 Brussels, Belgium. RP Dellinger, RP (reprint author), Cooper Univ Hosp, 1 Cooper Plaza,393 Dorrance, Camden, NJ 08103 USA. EM Dellinger-Phil@CooperHealth.edu RI Beale, Richard/J-7831-2013; Angus, Derek/E-9671-2012; Calandra, Thierry/D-9017-2015 OI Calandra, Thierry/0000-0003-3051-1285 NR 1 TC 19 Z9 21 U1 1 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0342-4642 J9 INTENS CARE MED JI Intensive Care Med. PD APR PY 2008 VL 34 IS 4 BP 783 EP 785 DI 10.1007/s00134-008-1040-9 PG 3 WC Critical Care Medicine SC General & Internal Medicine GA 278BV UT WOS:000254259400031 ER PT J AU Hauser, R AF Hauser, Russ TI Urinary phthalate metabolites and semen quality: a review of a potential biomarker of susceptibility SO INTERNATIONAL JOURNAL OF ANDROLOGY LA English DT Article; Proceedings Paper CT 4th Copenhagen Workshop on Endocrine Disrupters CY MAY 28-31, 2007 CL Copenhagen Univ Hosp, Copenhagen, DENMARK HO Copenhagen Univ Hosp DE phthalates; semen quality; sperm DNA damage; susceptibility ID DEUTERIUM-LABELED DEHP; DI(2-ETHYLHEXYL) PHTHALATE; OXIDATIVE METABOLITES; HUMAN SPERM; DNA-DAMAGE; EXPOSURES; MONOESTER; SERUM; DUST AB Phthalates are a class of chemicals with widespread general population exposure. Some phthalates are reproductive and developmental toxicants in laboratory animals. Advances in the field of phthalate research in humans are dependent on the development and implementation of biomarkers to assess exposure and outcome, as well as potential markers that may be indicative of increased susceptibility. Recently, we incorporated a novel biomarker of potential 'susceptibility' into our study on the relationship of phthalates with semen quality and sperm DNA damage among men recruited from an infertility clinic. We measured urinary concentrations of three di(2-ethylhexyl) phthalate (DEHP) metabolites, mono(2-ethylhexyl) phthalate (MEHP) and two oxidative metabolites, mono-(2-ethyl-5-hydroxylhexyl) phthalate (MEHHP) and mono-(2-ethyl-5-oxohexyl) phthalate (MEOHP). We calculated the percent of DEHP excreted as the hydrolytic monoester (i.e., MEHP). We referred to this as %MEHP and considered it a phenotypic marker of the proportion of DEHP excreted in the urine as MEHP. In our sperm DNA study, we found novel results for the DEHP metabolites. Although MEHP was positively correlated with the oxidative metabolites, the association of sperm DNA damage with MEHP, as compared to MEHHP and MEOHP, were in opposite directions. We hypothesized that MEHP is the bioactive toxicant and further metabolism to MEHHP/MEOHP may lower internal burden of MEHP and thus be protective from sperm DNA damage. An alternative explanation may include that the relative percentage of DEHP excreted as MEHP was a surrogate for the function of phase I enzymes. Men with high %MEHP may have higher levels of sperm DNA damage because of poor metabolism (detoxification) of other genotoxic chemicals. Our hypothesis that %MEHP may represent a phenotypic marker of metabolism is novel but requires further exploration to confirm. C1 [Hauser, Russ] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA. [Hauser, Russ] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Fertil Ctr,Vincent Mem Obstet & Gynecol Serv, Boston, MA 02115 USA. RP Hauser, R (reprint author), Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, 665 Huntington Ave,Bldg 1,Room 1405, Boston, MA 02115 USA. EM hauser@hohp.harvard.edu FU NIEHS NIH HHS [ES09718]; NIOSH CDC HHS [OH008578] NR 17 TC 55 Z9 57 U1 4 U2 20 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0105-6263 J9 INT J ANDROL JI Int. J. Androl. PD APR PY 2008 VL 31 IS 2 BP 112 EP 116 DI 10.1111/j.1365-2605.2007.00844.x PG 5 WC Andrology SC Endocrinology & Metabolism GA 270GW UT WOS:000253710200008 PM 18067563 ER PT J AU Fowler, CG Chiasson, KB Hart, DB Beasley, TM Kemnitz, J Weindruch, R AF Fowler, Cynthia G. Chiasson, Kirstin Beach Hart, Dianna Brown Beasley, T. Mark Kemnitz, Joseph Weindruch, Richard TI Tympanometry in rhesus monkeys: Effects of aging and caloric restriction SO INTERNATIONAL JOURNAL OF AUDIOLOGY LA English DT Article; Proceedings Paper CT Annual Convention of the American-Speech-Language-Hearing-Association CY NOV 18-20, 2004 CL Philadelphia, PA SP Amer Speech Language Hearing Assoc DE caloric restriction; aging; rhesus monkeys; tympanometry; middle ear; hearing ID MACACA-MULATTA; MIDDLE-EAR; OTOACOUSTIC EMISSIONS; AUDITORY FUNCTION; OLDER-ADULTS; WISCONSIN; HEARING; HUMANS; AGE AB Caloric restriction is the only known method of increasing lifespan in laboratory animals. The present study was conducted as part of a larger investigation into the effect of caloric restriction on longevity of rhesus monkeys as a model for human aging. This study focused on the effects of caloric restriction and aging on measures of middle-ear function measured with tympanometry. Peak compensated static acoustic admittance (peak Y-tm) tended to be reduced with aging. For tympanometric width (TW), the effect of age was significant with TW increasing with age. Males had a trend of narrower TW than females. A significant age by sex interaction indicated that TW for males stays relatively constant, whereas TW for females increases with age. The equivalent ear canal volume (V,,) was significantly larger in male monkeys than in female monkeys, and marginally larger for the control monkeys than for the caloric restricted monkeys. These results parallel many findings in middle-car function in aging humans. Longitudinal studies are planned. C1 [Fowler, Cynthia G.] Univ Wisconsin, Dept Communicat Disorders, Madison, WI 53706 USA. [Chiasson, Kirstin Beach] Oregon Inst Technol, Klamath Falls, OR USA. [Hart, Dianna Brown] Univ Minnesota, Med Ctr, Fairview, MN USA. [Beasley, T. Mark] Univ Alabama, Dept Biostat, Birmingham, AL 35294 USA. [Kemnitz, Joseph] Univ Wisconsin, Wisconsin Natl Primate Res Ctr, Madison, WI 53706 USA. [Kemnitz, Joseph] Univ Wisconsin, Dept Physiol, Madison, WI 53706 USA. [Weindruch, Richard] William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA. [Weindruch, Richard] Univ Wisconsin, Dept Med, Madison, WI 53706 USA. RP Fowler, CG (reprint author), Univ Wisconsin, Dept Communicat Disorders, 1975 Willow Dr, Madison, WI 53706 USA. EM cgfowler@wisc.edu FU NIA NIH HHS [P01 AG011915, P01 AG11915, R01 AG040178]; NIH HHS [P51 OD011106] NR 27 TC 3 Z9 4 U1 0 U2 2 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1499-2027 J9 INT J AUDIOL JI Int. J. Audiol. PD APR PY 2008 VL 47 IS 4 BP 209 EP 214 DI 10.1080/14992020701851882 PG 6 WC Audiology & Speech-Language Pathology; Otorhinolaryngology SC Audiology & Speech-Language Pathology; Otorhinolaryngology GA 293NA UT WOS:000255340800008 PM 18389417 ER PT J AU Thompson-Brenner, H Eddy, KT Franko, DL Dorer, D Vashchenko, M Herzog, DB AF Thompson-Brenner, Heather Eddy, Kamryn T. Franko, Debra L. Dorer, David Vashchenko, Maryna Herzog, David B. TI Personality pathology and substance abuse in eating disorders: A longitudinal study SO INTERNATIONAL JOURNAL OF EATING DISORDERS LA English DT Article DE substance; alcohol; drug; eating disorder; anorexia; bulimia; personality ID RESEARCH DIAGNOSTIC-CRITERIA; BULIMIA-NERVOSA; DSM-III; AXIS-I; RELIABILITY; CLASSIFICATION; COMORBIDITY; PREDICTORS; PROFILES; FEIGHNER AB Objective: Substance abuse has been shown to predict poor outcome in eating disorder (ED) samples, and prior cross-sectional data on personality subtypes of EDs suggest that substance abuse is associated with dysregulated and possibly avoidant-insecure subtypes. This study investigates longitudinal associations between personality and substance use. Method: Personality pathology and substance use were assessed in 213 individuals with anorexia nervosa and bulimia nervosa at baseline; substance use was assessed at regular follow-up intervals over a 9-year period. Results: Of the five personality factors identified, the obsessional-sensitive and high-functioning types were negatively associated with substance abuse at baseline, while the behaviorally dysregulated type was positively associated with substance abuse at baseline. Longitudinal associations were observed, suggesting that obsessional-sensitive personality type was protective against the development of substance abuse. Longitudinal associations between the other personality types and substance abuse were nonsignificant after baseline substance abuse history was included as a covariate in the model. Conclusion: Substance use demonstrates cross-sectional associations with personality style, but substance abuse history appears to be the most important predictor of future substance abuse in women with eating disorders. (c) 2007 by Wiley Periodicals, Inc. C1 [Thompson-Brenner, Heather; Vashchenko, Maryna] Boston Univ, Ctr Anxiety & Related Disorders, Boston, MA 02215 USA. [Eddy, Kamryn T.; Franko, Debra L.; Dorer, David; Herzog, David B.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. RP Thompson-Brenner, H (reprint author), Boston Univ, Ctr Anxiety & Related Disorders, 648 Beacon St, Boston, MA 02215 USA. EM heatherthompsonbrenner@gmail.com FU NIDA NIH HHS [R03 DA015414-01A1]; NIMH NIH HHS [5R01 MH 38333 05, K23 MH071641-01A2] NR 30 TC 19 Z9 20 U1 2 U2 4 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0276-3478 J9 INT J EAT DISORDER JI Int. J. Eating Disord. PD APR PY 2008 VL 41 IS 3 BP 203 EP 208 DI 10.1002/eat.20489 PG 6 WC Psychology, Clinical; Nutrition & Dietetics; Psychiatry; Psychology SC Psychology; Nutrition & Dietetics; Psychiatry GA 276AV UT WOS:000254114400002 PM 18027859 ER PT J AU Counselman, EF AF Counselman, Eleanor F. TI Why study group therapy? SO INTERNATIONAL JOURNAL OF GROUP PSYCHOTHERAPY LA English DT Article ID GROUP-PSYCHOTHERAPY; SHAME AB Group therapy training is highly valuable for the overall professional practice of psychotherapy. Learning to be a group therapist means learning about shame, resistance, fears of engulfment and abandonment, maintaining a self in relation to others, promoting empathic connection, strong affects in the moment, multiple experiences of the same interaction or event, and g-roup dynamics. These concepts are highly relevant to all clinical work and other aspects of professional life. Training in group therapy should place greater emphasis on its broader applicability. C1 [Counselman, Eleanor F.] Harvard Univ, Sch Med, Boston, MA USA. [Counselman, Eleanor F.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Counselman, EF (reprint author), 67 Leonard St,Suite 2, Belmont, MA 02478 USA. EM EleanorF@Counselman.com NR 12 TC 1 Z9 1 U1 0 U2 1 PU GUILFORD PUBLICATIONS INC PI NEW YORK PA 72 SPRING STREET, NEW YORK, NY 10012 USA SN 0020-7284 J9 INT J GROUP PSYCHOTH JI Int. J. Group Psychother. PD APR PY 2008 VL 58 IS 2 BP 265 EP 272 DI 10.1521/ijgp.2008.58.2.265 PG 8 WC Psychology, Clinical SC Psychology GA 282HB UT WOS:000254557300008 PM 18399741 ER PT J AU Katsanos, GS Anogianaki, A Castellani, ML Ciampoli, C De Amicis, D Orso, C Pollice, R Vecchiet, J Tete, S Salini, V Caraffa, A Patruno, A Shaik, YB Kempuraj, D Doyle, R Antinolfi, PL Cerulli, G Conti, CM Fulcheri, M Neri, G Sabatino, G AF Katsanos, G. S. Anogianaki, A. Castellani, M. L. Ciampoli, C. De Amicis, D. Orso, C. Pollice, R. Vecchiet, J. Tete, S. Salini, V. Caraffa, A. Patruno, A. Shaik, Y. B. Kempuraj, D. Doyle, R. Antinolfi, P. L. Cerulli, G. Conti, C. M. Fulcheri, M. Neri, G. Sabatino, G. TI Biology of neurotensin: Revisited study SO INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY LA English DT Editorial Material DE neurotensin; substance P; neurotransmitter ID IN-VITRO; TNF-ALPHA; EXPRESSION; CELLS; MACROPHAGES; ENHANCEMENT; MODULATION; RECEPTORS; DISEASES; AGONISTS AB The tridecapeptide neurotensin (NT) acts in the mammalian brain as a primary neurotransmitter or neuromodulator of classical neurotransmitters. Morphological and functional in vitro and in vivo studies have demonstrated the existence of close interactions between NT and dopamine both in limbic and in striatal brain regions. Additionally, biochemical and neurochemical evidence indicates that in these brain regions NT also plays a crucial role in the regulation of the aminoacidergic signalling. Immune cells, such as lymphocytes, macrophages and mast cells are reported to be activated by neuropeptides, such as neurotensin; this activation leads to cytokine and immunoglobulin production. In addition, neurotensin increases calcium level and the production of nitric oxide, therefore neurotensin is deeply involved in immunity and inflammation but its real function still remains to be elucidated. C1 Univ G dAnnunzio, Paediat Div, Chieti, Italy. Univ G dAnnunzio, Otolaryngol Div, Chieti, Italy. Univ G dAnnunzio, Clin Psychol, Chieti, Italy. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Psychiat, Boston, MA USA. Tufts Univ, Sch Med, Dept Pharmacol, Boston, MA 02111 USA. Boston Univ, Sch Med, Dept Med, Infect Dis Sect, Boston, MA 02118 USA. Univ G dAnnunzio, Div Biol, Chieti, Italy. Univ Perugia, Orthopaed Div, I-06100 Perugia, Italy. Univ G dAnnunzio, Sch Med, Clin Infect Dis, Chieti, Italy. Univ Aquila, Dept Expt Med, I-67100 Laquila, Italy. Univ G dAnnunzio, Orthopaed Div, Chieti, Italy. Univ G dAnnunzio, Sch Dent, Chieti, Italy. Univ G dAnnunzio, Div Immunol, Chieti, Italy. Aristotle Univ Thessaloniki, Thessaloniki, Greece. RP Sabatino, G (reprint author), Univ G dAnnunzio, Paediat Div, Via Vestini, Chieti, Italy. EM sabatino@unich.it OI Fulcheri, Mario/0000-0002-2389-9800 NR 41 TC 23 Z9 23 U1 0 U2 5 PU BIOLIFE SAS PI SILVA MARINA (TE) PA VIA S STEFANO 39 BIS, 64029 SILVA MARINA (TE), ITALY SN 0394-6320 J9 INT J IMMUNOPATH PH JI Int. J. Immunopathol. Pharmacol. PD APR-JUN PY 2008 VL 21 IS 2 BP 255 EP 259 PG 5 WC Immunology; Pathology; Pharmacology & Pharmacy SC Immunology; Pathology; Pharmacology & Pharmacy GA 325GL UT WOS:000257576900001 PM 18547468 ER PT J AU Cochran, DM Yock, TI Adams, JA Tarbell, NJ AF Cochran, David M. Yock, Torunn I. Adams, Judith A. Tarbell, Nancy J. TI Radiation dose to the lens during craniospinal irradiation - An improvement in proton radiotherapy technique SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Article DE medulloblastoma; craniospinal irradiation; proton beam therapy; radiation-induced cataract ID TOTAL-BODY IRRADIATION; MEDULLOBLASTOMA; RECURRENCE; TUMORS; CATARACTS AB Purpose: To evaluate the effect of angle modification of cranial field proton beam therapy on the radiation dose delivered to the lens during craniospinal irradiation (CSI). Methods and Materials: Thirty-nine patients with central nervous system tumors who received CSI with a posterior fossa boost were analyzed for the radiation dose to the lens. Thirteen patients received cranial field treatment using standard opposed-lateral proton beams, and 26 patients received treatment with angled posterior-oblique proton beams. The lens dose in a test case also was evaluated by comparing conventional X-rays with the two proton beam planning methods by using a CMS/Xio three-dimensional planning system. Results: Substantial lens dose sparing was realized with the angling of the cranial proton beams 15 degrees-20 degrees to the posterior. In the 39 treated patients who were analyzed (median age, 7 years), average dose delivered to the lens was decreased by approximately 50% by angling of the proton beams, with the average maximum dose decreasing from 74% to 40% of the prescribed dose (p < 0.0001). Significant lens sparing was seen in patients 10 years and younger (median age, 6 years; p < 0.0001), whereas an insignificant decrease was seen in older patients (median age, 16 years; p = 0.14). With the opposed-lateral technique (median age, 6 years), the lens dose increased significantly with decreasing age (p = 0.002), whereas there was no effect of age on lens dose in the angled beam-treated group (median age, 8.5 years; p = 0.73). Conclusion: The present study clearly shows an advantage in sparing of the lens dose by angling the beams used during proton beam CSI. This effect is most pronounced in patients 10 years and younger because of anatomic effects of sinus development. (c) 2008 Elsevier Inc. C1 [Yock, Torunn I.; Adams, Judith A.; Tarbell, Nancy J.] Harvard Univ, Dept Radiat Oncol, Sch Med, Massachusetts Gen Hosp, Boston, MA 02114 USA. [Cochran, David M.] Harvard Univ, Sch Med, Div Hlth Sci & Technol, Cambridge, MA 02138 USA. [Cochran, David M.] MIT, Cambridge, MA 02139 USA. RP Tarbell, NJ (reprint author), Harvard Univ, Dept Radiat Oncol, Sch Med, Massachusetts Gen Hosp, BUL 370, Boston, MA 02114 USA. EM ntarbell@partners.org NR 18 TC 19 Z9 19 U1 0 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD APR 1 PY 2008 VL 70 IS 5 BP 1336 EP 1342 DI 10.1016/j.ijrobp.2007.08.027 PG 7 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 283UA UT WOS:000254660800008 PM 18029111 ER PT J AU Suh, WW Blackstock, AW Herman, J Konski, AA Mohiuddin, M Poggi, MM Regine, WF Cosman, BC Saltz, L Johnstone, PAS AF Suh, W. Warren Blackstock, A. William Herman, Joseph Konski, Andre A. Mohiuddin, Mohammed Poggi, Matthew M. Regine, William F. Cosman, Bard C. Saltz, Leonard Johnstone, Peter A. S. TI ACR appropriateness criteria on resectable rectal cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Article DE appropriateness criteria; rectal cancer; radiotherapy; chemotherapy ID PREOPERATIVE RADIOTHERAPY; RADIATION-THERAPY; ADJUVANT THERAPY; POSTOPERATIVE RADIOTHERAPY; RANDOMIZED-TRIAL; POOLED ANALYSIS; CHEMOTHERAPY; FLUOROURACIL; SURVIVAL; CARCINOMA AB The American College of Radiology (ACR) Appropriateness Criteria (R) on Resectable Rectal Cancer was updated by the Expert Panel on Radiation Oncology-Rectal/Anal Cancer, based on a literature review completed in 2007. (c) 2008 Elsevier Inc. C1 [Suh, W. Warren] Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02459 USA. [Blackstock, A. William; Mohiuddin, Mohammed] Wake Forest Univ, Sch Med, Dept Radiat Oncol, Winston Salem, NC 27109 USA. [Herman, Joseph] Johns Hopkins Univ Hosp, Dept Radiat Oncol, Baltimore, MD 21287 USA. [Konski, Andre A.] Fox Chase Canc Ctr, Dept Radiat Oncol, Philadelphia, PA 19111 USA. [Mohiuddin, Mohammed] Univ Kentucky, Med Ctr, Dept Radiat Med, Lexington, KY 40506 USA. [Poggi, Matthew M.] Inova Alexandria Canc Ctr, Alexandria, VA USA. [Regine, William F.] Univ Maryland, Med Ctr, Dept Radiat Oncol, Baltimore, MD 21201 USA. [Cosman, Bard C.] VA Med Ctr, San Diego, CA USA. [Saltz, Leonard] Mem Sloan Kettering Canc Ctr, Dept Med Oncol, New York, NY 10021 USA. [Johnstone, Peter A. S.] Emory Univ, Sch Med, Dept Radiat Oncol, Atlanta, GA USA. RP Suh, WW (reprint author), Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiat Oncol, 75 Francis St,ASB1-L2, Boston, MA 02459 USA. EM wsuh@troc.harvard.edu NR 16 TC 7 Z9 7 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD APR 1 PY 2008 VL 70 IS 5 BP 1427 EP 1430 DI 10.1016/j.ijrobp.2007.09.029 PG 4 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 283UA UT WOS:000254660800021 PM 18374227 ER PT J AU Li, FH Szallasi, A Young, RH AF Li, Fanghong Szallasi, Arpad Young, Robert H. TI Wolffian tumor of the ovary with a prominent spindle cell component: Report of a case with brief discussion of unusual problems in differential diagnosis, and literature review SO INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY LA English DT Review DE Wolffian tumor of the ovary; cellular fibroma ID FEMALE ADNEXAL TUMOR; ENDOMETRIOID CARCINOMA; ORIGIN AB An 87-year-old woman underwent total abdominal hysterectomy and bilateral salpingo-oophorectomy for endometrioid adenocarcinoma. At operation, a 4.5-cm partially solid and partially cystic right ovarian mass was identified. Frozen section showed a cytologically bland spindle cell proliferation reminiscent of cellular fibroma. Extensive sampling of the ovarian mass revealed a focus with the classic sieve-like pattern of a Wolffian adnexal tumor that merged with the fibroma-like appearance. The uterus showed well-differentiated, superficially invasive endometrioid adenocarcinoma arising in a background of atypical complex hyperplasia. Given the recent reports implying a therapeutic value for Gleevec (Novartis, Stein, Switzerland) (STI-571) in the treatment of Wolffian tumor of the ovary, paraffin immunostain for CD117 (c-kit) was performed that yielded negative results. Without further therapy, the patient was alive without disease 7 months after surgery. This case demonstrates the heterogeneity of Wolffian tumor of the ovary and shows how crucial sampling is in arriving at the correct diagnosis. C1 [Li, Fanghong; Szallasi, Arpad] Monmouth Med Ctr, Dept Pathol, Long Branch, NJ 07740 USA. [Young, Robert H.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. RP Szallasi, A (reprint author), Monmouth Med Ctr, Dept Pathol, Long Branch, NJ 07740 USA. EM aszallasi@sbhcs.com NR 21 TC 3 Z9 6 U1 0 U2 0 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1066-8969 EI 1940-2465 J9 INT J SURG PATHOL JI Int. J. Surg. Pathol. PD APR PY 2008 VL 16 IS 2 BP 222 EP 225 DI 10.1177/1066896907307034 PG 4 WC Pathology; Surgery SC Pathology; Surgery GA 291GT UT WOS:000255183200022 ER PT J AU Kahn, JA Huang, B Gillman, MW Field, AE Austin, SB Colditz, GA Frazier, AL AF Kahn, Jessica A. Huang, Bin Gillman, Matthew W. Field, Alison E. Austin, S. Bryn Colditz, Graham A. Frazier, A. Lindsay TI Patterns and determinants of physical activity in US adolescents SO JOURNAL OF ADOLESCENT HEALTH LA English DT Article DE adolescent; exercise; physical activity; trajectories; longitudinal; individual; parental ID BODY-MASS INDEX; HEALTH-RISK BEHAVIORS; UNITED-STATES; YOUTH; GIRLS; SEDENTARY; EXERCISE; OBESITY; BOYS; PREADOLESCENT AB Purpose: The objectives of this study were to describe longitudinal trends in adolescent physical activity in a sample of U.S. adolescents and to assess the effect of multiple individual, parental, and environmental factors on initial level and rates of change in adolescent physical activity. Methods: Study subjects were 12,812 boys and girls 10 to 18 years of age who were participating in the Growing Up Today Study and their mothers. We used accelerated longitudinal analysis to describe trajectories of physical activity from 1997-1999, and random effects linear mixed models to determine which factors were independently associated with baseline physical activity and changes in physical activity over time. Results: Mean hours of physical activity ranged from 7.3-11.6 hours per week in boys and from 8.0-11.2 hours per week in girls. Physical activity was best modeled as a quadratic function of age, increasing until early adolescence and declining after age 13 in boys and girls. Multivariable modeling demonstrated that variables associated with physical activity level at baseline in boys and girls were age, body mass index, psychosocial variables, personal attitudes about body shape, perceived peer attitudes about body shape/fitness, parental attitudes about physical activity, parental physical activity, and environmental barriers to physical activity. Age was the only factor that predicted change in physical activity over time. Conclusions: Interventions to increase physical activity in adolescents should begin before adolescence. Interventions may be more effective if they are multimodal and focus on modifiable individual, parental, and environmental factors. (c) 2008 Society for Adolescent Medicine. All rights reserved. C1 [Kahn, Jessica A.] Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp, Med Ctr,Div Adolescent Med, Cincinnati, OH 45229 USA. [Huang, Bin] Childrens Hosp, Med Ctr, Ctr Biostat & Epidemiol, Cincinnati, OH 45229 USA. [Gillman, Matthew W.; Field, Alison E.; Austin, S. Bryn; Colditz, Graham A.; Frazier, A. Lindsay] Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02115 USA. [Gillman, Matthew W.] Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Boston, MA 02115 USA. [Field, Alison E.; Austin, S. Bryn] Harvard Univ, Childrens Hosp, Div Adolescent Med, Boston, MA 02115 USA. [Frazier, A. Lindsay] Harvard Univ, Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA. [Frazier, A. Lindsay] Harvard Univ, Dana Farber Canc Inst, Boston, MA 02115 USA. RP Kahn, JA (reprint author), Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp, Med Ctr,Div Adolescent Med, MLC 4000,3333 Burnet Ave, Cincinnati, OH 45229 USA. EM jessica.kahn@cchmc.org RI Colditz, Graham/A-3963-2009; Loureiro, Nuno/I-6400-2012; Huang, bin/G-2468-2014 OI Colditz, Graham/0000-0002-7307-0291; Loureiro, Nuno/0000-0002-1166-3219; FU NIAID NIH HHS [K23 AI50923] NR 39 TC 87 Z9 89 U1 3 U2 41 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD APR PY 2008 VL 42 IS 4 BP 369 EP 377 DI 10.1016/j.jadohealth.2007.11.143 PG 9 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA 282CV UT WOS:000254546100009 PM 18346662 ER PT J AU Zeber, JE Copeland, LA Good, CB Fine, MJ Bauer, MS Kilbourne, AM AF Zeber, John E. Copeland, Laurel A. Good, Chester B. Fine, Michael J. Bauer, Mark S. Kilbourne, Amy M. TI Therapeutic alliance perceptions and medication adherence in patients with bipolar disorder SO JOURNAL OF AFFECTIVE DISORDERS LA English DT Article DE therapeutic alliance; medication adherence; treatment barriers; ethnicity; veterans ID COST-EFFECTIVENESS; LITHIUM TREATMENT; AFRICAN-AMERICAN; WHITE PATIENTS; GLOBAL BURDEN; NONADHERENCE; MAINTENANCE; SCHIZOPHRENIA; PHARMACOTHERAPY; INTERVENTIONS AB Background: Despite the dissemination of practice guidelines for bipolar disorder, outcomes remain suboptimal, largely due to poor treatment adherence. The episodic nature of bipolar disorder disrupts appropriate patient-provider dynamics, interfering with appropriate care. Maintaining a beneficial therapeutic alliance with providers is one important strategy for improving adherence. We examine the association between adherence and therapeutic environment perceptions among veterans with bipolar disorder. Methods: Participants were recruited from the Continuous Improvement for Veterans in Care - Mood Disorders (CIVIC-MD) study (N=435). Individual items and a summary score from the Health Care Climate Questionnaire (HCCQ) for bipolar disorder solicited patient evaluations of their therapeutic environment. Multivariable logistic analyses examined the association between therapeutic alliance and two measures of adherence (missed medication days and intrapersonal barriers), adjusting for relevant patient characteristics. Results: Adherence difficulty was reported on both measures, with substantial differences between perceived barriers and actual medication behavior. Significantly fewer minority veterans endorsed good adherence than white patients (59% versus 77%), although no ethnic differences were noted in therapeutic environment perceptions. Multivariable results indicated that positive therapeutic alliance was associated with better adherence (HCCQ effect sizes 13-20%). Notably, patients reporting providers encouraged "staying in regular contact" were more likely to be adherent, as were patients whose "providers regularly review their progress". Limitations: Generalizability from observational study; adherence defined by cross-sectional patient self-report. Conclusions: The observed association between medication adherence and therapeutic alliance with bipolar treatment supports intervention efforts to strengthen the patient-provider relationship, a bond likely to yield positive clinical outcomes. Published by Elsevier B.V. C1 [Zeber, John E.; Copeland, Laurel A.] S Texas Vet Hlth Care Syst VERDICT, Vet Affairs HSR&D, San Antonio, TX 78229 USA. [Zeber, John E.; Copeland, Laurel A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. [Good, Chester B.; Fine, Michael J.] VA Pittsburgh Healthcare Syst, CHERP, Pittsburgh, PA USA. [Good, Chester B.; Fine, Michael J.] Univ Pittsburgh, Dept Med, Div Gen Internal Med, Pittsburgh, PA 15260 USA. [Good, Chester B.; Fine, Michael J.] Brown Univ, Dept Psychiat, Providence, RI 02912 USA. [Bauer, Mark S.] Vet Affairs Med Ctr, Providence, RI USA. [Kilbourne, Amy M.] Serious Mental Illness Treatment Res & Evaluat Ct, VA Ann Arbor Healthcare Syst, Ann Arbor, MI USA. [Kilbourne, Amy M.] Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA. RP Zeber, JE (reprint author), S Texas Vet Hlth Care Syst VERDICT, Vet Affairs HSR&D, 7400 Merton Minter Blvd Verdict 11c6, San Antonio, TX 78229 USA. EM zeber@uthscsa.edu OI Copeland, Laurel/0000-0002-9478-0209 NR 48 TC 54 Z9 54 U1 1 U2 5 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0327 J9 J AFFECT DISORDERS JI J. Affect. Disord. PD APR PY 2008 VL 107 IS 1-3 BP 53 EP 62 DI 10.1016/j.jad.2007.07.026 PG 10 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 282CU UT WOS:000254546000007 PM 17822779 ER PT J AU Pompili, M Girardi, P Tatarelli, R Lliceto, P De Pisa, E Tondo, L Akiskal, KK Akiskal, HS AF Pompili, Maurizio Girardi, Paolo Tatarelli, Roberto Lliceto, Paolo De Pisa, Eleonora Tondo, Leonardo Akiskal, Kareen K. Akiskal, Hagop S. TI TEMPS-A (Rome): Psychometric validation of affective temperaments in clinically well subjects in mid- and south Italy SO JOURNAL OF AFFECTIVE DISORDERS LA English DT Article DE temperament; psychometrics; TEMPS-A; TEMPS-I; Italy ID BIPOLAR-II; CYCLOTHYMIC TEMPERAMENT; ATYPICAL DEPRESSION; SAN-DIEGO; DISORDERS; SPECTRUM; SUBTYPES; POPULATION; INTERVIEW; STUDENTS AB Background: Our aim was to study the psychometrics and factor structure replicability of the Temperament Evaluation of Memphis, Pisa, Paris and San Diego Autoquestionnaire (TEMPS-A) in its Italian (Rome) Version. The questionnaire is a self-report 110-item measure that postulates five affective temperaments-the depressive, cyclothymic, irritable, hyperthymic, and anxiouswhich embody both strengths and liabilities along affective reactivity. In Italian, the TEMPS has previously been validated in its original 32-item version, the TEMPS-I (Pisa), one which did not yet include an anxious subscale. Methods: The present sample consisted of 948 tionclinical subjects (27.39 years 8.22 S.D.). There were 476 men (50.2%: 28.56 years 8.63 S.D.) and 472 women (49.8%: 26.21 years +/- 7.61 S.D.). Reliability and validity were assessed by standard psychometric tests. Results: Principal Components Analysis with Varimax rotation resulted in a 3-factor solution: the first with highest explained variance (8.84%) represents Dysthymic, Cyclothymic and Anxious (Dys-Cyc-Anx) temperaments combined; the second identifies Irritable temperament (5.65% of variance); and the third Hyperthymic temperament (5.16% of variance). Cronbach Alpha coefficients for the three subscales were respectively.89,.77 and.74. The rates for the Dys-Cyc-Anx were 2.7%, and for the Irritable 3.1%. Despite the low rate of the Hyperthymic temperament (.2%), nonetheless 16% were between Ist and 2nd SD. Exploratory factor analysis revealed a positive loading combining Dys-Cyc-Anx with the Irritable; the Hyperthymic loaded negatively on this factor. In terms of dominant temperaments, based on z-scores, 2.7% were dysthymic, 1.7% cyclothymic,.7% hyperthymic, 3.5% irritable and 3% anxious. Limitation: Although developed for self-rated use, the Italian authors nonetheless administered the TEMPS-A in an interview format. It is uncertain in what ways this procedure could have influenced our results, if any. Another limitation is that we did not assess test-retest reliability. Conclusions: These data,identify at least 3-factors, Dys-Cyc-Anx and Irritable (which are correlated), and Hyperthymic, which is uncorrelated with the others. Though our data are reminiscent of the neuroticism-extraversion distinction, importantly traits are operationalized in affective terms. Beyond the well-known relationship between the Dysthymic and Cyclothymic subscales and that between the Dysthymic and Anxious, the present data reveal a strong relationship between the Cyclothymic and Anxious as well, which is of great relevance for bipolar II. It is also provocative that much of hyperthymia (16%) in the + SD is between the 1st and 2nd SD, thereby "normalizing" this temperament in Italy, as previously reported by TEMPS-I (Pisa) from Northern Italy (and TEMPS-A from Lebanon and Argentina). (C) 2007 Elsevier B.V. All rights reserved. C1 [Pompili, Maurizio; Girardi, Paolo; Tatarelli, Roberto; Lliceto, Paolo; De Pisa, Eleonora] Univ Roma La Sapienza, Dept Psychiat, Sant Andrea Hosp, I-00189 Rome, Italy. [Pompili, Maurizio; Tondo, Leonardo] McLean Div Massachusetts Gen Hosp, Int Consortium Bipolar Disorder Res, Belmont, MA 02478 USA. [Pompili, Maurizio; Tondo, Leonardo] Harvard Univ, Sch Med, Dept Psychiat, Belmont, MA 02178 USA. [Tondo, Leonardo] Univ Cagliari, Dept Psychol, Ctr Lucio Bini Mood Disorders Res Ctr, Cagliari, Sardinia, Italy. [Akiskal, Kareen K.; Akiskal, Hagop S.] Int Mood Ctr, La Jolla, CA USA. [Akiskal, Hagop S.] San Diego Vet Adm Med Ctr, San Diego, CA USA. RP Pompili, M (reprint author), Univ Roma La Sapienza, Dept Psychiat, Sant Andrea Hosp, Via Grottarossa 1035, I-00189 Rome, Italy. EM maurizio.pompili@uniromal.it OI Tatarelli, Roberto/0000-0003-4396-2632; Pompili, Maurizio/0000-0003-1886-4977 NR 39 TC 42 Z9 44 U1 0 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0327 J9 J AFFECT DISORDERS JI J. Affect. Disord. PD APR PY 2008 VL 107 IS 1-3 BP 63 EP 75 DI 10.1016/j.jad.2007.07.031 PG 13 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 282CU UT WOS:000254546000008 PM 17884175 ER PT J AU Holm-Denoma, JM Witte, TK Gordon, KH Herzog, DB Franko, DL Fichter, M Quadflieg, N Joiner, TE AF Holm-Denoma, Jill M. Witte, Tracy K. Gordon, Kathryn H. Herzog, David B. Franko, Debra L. Fichter, Manfred Quadflieg, Norbert Joiner, Thomas E., Jr. TI Deaths by suicide among individuals with anorexia as arbiters between competing explanations of the anorexia-suicide link SO JOURNAL OF AFFECTIVE DISORDERS LA English DT Article DE suicide; Anorexia nervosa; mortality; eating disorders; suicidology ID EATING-DISORDERS; BULIMIA-NERVOSA; FOLLOW-UP; PREDICTORS; MORTALITY AB Background: Suicide is a leading cause of death among individuals with anorexia nervosa (AN). In this paper, we examined competing explanations of the high rate of death by suicide among individuals with anorexia nervosa (AN). Methods: Nine case reports of individuals with AN who died by suicide were evaluated to determine whether death by suicide occurred a) because physical health was so compromised that what would be a non-lethal suicide attempt in a healthy adult became a fatal suicide attempt, or b) because highly lethal suicide attempts that would have killed any adult, healthy or medically compromised, were made. Results: The findings converged with the latter hypothesis, as predicted by Joiner's [Joiner, T., 2006. Why People Die By Suicide. Harvard University Press, Cambridge, MA] theory of suicide, which suggests individuals with AN may habituate to the experience of pain during the course of their illness and accordingly die by suicide using methods that are highly lethal. Limitations: This study utilized case reports instead of an experimental design, which impedes its ability to comment on whether there is a causal relationship between Joiner's theory and death by suicide among individuals with AN. Conclusions: Clinicians are encouraged to carefully assess suicidality in AN patients, paying particular attention to issues related to lethality. (C) 2007 Elsevier B.V. All rights reserved. C1 [Holm-Denoma, Jill M.] Univ Vermont, Burlington, VT 05405 USA. [Witte, Tracy K.; Gordon, Kathryn H.; Joiner, Thomas E., Jr.] Florida State Univ, Tallahassee, FL 32306 USA. [Herzog, David B.; Franko, Debra L.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Fichter, Manfred] Klin Roseneck Hosp Behav Med, Prien Am Chiemsee, Germany. [Fichter, Manfred] Univ Munich, Dept Psychiat, D-80539 Munich, Germany. [Quadflieg, Norbert] Univ Munich, Dept Psychiat, D-80539 Munich, Germany. RP Holm-Denoma, JM (reprint author), Univ Vermont, Burlington, VT 05405 USA. EM Jill.Holm-Denoma@uvm.edu FU NIMH NIH HHS [1 F31 MH077386-01, 5 R01 MH3833305, K24 MH01759, R01 MH51201, R29 MH48097] NR 26 TC 22 Z9 23 U1 1 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0327 J9 J AFFECT DISORDERS JI J. Affect. Disord. PD APR PY 2008 VL 107 IS 1-3 BP 231 EP 236 DI 10.1016/j.jad.2007.07.029 PG 6 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 282CU UT WOS:000254546000030 PM 17761307 ER PT J AU Tichenor, WS Adinoff, A Smart, B Hamilos, DL AF Tichenor, Wellington S. Adinoff, Allen Smart, Brian Hamilos, Daniel L. TI Nasal and sinus endoscopy for medical management of resistant rhinosinusitis, including postsurgical patients SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Article DE sinusitis; rhinosinusitis; endoscopy; sinus; nasal; surgery; FESS; maxillary; ethmoid; culture ID MIDDLE TURBINATE RESECTION; IMAGE-GUIDED SURGERY; FRONTAL-SINUS; ADENOID HYPERTROPHY; DIAGNOSIS; CHILDREN; CULTURE; COMPLICATIONS; MICROBIOLOGY; OBSTRUCTION AB Nasal endoscopy has been practiced by allergists since the early 1980s; however, allergists in general have not embraced endoscopic evaluation of patients with sinus disease, either before or after surgery. Allergists are in a unique position to render medical (as opposed to surgical) care of patients with sinusitis. There has been a growing realization that endoscopy is a valuable procedure for the evaluation and medical treatment of patients with difficult sinusitis. This has resulted in the need for a resource to allow allergists to understand the nature of endoscopic findings in patients with sinusitis, either preoperatively or postoperatively. This article introduces the findings at endoscopy that are common in patients with sinusitis, including those that may be seen after surgery. The findings include perforation of the septum, retained secretions, small surgical ostium caused by postoperative ostial stenosis, previous Caldwell Luc procedure, recirculation of mucus, hyperplastic nasal disease, synechiae, recurrent disease in previously unaffected sinuses, empty nose syndrome, frontal sinus disease, dental disease, and other, more complicated entities. C1 [Tichenor, Wellington S.] Ctr Allergy Asthma & Sinusitis, New York, NY USA. [Tichenor, Wellington S.] New York Med Coll, Valhalla, NY 10595 USA. [Adinoff, Allen] Univ Colorado, Hlth Sci Ctr, Denver, CO USA. [Adinoff, Allen] Colorado Allergy & Asthma Ctr, Denver, CO USA. [Hamilos, Daniel L.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Smart, Brian] DuPage Med Grp, Glen Ellyn, IL USA. [Hamilos, Daniel L.] Harvard Univ, Sch Med, Boston, MA USA. RP Tichenor, WS (reprint author), 642 Pk Ave, New York, NY 10021 USA. EM wtichenor@sinuses.com NR 70 TC 12 Z9 12 U1 0 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD APR PY 2008 VL 121 IS 4 BP 917 EP 927 DI 10.1016/j.jaci.2007.08.065 PG 11 WC Allergy; Immunology SC Allergy; Immunology GA 286YY UT WOS:000254884000016 PM 17981318 ER PT J AU Bekris, LM Millard, SP Galloway, NM Vuletic, S Albers, JJ Lie, G Galasko, DR DeCarli, C Farlow, MR Clark, CM Quinn, JF Kaye, JA Schellenberg, GD Tsuang, D Peskind, ER Yu, CE AF Bekris, Lynn M. Millard, Steven P. Galloway, Nichole M. Vuletic, Simona Albers, John J. Lie, Ge Galasko, Douglas R. DeCarli, Charles Farlow, Martin R. Clark, Chris M. Quinn, Joseph F. Kaye, Jeffrey A. Schellenberg, Gerard D. Tsuang, Debby Peskind, Elaine R. Yu, Chang-En TI Multiple SNPs within and surrounding the apolipoprotein E gene influence cerebrospinal fluid apolipoprotein E protein levels SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE apolipoprotein E gene; apolipoprotein E protein; cerebroshinal fluid; enhancer; promoter; SNP ID AMYLOID PRECURSOR PROTEIN; ALZHEIMERS-DISEASE BRAIN; TRANSGENIC MICE; PROMOTER POLYMORPHISMS; LINKAGE DISEQUILIBRIUM; APOE POLYMORPHISM; REGULATORY REGION; EXPRESSION; RISK; BETA AB The epsilon 4 allele of the apolipoprotein E gene (APOE) is associated with increased risk and earlier age at onset in late onset Alzheimer's disease (AD). Other factors, such as expression level of apolipoprotein E protein (apoE), have been postulated to modify the APOE related risk of developing AD. Multiple loci in and outside of APOE are associated with a high risk of AD. The aim of this exploratory hypothesis generating investigation was to determine if some of these loci predict cerebrospinal fluid (CSF) apoE levels in healthy non-demented subjects. CSF apoE levels were measured from healthy non-demented subjects 21-87 years of age (n = 134). Backward regression models were used to evaluate the influence of 21 SNPs, within and surrounding APOE, on CSF apoE levels while taking into account age, gender, APOE epsilon 4 and correlation between SNPs (linkage disequilibrium). APOE epsilon 4 genotype does not predict CSF apoE levels. Three SNPs within the TOMM40 gene, one APOE promoter SNP and two SNPs within distal APOE enhancer elements (MEI and BCR) predict CSF apoE levels. Further investigation of the genetic influence of these loci on apoE expression levels in the central nervous system is likely to provide new insight into apoE regulation as well as AD pathogenesis. C1 [Bekris, Lynn M.; Yu, Chang-En] Univ Washington, Dept Med, Seattle, WA 98108 USA. [Bekris, Lynn M.; Millard, Steven P.; Galloway, Nichole M.; Schellenberg, Gerard D.; Yu, Chang-En] VA Puget Sound Hlth Care Syst, GRECC, Seattle, WA USA. [Galloway, Nichole M.; Tsuang, Debby; Peskind, Elaine R.] Univ Washington, Sch Med, NW Network VISN 20, MIRECC, Seattle, WA 98108 USA. [Vuletic, Simona; Albers, John J.] Univ Washington, Sch Med, NW Lipid Metab & Diabet Res Labs, Seattle, WA 98108 USA. [Galasko, Douglas R.] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA. [Galasko, Douglas R.] VA Med Ctr, San Diego, CA USA. [DeCarli, Charles] Univ Calif Davis, Dept Neurol, Sacramento, CA 95817 USA. [Farlow, Martin R.] Indiana Univ, Sch Med, Dept Neurol, Indianapolis, IN 46202 USA. [Clark, Chris M.] Univ Penn, Dept Neurol, Inst Aging, Philadelphia, PA 19104 USA. [Quinn, Joseph F.; Kaye, Jeffrey A.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Quinn, Joseph F.] Portland VA Med Ctr, Portland, OR USA. [Schellenberg, Gerard D.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA 98108 USA. RP Bekris, LM (reprint author), Univ Washington, Dept Med, Box 358280,VAPSHCS GRECC 182B,1660 S Columbian Wa, Seattle, WA 98108 USA. EM lbekris@u.washington.edu RI DeCarli, Charles/B-5541-2009; Tsuang, Debby/L-7234-2016; OI Tsuang, Debby/0000-0002-4716-1894; Kaye, Jeffrey/0000-0002-9971-3478 FU NHLBI NIH HHS [P01 HL030086, P01HL30086]; NIA NIH HHS [5T32AG000258-07, AG05136, AG08017, P30 AG008017, P30 AG010129, P30 AG010129-18, P50 AG005136, P50 AG005136-25, R21 AG024486, R21 AG24486-01, T32 AG000258, U01 AG016976]; NINDS NIH HHS [R01 NS048595, R01 NS48595] NR 47 TC 45 Z9 45 U1 0 U2 1 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PD APR PY 2008 VL 13 IS 3 BP 255 EP 266 PG 12 WC Neurosciences SC Neurosciences & Neurology GA 306EA UT WOS:000256229900003 PM 18430993 ER PT J AU Reger, MA Watson, GS Green, PS Baker, LD Cholerton, B Fishel, MA Plymate, SR Cherrier, MM Schellenberg, GD Frey, WH Craft, S AF Reger, Mark A. Watson, G. Stennis Green, Pattie S. Baker, Laura D. Cholerton, Brenna Fishel, Mark A. Plymate, Stephen R. Cherrier, Monique M. Schellenberg, Gerard D. Frey, William H., II Craft, Suzanne TI Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Alzheimer's disease; amyloid-beta; insulin; intranasal administration; memory; mild cognitive impairment ID CENTRAL-NERVOUS-SYSTEM; APOLIPOPROTEIN-E GENOTYPE; POSITRON-EMISSION-TOMOGRAPHY; MILD COGNITIVE IMPAIRMENT; ALZHEIMERS-DISEASE; DIABETES-MELLITUS; ADMINISTERED INSULIN; CEREBROSPINAL-FLUID; GLUCOSE-UTILIZATION; GENETICALLY-OBESE AB Intranasal insulin administration raises central nervous system (CNS) insulin levels in humans and acutely facilitates verbal memory in patients with Alzheimer's disease (AD), an effect that may differ by APOE genotype. The purpose of this study was to examine the cognitive dose response curves for intranasal insulin administration, and determine whether the effects of insulin differ between participants with (epsilon 4+) and without (epsilon 4-) the APOE- epsilon 4 allele. On separate mornings, 33 memory-impaired adults with AD or amnestic mild cognitive impairment and 59 normal adults each underwent five intranasal treatment conditions consisting of insulin (10, 20, 40, or 60 IU) or placebo. Cognition was tested 15-minutes post-treatment, and blood was acquired at baseline and 45-minutes post-treatment. Plasma insulin and glucose levels were unaffected by treatment. Insulin administration facilitated recall on two measures of verbal memory in memory-impaired epsilon 4- adults, with performance generally peaking at 20 IU. In contrast, memory-impaired epsilon 4+ subjects demonstrated a relative decline in verbal memory. Insulin also differentially modulated plasma amyloid-beta for memory-impaired subjects and normal controls, effects that again differed by APOE genotype. These findings suggest that groups with different genetic risks for AD may show differential dose-response curves following intranasal insulin administration. C1 [Reger, Mark A.; Watson, G. Stennis; Green, Pattie S.; Baker, Laura D.; Cholerton, Brenna; Fishel, Mark A.; Plymate, Stephen R.; Schellenberg, Gerard D.; Craft, Suzanne] Vet Affairs Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA 98108 USA. [Reger, Mark A.; Watson, G. Stennis; Baker, Laura D.; Cholerton, Brenna; Cherrier, Monique M.; Craft, Suzanne] Univ Washington, Sch Med, Dept Psychiat, Seattle, WA 98195 USA. [Reger, Mark A.; Watson, G. Stennis; Baker, Laura D.; Cholerton, Brenna; Cherrier, Monique M.; Craft, Suzanne] Univ Washington, Sch Med, Dept Behav Sci, Seattle, WA 98195 USA. [Frey, William H., II] Reg Hosp, Alzheimers Res Ctr, St Paul, MN 55101 USA. RP Craft, S (reprint author), 1660 S Columbian Way,S182-GRECC, Seattle, WA 98108 USA. EM scraft@u.washington.edu FU NIA NIH HHS [P50 AG005136, P50 AG005136-25] NR 60 TC 213 Z9 219 U1 3 U2 13 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PD APR PY 2008 VL 13 IS 3 BP 323 EP 331 PG 9 WC Neurosciences SC Neurosciences & Neurology GA 306EA UT WOS:000256229900009 PM 18430999 ER PT J AU Micco, JA Ehrenreich, JT AF Micco, Jamie A. Ehrenreich, Jill T. TI Children's interpretation and avoidant response biases in response to non-salient and salient situations: Relationships with mothers' threat perception and coping expectations SO JOURNAL OF ANXIETY DISORDERS LA English DT Article DE child anxiety; anxiety disorders; interpretation bias; mother-child relationships; information processing ID DISORDERS INTERVIEW SCHEDULE; GENERALIZED-ANXIETY-DISORDER; CHILDHOOD ANXIETY; ANXIOUS CHILDREN; DSM-IV; PSYCHOMETRIC PROPERTIES; FAMILY INFLUENCES; DEPRESSION SCALE; PARENT VERSIONS; ATTENTION AB This study examined the effect of situation salience on interpretation and avoidant response biases in clinically anxious and non-clinical children. The relationship between mothers' threat perception and expectations of their children's coping, and children's threat perception and coping expectations was also assessed. Forty clinically anxious and 40 non-clinical children (ages 7-14) participated with their mothers. In response to hypothetical situations, children described their likely thoughts and actions; mothers listed a typical child's thoughts and what their child would do. Consistent with information processing theories of anxiety, anxious children displayed amplified cognitive biases in response to personally salient situations, compared to non-clinical children. Mothers of anxious children had lower expectations for their children's coping than mothers of non-anxious children, mirroring differences between the groups of children. Mothers' expectations of their children's coping predicted children's coping expectations in non-salient and salient situations and threat perception in salient situations. Implications of findings are discussed. (C) 2007 Elsevier Ltd. All rights reserved. C1 [Micco, Jamie A.; Ehrenreich, Jill T.] Boston Univ, Ctr Anxiety & Related Disorders, Boston, MA 02215 USA. RP Micco, JA (reprint author), Massachusetts Gen Hosp, Dept Psychiat, 15 Parkman St,ACC 812, Boston, MA 02144 USA. EM jmicco@partners.org NR 41 TC 22 Z9 22 U1 4 U2 13 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0887-6185 J9 J ANXIETY DISORD JI J. Anxiety Disord. PD APR PY 2008 VL 22 IS 3 BP 371 EP 385 DI 10.1016/j.janxdis.2007.03.009 PG 15 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 290OJ UT WOS:000255131800002 PM 17434288 ER PT J AU Petty, CR Rosenbaum, JF Hirshfeld-Becker, DR Henin, A Hubley, S LaCasse, S Faraone, SV Biederman, J AF Petty, Carter R. Rosenbaum, Jerrold F. Hirshfeld-Becker, Dina R. Henin, Aude Hubley, Samuel LaCasse, Sara Faraone, Stephen V. Biederman, Joseph TI The child behavior checklist broad-band scales predict subsequent psychopathology: A 5-year follow-up SO JOURNAL OF ANXIETY DISORDERS LA English DT Article DE child behavior; high-risk; longitudinal studies; depression ID DEFICIT HYPERACTIVITY DISORDER; HIGH-RISK CHILDREN; PANIC DISORDER; MAJOR DEPRESSION; PSYCHIATRIC DIAGNOSES; ANXIETY DISORDERS; PARENTS; CBCL; ADHD; CONVERGENCE AB Objective: To evaluate the utility of the Child Behavior Check list (CBCL) for identifying children of parents with panic disorder or major depression at high-risk for future psychopathology. Methods: Baseline Internalizing and Externalizing CBCL T-scores were used to predict subsequent depressive, anxiety, and disruptive behavior disorders at a 5-year follow-up in children of parents with panic disorder, major depression, or neither disorder. Results: The Internalizing scale predicted subsequent agoraphobia, generalized anxiety disorder, separation anxiety disorder, and social phobia. In contrast, the Externalizing scale predicted subsequent disruptive behavior disorders and major depression. Conclusions: The convergence of these results with previous findings based on structured diagnostic interviews suggests that the CBCL broad-band scales can inexpensively and efficiently help identify children at high risk for future psychopathology within a population of children already at risk by virtue of parental psychopathology. (C) 2007 Elsevier Ltd. All rights reserved. C1 [Petty, Carter R.; Rosenbaum, Jerrold F.; Hirshfeld-Becker, Dina R.; Henin, Aude; Hubley, Samuel; LaCasse, Sara; Biederman, Joseph] Massachusetts Gen Hosp, Pediat Psychopharmacol Unit, Boston, MA 02114 USA. [Rosenbaum, Jerrold F.; Hirshfeld-Becker, Dina R.; Biederman, Joseph] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02114 USA. [Faraone, Stephen V.] SUNY Upstate Med Univ, Dept Psychiat Neurosci & Physiol, Syracuse, NY 13210 USA. RP Petty, CR (reprint author), Massachusetts Gen Hosp, Pediat Psychopharmacol Unit, Warren 705,15 Parkman St, Boston, MA 02114 USA. EM cpetty@partners.org OI Faraone, Stephen/0000-0002-9217-3982 FU NIMH NIH HHS [MH-47077-05, R01 MH047077, R01 MH047077-15] NR 36 TC 22 Z9 22 U1 1 U2 4 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0887-6185 J9 J ANXIETY DISORD JI J. Anxiety Disord. PD APR PY 2008 VL 22 IS 3 BP 532 EP 539 DI 10.1016/j.janxdis.2007.04.003 PG 8 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 290OJ UT WOS:000255131800016 PM 17521868 ER PT J AU Buhlmann, U Etcoff, NL Wilhelm, S AF Buhlmann, Ulrike Etcoff, Nancy L. Wilhelm, Sabine TI Facial attractiveness ratings and perfectionism in body dysmorphic disorder and obsessive-compulsive disorder SO JOURNAL OF ANXIETY DISORDERS LA English DT Article DE body dysmorphic disorder; obsessive-compulsive disorder; physical attractiveness; facial attractiveness; perfectionism; self-discrepancy ID VULNERABILITY HYPOTHESIS; EATING-DISORDERS; SELF-DISCREPANCY; SOCIAL PHOBIA; DEPRESSION; RELIABILITY; DIMENSIONS; SEVERITY; FEATURES; SCALE AB Individuals with body dysmorphic disorder (BDD) suffer from a preoccupation about imagined or slight appearance flaws. We evaluated facial physical attractiveness ratings and perfectionistic thinking among individuals with BDD (n = 19), individuals with obsessive-compulsive disorder (OCD; n = 21), and mentally healthy control participants (n = 21). We presented participants with photographs displaying faces varying in facial attractiveness (attractive, average, unattractive) and asked them to rate them in terms of their physical attractiveness. We further examined how the participants evaluated their own physical attractiveness, relative to independent evaluators (lEs). As predicted, BDD participants perceived their own attractiveness as significantly lower than did the lEs, and they rated photographs from the category "Attractive" as significantly more attractive than did the other groups. Furthermore, both clinical groups were characterized by more perfectionistic thinking than controls. These findings mostly support cognitive-behavioral models of BDD that suggest that individuals with BDD exhibit perfectionistic thinking and maladaptive attractiveness beliefs. (C) 2007 Elsevier Ltd. All rights reserved. C1 [Wilhelm, Sabine] Massachusetts Gen Hosp, Dept Psychiat, Body Dysmorph Disorder Clin, Boston, MA 02114 USA. Harvard Univ, Sch Med, Cambridge, MA 02138 USA. RP Wilhelm, S (reprint author), Massachusetts Gen Hosp, Dept Psychiat, Body Dysmorph Disorder Clin, Simches Res Bldg,185 Cambridge St, Boston, MA 02114 USA. EM wilhelm@psych.mgh.harvard.edu NR 30 TC 39 Z9 39 U1 1 U2 12 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0887-6185 J9 J ANXIETY DISORD JI J. Anxiety Disord. PD APR PY 2008 VL 22 IS 3 BP 540 EP 547 DI 10.1016/j.janxdis.2007.05.004 PG 8 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 290OJ UT WOS:000255131800017 PM 17624717 ER PT J AU Baggish, AL Wang, F Weiner, RB Elinoff, JM Tournoux, F Boland, A Picard, MH Hutter, AM Wood, MJ AF Baggish, Aaron L. Wang, Francis Weiner, Rory B. Elinoff, Jason M. Tournoux, Francois Boland, Arthur Picard, Michael H. Hutter, Adolph M., Jr. Wood, Malissa J. TI Training-specific changes in cardiac structure and function: a prospective and longitudinal assessment of competitive athletes SO JOURNAL OF APPLIED PHYSIOLOGY LA English DT Article DE exercise physiology; cardiac remodeling; athlete's heart ID LEFT-VENTRICULAR DIMENSIONS; HYPERTROPHIC CARDIOMYOPATHY; WEIGHT LIFTERS; HEART; ENDURANCE; MORPHOLOGY; DYSFUNCTION; STRENGTH; EXERCISE; MEN AB This prospective, longitudinal study examined the effects of participation in team-based exercise training on cardiac structure and function. Competitive endurance athletes (EA, n = 40) and strength athletes (SA, n = 24) were studied with echocardiography at baseline and after 90 days of team training. Left ventricular (LV) mass increased by 11% in EA (116 +/- 18 vs. 130 +/- 19 g/m(2); P < 0.001) and by 12% in SA (115 +/- 14 vs. 132 +/- 11 g/m(2); P < 0.001; P value for the compared Delta = NS). EA experienced LV dilation (end-diastolic volume: 66.6 +/- 10.0 vs. 74.7 +/- 9.8 ml/m(2), Delta = 8.0 +/- 4.2 ml/m(2); P < 0.001), enhanced diastolic function (lateral E': 10.9 +/- 0.8 vs. 12.4 +/- 0.9 cm/s, P < 0.001), and biatrial enlargement, while SA experience LV hypertrophy (posterior wall: 4.5 +/- 0.5 vs. 5.2 +/- 0.5 mm/m(2), P < 0.001) and diminished diastolic function (E' basal lateral LV: 11.6 +/- 1.3 vs. 10.2 +/- 1.4 cm/s, P < 0.001). Further, EA experienced right ventricular (RV) dilation (end-diastolic area: 1,460 +/- 220 vs. 1,650 +/- 200 mm/m(2), P < 0.001) coupled with enhanced systolic and diastolic function (E' basal RV: 10.3 +/- 1.5 vs. 11.4 +/- 1.7 cm/s, P < 0.001), while SA had no change in RV parameters. We conclude that participation in 90 days of competitive athletics produces significant training-specific changes in cardiac structure and function. EA develop biventricular dilation with enhanced diastolic function, while SA develop isolated, concentric left ventricular hypertrophy with diminished diastolic relaxation. C1 [Baggish, Aaron L.; Weiner, Rory B.; Elinoff, Jason M.; Tournoux, Francois; Picard, Michael H.; Hutter, Adolph M., Jr.; Wood, Malissa J.] Massachusetts Gen Hosp, Div Cardiol, Dept Med, Boston, MA 02114 USA. [Wang, Francis; Boland, Arthur] Harvard Univ, Univ Hlth Serv, Cambridge, MA 02138 USA. RP Baggish, AL (reprint author), Massachusetts Gen Hosp, Div Cardiol, Dept Med, Yawkey 5 55 Fruit St, Boston, MA 02114 USA. EM abaggish@partners.org OI Picard, Michael/0000-0002-9264-3243 NR 37 TC 111 Z9 111 U1 2 U2 19 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 8750-7587 J9 J APPL PHYSIOL JI J. Appl. Physiol. PD APR PY 2008 VL 104 IS 4 BP 1121 EP 1128 DI 10.1152/japplphysiol.01170.2007 PG 8 WC Physiology; Sport Sciences SC Physiology; Sport Sciences GA 283FV UT WOS:000254623000032 PM 18096751 ER PT J AU Dobalian, A Rivers, PA AF Dobalian, Aram Rivers, Patrick A. TI Racial and ethnic disparities in the use of mental health services SO JOURNAL OF BEHAVIORAL HEALTH SERVICES & RESEARCH LA English DT Article ID UNITED-STATES; PSYCHIATRIC-DISORDERS; PRIMARY-CARE; DEPRESSION; POPULATION; AMERICANS; BARRIERS; BLACK; DETERMINANTS; PREVALENCE AB The authors used data from the 1998-1999 Community Tracking Study (CTS) household survey to examine variations in predictors of use of mental health services among different racial and ethnic groups (white, African American, Hispanic, and other). African Americans and Hispanics were less likely to have visited a mental health professional (MHP) in the prior year than were whites. Independent of health insurance and health status, low- to middle-income African Americans may be at particular risk for inadequate use of an MHP compared to higher-income African Americans. Similarly, upper-income Hispanics were more likely to have visited an MHP than Hispanics in the lowest income range. Adults aged 50 and older were less likely to visit an MHP than individuals aged 18-49. Depressed men were more likely to visit an MHP than depressed women. Efforts to reduce disparities should focus on lower-income racial and ethnic minorities. C1 [Dobalian, Aram] Sepulveda Ambulatory Care Ctr & Nusing Home, HSR & D Ctr Excellence Study Healthcare Provider, VA Greater Los Angeles Healthcare Syst, Sepulveda, CA 91343 USA. [Rivers, Patrick A.] So Illinois Univ, Coll Appl Sci & Arts, Carbondale, IL 62901 USA. RP Dobalian, A (reprint author), Sepulveda Ambulatory Care Ctr & Nusing Home, HSR & D Ctr Excellence Study Healthcare Provider, VA Greater Los Angeles Healthcare Syst, 16111 Plummer St 152, Sepulveda, CA 91343 USA. EM adobalia@ucla.edu NR 45 TC 31 Z9 31 U1 4 U2 8 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 1094-3412 J9 J BEHAV HEALTH SER R JI J. Behav. Health Serv. Res. PD APR PY 2008 VL 35 IS 2 BP 128 EP 141 DI 10.1007/s11414-007-9097-8 PG 14 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 289MT UT WOS:000255059300002 PM 18074230 ER PT J AU Kaysen, D Pantalone, DW Chawla, N Lindgren, KP Clum, GA Lee, C Resick, PA AF Kaysen, Debra Pantalone, David W. Chawla, Neharika Lindgren, Kristen P. Clum, Gretchen A. Lee, Christine Resick, Patricia A. TI Posttraumatic stress disorder, alcohol use, and physical health concerns SO JOURNAL OF BEHAVIORAL MEDICINE LA English DT Review DE Posttraumatic stress disorder; alcohol use; victimization; family violence; physical health ID INTIMATE PARTNER VIOLENCE; SELF-REPORTED HEALTH; NATIONAL COMORBIDITY SURVEY; CORONARY-HEART-DISEASE; ALL-CAUSE MORTALITY; SUBSTANCE-ABUSE; SEXUAL ASSAULT; MENTAL-HEALTH; VIETNAM VETERANS; PROBLEM DRINKING AB PTSD is a risk factor for alcohol problems and both in turn have been independently associated with increased health problems. However, it is unclear whether alcohol use moderates the relationship between PTSD and health. Participants were battered women (N = 336) recruited from local domestic violence shelters and non-shelter victim-assistance agencies. A 2 (PTSD diagnosis) x 3 (abstainer, infrequent/light, regular/heavy drinking) ANCOVA was conducted, with injuries and length of abuse as covariates and health concerns as the dependent variable. Main effects for PTSD and alcohol use were significant but not the interaction. Women with PTSD reported the greatest number of health concerns. Women who abstained from drinking and those who drank regularly/heavily reported more health concerns than the infrequent/light drinkers. Health concerns associated with PTSD do not appear to be due to problem drinking. In addition, infrequent/light drinking, even for women with PTSD, may be associated with fewer health concerns. C1 [Kaysen, Debra; Lindgren, Kristen P.; Lee, Christine] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Kaysen, Debra; Resick, Patricia A.] Univ Missouri, Ctr Trauma Recovery, St Louis, MO 63121 USA. [Pantalone, David W.] CUNY Hunter Coll, Dept Psychol, Ctr HIV AIDS Educ Studies & Training, New York, NY 10021 USA. [Chawla, Neharika] Univ Washington, Dept Psychol, Seattle, WA 98195 USA. [Clum, Gretchen A.] Tulane Univ, Sch Publ Hlth & Trop Med, Dept Community Hlth Sci, New Orleans, LA USA. [Resick, Patricia A.] VA Boston Healthcare Syst, Natl Ctr PTSD, Womens Hlth Sci Div, Boston, MA USA. [Resick, Patricia A.] Boston Univ, Dept Psychol, Boston, MA 02215 USA. [Resick, Patricia A.] Boston Univ, Dept Psychiat, Boston, MA 02215 USA. RP Lindgren, KP (reprint author), Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Box 356560, Seattle, WA 98195 USA. EM dkaysen@u.washington.edu FU NIAAA NIH HHS [F32 AA014728, F32AA014728]; NIMH NIH HHS [F31 MH071179, F31MH071179, R01 MH055542, R01 MH055542-03, R01MH55542] NR 104 TC 7 Z9 7 U1 3 U2 8 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0160-7715 J9 J BEHAV MED JI J. Behav. Med. PD APR PY 2008 VL 31 IS 2 BP 115 EP 125 DI 10.1007/s10865-007-9140-5 PG 11 WC Psychology, Clinical SC Psychology GA 300QA UT WOS:000255839100003 PM 18095150 ER PT J AU Funakoshi, T Schmid, T Hsu, HP Spector, M AF Funakoshi, Tadanao Schmid, Thomas Hsu, Hu-Ping Spector, Myron TI Lubricin distribution in the goat infraspinatus tendon: A basis for interfascicular lubrication SO JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME LA English DT Article ID SUPERFICIAL ZONE PROTEIN; SYNOVIAL-FLUID; CARTILAGE; PROTEOGLYCAN; EXPRESSION; BOVINE; IMMUNOLOCALIZATION; CHONDROCYTES; FIBROBLASTS; COLLAGEN AB Background: This study was motivated by the need to better understand the tribology of the rotator cuff, as it could provide insights into degenerative processes and suggest therapeutic approaches to cuff disorders. The objective was to evaluate the distribution of a known lubricating protein in the infraspinatus tendon of the rotator cuff in adult goats. The hypothesis was that lubricin, also known as superficial zone protein or proteoglycan 4, serves as an interfascicular lubricant. Methods: Eight infraspinatus tendons were resected from eight Spanish goats, and five patellar tendons and articular cartilage samples were also resected from five of the goats. Samples were processed for immunolocalization of lubricin with use of a purified monoclonal antibody and for histological analysis with Masson trichrome staining for collagen. The locations of lubricin within the tendon were documented, and measurements were made of the distance to which lubricin was detected in the tendon, relative to the humeral insertion site, and the depth of lubricin staining into the fibrocartilage of the fascicle bordering the humeral joint space. Images from polarized light microscopy were used to measure the fascicle diameter and the crimp length. Results: Lubricin was prominent in layers separating the fascicles in the infraspinatus tendon, with occasional intrafascicular staining. The fibrocartilaginous portion of the fascicle bordering the humeral joint space displayed diffuse lubricin staining. The Masson trichrome staining of the collagen in this lubricin-containing fibrocartilage indicated that it was not being tensioned at the time of fixation, whereas the collagen contained in the body of the tendon was under tension. The crimp of the fascicles near the humeral joint side of the tendon displayed a shorter peak-to-peak length than the crimp of the fascicles in the superior region of the tendon. Only the surface of two of the five patellar tendon samples stained for lubricin; there was no staining within these ligaments. Conclusions: The sheaths of the fascicles of the infraspinatus tendon near the bone insertion site contain lubricin, indicating that this lubricating protein may be facilitating interfascicular movement. The fact that the crimp pattern of fascicles changes with location in the tendon provides support for the supposition that fascicles move relative to one another as the tendon is loaded, underscoring the importance of a lubricating protein in the layer separating the fascicles. Clinical Relevance: The results provide a basis for the hypothesis that the loss of lubricin may favor the wear of tendons during interfascicular movement. Moreover, should lubricin in the infraspinatus be found to serve as a lubricant, the present work provides a rationale for the investigation of an injectable form of lubricin as a therapeutic agent to treat certain rotator cuff problems. C1 [Funakoshi, Tadanao; Hsu, Hu-Ping; Spector, Myron] VA Boston Healthcare Syst, Boston, MA 02130 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. RP Funakoshi, T (reprint author), VA Boston Healthcare Syst, 150 S Huntington Ave,MS 151, Boston, MA 02130 USA. EM mspector@rics.bwh.harvard.edu NR 32 TC 42 Z9 42 U1 0 U2 6 PU JOURNAL BONE JOINT SURGERY INC PI NEEDHAM PA 20 PICKERING ST, NEEDHAM, MA 02192 USA SN 0021-9355 J9 J BONE JOINT SURG AM JI J. Bone Joint Surg.-Am. Vol. PD APR PY 2008 VL 90A IS 4 BP 803 EP 814 DI 10.2106/JBJS.G.00627 PG 12 WC Orthopedics; Surgery SC Orthopedics; Surgery GA 283SJ UT WOS:000254656500017 PM 18381319 ER PT J AU Elhassan, B Chung, ST Ozbaydar, M Diller, D Warner, JJP AF Elhassan, Bassem Chung, Soo Tai Ozbaydar, Mehmet Diller, David Warner, Jon J. P. TI Scapulothoracic fusion for clavicular insufficiency - A report of two cases SO JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME LA English DT Article ID FACIOSCAPULOHUMERAL MUSCULAR-DYSTROPHY; ARTHRODESIS; SHOULDER; ELEVATION; RESECTION C1 [Elhassan, Bassem; Chung, Soo Tai; Ozbaydar, Mehmet; Diller, David; Warner, Jon J. P.] Massachusetts Gen Hosp, Dept Orthopaed Surg, Div Shoulder Surg, Boston, MA 02114 USA. RP Elhassan, B (reprint author), Massachusetts Gen Hosp, Dept Orthopaed Surg, Div Shoulder Surg, 55 Fruit St, Boston, MA 02114 USA. EM belhassan@partners.org; schung@partner.org; mozbaydar@partners.org; ddiller@partners.org; JWarner@partners.org RI Ozbaydar, Mehmet/D-7391-2016 NR 25 TC 3 Z9 3 U1 0 U2 0 PU JOURNAL BONE JOINT SURGERY INC PI NEEDHAM PA 20 PICKERING ST, NEEDHAM, MA 02192 USA SN 0021-9355 J9 J BONE JOINT SURG AM JI J. Bone Joint Surg.-Am. Vol. PD APR PY 2008 VL 90A IS 4 BP 875 EP 880 DI 10.2106/JBJS.G.00986 PG 6 WC Orthopedics; Surgery SC Orthopedics; Surgery GA 283SJ UT WOS:000254656500025 PM 18381326 ER PT J AU Baskies, MA Ruchelsman, DE Capeci, CM Zuckerman, JD Egol, KA AF Baskies, Michael A. Ruchelsman, David E. Capeci, Craig M. Zuckerman, Joseph D. Egol, Kenneth A. TI Operative experience in an orthopaedic surgery residency program: The effect of work-hour restrictions SO JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME LA English DT Article ID REGULATIONS AB Background: The implementation of Section 405 of the New York State Public Health Code and the adoption of similar policies by the Accreditation Council for Graduate Medical Education in 2002 restricted resident work hours to eighty hours per week. The effect of these policies on operative volume in an orthopaedic surgery residency training program is a topic of concern. The purpose of this study was to evaluate the effect of the work-hour restrictions on the operative experiences of residents in a large university-based orthopaeclic surgery residency training program in an urban setting. Methods: We analyzed the operative logs of 109 consecutive orthopaeclic surgery residents (postgraduate years 2 through 5) from 2000 through 2006, representing a consecutive interval of years before and after the adoption of the work-hour restrictions. Results: Following the implementation of the new work-hour policies, there was no significant difference in the operative volume for postgraduate year-2, 3, or 4 residents. However, the average operative volume for a postgraduate year-5 resident increased from 274.8 to 348.4 cases (p = 0.001). In addition, on analysis of all residents as two cohorts (before 2002 and after 2002), the operative volume for residents increased by an average of 46.6 cases per year (p = 0.02). Conclusions: On the basis of the findings of this study, concerns over the potential adverse effects of the resident work-hour polices on operative volume for orthopaeclic surgery residents appear to be unfounded. RP Baskies, MA (reprint author), Harvard Univ, Massachusetts Gen Hosp, Orthopaed Surg Hand Serv, 55 Fruit St,YAW 2100, Boston, MA 02114 USA. EM baskiesm@hotmail.com; der231@med.nyu.edu; cmc352@med.nyu.edu; Joseph.Zuckerman@nyumc.org; egolkol@nyumc.org NR 9 TC 32 Z9 32 U1 0 U2 0 PU JOURNAL BONE JOINT SURGERY INC PI NEEDHAM PA 20 PICKERING ST, NEEDHAM, MA 02192 USA SN 0021-9355 J9 J BONE JOINT SURG AM JI J. Bone Joint Surg.-Am. Vol. PD APR PY 2008 VL 90A IS 4 BP 924 EP 927 DI 10.2106/JRJS.G.00918 PG 4 WC Orthopedics; Surgery SC Orthopedics; Surgery GA 283SJ UT WOS:000254656500031 PM 18381332 ER PT J AU Reddy, VY Schmidt, EJ Holmvang, G Fung, M AF Reddy, Vivek Y. Schmidt, Ehud J. Holmvang, Godtfred Fung, Maggie TI Arrhythmia recurrence after atrial fibrillation ablation: Can magnetic resonance imaging identify gaps in atrial ablation lines? SO JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY LA English DT Article ID PULMONARY VEIN; ENHANCEMENT AB Arrhythmia Recurrence After Atrial Fibrillation Ablation. After pulmonary vein isolation for the treatment of atrial fibrillation, clinical arrhythmia recurrence is often a result of vein reconnection. By selectively visualizing scarred tissue, delayed enhancement magnetic resonance imaging may provide for a noninvasive means to identify gaps in radiofrequency ablation lines. This report correlates three-dimensional magnetic resonance imaging with invasive electroanatomical mapping in a patient with recurrent atrial arrhythmia after multiple unsuccessful ablations for atrial fibrillation. C1 [Reddy, Vivek Y.; Holmvang, Godtfred] Harvard Univ, Cardiac Arrhythmia Serv, Sch Med, Massachusetts Gen Hosp,Heart Ctr, Boston, MA 02114 USA. [Schmidt, Ehud J.; Fung, Maggie] GE Healthcare Appl Sci Lab, Boston, MA USA. RP Reddy, VY (reprint author), Harvard Univ, Cardiac Arrhythmia Serv, Sch Med, Massachusetts Gen Hosp,Heart Ctr, 55 Fruit St,GRB 109, Boston, MA 02114 USA. EM vreddy@partners.org FU NHLBI NIH HHS [K23 HL68064] NR 7 TC 32 Z9 32 U1 0 U2 1 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1045-3873 J9 J CARDIOVASC ELECTR JI J. Cardiovasc. Electrophysiol. PD APR PY 2008 VL 19 IS 4 BP 434 EP 437 DI 10.1111/j.1540-8167.2007.01055.x PG 4 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 281MP UT WOS:000254502000020 PM 18179530 ER PT J AU Kojima, T Hallak, JA Azar, DT AF Kojima, Takashi Hallak, Joelle A. Azar, Dimitri T. TI Control-matched analysis of laser in situ keratomileusis outcomes in high myopia SO JOURNAL OF CATARACT AND REFRACTIVE SURGERY LA English DT Article ID PHAKIC INTRAOCULAR-LENS; FEMTOSECOND LASER; FLAP THICKNESS; FOLLOW-UP; LASIK; SENSITIVITY; SURGERY; PREDICTABILITY; MICROKERATOME; EFFICACY AB PURPOSE: To evaluate the outcomes of laser in situ keratomileusis (LASIK) for high myopia. SETTING: Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, USA. METHODS: The refractive and visual outcomes in 320 eyes (227 patients) that had LASIK for high myopia (spherical equivalent [SE] -6.00 to -10.00 diopters [D]) were analyzed. Two hundred fiftyeight eyes that had LASIK for low myopia were reviewed, and a subsequent control-matched comparative analysis of visual outcomes in highly myopic eyes (SE -7.54 +/- 1.43 D) versus low myopic eyes (SE -2.26 +/- 0.51 D) was performed after controlling for preoperative and surgical parameters. Descriptive and control-matched analyses of eyes with thick corneal pachymetry ( 570 mu m) versus eyes with thinner corneal pachymetry (<= 530 mu m) were performed to evaluate the influence of corneal pachymetry on visual outcomes of LASIK for high myopia. RESULTS: The postoperative uncorrected visual acuity (Snellen; mean -logMAR +/- SD) in the low myopia group (20/22; 0.04 +/- 0.11) was statistically significantly better than in the high myopia group (20/26; 0.11 +/- 0.18) (P =.006). More eyes in the low myopia group (84.7%) than in the high myopia group (56.9%) achieved an SE within +/-0.5 D (P<.001). There were no significant differences in visual and refractive outcomes between the thin and thick cornea groups. CONCLUSION: Laser in situ keratomileusis for high myopia was safe, although the efficacy and predictability was slightly lower than for low myopia. There was no relationship between preoperative pachymetry and visual and refractive outcomes. C1 [Kojima, Takashi; Hallak, Joelle A.; Azar, Dimitri T.] Univ Illinois, Illinois Eye & Ear Infirm, Dept Ophthalmol & Visual Sci, Chicago, IL 60612 USA. [Kojima, Takashi; Hallak, Joelle A.; Azar, Dimitri T.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Boston, MA USA. [Kojima, Takashi; Hallak, Joelle A.; Azar, Dimitri T.] Harvard Univ, Schepens Eye Res Inst, Sch Med, Boston, MA USA. RP Azar, DT (reprint author), Univ Illinois, Illinois Eye & Ear Infirm, Dept Ophthalmol & Visual Sci, 1855 W Taylor St, Chicago, IL 60612 USA. EM dazar@uic.edu FU NEI NIH HHS [EY 10101] NR 27 TC 4 Z9 4 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0886-3350 J9 J CATARACT REFR SURG JI J. Cataract. Refract. Surg. PD APR PY 2008 VL 34 IS 4 BP 544 EP 550 DI 10.1016/j.jcrs.2007.11.031 PG 7 WC Ophthalmology; Surgery SC Ophthalmology; Surgery GA 283TW UT WOS:000254660400011 PM 18361973 ER PT J AU Grisanzio, C Signoretti, S AF Grisanzio, Chiara Signoretti, Sabina TI p63 in prostate biology and pathology SO JOURNAL OF CELLULAR BIOCHEMISTRY LA English DT Review DE prostate; cancer; stem cells; cell lineage; development; p63; markers; diagnosis ID METHYLACYL-COA-RACEMASE; MOLECULAR-WEIGHT CYTOKERATIN; NEEDLE-BIOPSY SPECIMENS; SQUAMOUS-CELL CARCINOMA; EPITHELIAL STEM-CELLS; NEOPLASTIC HUMAN-PROSTATE; COENZYME-A RACEMASE; HAY-WELLS-SYNDROME; P53 HOMOLOG P63; BASAL-CELLS AB The identification of stem cells and differentiation programs regulating the development and maintenance of the normal prostate epithelium is essential for the identification of the cell type(s) and molecular alterations involved in the development and propagation of prostate cancer (CaP). The p53-homologue p63 is highly expressed in normal prostate basal cells and is a clinically useful biomarker for the diagnosis of CaP. Importantly, p63 has been shown to play a critical role in prostate development. Recent experimental evidence also suggests that this gene is essential for normal stem cell function in the prostate as well as other epithelial organs. Future studies aimed at better defining the role of p63 in the renewal of the adult prostate epithelium are likely to shed new light on the mechanisms involved in prostate carcinogenesis. C1 [Grisanzio, Chiara; Signoretti, Sabina] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. [Grisanzio, Chiara; Signoretti, Sabina] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. RP Signoretti, S (reprint author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA. EM ssignoretti@partners.org FU NIDDK NIH HHS [5R21DK072152-02] NR 154 TC 47 Z9 50 U1 0 U2 1 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0730-2312 J9 J CELL BIOCHEM JI J. Cell. Biochem. PD APR 1 PY 2008 VL 103 IS 5 BP 1354 EP 1368 DI 10.1002/jcb.21555 PG 15 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 285HP UT WOS:000254768200003 PM 17879953 ER PT J AU van der Zijden, JP Bouts, MJRJ Roeling, TAP Bleys, RLAW van der Toorn, A Dijkhuizen, RM AF van der Zijden, Jet P. Bouts, Mark J. R. J. Roeling, Tom A. P. Bleys, Ronald L. A. W. van der Toorn, Annette Dijkhuizen, Rick M. TI Manganese-enhanced MRI of brain plasticity in relation to functional recovery after experimental stroke SO JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM LA English DT Article DE stroke; functional recovery; neuronal plasticity; magnetic resonance imaging; neuronal tract tracing; manganese ID CEREBRAL-ARTERY OCCLUSION; RESONANCE-IMAGING MEMRI; IN-VIVO; NEOCORTICAL INFARCTION; BEHAVIORAL RECOVERY; SENSORIMOTOR CORTEX; ADULT-RATS; DAMAGE; SYNAPTOGENESIS; PROJECTIONS AB Restoration of function after stroke may be associated with structural remodeling of neuronal connections outside the infarcted area. However, the spatiotemporal profile of poststroke alterations in neuroanatomical connectivity in relation to functional recovery is still largely unknown. We performed in vivo magnetic resonance imaging (MRI)-based neuronal tract tracing with manganese in combination with immunohistochemical detection of the neuronal tracer wheat-germ agglutinin horseradish peroxidase (WGA-HRP), to assess changes in intra- and interhemispheric sensorimotor network connections from 2 to 10 weeks after unilateral stroke in rats. In addition, functional recovery was measured by repetitive behavioral testing. Four days after tracer injection in perilesional sensorimotor cortex, manganese enhancement and WGA-HRP staining were decreased in subcortical areas of the ipsilateral sensorimotor network at 2 weeks after stroke, which was restored at later time points. At 4 to 10 weeks after stroke, we detected significantly increased manganese enhancement in the contralateral hemisphere. Behaviorally, sensorimotor functions were initially disturbed but subsequently recovered and plateaued 17 days after stroke. This study shows that manganese-enhanced MRI can provide unique in vivo information on the spatiotemporal pattern of neuroanatomical plasticity after stroke. Our data suggest that the plateau stage of functional recovery is associated with restoration of ipsilateral sensorimotor pathways and enhanced interhemispheric connectivity. C1 [van der Zijden, Jet P.; Bouts, Mark J. R. J.; van der Toorn, Annette; Dijkhuizen, Rick M.] Univ Med Ctr Utrecht, Image Sci Inst, NL-3584 CJ Utrecht, Netherlands. [Bouts, Mark J. R. J.] Harvard Med Sch, MIT, Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA. [Roeling, Tom A. P.; Bleys, Ronald L. A. W.] Univ Med Ctr Utrecht, Rudolf Magnus Inst Neurosci, Utrecht, Netherlands. RP Dijkhuizen, RM (reprint author), Univ Med Ctr Utrecht, Image Sci Inst, Bolognalaan 50, NL-3584 CJ Utrecht, Netherlands. EM rick@invivonmr.uu.nl RI Dijkhuizen, Richard/A-6506-2008; OI Dijkhuizen, Rick/0000-0002-4623-4078 NR 43 TC 33 Z9 33 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0271-678X J9 J CEREBR BLOOD F MET JI J. Cereb. Blood Flow Metab. PD APR PY 2008 VL 28 IS 4 BP 832 EP 840 DI 10.1038/sj.jcbfm.9600576 PG 9 WC Endocrinology & Metabolism; Hematology; Neurosciences SC Endocrinology & Metabolism; Hematology; Neurosciences & Neurology GA 280GS UT WOS:000254414500016 PM 17987047 ER PT J AU Martin, KA Chang, RJ Ehrmann, DA Ibanez, L Lobo, RA Rosenfield, RL Shapiro, J Montori, VM Swiglo, BA AF Martin, Kathryn A. Chang, R. Jeffrey Ehrmann, David A. Ibanez, Lourdes Lobo, Rogerio A. Rosenfield, Robert L. Shapiro, Jerry Montori, Victor M. Swiglo, Brian A. TI Evaluation and treatment of hirsutism in premenopausal women: An endocrine society clinical practice guideline SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Review ID POLYCYSTIC-OVARY-SYNDROME; RANDOMIZED CONTROLLED-TRIAL; HCL 13.9-PERCENT CREAM; MODE RUBY-LASER; ONSET ADRENAL-HYPERPLASIA; ORAL-CONTRACEPTIVE PILLS; ASSISTED HAIR REMOVAL; LONG-TERM TREATMENT; FLUTAMIDE 250 MG/D; ND-YAG LASER AB Objective: Our objective was to develop clinical practice guidelines for the evaluation and treatment of hirsutism in premenopausal women. Participants: The Task Force was composed of a chair, selected by the Clinical Guidelines Subcommittee (CGS) of The Endocrine Society, six additional experts, two methodologists, and a medical writer. The Task Force received no corporate funding or remuneration. Evidence: Systematic reviews of available evidence were used to formulate the key treatment and prevention recommendations. We used the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) group criteria to describe both the quality of evidence and the strength of recommendations. We used "recommend" for strong recommendations, and "suggest" for weak recommendations. Consensus Process: Consensus was guided by systematic reviews of evidence and discussions during one group meeting, several conference calls, and e-mail communications. The drafts prepared by the Task Force with the help of a medical writer were reviewed successively by The Endocrine Society's CGS, Clinical Affairs Core Committee (CACC), and Council. The version approved by the CGS and CACC was placed on The Endocrine Society's Web site for comments by members. At each stage of review, the Task Force received written comments and incorporated needed changes. Conclusions: We suggest testing for elevated androgen levels in women with moderate or severe hirsutism or hirsutism of any degree when it is sudden in onset, rapidly progressive, or associated with other abnormalities such as menstrual dysfunction, obesity, or clitoromegaly. For women with patient-important hirsutism despite cosmetic measures, we suggest either pharmacological therapy or direct hair removal methods. For pharmacological therapy, we suggest oral contraceptives for the majority of women, adding an antiandrogen after 6 months if the response is suboptimal. We recommend against antiandrogen monotherapy unless adequate contraception is used. We suggest against using insulin-lowering drugs. For women who choose hair removal therapy, we suggest laser/ photoepilation. C1 [Martin, Kathryn A.] Harvard Univ, Sch Med, Boston, MA 02114 USA. [Martin, Kathryn A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Chang, R. Jeffrey] Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA. [Ehrmann, David A.] Univ Chicago, Gen Clin Res Ctr, Chicago, IL 60637 USA. [Ibanez, Lourdes] Univ Barcelona, E-08950 Barcelona, Spain. [Lobo, Rogerio A.] Columbia Univ, Med Ctr, New York, NY 10032 USA. [Rosenfield, Robert L.] Univ Chicago, Comer Childrens Hosp, Chicago, IL 60637 USA. [Shapiro, Jerry] Univ British Columbia, Vancouver Coastal Hlth Res Inst, Vancouver, BC V5Z 4E8, Canada. [Montori, Victor M.; Swiglo, Brian A.] Mayo Clin, Rochester, MN 55905 USA. RP Martin, KA (reprint author), Harvard Univ, Sch Med, Boston, MA 02114 USA. RI Ibanez, Lourdes/F-8316-2014; OI Ibanez, Lourdes/0000-0002-5058-1603; Montori, Victor/0000-0003-0595-2898 NR 160 TC 134 Z9 147 U1 0 U2 12 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD APR PY 2008 VL 93 IS 4 BP 1105 EP 1120 DI 10.1210/jc.2007-2437 PG 16 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 284AI UT WOS:000254677200002 PM 18252793 ER PT J AU Misra, M Prabhakaran, R Miller, KK Goldstein, MA Mickley, D Clauss, L Lockhart, P Cord, J Herzog, DB Katzman, DK Klibanski, A AF Misra, Madhusmita Prabhakaran, Rajani Miller, Karen K. Goldstein, Mark A. Mickley, Diane Clauss, Laura Lockhart, Patrice Cord, Jennalee Herzog, David B. Katzman, Debra K. Klibanski, Anne TI Weight gain and restoration of menses as predictors of bone mineral density change in adolescent girls with anorexia nervosa-1 SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID X-RAY ABSORPTIOMETRY; HEALTHY ADOLESCENTS; WHOLE-BODY; COMPUTED-TOMOGRAPHY; SECRETORY DYNAMICS; CHILDREN; MASS; ACQUISITION; METABOLISM; GHRELIN AB Context: Adolescents with anorexia nervosa (AN) have low bone mineral density. However, the effect of disease recovery, first, on bone density measures assessed using the Molgaard approach, which differentiates between reported low bone density resulting from short bones (based on height Z-scores) and that resulting from thin bones [based on measures of bone area (BA) for height] or light bones [based on measures of bone mineral content (BMC) for BA]; and second, on height-adjusted bone density measures, has not been well characterized. We hypothesized that menstrual recovery and weight gain (>= 10% increase in body mass index) would predict an increase in these measures of bone density. Methods: In a prospective observational study, lumbar and whole-body (WB) bone density was measured at 0, 6, and 12 months in 34 AN girls aged 12-18 yr and 33 controls. Using Ward's modification of the Molgaard approach, we determined measures of BMC for BA and BA for height at the lumbar spine and WB and also determined spine bone mineral apparent density and WB BMC adjusted for height. Results: Girls with AN had lower spine BMC for BAZ-scores (P = 0.0009), and lower WBBA for height Z (P = 0.0001), compared with controls. Menstrual recovery and weight gain in AN (AN-recovered) (median 9 months) resulted in a stabilization of BMD measures, whereas BMD continued to decrease in AN who did not gain weight and recover menses (AN-not recovered). AN-recovered also predicted greater increases in spine BMC for BA and WB BA for height, compared with AN-not recovered (P < 0.05). Conclusions: Even short-term weight gain with menstrual recovery is associated with a stabilization of BMD measures. C1 [Misra, Madhusmita; Prabhakaran, Rajani; Miller, Karen K.; Cord, Jennalee; Klibanski, Anne] Massachusetts Gen Hosp, BUL 457, Neuroendocrine Unit, Boston, MA 02114 USA. [Misra, Madhusmita; Prabhakaran, Rajani] Harvard Univ, Sch Med, Pediat Endocrine Unit, Boston, MA 02114 USA. [Goldstein, Mark A.] Massachusetts Gen Hosp, Adolescent Med Unit, Boston, MA 02114 USA. [Herzog, David B.] Massachusetts Gen Hosp, Harris Ctr, Boston, MA 02114 USA. [Mickley, Diane] Wilkins Ctr Eating Disorders, Greenwich, CT 06831 USA. [Clauss, Laura] Bedford Ctr Eating Disorders, Bedford, NH 03110 USA. [Lockhart, Patrice] Mercy Hosp, Eating Disorders Ctr, Portland, ME 04101 USA. [Katzman, Debra K.] Hosp Sick Children, Dept Pediat, Div Adolescent Med, Toronto, ON M5G 1X8, Canada. RP Misra, M (reprint author), Massachusetts Gen Hosp, BUL 457, Neuroendocrine Unit, 55 Fruit St, Boston, MA 02114 USA. EM mmisra@partners.org FU NCRR NIH HHS [K23 RR018851, M01-RR-01066, M01 RR001066]; NIDDK NIH HHS [R01 DK062249, P30 DK040561, R01 DK 062249, P30 DK040561-13] NR 32 TC 71 Z9 73 U1 0 U2 3 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD APR PY 2008 VL 93 IS 4 BP 1231 EP 1237 DI 10.1210/jc.2007-1434 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 284AI UT WOS:000254677200024 PM 18089702 ER PT J AU Misra, M Prabhakaran, R Miller, KK Goldstein, MA Mickley, D Clauss, L Lockhart, P Cord, J Herzog, DB Katzman, DK Klibanski, A AF Misra, Madhusmita Prabhakaran, Rajani Miller, Karen K. Goldstein, Mark A. Mickley, Diane Clauss, Laura Lockhart, Patrice Cord, Jennalee Herzog, David B. Katzman, Debra K. Klibanski, Anne TI Prognostic indicators of changes in bone density measures in adolescent girls with anorexia nervosa-II SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID MINERAL DENSITY; SECRETORY DYNAMICS; HEALTHY ADOLESCENTS; PEPTIDE YY; GHRELIN; LEPTIN; METABOLISM; CHILDREN; TURNOVER; CORTISOL AB Introduction: Adolescents with anorexia nervosa (AN) have low bone mineral density (BMD). Baseline predictors of temporal BMD changes (Delta BMD) in AN, including 1) gastrointestinal peptides regulating food intake and appetite that have been related to bone metabolism and 2) bone turnover markers, have not been well characterized. We hypothesized that baseline levels of nutritionally regulated hormones and of bone turnover markers would predict Delta BMD overall. Methods: In a prospective observational study, lumbar and whole-body BMD was measured at 0, 6, and 12 months in 34 AN girls aged 12-18 yr and 33 controls. Baseline body mass index, lean mass, nutritionally regulated hormones [IGF-I, cortisol, ghrelin, leptin, and peptide YY (PYY)], bone formation, and resorption markers were examined to determine nutritional and hormonal predictors of bone density changes. Results: In a regression model, baseline ghrelin and PYY predicted changes in spine bone measures; and baseline ghrelin, cortisol, and PYY predicted changes in whole-body bone measures independent of baseline nutritional status. Conclusions: Neuroendocrine gastrointestinal-derived peptides regulating food intake are independent predictors of changes in bone mass in AN. C1 [Misra, Madhusmita; Prabhakaran, Rajani; Miller, Karen K.; Cord, Jennalee; Klibanski, Anne] Massachusetts Gen Hosp, Neuroendocrine Unit, Boston, MA 02114 USA. [Misra, Madhusmita; Prabhakaran, Rajani] Massachusetts Gen Hosp, Pediat Endocrine Unit, Boston, MA 02114 USA. [Goldstein, Mark A.] Massachusetts Gen Hosp, Adolescent Med Unit, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02114 USA. [Mickley, Diane] Wilkins Ctr Eating Disorders, Greenwich, CT 06831 USA. [Clauss, Laura] Bedford Ctr Eating Disorders, Bedford, NH 03110 USA. [Lockhart, Patrice] Mercy Hosp, Eating Disorders Unit, Portland, ME 04101 USA. [Herzog, David B.] Massachusetts Gen Hosp, Harris Ctr, Boston, MA 02114 USA. [Katzman, Debra K.] Hosp Sick Kids, Dept Paediat, Div Adolescent Med, Toronto, ON M5G 1X8, Canada. RP Misra, M (reprint author), Massachusetts Gen Hosp, Neuroendocrine Unit, BUL 457,55 Fruit St, Boston, MA 02114 USA. EM mmisra@partners.org FU NCRR NIH HHS [K23 RR018851, M01 RR001066, M01-RR-01066]; NIDDK NIH HHS [P30 DK040561, R01 DK062249, P30 DK040561-13, R01 DK 062249] NR 44 TC 34 Z9 34 U1 0 U2 1 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD APR PY 2008 VL 93 IS 4 BP 1292 EP 1297 DI 10.1210/jc.2007-2419 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 284AI UT WOS:000254677200032 PM 18089697 ER PT J AU Musen, G Simonson, DC Bolo, NR Driscoll, A Weinger, K Raji, A Theberge, J Renshaw, PF Jacobson, AM AF Musen, Gail Simonson, Donald C. Bolo, Nicolas R. Driscoll, Amy Weinger, Katie Raji, Annaswamy Theberge, Jean Renshaw, Perry F. Jacobson, Alan M. TI Regional brain activation during hypoglycemia in type 1 diabetes SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID INTENSIVE INSULIN THERAPY; GLYCEMIC THRESHOLDS; GLUCOSE COUNTERREGULATION; SUBSEQUENT HYPOGLYCEMIA; AUTONOMIC RESPONSES; BLOOD OXYGENATION; MELLITUS; SYMPTOMS; UNAWARENESS; HUMANS AB Context: Mechanisms underlying the brain response to hypoglycemia are not well understood. Objective: Our objective was to determine the blood glucose level at which the hypothalamus and other brain regions are activated in response to hypoglycemia in type 1 diabetic patients and control subjects. Design: This was a cross-sectional study evaluating brain activity using functional magnetic resonance imaging in conjunction with a hyperinsulinemic hypoglycemic clamp to lower glucose from euglycemia (90 mg/dl) to hypoglycemia (50 mg/dl). Setting: The study was performed at the Brain Imaging Center in the McLean Hospital. Study Participants: Seven type 1 diabetic patients between 18 and 50 yr old and six matched control subjects were included in the study. Intervention: Hyperinsulinemic hypoglycemic clamp was performed. Main Outcome Measures: Blood glucose level at peak hypothalamic activation, amount of regional brain activity during hypoglycemia in both groups, and difference in regional brain activation between groups were calculated. Results: The hypothalamic region activates at 68 +/- 9 mg/dl in control subjects and 76 +/- 8 mg/dl in diabetic patients during hypoglycemia induction. Brainstem, anterior cingulate cortex, uncus, and putamen were activated in both groups (P < 0.001). Each group also activated unique brain areas not active in the other group. Conclusions: This application of functional magnetic resonance imaging can be used to identify the glucose level at which the hypothalamus is triggered in response to hypoglycemia and whether this threshold differs across patient populations. This study suggests that a core network of brain regions is recruited during hypoglycemia in both diabetic patients and control subjects. C1 [Musen, Gail; Driscoll, Amy; Weinger, Katie; Jacobson, Alan M.] Joslin Diabet Ctr, Div Res, Boston, MA 02215 USA. [Musen, Gail; Bolo, Nicolas R.; Weinger, Katie; Renshaw, Perry F.; Jacobson, Alan M.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA. [Simonson, Donald C.; Raji, Annaswamy] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA. [Simonson, Donald C.; Raji, Annaswamy] Brigham & Womens Hosp, Div Endocrinol Diabet & Hypertens, Boston, MA 02115 USA. [Bolo, Nicolas R.; Renshaw, Perry F.] McLean Hosp, Brain Imaging Ctr, Belmont, MA 02478 USA. [Theberge, Jean] St Josephs Hlth Care, Dept Diagnost Imaging, London, ON N6A 4V2, Canada. RP Musen, G (reprint author), Joslin Diabet Ctr, Div Res, 1 Joslin Pl,Room 350, Boston, MA 02215 USA. EM gail.musen@joslin.harvard.edu RI Theberge, Jean/A-3087-2008 OI Theberge, Jean/0000-0001-7578-4469 FU NIDDK NIH HHS [DK073843, DK60754, DK62218, P30 DK036836, P30 DK36836, R01 DK060754, R01 DK062218, R01 DK073843] NR 37 TC 21 Z9 23 U1 0 U2 3 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD APR PY 2008 VL 93 IS 4 BP 1450 EP 1457 DI 10.1210/jc.2007-2007 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 284AI UT WOS:000254677200057 PM 18198228 ER PT J AU Braunwald, E AF Braunwald, Eugene TI The American Society for Clinical Investigation, 1952-1975: a personal perspective SO JOURNAL OF CLINICAL INVESTIGATION LA English DT Article AB In this perspective, I trace my experiences with the ASCI, beginning in 1952, when as a medical student I attended my first meeting, until 1975, when I completed my term as president of the Society. I focus attention on the sociological aspects of the Atlantic City meetings and the critically important role these meetings played in the evolution of academic medicine during the third quarter of the 20th century. C1 [Braunwald, Eugene] Brigham & Womens Hosp, Div Cardiovasc, TIMI Study Grp, Boston, MA 02115 USA. [Braunwald, Eugene] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. RP Braunwald, E (reprint author), TIMI Study Grp, 350 Longwood Ave, Boston, MA 02115 USA. EM ebraunwald@partners.org NR 1 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC CLINICAL INVESTIGATION INC PI ANN ARBOR PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA SN 0021-9738 J9 J CLIN INVEST JI J. Clin. Invest. PD APR PY 2008 VL 118 IS 4 BP 1228 EP 1230 DI 10.1172/JCI34653 PG 3 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 282SX UT WOS:000254588600010 PM 18382730 ER PT J AU Hayward, LJ Kim, JS Lee, MY Zhou, H Kim, JW Misra, K Salajegheh, M Wu, FF Matsuda, C Reid, V Cros, D Hoffman, EP Renaud, JM Cannon, SC Brown, RH AF Hayward, Lawrence J. Kim, Joanna S. Lee, Ming-Yang Zhou, Hongru Kim, Ji W. Misra, Kumudini Salajegheh, Mohammad Wu, Fen-fen Matsuda, Chie Reid, Valerie Cros, Didier Hoffman, Eric P. Renaud, Jean-Marc Cannon, Stephen C. Brown, Robert H., Jr. TI Targeted mutation of mouse skeletal muscle sodium channel produces myotonia and potassium-sensitive weakness SO JOURNAL OF CLINICAL INVESTIGATION LA English DT Article ID HYPERKALEMIC PERIODIC PARALYSIS; NA+-K+ PUMP; ADYNAMIA-EPISODICA-HEREDITARIA; SLOW INACTIVATION; ALPHA-SUBUNIT; PARAMYOTONIA-CONGENITA; RAT MUSCLE; CHANNELOPATHIES; CONTRACTILITY; STIMULATION AB Hyperkalemic periodic paralysis (HyperKPP) produces myotonia and attacks of muscle weakness triggered by rest after exercise or by K+ ingestion. We introduced a missense substitution corresponding to a human familial HyperKPP mutation (Met1592Val) into the mouse gene encoding the skeletal muscle voltage-gated Na+ channel Na(v)1.4. Mice heterozygous for this mutation exhibited prominent myotonia at rest and muscle fiber-type switching to a more oxidative phenotype compared with controls. Isolated mutant extensor digitorum longus muscles were abnormally sensitive to the Na+/K+ pump inhibitor ouabain and exhibited age-dependent changes, including delayed relaxation and altered generation of tetanic force. Moreover, rapid and sustained weakness of isolated mutant muscles was induced when the extracellular K+ concentration was increased from 4 mM to 10 mM, a level observed in the muscle interstitium of humans during exercise. Mutant muscle recovered from stimulation-induced fatigue more slowly than did control muscle, and the extent of recovery was decreased in the presence of high extracellular K+ levels. These findings demonstrate that expression of the Met1592Val Na+ channel in mouse muscle is sufficient to produce important features of HyperKPP, including myotonia, K+-sensitive paralysis, and susceptibility to delayed weakness during recovery from fatigue. C1 [Hayward, Lawrence J.; Lee, Ming-Yang; Zhou, Hongru; Misra, Kumudini; Salajegheh, Mohammad] Univ Massachusetts, Sch Med, Dept Neurol, Worcester, MA 01655 USA. [Kim, Joanna S.; Kim, Ji W.; Matsuda, Chie; Reid, Valerie; Cros, Didier; Brown, Robert H., Jr.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Wu, Fen-fen; Cannon, Stephen C.] Univ Texas SW Med Ctr Dallas, Dept Neurol, Dallas, TX 75390 USA. [Hoffman, Eric P.] Childrens Natl Med Ctr, Microarray Ctr, Washington, DC 20010 USA. [Renaud, Jean-Marc] Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON, Canada. RP Hayward, LJ (reprint author), Univ Massachusetts, Sch Med, Dept Neurol, 55 Lake Ave N, Worcester, MA 01655 USA. EM lawrence.hayward@umassmed.edu FU NIAMS NIH HHS [R01 AR042703]; NINDS NIH HHS [K08 NS01990] NR 59 TC 25 Z9 25 U1 1 U2 7 PU AMER SOC CLINICAL INVESTIGATION INC PI ANN ARBOR PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA SN 0021-9738 J9 J CLIN INVEST JI J. Clin. Invest. PD APR PY 2008 VL 118 IS 4 BP 1437 EP 1449 DI 10.1172/JCI32638 PG 13 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 282SX UT WOS:000254588600037 PM 18317596 ER PT J AU Austin, KM Gupta, ML Coats, SA Tulpule, A Mostoslavsky, G Balazs, AB Mulligan, RC Daley, G Pellman, D Shimamura, A AF Austin, Karyn M. Gupta, Mohan L., Jr. Coats, Scott A. Tulpule, Asmin Mostoslavsky, Gustavo Balazs, Alejandro B. Mulligan, Richard C. Daley, George Pellman, David Shimamura, Akiko TI Mitotic spindle destabilization and genomic instability in Shwachman-Diamond syndrome SO JOURNAL OF CLINICAL INVESTIGATION LA English DT Article ID LINKED DYSKERATOSIS-CONGENITA; SYNDROME PROTEIN; RIBOSOMAL-RNA; SBDS; CANCER; CELLS; MUTATIONS; TELOMERASE; GENE; ANEUPLOIDY AB Deficiencies in the SBDS gene result in Shwachman-Diamond syndrome (SDS), an inherited bone marrow failure syndrome associated with leukemia predisposition. SBDS encodes a highly conserved protein previously implicated in ribosome biogenesis. Using human primary bone marrow stromal cells (BMSCs), lymphoblasts, and skin fibroblasts, we show that SBDS stabilized the mitotic spindle to prevent genomic instability. SBDS colocalized with the mitotic spindle in control primary BMSCs, lymphoblasts, and skin fibroblasts and bound to purified microtubules. Recombinant SBDS protein stabilized microtubules in vitro. We observed that primary BMSCs and lymphoblasts from SDS patients exhibited an increased incidence of abnormal mitoses. Similarly, depletion of SBDS by siRNA in human skin fibroblasts resulted in increased mitotic abnormalities and aneuploidy that accumulated over time. Treatment of primary BMSCs and lymphoblasts from SDS patients with nocodazole, a microtubule destabilizing agent, led to increased mitotic arrest and apoptosis, consistent with spindle destabilization. Conversely, SDS patient cells were resistant to taxol, a microtubule stabilizing agent. These findings suggest that spindle instability in SDS contributes to bone marrow failure and leukemogenesis. C1 [Austin, Karyn M.; Tulpule, Asmin; Daley, George; Pellman, David; Shimamura, Akiko] Childrens Hosp, Dept Pediat Hematol, Boston, MA 02115 USA. [Gupta, Mohan L., Jr.; Daley, George; Pellman, David; Shimamura, Akiko] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. [Mostoslavsky, Gustavo; Balazs, Alejandro B.; Mulligan, Richard C.; Daley, George; Pellman, David; Shimamura, Akiko] Harvard Univ, Sch Med, Dept Genet, Boston, MA USA. [Mostoslavsky, Gustavo; Balazs, Alejandro B.; Mulligan, Richard C.] Childrens Hosp, Div Mol Med, Boston, MA 02115 USA. [Coats, Scott A.; Shimamura, Akiko] Univ Washington, Childrens Hosp & Reg Med Ctr, Dept Pediat Hematol Oncol, Seattle, WA 98195 USA. RP Shimamura, A (reprint author), Univ Washington, Dept Pediat Hematol Oncol, 815 Mercer St,Room 356, Seattle, WA 98109 USA. EM shima2@u.washington.edu FU NHLBI NIH HHS [R01 HL079582, 7R01 HL079582-06] NR 39 TC 60 Z9 63 U1 0 U2 4 PU AMER SOC CLINICAL INVESTIGATION INC PI ANN ARBOR PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA SN 0021-9738 J9 J CLIN INVEST JI J. Clin. Invest. PD APR PY 2008 VL 118 IS 4 BP 1511 EP 1518 DI 10.1172/JCI33764 PG 8 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 282SX UT WOS:000254588600044 PM 18324336 ER PT J AU Ivancic, V Mastali, M Percy, N Gornbein, J Babbitt, JT Li, Y Landaw, EM Bruckner, DA Churchill, BM Haake, DA AF Ivancic, Vesna Mastali, Mitra Percy, Neil Gornbein, Jeffrey Babbitt, Jane T. Li, Yang Landaw, Elliot M. Bruckner, David A. Churchill, Bernard M. Haake, David A. TI Rapid antimicrobial susceptibility determination of uropathogens in clinical urine specimens by use of ATP bioluminescence SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID ANTIBIOTIC SUSCEPTIBILITY; ADENOSINE-TRIPHOSPHATE; SIGNIFICANT BACTERIURIA; ACUTE PYELONEPHRITIS; LUCIFERASE ASSAY; TRACT-INFECTION; LUMAC SYSTEMS; TESTS; RESISTANCE; WOMEN AB We describe the first direct testing of the antimicrobial susceptibilities of bacterial pathogens in human clinical fluid samples by the use of ATP bioluminescence. We developed an ATP bioluminescence assay that eliminates somatic sources of ATP to selectively quantify the bacterial load in clinical urine specimens with a sensitivity of < 1,000 CFU per milliliter. There was a log-log relationship between light emission and the numbers of CFU in clinical urine specimens. A clinical study was performed to evaluate the accuracy of the ATP bioluminescence assay for determination of the antimicrobial susceptibilities of uropathogens in clinical urine specimens tested in a blinded manner. ATP bioluminescent bacterial density quantitation was used to determine the inoculation volume in growth medium with and without antibiotics. After incubation at 37 degrees C for 120 min, the ATP bioluminescence assay was repeated to evaluate the uropathogen response to antibiotics. The ability of the ATP bioluminescence assay to discriminate between antimicrobial susceptibility and resistance was determined by comparison of the results obtained by the ATP bioluminescence assay with the results obtained by standard clinical microbiology methods. Receiver operator characteristic curves were used to determine the optimal threshold for discriminating between susceptibility and resistance. Susceptibility and resistance were correctly predicted in 87% and 95% of cases, respectively, for an overall unweighted accuracy of 91%, when the results were stratified by antibiotic. For samples in which the pathogen was susceptible, the accuracy improved to 95% when the results for samples with less than a 25-fold increase in the amount of bacterial ATP in the medium without antibiotics were excluded. These data indicate that a rapid bioluminescent antimicrobial susceptibility assay may be useful for the management of urinary tract infections. C1 [Ivancic, Vesna; Li, Yang; Churchill, Bernard M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Los Angeles, CA 90095 USA. [Mastali, Mitra; Babbitt, Jane T.; Haake, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Gornbein, Jeffrey; Landaw, Elliot M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Biomath, Los Angeles, CA 90095 USA. [Bruckner, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA. [Percy, Neil] Hygiena, Camarillo, CA 93012 USA. [Haake, David A.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. RP Haake, DA (reprint author), VA Greater LA Healthcare, Div Infect Dis, 111F, Los Angeles, CA 90073 USA. EM dhaake@ucla.edu FU NIAID NIH HHS [AI075565, U01 AI075565, U01 AI075565-01]; NIBIB NIH HHS [R01 EB000127, EB00127] NR 32 TC 16 Z9 17 U1 1 U2 6 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD APR PY 2008 VL 46 IS 4 BP 1213 EP 1219 DI 10.1128/JCM.02036-07 PG 7 WC Microbiology SC Microbiology GA 286SN UT WOS:000254866400009 PM 18272708 ER PT J AU Cortelli, JR Aquino, DR Cortelli, SC Fernandes, CB de Carvalho, J Franco, GCN Costa, FO Kawai, T AF Cortelli, Jose Roberto Aquino, Davi Rorneiro Cortelli, Sheila Cavalca Fernandes, Carnila Borges de Carvalho-Filho, Jonas Franco, Gilson Cesar Nobre Costa, Fernando Oliveira Kawai, Toshihisa TI Etiological analysis of initial colonization of periodontal pathogens in oral cavity SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID LOCALIZED JUVENILE PERIODONTITIS; EARLY-ONSET PERIODONTITIS; POLYMERASE-CHAIN-REACTION; ACTINOBACILLUS-ACTINOMYCETEMCOMITANS; PORPHYROMONAS-GINGIVALIS; RISK INDICATORS; SUBGINGIVAL MICROFLORA; BRAZILIAN POPULATION; DISEASE; BACTERIA AB It is unclear when the initial colonization by periodontal pathogens occurs in the oral cavity. Therefore, we report here the association between specific age groups and the time when the initial colonization by periodontal pathogens occurs in the oral cavity in such groups. Findings are based on an epidemiological analysis of the prevalence of five periodontal pathogens in the oral cavities of a wide range of age populations, from newborn to elderly, who were randomly selected in a geographic region of Brazil. These periodontal pathogens include Campylobacter rectus, Porphyromonas gingivalis, Aggregatibacter actinomycetemcomitans, Prevotella intermedia, and Tannerella forsythia and were analyzed in the bacterial samples isolated from gingival sulcus, the dorsum of the tongue, and cheek mucosa of diverse age groups, using a bacterial DNA-specific PCR method. Results indicated that there are distinct age-related groups where initial colonization by the five periodontal pathogens examined in this study can be detected and that the presence of teeth is a permissive factor for colonization by P. gingivalis, P. intermedia, and T. forsythia. Although it remains unclear exactly how or when target pathogens colonize healthy subjects, an understanding of age-related groups does provide a potentially useful tool in the early detection and prevention of periodontitis in healthy individuals. C1 [Cortelli, Jose Roberto; Aquino, Davi Rorneiro; Cortelli, Sheila Cavalca; Fernandes, Carnila Borges; de Carvalho-Filho, Jonas; Franco, Gilson Cesar Nobre] Univ Taubate, Dept Dent, Taubate, SP, Brazil. [Costa, Fernando Oliveira] Univ Fed Minas Gerais, Belo Horizonte, MG, Brazil. [Kawai, Toshihisa] Forsyth Inst, Dept Immunol, Boston, MA USA. RP Cortelli, JR (reprint author), Rua Nelson freire Campelo 343, BR-12010700 Sao Paulo, Brazil. EM jrcortelli@uol.com.br RI Franco, Gilson/F-9312-2012 FU NIDCR NIH HHS [DE18310, R21 DE018310] NR 36 TC 37 Z9 44 U1 0 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD APR PY 2008 VL 46 IS 4 BP 1322 EP 1329 DI 10.1128/JCM.02051-07 PG 8 WC Microbiology SC Microbiology GA 286SN UT WOS:000254866400025 PM 18287326 ER PT J AU Riedel, S Bourbeau, P Swartz, B Brecher, S Carroll, KC Stamper, PD Dunne, WM McCardle, T Walk, N Fiebelkorn, K Sewell, D Richter, SS Beckmann, S Doern, GV AF Riedel, Stefan Bourbeau, Paul Swartz, Brandi Brecher, Steven Carroll, Karen C. Stamper, Paul D. Dunne, W. Michael McCardle, Timothy Walk, Nathan Fiebelkorn, Kristin Sewell, David Richter, Sandra S. Beckmann, Susan Doern, Gary V. TI Timing of specimen collection for blood cultures from febrile patients with bacteremia SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID ILL ADULT PATIENTS; STREAM INFECTIONS; ANTIMICROBIAL THERAPY; CLINICAL-SIGNIFICANCE; ACQUIRED BACTEREMIA; RISK-FACTORS; FUNGEMIA; VOLUME; FEVER; COMMUNITY AB Bloodstream infections are an important cause of morbidity and mortality. Physician orders for blood cultures often specify that blood specimens be collected at or around the time of a temperature elevation, presumably as a means of enhancing the likelihood of detecting significant bacteremia. In a multicenter study, which utilized retrospective patient chart reviews as a means of collecting data, we evaluated the timing of blood culture collection in relation to temperature elevations in 1,436 patients with bacteremia and fungemia. The likelihood of documenting bloodstream infections was not significantly enhanced by collecting blood specimens for culture at the time that patients experienced temperature spikes. A subset analysis based on patient age, gender, white blood cell count and specific cause of bacteremia generally also failed to reveal any associations. C1 [Riedel, Stefan; Richter, Sandra S.; Beckmann, Susan; Doern, Gary V.] Univ Iowa, Coll Med, Iowa City, IA USA. [Bourbeau, Paul; Swartz, Brandi] Geisinger Med Ctr, Danville, PA 17822 USA. [Brecher, Steven] VA Boston Healthcare Syst, W Roxbury, MA USA. [Carroll, Karen C.; Stamper, Paul D.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Dunne, W. Michael; McCardle, Timothy; Walk, Nathan] Washington Univ, Sch Med, Barnes Jewish Hosp, St Louis, MO USA. [Fiebelkorn, Kristin] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Sewell, David] VA Med Ctr, Portland, OR USA. RP Doern, GV (reprint author), Univ Iowa Hosp & Clin, Dept Pathol, Div Microbiol, 200 Hawkins Dr,C606 GH, Iowa City, IA 52242 USA. EM gary-doern@uiowa.edu NR 34 TC 31 Z9 34 U1 0 U2 2 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD APR PY 2008 VL 46 IS 4 BP 1381 EP 1385 DI 10.1128/JCM.02033-07 PG 5 WC Microbiology SC Microbiology GA 286SN UT WOS:000254866400034 PM 18305133 ER PT J AU Aas, JA Griffen, AL Dardis, SR Lee, AM Olsen, I Dewhirst, FE Leys, EJ Paster, BJ AF Aas, Jorn A. Griffen, Ann L. Dardis, Sara R. Lee, Alice M. Olsen, Ingar Dewhirst, Floyd E. Leys, Eugene J. Paster, Bruce J. TI Bacteria of dental caries in primary and permanent teeth in children and young adults SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID ORAL MICROBIAL COMMUNITIES; HUMAN CARIOUS DENTIN; MOLECULAR ANALYSIS; VEILLONELLA-ALCALESCENS; STREPTOCOCCUS-MUTANS; CHILDHOOD CARIES; CULTIVABLE FLORA; MICROFLORA; DIVERSITY; PLAQUE AB Although Streptococcus mutans has been implicated as a major etiological agent of dental caries, our cross-sectional preliminary study indicated that 10% of subjects with rampant caries in permanent teeth do not have detectable levels of S. mutans. Our aims were to use molecular methods to detect all bacterial species associated with caries in primary and permanent teeth and to determine the bacterial profiles associated with different disease states. Plaque was collected from 39 healthy controls and from intact enamel and white-spot lesions, dentin lesions, and deep-dentin lesions in each of 51 subjects with severe caries. 16S rRNA genes were PCR amplified, cloned, and sequenced to determine species identities. In a reverse-capture checkerboard assay, 243 samples were analyzed for 110 prevalent bacterial species. A sequencing analysis of 1,285 16S rRNA clones detected 197 bacterial species/phylotypes, of which 50% were not cultivable. Twenty-two new phylotypes were identified. PROC MIXED tests revealed health- and disease-associated species. In subjects with S. mutans, additional species, e.g., species of the genera Atopobium, Propionibacterium, and Lactobacillus, were present at significantly higher levels than those of S. mutans. Lactobacillus spp., Bifidobacterium dentium, and low-pH non-S. mutans streptococci were predominant in subjects with no detectable S. mutans. Actinomyces spp. and non-S. mutans streptococci were predominant in white-spot lesions, while known acid producers were found at their highest levels later in disease. Bacterial profiles change with disease states and differ between primary and secondary dentitions. Bacterial species other than S. mutans, e.g., species of the genera Veillonella, Lactobacillus, Bifidobacterium, and Propionibacterium, low-pH non-S. mutans streptococci, Actinomyces spp., and Atopobium spp., likely play important roles in caries progression. C1 [Aas, Jorn A.; Olsen, Ingar] Univ Oslo, Inst Oral Biol, Fac Dent, N-0316 Oslo, Norway. [Aas, Jorn A.; Lee, Alice M.; Dewhirst, Floyd E.; Paster, Bruce J.] Harvard Univ, Sch Dent Med, Dept Mol Genet, Forsyth Inst, Boston, MA 02115 USA. [Dewhirst, Floyd E.; Paster, Bruce J.] Harvard Univ, Sch Dent Med, Dept Oral Med Infect & Immun, Boston, MA 02115 USA. [Griffen, Ann L.; Dardis, Sara R.] Ohio State Univ, Coll Dent, Dept Pediat Dent, Columbus, OH 43210 USA. [Leys, Eugene J.] Ohio State Univ, Coll Dent, Dept Oral Biol, Columbus, OH 43210 USA. RP Aas, JA (reprint author), Univ Oslo, Inst Oral Biol, Fac Dent, POB 1052 Blindern, N-0316 Oslo, Norway. EM jornaaas@odont.uio.no FU NIDCR NIH HHS [DE016125, DE11443, R01 DE011443, R01 DE016125, U01 DE016937] NR 39 TC 228 Z9 252 U1 8 U2 33 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD APR PY 2008 VL 46 IS 4 BP 1407 EP 1417 DI 10.1128/JCM.01410-07 PG 11 WC Microbiology SC Microbiology GA 286SN UT WOS:000254866400038 PM 18216213 ER PT J AU Seidman, AD Berry, D Cirrincione, C Harris, L Muss, H Marcom, PK Gipson, G Burstein, H Lake, D Shapiro, CL Ungaro, P Norton, L Winer, E Hudis, C AF Seidman, Andrew D. Berry, Donald Cirrincione, Constance Harris, Lyndsay Muss, Hyman Marcom, P. Kelly Gipson, Grandella Burstein, Harold Lake, Diana Shapiro, Charles L. Ungaro, Peter Norton, Larry Winer, Eric Hudis, Clifford TI Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: Final results of cancer and leukemia group B protocol 9840 SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article; Proceedings Paper CT 40th Annual Meeting of the American-Society-of-Clinical-Oncology CY JUN 05-08, 2004 CL New Orleans, LA SP Amer Soc Clin Oncol ID EVERY 3 WEEKS; DOSE PACLITAXEL; CLINICAL-TRIALS; HOUR INFUSION; MULTICENTER; CHEMOTHERAPY; THERAPY; PLUS AB Purpose Phase II trials suggested that weekly paclitaxel might be more effective and less toxic than every-3-weeks administration for metastatic breast cancer (MBC). Cancer and Leukemia Group B (CALGB) protocol 9840 was initiated to address this question. Subsequently trastuzumab was demonstrated to improve outcomes of paclitaxel therapy for human epidermal growth factor receptor-2 (HER-2)-positive patients, and was therefore incorporated. Because inhibition of HER-family signaling had potential efficacy even without HER-2 overexpression, we randomly assigned for trastuzumab in this population. Patients and Methods Patients were randomly assigned to paclitaxel 175 mg/m(2) every 3 weeks or 80 mg/m(2) weekly. After the first 171 patients, all HER-2-positive patients received trastuzumab; HER-2 nonoverexpressors were randomly assigned for trastuzumab, in addition to paclitaxel schedule. A total of 577 patients were treated on 9840. An additional 158 patients were included in analyses, for combined sample of 735. The primary end point was response rate (RR); secondary end points were time to progression (TTP), overall survival, and toxicity. Primary comparisons were between weekly versus every-3-weeks paclitaxel, and trastuzumab versus no trastuzumab in HER-2 nonoverexpressors. Results In the combined sample, weekly paclitaxel was superior to every-3-weeks administration: RR ( 42% v 29%, unadjusted odds ratio [ OR] = 1.75; P = .0004), TTP ( median, 9 v 5 months; adjusted HR = 1.43; P < .0001), and survival ( median, 24 v 12 months; adjusted HR = 1.28; P = .0092). For HER-2 nonoverexpressors, trastuzumab did not improve efficacy. Grade 3 neuropathy was more common with weekly dosing (24% v 12%; P = .0003). Conclusion Weekly paclitaxel is more effective than every-3-weeks administration for MBC. Trastuzumab did not improve efficacy for HER-2 nonoverexpressors. Neurotoxicity is a treatment-limiting toxicity for weekly paclitaxel. C1 [Seidman, Andrew D.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Duke Univ, Med Ctr, Canc & Leukemia Grp B, Ctr Stat, Durham, NC 27706 USA. Univ N Carolina, Chapel Hill, NC USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Vermont Canc Ctr, Burlington, VT USA. Ohio State Univ, Med Ctr, Columbus, OH 43210 USA. RP Seidman, AD (reprint author), Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA. EM seidmana@mskcc.org FU NCI NIH HHS [CA47559, CA47577, CA77406, CA32291, CA77651, CA77658, CA33601] NR 27 TC 326 Z9 329 U1 0 U2 5 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 330 JOHN CARLYLE ST, STE 300, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD APR 1 PY 2008 VL 26 IS 10 BP 1642 EP 1649 DI 10.1200/JCO.2007.11.6699 PG 8 WC Oncology SC Oncology GA 281WY UT WOS:000254530800013 PM 18375893 ER PT J AU Wolfe, J Hammel, JF Edwards, KE Duncan, J Comeau, M Breyer, J Aldridge, SA Grier, HE Berde, C Dussel, V Weeks, JC AF Wolfe, Joanne Hammel, Jim F. Edwards, Kelly E. Duncan, Janet Comeau, Michael Breyer, Joanna Aldridge, Sarah A. Grier, Holcombe E. Berde, Charles Dussel, Veronica Weeks, Jane C. TI Easing of suffering in children with cancer at the end of life: Is care changing? SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article ID PEDIATRIC PALLIATIVE CARE; QUALITY-OF-LIFE; FAMILY PERSPECTIVES; CONTROLLED-TRIAL; SYMPTOMS; PARENTS; NATIONWIDE; THERAPY; SUPPORT; IMPACT AB Purpose In the past decade studies have documented substantial suffering among children dying of cancer, prompting national attention on the quality of end-of-life care and the development of a palliative care service in our institutions. We sought to determine whether national and local efforts have led to changes in patterns of care, advanced care planning, and symptom control among children with cancer at the end of life. Methods Retrospective cohort study from a US tertiary level pediatric institution. Parent survey and chart review data from 119 children who died between 1997 and 2004 (follow-up cohort) were compared with 102 children who died between 1990 and 1997 (baseline cohort). Results In the follow-up cohort, hospice discussions occurred more often (76% v 54%; adjusted risk difference [RD], 22%; P < .001) and earlier (adjusted geometric mean 52 days v 28 days before death; P = .002) compared with the baseline cohort. Do-not-resuscitate orders were also documented earlier (18 v 12 days; P = .031). Deaths in the intensive care unit or other hospitals decreased significantly (RD, 16%; P = .024). Parents reported less child suffering from pain (RD, 19%; P = .018) and dyspnea (RD, 21%; P = .020). A larger proportion of parents felt more prepared during the child's last month of life (RD, 29%; P < .001) and at the time of death (RD, 24%; P = .002). Conclusion Children dying of cancer are currently receiving care that is more consistent with optimal palliative care and according to parents, are experiencing less suffering. With ongoing growth of the field of hospice and palliative medicine, further advancements are likely. C1 [Wolfe, Joanne] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. Dana Farber Canc Inst, Ctr Outcomes & Policy Res, Boston, MA 02115 USA. Childrens Hosp, Dept Med, Boston, MA 02115 USA. Childrens Hosp, Dept Anesthesia, Boston, MA 02115 USA. Brigham & Womens Hosp, Dept Psychiat, Boston, MA 02115 USA. Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. RP Wolfe, J (reprint author), Dana Farber Canc Inst, Dept Pediat Oncol, 44 Binney St,SM-205, Boston, MA 02115 USA. EM Joanne_wolfe@dfci.harvard.edu FU NCI NIH HHS [5 K07 CA096746, K07 CA096746]; PHS HHS [T32HP10018] NR 47 TC 88 Z9 89 U1 4 U2 5 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 330 JOHN CARLYLE ST, STE 300, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD APR 1 PY 2008 VL 26 IS 10 BP 1717 EP 1723 DI 10.1200/JCO.2007.14.0277 PG 7 WC Oncology SC Oncology GA 281WY UT WOS:000254530800024 PM 18375901 ER PT J AU Yonkers, KA Lin, HQ Howell, HB Heath, AC Cohen, LS AF Yonkers, Kimberly A. Lin, Haiqun Howell, Heather B. Heath, A. Christopher Cohen, Lee S. TI Pharmacologic treatment of postpartum women with new-onset major depressive disorder: A randomized controlled trial with paroxetine SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID POSTNATAL DEPRESSION; MINORITY PATIENTS; CLINICAL-TRIAL; ANXIETY; METAANALYSIS; PREVENTION; FLUOXETINE; OUTCOMES; RATES AB Objective: Approximately 6% to 8% of postpartum women suffer from major depressive disorder (MDD), but only a few controlled trials have investigated the efficacy of pharmacologic treatments. The current study determined the relative efficacy of paroxetine compared to placebo in the treatment of acute postpartum MDD. Method: This was an 8-week, multicenter, parallel, placebo-controlled trial of paroxetine for treatment of postpartum depression. Subjects were eligible if they had an onset of DSM-IV MDD after, but within 3 months of, delivery and had a minimum score of 16 on the 17-item Hamilton Rating Scale for Depression (HAM-D-17) at intake. Seventy women were randomly assigned to either immediate-release paroxetine or matching placebo, and 3 1 completed the trial. Subjects were reassessed with the HAM-D-17, the Inventory of Depressive Symptomatology-Self-Report (IDS-SR) form and the Clinical Global Impressions (CGI) scales. The study was conducted between 1997 and 2004. Results: Both groups improved over time and did not differ significantly on the HAM-D-17 or IDS-SR at follow-up. However, greater improvement in overall mean +/- SD clinical severity was found for the paroxetine (Clinical Global Irnpressions-Severity of Illness [CGI-S] score = 1.8 +/- 1.4) compared with the control group (CGI-S score = 3.1 +/- 1.4; p =.05). The paroxetine group also had a significantly higher rate of remission, compared to the placebo group (37% vs. 15%, odds ratio = 3.5, 95% CI = 1.1 to 11.5). The rate of adverse effects did not differ significantly between groups. Conclusion: Study results were limited by lower than expected enrollment and higher than anticipated attrition. Nonetheless, paroxetine treatment was associated with a significantly higher rate of remission among women with postpartum onset of MDD. C1 [Yonkers, Kimberly A.] Yale Univ, Sch Med, Dept Obstet Gynecol & Reprod Sci, New Haven, CT 06520 USA. [Yonkers, Kimberly A.] Yale Univ, Sch Med, Dept Psychiat Epidemiol & Publ Hlth, New Haven, CT USA. [Lin, Haiqun] Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, Div Biostat, New Haven, CT USA. [Heath, A. Christopher] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. Massachusetts Gen Hosp, Perinatal & Reprod Psychiat Clin Res Program, Boston, MA 02114 USA. [Howell, Heather B.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. RP Yonkers, KA (reprint author), Yale Univ, Sch Med, Dept Obstet Gynecol & Reprod Sci, 142 Temple St,Suite 301, New Haven, CT 06520 USA. EM Kimberly.Yonkers@yale.edu FU NIMH NIH HHS [K08 MH001908-05, R21 MH080959, MH01648, K08 MH001908, R21 MH080959-01A1] NR 24 TC 34 Z9 34 U1 1 U2 3 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD APR PY 2008 VL 69 IS 4 BP 659 EP 665 PG 7 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 291RT UT WOS:000255215200020 PM 18363420 ER PT J AU Marcus, RN McQuade, RD Carson, WH Hennicken, D Fava, M Simon, JS Trivedi, MH Thase, ME Berman, RM AF Marcus, Ronald N. McQuade, Robert D. Carson, William H. Hennicken, Delphine Fava, Maurizio Simon, Jeffrey S. Trivedi, Madhukar H. Thase, Michael E. Berman, Robert M. TI The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder - A second multicenter, randomized, double-blind, placebo-controlled study SO JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY LA English DT Article ID TREATMENT-RESISTANT DEPRESSION; SEROTONIN REUPTAKE INHIBITORS; OLANZAPINE/FLUOXETINE COMBINATION; ANTIPSYCHOTIC ARIPIPRAZOLE; PARTIAL AGONIST; AUGMENTATION; OUTPATIENTS; SCALE; FLUOXETINE; DISABILITY AB Nonresponse to one or more antidepressants is common and an important public health problem. This study evaluated the efficacy and safety of adjunctive aripiprazole or placebo to standard antidepressant therapy (ADT) in patients with major depressive disorder who showed an inadequate response to at least 1 and up to 3 historical and 1 additional prospective ADT. The study comprised a 7-28-day screening, an 8-week prospective treatment, and a 6-week randomization phase. During prospective treatment, patients experiencing a major depressive episode (17-item Hamilton Rating Scale for Depression total score >18) received single-blind adjunctive placebo plus clinicians' choice of ADT (escitalopram, fluoxetine, paroxetine controlled-release, sertraline, or venlafaxine extended-release). Subjects with inadequate response were randomized to adjunctive placebo (n = 190) or adjunctive aripiprazole (n = 191) (starting dose 5 mg/d, dose adjustments 2-20 mg/d, mean end-point dose of 11.0 mg/d). The primary efficacy endpoint was the mean change in Montgomery-Asberg Depression Rating Scale total score from end of prospective treatment phase to end of randomized treatment phase (last observation carried forward). Mean change in Montgomery-Asberg Depression Rating Scale total score was significantly greater with adjunctive aripiprazole than placebo (-8.5 vs -5.7; P = 0.001). Remission rates were significantly greater with adjunctive aripiprazole than placebo (25.4% vs 15.2%; P = 0.016) as were response rates (32.4% vs 17.4%; P < 0.001). Adverse events occurring in 10% of patients or more with adjunctive placebo or aripiprazole were akathisia (4.2% vs 25.9%), headache (10.5% vs 9.0%), and fatigue (3.7% vs 10.1%). Incidence of adverse events leading to discontinuation was low (adjunctive placebo [1.1%] vs adjunctive aripiprazole [3.7%]). Aripiprazole is an effective and safe adjunctive therapy as demonstrated in this short-term study for patients who are nonresponsive to standard ADT. C1 [Marcus, Ronald N.; Berman, Robert M.] Bristol Myers Squibb Co, Wallingford, CT 06492 USA. [McQuade, Robert D.; Carson, William H.] Otsuka Pharmaceut Dev & Commercializat Inc, Princeton, NJ USA. [Hennicken, Delphine] Bristol Myers Squibb, Braine Ialleud, Belgium. [Fava, Maurizio] Massachusetts Gen Hosp, Depress Clin & Res Program, Boston, MA 02114 USA. [Simon, Jeffrey S.] Northbrooke Res Ctr, Brown Deer, WI USA. [Trivedi, Madhukar H.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. [Thase, Michael E.] Univ Penn, Sch Med, Univ Pittsburgh Med Ctr, Dept Psychiat, Philadelphia, PA 19104 USA. [Thase, Michael E.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Berman, RM (reprint author), Bristol Myers Squibb Co, 5 Res Pkwy, Wallingford, CT 06492 USA. EM Robert.Berman@bms.com NR 31 TC 204 Z9 209 U1 8 U2 19 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0271-0749 J9 J CLIN PSYCHOPHARM JI J. Clin. Psychopharmacol. PD APR PY 2008 VL 28 IS 2 BP 156 EP 165 DI 10.1097/JCP.0b13e318677489 PG 10 WC Pharmacology & Pharmacy; Psychiatry SC Pharmacology & Pharmacy; Psychiatry GA 277JR UT WOS:000254209000005 PM 18344725 ER PT J AU Kennedy, A Wood, AE Saxon, AJ Malte, C Harvey, M Jurik, J Kilzieh, N Lofgreen, C Tapp, A AF Kennedy, Annette Wood, Amanda Ernst Saxon, Andrew J. Malte, Carol Harvey, Megan Jurik, Jennifer Kilzieh, Nael Lofgreen, Cassin Tapp, Andre TI Quetiapine for the treatment of cocaine dependence - An open-label trial SO JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY LA English DT Article; Proceedings Paper CT 2nd International Congress of Biological Psychiatry CY APR 17-21, 2007 CL Santiago, CHILE ID INDUCED WEIGHT-GAIN; RATING-SCALE; RISPERIDONE; OLANZAPINE; RECEPTORS AB The monaminergic properties of second generation antipsychotics are prompting research on their use to treat cocaine dependence, with inconclusive results to date. In preliminary reports, the atypical antipsychotic quetiapine has shown promise for the treatment of substance abuse disorders. The primary objective of the current study was to assess the efficacy of quetiapine in reducing cocaine cravings and use in nonpsychotic subjects with cocaine dependence over 6 weeks of open-label treatment. Twenty-two cocaine-dependent, nonpsychotic men were initiated to open-label treatment with quetiapine (300-600 mg/d). The primary outcome measure was weekly self-report of cocaine cravings as assessed with the Brief Substance Craving Scale. Cocaine use was captured with a self-report Timeline Follow-back calendar, administered every 2 weeks. Side effect monitoring was conducted weekly, and movement disorders were assessed every 2 weeks. Intent-to-treat regression analyses (n = 22) indicated that the Brief Substance Craving Scale total score decreased significantly overtime (P < 0.001). Self-reports also suggested decreased cocaine use. There was no treatment-related increase in movement disorders, and most side effects were mild. However, all subjects did experience sedation, and several subjects dropped out because of it. What is more, weight increased significantly over time (P < 0.001). Open-label quetiapine treatment reduced cravings and improved some aspects of cocaine dependence in nonpsychotic individuals. Additional research is needed to confirm the current findings and to further delineate the role quetiapine may play in the treatment of cocaine use disorders. C1 [Kennedy, Annette; Wood, Amanda Ernst; Harvey, Megan; Jurik, Jennifer; Kilzieh, Nael; Lofgreen, Cassin; Tapp, Andre] Vet Affairs Puget Sound Hlth Care Syst, Amer Lake Div, MIRECC, Tacoma, WA 98493 USA. [Kennedy, Annette; Wood, Amanda Ernst; Harvey, Megan; Jurik, Jennifer; Kilzieh, Nael; Lofgreen, Cassin; Tapp, Andre] Vet Affairs Puget Sound Hlth Care Syst, Amer Lake Div, MIRECC, Seattle, WA USA. [Kennedy, Annette] Seattle Inst Biomed & Clin Res, Seattle, WA USA. [Wood, Amanda Ernst; Saxon, Andrew J.; Kilzieh, Nael; Tapp, Andre] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Saxon, Andrew J.; Malte, Carol] Vet Affairs Puget Sound Hlth Care Syst, CESATE, Tacoma, WA 98493 USA. [Saxon, Andrew J.; Malte, Carol] Vet Affairs Puget Sound Hlth Care Syst, CESATE, Seattle, WA USA. RP Kennedy, A (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Amer Lake Div, MIRECC, 9600 Vet Dr,A-116-R, Tacoma, WA 98493 USA. EM Annette.Kennedy@va.gov NR 23 TC 23 Z9 23 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0271-0749 J9 J CLIN PSYCHOPHARM JI J. Clin. Psychopharmacol. PD APR PY 2008 VL 28 IS 2 BP 221 EP 224 DI 10.1097/JCP.0b013e318166f50d PG 4 WC Pharmacology & Pharmacy; Psychiatry SC Pharmacology & Pharmacy; Psychiatry GA 277JR UT WOS:000254209000015 PM 18344735 ER PT J AU Operskalski, EA Mack, WJ Strickler, HD French, AL Augenbraun, M Tien, PC Villacres, MC Spencer, LY DeGiacomo, M Kovacs, A AF Operskalski, Eva A. Mack, Wendy J. Strickler, Howard D. French, Audrey L. Augenbraun, Michael Tien, Phyllis C. Villacres, Maria C. Spencer, LaShonda Y. DeGiacomo, Marina Kovacs, Andrea TI Factors associated with hepatitis C viremia in a large cohort of HIV-infected and -uninfected women SO JOURNAL OF CLINICAL VIROLOGY LA English DT Article DE hepatitis C; hepatitis C RNA levels; hepatitis C viremia; HIV/hepatitis C virus co-infection ID HUMAN-IMMUNODEFICIENCY-VIRUS; MONONUCLEAR CELL-CULTURES; DRUG-USERS; RNA LEVELS; UNITED-STATES; SMOKING; TRANSMISSION; HEMOPHILIA; SUPPRESSION; PREVALENCE AB Background: Co-infection with hepatitis C virus (HCV) is common among HIV-infected women. Objective: To further our understanding of the risk factors for HCV viremia and the predictors of HCV viral load among women. Study design: We investigated sociodemographic, immunologic, and virologic factors associated with presence and level of HCV viremia among 1049 HCV-seropositive women, 882 of whom were HIV-infected and 167 HIV-uninfected at their entry into the Women's Interagency HIV Study. Results: Plasma HCV RNA was detected in 852 (81%) of these 1049 women (range: 1.2-7.8 log(10) copies/ml). HCV-viremic women were more likely to have an HIV RNA level >100,000copies/ml (P=0.0004), to have reported smoking (P=0.01), or to be Black (P=0.005). They were less likely to have current or resolved hepatitis B infection. HCV RNA levels were higher in women who were >35 years old, or HIV-infected. Current smoking and history of drug use (crack/freebase cocaine, marijuana, amphetamines, or heroin) were each associated with both presence and level of viremia. Conclusions: Substance abuse counseling aimed at eliminating ongoing use of illicit drugs and tobacco may reduce clinical progression, improve response to treatment, and decrease HCV transmission by lowering levels of HCV viremia in women. (C) 2007 Elsevier B.V. All rights reserved. C1 [Operskalski, Eva A.; Villacres, Maria C.; Spencer, LaShonda Y.; DeGiacomo, Marina; Kovacs, Andrea] Univ So Calif, Keck Sch Med, Dept Pediat, Mat Child & Adolescent Ctr Infect Dis & Virol, Los Angeles, CA 90033 USA. [Mack, Wendy J.] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA. [Strickler, Howard D.] Albert Einstein Coll Med, Bronx, NY 10467 USA. [French, Audrey L.] CORE Ctr Stroger Cook Cty Hosp, Rush Med Coll, Chicago, IL USA. [Augenbraun, Michael] SUNY Hlth Sci Ctr, Dept Med, Brooklyn, NY 11203 USA. [Tien, Phyllis C.] Univ Calif San Francisco, Dept Med, San Francisco Vet Affairs Med Ctr, San Francisco, CA USA. RP Operskalski, EA (reprint author), Univ So Calif, Keck Sch Med, Dept Pediat, Mat Child & Adolescent Ctr Infect Dis & Virol, 1640 Marengo St,Suite 300, Los Angeles, CA 90033 USA. EM eva@usc.edu FU NCRR NIH HHS [M01 RR000071, M01 RR000079, M01 RR000083, M01-RR-00079, M01-RR-00083, M01-RR-0071]; NIAID NIH HHS [U01 AI034993-14, K23 AI066943, K23 AI066943-05, R01 AI052065, R01 AI052065-01, R01 AI052065-04, R01 AI057006, R01 AI057006-04, R01-AI0577006, U01 AI031834, U01 AI031834-15, U01 AI034989, U01 AI034993, U01 AI034993-13, U01 AI034994, U01 AI034994-09, U01 AI035004, U01 AI035004-14, U01 AI042590, U01 AI042590-06, U01 AI042590-07, U01-AI-31834, U01-AI-34989, U01-AI-34993, U01-AI-34994, U01-AI-35004, U01-AI-42590]; NICHD NIH HHS [U01 HD032632-14]; NIDDK NIH HHS [U01 DK066116]; OID CDC HHS [U01-CH-32632] NR 45 TC 24 Z9 24 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1386-6532 J9 J CLIN VIROL JI J. Clin. Virol. PD APR PY 2008 VL 41 IS 4 BP 255 EP 263 DI 10.1016/j.jcv.2007.08.021 PG 9 WC Virology SC Virology GA 291PK UT WOS:000255209100002 PM 18243785 ER PT J AU Yee, E Blumstein, SE Sedivy, JC AF Yee, Eiling Blumstein, Sheila E. Sedivy, Julie C. TI Lexical-Semantic Activation in Broca's and Wernicke's Aphasia: Evidence from Eye Movements SO JOURNAL OF COGNITIVE NEUROSCIENCE LA English DT Article; Proceedings Paper CT 42nd Annual Meeting of the Academy-of-Aphasia CY OCT, 2004 CL Chicago, IL SP Acad Aphasia ID SPOKEN-WORD RECOGNITION; LEFT PREFRONTAL CORTEX; AUTOMATIC ACCESS; TIME-COURSE; FUNCTIONAL MRI; RETRIEVAL; ANATOMY; COMPETITION; LANGUAGE; MODEL AB Lexical processing requires both activating stored representations and selecting among active candidates. The current work uses an eye-tracking paradigm to conduct a detailed temporal investigation of lexical processing. Patients with Broca's and Wernicke's aphasia are studied to shed light on the roles of anterior and posterior brain regions in lexical processing as well as the effects of lexical competition on such processing. Experiment 1 investigates whether objects semantically related to an uttered word are preferentially fixated, for example, given the auditory target "hammer," do participants fixate a picture of a nail? Results show that, like normal controls, both groups of patients are more likely to fixate on an object semantically related to the target than an unrelated object. Experiment 2 explores whether Broca's and Wernicke's aphasics show competition effects when words share onsets with the uttered word, for instance, given the auditory target "hammer," do participants fixate a picture of a hammock? Experiment 3 investigates whether these patients activate words semantically related to onset competitors of the uttered word, for example, given the auditory target "hammock," do participants fixate a nail due to partial activation of the onset competitor hammer? Results of Experiments 2 and 3 show pathological patterns of performance for both Broca's and Wernicke's aphasics under conditions of lexical onset competition. However, the patterns of deficit differed, suggesting different functional and computational roles for anterior and posterior areas in lexical processing. Implications of the findings for the functional architecture of the lexical processing system and its potential neural substrates are considered. C1 [Yee, Eiling] Univ Penn, Dept Psychol, Philadelphia, PA 19104 USA. [Sedivy, Julie C.] Brown Univ, Providence, RI 02912 USA. [Blumstein, Sheila E.] Boston Univ, Harold Goodglass Aphasia Res Ctr, VA Boston Healthcare Syst, Boston, MA 02130 USA. [Blumstein, Sheila E.] Dept Vet Affairs Med Ctr, Res Serv, Providence, RI 02908 USA. [Blumstein, Sheila E.] VA Boston Healthcare Syst, Res Serv, Boston, MA 02130 USA. RP Yee, E (reprint author), Univ Penn, Dept Psychol, 3720 Walnut St, Philadelphia, PA 19104 USA. EM eiling@psych.upenn.edu RI Yee, Eiling/F-2161-2010 FU NIA NIH HHS [R01 AG014345]; NIDCD NIH HHS [P30 DC005207, R01 DC000142]; PHS HHS [NIDCD00314, NIDCD0081] NR 58 TC 40 Z9 40 U1 6 U2 15 PU MIT PRESS PI CAMBRIDGE PA 55 HAYWARD STREET, CAMBRIDGE, MA 02142 USA SN 0898-929X J9 J COGNITIVE NEUROSCI JI J. Cogn. Neurosci. PD APR PY 2008 VL 20 IS 4 BP 592 EP 612 DI 10.1162/jocn.2008.20056 PG 21 WC Neurosciences; Psychology, Experimental SC Neurosciences & Neurology; Psychology GA 436BK UT WOS:000265387400004 PM 18052783 ER PT J AU Caplan, D Stanczak, L Waters, G AF Caplan, David Stanczak, Louise Waters, Gloria TI Syntactic and Thematic Constraint Effects on Blood Oxygenation Level Dependent Signal Correlates of Comprehension of Relative Clauses SO JOURNAL OF COGNITIVE NEUROSCIENCE LA English DT Article ID EVENT-RELATED FMRI; SENTENCE COMPREHENSION; WORKING-MEMORY; BROCAS AREA; INDIVIDUAL-DIFFERENCES; ACTIVATION; AMBIGUITY; APHASIA AB The effects of plausibility of thematic role assignment and syntactic structure on blood oxygenation level dependent (BOLD) signal were studied using event-related functional magnetic resonance imaging by orthogonally varying syntactic structure (subject- vs. object-extracted relative clauses) and the plausibility of nouns playing thematic roles (constrained vs. unconstrained sentences) in a plausibility judgment task. In plausible sentences, BOLD signal increased for object-compared to subject-extracted clauses in unconstrained sentences in left middle temporal and left inferior frontal areas, for this contrast in constrained sentences in left middle temporal but not left inferior frontal areas, and for constrained subject-extracted sentences compared to unconstrained subject-extracted sentences in the left inferior frontal gyrus and the left dorsolateral prefrontal cortex. We relate these areas of activation to the assignment of the syntactic structure of object-compared to subject-extracted structures and the process of checking which thematic roles activated in the course of processing a sentence are licensed by the syntactic structure of the sentence. C1 [Caplan, David] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Stanczak, Louise; Waters, Gloria] Boston Univ, Boston, MA 02215 USA. RP Caplan, D (reprint author), Neuropsychol Lab, 175 Cambridge St,Suite 340, Boston, MA 02114 USA. EM dcaplan@partners.org FU NIDCD [DC02146] FX This research was supported by a grant from the NIDCD (DC02146). NR 46 TC 43 Z9 44 U1 3 U2 6 PU MIT PRESS PI CAMBRIDGE PA 55 HAYWARD STREET, CAMBRIDGE, MA 02142 USA SN 0898-929X J9 J COGNITIVE NEUROSCI JI J. Cogn. Neurosci. PD APR PY 2008 VL 20 IS 4 BP 643 EP 656 DI 10.1162/jocn.2008.20044 PG 14 WC Neurosciences; Psychology, Experimental SC Neurosciences & Neurology; Psychology GA 436BK UT WOS:000265387400007 PM 18052788 ER PT J AU Pole, N Ablon, JS O'Connor, LE AF Pole, Nnamdi Ablon, J. Stuart O'Connor, Lynn E. TI Using Psychodynamic, Cognitive Behavioral, and Control Mastery Prototypes to Predict Change: A New Look at an Old Paradigm for Long-Term Single-Case Research SO JOURNAL OF COUNSELING PSYCHOLOGY LA English DT Article DE prototypes; single-case studies; control mastery theory; psychotherapy process research; time series analysis ID COLLABORATIVE RESEARCH-PROGRAM; CONTROLLED CLINICAL-TRIALS; MENTAL-HEALTH-TREATMENT; THERAPIST ADHERENCE; NATIONAL-INSTITUTE; PSYCHOTHERAPY-RESEARCH; DEPRESSION; COMPETENCE; ALLIANCE AB This article illustrates a method of testing models of change in individual long-term psychotherapy cases. A depressed client was treated with 208 sessions of control mastery therapy (CMT), an unmanualized approach that integrates elements of psychodynamic therapy (PDT) and cognitive behavioral therapy (CBT). Panels of experts developed prototypes of ideal PDT, CBT, and CMT process using the Psychotherapy Process Q-set (PQS; J. S. Ablon & E. E. Jones, 1999; E. E. Jones, L. A. Parke, & S. Pulos, 1992; E. E. Jones & S. M. Pulos, 1993). Independent observers rated every 4th session (N = 53) with the PQS. Using correlations between ideal and actual PQS ratings followed by paired t tests, the authors compared adherence to the CMT prototype with adherence to plausible alternative models advocated by the PDT and CBT experts. Bivariate time series analyses determined whether prototype adherence predicted an estimated index of symptom change. Results showed that the therapist's behavior was most consistent with the CMT prototype and that this aspect of the CMT prototype along with particular aspects of the other prototypes influenced estimated symptom change. The results, which replicate and extend earlier findings, support the validity of this approach to studying long-term therapies but also highlight its limitations. C1 [Pole, Nnamdi] Univ Michigan, Dept Psychol, Ann Arbor, MI 48109 USA. [Ablon, J. Stuart] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Ablon, J. Stuart] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [O'Connor, Lynn E.] Univ Calif Berkeley, Dept Psychol, Berkeley, CA 94720 USA. [O'Connor, Lynn E.] Wright Inst, Berkeley, CA USA. RP Pole, N (reprint author), Univ Michigan, Dept Psychol, 530 Church St,2260 E Hall, Ann Arbor, MI 48109 USA. EM npole@email.smith.edu NR 56 TC 11 Z9 12 U1 4 U2 9 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0022-0167 J9 J COUNS PSYCHOL JI J. Couns. Psychol. PD APR PY 2008 VL 55 IS 2 BP 221 EP 232 DI 10.1037/0022-0167.55.2.221 PG 12 WC Psychology, Educational; Psychology, Applied SC Psychology GA 471QR UT WOS:000268073800008 ER PT J AU Dasanayake, AP Chhun, N Tanner, ACR Craig, RG Lee, MJ Moore, AF Norman, RG AF Dasanayake, A. P. Chhun, N. Tanner, A. C. R. Craig, R. G. Lee, M. J. Moore, A. F. Norman, R. G. TI Periodontal pathogens and gestational diabetes mellitus SO JOURNAL OF DENTAL RESEARCH LA English DT Article DE maternal periodontal disease; gestational diabetes mellitus; Tannerella forsythia ID RISK-FACTORS; PREGNANCY OUTCOMES; INSULIN-RESISTANCE; GLUCOSE-TOLERANCE; PREVALENCE; POPULATION; DISEASE; WOMEN; PROTEIN; BIRTH AB In previous cross-sectional or case-control studies, clinical periodontal disease has been associated with gestational diabetes mellitus. To test the hypothesis that, in comparison with women who do not develop gestational diabetes mellitus, those who do develop it will have had a greater exposure to clinical and other periodontal parameters, we measured clinical, bacteriological ( in plaque and cervico-vaginal samples), immunological, and inflammatory mediator parameters 7 weeks before the diagnosis of gestational diabetes mellitus in 265 predominantly Hispanic (83%) women in New York. Twenty-two cases of gestational diabetes mellitus emerged from the cohort (8.3%). When the cases were compared with healthy control individuals, higher pre-pregnancy body mass index ( p = 0.004), vaginal levels of Tannerella forsythia ( p = 0.01), serum C-reactive protein ( p = 0.01), and prior gestational diabetes mellitus ( p = 0.006) emerged as risk factors, even though the clinical periodontal disease failed to reach statistical significance (50% in those with gestational diabetes mellitus vs. 37.3% in the healthy group; p = 0.38). C1 [Dasanayake, A. P.; Chhun, N.; Moore, A. F.; Norman, R. G.] NYU, Coll Dent, Dept Epidemiol & Hlth Promot, New York, NY 10010 USA. [Craig, R. G.] NYU, Coll Dent, Dept Basic Sci & Craniofacial Biol, New York, NY 10010 USA. [Craig, R. G.] NYU, Coll Dent, Dept Periodontol & Implant Surg, New York, NY 10010 USA. [Lee, M. J.] Yale Univ, Sch Med, Dept Obstet Gynecol & Reprod Sci, New Haven, CT USA. [Tanner, A. C. R.] Forsyth Inst, Dept Mol Genet, Boston, MA USA. RP Dasanayake, AP (reprint author), NYU, Coll Dent, Dept Epidemiol & Hlth Promot, 345 E 24th St, New York, NY 10010 USA. EM ad75@nyu.edu FU NIDCR NIH HHS [5R01 DE15594, R01 DE015594, R01 DE015594-01A1] NR 35 TC 25 Z9 26 U1 2 U2 4 PU INT AMER ASSOC DENTAL RESEARCHI A D R/A A D R PI ALEXANDRIA PA 1619 DUKE ST, ALEXANDRIA, VA 22314-3406 USA SN 0022-0345 J9 J DENT RES JI J. Dent. Res. PD APR PY 2008 VL 87 IS 4 BP 328 EP 333 PG 6 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 292ZB UT WOS:000255303500006 PM 18362313 ER PT J AU Akilov, OE Kosaka, S Maytin, EV Hasan, T AF Akilov, Oleg E. Kosaka, Sachiko Maytin, Edward V. Hasan, Tayyaba TI Prospects for the use of differentiation-modulating agents as adjuvant of photodynamic therapy for proliferative dermatoses SO JOURNAL OF DERMATOLOGY LA English DT Article DE differentiation; keratinocyte; photodynamic therapy; protoporphyrin IX ID TOPICAL 5-AMINOLEVULINIC ACID; DELTA-AMINOLEVULINIC-ACID; NONMELANOMA SKIN-CANCER; PROTOPORPHYRIN-IX ACCUMULATION; BASAL-CELL CARCINOMA; CUTANEOUS LEISHMANIASIS; HUMAN KERATINOCYTES; ACTINIC KERATOSES; PSORIATIC PLAQUES; IN-VITRO AB Current interest in photodynamic therapy (PDT) in dermatology stems from its recognized success in dermatological oncology, straightforward approach, easy accessibility and low cost. PDT is a photochemistry-based modality in which a light-activated photosensitizer (PS) destroys tissue through oxygen-dependent and -independent mechanisms. Although PDT has been used in dermatology for several decades, its application has still not extended significantly into the routine management of neoplastic and proliferative dermatoses because of continuing issues with the selectivity of the PS for affected tissues. This review analyzes prospects for optimization of PDT for the management of dermatoses with defects in keratinocyte proliferation/differentiation, and discusses the use of differentiating agents that redirect metabolic utilization within cells and lead to high levels of PS accumulation. C1 [Akilov, Oleg E.; Kosaka, Sachiko; Hasan, Tayyaba] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Wellman Ctr Photomed,Dept Dermatol, Boston, MA 02114 USA. [Maytin, Edward V.] Cleveland Clin, Dept Dermatol, Cleveland, OH 44106 USA. RP Hasan, T (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Wellman Ctr Photomed,Dept Dermatol, 40 Blossom St,BAR 314, Boston, MA 02114 USA. EM thasan@partners.org FU NCI NIH HHS [5P01 CA 084203-05] NR 61 TC 12 Z9 12 U1 0 U2 4 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0385-2407 J9 J DERMATOL JI J. Dermatol. PD APR PY 2008 VL 35 IS 4 BP 197 EP 205 DI 10.1111/j.1346-8138.2008.00445.x PG 9 WC Dermatology SC Dermatology GA 289NH UT WOS:000255060700001 PM 18419676 ER PT J AU Wanner, M Avrarn, M AF Wanner, Molly Avrarn, Mathew TI An evidence-based assessment of treatments for cellulite SO JOURNAL OF DRUGS IN DERMATOLOGY LA English DT Article ID CARBON-DIOXIDE THERAPY; LIPOSUCTION; PHOSPHATIDYLCHOLINE; AMINOPHYLLINE; ULTRASOUND; SUBCISION; SURGERY; TRIAL; SKIN AB Cellulite, a skin surface change that is nearly ubiquitous in women, is a condition that remains elusive to treatment. In fact, no treatment is completely successful as none are more than mildly and temporarily effective. Despite the lack of evidence to support efficacy, treatment options continue to proliferate. This article will briefly review the currently available data about cellulite treatments including noninvasive devices such as massage, radiofrequency, and laser and light, based treatments; invasive modalities including liposuction, mesotherapy, and subcision; and other treatments including topical creams and carboxy therapy. C1 [Wanner, Molly; Avrarn, Mathew] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Dermatol, Boston, MA 02114 USA. RP Wanner, M (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Dermatol, 50 Staniford St,Suite 200, Boston, MA 02114 USA. EM mwanner@partners.org NR 51 TC 33 Z9 34 U1 3 U2 14 PU JOURNAL OF DRUGS IN DERMATOLOGY PI NEW YORK PA 377 PARK AVE SOUTH, 6TH FLOOR, NEW YORK, NY 10016 USA SN 1545-9616 J9 J DRUGS DERMATOL JI J. Drugs Dermatol. PD APR PY 2008 VL 7 IS 4 BP 341 EP 345 PG 5 WC Dermatology SC Dermatology GA 294AH UT WOS:000255376000004 PM 18459514 ER PT J AU Ahdout, J Mandel, H Chiu, M AF Ahdout, Jennifer Mandel, Hilary Chiu, Melvin TI Case reports: Erythroderma in a patient taking acitretin for plaque psoriasis SO JOURNAL OF DRUGS IN DERMATOLOGY LA English DT Article ID MULTICENTER; ETRETINATE AB Acitretin is a second generation retinoid used in the treatment of psoriasis. It has shown particular efficacy in the treatment of pustular or erythrodermic psoriasis. A case of a patient who was being treated for plaque psoriasis with acitretin, who subsequently developed erythrodermic psoriasis is reported. The patient's erythroderma promptly resolved after discontinuing acitretin and initiating treatment with cyclosporine. Acitretin has been reported to induce erythrodermic psoriasis on occasion, but is more frequently reported as a treatment for it. C1 [Ahdout, Jennifer; Chiu, Melvin] Univ Calif Los Angeles, David Geffen Sch Med, Div Dermatol, Los Angeles, CA 90095 USA. [Mandel, Hilary; Chiu, Melvin] Greater Los Angeles Vet Adm Healthcare Syst, Los Angeles, CA USA. RP Chiu, M (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Dermatol, 52-121 Ctr Hlth Sci, Los Angeles, CA 90095 USA. EM mchiu@mednet.ucta.edu NR 7 TC 2 Z9 2 U1 1 U2 1 PU JOURNAL OF DRUGS IN DERMATOLOGY PI NEW YORK PA 377 PARK AVE SOUTH, 6TH FLOOR, NEW YORK, NY 10016 USA SN 1545-9616 J9 J DRUGS DERMATOL JI J. Drugs Dermatol. PD APR PY 2008 VL 7 IS 4 BP 391 EP 394 PG 4 WC Dermatology SC Dermatology GA 294AH UT WOS:000255376000012 PM 18459522 ER PT J AU Edlow, JA Malek, AM Ogilvy, CS AF Edlow, Jonathan A. Malek, Adel M. Ogilvy, Christopher S. TI Aneurysmal subarachnoid hemorrhage: Update for emergency physicians SO JOURNAL OF EMERGENCY MEDICINE LA English DT Review DE subarachnoid hemorrhage; diagnosis; lumbar puncture; cerebral angiography; xanthochromia; stroke ID COMPUTED TOMOGRAPHIC ANGIOGRAPHY; UNRUPTURED INTRACRANIAL ANEURYSMS; DIGITAL-SUBTRACTION-ANGIOGRAPHY; MAGNETIC-RESONANCE ANGIOGRAPHY; TRAUMATIC LUMBAR PUNCTURE; SUB-ARACHNOID HEMORRHAGE; SUDDEN ONSET HEADACHE; CEREBROSPINAL-FLUID; THUNDERCLAP HEADACHE; CEREBRAL VASOSPASM AB Aneurysmal subarachnoid hemorrhage (SAH) is a serious cause of stroke that affects 30,000 patients in North America annually. Due to a wide spectrum of presentations, misdiagnosis of SAH has been reported to occur in a significant proportion of cases. Headache, the most common chief complaint, may be an isolated finding; the neurological examination may be normal and neck stiffness absent. Emergency physicians must decide which patients to evaluate beyond history and physical examination. This evaluation-computed tomography (CT) scanning and lumbar puncture (LP)-is straightforward, but each test has important limitations. CT sensitivity falls with time from onset of symptoms and is lower in mildly affected patients. Traumatic LP must be distinguished from true SAH. Cerebrospinal fluid analysis centers on measuring xanthochromia. Debate exists about the best method to measure it-visual inspection or spectrophotometry. An LP-first strategy is also discussed. If SAH is diagnosed, the priority shifts to specialist consultation and cerebrovascular imaging to define the offending vascular lesion. The sensitivity of CT and magnetic resonance angiography are approaching that of conventional catheter angiography. Emergency physicians must also address various management issues to treat or prevent early complications. Endovascular therapy is being increasingly used, and disposition to neurovascular centers that offer the full range of treatments leads to better patient outcomes. Emergency physicians must be expert in the diagnosis and initial stabilization of patients with SAH. Treatment in a hospital with both neurosurgical and endovascular capability is becoming the norm. (C) 2008 Elsevier Inc. C1 [Edlow, Jonathan A.] Beth Israel Deaconess Med Ctr, Dept Emergency Med, Boston, MA 02215 USA. [Edlow, Jonathan A.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. [Malek, Adel M.] Tufts Univ New England Med Ctr, Dept Cerebrovasc Surg, Boston, MA USA. [Malek, Adel M.] Tufts Sch Med, Dept Surg, Boston, MA USA. [Ogilvy, Christopher S.] Massachusetts Gen Hosp, Dept Cerebrovasc Surg, Boston, MA 02114 USA. [Ogilvy, Christopher S.] Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA. RP Edlow, JA (reprint author), Beth Israel Deaconess Med Ctr, Dept Emergency Med, 1 Deaconess Pl,CC-2, Boston, MA 02215 USA. NR 210 TC 43 Z9 43 U1 1 U2 9 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0736-4679 J9 J EMERG MED JI J. Emerg. Med. PD APR PY 2008 VL 34 IS 3 BP 237 EP 251 DI 10.1016/j.jemermed.2007.10.003 PG 15 WC Emergency Medicine SC Emergency Medicine GA 280LF UT WOS:000254427600002 PM 18155383 ER PT J AU Agrawal, P Nadel, ES Brown, DFM AF Agrawal, Pooja Nadel, Eric S. Brown, David F. M. TI Tricyclic antidepressant overdose SO JOURNAL OF EMERGENCY MEDICINE LA English DT Article ID ST-SEGMENT ELEVATION; BRUGADA ELECTROCARDIOGRAPHIC PATTERN; SUDDEN CARDIAC DEATH; BUNDLE-BRANCH BLOCK; CYCLIC ANTIDEPRESSANTS; INGESTION; DRUGS C1 [Nadel, Eric S.] Brigham & Womens Hosp, Dept Emergency Med, Boston, MA 02115 USA. [Agrawal, Pooja; Nadel, Eric S.; Brown, David F. M.] Harvard Univ, Sch Med, Div Emergency Med, Boston, MA USA. [Nadel, Eric S.; Brown, David F. M.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA. RP Nadel, ES (reprint author), Brigham & Womens Hosp, Dept Emergency Med, 75 Francis St, Boston, MA 02115 USA. NR 17 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0736-4679 J9 J EMERG MED JI J. Emerg. Med. PD APR PY 2008 VL 34 IS 3 BP 321 EP 325 DI 10.1016/j.jemermed.2008.01.001 PG 5 WC Emergency Medicine SC Emergency Medicine GA 280LF UT WOS:000254427600016 PM 18296006 ER PT J AU Hu, JC Silletti, JP Williams, SB AF Hu, Jim C. Silletti, Joseph P. Williams, Stephen B. TI Initial experience with robot-assisted minimally invasive nephroureterectomy SO JOURNAL OF ENDOUROLOGY LA English DT Article ID UPPER URINARY-TRACT; TRANSITIONAL-CELL CARCINOMA; LAPAROSCOPIC RADICAL NEPHRECTOMY; RETROPERITONEOSCOPIC NEPHROURETERECTOMY; OPEN SURGERY; CANCER AB Purpose: Various techniques have been described for laparoscopic nephroureterectomy. We reviewed our initial experience of laparoscopic nephroureterectomy with robot-assisted extravesical excision of the distal ureter and bladder cuff. Materials and Methods: Nine consecutive patients aged 43 to 83 years underwent laparoscopic nephroureterectomy for transitional cell carcinoma (TCC) between August 2005 and March 2007. The first five patients were repositioned after laparoscopic nephrectomy from flank to lithotomy position to dock the robot for excision of the distal ureter and bladder cuff by a single surgeon. In contrast, the last four patients remained in flank position throughout the entire procedure, with the robot docked in flank position following laparoscopic nephrectomy. A two-layer closure re-approximated the cystotomy and a urethral catheter was left in place for a mean of 5 days. Results: Eight men and one woman with a mean age of 64.2 years and mean body mass index (BMI) of 28.4 kg/m(2) underwent flexible cystoscopy and laparoscopic nephroureterectomy for five right-sided and four left-sided tumors. Mean operative time was 303 minutes (range 210-430 minutes), estimated blood loss was 211 mL (range 50-700 mL), and mean length of hospital stay was 2.3 days. Pathologic staging revealed T-3 for five (55.6%), T-a for two (22.2%), carcinoma in situ (CIS) for two (22.2%) patients, and high-grade disease for seven (77.8%) patients. With a mean follow-up of 16.2 months (range 4.3-24.3 months), three patients with a history of bladder cancer have experienced recurrence in the bladder, and one of the three has also developed metastatic disease. Conclusions: Laparoscopic nephroureterectomy with robot-assisted extravesical excision of the distal ureter and bladder cuff appears to be a feasible alternative for patients with TCC of the upper urinary tract. C1 [Hu, Jim C.; Silletti, Joseph P.; Williams, Stephen B.] Harvard Univ, Sch Med, Dana Farber Canc Inst,Lank Ctr Genitourinary Onco, Brigham & Womens Hosp,Div Urol, Boston, MA 02115 USA. RP Hu, JC (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst,Lank Ctr Genitourinary Onco, Brigham & Womens Hosp,Div Urol, 45 Francis St,ASBII 3, Boston, MA 02115 USA. EM jhu2@partners.org NR 17 TC 19 Z9 19 U1 0 U2 0 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0892-7790 J9 J ENDOUROL JI J. Endourol. PD APR PY 2008 VL 22 IS 4 BP 699 EP 704 DI 10.1089/end.2007.0333 PG 6 WC Urology & Nephrology SC Urology & Nephrology GA 292DU UT WOS:000255247500029 PM 18338957 ER PT J AU Watkins, LE Taft, CT Hebenstreit, CL King, LA King, DW AF Watkins, Laura E. Taft, Casey T. Hebenstreit, Claire L. King, Lynda A. King, Daniel W. TI Predictors of child behavior problems among children of female vietnam veterans SO JOURNAL OF FAMILY VIOLENCE LA English DT Article DE relationship abuse; child behavior; female veterans; psychological aggression; physical aggression ID BATTERED WOMEN; INTERPARENTAL VIOLENCE; DOMESTIC VIOLENCE; PARTNER VIOLENCE; FAMILY VIOLENCE; ADJUSTMENT; AGGRESSION; STRESS; ASSOCIATIONS; EXPOSURE AB This study examined the impacts of intimate partner aggression by female Vietnam veterans and their male partners on their children's behavior problems (N=100 children). Veteran and partner psychological distress were also examined as potential mediators of these relationships. Results indicated that physical and psychological aggression perpetration by both the female veteran and the male partner was associated with child behavior problems. Contrary to expectations, psychological distress in the veteran and partner was not associated with child behavior problems and did not mediate the effects of physical and psychological aggression on this outcome. C1 [Watkins, Laura E.; Taft, Casey T.; Hebenstreit, Claire L.; King, Lynda A.; King, Daniel W.] VA Boston Healthcare Syst 116B 2, Natl Ctr PTSD, Boston, MA 02130 USA. [Taft, Casey T.; King, Lynda A.; King, Daniel W.] Boston Univ, Sch Med, Boston, MA 02215 USA. RP Taft, CT (reprint author), VA Boston Healthcare Syst 116B 2, Natl Ctr PTSD, 150 S Huntington Ave, Boston, MA 02130 USA. EM casey.taft@va.gov NR 29 TC 2 Z9 2 U1 1 U2 1 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0885-7482 J9 J FAM VIOLENCE JI J. Fam. Violence PD APR PY 2008 VL 23 IS 3 BP 135 EP 140 DI 10.1007/s10896-007-9135-6 PG 6 WC Psychology, Clinical; Family Studies SC Psychology; Family Studies GA 247UD UT WOS:000252107200001 ER PT J AU Kasuya, H Nomura, N Kanazumi, N Nomoto, S Takeda, S Sugimoto, H Shikano, T Tanabe, KK Nakao, A AF Kasuya, H. Nomura, N. Kanazumi, N. Nomoto, S. Takeda, S. Sugimoto, H. Shikano, T. Tanabe, K. K. Nakao, A. TI What is the next of oncolytic virus clinical trial SO JOURNAL OF GENE MEDICINE LA English DT Meeting Abstract CT 13th Annual Meeting of the Japan-Society-of-Gene-Therapy CY JUN 28-30, 2007 CL Nagoya, JAPAN SP Japan Soc Gene Therapy C1 [Kasuya, H.; Nomura, N.; Kanazumi, N.; Nomoto, S.; Takeda, S.; Sugimoto, H.; Shikano, T.; Nakao, A.] Nagoya Univ, Grad Sch Med, Dept Surg 2, Nagoya, Aichi 4648601, Japan. [Tanabe, K. K.] Massachusetts Gen Hosp, Div Surg Oncol, Boston, MA 02114 USA. [Tanabe, K. K.] Harvard Univ, Sch Med, Boston, MA 02115 USA. RI Kasuya, hideki/I-7278-2014 NR 0 TC 0 Z9 0 U1 1 U2 2 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND SN 1099-498X J9 J GENE MED JI J. Gene. Med. PD APR PY 2008 VL 10 IS 4 BP 446 EP 447 PG 2 WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine, Research & Experimental SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research & Experimental Medicine GA 290SG UT WOS:000255141900051 ER PT J AU Fukuhara, H Tsurumaki, Y Kitamura, T Martuza, RL Ino, Y Todo, T AF Fukuhara, Hiroshi Tsurumaki, Yuzuri Kitamura, Tadaichi Martuza, Robert L. Ino, Yasushi Todo, Tomoki TI Evaluation of oncolytic herpes simplex viruses expressing different types of IL-12 in mouse prostate cancer and neuroblastoma models SO JOURNAL OF GENE MEDICINE LA English DT Meeting Abstract CT 13th Annual Meeting of the Japan-Society-of-Gene-Therapy CY JUN 28-30, 2007 CL Nagoya, JAPAN SP Japan Soc Gene Therapy C1 [Fukuhara, Hiroshi; Tsurumaki, Yuzuri; Kitamura, Tadaichi] Univ Tokyo, Dept Dermatol, Bunkyo Ku, Tokyo 1138655, Japan. [Ino, Yasushi; Todo, Tomoki] Univ Tokyo, Dept Neurosurg, Bunkyo Ku, Tokyo 1138655, Japan. [Martuza, Robert L.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Mol Neurosurg Lab, Boston, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND SN 1099-498X J9 J GENE MED JI J. Gene. Med. PD APR PY 2008 VL 10 IS 4 BP 470 EP 470 PG 1 WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine, Research & Experimental SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research & Experimental Medicine GA 290SG UT WOS:000255141900104 ER PT J AU Fischer, MA Vogeli, C Stedman, MR Ferris, TG Weissman, JS AF Fischer, Michael A. Vogeli, Christine Stedman, Margaret R. Ferris, Timothy G. Weissman, Joel S. TI Uptake of electronic prescribing in community-based practices SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE health information technology; electronic prescribing; technology uptake ID PHYSICIAN ORDER ENTRY; SYSTEMS; INTERVENTION; MEDICATIONS; EXPERIENCES; TECHNOLOGY; PREVENTION; AGENTS; IMPACT; TIME AB BACKGROUND: Electronic prescribing (e-prescribing) has the potential to improve the safety and efficiency of medication use, but uptake of e-prescribing in community-based settings has been limited to date. In April 2004, 2 large insurers in Massachusetts began a program to fund e-prescribing systems for targeted clinicians and practices. We studied the adoption and uptake of e-prescribing by the targeted prescribers. METHODS: We obtained data on all e-prescriptions written from April 2004 to March 2005. We tabulated the number of clinicians using the e-prescribing system and the number of prescriptions written. We also obtained claims data from the 2 insurance companies and calculated the proportion of each clinician's prescriptions that were written electronically. We developed multivariable models to estimate the impact of different clinician characteristics on the proportional rate of e-prescribing. RESULTS: During the first 12 months of the e-prescribing program, 1,217 prescribers began using the e-prescribing system. In the final month of the study, over 55,000 e-prescriptions were written for patients covered by the 2 included insurance plans. The proportion of total reimbursed claims per clinician written electronically increased slowly during the study period and was still below 30% by the end of the study period. This number increased to 42% when we restricted the sample to medications normally used for acute indications. Multivariable models showed that younger clinicians, pediatricians, and prescribers in larger practices exhibited higher uptake rates as a proportion of total prescriptions. CONCLUSIONS: Clinician use of e-prescribing increased steadily in the first 12 months of an initiative sponsoring e-prescribing systems. Uptake of e-prescribing was only partial, with younger clinicians and pediatricians more likely to use the system. Research to understand why prescribers vary in their use of e-prescribing and to develop techniques to encourage more wide-spread adoption will be an important priority for future studies. C1 [Fischer, Michael A.; Stedman, Margaret R.] Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02120 USA. [Vogeli, Christine; Ferris, Timothy G.; Weissman, Joel S.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Inst Hlth Policy, Boston, MA 02115 USA. RP Fischer, MA (reprint author), Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, 1620 Tremont St,Suite 3030, Boston, MA 02120 USA. EM mfischer@partners.org OI Stedman, Margaret/0000-0001-9271-8332 FU AHRQ HHS [R01 HS015175, R01 HS15175] NR 21 TC 21 Z9 21 U1 1 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2008 VL 23 IS 4 BP 358 EP 363 DI 10.1007/s11606-007-0383-1 PG 6 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 280WD UT WOS:000254456400003 PM 18373130 ER PT J AU Fung, CH Tsai, JS Lulejian, A Glassman, P Patterson, E Doebbeling, BN Asch, SM AF Fung, Constance H. Tsai, Jerry S. Lulejian, Armine Glassman, Peter Patterson, Emily Doebbeling, Brad N. Asch, Steven M. TI An evaluation of the veterans health administration's clinical reminders system: A national survey of generalists SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE decision support systems clinical; primary health care; quality of health care; evidence-based medicine; medical records systems computerized ID PREVENTIVE CARE; OF-CARE; COMPUTER; COMPLETION; MANAGEMENT; PHYSICIANS; BARRIERS; QUALITY; TRIAL AB BACKGROUND: The Veterans Health Administration (VHA) is a leader in developing computerized clinical reminders (CCRs). Primary care physicians' (PCPs) evaluation of VHA CCRs could influence their future development and use within and outside the VHA. OBJECTIVE: Survey PCPs about usefulness and usability of VHA CCRs. DESIGN AND PARTICIPANTS: In a national survey, VHA PCPs rated on a 7-point scale usefulness and usability of VHA CCRs, and standardized scales (0-100) were constructed. A hierarchical linear mixed (HLM) model predicted physician- and facility-level variables associated with more positive global assessment of CCRs. RESULTS: Four hundred sixty-one PCPs participated (response rate, 69%). Scale Cronbach's alpha ranged from 0.62 to 0.82. Perceptions of VHA CCRs were primarily in the midrange, where higher ratings indicate more favorable attitudes (weighted standardized median, IQR): global assessment (50, 28-61), clinical/situational specificity (29, 17-42), integration with workflow/workload (39, 17-50), training (50, 33-67), VHA's management of CCR use (67, 50-83), design/interface (53, 40-67), perceived role in CCR use (67, 50-83), and self-efficacy (67, 57-78). In a HLM model, design/interface (p <.001), self-efficacy (p <.001), integration with workflow/workload (p <.001), and training (p <.001) were associated with more favorable global assessments of CCRs. Facilities in the west as compared to the south (p=.033), and physicians with academic affiliation (p=.045) had less favorable global assessment of CCRs. CONCLUSIONS: Our systematic assessment of end-users' perceptions of VHA CCRs suggests that CCRs need to be developed and implemented with a continual focus on improvement based on end-user feedback. Potential target areas include better integration into the primary care clinic workflow/workload. C1 [Fung, Constance H.; Tsai, Jerry S.; Lulejian, Armine; Glassman, Peter; Asch, Steven M.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Fung, Constance H.; Glassman, Peter; Asch, Steven M.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Patterson, Emily] VA Getting Patient Safety GAPS Ctr, Cincinnati, OH USA. [Patterson, Emily] Ohio State Univ, Columbus, OH 43210 USA. [Doebbeling, Brad N.] Richard L Roudebush Vet Affairs Med Ctr, VA Ctr Excellence Implementing Evidence Based Pra, Indianapolis, IN 46202 USA. [Doebbeling, Brad N.] Indiana Univ, Ctr Hlth Serv & Outcomes Res, Indianapolis, IN 46204 USA. [Doebbeling, Brad N.] Indiana Univ, Sch Med, Dept Med, Indianapolis, IN 46204 USA. RP Fung, CH (reprint author), 10880 Wilshire Blvd,Suite 300, Los Angeles, CA 90024 USA. EM cfung@stanfordalumni.org RI Patterson, Emily/B-4398-2011 OI Patterson, Emily/0000-0002-4514-2075 NR 29 TC 23 Z9 23 U1 1 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2008 VL 23 IS 4 BP 392 EP 398 DI 10.1007/s11606-007-0417-8 PG 7 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 280WD UT WOS:000254456400008 PM 18373135 ER PT J AU Leveille, SG Huang, A Tsai, SB Weingart, SN Iezzoni, LI AF Leveille, Suzanne G. Huang, Annong Tsai, Stephanie B. Weingart, Saul N. Iezzoni, Lisa I. TI Screening for chronic conditions using a patient internet portal: Recruitment for an internet-based primary care intervention SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE internet; ambulatory care; pain; screening; mobility ID HEALTH SURVEY; VALIDITY; RELIABILITY; PAIN AB BACKGROUND: Patient Internet portals have created new opportunities for assessment and management of chronic conditions. OBJECTIVE: To conduct an online screening survey for a study recruitment using a secure patient Internet portal to identify primary care patients with untreated depression, chronic pain, or mobility difficulty before nonurgent office visits. DESIGN: Internet-based screening survey for a randomized trial. PARTICIPANTS: Patients who were registered portal users who had scheduled primary care appointments. APPROACH: Electronic study invitations via the portal were sent to 4,047 patients with scheduled visits to 34 primary care physicians participating in the study. After clicking on a link in the study invitation, patients were consecutively shown the study description, consent form, and lastly, the screening survey to determine final eligibility for study participation. RESULTS: Of the 2,113 (52%) patients who opened the study invitation, 1,001 consented online to join the study and 981 (98%) of these completed the screening survey. Of the respondents, 319 (33%) screened positive for 1 or more of the 3 conditions. CONCLUSIONS: The online screening survey conducted through the patient portal was effective in identifying patients with chronic conditions in advance of scheduled primary care visits for participation in an intervention study. C1 [Leveille, Suzanne G.; Huang, Annong; Tsai, Stephanie B.; Iezzoni, Lisa I.] Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, Brookline, MA 02446 USA. [Leveille, Suzanne G.; Weingart, Saul N.; Iezzoni, Lisa I.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA. [Weingart, Saul N.] Dana Farber Canc Inst, Ctr Patient Safety, Boston, MA 02115 USA. [Iezzoni, Lisa I.] Massachusetts Gen Hosp, Inst Hlth Policy, Boston, MA 02114 USA. RP Leveille, SG (reprint author), Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, 1309 Beacon St CO-219, Brookline, MA 02446 USA. EM sleveill@bidmc.harvard.edu NR 13 TC 11 Z9 11 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2008 VL 23 IS 4 BP 472 EP 475 DI 10.1007/s11606-007-0443-6 PG 4 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 280WD UT WOS:000254456400020 PM 18373147 ER PT J AU Lin, HX Fen, Y Wong, G Wang, LP Li, B Zhao, XS Li, Y Smaill, F Zhang, CS AF Lin, Han-Xin Fen, Yan Wong, Gillian Wang, Liping Li, Bei Zhao, Xuesen Li, Yan Smaill, Fiona Zhang, Chengsheng TI Identification of residues in the receptor-binding domain (RBD) of the spike protein of human coronavirus NL63 that are critical for the RBD-ACE2 receptor interaction SO JOURNAL OF GENERAL VIROLOGY LA English DT Article ID ACUTE RESPIRATORY SYNDROME; ANGIOTENSIN-CONVERTING ENZYME-2; FELINE AMINOPEPTIDASE N; SARS-CORONAVIRUS; TRACT INFECTIONS; AMINO-ACIDS; CHILDREN; VIRUS; NEUTRALIZATION; DETERMINANTS AB Human coronavirus NL63 (NL63), a member of the group I coronaviruses, may cause acute respiratory diseases in young children and immunocompromised adults. Like severe acute respiratory syndrome coronavirus (SARS-CoV), NL63 also employs the human angiotensin-converting enzyme 2 (hACE2) receptor for cellular entry. To identify residues in the spike protein of NL63 that are important for hACE2 binding, this study first generated a series of S1-truncated variants, examined their associations with the hACE2 receptor and subsequently mapped a minimal receptor-binding domain (RBD) that consisted of 141 residues (aa 476-616) towards the C terminus of the S1 domain. The data also demonstrated that the NL63 RBD bound to hACE2 more efficiently than its full-length counterpart and had a binding efficiency comparable to the S1 or RBD of SARS-CoV. A further series of RBD variants was generated using site-directed mutagenesis and random mutant library screening assays, and identified 15 residues (C497, Y498, V499, C500, K501, R518, R530, V531, G534, G537, D538, S540, E582, W585 and T591) that appeared to be critical for the RBD-hACE2 association. These critical residues clustered in three separate regions (designated RI, RII and RIII) inside the RBD, which may represent three receptor-binding sites. These results may help to delineate the molecular interactions between the S protein of NL63 and the hACE2 receptor, and may also enhance our understanding of the pathogenesis of NL63 and SARS-CoV. C1 [Lin, Han-Xin; Fen, Yan; Wong, Gillian; Li, Bei; Zhao, Xuesen; Smaill, Fiona; Zhang, Chengsheng] McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON L8N 4A6, Canada. [Lin, Han-Xin; Fen, Yan; Wong, Gillian; Li, Bei; Zhao, Xuesen; Smaill, Fiona; Zhang, Chengsheng] St Josephs Hlthcare, Dept Microbiol, Hamilton, ON L8N 4A6, Canada. [Wang, Liping] Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA. [Li, Yan] Canadian Sci Ctr Human & Anim Hlth, Natl Microbiol Lab, Winnipeg, MB R3E 3R2, Canada. RP Zhang, CS (reprint author), McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON L8N 4A6, Canada. EM zhangch@mcmaster.ca NR 41 TC 18 Z9 18 U1 0 U2 1 PU SOC GENERAL MICROBIOLOGY PI READING PA MARLBOROUGH HOUSE, BASINGSTOKE RD, SPENCERS WOODS, READING RG7 1AG, BERKS, ENGLAND SN 0022-1317 J9 J GEN VIROL JI J. Gen. Virol. PD APR PY 2008 VL 89 BP 1015 EP 1024 DI 10.1099/vir.0.83331-0 PN 4 PG 10 WC Biotechnology & Applied Microbiology; Virology SC Biotechnology & Applied Microbiology; Virology GA 287BI UT WOS:000254890900021 PM 18343844 ER PT J AU Ring, D Lozano-Calderon, S Shin, R Bastian, P Mudgal, C Jupiter, J AF Ring, David Lozano-Calderon, Santiago Shin, Robert Bastian, Peter Mudgal, Chaitanya Jupiter, Jesse TI A prospective randomized controlled trial of injection of dexamethasone versus triamcinolone for idiopathic trigger finger SO JOURNAL OF HAND SURGERY-AMERICAN VOLUME LA English DT Article DE clinical trial; corticosteroid injection; trigger finger; dexamethasone; triamcinolone ID LOCAL STEROID INJECTION; STENOSING TENOVAGINITIS; FLEXOR TENOSYNOVITIS; HEALTH-STATUS; THUMB; MANAGEMENT; EFFICACY; RELEASE; PAIN; ARM AB Purpose This study was designed to test the null hypothesis that there is no difference in resolution of triggering 3 months after injection with either a soluble (dexamethasone) or insoluble (triamcinolone) corticosteroid for idiopathic trigger finger. Methods Fighty-four patients were enrolled in a prospective randomized controlled trial comparing dexamethasone and triamcinolone injection for idiopathic trigger finger. Sixty-seven patients completed the 6-week follow-up (35 triamcinolone arm, 32 dexamethasone arm), and 72 patients completed the 3-month follow-up (41 triamcinolone arm, 31 dexamethasone arm). Outcome measures included the Disabilities of the Arm, Shoulder, and Hand (DASH) questionnaire, trigger finger grading according to Quinnell, and satisfaction on a visual analog scale. To preserve autonomy, patients were permitted additional injections and operative treatment at any time. Twenty-five patients requested a second injection (10 triamcinolone arm, 15 dexamethasone arm), and 21 elected operative treatment (10 triamcinolone arm, 11 dexamethasone arm) during the study period, The analysis was according to intention to treat principles, Results Six weeks after injection, absence of triggering was documented in 22 of 35 patients in the triamcinolone cohort and in 12 of 32 patients in the dexamethasone cohort. The rates 3 months after injection were 27 of 41 in the triamcinolone cohort and 22 of 31 in the dexamethasone cohort. The triamcinolone cohort had significantly better satisfaction and Quinnell grades than did the dexamethasone cohort at the 6-week follow-up but not at the 3-month follow-up. There were no significant differences between Disabilities of the Arm, Shoulder, and Hand scores at the 6-week follow-up and the 3-month follow-up. After the close of the study, there were 8 recurrences among patients with documented absence of triggering in the triamcinolone cohort and I in the dexamethasone cohort. Conclusions Although there were no differences 3 months after injection, our data suggest that triamcinolone may have a more rapid but ultimately less durable effect on idiopathic trigger finger than does dexamethasone. (J Hand Surg 2008;33A:516-522. Copyright (c) 2008 by the American Society for Surgery of the Hand.) Type of study/level of evidence Therapeutic I. C1 Harvard Univ, Sch Med, Boston, MA USA. Massachusetts Gen Hosp, Dept Orthopaed Surg, Hand & Upper Extrem Serv, Boston, MA 02114 USA. RP Ring, D (reprint author), Massachusetts Gen Hosp, Orthopaed Hand & Upper Extrem Serv, Yawkey Ctr Suite 2100,55 Fruit St, Boston, MA 02114 USA. EM dring@partners.org NR 24 TC 24 Z9 25 U1 1 U2 3 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0363-5023 J9 J HAND SURG-AM JI J. Hand Surg.-Am. Vol. PD APR PY 2008 VL 33A IS 4 BP 516 EP 522 DI 10.1016/j.jhsa.2008.01.001 PG 7 WC Orthopedics; Surgery SC Orthopedics; Surgery GA 293ZN UT WOS:000255374000007 PM 18406955 ER PT J AU Lozano-Calderon, S Anthony, S Ring, D AF Lozano-Calderon, Santiago Anthony, Shawn Ring, David TI The quality and strength of evidence for etiology: Example of carpal tunnel syndrome SO JOURNAL OF HAND SURGERY-AMERICAN VOLUME LA English DT Review DE Bradford Hill criteria; carpal tunnel syndrome; etiology; genetic factors; environmental factors ID LUNG-CANCER RISK; BODY-MASS INDEX; UPPER-LIMB DISORDERS; HAND-ARM VIBRATION; ENVIRONMENTAL TOBACCO-SMOKE; MEDIAN NERVE; SENSORY CONDUCTION; GENERAL-POPULATION; MUSCULOSKELETAL DISORDERS; INDUSTRIAL-WORKERS AB Purpose The purpose of this investigation was to evaluate the quality and strength of scientific evidence supporting an etiologic relationship between a disease and a proposed risk factor using a scoring system based on the Bradford Hill criteria for causal association. Methods A quantitative score based on the Bradford Hill criteria (qBHs) was used to evaluate 117 articles presenting original data regarding the etiology of carpal tunnel syndrome: 33 (28%) that evaluated biological (structural or genetic) risk factors, 51 (44%) that evaluated occupational (environment or activity-related) risk factors, and 33 (28%) that evaluated both types of risk factors. Results The quantitative Bradford Hill scores of 2 independent observers showed very good agreement, supporting the reliability of the instrument. The average qBHs was 12.2 points (moderate association) among biological risk factors compared with 5.2 points (poor association) for occupational risk factors. The highest average qBHs was observed for genetic factors (14.2), race (11.7), and anthropometric measures of the wrist (11.3 points) with all studies finding a moderate causal association. The highest average qBHs among occupational risk factors was observed for activities requiring repetitive hand use (6.5 points among the 30 of 45 articles that reported a causal association), substantial exposure to vibration (6.3 points; 14 of 20 articles), and type of occupation (5.6 points, 38 of 53 articles), with the findings being much less consistent. Conclusions According to a quantitative analysis of published scientific evidence, the etiology of carpal tunnel syndrome is largely structural, genetic, and biological, with environmental and occupational factors such as repetitive hand use playing a minor and more debatable role. Speculative causal theories should be analyzed through a rigorous approach prior to wide adoption. (J HandSurg 2008;33A:525-538. Copyright (c) 2008 by the American Society for Surgery of the Hand.) Type of study/level of evidence Diagnostic III. C1 [Lozano-Calderon, Santiago; Anthony, Shawn; Ring, David] Massachusetts Gen Hosp, Yawkey Ctr, Dept Orthopaed Surg, Hand & Upper Extrem Serv, Boston, MA 02114 USA. RP Ring, D (reprint author), Massachusetts Gen Hosp, Yawkey Ctr, Dept Orthopaed Surg, Hand & Upper Extrem Serv, Suite 2100,55 Fruit St, Boston, MA 02114 USA. EM dring@partners.org NR 141 TC 31 Z9 34 U1 0 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0363-5023 J9 J HAND SURG-AM JI J. Hand Surg.-Am. Vol. PD APR PY 2008 VL 33A IS 4 BP 525 EP 538 DI 10.1016/j.jhsa.2008.01.004 PG 14 WC Orthopedics; Surgery SC Orthopedics; Surgery GA 293ZN UT WOS:000255374000009 PM 18406957 ER PT J AU Valledor, AF Sanchez-Tillo, E Arpa, L Park, JM Caelles, C Lloberas, J Celada, A AF Valledor, Annabel F. Sanchez-Tillo, Ester Arpa, Luis Park, Jin Mo Caelles, Carme Lloberas, Jorge Celada, Antonio TI Selective roles of MAPKs during the macrophage response to IFN-gamma SO JOURNAL OF IMMUNOLOGY LA English DT Article ID PROTEIN-KINASE PHOSPHATASE-1; INTERFERON-GAMMA; SERINE PHOSPHORYLATION; GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVATION; TARGETED DISRUPTION; SIGNAL-TRANSDUCTION; STAT1; PATHWAY; PROLIFERATION AB Macrophages perform essential functions in the infection and resolution of inflammation. IFN-gamma is the main endogenous macrophage Th1 type activator. The classical IFN-gamma signaling pathway involves activation of Stat-1. However, IFN-gamma has also the capability to activate members of the MAPK family. In primary bone marrow-derived macrophages, we have observed strong activation of p38 at early time points of IFN-gamma stimulation, whereas weak activation of ERK-1/2 and JNK-1 was detected at a more delayed stage. In parallel, IFN-gamma exerted repressive effects on the expression of a number of MAPK phosphatases. By using selective inhibitors and knockout models, we have explored the contributions of MAPK activation to the macrophage response to IFN-gamma. Our findings indicate that these kinases regulate IFN-gamma-mediated gene expression in a rather selective way: p38 participates mainly in the regulation of the expression of genes required for the innate immune response, including chemokines such as CCLS, CXCL9, and CXCL10; cytokines such as TNF-alpha; and inducible NO synthase, whereas JNK-1 acts on genes involved in Ag presentation, including CIITA and genes encoding MHC class II molecules. Modest effects were observed for ERK-1/2 in these studies. Interestingly, some of the MAPK-dependent changes in gene expression observed in these studies are based on posttranscriptional regulation of mRNA stability. C1 [Sanchez-Tillo, Ester; Arpa, Luis; Lloberas, Jorge; Celada, Antonio] Inst Biomed Res, Macrophage Biol Grp, Barcelona 08028, Spain. [Valledor, Annabel F.] Inst Biomed Res, Sch Biol, Dept Physiol, Nucl Receptors Grp, Barcelona 08028, Spain. [Caelles, Carme] Inst Biomed Res, Cell Signaling Grp, Barcelona 08028, Spain. [Caelles, Carme] Univ Barcelona, Barcelona, Spain. [Park, Jin Mo] Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA. [Park, Jin Mo] Harvard Univ, Sch Med, Charlestown, MA 02129 USA. RP Valledor, AF (reprint author), Inst Biomed Res, Macrophage Biol Grp, Josep Samitier 1-5, Barcelona 08028, Spain. EM acelada@ub.edu RI Lloberas, Jorge/D-4303-2014 OI Lloberas, Jorge/0000-0001-7075-4201 NR 39 TC 51 Z9 51 U1 1 U2 2 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD APR 1 PY 2008 VL 180 IS 7 BP 4523 EP 4529 PG 7 WC Immunology SC Immunology GA 324GT UT WOS:000257506700023 PM 18354174 ER PT J AU Schnickel, GT Bastani, S Hsieh, GR Shefizadeh, A Bhatia, R Fishbein, MC Belperio, J Ardehali, A AF Schnickel, Gabriel T. Bastani, Sam Hsieh, George R. Shefizadeh, Ali Bhatia, Rubina Fishbein, Michael C. Belperio, John Ardehali, Abbas TI Combined CXCR3/CCR5 blockade attenuates acute and chronic rejection SO JOURNAL OF IMMUNOLOGY LA English DT Article ID ACUTE ALLOGRAFT-REJECTION; REGULATORY T-CELLS; HUMAN CARDIAC ALLOGRAFTS; CHEMOKINE RECEPTOR; IFN-GAMMA; IN-VIVO; CCR5; MICE; PATHOGENESIS; TOLERANCE AB Chemokine-chemokine receptor interactions orchestrate mononuclear cells recruitment to the allograft, leading to acute and chronic rejection. Despite biologic redundancy, several experimental studies have demonstrated the importance of CXCR3 and CCR5 in acute rejection of allografts. In these studies, deficiency or blockade of CXCR3 or CCR5 led to prolongation of allograft survival, yet allografts were ultimately lost to acute rejection. Given the above findings and the specificity of mononuclear cells bearing CXCR3 and CCR5, we hypothesized that combined blockade of CXCR3 and CCR5 will lead to indefinite (>100 days) graft survival in a full MHC-mismatched murine cardiac allograft model. The donor hearts in the control group were rejected in 6 +/- 1 days after transplantation. Combined blockade of CXCR3 and CCR5 prolonged allograft survival >15-fold vs the control group; all allografts survived for >100 days. More importantly, the donor hearts did not display any intimal lesions characteristic of chronic rejection. Further analysis of the donor hearts in the CXCR3/CCR5 blockade group demonstrated graft infiltration with CD4(+)CD25(+) T cells expressing the Foxp3 gene. Depletion of CD25(+) cells in the combined CXCR3 and CCR5 blockade group resulted in acute rejection of the allografts in 22 +/- 2 days. Combined CXCR3 and CCR5 blockade also reduced alloantigen-specific T lymphocyte proliferation. Combined CXCR3 and CCR5 blockade is effective in preventing acute and chronic rejection in a robust murine model. This effect is mediated, in part, by CD25(+) regulatory T cell recruitment and control of T lymphocyte proliferation. C1 [Fishbein, Michael C.] Univ Calif Los Angeles, David Geffen Sch Med, Lab Med, Los Angeles, CA 90095 USA. [Belperio, John] Univ Calif Los Angeles, Div Cardiothorac Surg, Med Ctr, Div Pulm & Crit Care Med,David Geffen Sch Med, Los Angeles, CA 90095 USA. [Schnickel, Gabriel T.; Bastani, Sam; Hsieh, George R.; Shefizadeh, Ali; Bhatia, Rubina; Ardehali, Abbas] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA. [Fishbein, Michael C.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol, Los Angeles, CA 90095 USA. [Schnickel, Gabriel T.; Bastani, Sam; Hsieh, George R.; Ardehali, Abbas] W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. RP Ardehali, A (reprint author), Univ Calif Los Angeles, Div Cardiothorac Surg, Med Ctr, Div Pulm & Crit Care Med,David Geffen Sch Med, 62-182 CHS,10833 Le Conte Ave, Los Angeles, CA 90095 USA. EM aardehali@mednet.ucla.edu OI Schnickel, Gabriel/0000-0003-4392-2200 NR 33 TC 41 Z9 45 U1 1 U2 2 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD APR 1 PY 2008 VL 180 IS 7 BP 4714 EP 4721 PG 8 WC Immunology SC Immunology GA 324GT UT WOS:000257506700044 PM 18354195 ER PT J AU Day, CL Mkhwanazi, N Reddy, S Mncube, Z van der Stok, M Klenerman, P Walker, BD AF Day, Cheryl L. Mkhwanazi, Nompumelelo Reddy, Sharon Mncube, Zenele van der Stok, Mary Klenerman, Paul Walker, Bruce D. TI Detection of polyfunctional Mycobacterium tuberculosis-specific T cells and association with viral load in HIV-1-infected persons SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article; Proceedings Paper CT 3rd South African AIDS Conference CY JUN, 2007 CL Durban, SOUTH AFRICA ID IMMUNODEFICIENCY-VIRUS-INFECTION; INTERFERON-GAMMA; IFN-GAMMA; LATENT TUBERCULOSIS; HIV-1 INFECTION; ESAT-6 ANTIGEN; HUMAN CD4(+); RESPONSES; MEMORY; INDIVIDUALS AB Background. The human immunodeficiency virus type 1 ( HIV-1) epidemic is associated with a significant increase in the incidence of tuberculosis ( TB); however, little is known about the quality of Mycobacterium tuberculosis ( MTB)-specific cellular immune responses in coinfected individuals. Methods. A total of 137 HIV-1-positive individuals in Durban, South Africa, were screened with the use of overlapping peptides spanning Ag85A, culture filtrate protein 10 ( CFP-10), early secretory antigen target 6 ( ESAT-6), and TB10.4, in an interferon ( IFN)-gamma enzyme-linked immunospot ( ELISPOT) assay. Intracellular cytokine staining for MTB-specific production of IFN-gamma, tumor necrosis factor ( TNF)-alpha, and interleukin ( IL)-2 was performed, as was ex vivo phenotyping of memory markers on MTB-specific T cells. Results. A total of 41% of subjects responded to ESAT-6 and/or CFP-10, indicating the presence of latent MTB infection. The proportion of MTB-specific IFN-gamma(+)/TNF-alpha(+) CD4(+) cells was significantly higher than the proportion of IFN-gamma(+)/IL-2(+) CD4(+) cells ( P = .0220), and the proportion of MTB- specific IL-2-secreting CD4 cells was inversely correlated with the HIV-1 load ( P = .0098). MTB- specific CD8 T cells were predominately IFN-gamma(+)/TNF-alpha(+)/IL-2(-). Ex vivo memory phenotyping of MTB- specific CD4 and CD8 T cells indicated an early to intermediate differentiated phenotype for the population of effector memory cells. Conclusions. Polyfunctional MTB- specific CD4 and CD8 T cell responses are maintained in the peripheral blood of HIV-1-positive individuals, in the absence of active disease, and the functional capacity of these responses is affected by HIV-1 disease status. C1 [Day, Cheryl L.; Mkhwanazi, Nompumelelo; Reddy, Sharon; Mncube, Zenele; van der Stok, Mary; Walker, Bruce D.] Univ KwaZulu Natal, HIV Pathogenesis Programme, Doris Duke Med Res Inst, Durban, South Africa. [Klenerman, Paul] Univ Oxford, Nuffield Dept Med, Oxford, England. [Day, Cheryl L.; Walker, Bruce D.] Harvard Univ, Sch Med, Div AIDS, Boston, MA USA. [Day, Cheryl L.; Walker, Bruce D.] Massachusetts Gen Hosp, Partners AIDS Res Ctr, Boston, MA 02114 USA. [Walker, Bruce D.] Howard Hughes Med Inst, Chevy Chase, MD USA. RP Day, CL (reprint author), Univ Cape Town, Inst Infect Dis & Mol Med, S1-02 Wernher & Beit Bldg,Anzio Rd,Observ 7925, ZA-7925 Cape Town, South Africa. EM cheryl.day@uct.ac.za RI Day, Cheryl/J-9844-2012 FU NIAID NIH HHS [R01 AI067073] NR 49 TC 79 Z9 79 U1 0 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD APR 1 PY 2008 VL 197 IS 7 BP 990 EP 999 DI 10.1086/529048 PG 10 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 277YB UT WOS:000254249500010 PM 18419535 ER PT J AU Cannon, CP AF Cannon, C. P. TI Combination therapy in the management of mixed dyslipidaemia SO JOURNAL OF INTERNAL MEDICINE LA English DT Review DE combination therapy; dyslipidaemia; fenofibrate; niacin; statin ID CORONARY-HEART-DISEASE; HIGH-DENSITY-LIPOPROTEIN; EXTENDED-RELEASE NIACIN; SIGNIFICANT PHARMACOKINETIC INTERACTION; FAMILIAL COMBINED HYPERLIPIDEMIA; POLYUNSATURATED FATTY-ACIDS; FISH-OIL SUPPLEMENTATION; CARDIOVASCULAR-DISEASE; PLASMA-CONCENTRATIONS; SECONDARY PREVENTION AB Whilst statin monotherapy is often sufficient to reach LDL-C goals, treatment may not reach all lipid goals in individuals with mixed dyslipidaemia typically associated with metabolic syndrome or type 2 diabetes. Double or triple combination therapy, which provides the opportunity to address multiple lipid abnormalities simultaneously, may be required to achieve targets in some patients. Addition of fenofibrate or niacin (nicotinic acid) to statin therapy is likely to be the first option, as recommended by national treatment guidelines; omega-3 fatty acids may also be useful. Careful monitoring is required when adding additional agents given the increased potential for drug interactions and side effects. C1 [Cannon, C. P.] TIMI Study Grp, Boston, MA 02115 USA. [Cannon, C. P.] Harvard Univ, Sch Med, Boston, MA USA. [Cannon, C. P.] Brigham & Womens Hosp, Div Cardiovasc, TIMI Study Grp, Boston, MA USA. RP Cannon, CP (reprint author), TIMI Study Grp, 350 Longwood Ave,1st Floor, Boston, MA 02115 USA. EM cpcannon@partners.org NR 87 TC 14 Z9 14 U1 0 U2 3 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0954-6820 J9 J INTERN MED JI J. Intern. Med. PD APR PY 2008 VL 263 IS 4 BP 353 EP 365 DI 10.1111/j.1365-2796.2008.01933.x PG 13 WC Medicine, General & Internal SC General & Internal Medicine GA 270ZY UT WOS:000253759900003 PM 18324928 ER PT J AU Akilov, OE Jin, Y Zhou, Z Wu, MX Hasan, T AF Akilov, O. E. Jin, Y. Zhou, Z. Wu, M. X. Hasan, T. TI The lysate of allogenic apoptotic non-infected macrophages diminishes Leishmania major burden by involvement of Foxp3-positive regulatory T-cells SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT International Investigative Dermatology Meeting CY MAY 14-17, 2008 CL Kyoto, JAPAN SP Japanese Soc Investigat Dermatol, Soc Investigat Dermatol, European Soc Dermatol Res, Federat Pharmaceut Manufactures Assoc Japan, Galderma, Janssen Pharmaceut KK, Maruho Co Ltd, Sanofi Aventis KK, Torii Pharmaceut Co Ltd, Abbott Japan Co Ltd, CERIES, Chanel, Clin Labs KK, Dainippon Sumitomo Pharma, Eisai Co Ltd, GlaxoSmithKline KK, Kyowa Hakko Kogyo Co Ltd, Mistubishi Tanabe Pharma Corp, Nippon Boehringer Ingelheim, Novartis Pharma KK, Schering Plough, Shionogi & Co Ltd, Shiseido Co Ltd, Japan Cosmet Ind Assoc, Igaku Shoin, Pierre Fabre Japan Co Ltd C1 [Akilov, O. E.; Jin, Y.; Zhou, Z.; Wu, M. X.; Hasan, T.] Harvard Univ, Sch Med, Boston, MA USA. [Akilov, O. E.; Jin, Y.; Zhou, Z.; Wu, M. X.; Hasan, T.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 2008 VL 128 SU 1 MA 1124 BP S188 EP S188 PG 1 WC Dermatology SC Dermatology GA 279KJ UT WOS:000254353801121 ER PT J AU Armstrong, AW Watson, A Kazanis, M Frangos, J Brown, J Munkacsy, T McClure, D Rosa, D Kimball, AB Kvedar, J AF Armstrong, A. W. Watson, A. Kazanis, M. Frangos, J. Brown, J. Munkacsy, T. McClure, D. Rosa, D. Kimball, A. B. Kvedar, J. TI A randomized, controlled trial evaluating adherence to topical medications using electronic monitoring and text-message reminders SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT International Investigative Dermatology Meeting CY MAY 14-17, 2008 CL Kyoto, JAPAN SP Japanese Soc Investigat Dermatol, Soc Investigat Dermatol, European Soc Dermatol Res, Federat Pharmaceut Manufactures Assoc Japan, Galderma, Janssen Pharmaceut KK, Maruho Co Ltd, Sanofi Aventis KK, Torii Pharmaceut Co Ltd, Abbott Japan Co Ltd, CERIES, Chanel, Clin Labs KK, Dainippon Sumitomo Pharma, Eisai Co Ltd, GlaxoSmithKline KK, Kyowa Hakko Kogyo Co Ltd, Mistubishi Tanabe Pharma Corp, Nippon Boehringer Ingelheim, Novartis Pharma KK, Schering Plough, Shionogi & Co Ltd, Shiseido Co Ltd, Japan Cosmet Ind Assoc, Igaku Shoin, Pierre Fabre Japan Co Ltd C1 [Armstrong, A. W.; Kazanis, M.; Frangos, J.; Rosa, D.; Kimball, A. B.; Kvedar, J.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA. [Watson, A.; Brown, J.; Munkacsy, T.; McClure, D.; Kvedar, J.] Massachusetts Gen Hosp, Ctr Connected Hlth, Boston, MA 02114 USA. [Rosa, D.] Clin Technol Advisors, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 2008 VL 128 SU 1 BP S80 EP S80 PG 1 WC Dermatology SC Dermatology GA 279KJ UT WOS:000254353800476 ER PT J AU Freeman, SR Greene, RE Kimball, AB Freiman, A Barzilai, DA Muller, S Duke, JK Dellavalle, RP AF Freeman, S. R. Greene, R. E. Kimball, A. B. Freiman, A. Barzilai, D. A. Muller, S. Duke, J. K. Dellavalle, R. P. TI US dermatology resident training satisfaction is positively associated with mentoring: Survey results from a national conference in 2005 and 2006 SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT International Investigative Dermatology Meeting CY MAY 14-17, 2008 CL Kyoto, JAPAN SP Japanese Soc Investigat Dermatol, Soc Investigat Dermatol, European Soc Dermatol Res, Federat Pharmaceut Manufactures Assoc Japan, Galderma, Janssen Pharmaceut KK, Maruho Co Ltd, Sanofi Aventis KK, Torii Pharmaceut Co Ltd, Abbott Japan Co Ltd, CERIES, Chanel, Clin Labs KK, Dainippon Sumitomo Pharma, Eisai Co Ltd, GlaxoSmithKline KK, Kyowa Hakko Kogyo Co Ltd, Mistubishi Tanabe Pharma Corp, Nippon Boehringer Ingelheim, Novartis Pharma KK, Schering Plough, Shionogi & Co Ltd, Shiseido Co Ltd, Japan Cosmet Ind Assoc, Igaku Shoin, Pierre Fabre Japan Co Ltd C1 [Freeman, S. R.; Greene, R. E.; Duke, J. K.; Dellavalle, R. P.] Univ Colorado, Sch Med, Denver, CO USA. [Dellavalle, R. P.] VA Med Ctr, Denver, CO USA. [Kimball, A. B.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Kimball, A. B.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Freiman, A.] Univ Toronto, Toronto, ON, Canada. [Barzilai, D. A.] Brown Univ, Providence, RI 02912 USA. [Muller, S.] Univ Nevada, Las Vegas, NV 89154 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 2008 VL 128 SU 1 BP S86 EP S86 PG 1 WC Dermatology SC Dermatology GA 279KJ UT WOS:000254353800507 ER PT J AU Hong, X Yang, G Shipla, S Zhou, A Qin, J Denning, M Nickoloff, B Cui, R AF Hong, X. Yang, G. Shipla, S. Zhou, A. Qin, J. Denning, M. Nickoloff, B. Cui, R. TI Inhibition of PAX3 by TGF-beta modulates melanocytes viability SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT International Investigative Dermatology Meeting CY MAY 14-17, 2008 CL Kyoto, JAPAN SP Japanese Soc Investigat Dermatol, Soc Investigat Dermatol, European Soc Dermatol Res, Federat Pharmaceut Manufactures Assoc Japan, Galderma, Janssen Pharmaceut KK, Maruho Co Ltd, Sanofi Aventis KK, Torii Pharmaceut Co Ltd, Abbott Japan Co Ltd, CERIES, Chanel, Clin Labs KK, Dainippon Sumitomo Pharma, Eisai Co Ltd, GlaxoSmithKline KK, Kyowa Hakko Kogyo Co Ltd, Mistubishi Tanabe Pharma Corp, Nippon Boehringer Ingelheim, Novartis Pharma KK, Schering Plough, Shionogi & Co Ltd, Shiseido Co Ltd, Japan Cosmet Ind Assoc, Igaku Shoin, Pierre Fabre Japan Co Ltd C1 [Hong, X.; Qin, J.; Denning, M.; Nickoloff, B.; Cui, R.] Loyola Univ Chicago, Maywood, IL USA. [Yang, G.; Shipla, S.; Zhou, A.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 2008 VL 128 SU 1 MA 1353 BP S226 EP S226 PG 1 WC Dermatology SC Dermatology GA 279KJ UT WOS:000254353801347 ER PT J AU Jensen, J Howe, W Vance, K Dunnick, CA Dellavalle, RP AF Jensen, J. Howe, W. Vance, K. Dunnick, C. A. Dellavalle, R. P. TI Dermatology patient information on Gargle: An appraisal of the top three most highly ranked websites addressing each of the top ten most common dermatologic conditions SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT International Investigative Dermatology Meeting CY MAY 14-17, 2008 CL Kyoto, JAPAN SP Japanese Soc Investigat Dermatol, Soc Investigat Dermatol, European Soc Dermatol Res, Federat Pharmaceut Manufactures Assoc Japan, Galderma, Janssen Pharmaceut KK, Maruho Co Ltd, Sanofi Aventis KK, Torii Pharmaceut Co Ltd, Abbott Japan Co Ltd, CERIES, Chanel, Clin Labs KK, Dainippon Sumitomo Pharma, Eisai Co Ltd, GlaxoSmithKline KK, Kyowa Hakko Kogyo Co Ltd, Mistubishi Tanabe Pharma Corp, Nippon Boehringer Ingelheim, Novartis Pharma KK, Schering Plough, Shionogi & Co Ltd, Shiseido Co Ltd, Japan Cosmet Ind Assoc, Igaku Shoin, Pierre Fabre Japan Co Ltd C1 [Jensen, J.; Howe, W.; Vance, K.; Dunnick, C. A.; Dellavalle, R. P.] Univ Colorado, Denver, CO 80202 USA. [Dellavalle, R. P.] Denver Vet Affairs Med Ctr, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 2008 VL 128 SU 1 BP S87 EP S87 PG 1 WC Dermatology SC Dermatology GA 279KJ UT WOS:000254353800517 ER PT J AU Kunstield, R Hawighorst, T Streit, M Hong, YK Nguyen, L Brown, LF Detmar, M AF Kunstield, R. Hawighorst, T. Streit, M. Hong, Y. K. Nguyen, L. Brown, L. F. Detmar, M. TI Thrombospondin-2 overexpression in the skin of transgenic mice reduces the susceptibility to chemically-induced multistep carcinogenesis SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT International Investigative Dermatology Meeting CY MAY 14-17, 2008 CL Kyoto, JAPAN SP Japanese Soc Investigat Dermatol, Soc Investigat Dermatol, European Soc Dermatol Res, Federat Pharmaceut Manufactures Assoc Japan, Galderma, Janssen Pharmaceut KK, Maruho Co Ltd, Sanofi Aventis KK, Torii Pharmaceut Co Ltd, Abbott Japan Co Ltd, CERIES, Chanel, Clin Labs KK, Dainippon Sumitomo Pharma, Eisai Co Ltd, GlaxoSmithKline KK, Kyowa Hakko Kogyo Co Ltd, Mistubishi Tanabe Pharma Corp, Nippon Boehringer Ingelheim, Novartis Pharma KK, Schering Plough, Shionogi & Co Ltd, Shiseido Co Ltd, Japan Cosmet Ind Assoc, Igaku Shoin, Pierre Fabre Japan Co Ltd C1 [Kunstield, R.; Hawighorst, T.; Streit, M.; Hong, Y. K.; Nguyen, L.; Brown, L. F.; Detmar, M.] Harvard Univ, Sch Med, Charlestown, MA USA. [Kunstield, R.; Hawighorst, T.; Streit, M.; Hong, Y. K.; Nguyen, L.; Detmar, M.] Massachusetts Gen Hosp, Dept Dermatol, Charlestown, MA USA. [Kunstield, R.; Hawighorst, T.; Streit, M.; Hong, Y. K.; Nguyen, L.; Detmar, M.] Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA USA. [Brown, L. F.] Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA. [Kunstield, R.; Hawighorst, T.] Univ Gottingen, Dept Obstet & Gynaecol, D-3400 Gottingen, Germany. [Detmar, M.] Swiss Fed Inst Technol, Inst Pharmaceut Sci, Zurich, Switzerland. [Kunstield, R.] Med Univ Vienna, Dept Dermatol, Div Gen Dermatol, Vienna, Austria. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 2008 VL 128 SU 1 BP S34 EP S34 PG 1 WC Dermatology SC Dermatology GA 279KJ UT WOS:000254353800200 ER PT J AU Liu, Y Sakamaki, T Moyal, D Kollias, N AF Liu, Y. Sakamaki, T. Moyal, D. Kollias, N. TI Spectroscopic characterization of dynamics of pigment reactions of human skin to UVA radiation SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT International Investigative Dermatology Meeting CY MAY 14-17, 2008 CL Kyoto, JAPAN SP Japanese Soc Investigat Dermatol, Soc Investigat Dermatol, European Soc Dermatol Res, Federat Pharmaceut Manufactures Assoc Japan, Galderma, Janssen Pharmaceut KK, Maruho Co Ltd, Sanofi Aventis KK, Torii Pharmaceut Co Ltd, Abbott Japan Co Ltd, CERIES, Chanel, Clin Labs KK, Dainippon Sumitomo Pharma, Eisai Co Ltd, GlaxoSmithKline KK, Kyowa Hakko Kogyo Co Ltd, Mistubishi Tanabe Pharma Corp, Nippon Boehringer Ingelheim, Novartis Pharma KK, Schering Plough, Shionogi & Co Ltd, Shiseido Co Ltd, Japan Cosmet Ind Assoc, Igaku Shoin, Pierre Fabre Japan Co Ltd C1 [Liu, Y.; Sakamaki, T.; Kollias, N.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. [Moyal, D.] Oreal Rech, Clichy, France. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 2008 VL 128 SU 1 MA 1260 BP S210 EP S210 PG 1 WC Dermatology SC Dermatology GA 279KJ UT WOS:000254353801255 ER PT J AU Mullegger, RR Jones, KL Means, TK Lee, M Glickstein, LJ Damle, N Sikand, VK Luster, AD Steere, AC AF Muellegger, R. R. Jones, K. L. Means, T. K. Lee, M. Glickstein, L. J. Damle, N. Sikand, V. K. Luster, A. D. Steere, A. C. TI Higher mRNA levels of chemokines and cytokines associated with macrophage activation in erythema migrans skin lesions in patients from the United States than in patients from Austria with Lyme borreliosis SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT International Investigative Dermatology Meeting CY MAY 14-17, 2008 CL Kyoto, JAPAN SP Japanese Soc Investigat Dermatol, Soc Investigat Dermatol, European Soc Dermatol Res, Federat Pharmaceut Manufactures Assoc Japan, Galderma, Janssen Pharmaceut KK, Maruho Co Ltd, Sanofi Aventis KK, Torii Pharmaceut Co Ltd, Abbott Japan Co Ltd, CERIES, Chanel, Clin Labs KK, Dainippon Sumitomo Pharma, Eisai Co Ltd, GlaxoSmithKline KK, Kyowa Hakko Kogyo Co Ltd, Mistubishi Tanabe Pharma Corp, Nippon Boehringer Ingelheim, Novartis Pharma KK, Schering Plough, Shionogi & Co Ltd, Shiseido Co Ltd, Japan Cosmet Ind Assoc, Igaku Shoin, Pierre Fabre Japan Co Ltd C1 [Muellegger, R. R.] Med Univ Graz, Dept Dermatol, Graz, Austria. [Jones, K. L.; Means, T. K.; Lee, M.; Glickstein, L. J.; Damle, N.; Sikand, V. K.; Luster, A. D.; Steere, A. C.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Rheumatol Allergy & Immunol,Ctr Immunol & Inf, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 2008 VL 128 SU 1 MA 1166 BP S195 EP S195 PG 1 WC Dermatology SC Dermatology GA 279KJ UT WOS:000254353801163 ER PT J AU Osawa, M Moriyama, M Durham, A Radtke, F Nishikawa, S AF Osawa, M. Moriyama, M. Durham, A. Radtke, F. Nishikawa, S. TI Multiple roles of Notch signaling in the regulation of epidermal development SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT International Investigative Dermatology Meeting CY MAY 14-17, 2008 CL Kyoto, JAPAN SP Japanese Soc Investigat Dermatol, Soc Investigat Dermatol, European Soc Dermatol Res, Federat Pharmaceut Manufactures Assoc Japan, Galderma, Janssen Pharmaceut KK, Maruho Co Ltd, Sanofi Aventis KK, Torii Pharmaceut Co Ltd, Abbott Japan Co Ltd, CERIES, Chanel, Clin Labs KK, Dainippon Sumitomo Pharma, Eisai Co Ltd, GlaxoSmithKline KK, Kyowa Hakko Kogyo Co Ltd, Mistubishi Tanabe Pharma Corp, Nippon Boehringer Ingelheim, Novartis Pharma KK, Schering Plough, Shionogi & Co Ltd, Shiseido Co Ltd, Japan Cosmet Ind Assoc, Igaku Shoin, Pierre Fabre Japan Co Ltd C1 [Osawa, M.; Moriyama, M.] Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA USA. [Durham, A.; Radtke, F.] Ecole Polytech Fed Lausanne, Swiss Inst Expt Canc Res, Epalinges, Switzerland. [Nishikawa, S.] RIKEN, Ctr Dev Biol, Lab Stem Cell Biol, Kobe, Hyogo, Japan. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 2008 VL 128 SU 1 MA 895 BP S150 EP S150 PG 1 WC Dermatology SC Dermatology GA 279KJ UT WOS:000254353800890 ER PT J AU Purschke, M Laulbach, HJ Manstein, D AF Purschke, M. Laulbach, H. J. Manstein, D. TI Thermal bystander effect: Medium-mediated induction of DNA double strand breaks and apoplosis after thermal stress via intercellular communication SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT International Investigative Dermatology Meeting CY MAY 14-17, 2008 CL Kyoto, JAPAN SP Japanese Soc Investigat Dermatol, Soc Investigat Dermatol, European Soc Dermatol Res, Federat Pharmaceut Manufactures Assoc Japan, Galderma, Janssen Pharmaceut KK, Maruho Co Ltd, Sanofi Aventis KK, Torii Pharmaceut Co Ltd, Abbott Japan Co Ltd, CERIES, Chanel, Clin Labs KK, Dainippon Sumitomo Pharma, Eisai Co Ltd, GlaxoSmithKline KK, Kyowa Hakko Kogyo Co Ltd, Mistubishi Tanabe Pharma Corp, Nippon Boehringer Ingelheim, Novartis Pharma KK, Schering Plough, Shionogi & Co Ltd, Shiseido Co Ltd, Japan Cosmet Ind Assoc, Igaku Shoin, Pierre Fabre Japan Co Ltd C1 [Purschke, M.; Laulbach, H. J.; Manstein, D.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 2008 VL 128 SU 1 MA 231 BP S39 EP S39 PG 1 WC Dermatology SC Dermatology GA 279KJ UT WOS:000254353800230 ER PT J AU Schatton, T Murphy, GF Yamaura, K Waaga-Gasser, A Gasser, M Zhan, Q Jordan, S Duncan, IM Weishaupt, C Fuhlbrigge, RC Kupper, TS Sayegh, MH Frank, MH AF Schatton, T. Murphy, G. F. Yamaura, K. Waaga-Gasser, A. Gasser, M. Zhan, Q. Jordan, S. Duncan, I. M. Weishaupt, C. Fuhlbrigge, R. C. Kupper, T. S. Sayegh, M. H. Frank, M. H. TI Identification of cells initiating human melanomas SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT International Investigative Dermatology Meeting CY MAY 14-17, 2008 CL Kyoto, JAPAN SP Japanese Soc Investigat Dermatol, Soc Investigat Dermatol, European Soc Dermatol Res, Federat Pharmaceut Manufactures Assoc Japan, Galderma, Janssen Pharmaceut KK, Maruho Co Ltd, Sanofi Aventis KK, Torii Pharmaceut Co Ltd, Abbott Japan Co Ltd, CERIES, Chanel, Clin Labs KK, Dainippon Sumitomo Pharma, Eisai Co Ltd, GlaxoSmithKline KK, Kyowa Hakko Kogyo Co Ltd, Mistubishi Tanabe Pharma Corp, Nippon Boehringer Ingelheim, Novartis Pharma KK, Schering Plough, Shionogi & Co Ltd, Shiseido Co Ltd, Japan Cosmet Ind Assoc, Igaku Shoin, Pierre Fabre Japan Co Ltd C1 [Schatton, T.; Yamaura, K.; Waaga-Gasser, A.; Duncan, I. M.; Sayegh, M. H.; Frank, M. H.] Childrens Hosp, Boston, MA 02115 USA. [Murphy, G. F.; Yamaura, K.; Zhan, Q.; Weishaupt, C.; Fuhlbrigge, R. C.; Kupper, T. S.; Sayegh, M. H.; Frank, M. H.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Waaga-Gasser, A.; Gasser, M.] Univ Wurzburg, Wurzburg, Germany. [Duncan, I. M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 1 U2 7 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 2008 VL 128 SU 1 MA 1278 BP S213 EP S213 PG 1 WC Dermatology SC Dermatology GA 279KJ UT WOS:000254353801273 ER PT J AU Sepehr, A Cummins, J Kroshinsky, D AF Sepehr, A. Cummins, J. Kroshinsky, D. TI Acute febrile neutrophilic dermatosis mimicking necrotizing fasciitis SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT International Investigative Dermatology Meeting CY MAY 14-17, 2008 CL Kyoto, JAPAN SP Japanese Soc Investigat Dermatol, Soc Investigat Dermatol, European Soc Dermatol Res, Federat Pharmaceut Manufactures Assoc Japan, Galderma, Janssen Pharmaceut KK, Maruho Co Ltd, Sanofi Aventis KK, Torii Pharmaceut Co Ltd, Abbott Japan Co Ltd, CERIES, Chanel, Clin Labs KK, Dainippon Sumitomo Pharma, Eisai Co Ltd, GlaxoSmithKline KK, Kyowa Hakko Kogyo Co Ltd, Mistubishi Tanabe Pharma Corp, Nippon Boehringer Ingelheim, Novartis Pharma KK, Schering Plough, Shionogi & Co Ltd, Shiseido Co Ltd, Japan Cosmet Ind Assoc, Igaku Shoin, Pierre Fabre Japan Co Ltd C1 [Sepehr, A.; Cummins, J.; Kroshinsky, D.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 2008 VL 128 SU 1 MA 467 BP S78 EP S78 PG 1 WC Dermatology SC Dermatology GA 279KJ UT WOS:000254353800461 ER PT J AU Turner, RB Neel, VA Mandinova, A AF Turner, R. B. Neel, V. A. Mandinova, A. TI A phenolic antioxidant protects primary human keratinocytes against ultraviolet B-induced DNA damage SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT International Investigative Dermatology Meeting CY MAY 14-17, 2008 CL Kyoto, JAPAN SP Japanese Soc Investigat Dermatol, Soc Investigat Dermatol, European Soc Dermatol Res, Federat Pharmaceut Manufactures Assoc Japan, Galderma, Janssen Pharmaceut KK, Maruho Co Ltd, Sanofi Aventis KK, Torii Pharmaceut Co Ltd, Abbott Japan Co Ltd, CERIES, Chanel, Clin Labs KK, Dainippon Sumitomo Pharma, Eisai Co Ltd, GlaxoSmithKline KK, Kyowa Hakko Kogyo Co Ltd, Mistubishi Tanabe Pharma Corp, Nippon Boehringer Ingelheim, Novartis Pharma KK, Schering Plough, Shionogi & Co Ltd, Shiseido Co Ltd, Japan Cosmet Ind Assoc, Igaku Shoin, Pierre Fabre Japan Co Ltd C1 [Turner, R. B.; Neel, V. A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Neel, V. A.; Mandinova, A.] Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 2008 VL 128 SU 1 MA 1229 BP S205 EP S205 PG 1 WC Dermatology SC Dermatology GA 279KJ UT WOS:000254353801222 ER PT J AU Wertheimer, E Sirota, I Mizrahi, S Takeda, J Kahn, CR Shapira, R Hammel, I Weingarten, G AF Wertheimer, E. Sirota, I. Mizrahi, S. Takeda, J. Kahn, C. R. Shapira, R. Hammel, I. Weingarten, G. TI The skin specific insulin receptor knockout (SIRKO) mouse: A new outlook on diabetes complications and skin cancer SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT International Investigative Dermatology Meeting CY MAY 14-17, 2008 CL Kyoto, JAPAN SP Japanese Soc Investigat Dermatol, Soc Investigat Dermatol, European Soc Dermatol Res, Federat Pharmaceut Manufactures Assoc Japan, Galderma, Janssen Pharmaceut KK, Maruho Co Ltd, Sanofi Aventis KK, Torii Pharmaceut Co Ltd, Abbott Japan Co Ltd, CERIES, Chanel, Clin Labs KK, Dainippon Sumitomo Pharma, Eisai Co Ltd, GlaxoSmithKline KK, Kyowa Hakko Kogyo Co Ltd, Mistubishi Tanabe Pharma Corp, Nippon Boehringer Ingelheim, Novartis Pharma KK, Schering Plough, Shionogi & Co Ltd, Shiseido Co Ltd, Japan Cosmet Ind Assoc, Igaku Shoin, Pierre Fabre Japan Co Ltd C1 [Wertheimer, E.; Sirota, I.; Mizrahi, S.; Hammel, I.; Weingarten, G.] Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel. [Takeda, J.] Osaka Univ, Osaka, Japan. [Kahn, C. R.] Joslin Diabet Ctr, Boston, MA 02215 USA. [Shapira, R.] Shaarey Tzedek Hosp, Jerusalem, Israel. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 2008 VL 128 SU 1 MA 844 BP S141 EP S141 PG 1 WC Dermatology SC Dermatology GA 279KJ UT WOS:000254353800841 ER PT J AU Yu, CS Biesman, BS Shek, S Yeung, CK Ho, S Tse, RK Chan, H AF Yu, C. S. Biesman, B. S. Shek, S. Yeung, C. K. Ho, S. Tse, R. K. Chan, H. H. TI Asian eyelid rejuvenation using monopolar radiofrequency and botulinum toxin chemoden-ervation SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT International Investigative Dermatology Meeting CY MAY 14-17, 2008 CL Kyoto, JAPAN SP Japanese Soc Investigat Dermatol, Soc Investigat Dermatol, European Soc Dermatol Res, Federat Pharmaceut Manufactures Assoc Japan, Galderma, Janssen Pharmaceut KK, Maruho Co Ltd, Sanofi Aventis KK, Torii Pharmaceut Co Ltd, Abbott Japan Co Ltd, CERIES, Chanel, Clin Labs KK, Dainippon Sumitomo Pharma, Eisai Co Ltd, GlaxoSmithKline KK, Kyowa Hakko Kogyo Co Ltd, Mistubishi Tanabe Pharma Corp, Nippon Boehringer Ingelheim, Novartis Pharma KK, Schering Plough, Shionogi & Co Ltd, Shiseido Co Ltd, Japan Cosmet Ind Assoc, Igaku Shoin, Pierre Fabre Japan Co Ltd C1 [Yu, C. S.; Shek, S.; Yeung, C. K.; Ho, S.; Chan, H. H.] Univ Hong Kong, Div Dermatol, Hong Kong, Hong Kong, Peoples R China. [Yu, C. S.; Tse, R. K.] Caritas Med Ctr, Dept Ophthalmol, Hong Kong, Hong Kong, Peoples R China. [Biesman, B. S.] Vanderbilt Univ, Med Ctr, Dept Ophthalmol, Nashville, TN USA. [Chan, H. H.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 2008 VL 128 SU 1 MA 345 BP S58 EP S58 PG 1 WC Dermatology SC Dermatology GA 279KJ UT WOS:000254353800343 ER PT J AU Kimball, AB AF Kimball, Alexa B. TI Skin differences, needs, and disorders across global populations SO JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS LA English DT Article; Proceedings Paper CT State of the Art Workshop on Climate Change and Ontarios Parks CY FEB 25-27, 2004 CL Dorset, CANADA ID PHOTOPROTECTED HUMAN SKIN; ULTRAVIOLET-RADIATION; ETHNIC VARIATION; MELANIN CONTENT; RACE; CANCER; COLOR; RISK; PIGMENTATION; ASSESSMENTS AB Accurately determining the incidence and prevalence of dermatologic disease in most large populations has been challenging for reasons ranging from the lack of easily quantifiable tests and measures to imprecision around definitions of race, ethnicity, photo skin type, pigmentation, and population groups. Compounding the problems with these categorizations is the fact that skin disease and skin health are affected not just by inherent risk factors but also by habits and environment. Thus, a fundamental question remains as we evaluate the effects of cultural and environmental factors: do genetic factors account for most of the difference that we see in skin types? Is the primary influence the way the skin mediates the environmental insult of UV radiation or how inflammation is handled? Is melanization the primary characteristic that we should measure and consider? This article will provide an introduction to current knowledge and future directions researchers are taking in differentiating both the biological differences of skin and the clinical manifestations of skin disease among the groups described above. This discussion will be followed by a brief overview of cultural practices and environmental factors that are known to have significant impact on skin disease and a summary of the most common conditions that are encountered worldwide. C1 [Kimball, Alexa B.] Harvard Univ, CURTIS, Massachusetts Gen Hosp, Boston, MA 02114 USA. [Kimball, Alexa B.] Harvard Univ, CURTIS, Brigham & Womens Hosp, Boston, MA 02114 USA. RP Kimball, AB (reprint author), Harvard Univ, CURTIS, Massachusetts Gen Hosp, 50 Staniford St,246, Boston, MA 02114 USA. EM akimball@partners.org NR 50 TC 4 Z9 4 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 1087-0024 J9 J INVEST DERM SYMP P JI J. Invest. Dermatol. Symp. Proc. PD APR PY 2008 VL 13 IS 1 BP 2 EP 5 DI 10.1038/jidsymp.2008.5 PG 4 WC Dermatology SC Dermatology GA 282CO UT WOS:000254545400002 PM 18369331 ER PT J AU Cooley, J McDonald, B Accurso, FJ Crouch, EC Remold-O'Donnell, E AF Cooley, Jessica McDonald, Barbara Accurso, Frank J. Crouch, Erika C. Remold-O'Donnell, Eileen TI Patterns of neutrophil serine protease-dependent cleavage of surfactant protein D in inflammatory lung disease SO JOURNAL OF LEUKOCYTE BIOLOGY LA English DT Article DE cystic fibrosis; calcium ion; elastase; proteinase-3 ID CYSTIC-FIBROSIS SPUTUM; PSEUDOMONAS-AERUGINOSA; PULMONARY SURFACTANT; BINDING PROTEIN; HOST-DEFENSE; SP-A; ELASTASE; COLLECTIN; PROTEOLYSIS; INHIBITOR AB The manuscript presents definitive studies of surfactant protein D (SP-D) in the context of inflammatory lung fluids. The extent of SP-D depletion in bronchoalveolar lavage fluid (BALF) of children affected with cystic fibrosis (CF) is demonstrated to correlate best with the presence of the active neutrophil serine protease (NSP) elastase. Novel C-terminal SP-D fragments of 27 kDa and 11 kDa were identified in patient lavage fluid in addition to the previously described N-terminal, 35-kDa fragment by the use of isoelectrofocusing, modified blotting conditions, and region-specific antibodies. SP-D cleavage sites were identified. In vitro treatment of recombinant human SP-D dodecamers with NSPs replicated the fragmentation, but unexpectedly, the pattern of SP-D fragments generated by NSPs was dependent on calcium concentration. Whereas the 35- and 11-kDa fragments were generated when incubations were performed in low calcium (200 mu M CaCl(2)), incubations in physiological calcium (2 mM) with higher amounts of elastase or proteinase-3 generated C-terminal 27, 21, and 14 kDa fragments, representing cleavage within the collagen and neck regions. Studies in which recombinant SP-D cleavage by individual NSPs was quantitatively evaluated under low and high calcium conditions showed that the most potent NSP for cleaving SP-D is elastase, followed by proteinase-3, followed by cathepsin G. These relative potency findings were considered in the context of other studies that showed that active NSPs in CF BALF are in the order: elastase, followed by cathepsin G, followed by proteinase-3. The findings support a pre-eminent role for neutrophil elastase as the critical protease responsible for SP-D depletion in inflammatory lung disease. C1 [Cooley, Jessica; Remold-O'Donnell, Eileen] Harvard Univ, Sch Med, Immune Dis Inst, Boston, MA 02115 USA. [Remold-O'Donnell, Eileen] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA. [McDonald, Barbara; Crouch, Erika C.] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO USA. [Accurso, Frank J.] Univ Colorado, Sch Med, Dept Pediat, Denver, CO USA. [Accurso, Frank J.] Childrens Hosp, Denver, CO 80218 USA. RP Remold-O'Donnell, E (reprint author), Harvard Univ, Sch Med, Immune Dis Inst, 800 Huntington Ave, Boston, MA 02115 USA. EM remold@cbr.med.harvard.edu FU NHLBI NIH HHS [HL-29594, HL-44015, HL66548, R01 HL066548, U01 HL081335] NR 44 TC 24 Z9 24 U1 0 U2 2 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0741-5400 J9 J LEUKOCYTE BIOL JI J. Leukoc. Biol. PD APR 1 PY 2008 VL 83 IS 4 BP 946 EP 955 DI 10.1189/jlb.1007684 PG 10 WC Cell Biology; Hematology; Immunology SC Cell Biology; Hematology; Immunology GA 331NP UT WOS:000258019200018 PM 18211966 ER PT J AU Jack, CR Bernstein, MA Fox, NC Thompson, P Alexander, G Harvey, D Borowski, B Britson, PJ Whitwell, JL Ward, C Dale, AM Felmlee, JP Gunter, JL Hill, DLG Killiany, R Schuff, N Fox-Bosetti, S Lin, C Studholme, C DeCarli, CS Krueger, G Ward, HA Metzger, GJ Scott, KT Mallozzi, R Blezek, D Levy, J Debbins, JP Fleisher, AS Albert, M Green, R Bartzokis, G Glover, G Mugler, J Weiner, MW AF Jack, Clifford R., Jr. Bernstein, Matt A. Fox, Nick C. Thompson, Paul Alexander, Gene Harvey, Danielle Borowski, Bret Britson, Paula J. Whitwell, Jennifer L. Ward, Chadwick Dale, Anders M. Felmlee, Joel P. Gunter, Jeffrey L. Hill, Derek L. G. Killiany, Ron Schuff, Norbert Fox-Bosetti, Sabrina Lin, Chen Studholme, Colin DeCarli, Charles S. Krueger, Gunnar Ward, Heidi A. Metzger, Gregory J. Scott, Katherine T. Mallozzi, Richard Blezek, Daniel Levy, Joshua Debbins, Josef P. Fleisher, Adam S. Albert, Marilyn Green, Robert Bartzokis, George Glover, Gary Mugler, John Weiner, Michael W. CA ADNI Study TI The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods SO JOURNAL OF MAGNETIC RESONANCE IMAGING LA English DT Review DE MRI; Alzheimer's disease; clinical trials; imaging methods; imaging standardization ID MILD COGNITIVE IMPAIRMENT; MAGNETIC-RESONANCE IMAGES; ENTORHINAL CORTEX; HIPPOCAMPAL ATROPHY; BRAIN; PREDICT AB The Alzheimer's Disease Neuroimaging Initiative (ADNI) is a longitudinal multisite observational study of healthy elders, mild cognitive impairment (MCI), and Alzheimer's disease. Magnetic resonance imaging (MRI), (18F)-fluorodeoxyglucose positron emission tomography (FDG PET), urine serum, and cerebrospinal fluid (CSF) biomarkers, as well as clinical /psychometric assessments are acquired at multiple time points. All data will be cross-linked and made available to the general scientific community. The purpose of this report is to describe the MRI methods employed in ADNI. The ADNI MRI core established specifications that guided protocol development. A major effort was devoted to evaluating 3D T(1)-weighted sequences for morphometric analyses. Several options for this sequence were optimized for the relevant manufacturer platforms and then compared in a reduced-scale clinical trial. The protocol selected for the ADNI study includes: back-to-back 3D magnetization prepared rapid gradient echo (MP-RAGE) scans; B(1)-calibration scans when applicable; and an axial proton density-T(2) dual contrast (i.e., echo) fast spin echo/ turbo spin echo (FSE/TSE) for pathology detection. ADNI MRI methods seek to maximize scientific utility while minimizing the burden placed on participants. The approach taken in ADNI to standardization across sites and platforms of the MRI protocol, postacquisition corrections, and phantom-based monitoring of all scanners could be used as a model for other multisite trials. C1 [Jack, Clifford R., Jr.; Bernstein, Matt A.; Borowski, Bret; Britson, Paula J.; Whitwell, Jennifer L.; Ward, Chadwick; Felmlee, Joel P.; Gunter, Jeffrey L.; Lin, Chen; Ward, Heidi A.] Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA. [Fox, Nick C.] Natl Hosp Neurol & Neurosurg, London WC1N 3BG, England. [Thompson, Paul; Bartzokis, George] Univ Calif Los Angeles, Sch Med, Dept Neurol, Lab Neuro Imaging, Los Angeles, CA 90024 USA. [Alexander, Gene; Debbins, Josef P.] Arizona State Univ, Dept Psychol, Neuroimage Anal Lab, Tempe, AZ 85287 USA. [Harvey, Danielle] Univ Calif Davis, Dept Publ Hlth Sci, Davis, CA 95616 USA. [Dale, Anders M.; Fleisher, Adam S.] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA. [Hill, Derek L. G.] UCL, Ctr Med Image Comp, London WC1E 6BT, England. [Killiany, Ron] Boston Univ, Sch Med, Dept Anat & Neurobiol, Boston, MA 02118 USA. [Schuff, Norbert; Fox-Bosetti, Sabrina; Studholme, Colin; Weiner, Michael W.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Schuff, Norbert; Fox-Bosetti, Sabrina; Studholme, Colin; Weiner, Michael W.] CIND, Dept Vet Affairs Med Ctr, San Francisco, CA USA. [DeCarli, Charles S.] Univ Calif Davis, Sch Med, Dept Neurol, Davis, CA 95616 USA. [DeCarli, Charles S.] Univ Calif Davis, Sch Med, Alzheimers Dis Ctr, Davis, CA 95616 USA. [Krueger, Gunnar; Scott, Katherine T.] Siemens Med Solut, Erlangen, Germany. [Levy, Joshua] Phantom Lab, Greenwich, NY USA. [Albert, Marilyn] Massachusetts Gen Hosp, Dept Psychiat & Neurol, Boston, MA 02114 USA. [Albert, Marilyn] Johns Hopkins Univ, Sch Med, Div Cognit Neurosci, Baltimore, MD USA. [Green, Robert] Boston Univ, Sch Med, Genet Program & Alzheimers Dis Ctr, Boston, MA 02118 USA. [Glover, Gary] Stanford Univ, Lucas Magnet Resonance Imaging Ctr, Dept Radiol, Stanford, CA 94305 USA. [Mugler, John] Univ Virginia, Sch Med, Dept Radiol, Charlottesville, VA 22908 USA. RP Jack, CR (reprint author), Mayo Clin, Dept Radiol, 200 1st St SW, Rochester, MN 55905 USA. EM jack.clifford@mayo.edu RI Jack, Clifford/F-2508-2010; Dale, Anders/A-5180-2010; Mugler, John/B-9432-2013; Bartzokis, George/K-2409-2013; Fox, Nick/B-1319-2009; OI Jack, Clifford/0000-0001-7916-622X; Mugler, John/0000-0002-4140-308X; Fox, Nick/0000-0002-6660-657X; Bernstein, Matt/0000-0003-3770-0441 FU Medical Research Council [G0601846]; NIA NIH HHS [U01 AG024904-03, P30 AG010129, P30 AG010129-18, U01 AG024904, U19 AG010483] NR 21 TC 767 Z9 768 U1 9 U2 81 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1053-1807 J9 J MAGN RESON IMAGING JI J. Magn. Reson. Imaging PD APR PY 2008 VL 27 IS 4 BP 685 EP 691 DI 10.1002/jmri.21049 PG 7 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 284MC UT WOS:000254709500001 PM 18302232 ER PT J AU Wang, HH Menezes, NM Zhu, MW Ay, H Koroshetz, WJ Aronen, HJ Karonen, JO Liu, Y Nuutinen, J Wald, LL Sorensen, AG AF Wang, Harris H. Menezes, Nina M. Zhu, Ming Wang Ay, Hakan Koroshetz, Walter J. Aronen, Hannu J. Karonen, Jari O. Liu, Yawu Nuutinen, Juho Wald, Lawrence L. Sorensen, A. Gregory TI Physiological noise in MR images: An indicator of the tissue response to ischemia? SO JOURNAL OF MAGNETIC RESONANCE IMAGING LA English DT Article DE stroke; ischemia; MRI; vasomotion; noise ID PERFUSION-WEIGHTED MRI; ECHO-PLANAR MRI; FUNCTIONAL CONNECTIVITY; HYPERACUTE STROKE; CEREBRAL-ISCHEMIA; MOTOR CORTEX; DIFFUSION; FMRI; FLUCTUATIONS; PARAMETERS AB Purpose: To determine whether measuring signal intensity (SI) fluctuations in MRI time series data from acute stroke patients would identify ischemic tissue. Materials and Methods: Prebolus perfusion-weighted MRI data from 32 acute ischemic stroke patients (N = 32) was analyzed as a time series. Ischemic and normal tissue regions were outlined and compared. Results: The magnitude of the measured SI fluctuations was significantly lower in ischemic regions relative to normal tissue. Spatial differences in these fluctuations occurred in a manner that was different than other perfusion-based metrics. Conclusion: Prior studies have shown that SI fluctuations in MRI time series data correspond to the presence of physiological "noise," which includes vasomotion, an autoregulatory phenomenon that affects the tissue response to ischemia. In this study, SI fluctuations were found to decrease in ischemia, consistent with the notion that small vessels will remain open (fluctuations in vessel diameter will decrease) when there is a challenge to flow. Spatial variation in SI fluctuations appeared to be different from spatial variation seen on other perfusion-based metrics, suggesting that a separate contrast mechanism is responsible, one that might be of diagnostic and prognostic value in acute stroke in which the ability of tissue to withstand ischemia is currently not well visualized. C1 [Menezes, Nina M.; Zhu, Ming Wang; Ay, Hakan; Wald, Lawrence L.; Sorensen, A. Gregory] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Boston, MA 02129 USA. [Wang, Harris H.; Sorensen, A. Gregory] Harvard Univ, MIT, Div Hlth Sci & Technol, Med Engn Med Phys Program, Cambridge, MA 02138 USA. [Ay, Hakan; Koroshetz, Walter J.] Massachusetts Gen Hosp, Dept Neurol, Stroke Serv, Boston, MA 02114 USA. [Aronen, Hannu J.] Helsinki Brain Res Ctr, Funct Brain Imaging Unit, Helsinki, Finland. Finnish Def Forces, Ctr Mil Med, Helsinki, Finland. [Aronen, Hannu J.] Univ Turku, Dept Diagnost Radiol, Turku, Finland. [Karonen, Jari O.; Liu, Yawu; Nuutinen, Juho] Kuopio Univ Hosp, Dept Clin Radiol, SF-70210 Kuopio, Finland. [Karonen, Jari O.; Liu, Yawu; Nuutinen, Juho] Kuopio Univ Hosp, Dept Neurol, SF-70210 Kuopio, Finland. RP Sorensen, AG (reprint author), Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Bldg 149,13th St 2301, Boston, MA 02129 USA. EM sorensen@nmr.mgh.barvard.edu RI Wald, Lawrence/D-4151-2009 FU NCRR NIH HHS [P41RR14075]; NINDS NIH HHS [NS38477] NR 30 TC 9 Z9 9 U1 2 U2 3 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1053-1807 J9 J MAGN RESON IMAGING JI J. Magn. Reson. Imaging PD APR PY 2008 VL 27 IS 4 BP 866 EP 871 DI 10.1002/jmri.21007 PG 6 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 284MC UT WOS:000254709500025 PM 18383248 ER PT J AU Balu, N Chu, BC Hatsukami, TS Yuan, C Yarnykh, VL AF Balu, Niranjan Chu, Baocheng Hatsukami, Thomas S. Yuan, Chun Yarnykh, Vasily L. TI Comparison between 2D and 3D high-resolution black-blood techniques for carotid artery wall Imaging in clinically significant atherosclerosis SO JOURNAL OF MAGNETIC RESONANCE IMAGING LA English DT Article DE serial MRI; 3D carotid black-blood imaging; morphological measurements; vulnerable plaque imaging; plaque composition ID TURBO SPIN-ECHO; IN-VIVO; MEASUREMENT PRECISION; MR-ANGIOGRAPHY; PLAQUE AB Purpose: To compare two- (2D) and three-dimensional (3D) black-blood imaging methods for morphological measurements of the carotid artery wall and atherosclerotic plaque. Materials and Methods: A total of 18 subjects with 50% to 79% carotid stenosis were scanned with 2D (2-mm slice thickness) and 3D (1-mm/0.5-mm actual/interpolated slice thickness) T1-weighted fast spin-echo (FSE) black-blood imaging sequences with double inversion-recovery (DIR) blood suppression. Morphological measurements (lumen area, wall area, vessel area, mean wall thickness, and maximal wall thickness), signal-to-noise ratio (SNR) in the wall and lumen, and wall-lumen contrast-to-noise ratio (CNR) were compared between 2D and 3D images. The effect of improved slice resolution in 3D imaging was evaluated for visualization of small plaque components. Results: Lumen SNR (P = 0. 16), wall SNR (P = 0.65), and CNR (P = 0.94) were comparable between 2D/3D. There was no difference in average lumen area (P = 0. 16), average wall area (P = 0.99), average vessel area (P = 0. 0. 58), mean wall thickness (P = 0.09), and maximum wall thickness (P = 0.06) between 2D/3D. Distributions of small plaque components such as calcification were better characterized by the 3D acquisition. There was a higher sensitivity to motion artifacts with 3D imaging, resulting in three examinations with low image quality. Conclusion: 2D and 3D protocols provided comparable morphometric measurements of the carotid artery. The major advantage of 3D imaging is improved small plaque component visualization, while the 2D technique provides higher reliability for image quality.. C1 [Balu, Niranjan] Univ Washington, Dept Bioengn, Seattle, WA 98195 USA. [Chu, Baocheng; Yuan, Chun; Yarnykh, Vasily L.] Univ Washington, Dept Radiol, Seattle, WA 98195 USA. [Hatsukami, Thomas S.] Univ Washington, Dept Surg, Seattle, WA 98195 USA. [Hatsukami, Thomas S.] VA Puget Sound HCS, Seattle, WA 98195 USA. RP Balu, N (reprint author), Vasc Imaging Lab, 815 Mercer St,Box 358050, Seattle, WA 98019 USA. EM ninja@u.washington.edu RI Yarnykh, Vasily/G-8757-2016; Yarnykh, Vasiliy/N-7635-2014 OI Yarnykh, Vasily/0000-0002-1583-8979; FU NHLBI NIH HHS [R01 HL056874, R01 HL056874-08, R01 HL061851, R01 HL061851-04, R01-HL056784, R01-HL061851] NR 23 TC 47 Z9 51 U1 0 U2 4 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1053-1807 J9 J MAGN RESON IMAGING JI J. Magn. Reson. Imaging PD APR PY 2008 VL 27 IS 4 BP 918 EP 924 DI 10.1002/jmri.21282 PG 7 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 284MC UT WOS:000254709500032 PM 18383253 ER PT J AU Ma, YB Sun, CP Fields, M Li, Y Haake, DA Churchill, BM Ho, CM AF Ma, Yanbao Sun, Chien-Pin Fields, Michael Li, Yang Haake, David A. Churchill, Bernard M. Ho, Chih-Ming TI An unsteady microfluidic T-form mixer perturbed by hydrodynamic pressure SO JOURNAL OF MICROMECHANICS AND MICROENGINEERING LA English DT Article ID ELECTROOSMOTIC FLOW; CHAOTIC MIXER; MICROCHANNELS; MICROMIXERS; GEOMETRY; CHANNELS; DEVICES; DRIVEN; CHIP AB An unsteady microfluidic T-form mixer driven by pressure disturbances was designed and investigated. The performance of the mixer was examined both through numerical simulation and experimentation. Linear Stokes equations were used for these low Reynolds number flows. Unsteady mixing in a micro-channel of two aqueous solutions differing in concentrations of chemical species was described using a convection-dominated diffusion equation. The task was greatly simplified by employing linear superimposition of a velocity field for solving a scalar species concentration equation. Low-order-based numerical codes were found not to be suitable for simulation of a convection-dominated mixing process due to erroneous computational dissipation. The convection-dominated diffusion problem was addressed by designing a numerical algorithm with high numerical accuracy and computational-cost effectiveness. This numerical scheme was validated by examining a test case prior to being applied to the mixing simulation. Parametric analysis was performed using this newly developed numerical algorithm to determine the best mixing conditions. Numerical simulation identified the best mixing condition to have a Strouhal number (St) of 0.42. For a T-junction mixer (with channel width = 196 mu m), about 75% mixing can be finished within a mixing distance of less than 3 mm (i.e. 15 channel width) at St = 0.42 for flow with a Reynolds number less than 0.24. Numerical results were validated experimentally by mixing two aqueous solutions containing yellow and blue dyes. Visualization of the flow field under the microscope revealed a high level of agreement between numerical simulation and experimental results. C1 [Ma, Yanbao; Sun, Chien-Pin; Fields, Michael; Ho, Chih-Ming] Univ Calif Los Angeles, Dept Mech & Aerosp Engn, Los Angeles, CA 90095 USA. [Li, Yang; Haake, David A.; Churchill, Bernard M.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Haake, David A.] Vet Affairs Greater Los Angeles Healthcare Ctr, Los Angeles, CA 90073 USA. [Ho, Chih-Ming] NIH, Ctr Cell Control, Nanomed Dev Ctr, Bethesda, MD USA. RP Ma, YB (reprint author), Univ Calif Los Angeles, Dept Mech & Aerosp Engn, Los Angeles, CA 90095 USA. EM yanbao@seas.ucla.edu FU NIAID NIH HHS [U01 AI075565, U01 AI075565-01, U54 AI065359, U54 AI065359-030019]; NIBIB NIH HHS [R01 EB000127]; NIDDK NIH HHS [R33 DK070328, R33 DK070328-02] NR 43 TC 8 Z9 8 U1 1 U2 19 PU IOP PUBLISHING LTD PI BRISTOL PA DIRAC HOUSE, TEMPLE BACK, BRISTOL BS1 6BE, ENGLAND SN 0960-1317 J9 J MICROMECH MICROENG JI J. Micromech. Microeng. PD APR PY 2008 VL 18 IS 4 AR 045015 DI 10.1088/0960-1317/18/4/045015 PG 14 WC Engineering, Electrical & Electronic; Nanoscience & Nanotechnology; Instruments & Instrumentation; Physics, Applied SC Engineering; Science & Technology - Other Topics; Instruments & Instrumentation; Physics GA 276OL UT WOS:000254151800015 PM 19177174 ER PT J AU Breslau, J Javaras, KN Blacker, D Murphy, JM Normand, SLT AF Breslau, Joshua Javaras, Kristin N. Blacker, Deborah Murphy, Jane M. Normand, Sharon-Lise T. TI Differential item functioning between ethnic groups in the epidemiological assessment of depression SO JOURNAL OF NERVOUS AND MENTAL DISEASE LA English DT Article DE depression; measurement; bias; ethnicity; epidemiology ID NATIONAL-COMORBIDITY-SURVEY; MENTAL-HEALTH RESEARCH; NON-HISPANIC WHITES; MEXICAN-AMERICANS; PSYCHIATRIC-DISORDERS; MAJOR DEPRESSION; UNITED-STATES; PREVALENCE; DIAGNOSIS; HYPOTHESIS AB A potential explanation for the finding that disadvantaged minority status is associated with a lower lifetime risk for depression is that individuals from minority ethnic groups may be less likely to endorse survey questions about depression even when they have the same level of depression. We examine this possibility using a nonparametric item response theory approach to assess differential item functioning (DIF) in a national survey of psychiatric disorders, the National Comorbidity Survey. Of 20 questions used to assess depression symptoms, we found evidence of DIF in 3 questions when comparing non-Hispanic blacks with non-Hispanic whites and in 3 questions when comparing Hispanics with non-Hispanic whites. However, removal of the questions with DIF did not alter the relative prevalence of depression between ethnic groups. Ethnic differences do exist in response to questions concerning depression, but these differences do not account for the finding of relatively low prevalence of depression among minority groups. C1 [Breslau, Joshua] Univ Calif Davis, Sch Med, Dept Internal Med, Ctr Reducing Hlth Dispar, Sacramento, CA 95817 USA. [Javaras, Kristin N.; Normand, Sharon-Lise T.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Blacker, Deborah; Murphy, Jane M.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [Blacker, Deborah; Murphy, Jane M.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Normand, Sharon-Lise T.] Harvard Univ, Sch Med, Boston, MA USA. RP Breslau, J (reprint author), Univ Calif Davis, Sch Med, Dept Internal Med, Ctr Reducing Hlth Dispar, 2921 Stockton Blvd, Sacramento, CA 95817 USA. EM jabreslau@ucdavis.edu RI Breslau, Joshua/I-6956-2012 FU NIMH NIH HHS [T32 MH017119, K01 MH066057, K01 MH066057-03, K01 MH66057-02, R01 MH054693, R01-MH54693]; OMHHE CDC HHS [5 T32 MN17119-22] NR 39 TC 29 Z9 29 U1 2 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0022-3018 J9 J NERV MENT DIS JI J. Nerv. Ment. Dis. PD APR PY 2008 VL 196 IS 4 BP 297 EP 306 DI 10.1097/NMD.0b013e31816a490e PG 10 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 290EG UT WOS:000255105500006 PM 18414124 ER PT J AU Marci, CD AF Marci, Carl D. TI The descent of madness: Evolutionary origins of psychosis and the social brain SO JOURNAL OF NERVOUS AND MENTAL DISEASE LA English DT Book Review C1 [Marci, Carl D.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02115 USA. RP Marci, CD (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02115 USA. NR 1 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0022-3018 J9 J NERV MENT DIS JI J. Nerv. Ment. Dis. PD APR PY 2008 VL 196 IS 4 BP 346 EP 347 DI 10.1097/NMD.0b013e31816a70a9 PG 2 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 290EG UT WOS:000255105500015 ER PT J AU Dabus, G Gerstle, RJ Parsons, M Cross, DT Moran, CJ Thompson, R Derdeyn, CP AF Dabus, Guilherme Gerstle, Ronald J. Parsons, Matthew Cross, DeWitte T., III Moran, Christopher J. Thompson, Robert Derdeyn, Colin P. TI Rotational vertebrobasilar insufficiency due to dynamic compression of the dominant vertebral artery by the thyroid cartilage and occlusion of the contralateral vertebral artery at C1-2 level SO JOURNAL OF NEUROIMAGING LA English DT Article DE rotational vertebrobasilar insufficiency; bow hunter's stroke; vertebral artery stenosis; stroke ID BOW HUNTERS STROKE AB BACKGROUND Vertebrobasilar insufficiency caused by head rotation is an uncommon event. The mechanism is obstruction of the vertebral artery resulting in flow limitation or, less frequently, thromboembolism. CASE DESCRIPTION A 41-year-old male developed dizziness and light-headedness during chiropractic manipulation when his head was turned to the extreme right position. Computed tomography angiography (CTA) of the neck and selective digital subtraction angiography (DSA) of the vertebral arteries revealed that when the patient turned his head to the extreme right position the dominant right vertebral artery was compressed between the posterior aspect of the thyroid cartilage and anterior aspect of the right transverse process of C6 resulting in focal stenosis, while the left vertebral artery is severely compressed with significant flow limitation at the level of C1-2. Because the patient was healthy and asymptomatic, conservative management was adopted. At the 9-month follow-up visit the patient was asymptomatic and able to compensate for his problem avoiding turning his head to the extreme right position. CONCLUSIONS We present an uncommon case of rotational vertebrobasilar insufficiency (VBI) where the dominant vertebral artery has an anomalous course compressed by the thyroid cartilage at C6 level, associated with contralateral vertebral artery rotational stenosis at C1-2. The patient was successfully managed conservatively. C1 [Dabus, Guilherme] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Intervent Neuroradiol, Boston, MA 02114 USA. [Gerstle, Ronald J.; Parsons, Matthew; Cross, DeWitte T., III; Moran, Christopher J.] Washington Univ, Sch Med, Mallinckrodt Inst Radiol, St Louis, MO USA. [Thompson, Robert] Washington Univ, Sch Med, Dept Vasc Surg, St Louis, France. RP Dabus, G (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Intervent Neuroradiol, 55 Fruit St Gray 241, Boston, MA 02114 USA. EM gdabus@partners.org OI Derdeyn, Colin/0000-0002-5932-2683 NR 12 TC 6 Z9 7 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1051-2284 J9 J NEUROIMAGING JI J. Neuroimaging PD APR PY 2008 VL 18 IS 2 BP 184 EP 187 DI 10.1111/j.1552-6569.2007.00177.x PG 4 WC Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA 281MR UT WOS:000254502200013 PM 18298678 ER PT J AU Reddy, VB Iuga, AO Shimada, SG LaMotte, RH Lerner, EA AF Reddy, Vemuri B. Iuga, Aurel O. Shimada, Steve G. LaMotte, Robert H. Lerner, Ethan A. TI Cowhage-evoked itch is mediated by a novel cysteine protease: A ligand of protease-activated receptors SO JOURNAL OF NEUROSCIENCE LA English DT Article DE pruritus; cowhage; Mucuna pruriens; cysteine protease; protease-activated receptor; receptor ID HUMAN SKIN; PRURITUS; POPULATIONS; PROTEINASE; HISTAMINE; MAGNITUDE AB Cowhage spicules provide an important model for histamine-independent itch. We determined that the active component of cowhage, termed mucunain, is a novel cysteine protease. We isolated mucunain and demonstrate that both native and recombinant mucunain evoke the same quality of itch in humans. We also show that mucunain is a ligand for protease-activated receptors two and four. These results support and expand the relationship between proteases, protease-activated receptors, and itch. C1 [Reddy, Vemuri B.; Iuga, Aurel O.; Lerner, Ethan A.] Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Dept Dermatol, Charlestown, MA 02129 USA. [Shimada, Steve G.; LaMotte, Robert H.] Yale Univ, Sch Med, Dept Anesthesiol, New Haven, CT 06520 USA. RP Lerner, EA (reprint author), Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Dept Dermatol, Bldg 149,13th St, Charlestown, MA 02129 USA. EM elerner@partners.org FU NCRR NIH HHS [UL1 RR024139, UL1 RR024139-03, UL1 RR0249139]; NINDS NIH HHS [K25 NS047300, P01 NS 047300, P01 NS047399, P01 NS047399-04] NR 19 TC 105 Z9 107 U1 1 U2 11 PU SOC NEUROSCIENCE PI WASHINGTON PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA SN 0270-6474 J9 J NEUROSCI JI J. Neurosci. PD APR PY 2008 VL 28 IS 17 BP 4331 EP 4335 DI 10.1523/JNEUROSCI.0716-08.2008 PG 5 WC Neurosciences SC Neurosciences & Neurology GA 292YD UT WOS:000255301100007 PM 18434511 ER PT J AU Shah, K Hingtgen, S Kasmieh, R Figueiredo, JL Garcia-Garcia, E Martinez-Serrano, A Breakefield, X Weissleder, R AF Shah, Khalid Hingtgen, Shawn Kasmieh, Randa Figueiredo, Jose Luiz Garcia-Garcia, Elisa Martinez-Serrano, Alberto Breakefield, Xandra Weissleder, Ralph TI Bimodal viral vectors and in vivo imaging reveal the fate of human neural stem cells in experimental glioma model SO JOURNAL OF NEUROSCIENCE LA English DT Article DE neural stem cell; bimodal vector; luciferase; fluorescent proteins; glioma; in vivo imaging ID MAGNETIC-RESONANCE TRACKING; SPINAL-CORD-INJURY; PROGENITOR CELLS; LENTIVIRAL VECTORS; GROWTH-FACTOR; GENE-TRANSFER; BRAIN; TRANSPLANTATION; MIGRATION; DIFFERENTIATION AB Transplantation of genetically engineered cells into the CNS offers immense potential for the treatment of several neurological disorders. Monitoring expression levels of transgenes and following changes in cell function and distribution over time is critical in assessing therapeutic efficacy of such cells in vivo. We have engineered lentiviral vectors bearing fusions between different combinations of fluorescent and bioluminescent marker proteins and used bioluminescence imaging and intravital-scanning microscopy in real time to study the fate of human neural stem cells ( hNSCs) at a cellular resolution in glioma-bearing brains in vivo. Using Renilla luciferase (Rluc)-DsRed2 or GFP-Rluc-expressing malignant human glioma model, transduced hNSCs were shown to migrate extensively toward gliomas, with hNSCs populating gliomas at 10 d after transplantation. Furthermore, transduced hNSCs survived longer in mice with gliomas than in normal brain, but did not modulate glioma progression in vivo. These studies demonstrate the utility of bimodal viral vectors and real-time imaging in evaluating fate of NSCs in diseased models and thus provide a platform for accelerating cell-based therapies for CNS disorders. C1 [Shah, Khalid; Hingtgen, Shawn; Kasmieh, Randa; Figueiredo, Jose Luiz; Weissleder, Ralph] Harvard Univ, Sch Med, Massachusetts Mental Hlth Ctr, Ctr Mol Imaging Res,Dept Radiol, Boston, MA 02115 USA. [Shah, Khalid; Breakefield, Xandra] Harvard Univ, Sch Med, Massachusetts Mental Hlth Ctr, Dept Neurol, Boston, MA 02115 USA. [Weissleder, Ralph] Harvard Univ, Sch Med, Massachusetts Mental Hlth Ctr, Ctr Syst Biol,Dept Syst Biol, Boston, MA 02115 USA. [Garcia-Garcia, Elisa; Martinez-Serrano, Alberto] Univ Autonoma Madrid, Dept Mol Biol, Ctr Biol Mol Severo Ochoa, Consejo Super Invest Cientif, E-28049 Madrid, Spain. [Shah, Khalid; Weissleder, Ralph] Harvard Univ, Harvard Stem Cell Inst, Cambridge, MA 02138 USA. RP Shah, K (reprint author), 5421 Massachusetts Gen Hosp 149,13th St, Charlestown, MA 02129 USA. EM kshah@helix.mgh.harvard.edu RI Martinez-Serrano, Alberto/J-8146-2014 FU NCI NIH HHS [P01 CA069246, P01 CA069246-080006, P01 CA69246, P50 CA086355, P50 CA086355-07, P50 CA86355, R21 CA131980, R21 CA131980-01] NR 41 TC 62 Z9 62 U1 2 U2 9 PU SOC NEUROSCIENCE PI WASHINGTON PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA SN 0270-6474 J9 J NEUROSCI JI J. Neurosci. PD APR PY 2008 VL 28 IS 17 BP 4406 EP 4413 DI 10.1523/JNEUROSCI.0296-08.2008 PG 8 WC Neurosciences SC Neurosciences & Neurology GA 292YD UT WOS:000255301100015 PM 18434519 ER PT J AU Kohno, T Wang, HB Amaya, F Brenner, GJ Cheng, JK Ji, RR Woolf, CJ AF Kohno, Tatsuro Wang, Haibin Amaya, Fumimasa Brenner, Gary J. Cheng, Jen-Kun Ji, Ru-Rong Woolf, Clifford J. TI Bradykinin enhances AMPA and NMDA receptor activity in spinal cord dorsal horn neurons by activating multiple kinases to produce pain hypersensitivity SO JOURNAL OF NEUROSCIENCE LA English DT Article DE bradykinin; spinal cord; pain; glutamate; neuromodulator; signal transduction ID DEPENDENT PROTEIN-KINASE; INDUCED NOCICEPTOR SENSITIZATION; PROSTAGLANDIN E-2 RELEASE; ERK INTEGRATES PKA; SYNAPTIC-TRANSMISSION; INFLAMMATORY PAIN; KININ RECEPTORS; HEK-293 CELLS; RAT; PLASTICITY AB Bradykinin potentiates synaptic glutamate release and action in the spinal cord via presynaptic and postsynaptic B-2 receptors, contributing thereby to activity-dependent central sensitization and pain hypersensitivity (Wang et al., 2005). We have now examined the signaling pathways that are responsible for the postsynaptic modulatory actions of bradykinin on glutamatergic action and transmission in superficial dorsal horn neurons. B-2 receptors are coexpressed in dorsal horn neurons with protein kinase A(PKA) and the delta isoform of protein kinase C (PKC), and we find that the augmentation by bradykinin of AMPA and NMDA receptor-mediated currents in lamina II neurons requires coactivation of both PKC and PKA. The activation of PKA is downstream of COX1 (cyclooxygenase-1). Extracellular signal-regulated kinase (ERK) activation is involved after the PKC and PKA coactivation, and intrathecal administration of bradykinin induces a thermal hyperalgesia in vivo, which is reduced by inhibition of ERK, PKA, and PKC. We conclude that bradykinin, by activating multiple kinases in dorsal horn neurons, potentiates glutamatergic synaptic transmission to produce pain hypersensitivity. C1 [Kohno, Tatsuro; Wang, Haibin; Amaya, Fumimasa; Brenner, Gary J.; Woolf, Clifford J.] Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Neural Plast Res Grp, Charlestown, MA 02129 USA. [Kohno, Tatsuro; Wang, Haibin; Amaya, Fumimasa; Brenner, Gary J.; Woolf, Clifford J.] Harvard Univ, Sch Med, Charlestown, MA 02129 USA. [Kohno, Tatsuro] Niigata Univ, Grad Sch Med & Dent Sci, Div Anesthesiol, Niigata 9518510, Japan. [Cheng, Jen-Kun] Brigham & Womens Hosp, Dept Anesthesia, Pain Res Ctr, Boston, MA 02115 USA. [Cheng, Jen-Kun; Ji, Ru-Rong] Harvard Univ, Sch Med, Boston, MA 02115 USA. RP Woolf, CJ (reprint author), Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Neural Plast Res Grp, Charlestown, MA 02129 USA. EM cwoolf@partners.org OI Ji, Ru-Rong/0000-0002-9355-3688 FU NINDS NIH HHS [NS054932, R01 NS039518, R01 NS039518-08, R01 NS054932, K08 NS044139, R01 NS039518-07, NS039518, R37 NS039518] NR 45 TC 45 Z9 51 U1 0 U2 6 PU SOC NEUROSCIENCE PI WASHINGTON PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA SN 0270-6474 J9 J NEUROSCI JI J. Neurosci. PD APR PY 2008 VL 28 IS 17 BP 4533 EP 4540 DI 10.1523/JNEUROSCI.5349-07.2008 PG 8 WC Neurosciences SC Neurosciences & Neurology GA 292YD UT WOS:000255301100028 PM 18434532 ER PT J AU Zhang, GH Dong, YL Zhang, B Ichinose, F Wu, X Culley, DJ Crosby, G Tanzi, RE Xie, ZC AF Zhang, Guohua Dong, Yuanlin Bin Zhang Ichinose, Fumito Wu, Xu Culley, Deborah J. Crosby, Gregory Tanzi, Rudolph E. Xie, Zhongcong TI Isoflurane-induced caspase-3 activation is dependent on cytosolic calcium and can be attenuated by memantine SO JOURNAL OF NEUROSCIENCE LA English DT Article DE Alzheimer's disease; anesthesia; isoflurane; apoptosis; calcium; memantine ID HIPPOCAMPAL SLICE CULTURES; DEVELOPING RAT-BRAIN; D-ASPARTATE RECEPTOR; BETA-PROTEIN-LEVELS; INDUCED CELL-DEATH; ALZHEIMERS-DISEASE; VOLATILE ANESTHETICS; INTRACELLULAR CA2+; PRECURSOR PROTEIN; INDUCED APOPTOSIS AB Increasing evidence indicates that caspase activation and apoptosis are associated with a variety of neurodegenerative disorders, including Alzheimer's disease. We reported that anesthetic isoflurane can induce apoptosis, alter processing of the amyloid precursor protein (APP), and increase amyloid-beta protein (A beta) generation. However, the mechanism by which isoflurane induces apoptosis is primarily unknown. We therefore set out to assess effects of extracellular calcium concentration on isoflurane-induced caspase-3 activation in H4 human neuroglioma cells stably transfected to express human full-length APP (H4-APP cells). In addition, we tested effects of RNA interference (RNAi) silencing of IP3 receptor, NMDA receptor, and endoplasmic reticulum (ER) calcium pump, sacro-/ER calcium ATPase (SERCA1). Finally, we examined the effects of the NMDA receptor partial antagonist, memantine, in H4-APP cells and brain tissue of naive mice. EDTA (10 mM), BAPTA (10 mu M), and RNAi silencing of IP3 receptor, NMDA receptor, or SERCA1 attenuated capase-3 activation. Memantine (4 mu M) inhibited isoflurane-induced elevations in cytosolic calcium levels and attenuated isoflurane-induced caspase-3 activation, apoptosis, and cell viability. Memantine (20 mg/kg, i.p.) reduced isoflurane-induced caspase-3 activation in brain tissue of naive mice. These results suggest that disruption of calcium homeostasis underlies isoflurane-induced caspase activation and apoptosis. We also show for the first time that the NMDA receptor partial antagonist, memantine, can prevent isoflurane-induced caspase-3 activation and apoptosis in vivo and in vitro. These findings, indicating that isoflurane-induced caspase activation and apoptosis are dependent on cytosolic calcium levels, should facilitate the provision of safer anesthesia care, especially for Alzheimer's disease and elderly patients. C1 [Zhang, Guohua; Dong, Yuanlin; Bin Zhang; Wu, Xu; Tanzi, Rudolph E.; Xie, Zhongcong] Harvard Univ, Sch Med, Massachusetts Gen Hosp,Dept Neurol, Genet & Aging Res Unit,MassGen Inst Neurodegenera, Charlestown, MA 02129 USA. [Zhang, Guohua; Wu, Xu] China Med Univ, Fac Forens Med, Dept Forens Pathol, Shenyang 110001, Peoples R China. [Zhang, Guohua; Dong, Yuanlin; Bin Zhang; Ichinose, Fumito; Wu, Xu; Xie, Zhongcong] Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Boston, MA 02114 USA. [Zhang, Guohua; Dong, Yuanlin; Bin Zhang; Ichinose, Fumito; Wu, Xu; Xie, Zhongcong] Harvard Univ, Sch Med, Boston, MA 02114 USA. [Bin Zhang] Capital Med Univ, Beijing Friendship Hosp, Dept Anesthesia, Beijing 100050, Peoples R China. [Culley, Deborah J.; Crosby, Gregory] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Anesthesia, Boston, MA 02115 USA. RP Tanzi, RE (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp,Dept Neurol, Genet & Aging Res Unit,MassGen Inst Neurodegenera, 114 16th St,C3009, Charlestown, MA 02129 USA. EM tanzi@helix.mgh.harvard.edu; zxie@partners.org FU NIA NIH HHS [AG20253, AG014713, R01 AG014713, R01 AG020253, R21 AG029856]; NIGMS NIH HHS [GM077057, K08 GM077057]; NIMH NIH HHS [MH60009, R01 MH060009, R37 MH060009]; NINDS NIH HHS [K08 NS048140, NS048140] NR 65 TC 67 Z9 71 U1 0 U2 5 PU SOC NEUROSCIENCE PI WASHINGTON PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA SN 0270-6474 J9 J NEUROSCI JI J. Neurosci. PD APR PY 2008 VL 28 IS 17 BP 4551 EP 4560 DI 10.1523/JNEUROSCI.5694-07.2008 PG 10 WC Neurosciences SC Neurosciences & Neurology GA 292YD UT WOS:000255301100030 PM 18434534 ER PT J AU Zhang, HL Gu, ZL Savitz, SI Han, F Fukunaga, K Qin, ZH AF Zhang, Hui-Ling Gu, Zhen-Lun Savitz, Sean I. Han, Feng Fukunaga, Kohji Qin, Zheng-Hong TI Neuroprotective effects of prostaglandin A(1) in rat models of permanent focal cerebral ischemia are associated with nuclear Factor-kappa B inhibition and peroxisome proliferator-activated receptor-gamma up-regulation SO JOURNAL OF NEUROSCIENCE RESEARCH LA English DT Article DE prostaglandin A(1); ischemia; neuroprotection; NF-kappa B; PPAR-gamma ID NITRIC-OXIDE SYNTHASE; CELL-DEATH; CYCLOPENTENONE PROSTAGLANDINS; EXPERIMENTAL STROKE; INDUCED APOPTOSIS; EXPRESSION; BRAIN; AGONISTS; INJURY; A(1) AB We have previously reported that prostaglandin A, (PGA(1)) reduces infarct size in rodent models of focal ischemia. This study seeks to elucidate the possible molecular mechanisms underlying PGA(1)'s neuroprotective effects against ischemic injury. Rats were subjected to permanent middle cerebral artery occlusion (pMCAO) by intraluminal suture blockade. PGA, was injected intracerebroventricularly (icv) immediately after ischemic onset. Western blot analysis was employed to determine alterations in I kappa B alpha, pIKK alpha, and peroxisome proliferator-activated receptor-gamma (PPAR-gamma). Immunohistochemistry was used to confirm the nuclear translocation of nuclear factor-kappa B (NF-kappa B) p65 and the expression of PPAR-gamma. RT-PCR was used to detect levels of c-Myc mRNA. The contribution of PPAR-gamma to PGA1's neuroprotection was evaluated by pretreatment with the PPAR-gamma irreversible antagonist GW9662. A brief increase in pIKKa levels and rapid reduction in I kappa B alpha were observed after ischemia. PGA, blocked ischemia-induced increases in pIKK alpha levels and reversed the decline in I kappa B alpha levels. Ischemia-induced nuclear translocation of NF-kappa B p65 was attenuated by PGA1. PGA, also repressed the ischemia-induced increase in expression of NF-kappa B target gene c-Myc mRNA. Immunohistochemistry demonstrated an increase in PPAR-gamma immunoreactivity in the nucleus of striatal cells at 3 hr after pMCAO. Western blot analysis revealed that the expression of PPAR-gamma protein significantly increased at 12 hr and peaked at 24 hr. PGA, enhanced the ischemia-triggered induction of PPAR-gamma protein. Pretreatment with the irreversible PPAR-gamma antagonist GW9662 attenuated PGA1's neuroprotection against ischemia. These findings suggest that PGA(1)-mediated neuroprotective effect against ischemia appears to be associated with blocking NF-kappa B activation and likely with up-regulating PPAR-gamma expression. (C) 2007 Wiley-Liss, Inc. C1 [Zhang, Hui-Ling; Gu, Zhen-Lun; Qin, Zheng-Hong] Soochow Univ, Sch Med, Dept Pharmacol & Lab Aging & Nervous Dis, Suzhou, Peoples R China. [Zhang, Hui-Ling; Savitz, Sean I.] Massachusetts Gen Hosp, Dept Radiol, Charlestown, MA USA. [Han, Feng; Fukunaga, Kohji] Tohoku Univ, Grad Sch Pharmaceut Sci, Dept Pharmacol, Sendai, Miyagi 980, Japan. RP Qin, ZH (reprint author), Soochow Univ, Sch Med, Dept Pharmacol, 199 Ren Ai Rd, Suzhou 215123, Peoples R China. EM zhqin5@hotmail.com NR 33 TC 27 Z9 33 U1 0 U2 4 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0360-4012 J9 J NEUROSCI RES JI J. Neurosci. Res. PD APR PY 2008 VL 86 IS 5 BP 1132 EP 1141 DI 10.1002/jnr.21569 PG 10 WC Neurosciences SC Neurosciences & Neurology GA 284QD UT WOS:000254720000018 PM 18074385 ER PT J AU Woff, G Triolo, P Ponte, PR AF Woff, Gait Triolo, Pamela Ponte, Patricia Reid TI Magnet recognition program - The next generation SO JOURNAL OF NURSING ADMINISTRATION LA English DT Article AB Twenty-five years ago, the foundation of the Magnet Recognition Program was established. Magnet designation has served as the hallmark of excellence for nursing practice, and research has demonstrated a profound impact on nursing practice and patient care. The purpose of this article was to forecast the direction of the Magnet Recognition Program. The authors discussed the results of a multivariate structural analysis of the forces of magnet and the subsequent future model for Magnet. C1 [Woff, Gait] Univ Pittsburgh, Sch Nursing, Nursing Leadership Program, Pittsburgh, PA 15261 USA. [Triolo, Pamela] Univ Pittsburgh, Med Ctr, Pittsburgh, PA 15260 USA. [Ponte, Patricia Reid] Dana Farber Canc Inst, Boston, MA 02115 USA. RP Woff, G (reprint author), Univ Pittsburgh, Sch Nursing, Nursing Leadership Program, 336 Victoria Bldg,3500 Victoria St, Pittsburgh, PA 15261 USA. EM wolfg@pitt.edu NR 3 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0002-0443 J9 J NURS ADMIN JI J. Nurs. Adm. PD APR PY 2008 VL 38 IS 4 BP 200 EP 204 PG 5 WC Nursing SC Nursing GA 287ET UT WOS:000254900400009 ER PT J AU Nierenberg, AA Ostacher, MJ Huffman, JC Ametrano, RM Fava, M Perlis, RH AF Nierenberg, Andrew A. Ostacher, Michael J. Huffman, Jeffrey C. Ametrano, Rebecca M. Fava, Maurizio Perlis, Roy H. TI A brief review of antidepressant efficacy, effectiveness, indications, and usage for major depressive disorder SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Review ID SEROTONIN REUPTAKE INHIBITORS; COMORBIDITY SURVEY REPLICATION; SEQUENCED TREATMENT ALTERNATIVES; STAR-ASTERISK-D; COGNITIVE THERAPY; DISCONTINUATION SYNDROME; ATYPICAL DEPRESSION; RESIDUAL DEPRESSION; TREATMENT RESPONSE; CONTROLLED-TRIAL AB Objective: Antidepressants treat major depressive disorder (AMD) with burden of associated side effects and difficulties with compliance The purpose of this article is to review the efficacy and effectiveness of antidepressants for MDD. Methods: The authors conducted a focused review of selected key issues and references relevant to the clinically relevant pharmacologic treatment of MDD. Principles of treatment are reviewed. Antidepressants reviewed include SSRIs, mixed norepinephrine or serotonin uptake inhibitors, dopamine or norepinephrine uptake inhibitors, norepinephrine uptake inhibitors, antidepressants with mixed properties, and monoamine oxidase inhibitors. Augmentation and psychotherapy strategies are reviewed. Results: Antidepressant efficacy has been established in randomized clinical trials and effectiveness studies for acute and long-term treatment, but many patients do not achieve remission. Augmentation strategies and focused psychotherapy can be helpful. Conclusions: Antidepressants help most patients with MDD but some are resistant to treatment and have a difficult long-term course. C1 [Nierenberg, Andrew A.; Ostacher, Michael J.; Huffman, Jeffrey C.; Ametrano, Rebecca M.; Fava, Maurizio; Perlis, Roy H.] Massachusetts Gen Hosp, Bipolar Clin & Res Program, Dept Psychiat, Boston, MA 02114 USA. RP Nierenberg, AA (reprint author), Massachusetts Gen Hosp, Bipolar Clin & Res Program, Dept Psychiat, Suite 580,50 Staniford St, Boston, MA 02114 USA. EM anierenberg@partners.org OI Ostacher, Michael/0000-0003-0353-7535 NR 55 TC 31 Z9 33 U1 3 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1076-2752 J9 J OCCUP ENVIRON MED JI J. Occup. Environ. Med. PD APR PY 2008 VL 50 IS 4 BP 428 EP 436 DI 10.1097/JOM.0b013e31816b5034 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 290FG UT WOS:000255108100007 PM 18404015 ER PT J AU Afshari, NA Ma, JJK Duncan, SM Pineda, R Starr, CE Decroos, FC Johnson, CS Adelman, RA AF Afshari, Natalie A. Ma, Joseph J. K. Duncan, Scott M. Pineda, Roberto Starr, Christopher E. Decroos, Francis Char Johnson, Carl S. Adelman, Ron A. TI Trends in resistance to ciprofloxacin, cefazolin, and gentamicin in the treatment of bacterial keratitis SO JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS LA English DT Article ID CONVENTIONAL ANTIBIOTIC-THERAPY; CORNEAL ULCERS; TOPICAL CIPROFLOXACIN; INFECTIOUS KERATITIS; EMERGING RESISTANCE; SHIFTING TRENDS; FLUOROQUINOLONES; SUSCEPTIBILITY; TOBRAMYCIN; GATIFLOXACIN AB Purpose: The aim of this study was to evaluate the microbial profile, resistance patterns, and antibiotic sensitivity of bacterial keratitis to three commonly used ocular antibiotics. Methods: All cases of bacterial keratitis referred to the Massachusetts Eye and Ear Infirmary Microbiology Laboratory from two consecutive annual 10-month periods were reviewed. The bacterial profile and resistance to ciprofloxacin, cefazolin, and gentamicin was evaluated within the two intervals. Results: Of the 485 cultures analyzed, 66.4% (322) were positive for bacterial isolates. Of these, 19.2% were polymicrobial, 87.5% were gram-positive, and 12.5% were gram-negative. The most prevalent isolate was coagulase-negative Staphylococcus (45.5%), followed by S. aureus (15.2%). The resistance patterns for gram-positive bacteria for ciprofloxacin for the first versus second time interval were 12% and 22% (P = 0.04) respectively, for cefazolin 13% and 23% (P = 0.04), and for gentamicin 4% and 7% (P = 0.36). The resistance patterns for gram-negative bacteria for ciprofloxacin, cefazolin, and gentamicin were not significantly different in the two tested time periods (all P > 0.05). Conclusions: There was increased resistance of gram-positive organisms to ciprofloxacin and cefazolin, but not gentamicin, in the two examined time periods. Increased resistance to these commonly used antibiotics emphasizes the need for close follow-up after initial empiric treatment, and maintaining a low threshold for selecting alternative therapy. C1 [Afshari, Natalie A.; Duncan, Scott M.; Decroos, Francis Char; Johnson, Carl S.] Duke Univ, Med Ctr, Ctr Eye, Durham, NC 27710 USA. [Ma, Joseph J. K.; Pineda, Roberto; Starr, Christopher E.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Boston, MA USA. [Adelman, Ron A.] Yale Univ, Med Ctr, Ctr Eye, New Haven, CT USA. RP Afshari, NA (reprint author), Duke Univ, Med Ctr, Ctr Eye, Box 3802, Durham, NC 27710 USA. EM afsha003@mc.duke.edu NR 32 TC 15 Z9 19 U1 0 U2 5 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1080-7683 J9 J OCUL PHARMACOL TH JI J. Ocular Pharmacol. Ther. PD APR PY 2008 VL 24 IS 2 BP 217 EP 223 DI 10.1089/jop.2007.0085 PG 7 WC Ophthalmology; Pharmacology & Pharmacy SC Ophthalmology; Pharmacology & Pharmacy GA 280TL UT WOS:000254449000009 PM 18331204 ER PT J AU Wessel, JH Dodson, TB Zavras, AI AF Wessel, John H. Dodson, Thomas B. Zavras, Athanasios I. TI Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: A case-control study SO JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY LA English DT Article ID MULTIPLE-MYELOMA; AVASCULAR NECROSIS; BREAST-CANCER; BISPHOSPHONATES; BONE; ACID; ANGIOGENESIS; MANAGEMENT; LEVEL AB Purpose: Bisphosphonates (BPS) effectively treat metastatic bone disease, hypercalcemia, and osteoporosis. BP exposure, however, may be associated with osteonecrosis of the jaw (ONJ). The aim of the present study was to estimate the magnitude of the association between intravenous (IV) BP exposure and ONJ, and to identify potential confounders. Materials and Methods: Using a case-control study design, the investigators identified and adjudicated a sample of cases with ONJ and matched them randomly with 5 controls per case. The controls were matched to cases on age, gender, cancer type, and date of cancer diagnosis. The medical records were abstracted and data on BP exposure, cancer therapy, and comorbidities were recorded. Statistical analyses were carried out using conditional logistic regression in Stata 9.0 (Stata Corp, College Station, TX). Results: Thirty cases of ONJ were identified at Massachusetts General Hospital from February 2003 through February 2007. Zoledronate was found to confer significant risk toward development of ONJ (adjusted odds ratio = 31.8, P < .05). Although a trend toward increased risk was noted for pamidronate, this association was not significant after controlling for zoledronate. Obesity and smoking were associated significantly with ONJ development, whereas oral BPS had no effect. Conclusion: In this study, cancer patients who had received zoledronate exhibited a significant 30-fold increase in their risk to develop ONJ. More studies are needed to elucidate the exact role of obesity and smoking in the development of ONJ, and the complex interactions of IV BPS with other chemotherapies during cancer treatment. (C) 2008 American Association of Oral and Maxillofacial Surgeons. C1 [Wessel, John H.] Harvard Univ, Sch Dent Med Oral Hlth Policy & Epidemiol, Boston, MA 02115 USA. [Dodson, Thomas B.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Dodson, Thomas B.] Novartis Inc, E Hanover, NJ USA. [Zavras, Athanasios I.] Res Triangle Inst, Cary, NC USA. RP Zavras, AI (reprint author), Harvard Univ, Sch Dent Med Oral Hlth Policy & Epidemiol, 188 Longwood Ave,REB217, Boston, MA 02115 USA. EM zavras@hms.harvard.edu FU NIDCR NIH HHS [R21 DE018143, R21 DE018143-01] NR 26 TC 98 Z9 103 U1 0 U2 3 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0278-2391 J9 J ORAL MAXIL SURG JI J. Oral Maxillofac. Surg. PD APR PY 2008 VL 66 IS 4 BP 625 EP 631 DI 10.1016/j.joms.2007.11.032 PG 7 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 282TD UT WOS:000254589200004 PM 18355585 ER PT J AU Fufa, D Shealy, B Jacobson, M Kevy, S Murray, MM AF Fufa, Duretti Shealy, Blake Jacobson, May Kevy, Sherwin Murray, Martha M. TI Activation of platelet-rich plasma using soluble type I collagen SO JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY LA English DT Article ID ENDOTHELIAL GROWTH-FACTOR; ANTERIOR CRUCIATE LIGAMENT; PERIODONTAL-LIGAMENT; FACTOR-BETA; TRANSFORMING GROWTH-FACTOR-BETA-1; RHEUMATOID-ARTHRITIS; LATTICE CONTRACTION; PCCSPRP SYSTEM; PRP KIT; CELLS AB Purpose: Platelet-rich plasma (PRP) has recently been found to be a useful delivery system for growth factors important to oral tissue healing. But application of PRP in a liquid form to a wound site within the oral cavity can be complicated by significant loss of the PRP into the surrounding oral space unless gelation through the clotting mechanism is accomplished. Gelation is currently accomplished using bovine thrombin; however, rare but serious complications of this method have led to the search for alternative clotting mechanisms, including the use of soluble collagen as a clotting activator. In this work, our hypothesis was that soluble type I collagen would be as effective as bovine thrombin in causing clotting of the PRP and stimulating growth factor release from the platelets and granulocytes. Materials and Methods: PRP from human donors was clotted using type I collagen or bovine thrombin. Clot retraction was determined by measuring clot diameters over time. The release of platelet-derived growth factor (PDGF)-AB, transforming growth factor (TGF)-beta 1, and vascular endothelial growth factor (VEGF) from both types of clots was measured over 10 days using enzyme-linked immunosorbent assasy. Results: Clots formed using type I collagen exhibited far less retraction than those formed with bovine thrombin. Bovine thrombin and type I collagen stimulated similar release of PDGF-AB and VEGF between 1 and 10 days; however, thrombin activation resulted in a greater release of TGF-beta 1 during the first 5 days after activation. Conclusions: The use of type I collagen to activate clotting of PRP may be a safe and effective alternative to bovine thrombin. The use of collagen results in less clot retraction and equal release of PDGF-AB and VEGF compared with currently available methods of clot activation. (C) 2008 American Association of Oral and Maxillofacial Surgeons. C1 [Fufa, Duretti; Shealy, Blake; Murray, Martha M.] Harvard Univ, Sch Med, Childrens Hosp, Dept Orthoped Surg, Boston, MA 02115 USA. [Jacobson, May; Kevy, Sherwin] Harvard Univ, Sch Med, CBR Inst Biomed Res, Boston, MA USA. RP Murray, MM (reprint author), Harvard Univ, Sch Med, Childrens Hosp, Dept Orthoped Surg, 300 Longwood Ave, Boston, MA 02115 USA. EM Martha.murray@childrens.harvard.edu FU NIAMS NIH HHS [K02 AR049346-03, K02 AR049346, K02 AR049346-01A1, K02 AR049346-02, K02 AR049346-04, R01 AR054099, R01 AR054099-01, R01 AR054099-02, R01AR054099] NR 37 TC 79 Z9 84 U1 1 U2 10 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0278-2391 J9 J ORAL MAXIL SURG JI J. Oral Maxillofac. Surg. PD APR PY 2008 VL 66 IS 4 BP 684 EP 690 DI 10.1016/j.joms.2007.06.635 PG 7 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 282TD UT WOS:000254589200010 PM 18355591 ER PT J AU Morales, TI AF Morales, Teresa I. TI The quantitative and functional relation between insulin-like growth factor-I (IGF) and IGF-binding proteins during human osteoarthritis SO JOURNAL OF ORTHOPAEDIC RESEARCH LA English DT Article DE insulin-like growth factor-I (IGF-I); IGF-binding proteins (IGFBPs); human cartilage; osteoarthritis; IGF-I analog ID BOVINE ARTICULAR-CARTILAGE; FACTOR BINDING-PROTEIN-3; PROTEOGLYCAN SYNTHESIS; CHONDROCYTE RESPONSE; INCREASED EXPRESSION; EXPLANTS; RECEPTOR; ANALOGS; SERUM AB A previous hypothesis stated that during osteoarthritis (OA) increased insulin-like growth factor (IGF) binding proteins (IGFBPs) sequester IGFs and limit their access to the cell. The objective of this article was to test this by: (1) quantifying IGF and IGFBP-3 as well as their ratios in human CIA cartilages, and (2) measuring the metabolic responses of diseased cartilage to IGF-I and its IGFBP-insensitive analogs. Knee or hip OA cartilages were staged for OA by histology. Cartilage slices were either extracted for assays of IGF proteins, or maintained intact as organ cultures. Proteoglycan (PG) metabolism IGFs was measured by use of the S-35-sulfate precursor. IGFBP-3 (ng/mg protein) was weakly correlated with CIA score by regression analysis (R-2 = 0.122; p = 0.040; n = 35). IGF-I (ng/mg protein) was constant across all CIA groups (ANOVA; p=.428, n = 18) and the IGF-I/IGFBP-3 ratios were > 1 in most samples. All CIA cartilages responded to hrIGF-I by increasing PG synthesis [average 2.29-fold +/- 0.55 (+/- SD) at saturation, n = 12] irrespective of OA score. The des (1-3) IGF-I analog (which lacks the three N-terminal amino acids) had similar maximal effects (average 2.23-fold stimulation +/- 0.71, n = 10), but it was more effective in two out of three samples at suboptimal doses. The effect of hrIGF-I, des (1-3) IGF-I, or the B-chain analog on degradation was minimal. In summary, catabolism was insensitive to IGF-I, and this was probably not due to IGFBPs. By contrast, IGF-I exerted a robust stimulation of anabolism at sufficiently high doses, even though IGFBPs could tone down the ligand effect at low doses. (c) 2007 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. C1 [Morales, Teresa I.] Harvard Univ, Sch Med, Boston, MA 02114 USA. [Morales, Teresa I.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Morales, TI (reprint author), Harvard Univ, Sch Med, Jackson 1223,55 Fruit St, Boston, MA 02114 USA. EM tmorales@partners.org FU NIAMS NIH HHS [R01 AR048304, R01 AR048304-04, R01 AR48304] NR 32 TC 16 Z9 16 U1 2 U2 2 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0736-0266 J9 J ORTHOP RES JI J. Orthop. Res. PD APR PY 2008 VL 26 IS 4 BP 465 EP 474 DI 10.1002/jor.20549 PG 10 WC Orthopedics SC Orthopedics GA 275GS UT WOS:000254060500007 PM 18050312 ER PT J AU Hwang, RW Bae, DS Waters, PM AF Hwang, Raymond W. Bae, Donald S. Waters, Peter M. TI Brachial plexus palsy following proximal humerus fracture in patients who are skeletally immature SO JOURNAL OF ORTHOPAEDIC TRAUMA LA English DT Article DE proximal humerus fracture; neuropraxia; brachial plexus; pediatric ID EPIPHYSEAL FRACTURES; NERVE LESIONS; CHILDREN; SEPARATION AB From 1998 to 2006, 578 patients who were skeletally immature with proximal humerus fractures were treated at our institution. During that time period, 4 patients (0.7%) had associated brachial plexus and major peripheral nerve palsies. Average age at the time of injury was 12.3 years (range 10-14 years). Two fractures were physeal and 2 were metaphyseal. In all patients, the distal fracture fragment was displaced into the axilla, with resultant adduction and valgus malalignment at the time of injury. Two patients were treated with closed reduction and sling and swathe immobilization. One patient was treated with closed reduction and percutaneous pinning of the fracture. One patient was treated with sling immobilization without fracture reduction. All went on to bony healing with acceptable bony alignment. All patients were evaluated with serial physical examinations and radiographs to assess for neurologic recovery and bony healing. Average clinical and radiographic follow-up was 7.1 months (5-9 months). All patients demonstrated complete neurologic recovery by 5-9 months postinjury. All had neuropathic pain for at least 6 months after injury. No persistent neuropathic pain or functional limitations were seen at follow-up. Although rare, brachial plexus injury may accompany displaced proximal humeral fractures in patients who are skeletally immature. With careful attention to principles of fracture care, complete neurologic recovery may be expected within 9 months. C1 [Bae, Donald S.; Waters, Peter M.] Childrens Hosp, Dept Orthoped Surg, Boston, MA 02115 USA. [Hwang, Raymond W.] Massachusetts Gen Hosp, Dept Orthopaed Surg, Boston, MA 02114 USA. RP Bae, DS (reprint author), Childrens Hosp, Dept Orthoped Surg, 300 Longwood Ave, Boston, MA 02115 USA. EM donald.bae@childrens.harvard.edu NR 20 TC 4 Z9 4 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0890-5339 J9 J ORTHOP TRAUMA JI J. Orthop. Trauma PD APR PY 2008 VL 22 IS 4 BP 286 EP 290 DI 10.1097/BOT.0b013e31816b7898 PG 5 WC Orthopedics; Sport Sciences SC Orthopedics; Sport Sciences GA 287AI UT WOS:000254888300014 PM 18404040 ER PT J AU Block, SD AF Block, Susan D. TI Susan D. Block, MD - Learning from a life in medicine SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Biographical-Item C1 [Block, Susan D.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Psychosocial Oncol & Palliat Care, Boston, MA 02115 USA. [Block, Susan D.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. [Block, Susan D.] Harvard Univ, Dept Psychiat & Med, Sch Med, Harvard Med Sch Ctr Palliat Care, Boston, MA 02115 USA. RP Block, SD (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Psychosocial Oncol & Palliat Care, 44 Binney St, Boston, MA 02115 USA. EM sblock@partners.org NR 1 TC 1 Z9 1 U1 0 U2 0 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 J9 J PALLIAT MED JI J. Palliat. Med. PD APR PY 2008 VL 11 IS 3 BP 434 EP 437 DI 10.1089/jpm.2008.9954 PG 4 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 283QO UT WOS:000254651800010 PM 18363485 ER PT J AU Carlson, MDA Morrison, RS Bradley, EH AF Carlson, Melissa D. A. Morrison, R. Sean Bradley, Elizabeth H. TI Improving access to hospice care: Informing the debate SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Article ID PALLIATIVE CARE; PROGNOSTIC CRITERIA; UNITED-STATES; LIFE; SERVICES; END; ELIGIBILITY; ENROLLMENT; HOSPITALS; BARRIERS AB The most frequently cited policy solution for improving access to hospice care for patients and families is to expand hospice eligibility criteria under the Medicare Hospice Benefit. However, the substantial implications of such a policy change have not been fully articulated or evaluated. This paper seeks to identify and describe the implications of expanding Medicare Hospice Benefit eligibility on the nature of hospice care, the cost of hospice care to the Medicare program, and the very structure of hospice and palliative care delivery in the United States. The growth in hospice has been dramatic and the central issue facing policymakers and the hospice industry is defining the appropriate target population for hospice care. As policymakers and the hospice industry discuss the future of hospice and potential changes to the Medicare Hospice Benefit, it is critical to clearly delineate the options - and the implications and challenges of each option - for improving access to hospice care for patients and families. C1 [Carlson, Melissa D. A.; Morrison, R. Sean] Mt Sinai Sch Med, Brookdale Dept Geriatr & Adult Dev, New York, NY 10029 USA. [Morrison, R. Sean] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. [Bradley, Elizabeth H.] Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06510 USA. RP Carlson, MDA (reprint author), Mt Sinai Sch Med, Brookdale Dept Geriatr & Adult Dev, 1 Gustave L Levy Pl,Box 1070, New York, NY 10029 USA. EM melissa.carlson@mssm.edu FU NINR NIH HHS [K99 NR010495-01, K99 NR010495] NR 40 TC 18 Z9 18 U1 3 U2 7 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 J9 J PALLIAT MED JI J. Palliat. Med. PD APR PY 2008 VL 11 IS 3 BP 438 EP 443 DI 10.1089/jpm.2007.0152 PG 6 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 283QO UT WOS:000254651800011 PM 18363486 ER PT J AU Novak, MJ Potter, RM Blodgett, J Ebersole, JL AF Novak, M. John Potter, Richard M. Blodgett, Janet Ebersole, Jeffrey L. TI Periodontal disease in Hispanic Americans with type 2 diabetes SO JOURNAL OF PERIODONTOLOGY LA English DT Article DE calculus; diabetes; Hispanic Americans; periodontitis; smoking; tooth loss ID BLOOD-GLUCOSE LEVELS; CIGARETTE-SMOKING; RISK FACTOR; CARDIOVASCULAR-DISEASE; MEXICAN-AMERICANS; ATTACHMENT LOSS; PIMA-INDIANS; MELLITUS; INSULIN; HYPERTENSION AB Background: Diabetes is a major risk factor for the development of periodontal disease in certain populations. The prevalence of type 2 diabetes is increased in Hispanic Americans, but its impact on the extent and severity of periodontal disease in this population has not been determined. Methods: Sixty-three Hispanic Americans, aged 33 to 72 years, from South Texas were grouped based on the presence or absence of type 2 diabetes. Past medical histories, including smoking, were obtained. Periodontal status was evaluated by measuring probing depth (PD), clinical attachment level (CAL), plaque, bleeding on probing, visual gingival inflammation, and calculus. Results: Type 2 diabetes was associated frequently with major medical complications in this population. Diabetes was associated with significantly more calculus formation and tooth loss and an increased extent and severity of periodontitis. Subjects with diabetes had nearly three times the mean CAL and frequency of PD >6 mm than subjects without diabetes and nearly twice the frequency of moderate to advanced attachment loss ( >= 3 mm). Smoking and diabetes had significant independent effects on mean CAL and the frequency of deep pockets. Diabetes and smoking combined were associated with a significantly higher frequency of sites with CAL 3 mm compared to healthy non-smokers, healthy smokers, and nonsmokers with diabetes. Conclusions: Hispanic Americans with type 2 diabetes had more supra- and subgingival calculus, an increased extent and severity of periodontal destruction, and an increased frequency of tooth loss due to periodontitis. An additive/synergistic contribution of type 2 diabetes and smoking for increasing the extent of periodontal disease was observed. C1 [Novak, M. John; Ebersole, Jeffrey L.] Univ Kentucky, Ctr Oral Hlth Res, Lexington, KY 40536 USA. [Blodgett, Janet] S Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Novak, MJ (reprint author), Univ Kentucky, Ctr Oral Hlth Res, 414 Hlth Sci Res Bldg, Lexington, KY 40536 USA. EM mjnova2@uky.edu FU NIDCR NIH HHS [DE-10589] NR 58 TC 31 Z9 37 U1 0 U2 3 PU AMER ACAD PERIODONTOLOGY PI CHICAGO PA 737 NORTH MICHIGAN AVENUE, SUITE 800, CHICAGO, IL 60611-2690 USA SN 0022-3492 J9 J PERIODONTOL JI J. Periodont. PD APR PY 2008 VL 79 IS 4 BP 629 EP 636 DI 10.1902/jop.2008.070442 PG 8 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 294RK UT WOS:000255423000009 PM 18380555 ER PT J AU Ebersole, JL Holt, SC Hansard, R Novak, MJ AF Ebersole, Jeffrey L. Holt, Stanley C. Hansard, Richard Novak, M. John TI Microbiologic and immunologic characteristics of periodontal disease in Hispanic Americans with type 2 diabetes SO JOURNAL OF PERIODONTOLOGY LA English DT Article DE diabetes; Hispanic Americans; immunology; microbiology; periodontitis ID SERUM ANTIBODY; ACTINOBACILLUS-ACTINOMYCETEMCOMITANS; PORPHYROMONAS-GINGIVALIS; TREPONEMA-DENTICOLA; ADULT PERIODONTITIS; MELLITUS PATIENTS; ATTACHMENT LOSS; INSULIN; RESPONSES; HEALTHY AB Background: The microbiology of periodontitis in type 1 diabetes has been reported, but less is known about type 2 diabetes. Moreover, these data have not linked microbial Colonization, host response, and clinical presentation in type 1 or type 2 diabetes. The objectives of this study were to relate periodontal status, periodontal microorganisms, and host-response characteristics in Hispanic Americans with type 2 diabetes. Methods: Plaque and serum samples were obtained from 63 Hispanic American subjects with and without type 2 diabetes. The microbiology of subgingival plaque samples was evaluated using DNA checkerboard hybridization, and serum antibody to a battery of oral microorganisms was determined using an enzyme-linked immunosorbent assay. Results: In general, similar pathogens were present in periodontitis sites from subjects with and without type 2 diabetes, although the periodontitis sites in diabetes showed a higher frequency of Porphyromonas gingivalis, Aggregatibacter actinomycetemcomitans (previously Actinobacillus actinomycetemcomitans), and Campylobacter spp. Serum antibody to Campylobacter rectus was elevated in type 2 diabetes, whereas antibody to P. gingivalis and C. rectus were elevated in subjects with periodontitis, irrespective of diabetes status. Stratification of the population based upon antibody to P. gingivalis or C rectus suggested a linkage between elevated antibody to P. gingivalis, increased frequency of diabetes, and significantly worse periodontitis. Conclusion: The increased severity of periodontal disease with type 2 diabetes may reflect an alteration of the pathogenic potential of periodontal bacteria and/or a modification of the characteristics of the host's inflammatory response that may contribute to a breakdown in the homeostasis of the periodontium. C1 [Ebersole, Jeffrey L.; Novak, M. John] Univ Kentucky, Ctr Oral Hlth Res, Lexington, KY 40536 USA. [Holt, Stanley C.] Forsyth Inst, Boston, MA USA. RP Novak, MJ (reprint author), Univ Kentucky, Ctr Oral Hlth Res, 414 Hlth Sci Res Bldg, Lexington, KY 40536 USA. EM mjnova2@uky.edu FU NIDCR NIH HHS [DE-10589] NR 54 TC 43 Z9 50 U1 0 U2 6 PU AMER ACAD PERIODONTOLOGY PI CHICAGO PA 737 NORTH MICHIGAN AVENUE, SUITE 800, CHICAGO, IL 60611-2690 USA SN 0022-3492 J9 J PERIODONTOL JI J. Periodont. PD APR PY 2008 VL 79 IS 4 BP 637 EP 646 DI 10.1902/jop.2008.070455 PG 10 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 294RK UT WOS:000255423000010 PM 18380556 ER PT J AU Kim, T Miyamoto, T Nunn, ME Garcia, RI Dietrich, T AF Kim, Taera Miyamoto, Takanari Nunn, Martha E. Garcia, Raul I. Dietrich, Thomas TI Root proximity as a risk factor for progression of alveolar bone loss: The veterans affairs dental longitudinal study SO JOURNAL OF PERIODONTOLOGY LA English DT Article DE alveolar bone loss; periodontal disease; periodontitis; risk factor ID PERIODONTAL-DISEASE; ORTHODONTIC TREATMENT; AGREEMENT; HEALTH; WIDTH AB Background: The purpose of the present longitudinal study was to evaluate the association between root proximity and the risk for alveolar bone loss (ABL). Methods: We used data from the Veterans Affairs Dental Longitudinal Study, a closed-panel longitudinal cohort study of 1,231 men enrolled in 1968 with triennial follow-up examinations. Periapical radiographs of mandibular incisors from subjects with >= 10 years of follow-up were selected. Interradicular distance (IRD) at the cemento-enamel junction and alveolar bone levels at baseline and last follow-up were measured using digitized radiographs. The rate of progressive ABL was determined and expressed as millimeters per 10 years. Site-specific multivariate regression models were fit to evaluate the association between IRD and ABL rate, adjusting for age and smoking. Empirical standard errors and generalized estimating equations were used to account for the correlation among sites within subjects. Results: There were 473 dentate subjects, aged 28 to 71 years at baseline, with >= 10 years of follow-up data available for analyses. The mean follow-up time was 23 years. The mean IRD was 1.0 +/- 0.3 mm, and the mean ABL rate during 10 years was 0.61 +/- 0.59 mm. There was a significant non-linear association between IRD and ABL rate (P<0.005). Compared to sites with IRD >= 0.8 mm, sites with IRD <0.6 mm were 28% (95% confidence interval [Cl]: 11% to 48%) more likely to lose >= 0.5 mm of bone during 10 years (relative risk: 1.28 [95% Cl: 1.11 to 1.48]) and 56% (95% Cl: 11 % to 117%) more likely to lose >= 1.0 mm of bone during 10 years (relative risk: 1.56 [95% Cl: 1.11 to 2.17]). Conclusions: IRD <0.8 mm is a significant local risk factor for alveolar bone loss in mandibular anterior teeth. Measurement of IRD may have important prognostic value in making treatment decisions. C1 [Kim, Taera; Nunn, Martha E.; Garcia, Raul I.; Dietrich, Thomas] Boston Univ, Goldman Sch Dent Med, Dept Hlth Policy & Hlth Serv Res, Boston, MA 02215 USA. [Miyamoto, Takanari] Boston Univ, Goldman Sch Dent Med, Dept Gen Dent, Boston, MA 02215 USA. [Miyamoto, Takanari] Creighton Univ, Sch Dent, Dept Periodontol, Omaha, NE 68178 USA. [Garcia, Raul I.] VA Boston Hlth Care Syst, VA Dental Longitudinal Study, Boston, MA USA. [Dietrich, Thomas] Boston Univ, Goldman Sch Dent Med, Dept Periodontol & Oral Biol, Boston, MA 02215 USA. [Kim, Taera] Boston Univ, Goldman Sch Grad Med, Dept Orthodont, Boston, MA USA. RP Dietrich, T (reprint author), Univ Birmingham, Sch Dent, Dept Oral Surg, Birmingham B4 6NN, W Midlands, England. EM t.dietrich@bham.ac.uk OI Garcia, Raul/0000-0003-2153-4629; Dietrich, Thomas/0000-0002-2557-7645 FU NIDCR NIH HHS [R03 DE016924, K24 DE-00419] NR 20 TC 9 Z9 9 U1 0 U2 2 PU AMER ACAD PERIODONTOLOGY PI CHICAGO PA 737 NORTH MICHIGAN AVENUE, SUITE 800, CHICAGO, IL 60611-2690 USA SN 0022-3492 J9 J PERIODONTOL JI J. Periodont. PD APR PY 2008 VL 79 IS 4 BP 654 EP 659 DI 10.1902/jop.2008.070477 PG 6 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 294RK UT WOS:000255423000012 PM 18380558 ER PT J AU Teles, FR Haffajee, AD Socransky, SS AF Teles, Flavia R. Haffajee, Anne D. Socransky, Sigmund S. TI The reproducibility of curet sampling of subgingival biofilms SO JOURNAL OF PERIODONTOLOGY LA English DT Article DE biofilm; microbiology; periodontitis; sampling ID REPOSITIONED FLAP SURGERY; POLYMERASE-CHAIN-REACTION; DNA-DNA HYBRIDIZATION; PERIODONTAL PATHOGENS; MICROBIOLOGICAL PARAMETERS; PAPER POINTS; MICROBIOTA; PLAQUE; DISEASES; STRATEGY AB Background: Because few studies have examined the critical issue of sampling reproducibility, the purpose of the present study was to examine the reproducibility of curet sampling of subgingival biofilms. Methods: Seven subgingival biofilm samples were taken successively, using a curet, from each of 80 sites and individually analyzed for their content of 40 bacterial species using checkerboard DNA-DNA hybridization. One healthy site was sampled in each of 20 periodontally healthy subjects, and one sulcus/pocket of <= 3, 4 to 5, and >= 6 mm was sampled in each of 20 subjects with chronic periodontitis. The significance of differences in counts and proportions of individual species at the seven successive samplings for each probing depth (PD) category was determined using the Kruskal-Wallis test. The reproducibility of species proportions at each PD category was measured using the coefficient of variation (CV), and the consistency of microbial profiles across samples was examined using the minimum similarity coefficient. Results: There was no significant difference in the mean proportions of the 40 test species in the seven successive samples in each of the four PD categories. The median CV for individual species in the same site was 0.79 (95% confidence interval [Cl]: 0.76 to 0.82) compared to 1.76 (95% CI: 1.69 to 1.82) in samples from different sites. The within-site mean minimum similarity coefficient ( +/- SEM) was 51.2% +/- 2.2%, and it was 27.9% +/- 0.3% between sites. Conclusion: The proportions of species remained consistent in successive curet samples, indicating that the use of curets provided a reliable and reproducible method to obtain subgingival samples. C1 [Teles, Flavia R.; Haffajee, Anne D.; Socransky, Sigmund S.] Forsyth Inst, Dept Periodontol, Boston, MA 02115 USA. RP Teles, FR (reprint author), Forsyth Inst, Dept Periodontol, 140 Fenway, Boston, MA 02115 USA. EM fteles@forsyth.org FU NIDCR NIH HHS [DE-014242, T32-DE-07327] NR 36 TC 19 Z9 19 U1 0 U2 5 PU AMER ACAD PERIODONTOLOGY PI CHICAGO PA 737 NORTH MICHIGAN AVENUE, SUITE 800, CHICAGO, IL 60611-2690 USA SN 0022-3492 J9 J PERIODONTOL JI J. Periodont. PD APR PY 2008 VL 79 IS 4 BP 705 EP 713 DI 10.1902/jop.2008.070424 PG 9 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 294RK UT WOS:000255423000019 PM 18380565 ER PT J AU Anderson, KS Ramachandran, N Wong, J Raphael, JV Hainsworth, E Demirkan, G Cramer, D Aronzon, D Hodi, FS Harris, L Logvinenko, T LaBaer, J AF Anderson, Karen S. Ramachandran, Niroshan Wong, Jessica Raphael, Jacob V. Hainsworth, Eugenie Demirkan, Gokhan Cramer, Daniel Aronzon, Dina Hodi, F. Stephen Harris, Lyndsay Logvinenko, Tanya LaBaer, Joshua TI Application of protein microarrays for multiplexed detection of antibodies to tumor antigens in breast cancer SO JOURNAL OF PROTEOME RESEARCH LA English DT Article DE breast cancer; autoantibodies; tumor antigen; biomarker; proteomics ID SERUM P53 ANTIBODIES; OVARIAN-CANCER; IMMUNE-RESPONSE; LUNG-CANCER; BIOLOGICAL PARAMETERS; ANTI-P53 ANTIBODIES; DUCTAL CARCINOMA; PROSTATE-CANCER; NATURAL PROTEIN; AUTOANTIBODIES AB There is strong preclinical evidence that cancer, including breast cancer, undergoes immune surveillance. This continual monitoring, by both the innate and the adaptive immune systems, recognizes changes in protein expression, mutation, folding, glycosylation, and degradation. Local immune responses to tumor antigens are amplified in draining lymph nodes, and then enter the systemic circulation. The antibody response to tumor antigens, such as p53 protein, are robust, stable, and easily detected in serum; may exist in greater concentrations than their cognate antigens; and are potential highly specific biomarkers for cancer. However, antibodies have limited sensitivities as single analytes, and differences in protein purification and assay characteristics have limited their clinical application. For example, p53 autoantibodies in the sera are highly specific for cancer patients, but are only detected in the sera of 10-20% of patients with breast cancer. Detection of p53 autoantibodies is dependent on tumor burden, p53 mutation, rapidly decreases with effective therapy, but is relatively independent of breast cancer subtype. Although antibodies to hundreds of other tumor antigens have been identified in the sera of breast cancer patients, very little is known about the specificity and clinical impact of the antibody immune repertoire to breast cancer. Recent advances in proteomic technologies have the potential for rapid identification of immune response signatures for breast cancer diagnosis and monitoring. We have adapted programmable protein microarrays for the specific detection of autoantibodies in breast cancer. Here, we present the first demonstration of the application of programmable protein microarray ELISAs for the rapid identification of breast cancer autoantibodies. C1 [Ramachandran, Niroshan; Raphael, Jacob V.; Hainsworth, Eugenie; Demirkan, Gokhan; LaBaer, Joshua] Harvard Univ, Sch Med, Harvard Inst Proteom, Cambridge, MA 02141 USA. [Anderson, Karen S.; Wong, Jessica; Aronzon, Dina; Hodi, F. Stephen] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA. [Cramer, Daniel] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. [Harris, Lyndsay] Yale Univ, Dept Med, New Haven, CT 06520 USA. [Hainsworth, Eugenie] Harvard Univ, Sch Med, Technol & Engn Ctr, Boston, MA 02115 USA. [Logvinenko, Tanya] Tufts Univ New England Med Ctr, Inst Clin Res & Hlth Policy Studies, Boston, MA 02110 USA. [Anderson, Karen S.; Wong, Jessica; Aronzon, Dina; Hodi, F. Stephen] Harvard Univ, Sch Med, Dana Farber Canc Inst, Canc Vaccine Ctr, Boston, MA 02115 USA. RP LaBaer, J (reprint author), Harvard Univ, Sch Med, Harvard Inst Proteom, Cambridge, MA 02141 USA. EM josh@hms.harvard.edu FU NCI NIH HHS [U01 CA117374, 5U01CA117374-02] NR 70 TC 105 Z9 113 U1 1 U2 19 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 1535-3893 J9 J PROTEOME RES JI J. Proteome Res. PD APR PY 2008 VL 7 IS 4 BP 1490 EP 1499 DI 10.1021/pr700804c PG 10 WC Biochemical Research Methods SC Biochemistry & Molecular Biology GA 284MR UT WOS:000254711000014 PM 18311903 ER PT J AU Qiu, YH Patwa, TH Xu, L Shedden, K Misek, DE Tuck, M Jin, G Ruffin, MT Turgeon, DK Synal, S Bresalier, R Marcon, N Brenner, DE Lubman, DM AF Qiu, Yinghua Patwa, Tasneem H. Xu, Li Shedden, Kerby Misek, David E. Tuck, Missy Jin, Gracie Ruffin, Mack T. Turgeon, Danielle K. Synal, Sapna Bresalier, Robert Marcon, Norman Brenner, Dean E. Lubman, David M. TI Plasma glycoprotein profiling for colorectal cancer biomarker identification by lectin glycoarray and lectin blot SO JOURNAL OF PROTEOME RESEARCH LA English DT Article DE plasma glycoproteomics; lectin affinity enrichment; lectin glycoarrays; lectin blot; nano-LC-MS/MS ID TANDEM MASS-SPECTROMETRY; TUMOR-MARKERS CEA; CARCINOEMBRYONIC ANTIGEN; AFFINITY-CHROMATOGRAPHY; COLON-CANCER; SERUM GLYCOPROTEINS; PANCREATIC-CANCER; CA 242; DISCOVERY; GLYCOSYLATION AB Colorectal cancer (CRC) remains a major worldwide cause of cancer-related morbidity and mortality largely due to the insidious onset of the disease. The current clinical procedures utilized for disease diagnosis are invasive, unpleasant, and inconvenient; hence, the need for simple blood tests that could be used for the early detection of CRC. In this work, we have developed methods for glycoproteomics analysis to identify plasma markers with utility to assist in the detection of colorectal cancer (CRC). Following immunodepletion of the most abundant plasma proteins, the plasma N-linked glycoproteins were enriched using lectin affinity chromatography and subsequently further separated by nonporous silica reversed-phase (NPS-RP)-HPLC. Individual RP-HPLC fractions were printed on nitrocellulose coated slides which were then probed with lectins to determine glycan patterns in plasma samples from 9 normal, 5 adenoma, and 6 colorectal cancer patients. Statistical tools, including principal component analysis, hierarchical clustering, and Z-statistics analysis, were employed to identify distinctive glycosylation patterns. Patients diagnosed with colorectal cancer or adenomas were shown to have dramatically higher levels of sialylation and fucosylation as compared to normal controls. Plasma glycoproteins with aberrant glycosylation were identified by nano-LC-MS/MS, while a lectin blotting methodology was used to validate proteins with significantly altered glycosylation as a function of cancer progression. The potential markers identified in this study for diagnosis to distinguish colorectal cancer from adenoma and normal include elevated sialylation and fucosylation in complement C3, histidine-rich glycoprotein, and kininogen-1. These potential markers of colorectal cancer were subsequently validated by lectin blotting in an independent set of plasma samples obtained from 10 CRC patients, 10 patients with adenomas, and 10 normal subjects. These results demonstrate the utility of this strategy for the identification of Winked glycan patterns as potential markers of CRC in human plasma, and may have the utility to distinguish different disease states. C1 [Qiu, Yinghua; Patwa, Tasneem H.; Lubman, David M.] Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA. [Shedden, Kerby] Univ Michigan, Dept Stat, Ann Arbor, MI 48109 USA. [Ruffin, Mack T.] Univ Michigan, Dept Family Med, Ann Arbor, MI 48109 USA. [Turgeon, Danielle K.; Brenner, Dean E.] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA. [Misek, David E.; Tuck, Missy; Brenner, Dean E.; Lubman, David M.] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA. [Xu, Li; Misek, David E.; Jin, Gracie; Lubman, David M.] Univ Michigan, Med Ctr, Dept Surg, Ann Arbor, MI 48109 USA. [Synal, Sapna] Brigham & Womens Med Ctr, Dana Farber Canc Inst, Boston, MA 02115 USA. [Bresalier, Robert] Univ Texas Houston, MD Anderson Canc Ctr, Dept Gastroenterol Hepatol & Nutr, Houston, TX 77030 USA. [Xu, Li] Natl Sun Yat Sen Univ, Ctr Canc, Guang Zhou 510060, Peoples R China. [Marcon, Norman] Univ Toronto, St Michaels Hosp, Dept Gastroenterol, Toronto, ON M5B 1W8, Canada. RP Lubman, DM (reprint author), Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA. EM dmlubman@umich.edu OI Ruffin, Mack/0000-0001-8336-478X FU NCI NIH HHS [R21 CA124441, CA86400, R01 CA106402, R01 CA106402-05, R01CA106402, R21 CA124441-01A1, R21CA124441, U01 CA086400] NR 45 TC 114 Z9 118 U1 5 U2 36 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 1535-3893 J9 J PROTEOME RES JI J. Proteome Res. PD APR PY 2008 VL 7 IS 4 BP 1693 EP 1703 DI 10.1021/pr700706s PG 11 WC Biochemical Research Methods SC Biochemistry & Molecular Biology GA 284MR UT WOS:000254711000033 PM 18311904 ER PT J AU O'Farrell, TJ Murphy, M Alter, J Fals-Stewart, W AF O'Farrell, Timothy J. Murphy, Marie Alter, Jane Fals-Stewart, William TI Brief family treatment intervention to promote continuing care among alcohol-dependent patients in inpatient detoxification: A randomized pilot study SO JOURNAL OF SUBSTANCE ABUSE TREATMENT LA English DT Article; Proceedings Paper CT 27th Annual Meeting of the Research-Society-on-Alcoholism CY JUN 26-30, 2004 CL Vancouver, CANADA SP Res Soc Alcoholism DE family therapy; detoxification ID ABUSING PATIENTS; SUBSTANCE-USE AB Alcohol-dependent patients in inpatient detoxification were randomized to treatment-as-usual (TAU) intervention or brief family treatment (BFT) intervention to promote continuing care postdetoxification. BFT consisted of meeting with the patient and an adult family member (in person or over the phone) with whom the patient lived to review and recommend potential continuing care plans for the patient. Results showed that BFT patients (n = 24) were significantly more likely than TAU patients (n = 21) to enter a continuing care program after detoxification. This was a medium to large effect size. In the 3 months after detoxification, days using alcohol or drugs (a) trended lower for treatment-exposed BFT patients who had an in-person family meeting than for TAU counterparts (medium effect), and (b) were significantly lower for patients who entered continuing care regardless of treatment condition (large effect). (C) 2008 Elsevier Inc. All rights reserved. C1 [O'Farrell, Timothy J.; Murphy, Marie; Alter, Jane] Harvard Univ, Sch Med, Families & Addict Progrram, Dept Psychiat,VA Boston Healthcare Syst, Brockton, MA 02301 USA. [Fals-Stewart, William] Univ Rochester, Dept Psychiat, Rochester, NY USA. RP O'Farrell, TJ (reprint author), Harvard Univ, Sch Med, Families & Addict Progrram, Dept Psychiat,VA Boston Healthcare Syst, VAMC 116B1,940 Belmont St, Brockton, MA 02301 USA. EM timothy_ofarrell@hms.harvard.edu FU NIAAA NIH HHS [R21 AA011735, R21 AA011735-01A1, K02AA00234, K02 AA000234, R21AA11735, K02 AA000234-07] NR 23 TC 13 Z9 13 U1 0 U2 5 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0740-5472 J9 J SUBST ABUSE TREAT JI J. Subst. Abus. Treat. PD APR PY 2008 VL 34 IS 3 BP 363 EP 369 DI 10.1016/j.jsat.2007.05.006 PG 7 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA 276JT UT WOS:000254137800013 PM 17614242 ER PT J AU Alwayn, IPJ Verbesey, JE Kim, S Roy, R Arsenault, DA Greene, AK Novak, K Laforme, A Lee, S Moses, MA Puder, M AF Alwayn, Ian P. J. Verbesey, Jennifer E. Kim, Sendia Roy, Roopali Arsenault, Danielle A. Greene, Arin K. Novak, Katherine Laforme, Andrea Lee, Sang Moses, Marsha A. Puder, Mark TI A critical role for matrix metal loproteinases in liver regeneration SO JOURNAL OF SURGICAL RESEARCH LA English DT Article DE matrix metalloproteinase; MMP; liver regeneration; IL-6; TNF-alpha; microvessel density; metalloproteinase inhibitor; Marimastat ID PARTIAL-HEPATECTOMY; TISSUE INHIBITOR; HEPATIC REGENERATION; METALLOPROTEINASES; MICE; ACTIVATION; EXPRESSION; RAT; NEOVASCULARIZATION; INTERLEUKIN-6 AB Background. Matrix metalloproteinases (MMPs), tumor necrosis factor-alpha (TNF-alpha), and interleukin-6 (IL-6) are mediators of liver regeneration. To determine whether MMPs are required for normal hepatic regeneration, we performed 67% hepatectomies on mice treated with a broad-spectrum MMP-inhibitor, and assessed the effect on liver regeneration and urinary AMP activity. Methods. Mice were subjected to sham operations, 67% hepatectomy, or 67% hepatectomy plus treatment with the broad-spectrum AMP inhibitor Marimastat. Urine collected preoperatively and for 8 d postoperatively was tested for MMP-2 and MMP-9 activity using zymography. Serum aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, bilirubin, TNF-alpha, IL-6, and hepatocyte growth factor levels were measured. Liver sections were analyzed by CD31 immunohistochemistry and microvessel density. Mitotic index and proliferating cell nuclear antigen labeling index were determined. Results. The mean regenerating liver weight on postoperative day 8 was 0.72 +/- 0.01 grams for the hepatectomy Marimastat group, and 0.83 +/- 0.02 grams for the hepatectomy control group (P < 0.001). Urinary MMP-9 activity was elevated during hepatic regeneration, and decreased on postoperative day 8 when the liver returned to its preoperative mass. In contrast , urine from hepatectomy Marimastat mice, in which liver regeneration was successfully inhibited, showed consistently low levels of MMP-2 and AMP-9 activity. The hepatectomy Marimastat group also exhibited elevated serum IL-6 levels on post-operative day 8, while serum TNF-alpha soluble receptor 11 levels were unchanged. Hepatocyte growth factor levels were not significantly different between the control hepatectomy and hepatectomy Marimastat groups at days 2,4, and 8. Liver microvessel density was reduced in the hepatectomy Marimastat group at day 4. Mitotic index and proliferating cell nuclear antigen index were significantly decreased in the Marimastat hepatectomy group at post-operative day 2. Conclusions. The broad-spectrum AMP-inhibitor Marimastat inhibits liver regeneration. Microvessel density is reduced at day 4. Furthermore, urinary MMP-9 is elevated during liver regeneration, and this effect is not observed when regeneration is inhibited by the broad-spectrum AMP-inhibitor Marimastat. (C) 2008 Elsevier Inc. All rights reserved. C1 [Alwayn, Ian P. J.; Kim, Sendia; Roy, Roopali; Arsenault, Danielle A.; Greene, Arin K.; Novak, Katherine; Laforme, Andrea; Lee, Sang; Moses, Marsha A.; Puder, Mark] Childrens Hosp, Dept Surg, Boston, MA 02115 USA. [Alwayn, Ian P. J.; Kim, Sendia; Roy, Roopali; Arsenault, Danielle A.; Greene, Arin K.; Novak, Katherine; Laforme, Andrea; Lee, Sang; Moses, Marsha A.; Puder, Mark] Childrens Hosp, Vasc Biol Program, Boston, MA 02115 USA. [Alwayn, Ian P. J.] Univ Med Ctr, Erasmus MC, Dept Surg, Rotterdam, Netherlands. [Verbesey, Jennifer E.] Lahey Clin Med Ctr, Dept Hepatobiliary Surg & Liver Transplantat, Burlington, MA 01803 USA. [Laforme, Andrea] Dana Farber Canc Inst, Dept Pediat Neuro Oncol, Boston, MA 02115 USA. RP Puder, M (reprint author), Childrens Hosp, Dept Surg, Karp Family Res Bldg 11213,300 Longwood Ave, Boston, MA 02115 USA. EM mark.puder@childrens.harvard.edu FU NCI NIH HHS [P01 CA45548, P01 CA045548]; NIDDK NIH HHS [DK069621-01, 1 P50 DK065298, K08 DK069621, P50 DK065298] NR 31 TC 27 Z9 28 U1 0 U2 4 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0022-4804 J9 J SURG RES JI J. Surg. Res. PD APR PY 2008 VL 145 IS 2 BP 192 EP 198 DI 10.1016/j.jss.2007.04.002 PG 7 WC Surgery SC Surgery GA 274KE UT WOS:000253999400003 PM 18222481 ER PT J AU Bush, RL Kallen, MA Liles, DR Bates, JT Petersen, LA AF Bush, Ruth L. Kallen, Michael A. Liles, Debra R. Bates, Jeffrey T. Petersen, Laura A. TI Knowledge and awareness of peripheral vascular disease are poor among women at risk for cardiovascular disease SO JOURNAL OF SURGICAL RESEARCH LA English DT Article DE women; cardiovascular disease; screening; peripheral vascular disease; risk factor ID ANKLE-BRACHIAL INDEX; ARTERIAL-DISEASE; OCCLUSIVE DISEASE; VETERANS HEALTH; SEX-DIFFERENCES; HEART-DISEASE; PREVALENCE; ATHEROSCLEROSIS; PREVENTION; CORONARY AB Objective. Peripheral vascular disease (PVD), a manifestation of systemic atherosclerosis, is an independent risk factor for cardiovascular (CV) morbidity and mortality. PVD research has traditionally focused on male patients; thus, there is a lack of current studies focusing specifically on women. In a cross-sectional study, we assessed the prevalence of PVD and associated atherosclerotic risk factors in ambulatory women veterans as well as knowledge and awareness of PVD and its consequences. Materials and methods. We screened 162 ambulatory women veterans aged 40 to 85 who were enrolled for outpatient care at an urban, tertiary care, teaching hospital. Of 207 women who responded to advertisements or mailings about the study, 78.3% met eligibility criteria and gave informed consent to participate. The participants (N = 162, mean age 54.8 +/- 9.3 years) were evaluated via chart review and noninvasive screening procedures (ankle-brachial index [ABI]; carotid artery intimal-medial thickness [IMT]). PVD was defined by having an ABI <= 0.9, carotid IMT > 1.0 mm, documented PVD, or previous leg revascularization. CV risk levels were determined using a modification of the Framingham risk level score: low risk, +0-1 risk factor; moderate risk, +2 risk factors; and high risk, >= 2 risk factors. Women's knowledge and awareness were assessed with a psychometrically sound survey (average subscale reliability: 0.942) about risk factors, symptoms, and health consequences associated with PVD. Results. Of 162 patients, 66.2% were white and 84.2% had at least some college education. An ABI <= 0.9 was detected in 3.7% of patients and a carotid IMT > 1.0 mm was detected in 21.1%, while 1.2% had a prior diagnosis of PVD and 1.9% had previous leg revascularization. Risk factor stratification was as follows: low risk in 32.1%, moderate risk in 20.4%, and high risk in 47.5% of patients. Knowledge and awareness scores (% correct) for PVD were low regardless of CV risk factor group: low-risk average score was 45.7%; moderate risk, 42.1%; and high risk, 46.9% (F = 0.431, P = 0.650). Likewise, low scores for knowledge of CV risk factors and consequences were found in all CV risk factor groups: low-risk average score was 53.6%; moderate risk, 53.8%; and high risk, 54.4% (F =.013, P = 0.987). More than 68% of the women reported they had never discussed PVD or risk reduction with their physician, yet more than 44% believed they were at an increased risk for PVD. Conclusions. Despite the presence of multiple PVD risk factors, women in this study had low levels of knowledge and awareness about vascular diseases. Future work is needed to develop and disseminate information about PVD in women and its role in women's CV health. Improving education about the significance of PVD will allow women and their physicians to assess risk factors and implement preventive measures. (C) 2008 Elsevier Inc. All rights reserved. C1 [Bush, Ruth L.; Liles, Debra R.] VA Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Michael E DeBakey Dept Surg, Houston, TX USA. [Kallen, Michael A.; Bates, Jeffrey T.] VA Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Dept Med, Houston, TX USA. [Kallen, Michael A.; Petersen, Laura A.] VA Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Div Hlth Policy & Qual, Houston, TX USA. [Kallen, Michael A.; Petersen, Laura A.] Baylor Coll Med, Sect Hlth Serv Res, Houston, TX 77030 USA. RP Bush, RL (reprint author), Texas A&M Univ, Hlth Sci Ctr, Div Vasc Surg, Scott & White Hosp, 2401 S 31st St, Temple, TX 76508 USA. EM dliles@bcm.edu NR 35 TC 6 Z9 6 U1 1 U2 2 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0022-4804 J9 J SURG RES JI J. Surg. Res. PD APR PY 2008 VL 145 IS 2 BP 313 EP 319 DI 10.1016/j.jss.2007.03.022 PG 7 WC Surgery SC Surgery GA 274KE UT WOS:000253999400020 PM 18222479 ER PT J AU Lichtenhan, JT Chertoff, ME AF Lichtenhan, Jeffery T. Chertoff, Mark E. TI Temporary hearing loss influences post-stimulus time histogram and single neuron action potential estimates from human compound action potentials SO JOURNAL OF THE ACOUSTICAL SOCIETY OF AMERICA LA English DT Article ID BRAIN-STEM RESPONSE; COCHLEAR MECHANOELECTRIC TRANSDUCTION; SYSTEMS IDENTIFICATION TECHNIQUE; PRODUCT OTOACOUSTIC EMISSIONS; NERVE ACTION POTENTIALS; DAMAGE-RISK CRITERIA; OUTER HAIR-CELLS; AUDITORY-NERVE; BASILAR-MEMBRANE; THRESHOLD SHIFT AB An analytic compound action potential (CAP) obtained by convolving functional representations of the post-stimulus time histogram summed across auditory nerve neurons [P(t)] and a single neuron action potential [U(t)] was fit to human CAPs. The analytic CAP fit to pre- and postnoise-induced temporary hearing threshold shift (TTS) estimated in vivo P(t) and U(t) and the number of neurons contributing to the CAPs (N). The width of P(t) decreased with increasing signal level and was wider at the lowest signal level following noise exposure. P(t) latency decreased with increasing signal level and was shorter at all signal levels following noise exposure. The damping and oscillatory frequency of U(t) increased with signal level. For subjects with large amounts of TTS, U(t) had greater damping than before noise exposure particularly at low signal levels. Additionally, U(t) oscillation was lower in frequency at all click intensities following noise exposure. N increased with signal level and was smaller after noise exposure at the lowest signal level. Collectively these findings indicate that neurons contributing to the CAP during TTS are fewer in number, shorter in latency, and poorer in synchrony than before noise exposure. Moreover, estimate's of single neuron action potentials may decay more rapidly and have a lower oscillatory frequency during TTS. (C) 2008 Acoustical Society of America. C1 [Lichtenhan, Jeffery T.; Chertoff, Mark E.] Univ Kansas, Med Ctr, Dept Speech & Hearing, Kansas City, KS 66103 USA. RP Lichtenhan, JT (reprint author), Massachusetts Eye & Ear Infirm, Eaton Peabody Lab Auditory Physiol, 243 Charles St, Boston, MA 02114 USA. EM jlichtenhan@gmail.com FU NIDCD NIH HHS [R01 DC002117, R01DC02117] NR 70 TC 11 Z9 11 U1 0 U2 0 PU ACOUSTICAL SOC AMER AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0001-4966 J9 J ACOUST SOC AM JI J. Acoust. Soc. Am. PD APR PY 2008 VL 123 IS 4 BP 2200 EP 2212 DI 10.1121/1.2885748 PG 13 WC Acoustics; Audiology & Speech-Language Pathology SC Acoustics; Audiology & Speech-Language Pathology GA 289HD UT WOS:000255044700040 PM 18397026 ER PT J AU Biederman, J Ball, SW Monuteaux, MC Mick, E Spencer, TJ Mccreary, M Cote, M Faraone, SV AF Biederman, Joseph Ball, Sarah W. Monuteaux, Michael C. Mick, Eric Spencer, Thomas J. Mccreary, Michelle Cote, Michelle Faraone, Stephen V. TI New insights into the comorbidity between ADHD and major depression in adolescent and young adult females SO JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY LA English DT Article DE attention-deficit/hyperactivity disorder; major depression; adolescents; females ID ATTENTION-DEFICIT HYPERACTIVITY; BIPOLAR DISORDER; RISK-FACTORS; DEFICIT/HYPERACTIVITY DISORDER; CO-MORBIDITY; CHILDREN; FAMILY; PREVALENCE; CHILDHOOD; ANXIETY AB Objective: The main aim of this study was to evaluate the association between attention-deficit/hyperactivity disorder (ADHD) and major depression (MD) in adolescent and young adult females. Method: Subjects were females with (n = 140) and without (n = 122) ADHD ascertained from pediatric and psychiatric settings. Subjects were followed prospectively for 5 years into adolescence and young adulthood and reassessed in multiple nonoverlapping domains including psychiatric, cognitive, interpersonal, family, and educational functioning. Results: Females with ADHD had a 2.5 times higher risk for MD at adolescent follow-up compared with control females, adjusting for psychiatric comorbidity. MD in females with ADHD was associated with an earlier age at onset, greater than twice the duration, more severe depression-associated impairment, a higher rate of suicidality, and a greater likelihood of requiring psychiatric hospitalization than MD in control girls. Parental MD and proband mania were significant predictors of MD among females with ADHD, independently of other predictors. Conclusions: MD emerging in the context of ADHD in females is an impairing and severe comorbidity worthy of further clinical and scientific considerations. C1 [Biederman, Joseph; Ball, Sarah W.; Monuteaux, Michael C.; Mick, Eric; Spencer, Thomas J.; Mccreary, Michelle; Cote, Michelle] Massachusetts Gen Hosp, Clin Res Program Pediat Psychopharmacol, Boston, MA 02114 USA. [Biederman, Joseph] Harvard Univ, Sch Med, Dept Psychiat, Cambridge, MA 02138 USA. [Faraone, Stephen V.] SUNY Upstate Med Univ, Dept Psychiat, Syracuse, NY USA. [Faraone, Stephen V.] SUNY Upstate Med Univ, Dept Neurosci, Syracuse, NY USA. [Faraone, Stephen V.] SUNY Upstate Med Univ, Dept Physiol, Syracuse, NY USA. RP Biederman, J (reprint author), Massachusetts Gen Hosp, Clin Res Program Pediat Psychopharmacol, 55 Fruit St,Warren 705, Boston, MA 02114 USA. EM jbiederman@partners.org OI Mick, Eric/0000-0001-8505-8145; Faraone, Stephen/0000-0002-9217-3982 FU NICHD NIH HHS [5R01 HD-36317-07]; NIMH NIH HHS [1-R03-MH079954-01] NR 44 TC 76 Z9 79 U1 1 U2 17 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0890-8567 J9 J AM ACAD CHILD PSY JI J. Am. Acad. Child Adolesc. Psychiatr. PD APR PY 2008 VL 47 IS 4 BP 426 EP 434 DI 10.1097/CHI.0b013e31816429d3 PG 9 WC Psychology, Developmental; Pediatrics; Psychiatry SC Psychology; Pediatrics; Psychiatry GA 278EF UT WOS:000254266100011 PM 18388760 ER PT J AU Danforth, N Hart, A AF Danforth, Nicole Hart, Archibald TI Thrilled to death: How the endless pursuit of pleasure is leaving us numb SO JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY LA English DT Book Review C1 [Danforth, Nicole] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Danforth, N (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. EM ndanforth@partners.org NR 2 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0890-8567 J9 J AM ACAD CHILD PSY JI J. Am. Acad. Child Adolesc. Psychiatr. PD APR PY 2008 VL 47 IS 4 BP 474 EP 475 DI 10.1097/01.CHI.0000270813.63259.31 PG 2 WC Psychology, Developmental; Pediatrics; Psychiatry SC Psychology; Pediatrics; Psychiatry GA 278EF UT WOS:000254266100019 ER PT J AU Armstrong, AW Idriss, SZ Kimball, AB Bernhard, JD AF Armstrong, April W. Idriss, Shereene Z. Kimball, Alexandra B. Bernhard, Jeffrey D. TI Fate of manuscripts declined by the Journal of the American Academy of Dermatology SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY LA English DT Article AB Background: Submissions to the journal of the American Academy of Dermatology (JAAD) undergo a rigorous peer-review process. However, little is known regarding the fate of manuscripts declined by the JAAD. Objective. We sought to: (1) determine the proportion of manuscripts declined by the JAAD that are subsequently published elsewhere. (2) identify the journals in which they were published; and (3) study whether the authors of declined manuscripts adopted in their final publications the changes suggested by the JAAD reviewers. Methods: We reviewed the outcomes of the 489 submissions declined by the JAAD during two 4-month periods: from March 1, 2004, to June 30, 2004, and from March 1, 2005, to June 30, 2005. Results: Of the 981 manuscripts submitted to JAAD during the two 4-month periods studied, 489 manuscripts (50%) were declined. Among the declined manuscripts, 201 (41%) had been subsequently published in other medical journals as of March 1, 2007. Among the 55 journals that published manuscripts declined by JAAD, 23 (42%) were nondermatology journals. The median impact factor for these 55 journals was 1.638, Compared with the JAAD's impact factor of 2.402. Among the declined manuscripts, Case Reports comprised the largest proportion (n = 149, 31%), followed by Original Research Reports (n = 90, 18%). Overall, 46 (51%) rejected Original Research Reports were Subsequently published, compared with 145 (36%) rejected submissions in other categories that were later published (P <.01). Among the 101 subsequently published manuscripts for which full texts were available, 82% of the authors incorporated at least one change suggested by the JAAD reviewers. The manuscripts that adopted JAAD-reviewer suggestions were published in journals with higher impact factors than those that did not incorporate any JAAD-reviewer suggestions (P =.0305). Limitations: It is possible that the average lag time of 28 months in this study is not sufficient for some rejected manuscripts to reach subsequent publication. Conclusions: Approximately half of the manu scripts rejected by the JAAD were subsequently published in other journals within 28 months, among which, roughly 40% went to nondermatology journals. The median impact factor of the journals that published JAAD-rejectect manuscripts was lower than that of the JAAD. Rejected Original Research Reports have a significantly higher probability of being subsequently published than other category submissions. This may be a result of relative quality of Original Research Reports versus submissions for other sections of the journal (eg, Case Reports). Manuscripts that adopted JAAD-reviewer suggestions were subsequently published in journals with higher impact factors than those that did not incorporate JAAD-reviewer suggestions. This indicates that peer-reviewer comments can be useful and important for improving the quality of scientific publications. C1 [Kimball, Alexandra B.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Boston, MA 02114 USA. [Armstrong, April W.; Kimball, Alexandra B.] Brigham & Womens Hosp, Clin Unit Res Trials Skin, Boston, MA 02115 USA. [Idriss, Shereene Z.] George Washington Sch Med & Hlth Sci, Washington, DC USA. [Bernhard, Jeffrey D.] Univ Massachusetts, Sch Med, Worcester, MA USA. RP Kimball, AB (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, 50 Staniford St,246, Boston, MA 02114 USA. EM harvardskinstudies@partners.org NR 7 TC 11 Z9 11 U1 0 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0190-9622 J9 J AM ACAD DERMATOL JI J. Am. Acad. Dermatol. PD APR PY 2008 VL 58 IS 4 BP 632 EP 635 DI 10.1016/j.jaad.2007.12.025 PG 4 WC Dermatology SC Dermatology GA 278VS UT WOS:000254315000011 PM 18249470 ER PT J AU Hosalkar, HS Torbert, JT Fox, EJ Delaney, TF Aboulafia, AJ Lackman, RD AF Hosalkar, Harish S. Torbert, Jesse T. Fox, Edward J. Delaney, Thomas F. Aboulafia, Albert J. Lackman, Richard D. TI Musculoskeletal desmoid tumors SO JOURNAL OF THE AMERICAN ACADEMY OF ORTHOPAEDIC SURGEONS LA English DT Review ID FAMILIAL ADENOMATOUS POLYPOSIS; LOW-DOSE CHEMOTHERAPY; AGGRESSIVE FIBROMATOSIS; RADIATION-THERAPY; COMBINATION CHEMOTHERAPY; FOLLOW-UP; MANAGEMENT; RADIOTHERAPY; METHOTREXATE; VINBLASTINE AB Desmoid tumors are benign tumors that exhibit varying degrees of local aggressiveness and diverse growth patterns. Magnetic resonance imaging remains the modality of choice for assessment of the nature and size of the soft-tissue lesion and involvement of surrounding structures. Treatment strategies include surgery, chemotherapy, hormonal therapy, and radiation therapy, either individually or in combination. Despite the benign nature of these tumors, multidisciplinary care is needed to provide combined treatment options. Chemotherapy in low doses is an excellent first-round treatment in any patient in whom contemplated local treatment may produce local morbidity and adjacent tissue injury. C1 [Hosalkar, Harish S.; Torbert, Jesse T.; Fox, Edward J.; Lackman, Richard D.] Univ Penn, Dept Orthopaed Surg, Philadelphia, PA 19104 USA. [Delaney, Thomas F.] Massachusetts Gen Hosp, Proton Therapy Ctr, Boston, MA 02114 USA. [Aboulafia, Albert J.] Sinai Hosp, Dept Orthopaed Surg, Inst Canc, Baltimore, MD 21215 USA. RP Lackman, RD (reprint author), Univ Penn, Dept Orthopaed Surg, 2 Silverstein,3400 Spruce St, Philadelphia, PA 19104 USA. NR 65 TC 20 Z9 24 U1 0 U2 0 PU AMER ACAD ORTHOPAEDIC SURGEONS PI ROSEMENT PA 6300 N RIVER ROAD, ROSEMENT, IL 60018-4262 USA SN 1067-151X J9 J AM ACAD ORTHOP SUR JI J. Am. Acad. Orthop. Surg. PD APR PY 2008 VL 16 IS 4 BP 188 EP 198 PG 11 WC Orthopedics SC Orthopedics GA 283UE UT WOS:000254661200002 PM 18390481 ER PT J AU Setoguchi, S Glynn, RJ Avorn, J Mittleman, MA Levin, R Winkelmayer, WC AF Setoguchi, Soko Glynn, Robert J. Avorn, Jerry Mittleman, Murray A. Levin, Raisa Winkelmayer, Wolfgang C. TI Improvements in long-term mortality after myocardial infarction and increased use of cardiovascular drugs after discharge SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Article ID CORONARY-HEART-DISEASE; COST-EFFECTIVENESS; Q-WAVE; SECONDARY PREVENTION; ACC/AHA GUIDELINES; ELDERLY PATIENTS; UNSTABLE ANGINA; RISK-FACTORS; TRENDS; MANAGEMENT AB Objectives We sought to assess the relationship between increasing use of cardiovascular medications and trends in longterm prognosis after myocardial infarction (MI) in the elderly. Background During the past decade, statins, beta-blockers (BBs), angiotensin-converting enzyme inhibitors (ACEIs), and angiotensin-II receptor blockers (ARBs) have been increasingly used after MI. However, little is known about the relationship between increasing use of these medications and improvements in prognosis after MI. Methods Using data from pharmacy assistance programs and Medicare in 2 states (1995 to 2004), we identified patients with MI who survived >= 30 days after discharge. We assessed age, gender, race, comorbidities, and coronary interventions during the MI hospitalization and recorded filled prescriptions for statins, BBs, ACEIs/ARBs, or antiplatelet agents within 30 days after discharge. All patients were tracked until they died or until the end of the eligibility/study period. We built multivariate Cox proportional hazards regression models to assess trends in long-term mortality and the contribution to increasing medication use after MI. Results Of 21,484 patients identified, 12,142 died during 74,982 person-years of follow-up. After adjusting for demographics and comorbidities, we found that mortality after MI decreased significantly from 1995 to 2004 (hazard ratio for annual trend 0.97; 95% confidence interval 0.97 to 0.98), a 3% reduction in mortality each year. Adjusting for the use of statins, BBs, ACEIs/ARBs, and antiplatelet drugs after discharge completely eliminated the association between time trend and mortality (hazard ratio 1.00; 95% confidence interval 0.99 to 1.01). Conclusions The observed improvement in long-term mortality in elderly patients with MI may be mainly due to increased use of cardiovascular medications after discharge. C1 [Setoguchi, Soko; Glynn, Robert J.; Avorn, Jerry; Levin, Raisa] Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02120 USA. [Winkelmayer, Wolfgang C.] Brigham & Womens Hosp, Div Renal, Dept Med, Boston, MA 02120 USA. [Mittleman, Murray A.; Winkelmayer, Wolfgang C.] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Mittleman, Murray A.] Beth Israel Deaconess Med Ctr, Dept Med, Div Cardiovasc Med, Boston, MA 02215 USA. RP Setoguchi, S (reprint author), Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, 1620 Tremont St,Suite 3030, Boston, MA 02120 USA. EM soko@post.harvard.edu NR 37 TC 103 Z9 104 U1 1 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD APR 1 PY 2008 VL 51 IS 13 BP 1247 EP 1254 DI 10.1016/j.jacc.2007.10.063 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 283LF UT WOS:000254637000002 PM 18371553 ER PT J AU Weinrauch, LA Lin, J Solomon, SD AF Weinrauch, Larry A. Lin, Julie Solomon, Scott D. TI Mapping directions for the cardiorenal conundrum SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Editorial Material ID WORSENING RENAL-FUNCTION; CHRONIC KIDNEY-DISEASE; HEART-FAILURE; CARDIOVASCULAR OUTCOMES; MYOCARDIAL-INFARCTION; INHIBITION; EVENTS C1 [Lin, Julie] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Renal, Watertown, MA 02472 USA. [Weinrauch, Larry A.] Mt Auburn Hosp, Cambridge, England. [Weinrauch, Larry A.] Joslin Diabet Ctr, Boston, MA USA. [Solomon, Scott D.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Cardiovasc, Watertown, MA 02472 USA. RP Weinrauch, LA (reprint author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Renal, 521 Mt Auburn St, Watertown, MA 02472 USA. EM lweinrauch@hms.harvard.edu RI Solomon, Scott/I-5789-2013; OI Weinrauch, Larry/0000-0003-1357-9528 NR 12 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD APR 1 PY 2008 VL 51 IS 13 BP 1275 EP 1276 DI 10.1016/j.jacc.2007.12.019 PG 2 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 283LF UT WOS:000254637000007 PM 18371558 ER PT J AU Cummings, S Apovian, CM Khaodhiar, L AF Cummings, Sue Apovian, Caroline M. Khaodhiar, Lalita TI Obesity surgery: Evidence for diabetes Prevention/Management SO JOURNAL OF THE AMERICAN DIETETIC ASSOCIATION LA English DT Review ID GASTRIC BYPASS; WEIGHT-LOSS; INSULIN-RESISTANCE; BARIATRIC SURGERY; RISK-FACTORS; MELLITUS; MECHANISMS; GLUCOSE; GHRELIN; LEPTIN AB Obesity is associated with an increased risk of developing insulin resistance and type 2 diabetes. Development of type 2 diabetes can be delayed or sometimes prevented from manifestation in individuals with obesity that are able to lose weight. Weight loss can be achieved either medically with behavioral therapies that combine diet and exercise treatment or with behavioral therapies combined with weight-loss medications or weight-loss surgery. There is strong evidence of an amelioration or resolution of type 2 diabetes in patients undergoing gastric bypass surgery. A recently published retrospective cohort study indicated that long-term total mortality from diabetes, heart disease, and cancer after gastric bypass surgery was substantially reduced. In this review, we summarize the evidence of surgical interventions in the treatment of type 2 diabetes. C1 [Cummings, Sue] Massachusetts Gen Hosp, MGH Weight Ctr, Boston, MA 02114 USA. [Apovian, Caroline M.; Khaodhiar, Lalita] Boston Univ, Sch Med, Boston, MA 02118 USA. [Apovian, Caroline M.; Khaodhiar, Lalita] Boston Med Ctr, Nutr & Weight Management Ctr, Boston, MA 02118 USA. RP Cummings, S (reprint author), Massachusetts Gen Hosp, MGH Weight Ctr, 50 Staniford St,4th Floor, Boston, MA 02114 USA. OI Apovian, Caroline/0000-0002-8029-1922 NR 27 TC 24 Z9 26 U1 0 U2 1 PU AMER DIETETIC ASSOC PI CHICAGO PA 216 W JACKSON BLVD #800, CHICAGO, IL 60606-6995 USA SN 0002-8223 J9 J AM DIET ASSOC JI J. Am. Diet. Assoc. PD APR PY 2008 VL 108 IS 4 SU 1 BP S40 EP S44 DI 10.1016/j.jada.2008.01.017 PG 5 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 286CC UT WOS:000254822000009 PM 18358255 ER PT J AU Delahanty, LM Nathan, DM AF Delahanty, Linda M. Nathan, David M. TI Implications of the diabetes prevention program and look AHEAD clinical trials for lifestyle interventions SO JOURNAL OF THE AMERICAN DIETETIC ASSOCIATION LA English DT Article ID DISEASE RISK-FACTORS; WEIGHT-LOSS; ACTIVITY GOALS; COMMUNITY; INDIVIDUALS; REDUCTION; METFORMIN; DPP AB The Diabetes Prevention Program DPP) and Look AHEAD (Action for Health in Diabetes) trials are long-term randomized clinical trials that have the potential to direct diabetes care and medical nutrition therapy for obesity, prediabetes, and type 2 diabetes both now and in the future. This article summarizes and compares the important evidence-based results of these diabetes and obesity clinical trials and reviews the similarities and differences in lifestyle interventions that were designed for these trials. Although there were many similarities in the features of the DPP and Look AHEAD interventions, the Look AHEAD lifestyle intervention was more ambitious in several ways: higher individual weight-loss goals, lower calorie and fat-gram targets based on initial body weight, more intensive intervention frequency, combining closed group and individual session format, and use of more structured nutrition intervention strategies from the outset, including meal replacements, structured menus, and combined fat and calorie counting. Evidence, knowledge, and insights gained from working on these clinical trials will be very important in determining the strategies, methods, and approaches needed to make sure that the results of these trials will be fully applied in real-world practice settings for obesity, prediabetes, and type 2 diabetes. C1 [Delahanty, Linda M.; Nathan, David M.] Massachusetts Gen Hosp, MGH Diabet Ctr, Boston, MA 02114 USA. RP Delahanty, LM (reprint author), Massachusetts Gen Hosp, MGH Diabet Ctr, 50 Staniford St,Suite 340, Boston, MA 02114 USA. FU NIDDK NIH HHS [U01 DK057136-05, U01 DK057136, U01 DK057136-01, U01 DK057136-02, U01 DK057136-03, U01 DK057136-03S1, U01 DK057136-04, U01 DK057136-04S1, U01 DK057136-04S2, U01 DK057136-05S1, U01 DK057136-06, U01 DK057136-07, U01 DK057136-08, U01 DK057136-08S1, U01 DK057136-09, U01 DK057136-09S1, U01 DK057136-10] NR 27 TC 33 Z9 33 U1 1 U2 5 PU AMER DIETETIC ASSOC PI CHICAGO PA 216 W JACKSON BLVD #800, CHICAGO, IL 60606-6995 USA SN 0002-8223 J9 J AM DIET ASSOC JI J. Am. Diet. Assoc. PD APR PY 2008 VL 108 IS 4 SU 1 BP S66 EP S72 DI 10.1016/j.jada.2008.01.026 PG 7 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 286CC UT WOS:000254822000013 PM 18358260 ER PT J AU Casarett, D Pickard, A Bailey, FA Ritchie, C Furman, C Rosenfeld, K Shreve, S Chen, Z Shea, JA AF Casarett, David Pickard, Amy Bailey, F. Amos Ritchie, Christine Furman, Christian Rosenfeld, Ken Shreve, Scott Chen, Zhen Shea, Judy A. TI Do palliative consultations improve patient outcomes? SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE end-of-life care; quality improvement; measurement; veterans ID OF-LIFE CARE; FAMILY SATISFACTION; PROPENSITY SCORES; END; IMPACT; CANCER; MEDICINE; HOSPICE; MEMBERS; TRIAL AB OBJECTIVES: To determine whether inpatient palliative consultation services improve outcomes of care. DESIGN: Retrospective telephone surveys conducted with family members of veterans who received inpatient or outpatient care from a Department of Veterans Affairs (VA) medical facility in the last month of life. SETTING: Five VA Medical Centers or their affiliated nursing homes and outpatient clinics. PARTICIPANTS: Veterans had received inpatient or outpatient care from a participating VA in the last month of life. One family member completed each survey. MEASUREMENTS: The telephone survey assessed nine aspects of the care the patient received in his or her last month of life: the patient's well-being and dignity (4 items), adequacy of communication (5 items), respect for treatment preferences (2 items), emotional and spiritual support (3 items), management of symptoms (4 items), access to the inpatient facility of choice (1 item), care around the time of death (6 items), access to home care services (4 items), and access to benefits and services after the patient's death (3 items). RESULTS: Interviews were completed with 524 respondents. In a multivariable linear regression model, after adjusting for the likelihood of receiving a palliative consultation (propensity score), palliative care patients had higher overall scores: 65 (95% confidence interval (CI)=62-66) versus 54 (95% CI=51-56; P <.001) and higher scores for almost all domains. Earlier consultations were independently associated with better overall scores (beta=0.003; P=.006), a difference that was attributable primarily to improvements in communication and emotional support. CONCLUSION: Palliative consultations improve outcomes of care, and earlier consultations may confer additional benefit. C1 [Casarett, David; Pickard, Amy; Shea, Judy A.] Ctr Hlth Equ Res & Promot, Dept Vet Affairs, Philadelphia, PA USA. [Bailey, F. Amos; Ritchie, Christine] Dept Vet Affairs, Birmingham, AL USA. [Furman, Christian] Dept Vet Affairs, Louisville, KY USA. [Rosenfeld, Ken] Dept Vet Affairs, West Los Angeles, CA USA. [Shreve, Scott] Dept Vet Affairs, Lebanon, PA USA. [Chen, Zhen] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. RP Casarett, D (reprint author), 3615 Chestnut St, Philadelphia, PA 19104 USA. EM Casarett@mail.med.upenn.edu NR 34 TC 111 Z9 111 U1 0 U2 11 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2008 VL 56 IS 4 BP 593 EP 599 DI 10.1111/j.1532-5415.2007.01610.x PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 282IX UT WOS:000254562200001 PM 18205757 ER PT J AU French, DD Bass, E Bradham, DD Campbell, RR Rubenstein, LZ AF French, Dustin D. Bass, Elizabeth Bradham, Douglas D. Campbell, Robert R. Rubenstein, Laurence Z. TI Rehospitalization after hip fracture: Predictors and prognosis from a national veterans study SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE hip fracture; comorbidities; readmissions; veterans; dual enrollment; Medicare ID ADMINISTRATIVE DATA; FUNCTIONAL STATUS; OUTCOMES; INJURY; RISK; BENZODIAZEPINES; COMMUNITY; MORTALITY; FALLS AB OBJECTIVES: To estimate the risk and long-term prognostic significance of 30-day readmission postdischarge of a 4-year cohort of elderly veterans first admitted to Medicare hospitals for treatment of hip fractures (HFx), controlling for comorbidities. DESIGN: Retrospective, national secondary data analysis. SETTING: National Medicare and Veterans Health Administration (VHA) facilities. PARTICIPANTS: The study cohort was 41,331 veterans with a HFx first admitted to a Medicare eligible facility during 1999 to 2002. MEASUREMENTS: HFxs were linked with all other Medicare and VHA inpatient discharge files to capture dual inpatient use. Logistic regression was used to examine the relationship between 30-day readmission and age, sex, inpatient length of stay, and selected Elixhauser comorbidities. RESULTS: Approximately 18.3% (7,579/41,331) of HFx patients were readmitted within 30 days. Of those with 30-day readmissions, 48.5% (3,675/7,579) died within 1 year, compared with 24.9% (8,388/33,752) of those without 30-day readmissions. Readmission risk was significantly greater in the presence of specific comorbidities, ranging from 11% greater risk for patients with fluid and electrolyte disorders (95% confidence interval (CI)=1.04-1.20) to 43% for renal failure (95% CI=1.29-1.60). For this cohort, cardiac arrhythmias (24%), chronic pulmonary disease (28%), and congestive heart failure (16%) were common comorbidities, and all affected the risk of 30-day readmission. CONCLUSION: Patients with HFx with 30-day readmissions were nearly twice as likely to die within 1 year. Identification of several predictive comorbidities at discharge and examination of reasons for subsequent readmission suggests that readmission was largely due to active comorbid clinical problems. These comorbidity findings have implications for the current Centers for Medicare and Medicaid Services (CMS) pay-for-performance initiatives, especially those related to better coordination of care for patients with chronic illnesses. These comorbidity findings for elderly patients with HFx may also provide data to enable CMS and healthcare providers to more accurately differentiate between comorbidities and hospital-acquired complications under the current CMS initiative related to nonpayment for certain types of medical conditions and hospital acquired infections. C1 [French, Dustin D.; Bass, Elizabeth; Campbell, Robert R.] James A Haley VAMC, VISN 8, Patient Safety Ctr Inquiry, Tampa, FL 33612 USA. [Bradham, Douglas D.] Cooperat Studies Program Coordinating Ctr, Cherry Point, MD USA. [Bradham, Douglas D.] Univ Maryland, Dept Epidemiol & Prevent Med, Sch Med, Baltimore, MD 21201 USA. [Rubenstein, Laurence Z.] Univ Calif Los Angeles, Div Geriatr Med, David Geffen Sch Med, Los Angeles, CA USA. [Rubenstein, Laurence Z.] Ctr Geriatr Res Educ & Clin, Vet Affairs Greater Los Angeles Hlthcare Syst, Sepulveda, CA USA. RP French, DD (reprint author), James A Haley VAMC, VISN 8, Patient Safety Ctr Inquiry, 13000 Bruce B Down Blvd 118M, Tampa, FL 33612 USA. EM Dustin.French@va.gov OI French, Dustin/0000-0003-4064-3206 NR 20 TC 38 Z9 39 U1 1 U2 2 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2008 VL 56 IS 4 BP 705 EP 710 DI 10.1111/j.1532-5415.2007.01479.x PG 6 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 282IX UT WOS:000254562200017 PM 18005354 ER PT J AU Alvarez, A Chiodo, L Kadakia, A AF Alvarez, A. Chiodo, L. Kadakia, A. TI Recurrent falls and orthostasis in an elderly male with brain radiation induced panhypopituitarism SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY APR 30-MAY 04, 2008 CL Washington, DC SP Amer Geriatr Soc C1 [Alvarez, A.; Chiodo, L.; Kadakia, A.] UTHSCSA, San Antonio, TX USA. [Alvarez, A.; Chiodo, L.; Kadakia, A.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2008 VL 56 IS 4 SU S MA D20 BP S165 EP S165 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 286IT UT WOS:000254840300480 ER PT J AU Ashton, A Pierce, A Macias, D Chaudhuri, A Richardson, A Espinoza, S AF Ashton, A. Pierce, A. Macias, D. Chaudhuri, A. Richardson, A. Espinoza, S. TI Comparative proteomic analysis of plasma glycoproteins with age: a pilot study SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY APR 30-MAY 04, 2008 CL Washington, DC SP Amer Geriatr Soc C1 [Ashton, A.; Pierce, A.; Macias, D.; Chaudhuri, A.; Richardson, A.; Espinoza, S.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Chaudhuri, A.; Richardson, A.; Espinoza, S.] S Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX USA. RI Pierce, Anson/D-1079-2012 OI Pierce, Anson/0000-0002-1383-0180 NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2008 VL 56 IS 4 SU S MA C4 BP S112 EP S113 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 286IT UT WOS:000254840300327 ER PT J AU Chi, R Neuzil, K AF Chi, R. Neuzil, K. TI Safety of intradermal influenza vaccination in elderly persons SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY APR 30-MAY 04, 2008 CL Washington, DC SP Amer Geriatr Soc C1 Univ Washington, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Neuzil, K.] PATH, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2008 VL 56 IS 4 SU S MA C42 BP S125 EP S125 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 286IT UT WOS:000254840300365 ER PT J AU Chodosh, J Edelen, MO Buchanan, JL Yosef, JA Ouslander, JG Berlowitz, DR Streim, JE Saliba, D AF Chodosh, J. Edelen, M. Orlando Buchanan, J. L. Yosef, J. A. Ouslander, J. G. Berlowitz, D. R. Streim, J. E. Saliba, D. TI Nursing home assessment of cognitive impairment: Development and testing of a brief instrument of mental status SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY APR 30-MAY 04, 2008 CL Washington, DC SP Amer Geriatr Soc C1 [Chodosh, J.; Yosef, J. A.; Saliba, D.] VA Greater Los Angeles Healthcare Syst, GRECC, HSR&D, Ctr Excellence, Los Angeles, CA USA. [Chodosh, J.] Univ Calif Los Angeles, Div Geriatr, Los Angeles, CA USA. [Edelen, M. Orlando] Brown Univ, Sch Med, Dept Psychiat & Behav, Providence, RI 02912 USA. [Edelen, M. Orlando; Saliba, D.] Rand Hlth, Santa Monica, CA USA. [Buchanan, J. L.] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Ouslander, J. G.] Atlanta VA Med Ctr, Atlanta, GA USA. [Ouslander, J. G.] Emory Univ, Wesley Woods Geriatr Hosp, Atlanta, GA 30322 USA. [Berlowitz, D. R.] Ctr Hlth Qualit Outcomes & Econ Res, Bedford, MA USA. [Berlowitz, D. R.] Boston Univ, Sch Publ Hlth & Med, Boston, MA 02215 USA. [Streim, J. E.] Mental Illness Res Educ & Clin Care Ctr, Philadelphia, PA USA. [Streim, J. E.] Univ Penn, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2008 VL 56 IS 4 SU S MA P16 BP S6 EP S7 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 286IT UT WOS:000254840300017 ER PT J AU Ganz, DA Saliba, DM Shekelle, PG Yano, EM AF Ganz, D. A. Saliba, D. M. Shekelle, P. G. Yano, E. M. TI Health system variation in guideline adherence for falls SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY APR 30-MAY 04, 2008 CL Washington, DC SP Amer Geriatr Soc C1 [Ganz, D. A.; Saliba, D. M.; Shekelle, P. G.; Yano, E. M.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Ganz, D. A.; Saliba, D. M.; Shekelle, P. G.; Yano, E. M.] Univ Calif Los Angeles, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2008 VL 56 IS 4 SU S MA D91 BP S190 EP S191 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 286IT UT WOS:000254840300551 ER PT J AU Gupta, E Hartronft, S Prange, M AF Gupta, E. Hartronft, S. Prange, M. TI Neuroleptic malignant syndrome in a patient on chronic long-acting intramuscular (Depot) fluphenazine: A case report SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY APR 30-MAY 04, 2008 CL Washington, DC SP Amer Geriatr Soc C1 GEC OOE, San Antonio, TX USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2008 VL 56 IS 4 SU S MA A28 BP S27 EP S27 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 286IT UT WOS:000254840300074 ER PT J AU Gupta, E Hartronft, S Prange, M AF Gupta, E. Hartronft, S. Prange, M. TI Coca-cola: A new therapy for reflux SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY APR 30-MAY 04, 2008 CL Washington, DC SP Amer Geriatr Soc C1 Univ Texas San Antonio, Ctr Hlth, GEC Ltd, OOE, San Antonio, TX USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2008 VL 56 IS 4 SU S MA A27 BP S27 EP S27 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 286IT UT WOS:000254840300073 ER PT J AU Hanlon, JT Aspinall, S Handler, SM Rossi, M Fried, LF Weisbord, S Good, CB Fine, M Stone, R Pugh, M Semla, TP AF Hanlon, J. T. Aspinall, S. Handler, S. M. Rossi, M. Fried, L. F. Weisbord, S. Good, C. B. Fine, M. Stone, R. Pugh, M. Semla, T. P. TI Consensus guidelines for dosing primarily renally cleared medications in older outpatients SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY APR 30-MAY 04, 2008 CL Washington, DC SP Amer Geriatr Soc C1 [Hanlon, J. T.; Aspinall, S.; Handler, S. M.; Rossi, M.; Fried, L. F.; Weisbord, S.; Good, C. B.; Fine, M.; Stone, R.] Univ Pittsburgh, Pittsburgh, PA USA. [Hanlon, J. T.; Aspinall, S.; Fried, L. F.; Weisbord, S.; Good, C. B.; Fine, M.; Stone, R.] CHERP, VAPHS, Pittsburgh, PA USA. [Pugh, M.] S Texas Vet Hlth Care Syst, VERDICT, San Antonio, TX USA. [Semla, T. P.] VA, PBM, Hines, IL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2008 VL 56 IS 4 SU S MA D89 BP S190 EP S190 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 286IT UT WOS:000254840300549 ER PT J AU Karlawish, J Rubright, J Xie, S Casarett, DJ Gur, R Sankar, P AF Karlawish, J. Rubright, J. Xie, S. Casarett, D. J. Gur, R. Sankar, P. TI A memory and organizational aid improves research consent capacity in persons with Alzheimer's disease SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY APR 30-MAY 04, 2008 CL Washington, DC SP Amer Geriatr Soc C1 [Karlawish, J.; Rubright, J.; Casarett, D. J.] Univ Penn, Alzheimers Dis Ctr, Philadelphia, PA 19104 USA. [Sankar, P.] Univ Penn, Ctr Bioeth, Philadelphia, PA 19104 USA. [Casarett, D. J.] Dept Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2008 VL 56 IS 4 SU S MA P3 BP S1 EP S2 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 286IT UT WOS:000254840300004 ER PT J AU Kinosian, B Tompkins, H Edes, T AF Kinosian, B. Tompkins, H. Edes, T. TI Factors associated with reduction in inpatient days by home based primary care(HBPC) SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY APR 30-MAY 04, 2008 CL Washington, DC SP Amer Geriatr Soc C1 [Kinosian, B.] VAMC, Philadelphia, PA USA. [Tompkins, H.; Edes, T.] US Dept Vet Affairs, Geriatr & Extended Care, Washington, DC USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2008 VL 56 IS 4 SU S MA D111 BP S197 EP S198 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 286IT UT WOS:000254840300571 ER PT J AU Lawrence, VA Hazuda, HP Cornell, JE AF Lawrence, V. A. Hazuda, H. P. Cornell, J. E. TI Perioperative depression and elders' recovery after major open abdominal surgery SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY APR 30-MAY 04, 2008 CL Washington, DC SP Amer Geriatr Soc C1 [Lawrence, V. A.] S Texas Vet Hlth CAre Syst, San Antonio, TX USA. [Lawrence, V. A.; Hazuda, H. P.; Cornell, J. E.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2008 VL 56 IS 4 SU S MA D148 BP S211 EP S211 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 286IT UT WOS:000254840300608 ER PT J AU Lawrence, VA Cornell, JE Hazuda, HP AF Lawrence, V. A. Cornell, J. E. Hazuda, H. P. TI Elders' use of diverse adaptive strategies improves recovery after major abdominal surgery SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY APR 30-MAY 04, 2008 CL Washington, DC SP Amer Geriatr Soc C1 [Lawrence, V. A.; Cornell, J. E.; Hazuda, H. P.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Lawrence, V. A.; Cornell, J. E.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2008 VL 56 IS 4 SU S MA D146 BP S210 EP S210 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 286IT UT WOS:000254840300606 ER PT J AU Mitchell, SL Teno, JM Kiely, DK Shaffer, M Prigerson, HG Jones, RN Volicer, L Hamel, MB AF Mitchell, S. L. Teno, J. M. Kiely, D. K. Shaffer, M. Prigerson, H. G. Jones, R. N. Volicer, L. Hamel, M. B. TI The clinical course of advanced dementia: Complications, treatments, and symptoms SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY APR 30-MAY 04, 2008 CL Washington, DC SP Amer Geriatr Soc C1 [Mitchell, S. L.; Kiely, D. K.; Jones, R. N.] Hebrew Senior Life, Boston, MA USA. [Mitchell, S. L.; Jones, R. N.; Hamel, M. B.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Teno, J. M.] Brown Univ, Providence, RI 02912 USA. [Shaffer, M.] Penn State Univ, Hershey, PA USA. [Prigerson, H. G.] Childrens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. [Volicer, L.] Univ S Florida, Tampa, FL USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2008 VL 56 IS 4 SU S MA D34 BP S170 EP S170 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 286IT UT WOS:000254840300494 ER PT J AU Ringman, JM Romano, JD Medina, L Rodriguez, Y Schaffer, B Varpetian, A Ortiz, F Fitten, J Cummings, JL Baloh, RW AF Ringman, J. M. Romano, J. D. Medina, L. Rodriguez, Y. Schaffer, B. Varpetian, A. Ortiz, F. Fitten, J. Cummings, J. L. Baloh, R. W. TI Increased prevalence of significant recurrent headache in pre-clinical familial Alzheimer's disease mutation carriers SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY APR 30-MAY 04, 2008 CL Washington, DC SP Amer Geriatr Soc C1 [Ringman, J. M.; Medina, L.; Schaffer, B.; Ortiz, F.; Fitten, J.; Cummings, J. L.] Univ Calif Los Angeles, Alzheimers Dis Res Ctr, Los Angeles, CA USA. [Ringman, J. M.; Medina, L.; Schaffer, B.; Baloh, R. W.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA. [Romano, J. D.] Virginia Commonwealth Univ, Richmond, VA USA. [Rodriguez, Y.] Natl Inst Neurol & Neurosurg, Expt Psychol Lab, Mexico City, DF, Mexico. [Varpetian, A.] USC, Keck Sch Med, Dept Neurol, Downey, CA USA. [Ortiz, F.] Olive View UCLA Med Ctr, Neuropsychiat Res Memory Clin, Sylmar, CA 91342 USA. [Fitten, J.] Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA USA. [Baloh, R. W.] Univ Calif Los Angeles, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2008 VL 56 IS 4 SU S MA A118 BP S57 EP S57 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 286IT UT WOS:000254840300163 ER PT J AU Ross, JS Sanchez-Reilly, S Wittenberg-Lyles, E Lee, S AF Ross, J. S. Sanchez-Reilly, S. Wittenberg-Lyles, E. Lee, S. TI Assessment of geriatric attitudes in interdisciplinary palliative care healthcare providers SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY APR 30-MAY 04, 2008 CL Washington, DC SP Amer Geriatr Soc C1 [Ross, J. S.; Sanchez-Reilly, S.; Lee, S.] S Texas Vet Hlth Care Syst, GRECC, San Antonio, TX 76203 USA. [Wittenberg-Lyles, E.] Univ N Texas, Denton, TX USA. [Ross, J. S.; Sanchez-Reilly, S.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2008 VL 56 IS 4 SU S MA A66 BP S40 EP S40 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 286IT UT WOS:000254840300112 ER PT J AU Smith, A Driver, JA Buring, JE Gaziano, JM Kurth, T Logroscino, G AF Smith, A. Driver, J. A. Buring, J. E. Gaziano, J. M. Kurth, T. Logroscino, G. TI Prospective cohort study of type 2 Diabetes Mellitus and the risk of Parkinson's disease SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY APR 30-MAY 04, 2008 CL Washington, DC SP Amer Geriatr Soc C1 [Smith, A.; Kurth, T.; Logroscino, G.] Northeastern Ohio Univ Coll Med & Pharm, Dept Med, Ravenna, OH 02115 USA. [Driver, J. A.; Gaziano, J. M.; Kurth, T.] Brigham & Womens Hosp, Div Aging, Boston, MA 02115 USA. [Buring, J. E.] Brigham & Womens Hosp, Div Prevent Med, Boston, MA 02115 USA. [Buring, J. E.; Logroscino, G.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA USA. [Gaziano, J. M.] VA Boston Hlth Care Syst, Massachusetts Vet Epidemiol Res, Boston, MA USA. RI Kurth, Tobias/A-9243-2012; LOGROSCINO, GIANCARLO/K-5148-2016 OI Kurth, Tobias/0000-0001-7169-2620; LOGROSCINO, GIANCARLO/0000-0003-0423-3242 NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2008 VL 56 IS 4 SU S MA D116 BP S199 EP S199 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 286IT UT WOS:000254840300576 ER PT J AU Stavros, KA Rudolph, JL Jones, R Marcantonio, ER AF Stavros, K. A. Rudolph, J. L. Jones, R. Marcantonio, E. R. TI Delirium and the clinical assessment of attention in older adults SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY APR 30-MAY 04, 2008 CL Washington, DC SP Amer Geriatr Soc C1 [Stavros, K. A.] Albert Einstein Coll Med, Bronx, NY 10467 USA. [Rudolph, J. L.] VA Boston Healthcare Syst, Boston, MA USA. [Jones, R.] Hebrew Senior Life, Boston, MA USA. [Marcantonio, E. R.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Rudolph, J. L.; Jones, R.; Marcantonio, E. R.] Harvard Univ, Sch Med, Boston, MA 02215 USA. NR 0 TC 3 Z9 3 U1 0 U2 1 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2008 VL 56 IS 4 SU S MA D117 BP S199 EP S200 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 286IT UT WOS:000254840300577 ER PT J AU Sun, B Glenn, S Derose, S AF Sun, B. Glenn, S. Derose, S. TI Epidemiology and predictors of 30-day mortality after syncope SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY APR 30-MAY 04, 2008 CL Washington, DC SP Amer Geriatr Soc C1 [Sun, B.] Univ Calif Los Angeles, W Los Angeles Vet Adm Med Ctr, Los Angeles, CA USA. [Glenn, S.; Derose, S.] Kaiser Permanente So Calif, Pasadena, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2008 VL 56 IS 4 SU S MA D27 BP S167 EP S168 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 286IT UT WOS:000254840300487 ER PT J AU Waters, I Ross, J Wittenberg-Lyles, E Sanchez-Reilly, S AF Waters, I. Ross, J. Wittenberg-Lyles, E. Sanchez-Reilly, S. TI Assesing geriatric education and attitudes among interdisciplinary palliative care fellows: The AGE-PC study SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY APR 30-MAY 04, 2008 CL Washington, DC SP Amer Geriatr Soc C1 [Waters, I.; Ross, J.; Sanchez-Reilly, S.] Univ Texas Hlth Sci Ctr San Antonio, S Texas Vet Hlth Care Syst, San Antonio, TX 76203 USA. [Ross, J.; Wittenberg-Lyles, E.; Sanchez-Reilly, S.] GRECC, San Antonio, TX USA. [Wittenberg-Lyles, E.] Univ N Texas, Denton, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2008 VL 56 IS 4 SU S MA B81 BP S91 EP S92 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 286IT UT WOS:000254840300266 ER PT J AU Xie, Z Dong, Y Zhang, G Zhang, B Culley, DJ Crosby, G Tanzi, RE AF Xie, Z. Dong, Y. Zhang, G. Zhang, B. Culley, D. J. Crosby, G. Tanzi, R. E. TI Sevoflurane induces caspase-3 activation and increases amyloid-beta protein levels SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY APR 30-MAY 04, 2008 CL Washington, DC SP Amer Geriatr Soc C1 [Xie, Z.; Dong, Y.; Zhang, G.; Zhang, B.; Tanzi, R. E.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Culley, D. J.; Crosby, G.] Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 1 Z9 1 U1 1 U2 1 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2008 VL 56 IS 4 SU S MA D114 BP S198 EP S199 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 286IT UT WOS:000254840300574 ER PT J AU Wolkow, PP Niewczas, MA Perkins, B Ficociello, LH Lipinski, B Warram, JH Krolewski, AS AF Wolkow, Pawel P. Niewczas, Monika A. Perkins, Bruce Ficociello, Linda H. Lipinski, Boguslaw Warram, James H. Krolewski, Andrzej S. TI Association of urinary inflammatory markers and renal decline in microalbuminuric type 1 diabetics SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID MONOCYTE CHEMOATTRACTANT PROTEIN-1; STRUCTURAL-FUNCTIONAL RELATIONSHIPS; TUBULAR EPITHELIAL-CELLS; CHEMOKINE RECEPTORS; GENE-EXPRESSION; KIDNEY-DISEASE; CYSTATIN-C; NEPHROPATHY; INJURY; ACTIVATION AB Progressive renal function decline begins in one third of patients with microalbuminuria and type 1 diabetes. This study examined whether this decline is associated with elevated excretion of inflammatory markers in urine. Five inflammatory markers (IL-6, IL-8, monocyte chemoattractant protein-1, interferon-gamma-inducible protein (IP-10), and macrophage inflammatory protein-1 delta) were measured in urine samples from the First Joslin Study of the Natural History of Microalbuminuria in Type 1 Diabetes, a cohort recruited in 1991. Samples were obtained from 43 participants with microalbuminuria and stable renal function (nondecliners), from 28 with microalbuminuria and early progressive renal function decline (decliners), and from 74 with normoalbuminuria and stable renal function (reference). Urinary concentrations of all five inflammatory markers were significantly higher in decliners than in nondecliners, who were similar to the reference group. Multivariate analysis revealed that those with more than two markers elevated were more than five times as likely to have early progressive decline of renal function. In contrast, serum concentrations of C-reactive protein, IL-8, and macrophage inflammatory protein-1 delta did not differ between decliners and nondecliners. These results support the hypothesis that inflammatory processes in the kidney contribute to the progression of nephropathy in patients with type 1 diabetes. C1 [Wolkow, Pawel P.; Niewczas, Monika A.; Perkins, Bruce; Ficociello, Linda H.; Lipinski, Boguslaw; Warram, James H.; Krolewski, Andrzej S.] Joslin Diabet Ctr, Sect Genet & Epidemiol, Div Res, Boston, MA 02215 USA. [Wolkow, Pawel P.; Niewczas, Monika A.; Perkins, Bruce; Ficociello, Linda H.; Lipinski, Boguslaw; Warram, James H.; Krolewski, Andrzej S.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA. [Wolkow, Pawel P.] Jagiellonian Univ, Dept Pharmacol, Krakow, Poland. [Niewczas, Monika A.] Warsaw Med Univ, Dept Immunol Transplant Med & Internal Dis, Warsaw, Poland. [Perkins, Bruce] Univ Toronto, Sch Med, Dept Endocrinol, Toronto, ON, Canada. RP Krolewski, AS (reprint author), Joslin Diabet Ctr, Sect Genet & Epidemiol, Div Res, 1 Joslin Pl, Boston, MA 02215 USA. EM andrzej.krolewski@joslin.harvard.edu FU NIDDK NIH HHS [R01 DK041526, R01 DK067638, R01-DK41526, R01-DK67638] NR 40 TC 63 Z9 67 U1 2 U2 6 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1046-6673 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD APR PY 2008 VL 19 IS 4 BP 789 EP 797 DI 10.1681/ASN.2007050556 PG 9 WC Urology & Nephrology SC Urology & Nephrology GA 283TJ UT WOS:000254659100022 PM 18256362 ER PT J AU Akins, CW Miller, DC Turina, MI Kouchoukos, NT Blackstone, EH Grunkemeier, GL Takkenberg, JJM David, TE Butchart, EG Adams, DH Shahian, DM Hagl, S Mayer, JE Lytle, BW AF Akins, Cary W. Miller, D. Craig Turina, Marko I. Kouchoukos, Nicholas T. Blackstone, Eugene H. Grunkemeier, Gary L. Takkenberg, Johanna J. M. David, Tirone E. Butchart, Eric G. Adams, David H. Shahian, David M. Hagl, Siegfried Mayer, John E. Lytle, Bruce W. TI Guidelines for reporting mortality and morbidity after cardiac valve interventions SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY LA English DT Article ID CONFIDENCE-INTERVALS; VALVULAR OPERATIONS; REGRESSION-ANALYSIS; COX REGRESSION; EVENTS C1 [Akins, Cary W.; Miller, D. Craig; Blackstone, Eugene H.; David, Tirone E.; Lytle, Bruce W.] Amer Assoc Thorac Surg, New York, NY USA. [Kouchoukos, Nicholas T.; Grunkemeier, Gary L.; Adams, David H.; Shahian, David M.; Mayer, John E.] Soc Thorac Surg, New York, NY USA. RP Akins, CW (reprint author), Massachusetts Gen Hosp, Cox 648,55 Fruit St, Boston, MA 02114 USA. EM cakins@partners.org RI Takkenberg, Johanna/B-9368-2009; OI Takkenberg, Johanna/0000-0001-9809-5623 NR 33 TC 258 Z9 262 U1 1 U2 8 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5223 J9 J THORAC CARDIOV SUR JI J. Thorac. Cardiovasc. Surg. PD APR PY 2008 VL 135 IS 4 BP 732 EP 738 DI 10.1016/j.jtcvs.2007.12.002 PG 7 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 280JU UT WOS:000254423600003 PM 18374749 ER PT J AU Cruz-Gonzalez, I Sanchez-Ledesma, M Baron, SJ Healy, JL Watanabe, H Osakabe, M Yeh, RW Jang, IK AF Cruz-Gonzalez, Ignacio Sanchez-Ledesma, Maria Baron, Suzanne J. Healy, Josephine L. Watanabe, Hikari Osakabe, Masanori Yeh, Robert W. Jang, Ik-Kyung TI Efficacy and safety of argatroban with or without glycoprotein IIb/IIIa inhibitor in patients with heparin induced thrombocytopenia undergoing percutaneous coronary intervention for acute coronary syndrome SO JOURNAL OF THROMBOSIS AND THROMBOLYSIS LA English DT Article DE acute coronary syndrome; argatroban; glycoprotein IIb/IIIa inhibitors; heparin-induced thrombocytopenia; percutaneous coronary intervention ID MYOCARDIAL-INFARCTION; TRIAL; ANTICOAGULATION; BIVALIRUDIN; THROMBIN AB Background There is limited experience with the use of argatroban in combination with glycoprotein IIb/IIIa (GPIIb/IIIa) inhibitor in acute coronary syndrome (ACS) patients with heparin-induced thrombocytopenia (HIT) undergoing percutaneous coronary intervention (PCI). Materials and methods This single-center, retrospective study evaluated the efficacy (composite of death, myocardial infarction, or urgent revascularization) and safety (evaluated by TIMI major bleeding) of the argatroban with or without a GPIIb/IIIa inhibitor during PCI. Among 102 consecutive ACS patients (71.6% unstable angina or NSTEMI and 28.4% STEMI) who received argatroban (239 +/- 104 mu g/kg bolus, followed by a 17 +/- 11 mu g/kg/min infusion) for confirmed or suspected HIT during PCI, 52 patients (51%) received a GPIIb/IIIa inhibitor simultaneously (86% integrilin, 10% tirofiban, 4% abciximab) and 50 patients (49%) did not. Results There was no difference between the groups in the efficacy endpoint, which occurred in nine patients (17.3%) who received GPIIb/IIIa inhibitor and in eight patients (16%) who did not (P = 0.70). TIMI major bleeding occurred in three (5.8%) patients in the GPIIa/IIIb inhibitor group versus 0 (0%) patients in the argatroban alone group (P = 0.085). Conclusion In patients with suspected or confirmed HIT undergoing PCI for ACS, argatroban with or without GPIIb/IIIa appears to provide adequate anticoagulation and is well tolerated with a low rate of bleeding. C1 [Cruz-Gonzalez, Ignacio; Sanchez-Ledesma, Maria; Baron, Suzanne J.; Healy, Josephine L.; Jang, Ik-Kyung] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, Boston, MA 02114 USA. [Watanabe, Hikari; Osakabe, Masanori] Mitsubishi Pharma Corp, Osaka, Japan. [Yeh, Robert W.] Univ Calif San Francisco, Div Cardiol, San Francisco, CA 94143 USA. RP Jang, IK (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, Gray Bigelow 800,55 Fruit St, Boston, MA 02114 USA. EM ijang@partners.org RI 2008, Ibsal/A-1268-2012 NR 13 TC 12 Z9 14 U1 0 U2 4 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0929-5305 J9 J THROMB THROMBOLYS JI J. Thromb. Thrombolysis PD APR PY 2008 VL 25 IS 2 BP 214 EP 218 DI 10.1007/s11239-007-0071-3 PG 5 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA 289MO UT WOS:000255058800015 PM 17632689 ER PT J AU Li, YQ Yuan, ZQ Liu, BL Sailhamer, EA Shults, C Velmahos, GC Demoya, M Alam, HB AF Li, Yongqing Yuan, Zengqiang Liu, Baoling Sailhamer, Elizabeth A. Shults, Christian Velmahos, George C. Demoya, Marc Alam, Hasan B. TI Prevention of hypoxia-induced neuronal apoptosis through histone deacetylase inhibition SO JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE LA English DT Article; Proceedings Paper CT 66th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma CY SEP 27-29, 2007 CL Las Vegas, NV SP Amer Assoc Surg Trauma DE apoptosis; valproic acid; NF-kappa B; phospho-JNK; histone deacetylase inhibitor; hypoxia; neurons; survival ID NF-KAPPA-B; REACTIVE OXYGEN; CARDIAC HISTONES; CELL-DEATH; ACETYLATION; ACTIVATION; JNK; RESUSCITATION; ASTROCYTES; HEMORRHAGE AB Background., We have recently discovered that administration of valproic acid (VPA), a histone deacetylase inhibitor, enhances nuclear histone acetylation and improves survival after lethal hemorrhage in rats. In the present study, neurons were subjected to severe hypoxic condition in vitro to test whether VPA would prevent hypoxia-induced apoptosis, and to explore the possible mechanisms. Methods. Primary hippocampal and cortical cultures dissociated from E18 rat embryos were plated in quadruplicate at a density of 2 x 10(5)/well in neurobasal medium supplemented with B-27 on glass cover-slips coated with poly-L-lysine. On the 10th day after plating, cells were incubated in a hypoxia chamber (0.5% O-2, 10% CO2, 89.5% N-2) at 37 degrees C for 6 hour and 16 hour in the presence or absence of VPA (1 mmol/L). The cells were then fixed, stained with antiactivated caspase-3 and antiacetyl histone H3 lysine 9 (Ac H3 K9) antibodies and visualized under confocal microscope. The caspase-3 positive cells were counted as apoptotic. Ratio of the apoptotic to total cells stained with 4',6-diamidino-2-phenylindole was determined. Numerical data were subjected to t test analysis. p < 0.05 was considered statistically significant. Western blot was performed to determine the level of acetylation of nuclear factor-kappa B (NF-kappa B) and phospho-JNK (c-Jun N-terminal kinase) in cells treated with or without VPA. Luciferase report assay was employed to analyze the activation of NF-kappa B after the cells were transfected with NF-kappa BLuc with or without VPA treatment. Results. Exposure of neurons to VPA prevented apoptotic cell death under hypoxic conditions (20% apoptosis). In contrast, about 95% cells underwent apoptosis at the same level of hypoxia. VPA treatment induced acetylation of histone H3 K9 and NF-kappa B lysine 310. NF-kappa B was activated at the same time as the protein acetylation. Moreover, JNK phosphorylation was inhibited after the cells were treated with VPA under hypoxia condition. Conclusion:VPA enhances acetylation of histone 3 at lysine 9 and NF-kappa B at 310, induces NF-kappa B activation, reduces JNK activation, and protects the neurons from hypoxia-induced apoptosis in vitro. C1 [Li, Yongqing; Liu, Baoling; Sailhamer, Elizabeth A.; Shults, Christian; Velmahos, George C.; Demoya, Marc; Alam, Hasan B.] Harvard Univ, Sch Med, Massachusetts Gen Hosp,Dept Surg, Div Trauma Emergency Surg & Surg Crit Care, Boston, MA 02114 USA. [Shults, Christian] Washington Hosp Ctr, Dept Surg, Washington, DC 20010 USA. [Yuan, Zengqiang] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. RP Alam, HB (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp,Dept Surg, Div Trauma Emergency Surg & Surg Crit Care, 165 Cambridge St,Suite 810, Boston, MA 02114 USA. EM hbalam@partners.org FU NIGMS NIH HHS [F32 GM79880] NR 28 TC 44 Z9 51 U1 1 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0022-5282 J9 J TRAUMA JI J. Trauma-Injury Infect. Crit. Care PD APR PY 2008 VL 64 IS 4 BP 863 EP 870 DI 10.1097/TA.0b013e318166b822 PG 8 WC Critical Care Medicine; Surgery SC General & Internal Medicine; Surgery GA 287UN UT WOS:000254942100003 PM 18404049 ER PT J AU Alam, HB Duggan, M Li, YQ Spaniolas, K Liu, BL Tabbara, M deMoya, M Sailhamer, EA Shults, C Velmahos, GC AF Alam, Hasan B. Duggan, Michael Li, Yongqing Spaniolas, Konstantinos Liu, Baoling Tabbara, Malek deMoya, Marc Sailhamer, Elizabeth A. Shults, Christian Velmahos, George C. TI Putting life on hold - For how long? Profound hypothermic cardiopulmonary bypass in a swine model of complex vascular injuries SO JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE LA English DT Article; Proceedings Paper CT 37th Annual Meeting of the Western-Trauma-Association CY FEB 25-MAR 02, 2007 CL Steamboat Springs, CO SP Western Trauma Assoc DE hypothermia; uncontrolled hemorrhage; metabolic arrest; thoracotomy; organ preservation; neurologic function; sepsis; survival ID UNCONTROLLED HEMORRHAGIC-SHOCK; MILD PERIOPERATIVE HYPOTHERMIA; PROLONGS SURVIVAL-TIME; LOW-FLOW PERFUSION; CARDIAC-ARREST; CIRCULATORY ARREST; LETHAL HEMORRHAGE; BRAIN-DAMAGE; TRAUMATIC EXSANGUINATION; MODERATE HYPOTHERMIA AB Background: Rapid induction of profound hypothermia for emergency preservation and resuscitation can improve survival from uncontrolled lethal hemorrhage in large animal models. We have previously demonstrated that profound hypothermia (10 degrees C) must be induced rapidly (2 degrees C/min) and reversed gradually (0.5 degrees C/min) for best results. However, the maximum duration of hypothermic arrest in a clinically relevant trauma model remains unknown. Methods: Uncontrolled lethal hemorrhage was induced in 22 swine by creating an iliac artery and vein injury, followed 30 minutes later (simulating transport time) by laceration of the descending thoracic aorta. Through a thoracotomy approach, a catheter was placed in the aorta, and cold organ preservation solution was in-fused using a roller pump to rapidly induce profound hypothermia (10 degrees C) which was maintained with low-flow cardiopulmonary bypass. Vascular injuries were repaired during the asanguinous hypothermic low flow period. Profound hypothermia was maintained (n = 10-12 per group) for either 60 minutes or 120 minutes. After repair of injuries, animals were rewarmed (0.5 degrees C/min) and resuscitated on cardiopulmonary bypass, and whole blood was infused during this period. Animals were monitored for 4 weeks for neurologic deficits, organ dysfunction, and postoperative complications. Results: The 4-week survival rates in 60- and 120-minute groups were 92% and 50%, respectively (p < 0.05). The, surviving animals were neurologically intact and had no long-term organ dysfunction, except for one animal in the 120-minute group. The animals subjected to 120 minutes of hypothermia had significantly worse lactic acidosis, displayed markedly slower recovery, and had significantly higher rates of postoperative complications, including late deaths because of infections. Conclusion: In a model of lethal injuries, rapid induction of profound hypothermia can prevent death. Profound hypothermia decreases but does not abolish metabolism. With current methods, the upper limit of hypothermic arrest in the setting of uncontrolled hemorrhage is 60 minutes. C1 [Alam, Hasan B.; Duggan, Michael; Li, Yongqing; Spaniolas, Konstantinos; Liu, Baoling; Tabbara, Malek; deMoya, Marc; Sailhamer, Elizabeth A.; Shults, Christian; Velmahos, George C.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Trauma Emergency Surg & Surg Crit Care, Boston, MA 02114 USA. RP Alam, HB (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Trauma Emergency Surg & Surg Crit Care, 165 Cambridge St,Suite 810, Boston, MA 02114 USA. EM hbalam@partners.org OI Tabbara, Malek/0000-0003-1046-7803 FU NHLBI NIH HHS [R01 HL71698] NR 53 TC 18 Z9 19 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0022-5282 J9 J TRAUMA JI J. Trauma-Injury Infect. Crit. Care PD APR PY 2008 VL 64 IS 4 BP 912 EP 922 DI 10.1097/TA.0b013e3181659e7f PG 11 WC Critical Care Medicine; Surgery SC General & Internal Medicine; Surgery GA 287UN UT WOS:000254942100012 PM 18404056 ER PT J AU Rhee, P Brown, C Martin, M Salim, A Plurad, D Green, D Chambers, L Demetriades, D Velmahos, G Alam, H AF Rhee, Peter Brown, Carlos Martin, Matthew Salim, Ali Plurad, Dave Green, Donald Chambers, Lowell Demetriades, Demetrios Velmahos, George Alam, Hassan TI QuikClot use in trauma for hemorrhage control: Case series of 103 documented uses SO JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE LA English DT Article ID LETHAL GROIN INJURY; HEMOSTATIC DRESSINGS; ANIMAL-MODEL; SWINE MODEL AB Background: Local hemostatics have recently been introduced for field use to control external hemorrhage. The objective of this report is to describe the initial clinical experience with QuikClot, a zeolite that works by absorbing water and concentrating coagulation factors to stop bleeding in a series of patients. Methods: Documented cases using a self-reporting survey sheet submitted by the users and first-hand detailed interviews with the users when possible. Results: There were 103 documented cases of QuikClot use: 69 by the US military in Iraq, 20 by civilian trauma surgeons and 14 by civilian first responders. There were 83 cases involving application to external wounds and 20 cases of intracorporeal use by military and civilian surgeons. All field applications by first responders were successful in controlling hemorrhage. The overall efficacy rate was 92% with eight cases of ineffectiveness noted by physicians in morbid patients with massive injuries when the QuikClot was used as a last resort. These reported failures were thought to be a result of the coagulopathic state of the patient from massive resuscitation or the inability to get the product directly to the source of hemorrhage. When the QuikClot was applied on responsive patients, the heat generated by the exothermic reaction caused mild to severe pain and discomfort. There were three cases of burns caused by the heat generated by the QuikClot application with one case requiring skin grafting. There was one major complication from intracorporeal use caused by scar formation from a foreign body reaction. Conclusions: QuikClot has been effectively used by a wide range of providers in the field and hospital to control hemorrhage. C1 [Rhee, Peter] Univ Arizona, Dept Surg, Tucson, AZ USA. [Brown, Carlos] Brackenridge Hosp, Dept Surg, Austin, TX USA. [Martin, Matthew; Plurad, Dave; Green, Donald; Chambers, Lowell; Demetriades, Demetrios] Univ So Calif, Los Angeles Cty Med Ctr, Dept Surg, Los Angeles, CA 90033 USA. [Salim, Ali] Cedars Sinai Med Ctr, Dept Surg, Los Angeles, CA 90048 USA. [Velmahos, George; Alam, Hassan] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. RP Rhee, P (reprint author), Univ Med Ctr, 1501 N Campbell Ave, Tucson, AZ 85724 USA. EM prhee@surgery.arizona.edu RI Martin, Matthew/B-2676-2014 OI Martin, Matthew/0000-0002-9169-9069 NR 8 TC 97 Z9 99 U1 1 U2 12 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0022-5282 J9 J TRAUMA JI J. Trauma-Injury Infect. Crit. Care PD APR PY 2008 VL 64 IS 4 BP 1093 EP 1099 DI 10.1097/TA.0b013e31812f6dbc PG 7 WC Critical Care Medicine; Surgery SC General & Internal Medicine; Surgery GA 287UN UT WOS:000254942100041 PM 18404080 ER PT J AU Daly, ES Gulliver, SB Zimering, RT Knight, J Karnholz, BW Morissette, SB AF Daly, Erin Scott Gulliver, Suzy Bird Zimering, Rose T. Knight, Jeffrey Karnholz, Barbara W. Morissette, Sandra B. TI Disaster mental health workers responding to ground zero: One year later SO JOURNAL OF TRAUMATIC STRESS LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; ADMINISTERED PTSD SCALE; PSYCHOMETRIC PROPERTIES; ANNIVERSARY REACTIONS; GULF-WAR; INVENTORY; DEPRESSION; VETERANS; EXPOSURE AB The current study examined anniversary reactions in mental health disaster relief workers following traumatic exposure at the site of the World Trade Center terrorist attacks. Despite relatively low levels of symptom reporting, workers endorsed an increase in both negative mood symptoms and functional impairment at the one-year anniversary of their traumatic exposure (compared to 6 months postexposure). For those individuals who met at least partial criteria for PTSD immediately following exposure, overall self-reported PTSD symptoms tended to increase from 6 to 12 months. This tendency resulted specifically from an increase in hyperarousal symptoms. Although few endorsed symptoms at clinical levels, our results demonstrate that disaster relief workers may experience an increase in symptomatology at the anniversary of their traumatic exposure. C1 [Daly, Erin Scott] VA Boston Healthcare Syst, Psychol Serv, Boston, MA 02130 USA. Boston Univ, Sch Med, Boston, MA 02118 USA. RP Daly, ES (reprint author), VA Boston Healthcare Syst, Psychol Serv, 116B,150 S Huntington Ave,Jamaica Pl, Boston, MA 02130 USA. EM erin.daly@va.gov FU NIMH NIH HHS [R01 MH073808, R01MH66353] NR 15 TC 13 Z9 13 U1 0 U2 2 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0894-9867 J9 J TRAUMA STRESS JI J. Trauma Stress PD APR PY 2008 VL 21 IS 2 BP 227 EP 230 DI 10.1002/jts.20311 PG 4 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 295AE UT WOS:000255446600015 PM 18404624 ER PT J AU Palyo, SA Clapp, JD Beck, JG Grant, DM Marques, L AF Palyo, Sarah A. Clapp, Josh D. Beck, J. Gayle Grant, DeMond M. Marques, Luana TI Unpacking the relationship between posttraumatic numbing and hyperarousal in a sample of help-seeking motor vehicle accident survivors: Replication and extension SO JOURNAL OF TRAUMATIC STRESS LA English DT Article ID CONFIRMATORY FACTOR-ANALYSIS; ADMINISTERED PTSD SCALE; STRESS-DISORDER; SYMPTOM CLUSTERS; AVOIDANCE; DIMENSIONALITY; PREDICTORS AB The current study is a replication and extension of previous research that has found support for a relationship between posttraumatic numbing and hyperarousal. This study examined this association while controlling for depression in 345 motor vehicle accident survivors. Additionally, the relationships among specific hyperarousal symptoms and numbing were explored. Results provided further evidence for an association between hyperarousal and numbing, even while controlling for the influence of depression, and revealed that all hyperarousal symptoms (except hypervigilance) contribute to this association. C1 [Palyo, Sarah A.; Clapp, Josh D.; Beck, J. Gayle; Grant, DeMond M.] SUNY Buffalo, Dept Psychol, Buffalo, NY 14260 USA. [Marques, Luana] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cambridge, MA 02138 USA. RP Palyo, SA (reprint author), SUNY Buffalo, Dept Psychol, Pk Hall, Buffalo, NY 14260 USA. EM jgbeck@buffalo.edu OI Grant, DeMond/0000-0002-5231-6563 FU NIMH NIH HHS [MH64777] NR 17 TC 7 Z9 8 U1 1 U2 2 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0894-9867 J9 J TRAUMA STRESS JI J. Trauma Stress PD APR PY 2008 VL 21 IS 2 BP 235 EP 238 DI 10.1002/jts.20308 PG 4 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 295AE UT WOS:000255446600017 PM 18404628 ER PT J AU Eisner, BH Shaikh, M Uppot, RN Sahani, DV Dretler, SP AF Eisner, Brian H. Shaikh, Mehrine Uppot, Raul N. Sahani, Dushyant V. Dretler, Stephen P. TI Genitourinary imaging with noncontrast computerized tomography - Are we missing duplex ureters? SO JOURNAL OF UROLOGY LA English DT Article DE ureter; abnormalities; tomography; emission-computed; diagnosis ID UNENHANCED HELICAL CT; INTRAVENOUS UROGRAPHY; RENAL DUPLICATION; STONES AB Purpose: Noncontrast computerized tomography has replaced excretory urography as the first line diagnostic tool for evaluating nephrolithiasis at many centers. We evaluated the ability of noncontrast computerized tomography to detect ureteral duplication to determine how frequently these anomalies are under diagnosed. Materials and Methods: Computerized tomography images of 14 patients with known ureteral duplication who had previously undergone noncontrast and contrast enhanced computerized tomography and 5 control patients with normal ureteral anatomy were interpreted by 2 blinded radiologists who specialize in genitourinary imaging. Results: The sensitivity of axial computerized tomography with contrast material, axial computerized tomography without contrast material and coronal computerized tomography without contrast material was 96%, 59% and 65%, respectively. The negative predictive value of axial computerized tomography with contrast material, axial computerized tomography without contrast material and coronal computerized tomography without contrast material was 95%, 65% and 67%, respectively. The accuracy of axial computerized tomography with contrast medium was significantly higher than that of noncontrast axial or noncontrast coronal computerized tomography (each p <0.01). Conclusions: Duplicated ureters, which represent a challenge to the endourologist, are under diagnosed on noncontrast computerized tomography. Urologists and radiologists should be aware of this limitation and contrast studies should be done when anatomical anomalies are suspected. C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Kidney Stone Ctr,Dept Urol, Boston, MA 02114 USA. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Kidney Stone Ctr,Dept Radiol, Boston, MA 02114 USA. RP Eisner, BH (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Kidney Stone Ctr,Dept Urol, 55 Fruit St, Boston, MA 02114 USA. EM beisner@partners.org NR 10 TC 4 Z9 4 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5347 J9 J UROLOGY JI J. Urol. PD APR PY 2008 VL 179 IS 4 BP 1445 EP 1448 DI 10.1016/j.juro.2007.11.074 PG 4 WC Urology & Nephrology SC Urology & Nephrology GA 276WS UT WOS:000254175000060 PM 18295280 ER PT J AU McDougal, WS AF McDougal, W. Scott TI Ileal enterocystoplasty and B12 deficiency in pediatric patients - Comments SO JOURNAL OF UROLOGY LA English DT Editorial Material C1 [McDougal, W. Scott] Massachusetts Gen Hosp, Dept Urol, Boston, MA 02114 USA. RP McDougal, WS (reprint author), Massachusetts Gen Hosp, Dept Urol, Boston, MA 02114 USA. NR 2 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5347 J9 J UROLOGY JI J. Urol. PD APR PY 2008 VL 179 IS 4 BP 1547 EP 1548 DI 10.1016/j.juro.2007.11.116 PG 2 WC Urology & Nephrology SC Urology & Nephrology GA 276WS UT WOS:000254175000080 ER PT J AU Figueiredo, JL Passerotti, CC Sponholtz, T Nguyen, HT Weissleder, R AF Figueiredo, Jose Luiz Passerotti, Carlo C. Sponholtz, Todd Nguyen, Hiep T. Weissleder, Ralph TI A novel method of imaging calcium urolithiasis using fluorescence SO JOURNAL OF UROLOGY LA English DT Article DE urinary calculi; molecular probes; fluorescence; diagnostic imaging; mice ID ACUTE FLANK PAIN; TOMOGRAPHY; MANAGEMENT; STONES AB Purpose: In the surgical management of urolithiasis the goal of treatment is not only to remove calculi, but also prevent future stone formation by rendering the patient stone-free/fragment-free. Achieving this goal is often difficult with endoscopic procedures due to the inability to visualize small calculi well even with x-ray or ultrasound. We evaluated fluorescence probes as a novel method of identifying calculi in the urinary tract. Materials and Methods: In vitro calcium stones were incubated with each of the Osteosense (TM) 680 and Osteosense 750 calcium binding fluorescence probes, and imaged with a near infrared fluorescence imaging system. Using a mouse model calculi were placed in the renal pelvis and the probes were injected intravenously. Imaging was performed at various times after injection. Results: In vitro the Osteosense 680 probe demonstrated high binding affinity for calcium oxalate-struvite, calcium phosphate-struvite and ammonium urate-calcium oxalate-calcium phosphate stones, and lower binding affinity for the calcium phosphate stone. In contrast, the Osteosense 750 probe demonstrated high binding affinity for calcium oxalate-struvite and calcium phosphate-struvite stones, and lower binding affinity for calcium phosphate and ammonium urate-calcium oxalate-calcium phosphate stones. In vivo intravenous administration of the probes was successful in labeling all calcium stone types tested. Conclusions: Fluorescence imaging provides a new method for identifying calculi in the urinary tract. The improved visualization of these stones/fragments would make endoscopic procedures less difficult, decrease the risk of complications and increase the chance of rendering the patient stone-free/fragment-free. C1 [Passerotti, Carlo C.; Nguyen, Hiep T.] Childrens Hosp, Dept Urol, Boston, MA 02115 USA. [Passerotti, Carlo C.; Nguyen, Hiep T.] Massachusetts Gen Hosp, Ctr Mol Imaging Res, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. RP Nguyen, HT (reprint author), Childrens Hosp, Dept Urol, 300 Longwood Ave,Hunnewell 353, Boston, MA 02115 USA. EM nguyen@childrens.harvard.edu FU NCI NIH HHS [R24-CA92782] NR 14 TC 14 Z9 14 U1 1 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5347 J9 J UROLOGY JI J. Urol. PD APR PY 2008 VL 179 IS 4 BP 1610 EP 1614 DI 10.1016/j.juro.2007.11.100 PG 5 WC Urology & Nephrology SC Urology & Nephrology GA 276WS UT WOS:000254175000095 PM 18295253 ER PT J AU Cantwell, CP Perumpillichira, JJ Maher, MM Hahn, PF Arellano, R Gervais, DA Mueller, PR AF Cantwell, Colin P. Perumpillichira, James J. Maher, Michael M. Hahn, Peter F. Arellano, Ronald Gervais, Debra A. Mueller, Peter R. TI Antibiotic prophylaxis for percutaneous radiologic gastrostomy insertion in outpatients cancer and gastrojejunostomy with head and neck cancer SO JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY LA English DT Article ID T-FASTENER GASTROPEXY; ENDOSCOPIC GASTROSTOMY; EXPERIENCE; PEG AB PURPOSE: To determine the effect of antibiotic prophylaxis on the postprocedural infection rate after fluoroscopically guided percutaneous radiologic gastrostomy and gastrojejunostomy with gastropexy performed as an outpatient procedure in ambulatory patients with head and neck cancer. MATERIALS AND METHODS: Medical and imaging records of all outpatients with head and neck cancer referred for gastrostomy or gastrojejunostomy from February 2003 to November 2004 were retrospectively reviewed. A 14-F percutaneous gastrostomy was inserted through the anterior abdominal wall after T-fastener gastropexy. Fifty-seven patients (36 men; mean age, 57.2 years; age range, 17-76 y) had 53 percutaneous radiologic gastrostomies and four percutaneous radiologic gastrojejunostomies. Mean follow-up was 27 weeks (range, 4-62 weeks). Thirty-seven patients received antibiotic prophylaxis with 1 g cefazolin intravenously and twice-daily cephalexin 500 mg for 5 days orally or via gastrostomy (n = 35) or clindamycin 600 mg intravenously and 600 mg twice daily orally or via gastrostomy for 5 days (n = 2). RESULTS: Ten minor postprocedural complications occurred in 8 patients (14%). There was a 15% peristomal infection rate (n = 3) in patients who did not receive antibiotic prophylaxis; none occurred in those who received antibiotic prophylaxis. There were significantly fewer infections in the group that received antibiotic prophylaxis (P = .039). No major complications or deaths occurred. CONCLUSIONS: Administration of prophylactic antibiotics for percutaneous radiologic gastrostomy placement reduces peristomal infection in patients with head and neck cancer. C1 [Mueller, Peter R.] Massachusetts Gen Hosp, Div Abdominal & Intervent Radiol, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02114 USA. RP Mueller, PR (reprint author), Massachusetts Gen Hosp, Div Abdominal & Intervent Radiol, White 270,55 Fruit St, Boston, MA 02114 USA. EM pmueller@partners.org NR 22 TC 16 Z9 18 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1051-0443 J9 J VASC INTERV RADIOL JI J. Vasc. Interv. Radiol. PD APR PY 2008 VL 19 IS 4 BP 571 EP 575 DI 10.1016/j.jvir.2007.11.012 PG 5 WC Radiology, Nuclear Medicine & Medical Imaging; Peripheral Vascular Disease SC Radiology, Nuclear Medicine & Medical Imaging; Cardiovascular System & Cardiology GA 285EU UT WOS:000254760900016 PM 18375303 ER PT J AU Baumgarten, M Margolis, DJ Localio, R Kagan, SH Lowe, RA Kinosian, B Abbuhl, SB Kavesh, W Holmes, JH Ruffin, A Mehari, T AF Baumgarten, Mona Margolis, David J. Localio, Russell Kagan, Sarah H. Lowe, Robert A. Kinosian, Bruce Abbuhl, Stephanie B. Kavesh, William Holmes, John H. Ruffin, Althea Mehari, Tesfa TI Extrinsic risk factors for pressure ulcers early in the hospital stay: A nested case-control study SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES LA English DT Article; Proceedings Paper CT 14th Annual Meeting of the Wound-Healing-Society CY MAY 24, 2004 CL Atlanta, GA SP Wound Healing Soc DE pressure ulcers; intensive care unit; hospital patients; risk factors ID ELDERLY-PATIENTS; DEVICES; SORES; CARE; PREVENTION; SURGERY; PATIENT; PERIOD; RATES AB Background. Little is known about the impact of extrinsic factors on pressure ulcer risk. The objective of this study was to determine whether risk of pressure ulcers early in the hospital stay is associated with extrinsic factors such as longer emergency department (ED) stays, night or weekend admission, potentially immobilizing procedures and medications, and admission to an intensive care unit (ICU). Methods. A nested case-control study was performed in two teaching hospitals in Philadelphia, Pennsylvania. Participants were medical patients age >= 65 years admitted through the ED. Cases (n = 195) had >= 1 possibly or definitely hospital-acquired pressure ulcers. Three controls per case were sampled randomly from among noncases at the same hospital in the same month (n = 597). Pressure ulcer status was determined by a research nurse on the third day of hospitalization. Pressure ulcers were classified as preexisting, possibly hospital-acquired, or definitely hospital-acquired. Information on extrinsic factors was obtained by chart review. Results. The odds of pressure ulcers were twice as high for those with an ICU stay as for those without (adjusted odds ratio [aOR] 2.0, 95% confidence interval [CI], 1.2-3.5). The aOR was 0.6 (95% CI, 0.3-0.9) for use of any potentially immobilizing medications during the early inpatient period. Conclusions. Many of the procedures experienced by patients in the ED and early in the inpatient stay do not confer excess pressure ulcer risk. Having an ICU stay is associated with a doubling of risk. This finding emphasizes the importance of developing and evaluating interventions to prevent pressure ulcers among patients in the ICU. C1 [Baumgarten, Mona; Mehari, Tesfa] Univ Maryland, Sch Med, Dept Epidemiol & Prevent Med, Baltimore, MD 21201 USA. [Margolis, David J.; Localio, Russell; Kinosian, Bruce; Abbuhl, Stephanie B.; Holmes, John H.; Ruffin, Althea] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. [Kagan, Sarah H.] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA. [Lowe, Robert A.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Kavesh, William] Philadelphia VA Med Ct, Philadelphia, PA USA. RP Baumgarten, M (reprint author), Univ Maryland, Sch Med, Dept Epidemiol & Prevent Med, 660 W Redwood St,Suite 200, Baltimore, MD 21201 USA. EM mbaumgar@epi.umaryland.edu FU NIA NIH HHS [R01 AG014127-02, R01-AG-14127, R01 AG014127-04, R01 AG014127-03, R01 AG014127] NR 44 TC 24 Z9 24 U1 1 U2 10 PU GERONTOLOGICAL SOC AMER PI WASHINGTON PA 1030 15TH ST NW, STE 250, WASHINGTON, DC 20005202-842 USA SN 1079-5006 J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD APR PY 2008 VL 63 IS 4 BP 408 EP 413 PG 6 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 294SO UT WOS:000255426100009 PM 18426965 ER PT J AU Davis, TR Young, BA Eisenberg, MS Rea, TD Copass, MK Cobb, LA AF Davis, T. R. Young, B. A. Eisenberg, M. S. Rea, T. D. Copass, M. K. Cobb, L. A. TI Outcome of cardiac arrests attended by emergency medical services staff at community outpatient dialysis centers SO KIDNEY INTERNATIONAL LA English DT Article DE cardiac arrest; dialysis; ESRD; emergency medical service ID CARDIOPULMONARY-RESUSCITATION; CARDIOVASCULAR-DISEASE; HEMODIALYSIS-PATIENTS; DEFIBRILLATION; SURVIVAL; SUDDEN; DEATH AB Cardiac arrest is the leading cause of death among dialysis patients in the United States. We measured the outcome of cardiac arrests attended by Emergency Medical Services (EMS) staff at hemodialysis facilities in a 14-year population-based retrospective study to identify cardiac arrest cases at a dialysis unit. Associated factors were determined using unconditional logistic regression. Of the 102 cardiac arrests identified around the time of dialysis, 10 occurred before, 72 during, and 20 after hemodialysis. The initial measured abnormality was ventricular fibrillation or tachycardia in 72 cases. Of those who survived transportation to a hospital, survival to discharge was 24 with 15% survival at 1 year. Compared to arrests that occurred prior to dialysis, the odds of ventricular fibrillation were 5-fold greater in patients on dialysis but 14-fold greater in those arresting after dialysis. One-third of cases occurred after the introduction of automated external defibrillators, and in half of the cases these devices were attached prior to EMS arrival. Once these devices were attached, most were used for defibrillation. We conclude that ventricular arrhythmias are the predominant features among arrested in-center dialysis patients with most occurrences during dialysis. The role of these devices in dialysis units will need a larger study to evaluate their efficacy. C1 [Davis, T. R.] Univ Washington, Sch Med, Seattle, WA 98195 USA. [Young, B. A.; Eisenberg, M. S.; Rea, T. D.; Copass, M. K.; Cobb, L. A.] Univ Washington, Dept Med, Div Nephrol, Seattle, WA 98195 USA. [Young, B. A.] Univ Washington, Div Nephrol, Seattle, WA 98195 USA. [Eisenberg, M. S.; Rea, T. D.] Publ Hlth Seattle & King County, Emergency Med Serv Div, Seattle, WA USA. RP Young, BA (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Div Nephrol, Mail Stop 152-E,1660 S Columbian Way, Seattle, WA 98108 USA. EM youngb@u.washington.edu NR 21 TC 34 Z9 35 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0085-2538 J9 KIDNEY INT JI Kidney Int. PD APR PY 2008 VL 73 IS 8 BP 933 EP 939 DI 10.1038/sj.ki.5002749 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA 282HQ UT WOS:000254558900009 PM 18172435 ER PT J AU Gutierrez, OM Isakova, T Andress, DL Levin, A Wolf, M AF Gutierrez, O. M. Isakova, T. Andress, D. L. Levin, A. Wolf, M. TI Prevalence and severity of disordered mineral metabolism in Blacks with chronic kidney disease SO KIDNEY INTERNATIONAL LA English DT Article DE mineral metabolism; racial disparities; chronic kidney disease ID STAGE RENAL-DISEASE; INCIDENT HEMODIALYSIS-PATIENTS; NUTRITION EXAMINATION SURVEY; CARDIOVASCULAR RISK-FACTORS; VITAMIN-D DEFICIENCY; 3RD NATIONAL-HEALTH; SECONDARY HYPERPARATHYROIDISM; PARATHYROID-HORMONE; RACIAL-DIFFERENCES; VASCULAR CALCIFICATION AB Disorders of mineral metabolism develop early in chronic kidney disease, but it appears that Blacks with stage-5 disease have more severe secondary hyperparathyroidism than other races. We measured levels of parathyroid hormone, calcium, phosphorus, 25-hydroxyvitamin D (25D) and 1,25-dihydroxyvitamin D (1,25D) in 227 Black and 1633 non-Black participants in the SEEK study, a multi-center cohort of patients with early chronic kidney disease. Overall, Blacks had similar 1,25D levels compared with non-Blacks, but significantly lower levels of 25D with higher levels of calcium, phosphorus, and parathyroid hormone, and were significantly more likely to have hyperphosphatemia than non-Blacks. In multivariable analyses adjusted for age, gender, estimated glomerular filtration rate, body mass index, and diabetes, Blacks had significantly lower 25D and higher parathyroid hormone levels than non-Blacks, with the latter parameter remaining significant after further adjustment for calcium, phosphorus, 25D, and 1,25D. The association between Black race and secondary hyperparathyroidism, independent of known risk factors, suggests that novel mechanisms contribute to secondary hyperparathyroidism in Blacks with chronic kidney disease. C1 [Gutierrez, O. M.; Isakova, T.; Wolf, M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med,Renal Unit, Boston, MA 02114 USA. [Andress, D. L.] Univ Washington, Dept Med, Div Nephrol, Seattle, WA 98195 USA. [Levin, A.] Univ British Columbia, Dept Nephrol, Vancouver, BC V5Z 1M9, Canada. RP Gutierrez, OM (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med,Renal Unit, Gray Bigelow 100355 Friut St, Boston, MA 02114 USA. EM ogutierrez@partners.org FU NCRR NIH HHS [K23RR017376, K30RR02229207]; NIDDK NIH HHS [R01DK076116] NR 53 TC 39 Z9 39 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0085-2538 J9 KIDNEY INT JI Kidney Int. PD APR PY 2008 VL 73 IS 8 BP 956 EP 962 DI 10.1038/ki.2008.4 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA 282HQ UT WOS:000254558900012 PM 18256597 ER PT J AU Corsten, MF Shah, K AF Corsten, Maarten F. Shah, Khalid TI Therapeutic stem-cells for cancer treatment: hopes and hurdles in tactical warfare SO LANCET ONCOLOGY LA English DT Review ID NEURAL PROGENITOR CELLS; APOPTOSIS-INDUCING LIGAND; BONE-MARROW; GENE-THERAPY; IN-VIVO; GLIOMA MODEL; BRAIN-TUMORS; DISSEMINATED NEUROBLASTOMA; INTRACRANIAL GLIOMA; CELLULAR VEHICLES AB As our understanding of stem-cell behaviour rapidly increases, more and more reports suggest that use of stem-cell therapy will extend well beyond regenerative medicine in the near future. Due to their inherent tumoritropic migratory properties, stem cells can serve as vehicles for the delivery of effective, targeted treatment to isolated tumours and to metastatic disease. In vitro, stem cells can readily be engineered by inserting specifically tailored transgenes with antitumour effects to create tumour-seeking therapeutic vehicles. Transgene effects include direct tumour-cell killing, promotion of local immune responses, oncolytic virus production, and prodrug activation schemes. Many of these strategies have been validated in a wide range of studies assessing treatment feasibility or efficacy and establishing methods for real-time monitoring of stem-cell migration and fate in vivo. New insights into avenues for stem-cell sourcing have shortened the probable time to realisation of such treatments for patients. In this Review, we provide an outline of the rationale and status of stem-cell-based treatments fir tumours, and we discuss prospects for clinical implementation and the factors crucial for maintaining momentum towards this goal. C1 [Corsten, Maarten F.; Shah, Khalid] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Boston, MA 02115 USA. RP Shah, K (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Boston, MA 02115 USA. EM kshah@helix.mgh.harvard.edu NR 75 TC 61 Z9 63 U1 2 U2 21 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1470-2045 J9 LANCET ONCOL JI Lancet Oncol. PD APR PY 2008 VL 9 IS 4 BP 376 EP 384 DI 10.1016/S1470-2045(08)70099-8 PG 9 WC Oncology SC Oncology GA 284EL UT WOS:000254689000025 PM 18374291 ER PT J AU Izikson, L Avram, M Anderson, RR AF Izikson, Leonid Avram, Mathew Anderson, R. Rox TI Transient immunoreactivity after laser tattoo removal: Report of two cases SO LASERS IN SURGERY AND MEDICINE LA English DT Article DE immune activation; laser; lymphadenopathy; removal; tattoo ID CUTANEOUS PSEUDOLYMPHOMA AB Background and Objective: Laser tattoo removal is one of most commonly used indications for medical lasers. Professional tattoos contain a multitude of potentially immunogenic chemicals that are released or modified by laser treatment. We studied potential immunologic reactions following laser tattoo removal. Study design/Patients and Methods: Case report of two patients with immunologic reactions after laser tattoo removal. Results: Two patients developed transient immunoreactivity that presented as regional lymphadenopathy after laser tattoo removal of professional black and blue-green tattoos. These reactions resolved without any complications. Conclusions: Tattoo pigments released or modified by laser therapy may trigger transient immunoreactivity in susceptible individuals. C1 [Izikson, Leonid; Avram, Mathew; Anderson, R. Rox] Harvard Univ, Massachusetts Gen Hosp, Sch Med, MGH Laser & Cosmet Dermatol Ctr, Boston, MA 02445 USA. [Izikson, Leonid; Avram, Mathew; Anderson, R. Rox] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA 02445 USA. RP Izikson, L (reprint author), MGH, BHX 630,Bartlett Hall, Boston, MA 02114 USA. EM lizikson@partners.org NR 9 TC 14 Z9 14 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PD APR PY 2008 VL 40 IS 4 BP 231 EP 232 DI 10.1002/lsm.20618 PG 2 WC Dermatology; Surgery SC Dermatology; Surgery GA 296AD UT WOS:000255515000001 PM 18412226 ER PT J AU San-Miguel, JF Richardson, PG Sonneveld, P Schuster, MW Irwin, D Stadtmauer, EA Facon, T Harousseau, JL Ben-Yehuda, D Lonial, S Goldschmidt, H Reece, D Blade, J Boccadoro, M Cavenagh, JD Neuwirth, R Boral, AL Esseltine, DL Anderson, KC AF San-Miguel, J. F. Richardson, P. G. Sonneveld, P. Schuster, M. W. Irwin, D. Stadtmauer, E. A. Facon, T. Harousseau, J-L Ben-Yehuda, D. Lonial, S. Goldschmidt, H. Reece, D. Blade, J. Boccadoro, M. Cavenagh, J. D. Neuwirth, R. Boral, A. L. Esseltine, D-L Anderson, K. C. TI Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study SO LEUKEMIA LA English DT Article DE multiple myeloma; bortezomib; creatinine clearance; renal impairment; clinical trial ID DIAGNOSED MULTIPLE-MYELOMA; PRESENTING FEATURES; FAILURE; THERAPY; REVERSAL; IMPACT; TRANSPLANTATION; DEXAMETHASONE; PATHOGENESIS; THALIDOMIDE AB Renal impairment is associated with poor prognosis in multiple myeloma (MM). This subgroup analysis of the phase 3 Assessment of Proteasome Inhibition for Extending Remissions (APEX) study of bortezomib vs high-dose dexamethasone assessed efficacy and safety in patients with relapsed MM with varying degrees of renal impairment (creatinine clearance (CrCl) < 30, 30-50, 51-80 and > 80 ml min(-1)). Time to progression (TTP), overall survival ( OS) and safety were compared between subgroups with CrCl <= 50 ml min(-1) (severe-to-moderate) and > 50 ml min(-1) (no/mild impairment). Response rates with bortezomib were similar (36-47%) and time to response rapid (0.7-1.6 months) across subgroups. Although the trend was toward shorter TTP/OS in bortezomib patients with severe-to-moderate vs no/mild impairment, differences were not significant. OS was significantly shorter in dexamethasone patients with CrCl <= 50 vs > 50 ml min(-1) (P = 0.003), indicating that bortezomib is more effective than dexamethasone in overcoming the detrimental effect of renal impairment. Safety profile of bortezomib was comparable between subgroups. With dexamethasone, grade 3/4 adverse events (AEs), serious AEs and discontinuations for AEs were significantly elevated in patients with CrCl <= 50 vs > 50 ml min(-1). These results indicate that bortezomib is active and well tolerated in patients with relapsed MM with varying degrees of renal insufficiency. Efficacy/safety were not substantially affected by severe-to-moderate vs no/mild impairment. C1 [San-Miguel, J. F.] Hosp Univ Salamanca, Serv Hematol, Dept Hematol, CIC Univ Salamanca CSIC, Salamanca 37007, Spain. [Sonneveld, P.] Erasmus MC, Dept Hematol, Rotterdam, Netherlands. [Schuster, M. W.] Cornell Univ, New York Presbyterian Hosp, Ctr Lymphoma & Myeloma, Weill Med Coll, Ithaca, NY 14853 USA. [Irwin, D.] Alta Bates Canc Ctr, Bone & Marrow Transplantat Program, Berkeley, CA USA. [Stadtmauer, E. A.] Univ Penn, Bone Marrow & Stem Cell Transplant Program, Abramson Canc Ctr, Philadelphia, PA 19104 USA. [Richardson, P. G.] Dana Farber Canc Inst, Dept Med Oncol Hematol Malignancies, Boston, MA 02115 USA. [Facon, T.] Hosp Claude Huriez, Serv Malad Sang, Lille, France. [Harousseau, J-L] Hop Hotel Dieu, Dept Hematol, Nantes, France. [Ben-Yehuda, D.] Hadassah Univ Hosp, Dept Hematol, IL-91120 Jerusalem, Israel. [Lonial, S.] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA. [Goldschmidt, H.] Univ Heidelberg, Dept Internal Med 5, Heidelberg, Germany. [Reece, D.] Princess Margaret Hosp, Div Hematol Oncol, Toronto, ON M4X 1K9, Canada. [Blade, J.] Univ Barcelona, Hosp Clin, IDIBAPS, Barcelona, Spain. [Boccadoro, M.] Univ Turin, Div Hematol, Turin, Italy. [Cavenagh, J. D.] St Bartholomews Hosp, Dept Haematol, London, England. [Neuwirth, R.; Boral, A. L.; Esseltine, D-L] Millennium Pharmaceut Inc, Cambridge, MA USA. RP San-Miguel, JF (reprint author), Hosp Univ Salamanca, Serv Hematol, Dept Hematol, CIC Univ Salamanca CSIC, Paseo San Vicente 58-182, Salamanca 37007, Spain. EM sanmigiz@usal.es RI 2008, Ibsal/A-1268-2012; FACON, THIERRY/M-9736-2014 OI FACON, THIERRY/0000-0001-7705-8460 NR 32 TC 104 Z9 109 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0887-6924 J9 LEUKEMIA JI Leukemia PD APR PY 2008 VL 22 IS 4 BP 842 EP 849 DI 10.1038/sj.leu.2405087 PG 8 WC Oncology; Hematology SC Oncology; Hematology GA 288SR UT WOS:000255006600020 PM 18200040 ER PT J AU Bihl, F Loggi, E Chisholm, JV Biselli, M Morelli, MC Cursaro, C Terrault, NA Bernardi, M Bertoletti, A Andreone, P Brander, C AF Bihl, Florian Loggi, Elisabetta Chisholm, John V., III Biselli, Maurizio Morelli, Maria C. Cursaro, Carmela Terrault, Norah A. Bernardi, Mauro Bertoletti, Antonio Andreone, Pietro Brander, Christian TI Sustained and focused hepatitis B virus nucleocapsid-specific T-Cell immunity in liver transplant recipients compared to individuals with chronic and self-limited hepatitis B virus infection SO LIVER TRANSPLANTATION LA English DT Article ID SARCOMA-ASSOCIATED HERPESVIRUS; ACUTE VIRAL-HEPATITIS; LAMIVUDINE TREATMENT; LYMPHOCYTE RESPONSE; KAPOSIS-SARCOMA; PROTEINS; EPITOPES; ANTIGENS; THERAPY; CD8 AB Hepatitis B virus (HBV) recurrence after orthotopic liver transplantation (OLT) is associated with poor graft- and patient-survival. Treatment with HBV-specific immunoglobulins (HBIG) in combination with nucleos(t)ide analogs is effective in preventing HBV reinfection of the graft and improving OLT outcome. However, the role of HBV-specific cellular immunity in viral containment in immune suppressed patients in general and in OLT recipients in particular is unclear. To test whether or not OLT recipients maintain robust HBV-specific cellular immunity, the cellular immune response against HBV was assessed in 15 OLT recipients and 27 individuals with chronic and 24 subjects with self-limited HBV infection, respectively; using an overlapping peptide set spanning the viral nucleocapsid- and envelope-protein sequences. The data demonstrate that OLT recipients mounted fewer but stronger clusters of differentiation (CD)8 T cell responses than subjects with self-limited HBV infection and showed a preferential targeting of the nucleocapsid antigen. This focused response pattern was similar to responses seen in chronically infected subjects with undetectable viremia, but significantly different from patients who presented with elevated HBV viremia and who mounted mainly immune responses against the envelope protein. In conclusion, virus-specific CD4 T cell-mediated responses were only detected in subjects with self-limited HBV infection. Thus, the profile of the cellular immunity against HBV was in immune suppressed patients similar to subjects with chronic HBV infection with suppressed HBV-DNA. C1 [Bihl, Florian; Chisholm, John V., III] Univ Hosp Geneva, Div Gastroenterol & Hepatol, Geneva, Switzerland. [Loggi, Elisabetta; Biselli, Maurizio; Morelli, Maria C.; Cursaro, Carmela; Bernardi, Mauro; Andreone, Pietro] Azienda Ospeda Univ, Policlin St Orsola Malpighi, Dept Internal Med Cardioangiol & Hepatol, Bologna, Italy. [Terrault, Norah A.] Univ Calif San Francisco, Dept Med & Gastroenterol, San Francisco, CA 94143 USA. [Bertoletti, Antonio] Agcy Sci Technol & Res, Singapore Inst Clin Sci, Singapore, Singapore. [Brander, Christian] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Partners AIDS Res Ctr, Boston, MA USA. RP Andreone, P (reprint author), Univ Bologna, Dept Internal Med Cardioangiol & Hepatol, Via Massarenti 9, I-40138 Bologna, Italy. EM andreone@med.unibo.it RI Loggi, Elisabetta/K-7848-2016; OI Brander, Christian/0000-0002-0548-5778; Loggi, Elisabetta/0000-0003-4985-9783; Cursaro, Carmela/0000-0002-5644-2508; Bertoletti, Antonio/0000-0002-2942-0485; ANDREONE, PIETRO/0000-0002-4794-9809 NR 44 TC 6 Z9 6 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1527-6465 J9 LIVER TRANSPLANT JI Liver Transplant. PD APR PY 2008 VL 14 IS 4 BP 478 EP 485 DI 10.1002/lt.21384 PG 8 WC Gastroenterology & Hepatology; Surgery; Transplantation SC Gastroenterology & Hepatology; Surgery; Transplantation GA 284RS UT WOS:000254724100013 PM 18324666 ER PT J AU Gonen, O Liu, SL Goelman, G Ratai, EM Pilkenton, S Lentz, MR Gonzalez, G AF Gonen, Oded Liu, Songlao Goelman, Gadi Ratai, Eva-Maria Pilkenton, Sarah Lentz, Margaret R. Gonzalez, Gilberto TI Proton MR spectroscopic imaging of rhesus macaque brain in vivo at 7T SO MAGNETIC RESONANCE IN MEDICINE LA English DT Article DE animal models; high field (7T); MR spectroscopic imaging (MRSI); rhesus macaque ID MAGNETIC-RESONANCE SPECTROSCOPY; LOCALIZED H-1-NMR SPECTROSCOPY; WHITE-MATTER; MONKEY; MODEL; ASPARTATE; CREATINE; PRIMATES; INJURY; NOISE AB Due to the overall similarity of their brains' structure and physiology to its human counterpart, nonhuman primates provide excellent model systems for the pathogenesis of neurological diseases and their response to treatments. Its much smaller size, 80 versus 1250 cm(3), however, requires proportionally higher spatial resolution to study, nondestructively, as many analogous regions as efficiently as possible in anesthetized animals. The confluence of these requirements underscores the need for the highest sensitivity, spatial coverage, resolution, and exam speed. Accordingly, we demonstrate the feasibility of 3D multi-voxel, proton (H-1) MRSI at (0.375 cm)(3) = 0.05 cm(3) isotropic spatial resolution over 21 cm(3) (approximate to 25%) of the anesthetized rhesus macaques brain at 7T in 25 min. These voxels are x 10(2)-10(1) times smaller than the 8-1 cm(3) common to H-1-MRS in humans, retaining similar proportions between the macaque and human brain. The spectra showed a signal-to-noise- ratio (SNR) approximate to 9-10 for the major metabolites and the interanimal SNR spatial distribution reproducibility was in the +/- 10% range for the standard error of their means (SEMs). Their metabolites linewidths, 9 +/- 2 Hz, yield excellent spectral resolution as well. These results indicate that 3D H-1-MRSI can be integrated into comprehensive MR studies in primates at such high fields. C1 [Gonen, Oded; Liu, Songlao; Goelman, Gadi] NYU, Dept Radiol, Sch Med, New York, NY 10016 USA. [Ratai, Eva-Maria; Pilkenton, Sarah; Lentz, Margaret R.; Gonzalez, Gilberto] Massachusetts Gen Hosp, AA Martinos Ctr Biomed Imaging & Neuroradiol Div, Charlestown, MA USA. RP Gonen, O (reprint author), NYU, Dept Radiol, Sch Med, 650 1st Ave, New York, NY 10016 USA. EM oded.gonen@med.nyu.edu OI Gonen, Oded/0000-0002-3148-2028 FU NCRR NIH HHS [P41 RR014075, P41RR14075]; NIAID NIH HHS [P30 AI028691, AI028691]; NIBIB NIH HHS [R01 EB001015, EB01015]; NINDS NIH HHS [K25 NS051129, NS050520, K25 NS051129-04, R56 NS050520, NS051129, R01 NS050520, NS050041, R01 NS050041] NR 30 TC 4 Z9 4 U1 0 U2 2 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0740-3194 J9 MAGN RESON MED JI Magn. Reson. Med. PD APR PY 2008 VL 59 IS 4 BP 692 EP 699 DI 10.1002/mrm.21554 PG 8 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 283OI UT WOS:000254645500003 PM 18302225 ER EF